<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="0" size="14" family="Times" color="#000000"/>
	<fontspec id="1" size="10" family="Times" color="#000000"/>
	<fontspec id="2" size="19" family="Times" color="#000000"/>
	<fontspec id="3" size="11" family="Times" color="#000000"/>
	<fontspec id="4" size="16" family="Times" color="#000000"/>
	<fontspec id="5" size="14" family="Times" color="#000000"/>
<text top="832" left="725" width="12" height="17" font="0">1 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="113" left="470" width="523" height="19" font="2"><b>2014 Valvular Heart Disease Guideline Data Supplements </b></text>
<text top="154" left="570" width="322" height="12" font="3"><b>(Section numbers correspond to the full-text guideline.) </b></text>
<text top="152" left="892" width="4" height="15" font="0"> </text>
<text top="188" left="660" width="146" height="16" font="4"><b>Table of Contents  </b></text>
<text top="208" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#2">Data Supplement 1. Outcomes in Adults With Low-Flow/Low-Gradient Aortic Stenosis With Reduced Left Ventricular Ejection Fraction (stage S1) (Sections 3.2.1.1 and 3.2.3) ............... 2 </a></text>
<text top="227" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#5">Data Supplement 2. Hemodynamic Progression of Aortic Stenosis in Adult Patients (stages B and C) (Section 3.2.1.3) ............................................................................................................ 5 </a></text>
<text top="246" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#6">Data Supplement 3. Exercise Stress Testing in Asymptomatic Adults With Aortic Stenosis (stages B and C) (Sections 3.2.1.5 and 3.2.3) ................................................................................ 6 </a></text>
<text top="265" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#8">Data Supplement 4. Clinical Trials of Lipid Lowering Therapy in Adults With Asymptomatic Mild to Moderate Aortic Stenosis (stage B (Section 3.2.2) ...................................................... 8 </a></text>
<text top="284" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#9">Data Supplement 5. Clinical Outcomes in Asymptomatic Adults With Aortic Stenosis (stages B and C) of Known Hemodynamic Severity (Section 3.2.3) .................................................... 9 </a></text>
<text top="303" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#11">Data Supplement 6. Incidence of Sudden Death in Asymptomatic Adults With Aortic Stenosis (stages B and C) (Section 3.2.3) ............................................................................................ 11 </a></text>
<text top="322" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#12">Data Supplement 7. Clinical Outcomes in Symptomatic Adults With Aortic Stenosis of Known Hemodynamic Severity (Section 3.2.3) ............................................................................... 12 </a></text>
<text top="341" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#14">Data Supplement 8. Outcomes in Adults With Low-Flow/Low-Gradient Aortic Stenosis With Preserved Left Ventricular Ejection Fraction (stage S2) (Section 3.2.3) ............................... 14 </a></text>
<text top="360" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#16">Data Supplement 9. Choice of Intervention in Symptomatic Adults With Severe Aortic Stenosis (stage D): Surgical Versus Transcatheter Aortic Valve Replacement (Section 3.2.4) ........ 16 </a></text>
<text top="379" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#17">Data Supplement 10. Clinical Outcomes of Asymptomatic Patients With Chronic Aortic Regurgitation (Sections 4.3.1.1 and 4.3.3) ...................................................................................... 17 </a></text>
<text top="398" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#20">Data Supplement 11. Vasodilator Therapy in Asymptomatic Patients With Chronic Aortic Regurgitation (Section 4.3.2) ....................................................................................................... 20 </a></text>
<text top="417" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#21">Data Supplement 12. Determinants of Outcome After Surgery for Chronic Aortic Regurgitation (Section 4.3.3) ..................................................................................................................... 21 </a></text>
<text top="436" left="108" width="1210" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#27">Data Supplement 13. Hemodynamic Effects Percutaneous Mitral Balloon Commissurotomy (PMBC) Compared to Surgical Closed Commissurotomy (CC) or Open Commissurotomy </a></text>
<text top="455" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#27">(OC) (Section 6.2.3) ...................................................................................................................................................................................................................................................................... 27 </a></text>
<text top="474" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#28">Data Supplement 14. Echocardiographic Prediction of Outcome of Percutaneous Balloon Mitral Commissurotomy (Section 6.2.3) ....................................................................................... 28 </a></text>
<text top="493" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#29">Data Supplement 15. Randomized Trials of Percutaneous Mitral Balloon Commissurotomy Versus Surgery for Mitral Stenosis (Section 6.2.3) .................................................................... 29 </a></text>
<text top="512" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#31">Data Supplement 16. Preoperative Predictors of Surgical Outcome in Mitral Regurgitation (Section 7.3.3) .............................................................................................................................. 31 </a></text>
<text top="531" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#32">Data Supplement 17. Primary Mitral Regurgitation—Evidence for Intervention (Section 7.3.3) ................................................................................................................................................ 32 </a></text>
<text top="549" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#34">Data Supplement 18. Secondary Mitral Regurgitation—Evidence for Intervention (7.4.3) ......................................................................................................................................................... 34 </a></text>
<text top="569" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#35">Data Supplement 19. Functional Tricuspid Regurgitation: Outcomes Following Tricuspid Valve Surgery (Sections 8.2.3 and 8.4.3) ...................................................................................... 35 </a></text>
<text top="587" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#37">Data Supplement 20. Clinical Outcomes With Bioprosthetic and Mechanical Valves (Section 11.1.2) ...................................................................................................................................... 37 </a></text>
<text top="607" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#40">Data Supplement 21. Bridging Anticoagulation Therapy for Mechanical Heart Valves (Section 11.3.2) ................................................................................................................................... 40 </a></text>
<text top="625" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#42">Data Supplement 22. Fibrinolytic Therapy for Prosthetic Valve Thrombosis (Section 11.6.2) ................................................................................................................................................... 42 </a></text>
<text top="644" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#44">Data Supplement 23. Paravalvular Regurgitation (Section 11.8.3) .............................................................................................................................................................................................. 44 </a></text>
<text top="663" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#46">Data Supplement 24. Surgical Outcome in Infective Endocarditis (Section 12) .......................................................................................................................................................................... 46 </a></text>
<text top="682" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#51">Data Supplement 25.Outcomes in Pregnant Women With a Mechanical Prosthetic Valve Treated with Warfarin or Unfractionated Heparin (UFH) (Section 13.3.2) ................................... 51 </a></text>
<text top="701" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#54">Data Supplement 26. Outcomes in Pregnant Women With a Mechanical Prosthetic Valve Treated With Low Molecular Weight Heparin (LMWH) (Section 13.3.2) ................................... 54 </a></text>
<text top="720" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#56">Data Supplement 27. Outcomes With the Maze Procedure for Atrial Fibrillation in Patients With Valvular Heart Disease (Section 14.2.2) ............................................................................ 56 </a></text>
<text top="739" left="108" width="1246" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#59">Data Supplement 28. Noncardiac Surgery in Patients With Valvular Heart Disease (Section 15.3) ........................................................................................................................................... 59 </a></text>
<text top="758" left="108" width="1241" height="15" font="0"><a href="2014 VHD Guideline Data Supplements.html#61">References ..................................................................................................................................................................................................................................................................................... 61</a></text>
<text top="757" left="1349" width="4" height="17" font="0"><a href="2014 VHD Guideline Data Supplements.html#61"> </a></text>
<text top="778" left="108" width="4" height="15" font="5"><b> </b></text>
</page>
<page number="2" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="6" size="12" family="Times" color="#000000"/>
	<fontspec id="7" size="12" family="Times" color="#000000"/>
	<fontspec id="8" size="12" family="Times" color="#0000ff"/>
	<fontspec id="9" size="7" family="Times" color="#000000"/>
	<fontspec id="10" size="12" family="Symbol" color="#000000"/>
<text top="832" left="725" width="12" height="17" font="0">2 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="4" height="21" font="4"><b> </b></text>
<text top="128" left="32" width="1210" height="21" font="4"><b>Data Supplement 1. Outcomes in Adults With Low-Flow/Low-Gradient Aortic Stenosis With Reduced Left Ventricular Ejection Fraction (stage S1) (Sections 3.2.1.1 and 3.2.3) </b></text>
<text top="131" left="1243" width="3" height="17" font="6"><b> </b></text>
<text top="150" left="91" width="38" height="17" font="6"><b>Study </b></text>
<text top="150" left="229" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="150" left="379" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="150" left="485" width="66" height="17" font="6"><b>Study Size </b></text>
<text top="150" left="581" width="111" height="17" font="6"><b>Definition of LFLG </b></text>
<text top="167" left="569" width="134" height="17" font="6"><b>Severe AS With rLVEF </b></text>
<text top="150" left="728" width="61" height="17" font="6"><b>Exclusion </b></text>
<text top="167" left="736" width="46" height="17" font="6"><b>Criteria </b></text>
<text top="150" left="867" width="206" height="17" font="6"><b>Stress Findings/Clinical Outcomes </b></text>
<text top="167" left="969" width="3" height="17" font="6"><b> </b></text>
<text top="150" left="1209" width="67" height="17" font="6"><b>Comments </b></text>
<text top="185" left="42" width="107" height="17" font="7">DeFillippi, 1995 (1) </text>
<text top="202" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7810504">7810504</a></text>
<text top="202" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7810504"> </a></text>
<text top="185" left="190" width="137" height="17" font="7">To determine if DSE can </text>
<text top="202" left="190" width="151" height="17" font="7">distinguish severe fixed AS </text>
<text top="219" left="190" width="135" height="17" font="7">from flow-dependent AS </text>
<text top="185" left="359" width="71" height="17" font="7">Prospective  </text>
<text top="185" left="481" width="21" height="17" font="7">24  </text>
<text top="185" left="568" width="76" height="17" font="7">AVAi ≤0.5 cm</text>
<text top="186" left="644" width="4" height="11" font="9">2</text>
<text top="185" left="649" width="14" height="17" font="7">/m</text>
<text top="186" left="662" width="4" height="11" font="9">2</text>
<text top="185" left="667" width="3" height="17" font="7"> </text>
<text top="202" left="568" width="9" height="18" font="10"></text>
<text top="203" left="578" width="8" height="17" font="7">P</text>
<text top="209" left="586" width="22" height="11" font="9">mean </text>
<text top="203" left="608" width="68" height="17" font="7">≤30 mm Hg </text>
<text top="221" left="568" width="70" height="17" font="7">LVEF ≤45% </text>
<text top="238" left="568" width="90" height="17" font="7">All symptomatic </text>
<text top="185" left="717" width="36" height="17" font="7">Too ill </text>
<text top="202" left="717" width="19" height="17" font="7">AF </text>
<text top="185" left="814" width="248" height="17" font="6"><b>IA</b>. (n=7, 39%) No change in AVA with ≥20% </text>
<text top="202" left="814" width="241" height="17" font="7">improvement in LVEF (contractile reserve).  </text>
<text top="221" left="814" width="83" height="17" font="6"><b>IB</b>. (n=5, 28%) </text>
<text top="220" left="897" width="9" height="18" font="10"></text>
<text top="221" left="906" width="73" height="17" font="7">AVA ≥0.3 cm</text>
<text top="222" left="979" width="4" height="11" font="9">2</text>
<text top="221" left="983" width="138" height="17" font="7"> and contractile reserve.  </text>
<text top="238" left="814" width="204" height="17" font="6"><b>II</b>. (n=6, 33%) No contractile reserve. </text>
<text top="185" left="1140" width="198" height="17" font="6"><b>IA.</b> 4 underwent AVR with improved </text>
<text top="202" left="1140" width="190" height="17" font="7">symptoms (1 perioperative death). </text>
<text top="219" left="1140" width="193" height="17" font="6"><b>IB.</b> 4 medical Rx and alive at 1 y. 1 </text>
<text top="237" left="1140" width="67" height="17" font="7">CAD death. </text>
<text top="254" left="1140" width="187" height="17" font="6"><b>II.</b> 3 deaths and 3 persistent CHF. </text>
<text top="272" left="42" width="89" height="17" font="7">Connolly, 1997  </text>
<text top="289" left="42" width="19" height="17" font="7">(2) </text>
<text top="306" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9170402">9170402</a></text>
<text top="306" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9170402"> </a></text>
<text top="272" left="190" width="139" height="17" font="7">Determine outcome after </text>
<text top="289" left="190" width="152" height="17" font="7">AVR for severe AS with LG </text>
<text top="306" left="190" width="80" height="17" font="7">and low LVEF </text>
<text top="272" left="359" width="78" height="17" font="7">Retrospective </text>
<text top="289" left="359" width="100" height="17" font="7">surgical database </text>
<text top="272" left="481" width="24" height="17" font="7">154 </text>
<text top="273" left="568" width="34" height="17" font="7">LVEF </text>
<text top="272" left="602" width="8" height="18" font="10"></text>
<text top="273" left="611" width="28" height="17" font="7">35% </text>
<text top="290" left="568" width="96" height="17" font="7">Undergoing AVR </text>
<text top="272" left="717" width="66" height="17" font="7">Other valve </text>
<text top="289" left="717" width="46" height="17" font="7">disease </text>
<text top="272" left="814" width="175" height="17" font="7">Baseline mean AVA 0.6±0.2 cm</text>
<text top="273" left="989" width="4" height="11" font="9">2</text>
<text top="272" left="993" width="10" height="17" font="7">,  </text>
<text top="289" left="814" width="198" height="17" font="7">Mean cardiac output 4.1±1.5 L/min, </text>
<text top="306" left="814" width="186" height="17" font="7">Perioperative (30 d) mortality 9%, </text>
<text top="323" left="814" width="248" height="17" font="7">Postoperative LVEF improved in 76% of pts.  </text>
<text top="272" left="1140" width="194" height="17" font="7">Study group had low LVEF, but not </text>
<text top="289" left="1140" width="98" height="17" font="7">all had LG or LF.  </text>
<text top="341" left="42" width="96" height="17" font="7">Pereira, 2002 (3) </text>
<text top="359" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11955855">11955855</a></text>
<text top="359" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11955855"> </a></text>
<text top="341" left="190" width="156" height="17" font="7">Evaluate outcome with AVR </text>
<text top="359" left="190" width="130" height="17" font="7">vs. medical Rx in LFLG </text>
<text top="376" left="190" width="60" height="17" font="7">severe AS </text>
<text top="341" left="359" width="82" height="17" font="7">Retrospective, </text>
<text top="359" left="359" width="94" height="17" font="7">propensity score </text>
<text top="376" left="359" width="54" height="17" font="7">matched  </text>
<text top="341" left="481" width="17" height="17" font="7">68 </text>
<text top="341" left="568" width="80" height="17" font="7">AVA ≤0.75 cm</text>
<text top="343" left="648" width="4" height="11" font="9">2</text>
<text top="341" left="653" width="3" height="17" font="7"> </text>
<text top="359" left="568" width="9" height="18" font="10"></text>
<text top="360" left="578" width="8" height="17" font="7">P</text>
<text top="366" left="586" width="22" height="11" font="9">mean </text>
<text top="360" left="608" width="68" height="17" font="7">≤30 mm Hg </text>
<text top="377" left="568" width="70" height="17" font="7">LVEF ≤35% </text>
<text top="394" left="568" width="3" height="17" font="7"> </text>
<text top="341" left="717" width="66" height="17" font="7">Other valve </text>
<text top="359" left="717" width="49" height="17" font="7">disease. </text>
<text top="341" left="814" width="305" height="17" font="7">In propensity matched pts, survival at 4 y was 78% with </text>
<text top="359" left="814" width="232" height="17" font="7">AVR vs.15% with medical Rx (p&lt;0.0001).  </text>
<text top="341" left="1140" width="182" height="17" font="7">Multivariate predictors of survival </text>
<text top="359" left="1140" width="194" height="17" font="7">were AVR, age, and renal function. </text>
<text top="412" left="42" width="111" height="17" font="7">Nishimura, 2002 (4) </text>
<text top="429" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12176952">12176952</a></text>
<text top="429" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12176952"> </a></text>
<text top="412" left="190" width="155" height="17" font="7">Diagnostic value of invasive </text>
<text top="429" left="190" width="111" height="17" font="7">hemodynamics with </text>
<text top="447" left="190" width="104" height="17" font="7">dobutamine stress </text>
<text top="412" left="359" width="71" height="17" font="7">Prospective, </text>
<text top="429" left="359" width="92" height="17" font="7">comparison with </text>
<text top="447" left="359" width="92" height="17" font="7">surgical findings </text>
<text top="412" left="481" width="17" height="17" font="7">32 </text>
<text top="412" left="568" width="72" height="17" font="7">AVA &lt;1.0 cm</text>
<text top="413" left="640" width="4" height="11" font="9">2</text>
<text top="412" left="645" width="3" height="17" font="7"> </text>
<text top="430" left="568" width="9" height="18" font="10"></text>
<text top="431" left="578" width="8" height="17" font="7">P</text>
<text top="436" left="586" width="22" height="11" font="9">mean </text>
<text top="431" left="608" width="67" height="17" font="7">&lt;40 mm Hg </text>
<text top="448" left="568" width="69" height="17" font="7">LVEF &lt;40% </text>
<text top="412" left="717" width="24" height="17" font="7">N/A </text>
<text top="413" left="814" width="153" height="17" font="7">With dobutamine, final AVA </text>
<text top="412" left="967" width="8" height="18" font="10"></text>
<text top="413" left="975" width="37" height="17" font="7">1.2 cm</text>
<text top="415" left="1012" width="4" height="11" font="9">2</text>
<text top="413" left="1017" width="39" height="17" font="7"> with a </text>
<text top="412" left="1055" width="9" height="18" font="10"></text>
<text top="413" left="1065" width="8" height="17" font="7">P</text>
<text top="419" left="1073" width="22" height="11" font="9">mean </text>
<text top="413" left="1095" width="24" height="17" font="7">&gt;30 </text>
<text top="431" left="814" width="276" height="17" font="7">mm Hg in 21 pts; severe AS confirmed at surgery. </text>
<text top="448" left="814" width="275" height="17" font="7">In 15 pts with CR, mortality was 7% (1 death) with </text>
<text top="465" left="814" width="94" height="17" font="7">medical therapy. </text>
<text top="413" left="1140" width="81" height="17" font="7">CR defined as </text>
<text top="412" left="1221" width="9" height="18" font="10"></text>
<text top="413" left="1230" width="20" height="17" font="7">SV </text>
<text top="412" left="1250" width="8" height="18" font="10"></text>
<text top="413" left="1258" width="53" height="17" font="7">20% with </text>
<text top="431" left="1140" width="71" height="17" font="7">dobutamine. </text>
<text top="483" left="42" width="90" height="17" font="7">Monin, 2003 (5) </text>
<text top="500" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12835219">12835219</a></text>
<text top="500" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12835219"> </a></text>
<text top="483" left="190" width="149" height="17" font="7">Assess prognostic value of </text>
<text top="500" left="190" width="96" height="17" font="7">DSE in LFLG AS </text>
<text top="483" left="359" width="71" height="17" font="7">Prospective, </text>
<text top="500" left="359" width="64" height="17" font="7">multicenter </text>
<text top="483" left="481" width="24" height="17" font="7">136 </text>
<text top="483" left="568" width="73" height="17" font="7">AVA ≤1.0 cm</text>
<text top="484" left="641" width="4" height="11" font="9">2</text>
<text top="483" left="646" width="3" height="17" font="7"> </text>
<text top="501" left="568" width="78" height="17" font="7">Cardiac index </text>
<text top="500" left="647" width="8" height="18" font="10"></text>
<text top="501" left="655" width="10" height="17" font="7">3 </text>
<text top="519" left="568" width="44" height="17" font="7">L/min/m</text>
<text top="520" left="612" width="4" height="11" font="9">2</text>
<text top="519" left="617" width="3" height="17" font="7"> </text>
<text top="536" left="568" width="9" height="18" font="10"></text>
<text top="537" left="578" width="8" height="17" font="7">P</text>
<text top="543" left="586" width="22" height="11" font="9">mean </text>
<text top="537" left="608" width="68" height="17" font="7">≤40 mm Hg </text>
<text top="483" left="717" width="66" height="17" font="7">Other valve </text>
<text top="500" left="717" width="49" height="17" font="7">disease, </text>
<text top="517" left="717" width="40" height="17" font="7">severe </text>
<text top="535" left="717" width="76" height="17" font="7">comorbidities </text>
<text top="483" left="814" width="285" height="17" font="7">Operative mortality 5% with CR vs. 32% without CR </text>
<text top="500" left="814" width="298" height="17" font="7">(p=0.0002). Predictors of long-term survival were AVR </text>
<text top="517" left="814" width="49" height="17" font="7">and CR. </text>
<text top="484" left="1140" width="81" height="17" font="7">CR defined as </text>
<text top="483" left="1221" width="9" height="18" font="10"></text>
<text top="484" left="1230" width="20" height="17" font="7">SV </text>
<text top="483" left="1250" width="8" height="18" font="10"></text>
<text top="484" left="1258" width="78" height="17" font="7">20% on DSE. </text>
<text top="555" left="42" width="90" height="17" font="7">Quere, 2006 (6) </text>
<text top="572" left="42" width="55" height="17" font="8"><a href="file://share1/divisions/SQ/Clinical%20Policy%20&amp;%20Documents/Guidelines/2013%20VHD%20Full%20Revision/Current%20Draft/Evidence%20Tables/16585393">16585393</a></text>
<text top="572" left="96" width="3" height="17" font="7"><a href="file://share1/divisions/SQ/Clinical%20Policy%20&amp;%20Documents/Guidelines/2013%20VHD%20Full%20Revision/Current%20Draft/Evidence%20Tables/16585393"> </a></text>
<text top="555" left="190" width="126" height="17" font="7">Determine relationship </text>
<text top="572" left="190" width="141" height="17" font="7">between CR on DSE and </text>
<text top="589" left="190" width="111" height="17" font="7">postoperative LVEF </text>
<text top="555" left="359" width="71" height="17" font="7">Prospective, </text>
<text top="572" left="359" width="64" height="17" font="7">multicenter </text>
<text top="555" left="481" width="17" height="17" font="7">66 </text>
<text top="555" left="568" width="73" height="17" font="7">AVA ≤1.0 cm</text>
<text top="556" left="641" width="4" height="11" font="9">2</text>
<text top="555" left="646" width="3" height="17" font="7"> </text>
<text top="572" left="568" width="9" height="18" font="10"></text>
<text top="573" left="578" width="8" height="17" font="7">P</text>
<text top="579" left="586" width="22" height="11" font="9">mean </text>
<text top="573" left="608" width="68" height="17" font="7">≤40 mm Hg </text>
<text top="591" left="568" width="70" height="17" font="7">LVEF ≤40% </text>
<text top="608" left="568" width="90" height="17" font="7">All symptomatic </text>
<text top="555" left="717" width="54" height="17" font="7">Excluded </text>
<text top="572" left="717" width="54" height="17" font="7">operative </text>
<text top="589" left="717" width="40" height="17" font="7">deaths </text>
<text top="555" left="814" width="309" height="17" font="6"><b>I</b>. CR in 70%; post-AVR LVEF improved ≥10 LVEF units </text>
<text top="572" left="814" width="44" height="17" font="7">in 83%. </text>
<text top="589" left="814" width="271" height="17" font="6"><b>II</b>. No contractile reserve in 30%; post-AVR LVEF </text>
<text top="607" left="814" width="187" height="17" font="7">improved ≥10 LVEF units in 65%. </text>
<text top="555" left="1140" width="195" height="17" font="7">Symptoms improved by ≥2 classes </text>
<text top="572" left="1140" width="101" height="17" font="7">after AVR in 58%. </text>
<text top="589" left="1140" width="196" height="17" font="7">Mean LVEF increased from 29±6% </text>
<text top="607" left="1140" width="124" height="17" font="7">to 47±11% after AVR. </text>
<text top="626" left="42" width="83" height="17" font="7">Blais, 2006 (7) </text>
<text top="643" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16461844">16461844</a></text>
<text top="643" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16461844"> </a></text>
<text top="626" left="190" width="139" height="17" font="7">Improve differentiation of </text>
<text top="643" left="190" width="137" height="17" font="7">true from pseudo severe </text>
<text top="660" left="190" width="66" height="17" font="7">AS on DSE </text>
<text top="626" left="359" width="101" height="17" font="7">In vitro model and </text>
<text top="643" left="359" width="80" height="17" font="7">prospective pt </text>
<text top="660" left="359" width="35" height="17" font="7">group </text>
<text top="626" left="481" width="17" height="17" font="7">23 </text>
<text top="626" left="568" width="76" height="17" font="7">AVAi ≤0.6 cm</text>
<text top="627" left="644" width="4" height="11" font="9">2</text>
<text top="626" left="649" width="14" height="17" font="7">/m</text>
<text top="627" left="662" width="4" height="11" font="9">2</text>
<text top="626" left="667" width="3" height="17" font="7"> </text>
<text top="643" left="568" width="70" height="17" font="7">LVEF ≤40% </text>
<text top="660" left="568" width="9" height="18" font="10"></text>
<text top="661" left="578" width="8" height="17" font="7">P</text>
<text top="667" left="586" width="22" height="11" font="9">mean </text>
<text top="661" left="608" width="68" height="17" font="7">≤40 mm Hg </text>
<text top="678" left="568" width="89" height="17" font="7">All symptomatic </text>
<text top="696" left="568" width="94" height="17" font="7">undergoing AVR </text>
<text top="626" left="717" width="66" height="17" font="7">Other valve </text>
<text top="643" left="717" width="46" height="17" font="7">disease </text>
<text top="660" left="717" width="70" height="17" font="7">AF or paced </text>
<text top="677" left="717" width="41" height="17" font="7">rhythm </text>
<text top="626" left="814" width="307" height="17" font="7">Projected effective orifice area at a normal transvalvular </text>
<text top="643" left="814" width="290" height="17" font="7">flow rate was accurate for identifying true vs. pseudo </text>
<text top="660" left="814" width="252" height="17" font="7">severe AS in comparison to surgical findings.  </text>
<text top="626" left="1140" width="101" height="17" font="7">No outcome data. </text>
<text top="714" left="42" width="127" height="17" font="7">Bergler-Klein, 2007 (8) </text>
<text top="731" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15117847">15117847</a></text>
<text top="731" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15117847"> </a></text>
<text top="748" left="42" width="3" height="17" font="7"> </text>
<text top="714" left="190" width="149" height="17" font="7">Relationship between BNP </text>
<text top="731" left="190" width="145" height="17" font="7">and outcome in LFLG AS  </text>
<text top="714" left="359" width="71" height="17" font="7">Prospective, </text>
<text top="731" left="359" width="64" height="17" font="7">multicenter </text>
<text top="714" left="481" width="17" height="17" font="7">69 </text>
<text top="714" left="568" width="75" height="17" font="7">AVAi &lt;0.6 cm</text>
<text top="715" left="643" width="4" height="11" font="9">2</text>
<text top="714" left="648" width="14" height="17" font="7">/m</text>
<text top="715" left="661" width="4" height="11" font="9">2</text>
<text top="714" left="666" width="3" height="17" font="7"> </text>
<text top="731" left="568" width="9" height="18" font="10"></text>
<text top="732" left="578" width="8" height="17" font="7">P</text>
<text top="738" left="586" width="22" height="11" font="9">mean </text>
<text top="732" left="608" width="68" height="17" font="7">≤40 mm Hg </text>
<text top="749" left="568" width="70" height="17" font="7">LVEF ≤40% </text>
<text top="714" left="717" width="66" height="17" font="7">Other valve </text>
<text top="731" left="717" width="72" height="17" font="7">disease, AF, </text>
<text top="748" left="717" width="51" height="17" font="7">or paced </text>
<text top="765" left="717" width="41" height="17" font="7">rhythm </text>
<text top="714" left="814" width="274" height="17" font="7">BNP was higher with true-severe AS compared to </text>
<text top="731" left="814" width="158" height="17" font="7">pseudo-severe AS (p=0.12). </text>
<text top="749" left="814" width="162" height="17" font="7">1-y survival 47±9% with BNP </text>
<text top="748" left="976" width="8" height="18" font="10"></text>
<text top="749" left="985" width="124" height="17" font="7">550 pg/mL vs. 97±3% </text>
<text top="766" left="814" width="189" height="17" font="7">with BNP &lt;550 pg/mL (p=0.0001). </text>
<text top="714" left="1140" width="171" height="17" font="7">Classified as severe AS if DSE </text>
<text top="732" left="1140" width="74" height="17" font="7">showed AVA </text>
<text top="731" left="1213" width="8" height="18" font="10"></text>
<text top="732" left="1221" width="37" height="17" font="7">1.0 cm</text>
<text top="733" left="1258" width="4" height="11" font="9">2</text>
<text top="732" left="1263" width="71" height="17" font="7"> at projected </text>
<text top="749" left="1140" width="206" height="17" font="7">flow rate of 250 mL/s; pseudo-severe </text>
<text top="766" left="1140" width="81" height="17" font="7">if AVA &gt;1.0 cm</text>
<text top="768" left="1221" width="4" height="11" font="9">2</text>
<text top="766" left="1226" width="95" height="17" font="7"> projected at 250 </text>
<text top="784" left="1140" width="33" height="17" font="7">mL/s. </text>
</page>
<page number="3" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="11" size="12" family="Times" color="#000000"/>
	<fontspec id="12" size="-1" family="Times" color="#000000"/>
	<fontspec id="13" size="13" family="Symbol" color="#000000"/>
	<fontspec id="14" size="7" family="Times" color="#000000"/>
<text top="832" left="725" width="12" height="17" font="0">3 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="91" width="38" height="17" font="6"><b>Study </b></text>
<text top="108" left="229" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="379" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="485" width="66" height="17" font="6"><b>Study Size </b></text>
<text top="108" left="581" width="111" height="17" font="6"><b>Definition of LFLG </b></text>
<text top="126" left="569" width="134" height="17" font="6"><b>Severe AS With rLVEF </b></text>
<text top="108" left="728" width="61" height="17" font="6"><b>Exclusion </b></text>
<text top="126" left="736" width="46" height="17" font="6"><b>Criteria </b></text>
<text top="108" left="867" width="206" height="17" font="6"><b>Stress Findings/Clinical Outcomes </b></text>
<text top="126" left="969" width="3" height="17" font="6"><b> </b></text>
<text top="108" left="1209" width="67" height="17" font="6"><b>Comments </b></text>
<text top="144" left="42" width="74" height="17" font="7">Pai, 2008 (9) </text>
<text top="161" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19021976">19021976</a></text>
<text top="161" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19021976"> </a></text>
<text top="144" left="190" width="146" height="17" font="7">Surgical outcome with low-</text>
<text top="161" left="190" width="68" height="17" font="7">gradient AS </text>
<text top="144" left="359" width="78" height="17" font="7">Retrospective </text>
<text top="161" left="359" width="100" height="17" font="7">surgical database </text>
<text top="144" left="481" width="24" height="17" font="7">362 </text>
<text top="144" left="568" width="73" height="17" font="7">AVA ≤0.8 cm</text>
<text top="145" left="641" width="7" height="11" font="9">2 </text>
<text top="144" left="648" width="33" height="17" font="11"><i>AND</i>  </text>
<text top="161" left="568" width="9" height="18" font="10"></text>
<text top="162" left="578" width="8" height="17" font="7">P</text>
<text top="168" left="586" width="22" height="11" font="9">mean </text>
<text top="162" left="608" width="94" height="17" font="7">≤30 mm Hg <i>OR</i>  </text>
<text top="179" left="568" width="74" height="17" font="7">LVEF ≤35%  </text>
<text top="144" left="717" width="24" height="17" font="7">N/A </text>
<text top="144" left="814" width="301" height="17" font="7">In 194 pts with LVEF ≤35%, 5-y survival was 50% with </text>
<text top="161" left="814" width="214" height="17" font="7">AVR vs. 23% without AVR (p&lt;0.0001). </text>
<text top="178" left="814" width="3" height="17" font="7"> </text>
<text top="196" left="814" width="83" height="17" font="7">In 168 pts with </text>
<text top="195" left="896" width="9" height="18" font="10"></text>
<text top="196" left="906" width="8" height="17" font="7">P</text>
<text top="202" left="914" width="22" height="11" font="9">mean </text>
<text top="196" left="936" width="163" height="17" font="7">≤30 mm Hg, 5-y survival was </text>
<text top="214" left="814" width="267" height="17" font="7">80% with AVR vs. 22% without AVR (p&lt;0.0001). </text>
<text top="144" left="1140" width="179" height="17" font="7">Univariate predictors of mortality </text>
<text top="161" left="1140" width="189" height="17" font="7">were older age, lower LVEF, renal </text>
<text top="178" left="1140" width="169" height="17" font="7">insufficiency, and lack of AVR. </text>
<text top="232" left="42" width="89" height="17" font="7">Levy, 2008 (10) </text>
<text top="249" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18402902">18402902</a></text>
<text top="249" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18402902"> </a></text>
<text top="232" left="190" width="125" height="17" font="7">Evaluate perioperative </text>
<text top="249" left="190" width="149" height="17" font="7">mortality with LFLG severe </text>
<text top="266" left="190" width="20" height="17" font="7">AS </text>
<text top="232" left="359" width="84" height="17" font="7">Surgical series </text>
<text top="249" left="359" width="100" height="17" font="7">AVR for LGLF AS </text>
<text top="232" left="481" width="24" height="17" font="7">217 </text>
<text top="232" left="568" width="62" height="17" font="7">AVA &lt;1 cm</text>
<text top="233" left="630" width="4" height="11" font="9">2</text>
<text top="232" left="635" width="3" height="17" font="7"> </text>
<text top="249" left="568" width="70" height="17" font="7">LVEF ≤35% </text>
<text top="266" left="568" width="9" height="18" font="10"></text>
<text top="267" left="578" width="8" height="17" font="7">P</text>
<text top="273" left="586" width="22" height="11" font="9">mean </text>
<text top="267" left="608" width="68" height="17" font="7">≤30 mm Hg </text>
<text top="232" left="717" width="66" height="17" font="7">Other valve </text>
<text top="249" left="717" width="46" height="17" font="7">disease </text>
<text top="232" left="814" width="286" height="17" font="7">Perioperative mortality 16% overall (decreased from </text>
<text top="249" left="814" width="186" height="17" font="7">20% in 1990s to 10% after 2000). </text>
<text top="266" left="814" width="138" height="17" font="7">5-y survival was 49±4%. </text>
<text top="232" left="1140" width="197" height="17" font="7">Predictors of perioperative mortality </text>
<text top="249" left="1140" width="201" height="17" font="7">were very LG, multivessel CAD, and </text>
<text top="266" left="1140" width="134" height="17" font="7">absence of CR on DSE. </text>
<text top="285" left="42" width="97" height="17" font="7">Clavel, 2010 (11) </text>
<text top="302" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20975002">20975002</a></text>
<text top="302" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20975002"> </a></text>
<text top="285" left="190" width="139" height="17" font="7">Compare outcomes after </text>
<text top="302" left="190" width="139" height="17" font="7">TAVR vs. SAVR with low </text>
<text top="320" left="190" width="98" height="17" font="7">LVEF severe AS  </text>
<text top="285" left="359" width="67" height="17" font="7">Prospective </text>
<text top="302" left="359" width="81" height="17" font="7">comparison of </text>
<text top="320" left="359" width="57" height="17" font="7">echo data </text>
<text top="285" left="481" width="64" height="17" font="7">200 SAVR; </text>
<text top="302" left="481" width="53" height="17" font="7">83 TAVR </text>
<text top="285" left="568" width="63" height="17" font="7">AVA ≤1 cm</text>
<text top="286" left="631" width="4" height="11" font="9">2</text>
<text top="285" left="636" width="3" height="17" font="7"> </text>
<text top="302" left="568" width="70" height="17" font="7">LVEF ≤50% </text>
<text top="285" left="717" width="69" height="17" font="7">No LVEF by </text>
<text top="302" left="717" width="30" height="17" font="7">echo </text>
<text top="285" left="814" width="289" height="17" font="7">LVEF improved more with TAVR compared to SAVR </text>
<text top="302" left="814" width="222" height="17" font="7">(ΔLVEF, 14±15% vs. 7±11%; p=0.005). </text>
<text top="320" left="814" width="3" height="17" font="7"> </text>
<text top="337" left="814" width="301" height="17" font="7">At 1 y, LVEF was normal in 58% of TAVR compared to </text>
<text top="354" left="814" width="88" height="17" font="7">20% SAVR pts. </text>
<text top="285" left="1140" width="151" height="17" font="7">Treatment not randomized. </text>
<text top="372" left="42" width="119" height="17" font="7">Tribouilloy, 2009 (12) </text>
<text top="389" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19442886">19442886</a></text>
<text top="389" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19442886"> </a></text>
<text top="372" left="190" width="151" height="17" font="7">Effect of AVR on outcomes </text>
<text top="389" left="190" width="149" height="17" font="7">in LFLG severe AS without </text>
<text top="406" left="190" width="107" height="17" font="7">contractile reserve  </text>
<text top="372" left="359" width="71" height="17" font="7">Prospective, </text>
<text top="389" left="359" width="67" height="17" font="7">multicenter  </text>
<text top="372" left="481" width="17" height="17" font="7">81 </text>
<text top="372" left="568" width="62" height="17" font="7">AVA &lt;1 cm</text>
<text top="373" left="630" width="4" height="11" font="9">2</text>
<text top="372" left="635" width="3" height="17" font="7"> </text>
<text top="389" left="568" width="70" height="17" font="7">LVEF ≤40% </text>
<text top="407" left="568" width="9" height="18" font="10"></text>
<text top="408" left="578" width="8" height="17" font="7">P</text>
<text top="413" left="586" width="22" height="11" font="9">mean </text>
<text top="408" left="608" width="68" height="17" font="7">≤40 mm Hg </text>
<text top="425" left="568" width="127" height="17" font="7">No contractile reserve  </text>
<text top="372" left="717" width="24" height="17" font="7">N/A </text>
<text top="372" left="814" width="269" height="17" font="7">Survival at 5 y was higher with AVR compared to </text>
<text top="389" left="814" width="259" height="17" font="7">medical therapy (54±7% vs. 13±7%; p=0.001). </text>
<text top="406" left="814" width="3" height="17" font="7"> </text>
<text top="424" left="814" width="203" height="17" font="7">Operative mortality was 22% (n=12). </text>
<text top="373" left="1140" width="167" height="17" font="7">Contractile reserve defined as </text>
<text top="372" left="1306" width="9" height="18" font="10"></text>
<text top="373" left="1315" width="20" height="17" font="7">SV </text>
<text top="391" left="1140" width="8" height="18" font="10"></text>
<text top="392" left="1148" width="77" height="17" font="7">20% on DSE. </text>
<text top="409" left="1140" width="3" height="17" font="7"> </text>
<text top="426" left="1140" width="187" height="17" font="7">Multivariate predictors of mortality </text>
<text top="443" left="1140" width="179" height="17" font="7">were associated bypass surgery </text>
<text top="462" left="1140" width="80" height="17" font="7">(p=0.007) and </text>
<text top="461" left="1220" width="9" height="18" font="10"></text>
<text top="462" left="1229" width="8" height="17" font="7">P</text>
<text top="467" left="1237" width="22" height="11" font="9">mean </text>
<text top="462" left="1260" width="68" height="17" font="7">≤20 mm Hg </text>
<text top="479" left="1140" width="60" height="17" font="7">(p=0.035). </text>
<text top="497" left="42" width="120" height="17" font="7">Gotzmann, 2012 (13) </text>
<text top="514" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21805576">21805576</a></text>
<text top="514" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21805576"> </a></text>
<text top="497" left="190" width="149" height="17" font="7">Outcomes after TAVR with </text>
<text top="514" left="190" width="123" height="17" font="7">low LVEF and LG  AS </text>
<text top="497" left="359" width="67" height="17" font="7">Prospective </text>
<text top="514" left="359" width="97" height="17" font="7">CoreValve TAVR </text>
<text top="497" left="481" width="24" height="17" font="7">202 </text>
<text top="497" left="568" width="125" height="17" font="7">LVEF groups &gt;50% or </text>
<text top="514" left="568" width="36" height="17" font="7">≤50% </text>
<text top="531" left="568" width="9" height="18" font="10"></text>
<text top="532" left="578" width="8" height="17" font="7">P</text>
<text top="538" left="586" width="22" height="11" font="9">mean </text>
<text top="532" left="608" width="80" height="17" font="7">groups &gt;40 or </text>
<text top="550" left="568" width="68" height="17" font="7">≤40 mm Hg </text>
<text top="497" left="717" width="24" height="17" font="7">N/A </text>
<text top="496" left="814" width="0" height="1" font="12"> </text>
<text top="508" left="822" width="70" height="17" font="7">1 y mortality </text>
<text top="508" left="925" width="69" height="17" font="11"><i>LVEF &gt;50% </i></text>
<text top="508" left="1028" width="70" height="17" font="11"><i>LVEF ≤50% </i></text>
<text top="526" left="822" width="9" height="19" font="13"></text>
<text top="527" left="831" width="8" height="17" font="11"><i>P</i></text>
<text top="533" left="839" width="22" height="11" font="14"><i>mean </i></text>
<text top="527" left="862" width="24" height="17" font="11"><i>&gt;40 </i></text>
<text top="526" left="925" width="67" height="17" font="7">14% (n=86) </text>
<text top="526" left="1028" width="67" height="17" font="7">27% (n=45) </text>
<text top="545" left="822" width="9" height="19" font="13"></text>
<text top="546" left="831" width="8" height="17" font="11"><i>P</i></text>
<text top="552" left="839" width="22" height="11" font="14"><i>mean </i></text>
<text top="546" left="862" width="25" height="17" font="11"><i>≤40 </i></text>
<text top="545" left="925" width="67" height="17" font="7">22% (n=27) </text>
<text top="545" left="1028" width="67" height="17" font="7">39% (n=44) </text>
<text top="497" left="1140" width="198" height="17" font="7">1-y mortality after TAVR was higher </text>
<text top="514" left="1140" width="168" height="17" font="7">with LG, low LVEF severe AS. </text>
<text top="531" left="1140" width="179" height="17" font="7">Severe AS defined as AVA ≤1.0 </text>
<text top="548" left="1140" width="16" height="17" font="7">cm</text>
<text top="550" left="1156" width="4" height="11" font="9">2</text>
<text top="548" left="1160" width="7" height="17" font="7">. </text>
<text top="566" left="1140" width="169" height="17" font="7">All pts were high surgical risk.  </text>
<text top="584" left="42" width="115" height="17" font="7">Fougeres, 2012 (14) </text>
<text top="601" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22733832">22733832</a></text>
<text top="601" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22733832"> </a></text>
<text top="584" left="190" width="152" height="17" font="7">Outcome of pseudo-severe </text>
<text top="601" left="190" width="91" height="17" font="7">AS without AVR </text>
<text top="584" left="359" width="107" height="17" font="7">Multicenter registry </text>
<text top="601" left="359" width="54" height="17" font="7">of severe </text>
<text top="618" left="359" width="106" height="17" font="7">symptomatic LFLG </text>
<text top="635" left="359" width="20" height="17" font="7">AS </text>
<text top="584" left="481" width="24" height="17" font="7">107 </text>
<text top="584" left="568" width="63" height="17" font="7">AVA ≤1 cm</text>
<text top="585" left="631" width="7" height="11" font="9">2 </text>
<text top="584" left="638" width="45" height="17" font="7">or AVAi </text>
<text top="601" left="568" width="45" height="17" font="7">≤0.6 cm</text>
<text top="602" left="614" width="4" height="11" font="9">2</text>
<text top="601" left="618" width="14" height="17" font="7">/m</text>
<text top="602" left="632" width="4" height="11" font="9">2</text>
<text top="601" left="636" width="3" height="17" font="7"> </text>
<text top="618" left="568" width="70" height="17" font="7">LVEF ≤40% </text>
<text top="635" left="568" width="9" height="18" font="10"></text>
<text top="636" left="578" width="8" height="17" font="7">P</text>
<text top="642" left="586" width="22" height="11" font="9">mean </text>
<text top="636" left="608" width="68" height="17" font="7">≤40 mm Hg </text>
<text top="654" left="568" width="107" height="17" font="7">Cardiac index ≤3.0 </text>
<text top="671" left="568" width="44" height="17" font="7">L/min/m</text>
<text top="672" left="612" width="4" height="11" font="9">2</text>
<text top="671" left="617" width="3" height="17" font="7"> </text>
<text top="584" left="717" width="42" height="17" font="7">Severe </text>
<text top="601" left="717" width="79" height="17" font="7">comorbidities, </text>
<text top="618" left="717" width="66" height="17" font="7">Other valve </text>
<text top="635" left="717" width="49" height="17" font="7">disease, </text>
<text top="652" left="717" width="22" height="17" font="7">AF  </text>
<text top="584" left="814" width="150" height="17" font="6"><b>IA</b>: 43 with true-severe AS  </text>
<text top="601" left="814" width="299" height="17" font="6"><b>IB:</b> 29 with pseudo-severe AS defined as CR with final </text>
<text top="619" left="814" width="73" height="17" font="7">AVA ≥1.2 cm</text>
<text top="620" left="887" width="7" height="11" font="9">2 </text>
<text top="619" left="893" width="24" height="17" font="7">and </text>
<text top="618" left="917" width="9" height="18" font="10"></text>
<text top="619" left="927" width="8" height="17" font="7">P</text>
<text top="625" left="935" width="22" height="11" font="9">mean </text>
<text top="619" left="957" width="68" height="17" font="7">≤40 mm Hg </text>
<text top="638" left="814" width="99" height="17" font="6"><b>II:</b> 23 with no CR (</text>
<text top="637" left="913" width="9" height="18" font="10"></text>
<text top="638" left="922" width="59" height="17" font="7">SV &lt;20%) </text>
<text top="584" left="1140" width="204" height="17" font="7">74 deaths (69%) at a median interval </text>
<text top="601" left="1140" width="177" height="17" font="7">of 10 m. Outcomes with pseudo-</text>
<text top="618" left="1140" width="204" height="17" font="7">severe AS (Group IB) were similar to </text>
<text top="635" left="1140" width="134" height="17" font="7">pts with HF without AS.  </text>
<text top="652" left="1140" width="200" height="17" font="7">Multivariate predictors of mortality in </text>
<text top="670" left="1140" width="203" height="17" font="7">Group 1B were CAD (HR: 1.88; 95% </text>
<text top="687" left="1140" width="109" height="17" font="7">CI: 1.35–2.63) and  </text>
<text top="704" left="1140" width="9" height="18" font="10"></text>
<text top="705" left="1149" width="8" height="17" font="7">P</text>
<text top="711" left="1157" width="22" height="11" font="9">mean </text>
<text top="705" left="1179" width="155" height="17" font="7">&lt;20 mm Hg (HR: 1.55; 95% </text>
<text top="723" left="1140" width="92" height="17" font="7">CI: 1.07–02.23). </text>
<text top="741" left="42" width="114" height="17" font="7">Herrmann 2013 (15) </text>
<text top="758" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23661722">23661722</a></text>
<text top="758" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23661722"> </a></text>
<text top="741" left="190" width="142" height="17" font="7">Surgical vs. transcatheter </text>
<text top="758" left="190" width="156" height="17" font="7">AVR for in operable pts with </text>
<text top="775" left="190" width="119" height="17" font="7">LFLG severe AS with </text>
<text top="741" left="359" width="104" height="17" font="7">Subgroup analysis </text>
<text top="758" left="359" width="46" height="17" font="7">of RCT  </text>
<text top="741" left="481" width="17" height="17" font="7">42 </text>
<text top="758" left="481" width="68" height="17" font="7">randomized </text>
<text top="775" left="481" width="69" height="17" font="7">to TAVR vs. </text>
<text top="741" left="568" width="73" height="17" font="7">AVA ≤0.8 cm</text>
<text top="742" left="641" width="7" height="11" font="9">2 </text>
<text top="741" left="648" width="45" height="17" font="7">or AVAi </text>
<text top="758" left="568" width="44" height="17" font="7">&lt;0.5 cm</text>
<text top="759" left="612" width="4" height="11" font="9">2</text>
<text top="758" left="617" width="14" height="17" font="7">/m</text>
<text top="759" left="631" width="4" height="11" font="9">2</text>
<text top="758" left="635" width="3" height="17" font="7"> </text>
<text top="775" left="568" width="69" height="17" font="7">LVEF &lt;50% </text>
<text top="741" left="717" width="24" height="17" font="7">N/A </text>
<text top="741" left="814" width="285" height="17" font="7">Mortality at 2 y was 80.0% with medical therapy vs.  </text>
<text top="758" left="814" width="268" height="17" font="7">47.1% with TAVR (HR: 0.43; 95% CI: 0.19–0.98; </text>
<text top="775" left="814" width="52" height="17" font="7">p=0.040) </text>
<text top="741" left="1140" width="200" height="17" font="7">No difference in 2-y outcomes in the </text>
<text top="758" left="1140" width="188" height="17" font="7">105 pts with LFLG severe AS with </text>
<text top="775" left="1140" width="193" height="17" font="7">low LVEF randomized to SAVR vs. </text>
</page>
<page number="4" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="725" width="12" height="17" font="0">4 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="91" width="38" height="17" font="6"><b>Study </b></text>
<text top="108" left="229" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="379" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="485" width="66" height="17" font="6"><b>Study Size </b></text>
<text top="108" left="581" width="111" height="17" font="6"><b>Definition of LFLG </b></text>
<text top="126" left="569" width="134" height="17" font="6"><b>Severe AS With rLVEF </b></text>
<text top="108" left="728" width="61" height="17" font="6"><b>Exclusion </b></text>
<text top="126" left="736" width="46" height="17" font="6"><b>Criteria </b></text>
<text top="108" left="867" width="206" height="17" font="6"><b>Stress Findings/Clinical Outcomes </b></text>
<text top="126" left="969" width="3" height="17" font="6"><b> </b></text>
<text top="108" left="1209" width="67" height="17" font="6"><b>Comments </b></text>
<text top="144" left="190" width="82" height="17" font="7">reduced LVEF </text>
<text top="144" left="481" width="64" height="17" font="7">medical Rx </text>
<text top="144" left="568" width="9" height="18" font="10"></text>
<text top="145" left="578" width="8" height="17" font="7">P</text>
<text top="151" left="586" width="22" height="11" font="9">mean </text>
<text top="145" left="608" width="68" height="17" font="7">≤40 mm Hg </text>
<text top="162" left="568" width="81" height="17" font="7">SVi &lt; 35 mL/m</text>
<text top="163" left="649" width="4" height="11" font="9">2</text>
<text top="162" left="654" width="3" height="17" font="7"> </text>
<text top="144" left="1140" width="195" height="17" font="7">TAVR (42.9% vs. 37.1%; HR: 1.25, </text>
<text top="161" left="1140" width="158" height="17" font="7">95% CI: 0.66–2.36; p=0.50). </text>
<text top="180" left="34" width="1293" height="17" font="7">AF indicates atrial fibrillation; AS, aortic stenosis; AVA, aortic valve area; AVAi, aortic valve area indexed to body surface area; AVR, aortic valve replacement; BNP, brain natriuretic peptide; CAD, coronary artery disease; CHF, congestive </text>
<text top="198" left="34" width="977" height="17" font="7">heart failure; CR, contractile reserve; DSE, dobutamine stress echocardiography; HF, heart failure; LFLG, low-flow/low-gradient; LF, low flow; LG, low gradient; N/A, nonapplicable; </text>
<text top="197" left="1011" width="9" height="18" font="10"></text>
<text top="198" left="1020" width="8" height="17" font="7">P</text>
<text top="204" left="1028" width="20" height="11" font="9">mean</text>
<text top="198" left="1048" width="301" height="17" font="7">, mean transaortic systolic pressure gradient; pts, adult </text>
<text top="217" left="34" width="405" height="17" font="7">patients; Rx, prescription; rLVEF, left ventricular reduced ejection fraction; </text>
<text top="216" left="439" width="9" height="18" font="10"></text>
<text top="217" left="448" width="8" height="17" font="7">P</text>
<text top="222" left="456" width="27" height="11" font="9">mean , </text>
<text top="217" left="482" width="92" height="17" font="7">mean transaortic</text>
<text top="222" left="574" width="2" height="11" font="9"> </text>
<text top="217" left="577" width="770" height="17" font="7">pressure gradient; SAVR, surgical aortic valve replacement; SV, stroke volume; SVi, stroke volume indexed to body surface area; and TAVR, </text>
<text top="234" left="34" width="219" height="17" font="7">transcatheter aortic valve replacement.  </text>
<text top="234" left="465" width="3" height="17" font="7"> </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="15" size="7" family="Times" color="#000000"/>
<text top="832" left="725" width="12" height="17" font="0">5 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="825" height="21" font="4"><b>Data Supplement 2. Hemodynamic Progression of Aortic Stenosis in Adult Patients (stages B and C) (Section 3.2.1.3) </b></text>
<text top="110" left="857" width="3" height="17" font="6"><b> </b></text>
<text top="129" left="72" width="107" height="17" font="6"><b>First Author, Year </b></text>
<text top="129" left="262" width="12" height="17" font="6"><b>N </b></text>
<text top="129" left="374" width="85" height="17" font="6"><b>Type of Study </b></text>
<text top="129" left="577" width="81" height="17" font="6"><b>Entry Criteria </b></text>
<text top="129" left="732" width="115" height="17" font="6"><b>Mean Follow-up (y) </b></text>
<text top="130" left="890" width="68" height="17" font="6"><b>Increase in </b></text>
<text top="129" left="958" width="9" height="18" font="10"></text>
<text top="130" left="967" width="8" height="17" font="6"><b>P</b></text>
<text top="136" left="975" width="21" height="11" font="15"><b>mean</b></text>
<text top="130" left="996" width="3" height="17" font="6"><b> </b></text>
<text top="148" left="915" width="60" height="17" font="6"><b>(mmHg/y) </b></text>
<text top="165" left="908" width="73" height="17" font="6"><b>(mean± SD) </b></text>
<text top="129" left="1043" width="76" height="17" font="6"><b>Increase in V</b></text>
<text top="135" left="1119" width="18" height="11" font="15"><b>max </b></text>
<text top="129" left="1137" width="43" height="17" font="6"><b>(m/s/y) </b></text>
<text top="146" left="1075" width="76" height="17" font="6"><b>(mean± SD)  </b></text>
<text top="129" left="1200" width="123" height="17" font="6"><b>Decrease in AVA (cm</b></text>
<text top="130" left="1324" width="4" height="11" font="15"><b>2</b></text>
<text top="129" left="1328" width="18" height="17" font="6"><b>/y) </b></text>
<text top="146" left="1237" width="73" height="17" font="6"><b>(mean± SD) </b></text>
<text top="183" left="41" width="86" height="17" font="7">Otto, 1989 (16) </text>
<text top="200" left="41" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2918158">2918158</a></text>
<text top="200" left="88" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2918158"> </a></text>
<text top="183" left="224" width="17" height="17" font="7">42 </text>
<text top="183" left="325" width="68" height="17" font="7">Prospective </text>
<text top="183" left="520" width="92" height="17" font="7">Asymptomatic; V</text>
<text top="188" left="612" width="15" height="11" font="9">max</text>
<text top="183" left="627" width="55" height="17" font="7"> &gt;2.5 m/s </text>
<text top="183" left="729" width="21" height="17" font="7">1.7 </text>
<text top="183" left="862" width="53" height="17" font="7">8 (-7–23) </text>
<text top="183" left="1040" width="60" height="17" font="7">0.36±0.31 </text>
<text top="183" left="1197" width="21" height="17" font="7">0.1 </text>
<text top="218" left="41" width="96" height="17" font="7">Roger, 1990 (17) </text>
<text top="235" left="41" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2301222">2301222</a></text>
<text top="235" left="88" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2301222"> </a></text>
<text top="218" left="224" width="24" height="17" font="7">112 </text>
<text top="218" left="325" width="79" height="17" font="7">Retrospective </text>
<text top="218" left="520" width="67" height="17" font="7">AS on echo </text>
<text top="218" left="729" width="21" height="17" font="7">2.1 </text>
<text top="218" left="862" width="24" height="17" font="7">N/A </text>
<text top="218" left="1040" width="60" height="17" font="7">0.23±0.37 </text>
<text top="218" left="1197" width="24" height="17" font="7">N/A </text>
<text top="253" left="41" width="114" height="17" font="7">Faggiano, 1992 (18) </text>
<text top="270" left="41" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1626512">1626512</a></text>
<text top="270" left="88" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1626512"> </a></text>
<text top="253" left="224" width="17" height="17" font="7">45 </text>
<text top="253" left="325" width="68" height="17" font="7">Prospective </text>
<text top="253" left="520" width="67" height="17" font="7">AS on echo </text>
<text top="253" left="729" width="21" height="17" font="7">1.5 </text>
<text top="253" left="862" width="24" height="17" font="7">N/A </text>
<text top="253" left="1040" width="46" height="17" font="7">0.4±0.3 </text>
<text top="253" left="1197" width="53" height="17" font="7">0.1±0.13 </text>
<text top="288" left="41" width="92" height="17" font="7">Peter, 1993 (19) </text>
<text top="305" left="41" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8404089">8404089</a></text>
<text top="305" left="88" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8404089"> </a></text>
<text top="288" left="224" width="17" height="17" font="7">49 </text>
<text top="288" left="325" width="79" height="17" font="7">Retrospective </text>
<text top="288" left="520" width="67" height="17" font="7">AS on echo </text>
<text top="288" left="729" width="21" height="17" font="7">2.7 </text>
<text top="288" left="862" width="21" height="17" font="7">7.2 </text>
<text top="288" left="1040" width="24" height="17" font="7">N/A </text>
<text top="288" left="1197" width="24" height="17" font="7">N/A </text>
<text top="323" left="41" width="100" height="17" font="7">Brener, 1995 (20) </text>
<text top="341" left="41" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7829781">7829781</a></text>
<text top="341" left="88" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7829781"> </a></text>
<text top="323" left="224" width="24" height="17" font="7">394 </text>
<text top="323" left="325" width="79" height="17" font="7">Retrospective </text>
<text top="323" left="520" width="67" height="17" font="7">AS on echo </text>
<text top="323" left="729" width="21" height="17" font="7">6.3 </text>
<text top="323" left="862" width="24" height="17" font="7">N/A </text>
<text top="323" left="1040" width="24" height="17" font="7">N/A </text>
<text top="323" left="1197" width="27" height="17" font="7">0.14 </text>
<text top="359" left="41" width="86" height="17" font="7">Otto, 1997 (21) </text>
<text top="376" left="41" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9142003">9142003</a></text>
<text top="376" left="88" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9142003"> </a></text>
<text top="359" left="224" width="24" height="17" font="7">123 </text>
<text top="359" left="325" width="68" height="17" font="7">Prospective </text>
<text top="359" left="520" width="92" height="17" font="7">Asymptomatic, V</text>
<text top="364" left="612" width="15" height="11" font="9">max</text>
<text top="359" left="627" width="55" height="17" font="7"> &gt;2.5 m/s </text>
<text top="359" left="729" width="21" height="17" font="7">2.5 </text>
<text top="359" left="862" width="25" height="17" font="7">7±7 </text>
<text top="359" left="1040" width="60" height="17" font="7">0.32±0.34 </text>
<text top="359" left="1197" width="60" height="17" font="7">0.12±0.19 </text>
<text top="394" left="41" width="98" height="17" font="7">Bahler, 1999 (22) </text>
<text top="411" left="41" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10569661">10569661</a></text>
<text top="411" left="95" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10569661"> </a></text>
<text top="394" left="224" width="17" height="17" font="7">91 </text>
<text top="394" left="325" width="79" height="17" font="7">Retrospective </text>
<text top="394" left="520" width="67" height="17" font="7">AS on echo </text>
<text top="394" left="729" width="21" height="17" font="7">1.8 </text>
<text top="394" left="862" width="21" height="17" font="7">2.8 </text>
<text top="394" left="1040" width="21" height="17" font="7">0.2 </text>
<text top="394" left="1197" width="27" height="17" font="7">0.04 </text>
<text top="429" left="41" width="91" height="17" font="7">Palta, 2000 (23) </text>
<text top="446" left="41" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10831524">10831524</a></text>
<text top="446" left="95" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10831524"> </a></text>
<text top="429" left="224" width="24" height="17" font="7">170 </text>
<text top="429" left="325" width="79" height="17" font="7">Retrospective </text>
<text top="429" left="520" width="67" height="17" font="7">AS on echo </text>
<text top="429" left="729" width="21" height="17" font="7">1.9 </text>
<text top="429" left="862" width="24" height="17" font="7">N/A </text>
<text top="429" left="1040" width="24" height="17" font="7">N/A </text>
<text top="429" left="1197" width="60" height="17" font="7">0.10±0.27 </text>
<text top="464" left="41" width="118" height="17" font="7">Rosenhek, 2000 (24) </text>
<text top="481" left="41" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10965007">10965007</a></text>
<text top="481" left="95" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10965007"> </a></text>
<text top="464" left="224" width="24" height="17" font="7">128 </text>
<text top="464" left="325" width="68" height="17" font="7">Prospective </text>
<text top="464" left="520" width="8" height="17" font="7">V</text>
<text top="470" left="528" width="15" height="11" font="9">max</text>
<text top="464" left="543" width="51" height="17" font="7"> &gt;4.0m/s </text>
<text top="464" left="729" width="21" height="17" font="7">1.8 </text>
<text top="464" left="862" width="30" height="17" font="7">Slow </text>
<text top="464" left="1040" width="60" height="17" font="7">0.14±0.18 </text>
<text top="464" left="1197" width="24" height="17" font="7">N/A </text>
<text top="482" left="862" width="36" height="17" font="7">Rapid </text>
<text top="482" left="1040" width="60" height="17" font="7">0.45±0.38 </text>
<text top="482" left="1197" width="24" height="17" font="7">N/A </text>
<text top="500" left="41" width="118" height="17" font="7">Rosenhek, 2004 (25) </text>
<text top="517" left="41" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14972419">14972419</a></text>
<text top="517" left="95" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14972419"> </a></text>
<text top="500" left="224" width="24" height="17" font="7">176 </text>
<text top="500" left="325" width="79" height="17" font="7">Retrospective </text>
<text top="500" left="520" width="8" height="17" font="7">V</text>
<text top="506" left="528" width="15" height="11" font="9">max</text>
<text top="500" left="543" width="71" height="17" font="7"> 2.5–3.9 m/s </text>
<text top="500" left="729" width="21" height="17" font="7">3.8 </text>
<text top="500" left="862" width="24" height="17" font="7">N/A </text>
<text top="500" left="1040" width="60" height="17" font="7">0.24±0.30 </text>
<text top="500" left="1197" width="24" height="17" font="7">N/A </text>
<text top="535" left="41" width="111" height="17" font="7">Rossebo, 2008 (26) </text>
<text top="552" left="41" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18765433">18765433</a></text>
<text top="552" left="95" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18765433"> </a></text>
<text top="535" left="224" width="34" height="17" font="7">1,875 </text>
<text top="535" left="325" width="71" height="17" font="7">Prospective  </text>
<text top="535" left="520" width="8" height="17" font="7">V</text>
<text top="541" left="528" width="17" height="11" font="9">max </text>
<text top="535" left="545" width="58" height="17" font="7">2.5–4 m/s </text>
<text top="535" left="729" width="21" height="17" font="7">4.3 </text>
<text top="535" left="862" width="53" height="17" font="7">Statin Rx </text>
<text top="535" left="1040" width="63" height="17" font="7">0.15±0.01  </text>
<text top="535" left="1197" width="56" height="17" font="7">0.03±0.1  </text>
<text top="553" left="862" width="51" height="17" font="7">Placebo  </text>
<text top="553" left="1040" width="60" height="17" font="7">0.16±0.01 </text>
<text top="553" left="1197" width="56" height="17" font="7">0.03±0.1  </text>
<text top="572" left="34" width="534" height="17" font="7">AS indicates aortic stenosis; AVA, aortic valve area; echo, echocardiography; N/A, not applicable; </text>
<text top="571" left="568" width="9" height="18" font="10"></text>
<text top="572" left="577" width="8" height="17" font="7">P</text>
<text top="578" left="585" width="27" height="11" font="9">mean , </text>
<text top="572" left="612" width="92" height="17" font="7">mean transaortic</text>
<text top="578" left="704" width="2" height="11" font="9"> </text>
<text top="572" left="706" width="111" height="17" font="7">pressure gradient; V</text>
<text top="578" left="817" width="15" height="11" font="9">max</text>
<text top="572" left="832" width="115" height="17" font="7">, maximum velocity.  </text>
<text top="607" left="108" width="3" height="17" font="7"> </text>
<text top="607" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="6" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="725" width="12" height="17" font="0">6 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="946" height="21" font="4"><b>Data Supplement 3. Exercise Stress Testing in Asymptomatic Adults With Aortic Stenosis (stages B and C) (Sections 3.2.1.5 and 3.2.3) </b></text>
<text top="129" left="90" width="38" height="17" font="6"><b>Study </b></text>
<text top="129" left="228" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="129" left="378" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="485" width="66" height="17" font="6"><b>Study Size </b></text>
<text top="129" left="585" width="104" height="17" font="6"><b>Inclusion Criteria </b></text>
<text top="129" left="728" width="61" height="17" font="6"><b>Exclusion </b></text>
<text top="146" left="736" width="46" height="17" font="6"><b>Criteria </b></text>
<text top="129" left="864" width="220" height="17" font="6"><b>Exercise Findings/Clinical Outcomes </b></text>
<text top="146" left="972" width="3" height="17" font="6"><b> </b></text>
<text top="129" left="1213" width="67" height="17" font="6"><b>Comments </b></text>
<text top="164" left="42" width="112" height="17" font="7">Nylander, 1986 (27) </text>
<text top="182" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3707789">3707789</a></text>
<text top="182" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3707789"> </a></text>
<text top="164" left="190" width="141" height="17" font="7">Describe hemodynamics, </text>
<text top="182" left="190" width="91" height="17" font="7">clinical features, </text>
<text top="199" left="190" width="127" height="17" font="7">noninvasive findings in </text>
<text top="216" left="190" width="144" height="17" font="7">elderly pts with suspected </text>
<text top="233" left="190" width="133" height="17" font="7">severe symptomatic AS </text>
<text top="164" left="359" width="83" height="17" font="7">Observational, </text>
<text top="182" left="359" width="76" height="17" font="7">exercise test  </text>
<text top="164" left="481" width="51" height="17" font="7">76 (37 in </text>
<text top="182" left="481" width="69" height="17" font="7">NHYA class </text>
<text top="199" left="481" width="33" height="17" font="7">III/IV) </text>
<text top="164" left="568" width="134" height="17" font="7">Suspected symptomatic </text>
<text top="182" left="568" width="64" height="17" font="7">severe AS, </text>
<text top="199" left="568" width="85" height="17" font="7">Mean age 65 y </text>
<text top="164" left="719" width="24" height="17" font="7">N/A </text>
<text top="164" left="813" width="254" height="17" font="7">Inadequate BP increase with exercise in 82%. </text>
<text top="182" left="813" width="304" height="17" font="7">ETT was at variance with reported NYHA class in 25%. </text>
<text top="199" left="813" width="264" height="17" font="7">Exercise tolerance was &lt;80% expected for age. </text>
<text top="164" left="1148" width="174" height="17" font="7">ETT stopped for low BP in 36% </text>
<text top="182" left="1148" width="128" height="17" font="7">and chest pain in 29%. </text>
<text top="199" left="1148" width="141" height="17" font="7">No clinical outcome data. </text>
<text top="216" left="1148" width="166" height="17" font="7">Most pts were symptomatic at </text>
<text top="233" left="1148" width="56" height="17" font="7">baseline.  </text>
<text top="251" left="42" width="94" height="17" font="7">Clyne, 1991 (28) </text>
<text top="268" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1746429">1746429</a></text>
<text top="268" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1746429"> </a></text>
<text top="251" left="190" width="249" height="17" font="7">Evaluate exercise response   ETT, Thallium </text>
<text top="268" left="359" width="104" height="17" font="7">perfusion imaging, </text>
<text top="286" left="359" width="44" height="17" font="7">MUGA  </text>
<text top="251" left="481" width="17" height="17" font="7">14 </text>
<text top="251" left="568" width="100" height="17" font="7">Asymptomatic AS </text>
<text top="268" left="568" width="3" height="17" font="7"> </text>
<text top="251" left="719" width="24" height="17" font="7">N/A </text>
<text top="251" left="813" width="269" height="17" font="7">AS pts had decreased exercise tolerance and VO</text>
<text top="257" left="1082" width="20" height="11" font="9">2max</text>
<text top="251" left="1102" width="22" height="17" font="7"> vs. </text>
<text top="268" left="813" width="50" height="17" font="7">controls  </text>
<text top="251" left="1148" width="158" height="17" font="7">ST depression &gt;1 mm flat or </text>
<text top="268" left="1148" width="116" height="17" font="7">downsloping in 71%. </text>
<text top="286" left="1148" width="165" height="17" font="7">Reversible perfusion defect in </text>
<text top="303" left="1148" width="35" height="17" font="7">21%.  </text>
<text top="320" left="1148" width="9" height="18" font="10"></text>
<text top="321" left="1157" width="125" height="17" font="7">BP &gt;10 mm Hg in 7%. </text>
<text top="338" left="1148" width="141" height="17" font="7">No clinical outcome data. </text>
<text top="356" left="42" width="86" height="17" font="7">Otto, 1992 (29) </text>
<text top="374" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1401617">1401617</a></text>
<text top="374" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1401617"> </a></text>
<text top="356" left="190" width="115" height="17" font="7">Measure physiologic </text>
<text top="374" left="190" width="120" height="17" font="7">response to exercise  </text>
<text top="356" left="359" width="71" height="17" font="7">Prospective, </text>
<text top="374" left="359" width="83" height="17" font="7">Bruce protocol </text>
<text top="391" left="359" width="33" height="17" font="7">ETT,  </text>
<text top="408" left="359" width="76" height="17" font="7">Doppler echo </text>
<text top="356" left="481" width="17" height="17" font="7">28 </text>
<text top="356" left="568" width="100" height="17" font="7">Asymptomatic AS </text>
<text top="374" left="568" width="7" height="17" font="7">  </text>
<text top="356" left="719" width="24" height="17" font="7">N/A </text>
<text top="356" left="813" width="168" height="17" font="7">Exercise duration 6.7±4.3 min </text>
<text top="375" left="813" width="8" height="17" font="7">V</text>
<text top="380" left="821" width="15" height="11" font="9">max</text>
<text top="375" left="836" width="3" height="17" font="7"> </text>
<text top="374" left="839" width="9" height="18" font="10"></text>
<text top="375" left="848" width="219" height="17" font="7">3.99±0.93 to 4.61±1.12 m/s (p&lt;0.0001) </text>
<text top="392" left="813" width="9" height="18" font="10"></text>
<text top="393" left="822" width="8" height="17" font="7">P</text>
<text top="399" left="830" width="20" height="11" font="9">mean</text>
<text top="393" left="850" width="3" height="17" font="7"> </text>
<text top="392" left="853" width="9" height="18" font="10"></text>
<text top="393" left="862" width="198" height="17" font="7">39±20 to 52±26 mm Hg (p&lt;0.0001) </text>
<text top="412" left="813" width="82" height="17" font="7">Stroke volume </text>
<text top="411" left="895" width="9" height="18" font="10"></text>
<text top="412" left="904" width="162" height="17" font="7">98±29 to 89±32 mL (p=0.01) </text>
<text top="430" left="813" width="10" height="17" font="7">Q</text>
<text top="436" left="822" width="15" height="11" font="9">max</text>
<text top="430" left="837" width="3" height="17" font="7"> </text>
<text top="429" left="841" width="9" height="18" font="10"></text>
<text top="430" left="850" width="212" height="17" font="7">422±117 to 523±209 mL/s (p&lt;0.0001) </text>
<text top="448" left="813" width="28" height="17" font="7">SEP </text>
<text top="447" left="841" width="9" height="18" font="10"></text>
<text top="448" left="850" width="203" height="17" font="7">0.33±0.04 to 0.24±0.002 (p&lt;0.0001) </text>
<text top="467" left="813" width="83" height="17" font="7">Cardiac output </text>
<text top="466" left="896" width="9" height="18" font="10"></text>
<text top="467" left="905" width="205" height="17" font="7">6.5±1.7 to 10.2 4.4 L/min (p&lt;0.0001) </text>
<text top="484" left="813" width="204" height="17" font="7">AVA 1.17±0.45 to 1.28±0.65 (p=NS) </text>
<text top="357" left="1148" width="9" height="18" font="10"></text>
<text top="358" left="1157" width="132" height="17" font="7">BP &gt;10 mm Hg in 11%. </text>
<text top="375" left="1148" width="158" height="17" font="7">ST depression &gt;1 mm flat or </text>
<text top="392" left="1148" width="116" height="17" font="7">downsloping in 75%. </text>
<text top="409" left="1148" width="146" height="17" font="7">Occasional PVCS in 39%. </text>
<text top="426" left="1148" width="187" height="17" font="7">Asymptomatic 3-beat VT in 4% (1 </text>
<text top="444" left="1148" width="25" height="17" font="7">pt.). </text>
<text top="461" left="1148" width="3" height="17" font="7"> </text>
<text top="478" left="1148" width="141" height="17" font="7">No clinical outcome data. </text>
<text top="502" left="42" width="86" height="17" font="7">Otto, 1997 (21) </text>
<text top="519" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9142003">9142003</a></text>
<text top="519" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9142003"> </a></text>
<text top="502" left="190" width="154" height="17" font="7">Identify predictors of clinical </text>
<text top="519" left="190" width="51" height="17" font="7">outcome </text>
<text top="502" left="359" width="71" height="17" font="7">Prospective, </text>
<text top="519" left="359" width="101" height="17" font="7">clinical, echo, and </text>
<text top="536" left="359" width="57" height="17" font="7">ETT data  </text>
<text top="502" left="481" width="44" height="17" font="7">104 pts </text>
<text top="519" left="481" width="73" height="17" font="7">274 exercise </text>
<text top="536" left="481" width="29" height="17" font="7">tests </text>
<text top="502" left="568" width="100" height="17" font="7">Asymptomatic AS </text>
<text top="519" left="568" width="16" height="17" font="7"> (V</text>
<text top="525" left="584" width="17" height="11" font="9">max </text>
<text top="519" left="601" width="55" height="17" font="7">&gt;2.5 m/s) </text>
<text top="502" left="719" width="56" height="17" font="7">Unable to </text>
<text top="519" left="719" width="45" height="17" font="7">walk on </text>
<text top="536" left="719" width="50" height="17" font="7">treadmill </text>
<text top="502" left="813" width="306" height="17" font="7">Univariate predictors of clinical outcome (AVR or death) </text>
<text top="520" left="813" width="151" height="17" font="7">included a smaller exercise </text>
<text top="519" left="964" width="9" height="18" font="10"></text>
<text top="520" left="973" width="159" height="17" font="7">AVA, BP, and cardiac output </text>
<text top="539" left="813" width="24" height="17" font="7">and </text>
<text top="538" left="837" width="9" height="18" font="10"></text>
<text top="539" left="846" width="158" height="17" font="7">stroke volume with exercise. </text>
<text top="556" left="813" width="3" height="17" font="7"> </text>
<text top="573" left="813" width="267" height="17" font="7">Multivariate predictors of outcome were resting V</text>
<text top="579" left="1079" width="15" height="11" font="9">max</text>
<text top="573" left="1094" width="27" height="17" font="7">, the </text>
<text top="590" left="813" width="103" height="17" font="7">rate of change in V</text>
<text top="596" left="916" width="17" height="11" font="9">max </text>
<text top="590" left="933" width="197" height="17" font="7">(m/s/y), and functional status score; </text>
<text top="607" left="813" width="271" height="17" font="7">exercise variables did provide additive prognostic </text>
<text top="625" left="813" width="71" height="17" font="7">information.  </text>
<text top="502" left="1148" width="135" height="17" font="7">No complication in 85%. </text>
<text top="519" left="1148" width="9" height="18" font="10"></text>
<text top="520" left="1157" width="125" height="17" font="7">BP &gt;10 mm Hg in 9%. </text>
<text top="537" left="1148" width="158" height="17" font="7">ST depression &gt;1 mm flat or </text>
<text top="555" left="1148" width="116" height="17" font="7">downsloping in 69%. </text>
<text top="572" left="1148" width="158" height="17" font="7">ST depression &gt;2 mm flat or </text>
<text top="589" left="1148" width="172" height="17" font="7">downsloping persisting &gt;5 m in </text>
<text top="606" left="1148" width="88" height="17" font="7">recovery in 2%. </text>
<text top="643" left="42" width="95" height="17" font="7">Amato, 2001(30) </text>
<text top="660" left="42" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11559673"> </a></text>
<text top="660" left="45" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11559673">11559673</a></text>
<text top="660" left="100" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11559673"> </a></text>
<text top="643" left="190" width="136" height="17" font="7">To determine prognostic </text>
<text top="660" left="190" width="135" height="17" font="7">value of exercise testing </text>
<text top="643" left="359" width="71" height="17" font="7">Prospective  </text>
<text top="643" left="481" width="21" height="17" font="7">66  </text>
<text top="660" left="481" width="58" height="17" font="7">Mean age </text>
<text top="677" left="481" width="68" height="17" font="7">49.5 y, 67% </text>
<text top="694" left="481" width="27" height="17" font="7">men </text>
<text top="643" left="568" width="123" height="17" font="7">Severe AS (AVA ≤1.0 </text>
<text top="660" left="568" width="16" height="17" font="7">cm</text>
<text top="661" left="585" width="4" height="11" font="9">2</text>
<text top="660" left="589" width="11" height="17" font="7">)  </text>
<text top="643" left="719" width="33" height="17" font="7">CAD, </text>
<text top="660" left="719" width="71" height="17" font="7">arrhythmias, </text>
<text top="677" left="719" width="55" height="17" font="7">abnormal </text>
<text top="694" left="719" width="49" height="17" font="7">baseline </text>
<text top="711" left="719" width="33" height="17" font="7">ECG, </text>
<text top="729" left="719" width="54" height="17" font="7">comorbid </text>
<text top="746" left="719" width="49" height="17" font="7">disease  </text>
<text top="643" left="813" width="320" height="17" font="7">Main outcome measure of sudden death (6%) or symptom </text>
<text top="660" left="813" width="73" height="17" font="7">onset (52%). </text>
<text top="677" left="813" width="312" height="17" font="7">Positive ETT in 67%: symptoms in 35%, BP rise &lt;20 mm </text>
<text top="694" left="813" width="270" height="17" font="7">Hg in 20%, ST changes alone in 12%, ventricular </text>
<text top="711" left="813" width="103" height="17" font="7">arrhythmia in 7%.  </text>
<text top="729" left="813" width="299" height="17" font="7">Event free survival at 2 y was 19% with a positive ETT </text>
<text top="746" left="813" width="171" height="17" font="7">and 85% with a negative ETT.  </text>
<text top="643" left="1148" width="181" height="17" font="7">Dizziness during ETT in 12%, no </text>
<text top="660" left="1148" width="153" height="17" font="7">other complications of ETT. </text>
<text top="677" left="1148" width="174" height="17" font="7">The 66 pts were derived from a </text>
<text top="694" left="1148" width="167" height="17" font="7">cohort of 853 consecutive pts. </text>
<text top="711" left="1148" width="194" height="17" font="7">These data may not apply to all AS </text>
<text top="729" left="1148" width="27" height="17" font="7">pts.  </text>
<text top="764" left="42" width="83" height="17" font="7">Alborino, 2002 </text>
<text top="781" left="42" width="25" height="17" font="7">(31) </text>
<text top="764" left="190" width="110" height="17" font="7">Risk stratification of </text>
<text top="781" left="190" width="124" height="17" font="7">asymptomatic pts with </text>
<text top="764" left="359" width="68" height="17" font="7">Prospective </text>
<text top="764" left="481" width="17" height="17" font="7">30 </text>
<text top="781" left="481" width="58" height="17" font="7">Mean age </text>
<text top="764" left="568" width="104" height="17" font="7">Asymptomatic AS  </text>
<text top="764" left="719" width="24" height="17" font="7">N/A </text>
<text top="764" left="813" width="178" height="17" font="7">Abnormal ETT in 18 (60%) with: </text>
<text top="781" left="813" width="311" height="17" font="7">Fall in BP (3), angina (1), ECG ST changes (3), dyspnea </text>
<text top="764" left="1148" width="38" height="17" font="7">At 1 y: </text>
<text top="781" left="1148" width="157" height="17" font="7">All 12 pts with a normal ETT </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="725" width="12" height="17" font="0">7 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="90" width="38" height="17" font="6"><b>Study </b></text>
<text top="108" left="228" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="378" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="485" width="66" height="17" font="6"><b>Study Size </b></text>
<text top="108" left="585" width="104" height="17" font="6"><b>Inclusion Criteria </b></text>
<text top="108" left="728" width="61" height="17" font="6"><b>Exclusion </b></text>
<text top="126" left="736" width="46" height="17" font="6"><b>Criteria </b></text>
<text top="108" left="864" width="220" height="17" font="6"><b>Exercise Findings/Clinical Outcomes </b></text>
<text top="126" left="972" width="3" height="17" font="6"><b> </b></text>
<text top="108" left="1213" width="67" height="17" font="6"><b>Comments </b></text>
<text top="144" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12000161">12000161</a></text>
<text top="144" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12000161"> </a></text>
<text top="144" left="190" width="116" height="17" font="7">moderate-severe AS </text>
<text top="144" left="481" width="49" height="17" font="7">62±14 y </text>
<text top="144" left="813" width="29" height="17" font="7">(11)  </text>
<text top="144" left="1148" width="136" height="17" font="7">remained symptom free. </text>
<text top="161" left="1148" width="189" height="17" font="7">10/18 with abnormal ETT required </text>
<text top="178" left="1148" width="32" height="17" font="7">AVR  </text>
<text top="196" left="42" width="85" height="17" font="7">Das, 2005 (32) </text>
<text top="213" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15820999">15820999</a></text>
<text top="213" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15820999"> </a></text>
<text top="196" left="190" width="143" height="17" font="7">Accuracy of stress testing </text>
<text top="213" left="190" width="154" height="17" font="7">to predict symptom onset at </text>
<text top="230" left="190" width="38" height="17" font="7">12 mo </text>
<text top="196" left="359" width="71" height="17" font="7">Prospective  </text>
<text top="196" left="481" width="24" height="17" font="7">125 </text>
<text top="196" left="568" width="104" height="17" font="7">Asymptomatic AS  </text>
<text top="213" left="568" width="94" height="17" font="7">AVA &lt;1.4 (mean </text>
<text top="230" left="568" width="66" height="17" font="7">0.9±0.2) cm</text>
<text top="232" left="635" width="4" height="11" font="9">2</text>
<text top="230" left="639" width="14" height="17" font="7">/m</text>
<text top="232" left="653" width="7" height="11" font="9">2 </text>
<text top="230" left="659" width="3" height="17" font="7"> </text>
<text top="248" left="568" width="77" height="17" font="7">Normal LVEF </text>
<text top="196" left="719" width="66" height="17" font="7">Other valve </text>
<text top="213" left="719" width="49" height="17" font="7">disease. </text>
<text top="230" left="719" width="76" height="17" font="7">Regional wall </text>
<text top="248" left="719" width="47" height="17" font="7">motion.  </text>
<text top="196" left="813" width="268" height="17" font="7">At 1-y follow-up, 36 (29%) developed symptoms. </text>
<text top="213" left="813" width="277" height="17" font="7">ETT provoked symptoms in 26 (72%) of these pts. </text>
<text top="230" left="813" width="301" height="17" font="7">Abnormal BP response or ST changes did not improve </text>
<text top="248" left="813" width="258" height="17" font="7">accuracy of ETT for predicting symptom onset. </text>
<text top="196" left="1148" width="193" height="17" font="7">Symptoms provoked by ETT had a </text>
<text top="213" left="1148" width="182" height="17" font="7">PPV of 57% and NPV of 87% for </text>
<text top="230" left="1148" width="165" height="17" font="7">onset of symptoms within 1 y. </text>
<text top="248" left="1148" width="185" height="17" font="7">Accuracy was higher in pts under </text>
<text top="265" left="1148" width="71" height="17" font="7">70 y of age.  </text>
<text top="283" left="42" width="118" height="17" font="7">Lancellotti, 2005 (33) </text>
<text top="300" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16159850">16159850</a></text>
<text top="300" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16159850"> </a></text>
<text top="283" left="190" width="108" height="17" font="7">Role of quantitative </text>
<text top="300" left="190" width="99" height="17" font="7">exercise Doppler  </text>
<text top="283" left="359" width="71" height="17" font="7">Prospective  </text>
<text top="283" left="481" width="17" height="17" font="7">69 </text>
<text top="283" left="568" width="100" height="17" font="7">Asymptomatic AS </text>
<text top="300" left="568" width="72" height="17" font="7">AVA &lt;1.0 cm</text>
<text top="301" left="640" width="4" height="11" font="9">2</text>
<text top="300" left="645" width="3" height="17" font="7"> </text>
<text top="283" left="719" width="66" height="17" font="7">Other valve </text>
<text top="300" left="719" width="72" height="17" font="7">disease, AF, </text>
<text top="317" left="719" width="74" height="17" font="7">AVR within 2 </text>
<text top="335" left="719" width="21" height="17" font="7">mo </text>
<text top="283" left="813" width="277" height="17" font="7">Abnormal exercise response in 26 (38%) including </text>
<text top="300" left="813" width="246" height="17" font="7">symptoms, ST depression, failure of BP rise. </text>
<text top="283" left="1148" width="191" height="17" font="7">Cardiac events (n=18) at 15±7 mo </text>
<text top="300" left="1148" width="170" height="17" font="7">follow-up were predicted by an </text>
<text top="319" left="1148" width="49" height="17" font="7">exercise </text>
<text top="318" left="1197" width="18" height="18" font="10"></text>
<text top="319" left="1215" width="8" height="17" font="7">P</text>
<text top="324" left="1223" width="20" height="11" font="9">mean</text>
<text top="319" left="1244" width="92" height="17" font="7"> ≥18 mm Hg, an </text>
<text top="336" left="1148" width="186" height="17" font="7">abnormal exercise test or an AVA </text>
<text top="353" left="1148" width="51" height="17" font="7">&lt;0.75 cm</text>
<text top="354" left="1199" width="9" height="16" font="9">2. </text>
<text top="371" left="42" width="124" height="17" font="7">Marechaux, 2010 (34) </text>
<text top="388" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20308041">20308041</a></text>
<text top="388" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20308041"> </a></text>
<text top="371" left="190" width="102" height="17" font="7">Assess if exercise </text>
<text top="388" left="190" width="130" height="17" font="7">hemodynamics provide </text>
<text top="405" left="190" width="127" height="17" font="7">incremental prognostic </text>
<text top="422" left="190" width="152" height="17" font="7">value to standard ETT data </text>
<text top="371" left="359" width="71" height="17" font="7">Prospective, </text>
<text top="388" left="359" width="64" height="17" font="7">multicenter </text>
<text top="371" left="481" width="24" height="17" font="7">186 </text>
<text top="371" left="568" width="116" height="17" font="7">Moderate-severe AS </text>
<text top="388" left="568" width="100" height="17" font="7">Normal LV (LVEF </text>
<text top="405" left="568" width="40" height="17" font="7">≥50%) </text>
<text top="371" left="719" width="62" height="17" font="7">Symptoms </text>
<text top="388" left="719" width="66" height="17" font="7">Other valve </text>
<text top="405" left="719" width="46" height="17" font="7">disease </text>
<text top="422" left="719" width="29" height="17" font="7">CAD </text>
<text top="440" left="719" width="53" height="17" font="7">AF/flutter </text>
<text top="371" left="813" width="307" height="17" font="7">In the 73% with a normal ETT, 67 had an event (AVR or </text>
<text top="388" left="813" width="192" height="17" font="7">CV death) at 20±14 mo follow-up.  </text>
<text top="405" left="813" width="281" height="17" font="7">The 27% with an abnormal ETT (symptoms limiting </text>
<text top="422" left="813" width="313" height="17" font="7">exercise, fall in BP below baseline or complex ventricular </text>
<text top="440" left="813" width="237" height="17" font="7">arrhythmias) were excluded from analysis.  </text>
<text top="371" left="1148" width="175" height="17" font="7">Adverse events associated with </text>
<text top="388" left="1148" width="183" height="17" font="7">age 65 y, diabetes mellitus, LVH, </text>
<text top="407" left="1148" width="40" height="17" font="7">resting </text>
<text top="406" left="1188" width="9" height="18" font="10"></text>
<text top="407" left="1198" width="8" height="17" font="7">P</text>
<text top="412" left="1206" width="22" height="11" font="9">mean </text>
<text top="407" left="1228" width="120" height="17" font="7"> 35 mm Hg, exercise  </text>
<text top="424" left="1148" width="18" height="18" font="10"></text>
<text top="425" left="1166" width="8" height="17" font="7">P</text>
<text top="431" left="1174" width="20" height="11" font="9">mean</text>
<text top="425" left="1194" width="74" height="17" font="7"> &gt;20 mm Hg. </text>
<text top="458" left="42" width="98" height="17" font="7">Rajani, 2010 (35) </text>
<text top="475" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11479246">11479246</a></text>
<text top="475" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11479246"> </a></text>
<text top="492" left="42" width="3" height="17" font="7"> </text>
<text top="458" left="190" width="145" height="17" font="7">Test if exercise symptoms </text>
<text top="475" left="190" width="140" height="17" font="7">are due to changes in LV </text>
<text top="492" left="190" width="46" height="17" font="7">function </text>
<text top="458" left="359" width="68" height="17" font="7">Prospective </text>
<text top="458" left="481" width="17" height="17" font="7">38 </text>
<text top="458" left="568" width="81" height="17" font="7">Asymptomatic </text>
<text top="475" left="568" width="72" height="17" font="7">AVA &lt;1.5 cm</text>
<text top="476" left="640" width="4" height="11" font="9">2</text>
<text top="475" left="645" width="3" height="17" font="7"> </text>
<text top="458" left="719" width="24" height="17" font="7">N/A </text>
<text top="458" left="813" width="319" height="17" font="7">ETT revealed symptom in 10 (26%) which was associated </text>
<text top="475" left="813" width="262" height="17" font="7">with a lower cardiac index, stroke index, and VO</text>
<text top="481" left="1075" width="22" height="11" font="9">2max </text>
<text top="492" left="813" width="211" height="17" font="7">compared to those without symptoms. </text>
<text top="458" left="1148" width="186" height="17" font="7">The only independent predictor of </text>
<text top="475" left="1148" width="171" height="17" font="7">peak cardiac index was the log </text>
<text top="492" left="1148" width="156" height="17" font="7">BNP level (p&lt;0.001; r=0.71) </text>
<text top="510" left="33" width="1298" height="17" font="7">AF indicates atrial fibrillation, AS, aortic stenosis; AVA, aortic valve area; AVR, aortic valve replacement; BNP, brain natriuretic peptide; BP, blood pressure; CAD, coronary artery disease; CV, cardiovascular, echo; echocardiography; ECG, </text>
<text top="527" left="33" width="1315" height="17" font="7">electrocardiogram; ETT, exercise treadmill test; LV, left ventricular, LVEF, left ventricular ejection fraction; LVH; left ventricular hypertrophy; MUGA; multi gated acquisition scan; N/A, nonapplicable; NS, nonsignificant; NPV, negative predictive </text>
<text top="546" left="33" width="237" height="17" font="7">value; NYHA, New York Heart Association; </text>
<text top="545" left="271" width="9" height="18" font="10"></text>
<text top="546" left="280" width="8" height="17" font="7">P</text>
<text top="551" left="288" width="20" height="11" font="9">mean</text>
<text top="546" left="308" width="743" height="17" font="7">, mean transaortic systolic pressure gradient ; PPV, positive predictive value; pt(s), patients; PVCs, premature ventricular contractions; Q</text>
<text top="551" left="1051" width="15" height="11" font="9">max</text>
<text top="546" left="1066" width="279" height="17" font="7">, maximum flow rate; SEP, systolic ejection period; </text>
<text top="563" left="33" width="18" height="17" font="7">VO</text>
<text top="568" left="51" width="4" height="11" font="9">2</text>
<text top="563" left="56" width="23" height="17" font="7">max</text>
<text top="568" left="79" width="2" height="11" font="9">,</text>
<text top="563" left="81" width="172" height="17" font="7"> maximal oxygen consumption. </text>
<text top="580" left="108" width="3" height="17" font="7"> </text>
<text top="580" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="725" width="12" height="17" font="0">8 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="34" width="1039" height="21" font="4"><b>Data Supplement 4. Clinical Trials of Lipid Lowering Therapy in Adults With Asymptomatic Mild to Moderate Aortic Stenosis (stage B (Section 3.2.2) </b></text>
<text top="129" left="50" width="78" height="17" font="6"><b>Study Name, </b></text>
<text top="146" left="51" width="77" height="17" font="6"><b>First Author, </b></text>
<text top="164" left="74" width="30" height="17" font="6"><b>Year </b></text>
<text top="129" left="150" width="88" height="17" font="6"><b>Type of Study, </b></text>
<text top="146" left="153" width="78" height="17" font="6"><b>Mean Follow-</b></text>
<text top="164" left="175" width="38" height="17" font="6"><b>Up (y) </b></text>
<text top="129" left="262" width="12" height="17" font="6"><b>N </b></text>
<text top="129" left="312" width="81" height="17" font="6"><b>Entry Criteria </b></text>
<text top="129" left="447" width="108" height="17" font="6"><b>Exclusion Criteria </b></text>
<text top="129" left="605" width="63" height="17" font="6"><b>Treatment </b></text>
<text top="146" left="616" width="40" height="17" font="6"><b>Group </b></text>
<text top="129" left="690" width="87" height="17" font="6"><b>Serum LDL on </b></text>
<text top="146" left="692" width="84" height="17" font="6"><b>Rx (% change </b></text>
<text top="164" left="690" width="87" height="17" font="6"><b>from baseline) </b></text>
<text top="129" left="798" width="68" height="17" font="6"><b>Increase in </b></text>
<text top="146" left="797" width="8" height="17" font="6"><b>V</b></text>
<text top="152" left="805" width="16" height="11" font="15"><b>max</b></text>
<text top="146" left="821" width="47" height="17" font="6"><b> (m/s/y) </b></text>
<text top="165" left="803" width="16" height="17" font="6"><b>or </b></text>
<text top="164" left="819" width="9" height="18" font="10"></text>
<text top="165" left="828" width="8" height="17" font="6"><b>P</b></text>
<text top="170" left="836" width="23" height="11" font="15"><b>mean </b></text>
<text top="182" left="800" width="64" height="17" font="6"><b>(mm Hg/y) </b></text>
<text top="129" left="890" width="72" height="17" font="6"><b>Decrease in </b></text>
<text top="146" left="890" width="51" height="17" font="6"><b>AVA (cm</b></text>
<text top="148" left="941" width="4" height="11" font="15"><b>2</b></text>
<text top="146" left="945" width="18" height="17" font="6"><b>/y) </b></text>
<text top="129" left="985" width="100" height="17" font="6"><b>Other Endpoints </b></text>
<text top="129" left="1126" width="47" height="17" font="6"><b>Clinical </b></text>
<text top="146" left="1118" width="64" height="17" font="6"><b>Endpoints </b></text>
<text top="129" left="1217" width="107" height="17" font="6"><b>Study Limitations </b></text>
<text top="146" left="1210" width="121" height="17" font="6"><b>and Adverse Events </b></text>
<text top="200" left="42" width="55" height="17" font="7">SALTIRE </text>
<text top="217" left="42" width="74" height="17" font="7">Cowell, 2005 </text>
<text top="234" left="42" width="25" height="17" font="7">(36) </text>
<text top="252" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15944423">15944423</a></text>
<text top="252" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15944423"> </a></text>
<text top="200" left="150" width="76" height="17" font="7">Randomized, </text>
<text top="217" left="150" width="74" height="17" font="7">double-blind, </text>
<text top="234" left="150" width="48" height="17" font="7">Placebo </text>
<text top="252" left="150" width="57" height="17" font="7">controlled </text>
<text top="269" left="150" width="30" height="17" font="7">2.1 y </text>
<text top="200" left="251" width="24" height="17" font="7">134 </text>
<text top="200" left="298" width="8" height="17" font="7">V</text>
<text top="205" left="306" width="15" height="11" font="9">max</text>
<text top="200" left="322" width="55" height="17" font="7"> &gt;2.5 m/s </text>
<text top="217" left="298" width="83" height="17" font="7">Aortic valve Ca</text>
<text top="218" left="381" width="9" height="11" font="9">++</text>
<text top="217" left="390" width="3" height="17" font="7"> </text>
<text top="234" left="298" width="52" height="17" font="7">Age &gt;8 y </text>
<text top="252" left="298" width="81" height="17" font="7">Asymptomatic </text>
<text top="200" left="420" width="129" height="17" font="7">Severe MS, AR, or MR </text>
<text top="217" left="420" width="70" height="17" font="7">LVEF &lt;35% </text>
<text top="234" left="420" width="123" height="17" font="7">Statin Rx or indication </text>
<text top="252" left="420" width="134" height="17" font="7">Cholesterol &lt;150 mg/dL </text>
<text top="269" left="420" width="75" height="17" font="7">Pacer or ICD </text>
<text top="286" left="420" width="129" height="17" font="7">Child bearing potential  </text>
<text top="303" left="420" width="76" height="17" font="7">Liver disease </text>
<text top="320" left="420" width="123" height="17" font="7">Alcohol or drug abuse </text>
<text top="338" left="420" width="40" height="17" font="7">history </text>
<text top="200" left="595" width="68" height="17" font="7">Atorvastatin </text>
<text top="217" left="595" width="48" height="17" font="7">80 mg/d </text>
<text top="234" left="595" width="43" height="17" font="7">(n=77)  </text>
<text top="200" left="690" width="77" height="17" font="7">63±23 mg/dL </text>
<text top="218" left="690" width="4" height="17" font="7">(</text>
<text top="217" left="694" width="9" height="18" font="10"></text>
<text top="218" left="703" width="32" height="17" font="7">53%) </text>
<text top="200" left="791" width="8" height="17" font="7">V</text>
<text top="205" left="799" width="16" height="11" font="15"><b>max</b></text>
<text top="200" left="815" width="130" height="17" font="6"><b> </b>0.2±0.21  0.08±0.11 </text>
<text top="200" left="980" width="67" height="17" font="7">CT valve Ca</text>
<text top="201" left="1048" width="9" height="11" font="9">++</text>
<text top="200" left="1057" width="3" height="17" font="7"> </text>
<text top="217" left="980" width="9" height="18" font="10"></text>
<text top="218" left="989" width="84" height="17" font="7">22.3±21.0 %/y </text>
<text top="200" left="1102" width="46" height="17" font="7">Primary </text>
<text top="217" left="1102" width="87" height="17" font="7">endpoints were </text>
<text top="234" left="1102" width="86" height="17" font="7">hemodynamics </text>
<text top="252" left="1102" width="72" height="17" font="7">and valve Ca</text>
<text top="253" left="1173" width="9" height="11" font="9">++</text>
<text top="252" left="1183" width="3" height="17" font="7"> </text>
<text top="200" left="1210" width="63" height="17" font="7">Study drug </text>
<text top="217" left="1210" width="120" height="17" font="7">discontinued in 5% of </text>
<text top="234" left="1210" width="105" height="17" font="7">placebo and 9% of </text>
<text top="252" left="1210" width="100" height="17" font="7">treatment groups. </text>
<text top="269" left="1210" width="106" height="17" font="7">Study not powered </text>
<text top="286" left="1210" width="118" height="17" font="7">for clinical outcomes. </text>
<text top="252" left="595" width="48" height="17" font="7">Placebo </text>
<text top="270" left="595" width="39" height="17" font="7">(n=78) </text>
<text top="252" left="690" width="83" height="17" font="7">130±30 mg/dL </text>
<text top="270" left="690" width="33" height="17" font="7">(0%)  </text>
<text top="252" left="791" width="53" height="17" font="7">0.2±0.21 </text>
<text top="270" left="791" width="43" height="17" font="7">(p=NS) </text>
<text top="252" left="886" width="60" height="17" font="7">0.08±0.11 </text>
<text top="270" left="886" width="43" height="17" font="7">(p=NS) </text>
<text top="252" left="980" width="67" height="17" font="7">CT valve Ca</text>
<text top="253" left="1048" width="9" height="11" font="9">++</text>
<text top="252" left="1057" width="3" height="17" font="7"> </text>
<text top="270" left="980" width="9" height="18" font="10"></text>
<text top="271" left="989" width="84" height="17" font="7">21.7±19.8 %/y </text>
<text top="356" left="42" width="45" height="17" font="7">RAAVE </text>
<text top="373" left="42" width="73" height="17" font="7">Moura, 2007 </text>
<text top="390" left="42" width="25" height="17" font="7">(37) </text>
<text top="407" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17276178">17276178</a></text>
<text top="407" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17276178"> </a></text>
<text top="356" left="150" width="67" height="17" font="7">Open-label, </text>
<text top="373" left="150" width="70" height="17" font="7">prospective. </text>
<text top="390" left="150" width="30" height="17" font="7">1.4 y </text>
<text top="356" left="251" width="24" height="17" font="7">121 </text>
<text top="356" left="298" width="89" height="17" font="7">AVA 1.0–1.5 cm</text>
<text top="357" left="387" width="7" height="11" font="9">2 </text>
<text top="373" left="298" width="81" height="17" font="7">Asymptomatic </text>
<text top="356" left="420" width="156" height="17" font="7">CAD, rheumatic mitral valve </text>
<text top="373" left="420" width="156" height="17" font="7">disease, BAV, liver disease, </text>
<text top="390" left="420" width="110" height="17" font="7">elevated creatinine, </text>
<text top="407" left="420" width="76" height="17" font="7">comorbidities </text>
<text top="356" left="595" width="74" height="17" font="7">Rosuvastatin </text>
<text top="373" left="595" width="48" height="17" font="7">20 mg/d </text>
<text top="390" left="595" width="39" height="17" font="7">(n=61) </text>
<text top="356" left="690" width="77" height="17" font="7">93±21 mg/dL </text>
<text top="374" left="690" width="4" height="17" font="7">(</text>
<text top="373" left="694" width="9" height="18" font="10"></text>
<text top="374" left="703" width="32" height="17" font="7">42%) </text>
<text top="356" left="791" width="8" height="17" font="7">V</text>
<text top="361" left="799" width="15" height="11" font="9">max</text>
<text top="356" left="814" width="3" height="17" font="7"> </text>
<text top="373" left="791" width="60" height="17" font="7">0.04±0.38 </text>
<text top="356" left="886" width="60" height="17" font="7">0.05±0.12 </text>
<text top="356" left="980" width="74" height="17" font="7">Inflammatory </text>
<text top="373" left="980" width="94" height="17" font="7">markers showed </text>
<text top="390" left="980" width="9" height="18" font="10"></text>
<text top="391" left="989" width="75" height="17" font="7">CRP in statin </text>
<text top="410" left="980" width="38" height="17" font="7">group; </text>
<text top="409" left="1019" width="9" height="18" font="10"></text>
<text top="410" left="1028" width="49" height="17" font="7">IL-6 and </text>
<text top="427" left="980" width="9" height="18" font="10"></text>
<text top="428" left="989" width="91" height="17" font="7">sCD4OL in both </text>
<text top="445" left="980" width="44" height="17" font="7">groups  </text>
<text top="356" left="1102" width="88" height="17" font="7">Endpoints were </text>
<text top="373" left="1102" width="63" height="17" font="7">cholesterol </text>
<text top="390" left="1102" width="78" height="17" font="7">levels and AS </text>
<text top="407" left="1102" width="46" height="17" font="7">severity </text>
<text top="356" left="1210" width="103" height="17" font="7">Pts with LDL &gt;130 </text>
<text top="373" left="1210" width="100" height="17" font="7">mg/dL at baseline </text>
<text top="390" left="1210" width="109" height="17" font="7">were treated, those </text>
<text top="407" left="1210" width="82" height="17" font="7">with LDL &lt;130 </text>
<text top="424" left="1210" width="96" height="17" font="7">received placebo </text>
<text top="408" left="595" width="52" height="17" font="7">No statin </text>
<text top="425" left="595" width="39" height="17" font="7">(n=60) </text>
<text top="408" left="690" width="87" height="17" font="7">118±29 mg/dL  </text>
<text top="425" left="690" width="33" height="17" font="7">(0%)  </text>
<text top="408" left="791" width="60" height="17" font="7">0.24±0.30 </text>
<text top="425" left="791" width="56" height="17" font="7">(p=0.007) </text>
<text top="408" left="886" width="53" height="17" font="7">0.1±0.09 </text>
<text top="425" left="886" width="56" height="17" font="7">(p=0.041) </text>
<text top="463" left="42" width="92" height="17" font="7">ASTRONOMER </text>
<text top="480" left="42" width="92" height="17" font="7">Chan, 2010 (38) </text>
<text top="498" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20048204">20048204</a></text>
<text top="498" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20048204"> </a></text>
<text top="463" left="150" width="76" height="17" font="7">Randomized, </text>
<text top="480" left="150" width="74" height="17" font="7">double-blind, </text>
<text top="498" left="150" width="48" height="17" font="7">Placebo </text>
<text top="515" left="150" width="57" height="17" font="7">controlled </text>
<text top="532" left="150" width="30" height="17" font="7">3.5 y </text>
<text top="463" left="251" width="24" height="17" font="7">269 </text>
<text top="463" left="298" width="8" height="17" font="7">V</text>
<text top="469" left="306" width="15" height="11" font="9">max</text>
<text top="463" left="322" width="71" height="17" font="7"> 2.5–4.0 m/s </text>
<text top="480" left="298" width="73" height="17" font="7">Age 18–82 y </text>
<text top="498" left="298" width="81" height="17" font="7">Asymptomatic </text>
<text top="515" left="298" width="65" height="17" font="7">Trileaflet or </text>
<text top="532" left="298" width="85" height="17" font="7">bicuspid (49%) </text>
<text top="549" left="298" width="39" height="17" font="7">valve   </text>
<text top="463" left="420" width="149" height="17" font="7">Clinical indication for statin </text>
<text top="480" left="420" width="146" height="17" font="7">including CAD, CVD, PVD </text>
<text top="463" left="595" width="74" height="17" font="7">Rosuvastatin </text>
<text top="480" left="595" width="48" height="17" font="7">40 mg/d </text>
<text top="498" left="595" width="49" height="17" font="7">(n=134)  </text>
<text top="463" left="690" width="71" height="17" font="7">1.45 mmol/L </text>
<text top="482" left="690" width="4" height="17" font="7">(</text>
<text top="481" left="694" width="9" height="18" font="10"></text>
<text top="482" left="703" width="32" height="17" font="7">54%) </text>
<text top="463" left="791" width="9" height="18" font="10"></text>
<text top="464" left="800" width="8" height="17" font="7">P</text>
<text top="470" left="808" width="20" height="11" font="9">mean</text>
<text top="464" left="829" width="3" height="17" font="7"> </text>
<text top="481" left="791" width="46" height="17" font="7">3.8±4.4 </text>
<text top="463" left="886" width="60" height="17" font="7">0.08±0.21 </text>
<text top="463" left="980" width="94" height="17" font="7">7 cardiac deaths </text>
<text top="480" left="980" width="46" height="17" font="7">55 AVR </text>
<text top="463" left="1102" width="89" height="17" font="7">No difference in </text>
<text top="480" left="1102" width="88" height="17" font="7">survival or AVR </text>
<text top="498" left="1102" width="94" height="17" font="7">between groups. </text>
<text top="463" left="1210" width="121" height="17" font="7">Primary endpoint was </text>
<text top="480" left="1210" width="91" height="17" font="7">AS progression. </text>
<text top="498" left="1210" width="102" height="17" font="7">Composite clinical </text>
<text top="515" left="1210" width="76" height="17" font="7">outcome was </text>
<text top="532" left="1210" width="118" height="17" font="7">secondary outcome.  </text>
<text top="516" left="595" width="48" height="17" font="7">Placebo </text>
<text top="533" left="595" width="46" height="17" font="7">(n=135) </text>
<text top="516" left="690" width="75" height="17" font="7">1.61 mmol/L  </text>
<text top="534" left="690" width="4" height="17" font="7">(</text>
<text top="533" left="694" width="9" height="18" font="10"></text>
<text top="534" left="703" width="36" height="17" font="7">1.8%) </text>
<text top="516" left="791" width="49" height="17" font="7">3.9 ±4.9 </text>
<text top="533" left="791" width="43" height="17" font="7">(p=NS) </text>
<text top="516" left="886" width="60" height="17" font="7">0.07±0.15 </text>
<text top="533" left="886" width="43" height="17" font="7">(p=NS) </text>
<text top="567" left="42" width="36" height="17" font="7">SEAS </text>
<text top="584" left="42" width="87" height="17" font="7">Rossebø, 2008 </text>
<text top="602" left="42" width="25" height="17" font="7">(26) </text>
<text top="619" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18765433">18765433</a></text>
<text top="619" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18765433"> </a></text>
<text top="636" left="42" width="3" height="17" font="7"> </text>
<text top="567" left="150" width="76" height="17" font="7">Randomized, </text>
<text top="584" left="150" width="74" height="17" font="7">double-blind, </text>
<text top="602" left="150" width="48" height="17" font="7">Placebo </text>
<text top="619" left="150" width="57" height="17" font="7">controlled </text>
<text top="636" left="150" width="30" height="17" font="7">5.4 y </text>
<text top="567" left="251" width="55" height="17" font="7">1,873  V</text>
<text top="573" left="306" width="15" height="11" font="9">max</text>
<text top="567" left="322" width="71" height="17" font="7"> 2.5–4.0 m/s </text>
<text top="584" left="298" width="73" height="17" font="7">Age 45–85 y </text>
<text top="602" left="298" width="84" height="17" font="7">Asymptomatic  </text>
<text top="567" left="420" width="120" height="17" font="7">CAD, PVD, CVD, DM </text>
<text top="584" left="420" width="149" height="17" font="7">Clinical indication for statin </text>
<text top="567" left="595" width="67" height="17" font="7">Simvastatin </text>
<text top="584" left="595" width="63" height="17" font="7">40 mg plus </text>
<text top="602" left="595" width="73" height="17" font="7">ezetimibe 10 </text>
<text top="619" left="595" width="77" height="17" font="7">mg/d (n=944) </text>
<text top="567" left="690" width="73" height="17" font="7">53±23 mg/dl </text>
<text top="586" left="690" width="4" height="17" font="7">(</text>
<text top="585" left="694" width="9" height="18" font="10"></text>
<text top="586" left="703" width="32" height="17" font="7">61%) </text>
<text top="567" left="791" width="8" height="17" font="7">V</text>
<text top="573" left="799" width="18" height="11" font="9">max </text>
<text top="584" left="791" width="60" height="17" font="7">0.15±0.01 </text>
<text top="567" left="886" width="60" height="17" font="7">0.03±0.01 </text>
<text top="567" left="980" width="83" height="17" font="7">333 composite </text>
<text top="584" left="980" width="85" height="17" font="7">outcome of CV </text>
<text top="602" left="980" width="102" height="17" font="7">death, AVR, CHF, </text>
<text top="619" left="980" width="97" height="17" font="7">and CAD events  </text>
<text top="567" left="1102" width="94" height="17" font="7">No difference for </text>
<text top="584" left="1102" width="65" height="17" font="7">aortic valve </text>
<text top="602" left="1102" width="81" height="17" font="7">related events </text>
<text top="619" left="1102" width="83" height="17" font="7">HR: 1.00; 95% </text>
<text top="636" left="1102" width="77" height="17" font="7">CI: 0.84–1.18 </text>
<text top="567" left="1210" width="106" height="17" font="7">Noncardiac deaths </text>
<text top="584" left="1210" width="109" height="17" font="7">occurred in 5.9% of </text>
<text top="602" left="1210" width="114" height="17" font="7">treatment group and </text>
<text top="619" left="1210" width="87" height="17" font="7">4.75 of placebo </text>
<text top="636" left="1210" width="84" height="17" font="7">group (p=0.26) </text>
<text top="637" left="595" width="48" height="17" font="7">Placebo </text>
<text top="654" left="595" width="46" height="17" font="7">(n=929) </text>
<text top="637" left="690" width="87" height="17" font="7">139±35 mg/dL  </text>
<text top="654" left="690" width="33" height="17" font="7">(0%)  </text>
<text top="637" left="791" width="60" height="17" font="7">0.16±0.01 </text>
<text top="654" left="791" width="43" height="17" font="7">(p=NS) </text>
<text top="637" left="886" width="60" height="17" font="7">0.03±0.01 </text>
<text top="654" left="886" width="43" height="17" font="7">(p=NS) </text>
<text top="637" left="980" width="83" height="17" font="7">335 composite </text>
<text top="654" left="980" width="54" height="17" font="7">outcome  </text>
<text top="671" left="980" width="43" height="17" font="7">(p=NS) </text>
<text top="689" left="34" width="1318" height="17" font="7">AR indicates aortic regurgitation; AS, aortic stenosis; AVA, aortic valve area; AVR, aortic valve replacement; BAV, bicuspid aortic valve; CA++, calcium; CAD, coronary artery disease; CHF, congestive heart failure; CI, 95% confidence interval; </text>
<text top="706" left="34" width="1278" height="17" font="7">CRP,C-reactive protein; CVD, cardiovascular disease; DM, diabetes mellitus; HR, hazard ratio; ICD, implantable cardioverter defibrillator; IL-6; interleukin-6; LDL, low density lipoprotein; LVEF, left ventricular ejection fraction; MR, mitral </text>
<text top="725" left="34" width="296" height="17" font="7">regurgitation; MS, mitral stenosis; NS, non-significant; </text>
<text top="724" left="330" width="9" height="18" font="10"></text>
<text top="725" left="339" width="8" height="17" font="7">P</text>
<text top="730" left="347" width="20" height="11" font="9">mean</text>
<text top="725" left="367" width="955" height="17" font="7">, mean transaortic systolic pressure gradient; PVD, peripheral vascular disease; pt(s), patient(s); Rx, prescription; sCD4OL soluble CD40 ligand; Vmax, maximum transvalvular </text>
<text top="742" left="34" width="81" height="17" font="7">aortic velocity. </text>
<text top="759" left="108" width="3" height="17" font="7"> </text>
<text top="759" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="725" width="12" height="17" font="0">9 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="1058" height="21" font="4"><b>Data Supplement 5. Clinical Outcomes in Asymptomatic Adults With Aortic Stenosis (stages B and C) of Known Hemodynamic Severity (Section 3.2.3) </b></text>
<text top="129" left="47" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="129" left="152" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="146" width="49" height="17" font="6"><b>Size (N) </b></text>
<text top="129" left="213" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="146" left="216" width="104" height="17" font="6"><b>Inclusion Criteria </b></text>
<text top="129" left="342" width="108" height="17" font="6"><b>Exclusion Criteria </b></text>
<text top="129" left="472" width="46" height="17" font="6"><b>Pt. Age </b></text>
<text top="146" left="485" width="19" height="17" font="6"><b>(y) </b></text>
<text top="129" left="548" width="14" height="17" font="6"><b>% </b></text>
<text top="146" left="540" width="31" height="17" font="6"><b>Male </b></text>
<text top="129" left="593" width="43" height="17" font="6"><b>Follow-</b></text>
<text top="146" left="591" width="50" height="17" font="6"><b>Up (mo) </b></text>
<text top="129" left="671" width="86" height="17" font="6"><b>AS Severity at </b></text>
<text top="146" left="696" width="35" height="17" font="6"><b>Entry </b></text>
<text top="129" left="790" width="118" height="17" font="6"><b>Event-Free Survival </b></text>
<text top="129" left="961" width="92" height="17" font="6"><b>Cardiac Events </b></text>
<text top="129" left="1114" width="198" height="17" font="6"><b>Multivariate Predictors of Clinical </b></text>
<text top="146" left="1185" width="57" height="17" font="6"><b>Outcome </b></text>
<text top="183" left="42" width="64" height="17" font="7">Kelly, 1988 </text>
<text top="200" left="42" width="25" height="17" font="7">(39) </text>
<text top="218" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3337000">3337000</a></text>
<text top="218" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3337000"> </a></text>
<text top="183" left="143" width="17" height="17" font="7">51 </text>
<text top="183" left="211" width="8" height="17" font="7">V</text>
<text top="189" left="219" width="15" height="11" font="9">max</text>
<text top="183" left="234" width="55" height="17" font="7"> ≥3.5 m/s </text>
<text top="200" left="211" width="84" height="17" font="7">Asymptomatic  </text>
<text top="183" left="339" width="167" height="17" font="7">Other valve disease   63±19 </text>
<text top="183" left="535" width="28" height="17" font="7">75% </text>
<text top="183" left="589" width="32" height="17" font="7">17±0 </text>
<text top="183" left="656" width="9" height="18" font="10"></text>
<text top="184" left="665" width="94" height="17" font="7">P 68±19 mm Hg </text>
<text top="183" left="784" width="62" height="17" font="7">60% at 2 y </text>
<text top="183" left="926" width="127" height="17" font="7">21 AS symptom onset  </text>
<text top="200" left="926" width="116" height="17" font="7">8 deaths (2 cardiac)  </text>
<text top="183" left="1102" width="24" height="17" font="7">N/A </text>
<text top="236" left="42" width="80" height="17" font="7">Pellikka, 1990 </text>
<text top="253" left="42" width="25" height="17" font="7">(40) </text>
<text top="270" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2312954">2312954</a></text>
<text top="270" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2312954"> </a></text>
<text top="287" left="42" width="3" height="17" font="7"> </text>
<text top="236" left="143" width="24" height="17" font="7">113 </text>
<text top="236" left="211" width="8" height="17" font="7">V</text>
<text top="241" left="219" width="15" height="11" font="9">max</text>
<text top="236" left="234" width="55" height="17" font="7"> ≥4.0 m/s </text>
<text top="254" left="211" width="22" height="17" font="7">Age</text>
<text top="253" left="232" width="8" height="18" font="10"></text>
<text top="254" left="241" width="27" height="17" font="7">40 y </text>
<text top="271" left="211" width="84" height="17" font="7">Asymptomatic  </text>
<text top="236" left="339" width="112" height="17" font="7">Other valve disease </text>
<text top="253" left="339" width="29" height="17" font="7">CAD </text>
<text top="270" left="339" width="61" height="17" font="7">Prior valve </text>
<text top="287" left="339" width="59" height="17" font="7">procedure </text>
<text top="304" left="339" width="65" height="17" font="7">Early aortic </text>
<text top="322" left="339" width="67" height="17" font="7">intervention </text>
<text top="236" left="467" width="42" height="17" font="7">70 (40–</text>
<text top="253" left="467" width="21" height="17" font="7">94) </text>
<text top="236" left="535" width="28" height="17" font="7">67% </text>
<text top="236" left="589" width="17" height="17" font="7">20 </text>
<text top="236" left="656" width="8" height="17" font="7">V</text>
<text top="241" left="664" width="15" height="11" font="9">max</text>
<text top="236" left="679" width="79" height="17" font="7"> 4.3 (4–6) m/s </text>
<text top="236" left="784" width="62" height="17" font="7">62% at 2 y </text>
<text top="236" left="926" width="143" height="17" font="7">37 AS symptoms (20 with </text>
<text top="253" left="926" width="36" height="17" font="7">AVR)  </text>
<text top="270" left="926" width="119" height="17" font="7">14 deaths (6 cardiac) </text>
<text top="237" left="1102" width="8" height="17" font="7">V</text>
<text top="242" left="1110" width="15" height="11" font="9">max</text>
<text top="237" left="1125" width="3" height="17" font="7"> </text>
<text top="236" left="1128" width="8" height="18" font="10"></text>
<text top="237" left="1137" width="162" height="17" font="7">4.5 m/s; RR: 4.9 (1.64–14.6)  </text>
<text top="254" left="1102" width="195" height="17" font="7">LVEF &lt;50%; RR: 2.93 (0.84–10.2)  </text>
<text top="340" left="42" width="86" height="17" font="7">Kennedy, 1991 </text>
<text top="357" left="42" width="25" height="17" font="7">(41) </text>
<text top="374" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1991886">1991886</a></text>
<text top="374" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1991886"> </a></text>
<text top="340" left="143" width="17" height="17" font="7">66 </text>
<text top="340" left="211" width="89" height="17" font="7">AVA 0.7–1.2 cm</text>
<text top="341" left="299" width="4" height="11" font="9">2</text>
<text top="340" left="304" width="17" height="17" font="7"> at </text>
<text top="357" left="211" width="30" height="17" font="7">cath  </text>
<text top="340" left="339" width="116" height="17" font="7">Other valve disease  </text>
<text top="357" left="339" width="83" height="17" font="7">Previous valve </text>
<text top="374" left="339" width="48" height="17" font="7">surgery  </text>
<text top="340" left="467" width="39" height="17" font="7">67±10 </text>
<text top="340" left="535" width="28" height="17" font="7">77% </text>
<text top="340" left="589" width="17" height="17" font="7">35 </text>
<text top="340" left="656" width="100" height="17" font="7">AVA 0.92±0.13cm</text>
<text top="341" left="757" width="4" height="11" font="9">2</text>
<text top="340" left="761" width="3" height="17" font="7"> </text>
<text top="340" left="784" width="62" height="17" font="7">59% at 4 y </text>
<text top="340" left="926" width="148" height="17" font="7">21 AVR (13 for symptoms) </text>
<text top="357" left="926" width="115" height="17" font="7">14 deaths due to AS </text>
<text top="340" left="1102" width="195" height="17" font="7">LVEF &lt;50%; RR: 1.94 (0.86–4.41). </text>
<text top="357" left="1102" width="209" height="17" font="7">LV-end diastolic pressure &gt;18 mm Hg </text>
<text top="374" left="1102" width="122" height="17" font="7">RR: 2.71 (1.23–5.97). </text>
<text top="391" left="1102" width="105" height="17" font="7">AVA index &lt;0.5 cm</text>
<text top="392" left="1207" width="4" height="11" font="9">2</text>
<text top="391" left="1211" width="90" height="17" font="7"> RR: 1.93 (0.89–</text>
<text top="408" left="1102" width="35" height="17" font="7">4.23). </text>
<text top="426" left="42" width="61" height="17" font="7">Otto, 1997 </text>
<text top="444" left="42" width="25" height="17" font="7">(21) </text>
<text top="461" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9142003">9142003</a></text>
<text top="461" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9142003"> </a></text>
<text top="426" left="143" width="24" height="17" font="7">123 </text>
<text top="426" left="211" width="8" height="17" font="7">V</text>
<text top="432" left="219" width="15" height="11" font="9">max</text>
<text top="426" left="234" width="55" height="17" font="7"> &gt;2.6 m/s </text>
<text top="444" left="211" width="81" height="17" font="7">Asymptomatic </text>
<text top="426" left="339" width="96" height="17" font="7">Severe comorbid </text>
<text top="444" left="339" width="46" height="17" font="7">disease </text>
<text top="426" left="467" width="39" height="17" font="7">63±16 </text>
<text top="426" left="535" width="28" height="17" font="7">70% </text>
<text top="426" left="589" width="17" height="17" font="7">30 </text>
<text top="426" left="656" width="8" height="17" font="7">V</text>
<text top="432" left="664" width="15" height="11" font="9">max</text>
<text top="426" left="679" width="44" height="17" font="7"> &lt;3 m/s </text>
<text top="426" left="784" width="62" height="17" font="7">84% at 2 y </text>
<text top="426" left="926" width="123" height="17" font="7">48 AVR for symptoms </text>
<text top="444" left="926" width="51" height="17" font="7">8 deaths </text>
<text top="426" left="1102" width="8" height="17" font="7">V</text>
<text top="432" left="1110" width="15" height="11" font="9">max</text>
<text top="426" left="1125" width="3" height="17" font="7"> </text>
<text top="444" left="1102" width="130" height="17" font="7">Functional status score </text>
<text top="461" left="1102" width="108" height="17" font="7">Rate of change in V</text>
<text top="466" left="1210" width="15" height="11" font="9">max</text>
<text top="461" left="1225" width="7" height="17" font="7">  </text>
<text top="444" left="656" width="8" height="17" font="7">V</text>
<text top="450" left="664" width="15" height="11" font="9">max</text>
<text top="444" left="679" width="51" height="17" font="7"> 3–4 m/s </text>
<text top="444" left="784" width="62" height="17" font="7">66% at 2 y </text>
<text top="462" left="656" width="8" height="17" font="7">V</text>
<text top="468" left="664" width="15" height="11" font="9">max</text>
<text top="462" left="679" width="44" height="17" font="7"> &gt;4 m/s </text>
<text top="462" left="784" width="65" height="17" font="7">21% at 2 y  </text>
<text top="480" left="42" width="62" height="17" font="7">Rosenhek, </text>
<text top="498" left="42" width="56" height="17" font="7">2000 (24) </text>
<text top="515" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10965007">10965007</a></text>
<text top="515" left="96" width="7" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10965007">  </a></text>
<text top="480" left="143" width="24" height="17" font="7">128 </text>
<text top="480" left="211" width="8" height="17" font="7">V</text>
<text top="486" left="219" width="15" height="11" font="9">max</text>
<text top="480" left="234" width="55" height="17" font="7"> ≥4.0 m/s </text>
<text top="498" left="211" width="81" height="17" font="7">Asymptomatic </text>
<text top="480" left="339" width="167" height="17" font="7">Other valve disease   60±18 </text>
<text top="480" left="535" width="28" height="17" font="7">54% </text>
<text top="480" left="589" width="39" height="17" font="7">22±18 </text>
<text top="480" left="656" width="8" height="17" font="7">V</text>
<text top="486" left="664" width="15" height="11" font="9">max</text>
<text top="480" left="679" width="73" height="17" font="7"> 5.0±0.7 m/s </text>
<text top="480" left="784" width="62" height="17" font="7">67% at 1 y </text>
<text top="480" left="926" width="123" height="17" font="7">59 AVR for symptoms </text>
<text top="498" left="926" width="51" height="17" font="7">8 deaths </text>
<text top="480" left="1102" width="196" height="17" font="7">Extent of valve calcification RR: 4.6 </text>
<text top="498" left="1102" width="63" height="17" font="7">(1.6–14.0). </text>
<text top="498" left="784" width="62" height="17" font="7">56% at 2 y </text>
<text top="516" left="784" width="62" height="17" font="7">33% at 4 y </text>
<text top="534" left="42" width="62" height="17" font="7">Rosenhek, </text>
<text top="551" left="42" width="56" height="17" font="7">2004 (25) </text>
<text top="569" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14972419">14972419</a></text>
<text top="569" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14972419"> </a></text>
<text top="534" left="143" width="24" height="17" font="7">176 </text>
<text top="534" left="211" width="8" height="17" font="7">V</text>
<text top="540" left="219" width="15" height="11" font="9">max</text>
<text top="534" left="234" width="71" height="17" font="7"> 2.5–3.9 m/s </text>
<text top="551" left="211" width="69" height="17" font="7">LVEF &gt;50% </text>
<text top="569" left="211" width="102" height="17" font="7">No AS symptoms  </text>
<text top="534" left="339" width="167" height="17" font="7">Other valve disease   58±19 </text>
<text top="534" left="535" width="28" height="17" font="7">59% </text>
<text top="534" left="589" width="39" height="17" font="7">48±19 </text>
<text top="534" left="656" width="8" height="17" font="7">V</text>
<text top="540" left="664" width="15" height="11" font="9">max</text>
<text top="534" left="679" width="73" height="17" font="7"> 3.1±0.4 m/s </text>
<text top="534" left="784" width="62" height="17" font="7">95% at 1 y </text>
<text top="534" left="926" width="123" height="17" font="7">33 AVR for symptoms </text>
<text top="551" left="926" width="57" height="17" font="7">34 deaths </text>
<text top="534" left="1102" width="215" height="17" font="7">Severe valve calcification RR: 2.0 (1.3–</text>
<text top="551" left="1102" width="28" height="17" font="7">3.3). </text>
<text top="570" left="1102" width="8" height="17" font="7">V</text>
<text top="575" left="1110" width="15" height="11" font="9">max</text>
<text top="570" left="1125" width="3" height="17" font="7"> </text>
<text top="569" left="1128" width="8" height="18" font="10"></text>
<text top="570" left="1137" width="142" height="17" font="7">3 m/s RR: 1.6 (1.04–2.8). </text>
<text top="587" left="1102" width="130" height="17" font="7">CAD RR: 1.7 (1.2–2.7). </text>
<text top="552" left="784" width="62" height="17" font="7">75% at 2 y </text>
<text top="570" left="784" width="62" height="17" font="7">60% at 5 y </text>
<text top="605" left="42" width="80" height="17" font="7">Pellikka, 2005 </text>
<text top="622" left="42" width="25" height="17" font="7">(42) </text>
<text top="639" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15956131">15956131</a></text>
<text top="639" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15956131"> </a></text>
<text top="605" left="143" width="24" height="17" font="7">622 </text>
<text top="605" left="211" width="8" height="17" font="7">V</text>
<text top="611" left="219" width="15" height="11" font="9">max</text>
<text top="605" left="234" width="55" height="17" font="7"> ≥4.0 m/s </text>
<text top="622" left="211" width="98" height="17" font="7">No AS symptoms </text>
<text top="605" left="339" width="112" height="17" font="7">Other valve disease </text>
<text top="622" left="339" width="29" height="17" font="7">CAD </text>
<text top="605" left="467" width="39" height="17" font="7">72±11 </text>
<text top="605" left="535" width="28" height="17" font="7">62% </text>
<text top="605" left="589" width="39" height="17" font="7">65±48 </text>
<text top="605" left="656" width="8" height="17" font="7">V</text>
<text top="611" left="664" width="15" height="11" font="9">max</text>
<text top="605" left="679" width="76" height="17" font="7"> 4.4 ±0.4 m/s </text>
<text top="605" left="784" width="62" height="17" font="7">82% at 1 y </text>
<text top="605" left="926" width="149" height="17" font="7">297 AS symptoms (AVR in </text>
<text top="622" left="926" width="75" height="17" font="7">207 of these) </text>
<text top="639" left="926" width="150" height="17" font="7">103 deaths without AVR or </text>
<text top="657" left="926" width="83" height="17" font="7">AS symptoms  </text>
<text top="605" left="1102" width="134" height="17" font="7">AVA HR: 0.33 for a 1 cm</text>
<text top="606" left="1236" width="7" height="11" font="9">2 </text>
<text top="605" left="1243" width="53" height="17" font="7">increase  </text>
<text top="622" left="1102" width="114" height="17" font="7">(95%CI: 0.15–0.71). </text>
<text top="639" left="1102" width="84" height="17" font="7">LVH by ECG    </text>
<text top="657" left="1102" width="169" height="17" font="7">HR: 1.39 (95% CI: 1.02–1.89). </text>
<text top="623" left="784" width="62" height="17" font="7">67% at 2 y </text>
<text top="641" left="784" width="62" height="17" font="7">33% at 5 y </text>
<text top="675" left="42" width="86" height="17" font="7">Rossebo, 2008 </text>
<text top="692" left="42" width="25" height="17" font="7">(26) </text>
<text top="709" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18765433">18765433</a></text>
<text top="709" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18765433"> </a></text>
<text top="675" left="143" width="34" height="17" font="7">1,873 </text>
<text top="675" left="211" width="8" height="17" font="7">V</text>
<text top="680" left="219" width="15" height="11" font="9">max</text>
<text top="675" left="234" width="81" height="17" font="7"> 2.5 m/s to 4.0 </text>
<text top="692" left="211" width="23" height="17" font="7">m/s </text>
<text top="675" left="339" width="115" height="17" font="7">CAD, CHF, diabetes </text>
<text top="692" left="339" width="113" height="17" font="7">mellitus, CVA, PVD, </text>
<text top="709" left="339" width="87" height="17" font="7">and other valve </text>
<text top="726" left="339" width="46" height="17" font="7">disease </text>
<text top="675" left="467" width="32" height="17" font="7">68±9 </text>
<text top="675" left="535" width="28" height="17" font="7">59% </text>
<text top="675" left="589" width="17" height="17" font="7">52 </text>
<text top="692" left="589" width="52" height="17" font="7">(median) </text>
<text top="675" left="656" width="8" height="17" font="7">V</text>
<text top="680" left="664" width="15" height="11" font="9">max</text>
<text top="675" left="679" width="56" height="17" font="7"> 3.1±0.55 </text>
<text top="675" left="784" width="62" height="17" font="7">65% at 5 y </text>
<text top="675" left="926" width="154" height="17" font="7">668 (36%) Major CV events </text>
<text top="692" left="926" width="157" height="17" font="7">(death, AVR, CHF, coronary </text>
<text top="709" left="926" width="163" height="17" font="7">events, and ischemic stroke)  </text>
<text top="675" left="1102" width="215" height="17" font="7">No effect of statin therapy on major CV </text>
<text top="692" left="1102" width="43" height="17" font="7">events. </text>
<text top="744" left="42" width="62" height="17" font="7">Lancellotti, </text>
<text top="761" left="42" width="56" height="17" font="7">2010 (43) </text>
<text top="779" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20483891">20483891</a></text>
<text top="779" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20483891"> </a></text>
<text top="744" left="143" width="24" height="17" font="7">163 </text>
<text top="744" left="211" width="76" height="17" font="7">AVAi ≤0.6 cm</text>
<text top="745" left="286" width="4" height="11" font="9">2</text>
<text top="744" left="291" width="14" height="17" font="7">/m</text>
<text top="745" left="305" width="7" height="11" font="9">2 </text>
<text top="761" left="211" width="98" height="17" font="7">No AS symptoms </text>
<text top="779" left="211" width="70" height="17" font="7">LVEF ≥55% </text>
<text top="744" left="339" width="96" height="17" font="7">Nonsinus rhythm </text>
<text top="761" left="339" width="116" height="17" font="7">Other valve disease  </text>
<text top="744" left="467" width="39" height="17" font="7">70±10 </text>
<text top="744" left="535" width="28" height="17" font="7">65% </text>
<text top="744" left="589" width="39" height="17" font="7">20±19 </text>
<text top="744" left="656" width="45" height="17" font="7">≤0.6 cm</text>
<text top="745" left="701" width="4" height="11" font="9">2</text>
<text top="744" left="706" width="14" height="17" font="7">/m</text>
<text top="745" left="720" width="4" height="11" font="9">2</text>
<text top="744" left="724" width="3" height="17" font="7"> </text>
<text top="744" left="784" width="62" height="17" font="7">50% at 2 y </text>
<text top="744" left="926" width="150" height="17" font="7">11 symptoms, but no AVR  </text>
<text top="761" left="926" width="46" height="17" font="7">57 AVR </text>
<text top="779" left="926" width="51" height="17" font="7">6 deaths </text>
<text top="744" left="1102" width="8" height="17" font="7">V</text>
<text top="750" left="1110" width="15" height="11" font="9">max</text>
<text top="744" left="1125" width="143" height="17" font="7"> ≥4.4 m/s, LV longitudinal </text>
<text top="761" left="1102" width="202" height="17" font="7">deformation ≤15.9%, valvulo-arterial </text>
<text top="779" left="1102" width="145" height="17" font="7">impedance ≥4.9 mm Hg/m</text>
<text top="780" left="1247" width="4" height="11" font="9">2</text>
<text top="779" left="1252" width="53" height="17" font="7">, LA area </text>
<text top="762" left="784" width="62" height="17" font="7">44% at 4 y </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">10 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="47" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="108" left="152" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="146" width="49" height="17" font="6"><b>Size (N) </b></text>
<text top="108" left="213" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="126" left="216" width="104" height="17" font="6"><b>Inclusion Criteria </b></text>
<text top="108" left="342" width="108" height="17" font="6"><b>Exclusion Criteria </b></text>
<text top="108" left="472" width="46" height="17" font="6"><b>Pt. Age </b></text>
<text top="126" left="485" width="19" height="17" font="6"><b>(y) </b></text>
<text top="108" left="548" width="14" height="17" font="6"><b>% </b></text>
<text top="126" left="540" width="31" height="17" font="6"><b>Male </b></text>
<text top="108" left="593" width="43" height="17" font="6"><b>Follow-</b></text>
<text top="126" left="591" width="50" height="17" font="6"><b>Up (mo) </b></text>
<text top="108" left="671" width="86" height="17" font="6"><b>AS Severity at </b></text>
<text top="126" left="696" width="35" height="17" font="6"><b>Entry </b></text>
<text top="108" left="790" width="118" height="17" font="6"><b>Event-Free Survival </b></text>
<text top="108" left="961" width="92" height="17" font="6"><b>Cardiac Events </b></text>
<text top="108" left="1114" width="198" height="17" font="6"><b>Multivariate Predictors of Clinical </b></text>
<text top="126" left="1185" width="57" height="17" font="6"><b>Outcome </b></text>
<text top="162" left="1102" width="52" height="17" font="7">≥12.2 cm</text>
<text top="164" left="1154" width="4" height="11" font="9">2</text>
<text top="162" left="1158" width="14" height="17" font="7">/m</text>
<text top="164" left="1172" width="4" height="11" font="9">2</text>
<text top="162" left="1176" width="3" height="17" font="7"> </text>
<text top="180" left="42" width="66" height="17" font="7">Kang, 2010 </text>
<text top="198" left="42" width="25" height="17" font="7">(44) </text>
<text top="215" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20308614">20308614</a></text>
<text top="215" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20308614"> </a></text>
<text top="180" left="143" width="17" height="17" font="7">95 </text>
<text top="180" left="211" width="72" height="17" font="7">AVA 0.75 cm</text>
<text top="182" left="282" width="4" height="11" font="9">2</text>
<text top="180" left="287" width="33" height="17" font="7"> plus  </text>
<text top="198" left="211" width="8" height="17" font="7">V</text>
<text top="203" left="219" width="15" height="11" font="9">max</text>
<text top="198" left="234" width="70" height="17" font="7"> ≥4.5 m/s or </text>
<text top="215" left="211" width="9" height="18" font="10"></text>
<text top="216" left="220" width="8" height="17" font="7">P</text>
<text top="222" left="228" width="20" height="11" font="9">mean</text>
<text top="216" left="248" width="72" height="17" font="7"> ≥50 mm Hg </text>
<text top="233" left="211" width="102" height="17" font="7">No AS symptoms  </text>
<text top="180" left="339" width="69" height="17" font="7">LVEF &lt;50% </text>
<text top="198" left="339" width="112" height="17" font="7">Other valve disease </text>
<text top="215" left="339" width="59" height="17" font="7">Age &gt;85 y </text>
<text top="232" left="339" width="66" height="17" font="7">Malignancy </text>
<text top="249" left="339" width="70" height="17" font="7">Known CAD </text>
<text top="180" left="467" width="39" height="17" font="7">63±12 </text>
<text top="180" left="535" width="28" height="17" font="7">46% </text>
<text top="180" left="589" width="21" height="17" font="7">50  </text>
<text top="180" left="656" width="8" height="17" font="7">V</text>
<text top="186" left="664" width="15" height="11" font="9">max</text>
<text top="180" left="679" width="49" height="17" font="7"> 4.9±0.4 </text>
<text top="180" left="784" width="77" height="17" font="7">71±5% at 2 y </text>
<text top="180" left="926" width="101" height="17" font="7">18 cardiac deaths </text>
<text top="198" left="926" width="121" height="17" font="7">10 noncardiac deaths </text>
<text top="215" left="926" width="123" height="17" font="7">46 AVR for symptoms </text>
<text top="180" left="1102" width="8" height="17" font="7">V</text>
<text top="186" left="1110" width="15" height="11" font="9">max</text>
<text top="180" left="1125" width="193" height="17" font="7"> ≥5 m/s age, male sex, EuroScore, </text>
<text top="198" left="1102" width="158" height="17" font="7">degree of valve calcification. </text>
<text top="198" left="784" width="77" height="17" font="7">47±5% at 4 y </text>
<text top="216" left="784" width="77" height="17" font="7">28±6% at 6 y </text>
<text top="267" left="42" width="79" height="17" font="7">Stewart, 2010 </text>
<text top="284" left="42" width="25" height="17" font="7">(45) </text>
<text top="302" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20513730">20513730</a></text>
<text top="302" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20513730"> </a></text>
<text top="267" left="143" width="24" height="17" font="7">183 </text>
<text top="267" left="211" width="8" height="17" font="7">V</text>
<text top="273" left="219" width="15" height="11" font="9">max</text>
<text top="267" left="234" width="44" height="17" font="7"> &gt;3 m/s </text>
<text top="284" left="211" width="69" height="17" font="7">LVEF &gt;50% </text>
<text top="302" left="211" width="102" height="17" font="7">No AS symptoms  </text>
<text top="267" left="339" width="66" height="17" font="7">Other valve </text>
<text top="284" left="339" width="53" height="17" font="7">disease,  </text>
<text top="302" left="339" width="102" height="17" font="7">ACS in previous 6 </text>
<text top="319" left="339" width="27" height="17" font="7">mo,  </text>
<text top="336" left="339" width="103" height="17" font="7">LVOT obstruction, </text>
<text top="353" left="339" width="66" height="17" font="7">Respiratory </text>
<text top="371" left="339" width="49" height="17" font="7">disease, </text>
<text top="388" left="339" width="101" height="17" font="7">Renal dysfunction </text>
<text top="267" left="467" width="17" height="17" font="7">70 </text>
<text top="267" left="535" width="28" height="17" font="7">65% </text>
<text top="267" left="589" width="17" height="17" font="7">31 </text>
<text top="284" left="589" width="52" height="17" font="7">(median) </text>
<text top="267" left="656" width="88" height="17" font="7">AVA 0.81 (IQR: </text>
<text top="284" left="656" width="79" height="17" font="7">0.62–1.01) cm</text>
<text top="286" left="735" width="7" height="11" font="9">2 </text>
<text top="302" left="656" width="8" height="17" font="7">V</text>
<text top="307" left="664" width="15" height="11" font="9">max</text>
<text top="302" left="679" width="81" height="17" font="7"> 3.8 (IQR: 3.3–</text>
<text top="319" left="656" width="51" height="17" font="7">4.4) m/s  </text>
<text top="267" left="784" width="128" height="17" font="7">Probability of symptom </text>
<text top="284" left="784" width="103" height="17" font="7">free survival at 3 y </text>
<text top="302" left="784" width="55" height="17" font="7">(95% CI)  </text>
<text top="319" left="784" width="8" height="17" font="7">V</text>
<text top="325" left="792" width="15" height="11" font="9">max</text>
<text top="319" left="808" width="58" height="17" font="7"> &lt;3.5 m/s  </text>
<text top="336" left="784" width="118" height="17" font="7">      0.72 (0.61–0.84). </text>
<text top="353" left="784" width="8" height="17" font="7">V</text>
<text top="359" left="792" width="15" height="11" font="9">max</text>
<text top="353" left="808" width="71" height="17" font="7"> 3.5–4.0 m/s </text>
<text top="371" left="784" width="114" height="17" font="7">     0.46 (0.30   0.62). </text>
<text top="388" left="784" width="8" height="17" font="7">V</text>
<text top="393" left="792" width="15" height="11" font="9">max</text>
<text top="388" left="808" width="58" height="17" font="7"> &gt;4.0 m/s  </text>
<text top="405" left="784" width="118" height="17" font="7">     0.32 (0.20–0.44).  </text>
<text top="267" left="926" width="103" height="17" font="7">103 AS symptoms </text>
<text top="284" left="926" width="92" height="17" font="7">3 sudden death  </text>
<text top="267" left="1102" width="8" height="17" font="7">V</text>
<text top="273" left="1110" width="15" height="11" font="9">max</text>
<text top="267" left="1125" width="200" height="17" font="7"> HR: 1.43 for each 0.5 m/s increase  </text>
<text top="284" left="1102" width="117" height="17" font="7">(95% CI: 1.25–1.64). </text>
<text top="302" left="1102" width="169" height="17" font="7">AVA HR: 1.23 for each -0.1 cm</text>
<text top="303" left="1270" width="4" height="11" font="9">2</text>
<text top="302" left="1275" width="7" height="17" font="7">  </text>
<text top="319" left="1102" width="117" height="17" font="7">(95% CI: 1.12–1.35). </text>
<text top="423" left="42" width="62" height="17" font="7">Rosenhek, </text>
<text top="440" left="42" width="56" height="17" font="7">2010 (46) </text>
<text top="457" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20026771">20026771</a></text>
<text top="457" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20026771"> </a></text>
<text top="423" left="143" width="24" height="17" font="7">116 </text>
<text top="423" left="211" width="8" height="17" font="7">V</text>
<text top="429" left="219" width="15" height="11" font="9">max</text>
<text top="423" left="234" width="55" height="17" font="7"> ≥5.0 m/s </text>
<text top="440" left="211" width="98" height="17" font="7">No AS symptoms </text>
<text top="423" left="339" width="167" height="17" font="7">Other valve disease   67±15 </text>
<text top="423" left="535" width="28" height="17" font="7">49% </text>
<text top="423" left="589" width="17" height="17" font="7">41 </text>
<text top="440" left="589" width="52" height="17" font="7">(median) </text>
<text top="423" left="656" width="8" height="17" font="7">V</text>
<text top="429" left="664" width="15" height="11" font="9">max</text>
<text top="423" left="679" width="71" height="17" font="7"> 5.0–5.5 m/s </text>
<text top="423" left="784" width="62" height="17" font="7">43% at 2 y </text>
<text top="423" left="926" width="46" height="17" font="7">90 AVR </text>
<text top="440" left="926" width="94" height="17" font="7">6 cardiac deaths </text>
<text top="423" left="1102" width="8" height="17" font="7">V</text>
<text top="429" left="1110" width="19" height="11" font="9">max, </text>
<text top="423" left="1129" width="174" height="17" font="7">but not AVA predicted outcome </text>
<text top="441" left="656" width="8" height="17" font="7">V</text>
<text top="447" left="664" width="15" height="11" font="9">max</text>
<text top="441" left="679" width="55" height="17" font="7"> ≥5.5 m/s </text>
<text top="441" left="784" width="62" height="17" font="7">25% at 2 y </text>
<text top="475" left="42" width="75" height="17" font="7">Jander, 2011 </text>
<text top="493" left="42" width="25" height="17" font="7">(47) </text>
<text top="512" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21321152">21321152</a></text>
<text top="512" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21321152"> </a></text>
<text top="475" left="143" width="24" height="17" font="7">435 </text>
<text top="475" left="211" width="74" height="17" font="7">Low gradient </text>
<text top="493" left="211" width="72" height="17" font="7">“severe” AS: </text>
<text top="510" left="211" width="62" height="17" font="7">AVA &lt;1 cm</text>
<text top="511" left="272" width="4" height="11" font="9">2</text>
<text top="510" left="277" width="29" height="17" font="7"> with </text>
<text top="527" left="211" width="9" height="18" font="10"></text>
<text top="528" left="220" width="8" height="17" font="7">P</text>
<text top="534" left="228" width="20" height="11" font="9">mean</text>
<text top="528" left="248" width="72" height="17" font="7"> ≤40 mm Hg </text>
<text top="475" left="339" width="65" height="17" font="7">CAD, CHF, </text>
<text top="493" left="339" width="85" height="17" font="7">diabetes, CVA, </text>
<text top="510" left="339" width="87" height="17" font="7">PVD, and other </text>
<text top="527" left="339" width="78" height="17" font="7">valve disease </text>
<text top="544" left="339" width="104" height="17" font="7">(SEAS substudy)   </text>
<text top="475" left="467" width="32" height="17" font="7">70±9 </text>
<text top="475" left="535" width="28" height="17" font="7">45% </text>
<text top="475" left="589" width="39" height="17" font="7">46±14 </text>
<text top="475" left="656" width="8" height="17" font="7">V</text>
<text top="481" left="664" width="15" height="11" font="9">max</text>
<text top="475" left="679" width="73" height="17" font="7"> 3.3±0.5 m/s </text>
<text top="493" left="656" width="9" height="18" font="10"></text>
<text top="494" left="665" width="8" height="17" font="7">P</text>
<text top="500" left="673" width="20" height="11" font="9">mean</text>
<text top="494" left="694" width="60" height="17" font="7"> 26±7 mm </text>
<text top="511" left="656" width="22" height="17" font="7">Hg  </text>
<text top="528" left="656" width="104" height="17" font="7">AVA 0.82±0.13 cm</text>
<text top="529" left="760" width="4" height="11" font="9">2</text>
<text top="528" left="765" width="3" height="17" font="7"> </text>
<text top="475" left="784" width="123" height="17" font="7">No difference in event </text>
<text top="493" left="784" width="129" height="17" font="7">rates between groups   </text>
<text top="475" left="926" width="53" height="17" font="7">183 AVR </text>
<text top="493" left="926" width="37" height="17" font="7">17 HF </text>
<text top="510" left="926" width="75" height="17" font="7">34 CV death  </text>
<text top="475" left="1102" width="219" height="17" font="7">Low gradient “severe” AS defined as an </text>
<text top="494" left="1102" width="62" height="17" font="7">AVA &lt;1 cm</text>
<text top="495" left="1163" width="4" height="11" font="9">2</text>
<text top="494" left="1168" width="29" height="17" font="7"> with </text>
<text top="493" left="1197" width="9" height="18" font="10"></text>
<text top="494" left="1206" width="8" height="17" font="7">P</text>
<text top="500" left="1214" width="20" height="11" font="9">mean</text>
<text top="494" left="1234" width="72" height="17" font="7"> ≤40 mm Hg </text>
<text top="511" left="1102" width="221" height="17" font="7">was <b>NOT</b> a predictor of clinical outcome </text>
<text top="546" left="143" width="24" height="17" font="7">184 </text>
<text top="546" left="211" width="79" height="17" font="7">Moderate AS: </text>
<text top="563" left="211" width="92" height="17" font="7">AVA 1–1.5 cm2, </text>
<text top="581" left="211" width="9" height="18" font="10"></text>
<text top="582" left="220" width="8" height="17" font="7">P</text>
<text top="588" left="228" width="20" height="11" font="9">mean</text>
<text top="582" left="248" width="44" height="17" font="7"> 25–40  </text>
<text top="599" left="211" width="40" height="17" font="7">mmHg </text>
<text top="546" left="467" width="32" height="17" font="7">67±9 </text>
<text top="546" left="535" width="28" height="17" font="7">73% </text>
<text top="546" left="656" width="8" height="17" font="7">V</text>
<text top="552" left="664" width="15" height="11" font="9">max</text>
<text top="546" left="679" width="73" height="17" font="7"> 3.6±0.3 m/s </text>
<text top="564" left="656" width="9" height="18" font="10"></text>
<text top="565" left="665" width="8" height="17" font="7">P</text>
<text top="570" left="673" width="20" height="11" font="9">mean</text>
<text top="565" left="694" width="60" height="17" font="7"> 31±4 mm </text>
<text top="582" left="656" width="22" height="17" font="7">Hg  </text>
<text top="599" left="656" width="104" height="17" font="7">AVA 1.19±0.13 cm</text>
<text top="600" left="760" width="4" height="11" font="9">2</text>
<text top="599" left="765" width="3" height="17" font="7"> </text>
<text top="546" left="926" width="46" height="17" font="7">82 AVR </text>
<text top="563" left="926" width="30" height="17" font="7">4 HF </text>
<text top="581" left="926" width="65" height="17" font="7">9 CV death </text>
<text top="617" left="42" width="66" height="17" font="7">Saito, 2012 </text>
<text top="634" left="42" width="25" height="17" font="7">(48) </text>
<text top="651" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22497679">22497679</a></text>
<text top="651" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22497679"> </a></text>
<text top="669" left="42" width="3" height="17" font="7"> </text>
<text top="617" left="143" width="24" height="17" font="7">103 </text>
<text top="617" left="211" width="72" height="17" font="7">AVA &lt;1.0 cm</text>
<text top="618" left="283" width="7" height="11" font="9">2 </text>
<text top="634" left="211" width="105" height="17" font="7">No AS symptoms   </text>
<text top="617" left="339" width="48" height="17" font="7">Hx CAD </text>
<text top="634" left="339" width="112" height="17" font="7">Other valve disease </text>
<text top="651" left="339" width="35" height="17" font="7">HCM  </text>
<text top="617" left="467" width="39" height="17" font="7">72±11 </text>
<text top="617" left="535" width="28" height="17" font="7">45% </text>
<text top="617" left="589" width="39" height="17" font="7">36±27 </text>
<text top="617" left="656" width="75" height="17" font="7">AVAi &lt;0.6 cm</text>
<text top="618" left="731" width="4" height="11" font="9">2</text>
<text top="617" left="735" width="14" height="17" font="7">/m</text>
<text top="618" left="749" width="4" height="11" font="9">2</text>
<text top="617" left="754" width="3" height="17" font="7"> </text>
<text top="634" left="656" width="76" height="17" font="7">AVAi ≥0.6 cm</text>
<text top="635" left="732" width="4" height="11" font="9">2</text>
<text top="634" left="736" width="14" height="17" font="7">/m</text>
<text top="635" left="750" width="4" height="11" font="9">2</text>
<text top="634" left="755" width="3" height="17" font="7"> </text>
<text top="617" left="784" width="62" height="17" font="7">41% at 3 y </text>
<text top="634" left="784" width="62" height="17" font="7">86% at 3 y </text>
<text top="617" left="926" width="46" height="17" font="7">31 AVR </text>
<text top="634" left="926" width="101" height="17" font="7">20 cardiac deaths </text>
<text top="617" left="1102" width="75" height="17" font="7">AVAi &lt;0.6 cm</text>
<text top="618" left="1176" width="4" height="11" font="9">2</text>
<text top="617" left="1181" width="14" height="17" font="7">/m</text>
<text top="618" left="1195" width="7" height="11" font="9">2 </text>
<text top="617" left="1201" width="100" height="17" font="7">(HR: 2.6; 95% CI: </text>
<text top="634" left="1102" width="59" height="17" font="7">11.1–6.3). </text>
<text top="651" left="1102" width="8" height="17" font="7">V</text>
<text top="657" left="1110" width="15" height="11" font="9">max</text>
<text top="651" left="1125" width="178" height="17" font="7"> &gt;4.0 m/s (HR: 2.6; 95% CI: 1.2–</text>
<text top="669" left="1102" width="28" height="17" font="7">5.8). </text>
<text top="686" left="1102" width="79" height="17" font="7">(AVA&lt;0.75 cm</text>
<text top="687" left="1181" width="4" height="11" font="9">2</text>
<text top="686" left="1186" width="139" height="17" font="7"> did not predict outcome) </text>
<text top="703" left="1102" width="136" height="17" font="7">(Mean BSA 1.50±0.15 m</text>
<text top="704" left="1238" width="4" height="11" font="9">2</text>
<text top="703" left="1242" width="11" height="17" font="7">). </text>
<text top="721" left="32" width="1243" height="17" font="7">ACS indicates acute coronary syndrome; AS, aortic stenosis; AVA, aortic valve area; AVAi, indexed AVA; AVR, aortic valve replacement; BSA; body surface area; CAD, coronary artery disease; CHF, congestive heart failure; CV, </text>
<text top="738" left="32" width="1316" height="17" font="7">cardiovascular; CVA, cerebral vascular accident; HCM, hypertrophic cardiomyopathy; HF, heart failure; Hx, history; HR, hazard ratio; IQR, interquartile range; LA, left atrium; LV, left ventricular, LVEF, left ventricular ejection fraction; LVOT, left </text>
<text top="757" left="32" width="237" height="17" font="7">ventricular outflow tract; N/A, not available; </text>
<text top="756" left="269" width="9" height="18" font="10"></text>
<text top="757" left="278" width="8" height="17" font="7">P</text>
<text top="762" left="286" width="20" height="11" font="9">mean</text>
<text top="757" left="306" width="927" height="17" font="7">, mean transaortic systolic pressure gradient; pt(s), patient(s); PVD, peripheral vascular disease; RR, relative risk; SEAS, Simvastatin Ezetimibe in Aortic Stenosis study; V</text>
<text top="762" left="1234" width="20" height="11" font="9">max, </text>
<text top="757" left="1253" width="57" height="17" font="7">maximum </text>
<text top="774" left="32" width="44" height="17" font="7">velocity.</text>
<text top="779" left="77" width="2" height="11" font="9"> </text>
<text top="797" left="108" width="2" height="11" font="9"> </text>
<text top="797" left="324" width="2" height="11" font="9"> </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">11 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="110" left="32" width="3" height="17" font="6"><b> </b></text>
<text top="108" left="36" width="877" height="21" font="4"><b>Data Supplement 6. Incidence of Sudden Death in Asymptomatic Adults With Aortic Stenosis (stages B and C) (Section 3.2.3)</b></text>
<text top="110" left="913" width="3" height="17" font="6"><b> </b></text>
<text top="129" left="94" width="74" height="17" font="6"><b>First Author </b></text>
<text top="129" left="253" width="12" height="17" font="6"><b>N </b></text>
<text top="129" left="307" width="63" height="17" font="6"><b>Follow-Up </b></text>
<text top="146" left="321" width="35" height="17" font="6"><b>(mo)* </b></text>
<text top="129" left="417" width="8" height="17" font="6"><b>V</b></text>
<text top="135" left="425" width="16" height="11" font="15"><b>max</b></text>
<text top="129" left="441" width="56" height="17" font="6"><b> at Entry  </b></text>
<text top="146" left="439" width="33" height="17" font="6"><b>(m/s) </b></text>
<text top="129" left="548" width="78" height="17" font="6"><b>AVA at Entry </b></text>
<text top="146" left="570" width="22" height="17" font="6"><b>(cm</b></text>
<text top="148" left="592" width="4" height="11" font="15"><b>2</b></text>
<text top="146" left="597" width="7" height="17" font="6"><b>) </b></text>
<text top="129" left="684" width="96" height="17" font="6"><b>Sudden Deaths  </b></text>
<text top="146" left="721" width="19" height="17" font="6"><b>(n) </b></text>
<text top="129" left="833" width="93" height="17" font="6"><b>Sudden Deaths </b></text>
<text top="146" left="850" width="59" height="17" font="6"><b> (% per y) </b></text>
<text top="164" left="42" width="90" height="17" font="7">Kelly, 1988 (39) </text>
<text top="182" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3337000">3337000</a></text>
<text top="182" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3337000"> </a></text>
<text top="164" left="233" width="17" height="17" font="7">51 </text>
<text top="164" left="297" width="17" height="17" font="7">18 </text>
<text top="164" left="393" width="29" height="17" font="7">≥3.5 </text>
<text top="164" left="532" width="24" height="17" font="7">N/A </text>
<text top="164" left="656" width="10" height="17" font="7">0 </text>
<text top="164" left="818" width="10" height="17" font="7">0 </text>
<text top="200" left="42" width="114" height="17" font="7">Faggiano, 1992 (18) </text>
<text top="217" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1626512">1626512</a></text>
<text top="217" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1626512"> </a></text>
<text top="200" left="233" width="17" height="17" font="7">37 </text>
<text top="200" left="297" width="17" height="17" font="7">24 </text>
<text top="200" left="393" width="24" height="17" font="7">N/A </text>
<text top="200" left="532" width="56" height="17" font="7">0.85±015 </text>
<text top="200" left="656" width="10" height="17" font="7">0 </text>
<text top="200" left="818" width="10" height="17" font="7">0 </text>
<text top="235" left="42" width="86" height="17" font="7">Otto, 1997 (21) </text>
<text top="252" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9142003">9142003</a></text>
<text top="252" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9142003"> </a></text>
<text top="235" left="233" width="24" height="17" font="7">114 </text>
<text top="235" left="297" width="17" height="17" font="7">30 </text>
<text top="235" left="393" width="46" height="17" font="7">3.6±0.6 </text>
<text top="235" left="532" width="24" height="17" font="7">N/A </text>
<text top="235" left="656" width="10" height="17" font="7">0 </text>
<text top="235" left="818" width="10" height="17" font="7">0 </text>
<text top="270" left="42" width="118" height="17" font="7">Rosenhek, 2000 (24) </text>
<text top="287" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10965007">10965007</a></text>
<text top="287" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10965007"> </a></text>
<text top="270" left="233" width="24" height="17" font="7">128 </text>
<text top="270" left="297" width="17" height="17" font="7">22 </text>
<text top="270" left="393" width="29" height="17" font="7">≥4.0 </text>
<text top="270" left="532" width="24" height="17" font="7">N/A </text>
<text top="270" left="656" width="10" height="17" font="7">1 </text>
<text top="270" left="818" width="21" height="17" font="7">0.4 </text>
<text top="305" left="42" width="95" height="17" font="7">Amato, 2001(30) </text>
<text top="322" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11559673">11559673</a></text>
<text top="322" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11559673"> </a></text>
<text top="305" left="233" width="17" height="17" font="7">66 </text>
<text top="305" left="297" width="17" height="17" font="7">15 </text>
<text top="305" left="393" width="24" height="17" font="7">N/A </text>
<text top="305" left="532" width="29" height="17" font="7">≤1.0 </text>
<text top="305" left="656" width="10" height="17" font="7">4 </text>
<text top="305" left="818" width="21" height="17" font="7">4.8 </text>
<text top="340" left="42" width="85" height="17" font="7">Das, 2005 (32) </text>
<text top="357" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15820999">15820999</a></text>
<text top="357" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15820999"> </a></text>
<text top="340" left="233" width="24" height="17" font="7">125 </text>
<text top="340" left="297" width="17" height="17" font="7">12 </text>
<text top="340" left="393" width="24" height="17" font="7">N/A </text>
<text top="340" left="532" width="29" height="17" font="7">≤1.4 </text>
<text top="340" left="656" width="10" height="17" font="7">0 </text>
<text top="340" left="818" width="10" height="17" font="7">0 </text>
<text top="375" left="42" width="105" height="17" font="7">Pellikka, 2005 (42) </text>
<text top="393" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15956131">15956131</a></text>
<text top="393" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15956131"> </a></text>
<text top="375" left="233" width="24" height="17" font="7">270 </text>
<text top="375" left="297" width="17" height="17" font="7">65 </text>
<text top="375" left="393" width="29" height="17" font="7">≥4.0 </text>
<text top="375" left="532" width="24" height="17" font="7">N/A </text>
<text top="375" left="656" width="17" height="17" font="7">11 </text>
<text top="375" left="818" width="27" height="17" font="7">0.75 </text>
<text top="411" left="42" width="112" height="17" font="7">Rossebø, 2008 (26) </text>
<text top="428" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18765433">18765433</a></text>
<text top="428" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18765433"> </a></text>
<text top="411" left="233" width="34" height="17" font="7">1,873 </text>
<text top="411" left="297" width="17" height="17" font="7">52 </text>
<text top="411" left="393" width="44" height="17" font="7">2.5–4.0 </text>
<text top="411" left="532" width="24" height="17" font="7">N/A </text>
<text top="411" left="656" width="17" height="17" font="7">40 </text>
<text top="411" left="818" width="21" height="17" font="7">0.5 </text>
<text top="446" left="42" width="96" height="17" font="7">Monin, 2009 (49) </text>
<text top="463" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19546391">19546391</a></text>
<text top="463" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19546391"> </a></text>
<text top="446" left="233" width="24" height="17" font="7">211 </text>
<text top="446" left="297" width="17" height="17" font="7">22 </text>
<text top="446" left="393" width="29" height="17" font="7">≥3.0 </text>
<text top="446" left="532" width="29" height="17" font="7">≤1.5 </text>
<text top="446" left="656" width="10" height="17" font="7">2 </text>
<text top="446" left="818" width="21" height="17" font="7">0.5 </text>
<text top="481" left="42" width="118" height="17" font="7">Lancellotti, 2010 (43) </text>
<text top="498" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20483891">20483891</a></text>
<text top="498" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20483891"> </a></text>
<text top="481" left="233" width="24" height="17" font="7">163 </text>
<text top="481" left="297" width="17" height="17" font="7">20 </text>
<text top="481" left="393" width="24" height="17" font="7">N/A </text>
<text top="481" left="532" width="45" height="17" font="7">≤0.6 cm</text>
<text top="482" left="577" width="4" height="11" font="9">2</text>
<text top="481" left="581" width="14" height="17" font="7">/m</text>
<text top="482" left="595" width="4" height="11" font="9">2</text>
<text top="481" left="599" width="3" height="17" font="7"> </text>
<text top="481" left="656" width="10" height="17" font="7">3 </text>
<text top="481" left="818" width="21" height="17" font="7">1.1 </text>
<text top="516" left="42" width="92" height="17" font="7">Kang, 2010 (44) </text>
<text top="533" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20308614">20308614</a></text>
<text top="533" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20308614"> </a></text>
<text top="516" left="233" width="17" height="17" font="7">95 </text>
<text top="516" left="297" width="17" height="17" font="7">59 </text>
<text top="516" left="393" width="29" height="17" font="7">≥4.5 </text>
<text top="516" left="532" width="36" height="17" font="7">≥0.75 </text>
<text top="516" left="656" width="10" height="17" font="7">9 </text>
<text top="516" left="818" width="21" height="17" font="7">1.9 </text>
<text top="551" left="42" width="124" height="17" font="7">Marechaux, 2010 (34) </text>
<text top="568" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20308041">20308041</a></text>
<text top="568" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20308041"> </a></text>
<text top="551" left="233" width="24" height="17" font="7">135 </text>
<text top="551" left="297" width="17" height="17" font="7">20 </text>
<text top="551" left="393" width="24" height="17" font="7">N/A </text>
<text top="551" left="532" width="29" height="17" font="7">≤1.5 </text>
<text top="551" left="656" width="10" height="17" font="7">1 </text>
<text top="551" left="818" width="21" height="17" font="7">0.4 </text>
<text top="586" left="42" width="118" height="17" font="7">Rosenhek, 2010 (46) </text>
<text top="604" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20026771">20026771</a></text>
<text top="604" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20026771"> </a></text>
<text top="586" left="233" width="24" height="17" font="7">116 </text>
<text top="586" left="297" width="17" height="17" font="7">41 </text>
<text top="586" left="393" width="29" height="17" font="7">≥5.0 </text>
<text top="586" left="532" width="24" height="17" font="7">N/A </text>
<text top="586" left="656" width="10" height="17" font="7">1 </text>
<text top="586" left="818" width="21" height="17" font="7">0.3 </text>
<text top="622" left="42" width="31" height="17" font="7">Total </text>
<text top="622" left="233" width="34" height="17" font="7">3,384 </text>
<text top="622" left="297" width="25" height="17" font="7">31*  </text>
<text top="622" left="393" width="24" height="17" font="7">N/A </text>
<text top="622" left="532" width="24" height="17" font="7">N/A </text>
<text top="622" left="656" width="17" height="17" font="7">72 </text>
<text top="622" left="818" width="21" height="17" font="7">0.8 </text>
<text top="640" left="32" width="143" height="17" font="7">*Mean follow-up duration. </text>
<text top="657" left="32" width="319" height="17" font="7">AVA indicates aortic valve area; N/A, not applicable; and V</text>
<text top="662" left="352" width="15" height="11" font="9">max</text>
<text top="657" left="367" width="145" height="17" font="7">, maximum aortic velocity  </text>
<text top="674" left="32" width="309" height="17" font="7">From Rosenhek R et al., (50). (PERMISSION NEEDED) </text>
<text top="674" left="554" width="3" height="17" font="7"> </text>
</page>
<page number="12" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">12 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="924" height="21" font="4"><b>Data Supplement 7. Clinical Outcomes in Symptomatic Adults With Aortic Stenosis of Known Hemodynamic Severity (Section 3.2.3)</b></text>
<text top="110" left="957" width="3" height="17" font="6"><b> </b></text>
<text top="129" left="65" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="129" left="193" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="129" left="308" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="404" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="398" width="49" height="17" font="6"><b>Size (N) </b></text>
<text top="129" left="477" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="129" left="692" width="109" height="17" font="6"><b>Primary Endpoint  </b></text>
<text top="129" left="894" width="149" height="17" font="6"><b>Predictors of Mortality or </b></text>
<text top="146" left="954" width="36" height="17" font="6"><b>AVR   </b></text>
<text top="129" left="1135" width="67" height="17" font="6"><b>Comments </b></text>
<text top="164" left="42" width="94" height="17" font="7">Frank, 1973 (51) </text>
<text top="182" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4685905">4685905</a></text>
<text top="182" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4685905"> </a></text>
<text top="164" left="178" width="104" height="17" font="7">Outcomes with AS </text>
<text top="182" left="178" width="53" height="17" font="7">of known </text>
<text top="199" left="178" width="80" height="17" font="7">hemodynamic </text>
<text top="216" left="178" width="49" height="17" font="7">severity  </text>
<text top="164" left="301" width="79" height="17" font="7">Observational </text>
<text top="164" left="398" width="21" height="17" font="7">15  </text>
<text top="164" left="460" width="73" height="17" font="7">Isolated AS.  </text>
<text top="182" left="460" width="116" height="17" font="7">Not referred for AVR </text>
<text top="199" left="460" width="114" height="17" font="7">Symptomatic (10) or </text>
<text top="216" left="460" width="101" height="17" font="7">asymptomatic (5)  </text>
<text top="233" left="460" width="129" height="17" font="7">No other valve disease </text>
<text top="164" left="618" width="172" height="17" font="7">Mortality from symptom onset:  </text>
<text top="182" left="618" width="62" height="17" font="7">15% at 2 y </text>
<text top="199" left="618" width="62" height="17" font="7">36% at 3 y </text>
<text top="216" left="618" width="62" height="17" font="7">52% at 5 y </text>
<text top="233" left="618" width="68" height="17" font="7">90% at 10 y </text>
<text top="164" left="886" width="139" height="17" font="7">Overlap in hemodynamic </text>
<text top="182" left="886" width="126" height="17" font="7">parameters between 5 </text>
<text top="199" left="886" width="120" height="17" font="7">asymptomatic and 10 </text>
<text top="216" left="886" width="92" height="17" font="7">symptomatic pts </text>
<text top="164" left="1065" width="203" height="17" font="7">Indexed AVA ranged from 0.26–0.63 </text>
<text top="182" left="1065" width="16" height="17" font="7">cm</text>
<text top="183" left="1082" width="4" height="11" font="9">2</text>
<text top="182" left="1086" width="14" height="17" font="7">/m</text>
<text top="183" left="1100" width="9" height="16" font="9">2. </text>
<text top="199" left="1065" width="203" height="17" font="7">Transaortic gradient ranged from 30–</text>
<text top="216" left="1065" width="64" height="17" font="7">90 mm Hg. </text>
<text top="251" left="42" width="105" height="17" font="7">Chizner, 1980 (52) </text>
<text top="268" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7189084">7189084</a></text>
<text top="268" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7189084"> </a></text>
<text top="251" left="178" width="104" height="17" font="7">Outcomes with AS </text>
<text top="268" left="178" width="53" height="17" font="7">of known </text>
<text top="286" left="178" width="80" height="17" font="7">hemodynamic </text>
<text top="303" left="178" width="46" height="17" font="7">severity </text>
<text top="251" left="301" width="79" height="17" font="7">Observational </text>
<text top="251" left="398" width="17" height="17" font="7">32 </text>
<text top="251" left="460" width="94" height="17" font="7">Symptomatic AS </text>
<text top="268" left="460" width="116" height="17" font="7">Not referred for AVR </text>
<text top="251" left="618" width="168" height="17" font="7">Mortality from symptom onset: </text>
<text top="268" left="618" width="62" height="17" font="7">25% at 1 y </text>
<text top="286" left="618" width="64" height="17" font="7">57% by 3 y </text>
<text top="303" left="618" width="64" height="17" font="7">64% by 5 y </text>
<text top="320" left="618" width="64" height="17" font="7">80% by 8 y </text>
<text top="251" left="886" width="165" height="17" font="7">Mortality was no different with </text>
<text top="268" left="886" width="147" height="17" font="7">“moderate” (AVA 0.71–1.1 </text>
<text top="287" left="886" width="16" height="17" font="7">cm</text>
<text top="288" left="902" width="4" height="11" font="9">2</text>
<text top="287" left="907" width="37" height="17" font="7">, peak </text>
<text top="286" left="943" width="9" height="18" font="10"></text>
<text top="287" left="953" width="83" height="17" font="7">P &lt;70 mm Hg) </text>
<text top="304" left="886" width="140" height="17" font="7">compared to “severe” AS </text>
<text top="323" left="886" width="69" height="17" font="7">(AVA 0.7 cm</text>
<text top="324" left="955" width="4" height="11" font="9">2</text>
<text top="323" left="959" width="37" height="17" font="7">, peak </text>
<text top="321" left="996" width="9" height="18" font="10"></text>
<text top="323" left="1005" width="36" height="17" font="7">P &gt;70 </text>
<text top="340" left="886" width="54" height="17" font="7">mm Hg).  </text>
<text top="251" left="1065" width="197" height="17" font="7">Time from symptom onset to death: </text>
<text top="268" left="1065" width="135" height="17" font="7">Angina 1.4 (0.25–3.3) y  </text>
<text top="286" left="1065" width="141" height="17" font="7">Syncope 0.8 (0.25–2.0) y </text>
<text top="303" left="1065" width="111" height="17" font="7">CHF 2.0 (0.3–3.0) y </text>
<text top="357" left="42" width="105" height="17" font="7">Lombard &amp; Selzer, </text>
<text top="375" left="42" width="56" height="17" font="7">1987 (53) </text>
<text top="392" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3800187">3800187</a></text>
<text top="392" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3800187"> </a></text>
<text top="357" left="178" width="92" height="17" font="7">Describe clinical </text>
<text top="375" left="178" width="104" height="17" font="7">findings in pts with </text>
<text top="392" left="178" width="72" height="17" font="7">AS of known </text>
<text top="409" left="178" width="80" height="17" font="7">hemodynamic </text>
<text top="426" left="178" width="46" height="17" font="7">severity </text>
<text top="357" left="301" width="79" height="17" font="7">Retrospective </text>
<text top="357" left="398" width="24" height="17" font="7">397 </text>
<text top="357" left="460" width="136" height="17" font="7">Undergoing cardiac cath </text>
<text top="375" left="460" width="38" height="17" font="7">for AS </text>
<text top="392" left="460" width="85" height="17" font="7">Mean age 61 y </text>
<text top="409" left="460" width="62" height="17" font="7">AVA &lt;1 cm</text>
<text top="410" left="522" width="4" height="11" font="9">2</text>
<text top="409" left="527" width="44" height="17" font="7"> in 87% </text>
<text top="426" left="460" width="129" height="17" font="7">No other valve disease </text>
<text top="357" left="618" width="212" height="17" font="7">Early symptoms (angina and syncope) </text>
<text top="375" left="618" width="212" height="17" font="7">correlated with AS severity, but not LV </text>
<text top="392" left="618" width="50" height="17" font="7">function. </text>
<text top="409" left="618" width="216" height="17" font="7">Late symptoms (HF) correlated with LV </text>
<text top="426" left="618" width="66" height="17" font="7">dysfunction.</text>
<text top="427" left="684" width="2" height="11" font="9"> </text>
<text top="357" left="886" width="24" height="17" font="7">N/A </text>
<text top="357" left="1065" width="101" height="17" font="7">No outcome data  </text>
<text top="444" left="42" width="98" height="17" font="7">Turina, 1987 (54) </text>
<text top="461" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3609042">3609042</a></text>
<text top="461" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3609042"> </a></text>
<text top="444" left="178" width="60" height="17" font="7">Determine </text>
<text top="461" left="178" width="106" height="17" font="7">prognostic value of </text>
<text top="479" left="178" width="104" height="17" font="7">hemodynamic and </text>
<text top="496" left="178" width="93" height="17" font="7">clinical variables </text>
<text top="444" left="301" width="79" height="17" font="7">Observational </text>
<text top="444" left="398" width="24" height="17" font="7">N/A </text>
<text top="444" left="460" width="142" height="17" font="7">Referred for cardiac cath. </text>
<text top="461" left="460" width="131" height="17" font="7">No AVR due to disease </text>
<text top="479" left="460" width="114" height="17" font="7">severity or pt refusal </text>
<text top="444" left="618" width="204" height="17" font="7">Survival without AVR by AS severity; </text>
<text top="461" left="618" width="138" height="17" font="7">Severe AS (AVA &lt;0.9 cm</text>
<text top="463" left="756" width="4" height="11" font="9">2</text>
<text top="461" left="761" width="111" height="17" font="7">): 60% at 1 y, 9% at </text>
<text top="479" left="618" width="27" height="17" font="7">10 y </text>
<text top="496" left="618" width="175" height="17" font="7">Moderate AS (AVA 0.95–1.4 cm</text>
<text top="497" left="793" width="4" height="11" font="9">2</text>
<text top="496" left="798" width="63" height="17" font="7">): 97% at 1 </text>
<text top="513" left="618" width="81" height="17" font="7">y, 35% at 10 y </text>
<text top="530" left="618" width="122" height="17" font="7">Mild AS (AVA &gt;1.5 cm</text>
<text top="532" left="740" width="4" height="11" font="9">2</text>
<text top="530" left="744" width="79" height="17" font="7">): 85% at 10 y </text>
<text top="444" left="886" width="138" height="17" font="7">Survival without  AVR by </text>
<text top="461" left="886" width="155" height="17" font="7">symptom status with severe </text>
<text top="479" left="886" width="23" height="17" font="7">AS: </text>
<text top="496" left="886" width="94" height="17" font="7">Symptomatic AS </text>
<text top="513" left="886" width="62" height="17" font="7">27% at 2 y </text>
<text top="530" left="886" width="65" height="17" font="7">12% at 5 y  </text>
<text top="548" left="886" width="3" height="17" font="7"> </text>
<text top="565" left="886" width="104" height="17" font="7">Asymptomatic AS: </text>
<text top="582" left="886" width="68" height="17" font="7">100% at 2 y </text>
<text top="599" left="886" width="62" height="17" font="7">75% at 5 y </text>
<text top="444" left="1065" width="179" height="17" font="7">AS was more severe in severely </text>
<text top="461" left="1065" width="190" height="17" font="7">symptomatic vs. oligosymptomatic </text>
<text top="479" left="1065" width="27" height="17" font="7">pts:  </text>
<text top="496" left="1065" width="9" height="18" font="10"></text>
<text top="497" left="1074" width="8" height="17" font="7">P</text>
<text top="503" left="1082" width="20" height="11" font="9">mean</text>
<text top="497" left="1103" width="146" height="17" font="7"> 69 vs. 57 mm Hg (p=NS), </text>
<text top="514" left="1065" width="52" height="17" font="7">AVA 0.56</text>
<text top="516" left="1117" width="2" height="11" font="9"> </text>
<text top="514" left="1119" width="63" height="17" font="7">vs. 0.76 cm</text>
<text top="516" left="1182" width="4" height="11" font="9">2</text>
<text top="514" left="1187" width="50" height="17" font="7"> (&lt;0.01), </text>
<text top="532" left="1065" width="186" height="17" font="7">Cardiac index 2.6 vs. 3.3 L./min/m</text>
<text top="533" left="1251" width="4" height="11" font="9">2</text>
<text top="532" left="1256" width="3" height="17" font="7"> </text>
<text top="549" left="1065" width="53" height="17" font="7">(p&lt;0.01), </text>
<text top="566" left="1065" width="180" height="17" font="7">LVEDP 17 mm Hg vs.12 mm Hg </text>
<text top="583" left="1065" width="53" height="17" font="7">(p&lt;0.05). </text>
<text top="617" left="42" width="119" height="17" font="7">Horstkotte, 1988 (55) </text>
<text top="634" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3042404">3042404</a></text>
<text top="634" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3042404"> </a></text>
<text top="617" left="178" width="54" height="17" font="7">Compare </text>
<text top="634" left="178" width="82" height="17" font="7">outcomes with </text>
<text top="652" left="178" width="91" height="17" font="7">symptomatic vs. </text>
<text top="669" left="178" width="79" height="17" font="7">asymptomatic </text>
<text top="686" left="178" width="64" height="17" font="7">severe AS  </text>
<text top="617" left="301" width="118" height="17" font="7">Retrospective   35  </text>
<text top="617" left="460" width="135" height="17" font="7">Severe symptomatic AS </text>
<text top="634" left="460" width="81" height="17" font="7">Refused AVR. </text>
<text top="652" left="460" width="89" height="17" font="7">AVA 0.4–0.8 cm</text>
<text top="653" left="549" width="4" height="11" font="9">2</text>
<text top="652" left="554" width="3" height="17" font="7"> </text>
<text top="617" left="618" width="243" height="17" font="7">Mean interval from symptom onset to death: </text>
<text top="634" left="618" width="128" height="17" font="7">4.5 y for angina (n=18) </text>
<text top="652" left="618" width="136" height="17" font="7">2.6 y for syncope (n=13) </text>
<text top="669" left="618" width="104" height="17" font="7">&lt;1 y for HF (n=20) </text>
<text top="617" left="886" width="150" height="17" font="7">Mortality reached 100% at: </text>
<text top="634" left="886" width="85" height="17" font="7">10 y for angina </text>
<text top="652" left="886" width="87" height="17" font="7">5 y for syncope </text>
<text top="669" left="886" width="68" height="17" font="7">2.4 y for HF </text>
<text top="617" left="1065" width="198" height="17" font="7">There were 3 sudden deaths before </text>
<text top="634" left="1065" width="87" height="17" font="7">symptom onset </text>
<text top="704" left="42" width="93" height="17" font="7">Kelly, 1988  (39) </text>
<text top="721" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3337000">3337000</a></text>
<text top="721" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3337000"> </a></text>
<text top="704" left="178" width="54" height="17" font="7">Compare </text>
<text top="721" left="178" width="82" height="17" font="7">outcomes with </text>
<text top="739" left="178" width="91" height="17" font="7">symptomatic vs. </text>
<text top="756" left="178" width="79" height="17" font="7">asymptomatic </text>
<text top="773" left="178" width="64" height="17" font="7">severe AS  </text>
<text top="704" left="301" width="71" height="17" font="7">Prospective  </text>
<text top="704" left="398" width="17" height="17" font="7">39 </text>
<text top="704" left="460" width="117" height="17" font="7">Referred for echo for </text>
<text top="721" left="460" width="115" height="17" font="7">systolic murmur with </text>
<text top="740" left="460" width="46" height="17" font="7">Doppler </text>
<text top="739" left="507" width="9" height="18" font="10"></text>
<text top="740" left="516" width="80" height="17" font="7">P ≥50 mm Hg </text>
<text top="757" left="460" width="126" height="17" font="7">cardiac symptoms, but </text>
<text top="774" left="460" width="140" height="17" font="7">did not undergo AVR. No </text>
<text top="791" left="460" width="116" height="17" font="7">other valve disease.  </text>
<text top="704" left="618" width="239" height="17" font="7">Death in 15 (38%) with a mean follow-up of </text>
<text top="721" left="618" width="44" height="17" font="7">12 mo.  </text>
<text top="739" left="618" width="3" height="17" font="7"> </text>
<text top="756" left="618" width="218" height="17" font="7">Compared to 8 (%) deaths in 51 initially </text>
<text top="773" left="618" width="184" height="17" font="7">asymptomatic pts (See Table 6).  </text>
<text top="704" left="886" width="24" height="17" font="7">N/A </text>
<text top="704" left="1065" width="188" height="17" font="7">Study group represents 19% of all </text>
<text top="721" left="1065" width="173" height="17" font="7">surgical candidates for AVR for </text>
<text top="739" left="1065" width="182" height="17" font="7">severe symptomatic AS. Surgery </text>
<text top="756" left="1065" width="178" height="17" font="7">refused by 26/39 pts; symptoms </text>
<text top="773" left="1065" width="197" height="17" font="7">judged not severe in 13 by referring </text>
<text top="790" left="1065" width="54" height="17" font="7">clinician.  </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">13 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="65" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="108" left="193" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="308" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="404" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="398" width="49" height="17" font="6"><b>Size (N) </b></text>
<text top="108" left="477" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="108" left="692" width="109" height="17" font="6"><b>Primary Endpoint  </b></text>
<text top="108" left="894" width="149" height="17" font="6"><b>Predictors of Mortality or </b></text>
<text top="126" left="954" width="36" height="17" font="6"><b>AVR   </b></text>
<text top="108" left="1135" width="67" height="17" font="6"><b>Comments </b></text>
<text top="144" left="460" width="116" height="17" font="7">Other valve disease. </text>
<text top="144" left="1065" width="3" height="17" font="7"> </text>
<text top="161" left="1065" width="201" height="17" font="7">No difference in Doppler AS severity </text>
<text top="178" left="1065" width="197" height="17" font="7">between these 39 symptomatic and </text>
<text top="195" left="1065" width="174" height="17" font="7">51 asymptomatic pts during the </text>
<text top="212" left="1065" width="110" height="17" font="7">same time interval.  </text>
<text top="230" left="42" width="86" height="17" font="7">Otto, 1988 (56) </text>
<text top="248" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3143323">3143323</a></text>
<text top="248" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3143323"> </a></text>
<text top="265" left="42" width="3" height="17" font="7"> </text>
<text top="230" left="178" width="73" height="17" font="7">Identify echo </text>
<text top="248" left="178" width="87" height="17" font="7">criteria for AVR </text>
<text top="265" left="178" width="97" height="17" font="7">with symptomatic </text>
<text top="282" left="178" width="20" height="17" font="7">AS </text>
<text top="230" left="301" width="71" height="17" font="7">Prospective, </text>
<text top="248" left="301" width="68" height="17" font="7">split sample </text>
<text top="265" left="301" width="48" height="17" font="7">decision </text>
<text top="282" left="301" width="51" height="17" font="7">analysis  </text>
<text top="230" left="398" width="24" height="17" font="7">103 </text>
<text top="230" left="460" width="94" height="17" font="7">Symptomatic pts </text>
<text top="248" left="460" width="135" height="17" font="7">undergoing cardiac cath </text>
<text top="265" left="460" width="97" height="17" font="7">for suspected AS </text>
<text top="282" left="460" width="3" height="17" font="7"> </text>
<text top="299" left="460" width="137" height="17" font="7">Clinical outcome defined </text>
<text top="317" left="460" width="143" height="17" font="7">as AVR as determined by </text>
<text top="334" left="460" width="106" height="17" font="7">clinical cardiologist </text>
<text top="351" left="460" width="118" height="17" font="7">without knowledge of </text>
<text top="368" left="460" width="106" height="17" font="7">echo data or death </text>
<text top="230" left="618" width="228" height="17" font="7">Decision model recommended AVR in 73 </text>
<text top="248" left="618" width="32" height="17" font="7">with:  </text>
<text top="265" left="618" width="8" height="17" font="7">V</text>
<text top="270" left="626" width="15" height="11" font="9">max</text>
<text top="265" left="641" width="72" height="17" font="7"> &gt;4.0 m/s, or </text>
<text top="282" left="618" width="8" height="17" font="7">V</text>
<text top="288" left="626" width="15" height="11" font="9">max</text>
<text top="282" left="641" width="164" height="17" font="7"> 3 m/s-4 m/s and AVA&lt;1.0 cm</text>
<text top="283" left="805" width="7" height="11" font="9">2 </text>
<text top="282" left="812" width="18" height="17" font="7">or  </text>
<text top="299" left="618" width="8" height="17" font="7">V</text>
<text top="305" left="626" width="15" height="11" font="9">max</text>
<text top="299" left="641" width="203" height="17" font="7"> 3 m/s-4 m/s, AVA &gt;1.0 and 2-3+AR  </text>
<text top="230" left="886" width="136" height="17" font="7">AVR in 68, 2 noncardiac </text>
<text top="248" left="886" width="114" height="17" font="7">death, 2 nonsurgical </text>
<text top="265" left="886" width="121" height="17" font="7">candidates, 1 refused </text>
<text top="230" left="1065" width="171" height="17" font="7">Overall diagnostic accuracy for </text>
<text top="248" left="1065" width="119" height="17" font="7">clinical outcome 94% </text>
<text top="317" left="618" width="190" height="17" font="7">AVR not recommended in 30 with: </text>
<text top="335" left="618" width="8" height="17" font="7">V</text>
<text top="340" left="626" width="15" height="11" font="9">max</text>
<text top="335" left="641" width="69" height="17" font="7"> &lt;3.0 m/s or </text>
<text top="352" left="618" width="8" height="17" font="7">V</text>
<text top="357" left="626" width="17" height="11" font="9">max </text>
<text top="352" left="643" width="143" height="17" font="7">3-4 m/s with AVA ≥1.7 cm</text>
<text top="353" left="786" width="9" height="16" font="9">2  </text>
<text top="352" left="795" width="15" height="17" font="7">or </text>
<text top="369" left="618" width="8" height="17" font="7">V</text>
<text top="375" left="626" width="15" height="11" font="9">max</text>
<text top="369" left="641" width="137" height="17" font="7"> 3-4 m/s, AVA 1.1-1.6 cm</text>
<text top="370" left="779" width="4" height="11" font="9">2</text>
<text top="369" left="783" width="76" height="17" font="7"> and 0-1+ AR </text>
<text top="375" left="860" width="2" height="11" font="9"> </text>
<text top="317" left="886" width="128" height="17" font="7">No AVR in 28. AVR for </text>
<text top="335" left="886" width="161" height="17" font="7">severe AR in 2 pts confirmed </text>
<text top="352" left="886" width="140" height="17" font="7">absence of severe AS by </text>
<text top="369" left="886" width="105" height="17" font="7">surgical inspection </text>
<text top="387" left="42" width="79" height="17" font="7">Oh, 1988 (57) </text>
<text top="404" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3366997">3366997</a></text>
<text top="404" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3366997"> </a></text>
<text top="387" left="178" width="108" height="17" font="7">Compare echo and </text>
<text top="404" left="178" width="57" height="17" font="7">cath data  </text>
<text top="387" left="301" width="68" height="17" font="7">Prospective </text>
<text top="387" left="398" width="24" height="17" font="7">100 </text>
<text top="387" left="460" width="94" height="17" font="7">Symptomatic AS </text>
<text top="404" left="460" width="135" height="17" font="7">undergoing cardiac cath </text>
<text top="387" left="618" width="231" height="17" font="7">Severe AS at cath defined as (Gorlin AVA </text>
<text top="404" left="618" width="8" height="18" font="10"></text>
<text top="405" left="626" width="44" height="17" font="7">0.75 cm</text>
<text top="406" left="670" width="4" height="11" font="9">2</text>
<text top="405" left="675" width="7" height="17" font="7">) </text>
<text top="387" left="886" width="97" height="17" font="7">No outcome data </text>
<text top="387" left="1065" width="8" height="17" font="7">V</text>
<text top="393" left="1073" width="15" height="11" font="9">max</text>
<text top="387" left="1088" width="182" height="17" font="7"> &gt;4.5 m/s predicted severe AS at </text>
<text top="404" left="1065" width="193" height="17" font="7">cath with 60% accuracy–specificity </text>
<text top="421" left="1065" width="137" height="17" font="7">93%, but sensitivity 44% </text>
<text top="439" left="1065" width="3" height="17" font="7"> </text>
<text top="456" left="1065" width="176" height="17" font="7">Doppler velocity ratio &lt;0.25 had </text>
<text top="473" left="1065" width="176" height="17" font="7">sensitivity of 92% for severe AS </text>
<text top="491" left="42" width="96" height="17" font="7">Galan, 1991 (58) </text>
<text top="508" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2018003">2018003</a></text>
<text top="508" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2018003"> </a></text>
<text top="491" left="178" width="73" height="17" font="7">Identify echo </text>
<text top="508" left="178" width="100" height="17" font="7">predictors of AVR </text>
<text top="491" left="301" width="83" height="17" font="7">Observational, </text>
<text top="508" left="301" width="74" height="17" font="7">retrospective </text>
<text top="491" left="398" width="24" height="17" font="7">510 </text>
<text top="491" left="460" width="110" height="17" font="7">Consecutive AS pts </text>
<text top="508" left="460" width="141" height="17" font="7">undergoing Doppler echo </text>
<text top="491" left="618" width="236" height="17" font="7">Comparison with diagnosis of critical AS at </text>
<text top="509" left="618" width="154" height="17" font="7">cath, defined as Gorlin AVA </text>
<text top="508" left="772" width="8" height="18" font="10"></text>
<text top="509" left="781" width="44" height="17" font="7">0.75 cm</text>
<text top="510" left="825" width="4" height="11" font="9">2</text>
<text top="509" left="829" width="3" height="17" font="7"> </text>
<text top="491" left="886" width="91" height="17" font="7">In 160 pts with V</text>
<text top="497" left="976" width="15" height="11" font="9">max</text>
<text top="491" left="992" width="54" height="17" font="7"> &gt;4.5 m/s </text>
<text top="509" left="886" width="89" height="17" font="7">or Doppler AVA </text>
<text top="508" left="974" width="8" height="18" font="10"></text>
<text top="509" left="983" width="44" height="17" font="7">0.75 cm</text>
<text top="510" left="1026" width="4" height="11" font="9">2</text>
<text top="509" left="1031" width="7" height="17" font="7">, </text>
<text top="526" left="886" width="114" height="17" font="7">109 underwent AVR </text>
<text top="544" left="886" width="3" height="17" font="7"> </text>
<text top="561" left="886" width="152" height="17" font="7">No long-term outcome data </text>
<text top="492" left="1065" width="8" height="17" font="7">V</text>
<text top="498" left="1073" width="15" height="11" font="9">max</text>
<text top="492" left="1088" width="143" height="17" font="7"> &gt;4.5 m/s or Doppler AVA </text>
<text top="491" left="1232" width="8" height="18" font="10"></text>
<text top="492" left="1240" width="28" height="17" font="7">0.75 </text>
<text top="509" left="1065" width="16" height="17" font="7">cm</text>
<text top="510" left="1082" width="7" height="11" font="9">2 </text>
<text top="509" left="1088" width="177" height="17" font="7"> was 97% specific for critical AS </text>
<text top="526" left="1065" width="87" height="17" font="7">at cath (n=105) </text>
<text top="544" left="1065" width="3" height="17" font="7"> </text>
<text top="562" left="1065" width="8" height="17" font="7">V</text>
<text top="568" left="1073" width="15" height="11" font="9">max</text>
<text top="562" left="1088" width="3" height="17" font="7"> </text>
<text top="561" left="1092" width="8" height="18" font="10"></text>
<text top="562" left="1100" width="167" height="17" font="7">4.5 m/s or Doppler AVA &gt;0.75 </text>
<text top="579" left="1065" width="16" height="17" font="7">cm</text>
<text top="581" left="1082" width="7" height="11" font="9">2 </text>
<text top="579" left="1088" width="178" height="17" font="7"> was 95% specific for noncritical </text>
<text top="597" left="1065" width="106" height="17" font="7">AS at cath (n=133) </text>
<text top="615" left="42" width="86" height="17" font="7">Otto, 1994 (59) </text>
<text top="632" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8313553">8313553</a></text>
<text top="632" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8313553"> </a></text>
<text top="615" left="178" width="87" height="17" font="7">Outcomes after </text>
<text top="632" left="178" width="76" height="17" font="7">aortic balloon </text>
<text top="649" left="178" width="46" height="17" font="7">dilation  </text>
<text top="615" left="301" width="49" height="17" font="7">Registry </text>
<text top="615" left="398" width="24" height="17" font="7">674 </text>
<text top="615" left="460" width="134" height="17" font="7">Severe symptomatic AS </text>
<text top="632" left="460" width="141" height="17" font="7">undergoing aortic balloon </text>
<text top="649" left="460" width="46" height="17" font="7">dilation  </text>
<text top="666" left="460" width="8" height="17" font="7">V</text>
<text top="672" left="468" width="15" height="11" font="9">max</text>
<text top="666" left="484" width="102" height="17" font="7"> 4.4±0.8 (2.3–6.6) </text>
<text top="683" left="460" width="23" height="17" font="7">m/s </text>
<text top="701" left="460" width="45" height="17" font="7">AVA 0.6</text>
<text top="702" left="505" width="2" height="11" font="9"> </text>
<text top="701" left="507" width="85" height="17" font="7">±0.2 ( 0.1–1.4) </text>
<text top="718" left="460" width="16" height="17" font="7">cm</text>
<text top="719" left="477" width="4" height="11" font="9">2</text>
<text top="718" left="481" width="3" height="17" font="7"> </text>
<text top="615" left="618" width="243" height="17" font="7">Overall survival was 55% at 1 y, 35% at 2 y, </text>
<text top="632" left="618" width="250" height="17" font="7">and 23% at 3 y, with 70% of deaths classified </text>
<text top="649" left="618" width="60" height="17" font="7">as cardiac </text>
<text top="615" left="886" width="137" height="17" font="7">Multivariate predictors of </text>
<text top="632" left="886" width="137" height="17" font="7">outcome were functional </text>
<text top="649" left="886" width="151" height="17" font="7">status, LV systolic function, </text>
<text top="666" left="886" width="150" height="17" font="7">renal function, sex, cardiac </text>
<text top="683" left="886" width="87" height="17" font="7">output, and MR </text>
<text top="615" left="1065" width="174" height="17" font="7">All pts underwent aortic balloon </text>
<text top="632" left="1065" width="195" height="17" font="7">dilation in this registry so outcomes </text>
<text top="649" left="1065" width="196" height="17" font="7">may be worse with no intervention.  </text>
<text top="736" left="34" width="1279" height="17" font="7">AS indicates aortic stenosis; AVA, aortic valve area; AVR, aortic valve replacement; cath, catheterization; CHF, congestive heart failure, echo, echocardiography; HF, heart failure; LV, left ventricular; LVEDP, left ventricular end diastolic </text>
<text top="754" left="34" width="405" height="17" font="7">pressure; MR, mitral regurgitation; N/A, not applicable; NS, nonsignificant; </text>
<text top="753" left="439" width="9" height="18" font="10"></text>
<text top="754" left="448" width="8" height="17" font="7">P</text>
<text top="760" left="456" width="20" height="11" font="9">mean</text>
<text top="754" left="477" width="370" height="17" font="7">, mean transaortic systolic pressure gradient; pt(s), patient(s); and V</text>
<text top="760" left="846" width="15" height="11" font="9">max</text>
<text top="754" left="862" width="105" height="17" font="7">, maximum velocity</text>
<text top="760" left="966" width="7" height="11" font="9">.  </text>
<text top="777" left="108" width="2" height="11" font="9"> </text>
<text top="777" left="324" width="2" height="11" font="9"> </text>
</page>
<page number="14" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">14 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="1131" height="21" font="4"><b>Data Supplement 8. Outcomes in Adults With Low-Flow/Low-Gradient Aortic Stenosis With Preserved Left Ventricular Ejection Fraction (stage S2) (Section 3.2.3) </b></text>
<text top="129" left="81" width="38" height="17" font="6"><b>Study </b></text>
<text top="129" left="204" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="129" left="348" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="462" width="66" height="17" font="6"><b>Study Size </b></text>
<text top="129" left="558" width="174" height="17" font="6"><b>Definition of LFLG severe AS </b></text>
<text top="129" left="761" width="61" height="17" font="6"><b>Exclusion </b></text>
<text top="146" left="769" width="46" height="17" font="6"><b>Criteria </b></text>
<text top="129" left="924" width="111" height="17" font="6"><b>Clinical Outcomes </b></text>
<text top="129" left="1205" width="67" height="17" font="6"><b>Comments </b></text>
<text top="176" left="42" width="114" height="17" font="7">Hachicha, 2007 (60) </text>
<text top="194" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17533183">17533183</a></text>
<text top="194" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17533183"> </a></text>
<text top="176" left="170" width="127" height="17" font="7">Determine prevalence, </text>
<text top="194" left="170" width="137" height="17" font="7">mechanisms and clinical </text>
<text top="211" left="170" width="135" height="17" font="7">relevant of LFLG severe </text>
<text top="228" left="170" width="90" height="17" font="7">AS with pLVEF  </text>
<text top="176" left="330" width="82" height="17" font="7">Retrospective, </text>
<text top="194" left="330" width="88" height="17" font="7">consecutive pts </text>
<text top="211" left="330" width="85" height="17" font="7">with severe AS </text>
<text top="228" left="330" width="28" height="17" font="7">(AVA</text>
<text top="234" left="359" width="2" height="11" font="9">i</text>
<text top="228" left="361" width="49" height="17" font="7"> ≤0.6 cm</text>
<text top="229" left="409" width="7" height="11" font="9">2 </text>
<text top="245" left="330" width="98" height="17" font="7">and LVEF ≥50%) </text>
<text top="176" left="448" width="81" height="17" font="7">512 pts, mean </text>
<text top="194" left="448" width="76" height="17" font="7">age 70±14 y, </text>
<text top="211" left="448" width="75" height="17" font="7">43% women  </text>
<text top="176" left="553" width="154" height="17" font="7">181 (35%) LFLG severe AS </text>
<text top="194" left="553" width="48" height="17" font="7">pLVEF:  </text>
<text top="211" left="553" width="16" height="17" font="7">SV</text>
<text top="216" left="570" width="2" height="11" font="9">i</text>
<text top="211" left="571" width="60" height="17" font="7"> ≤35 mL/m</text>
<text top="212" left="631" width="4" height="11" font="9">2</text>
<text top="211" left="635" width="32" height="17" font="7"> <b>and</b>  </text>
<text top="228" left="553" width="25" height="17" font="7">AVA</text>
<text top="234" left="578" width="2" height="11" font="9">i</text>
<text top="228" left="580" width="49" height="17" font="7"> ≤0.6 cm</text>
<text top="229" left="628" width="7" height="11" font="9">2 </text>
<text top="228" left="635" width="92" height="17" font="6"><b>and</b> LVEF≥50% </text>
<text top="245" left="553" width="3" height="17" font="7"> </text>
<text top="263" left="553" width="152" height="17" font="7">331 (65%) with normal flow </text>
<text top="280" left="553" width="20" height="17" font="7">(SV</text>
<text top="285" left="574" width="2" height="11" font="9">i</text>
<text top="280" left="576" width="58" height="17" font="7"> &gt;35 mL/m</text>
<text top="281" left="634" width="4" height="11" font="9">2</text>
<text top="280" left="639" width="51" height="17" font="7">) despite </text>
<text top="297" left="553" width="25" height="17" font="7">AVA</text>
<text top="303" left="578" width="2" height="11" font="9">i</text>
<text top="297" left="580" width="49" height="17" font="7"> ≤0.6 cm</text>
<text top="298" left="628" width="7" height="11" font="9">2 </text>
<text top="297" left="635" width="94" height="17" font="7">and LVEF≥ 50% </text>
<text top="176" left="749" width="69" height="17" font="7">LVEF &lt;50% </text>
<text top="176" left="847" width="226" height="17" font="7">76% survival at 3 y with LFLG severe AS </text>
<text top="194" left="847" width="258" height="17" font="7">86% survival at 3 y with normal flow severe AS </text>
<text top="211" left="847" width="56" height="17" font="7">(p=0.006) </text>
<text top="228" left="847" width="241" height="17" font="7">Multivariate predictors of overall death were </text>
<text top="245" left="847" width="258" height="17" font="7">older age, valvulo-arterial impedance ≥5.5 mm </text>
<text top="263" left="847" width="50" height="17" font="7">Hg/mL/m</text>
<text top="264" left="897" width="4" height="11" font="9">2</text>
<text top="263" left="902" width="209" height="17" font="7">, and medical (vs. surgical) treatment  </text>
<text top="176" left="1124" width="146" height="17" font="7">In LFLG severe AS group: </text>
<text top="194" left="1124" width="133" height="17" font="7">Average BSA 1.8±0.2 m</text>
<text top="195" left="1257" width="7" height="11" font="9">2 </text>
<text top="211" left="1124" width="153" height="17" font="7">Average AVA 0.76±0.23 cm</text>
<text top="212" left="1277" width="7" height="11" font="9">2 </text>
<text top="228" left="1124" width="57" height="17" font="7">Average V</text>
<text top="234" left="1181" width="15" height="11" font="9">max</text>
<text top="228" left="1197" width="73" height="17" font="7"> 3.5±0.9 m/s </text>
<text top="245" left="1124" width="229" height="17" font="7">LFLG severe AS typically associated with </text>
<text top="263" left="1124" width="193" height="17" font="7">small LV with restrictive physiology </text>
<text top="315" left="42" width="101" height="17" font="7">Jander, 2011 (47) </text>
<text top="332" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21321152">21321152</a></text>
<text top="332" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21321152"> </a></text>
<text top="315" left="170" width="135" height="17" font="7">Evaluate outcome of LG </text>
<text top="332" left="170" width="60" height="17" font="7">severe AS </text>
<text top="315" left="330" width="71" height="17" font="7">Prospective  </text>
<text top="332" left="330" width="97" height="17" font="7">(SEAS substudy) </text>
<text top="315" left="448" width="69" height="17" font="7">435 with LG </text>
<text top="332" left="448" width="79" height="17" font="7">severe AS vs. </text>
<text top="349" left="448" width="49" height="17" font="7">184 with </text>
<text top="366" left="448" width="75" height="17" font="7">moderate AS </text>
<text top="315" left="553" width="72" height="17" font="7">AVA &lt;1.0 cm</text>
<text top="316" left="625" width="4" height="11" font="9">2</text>
<text top="315" left="630" width="31" height="17" font="7"> and  </text>
<text top="332" left="553" width="9" height="18" font="10"></text>
<text top="333" left="563" width="8" height="17" font="7">P</text>
<text top="339" left="571" width="20" height="11" font="9">mean</text>
<text top="333" left="591" width="72" height="17" font="7"> ≤40 mm Hg </text>
<text top="350" left="553" width="167" height="17" font="7">(Moderate AS defined as AVA </text>
<text top="369" left="553" width="61" height="17" font="7">1.0–1.5 cm</text>
<text top="370" left="614" width="4" height="11" font="9">2</text>
<text top="369" left="619" width="7" height="17" font="7">, </text>
<text top="368" left="626" width="9" height="18" font="10"></text>
<text top="369" left="635" width="8" height="17" font="7">P</text>
<text top="375" left="643" width="22" height="11" font="9">mean </text>
<text top="369" left="665" width="65" height="17" font="7"> 25–40 mm </text>
<text top="386" left="553" width="23" height="17" font="7">Hg) </text>
<text top="315" left="749" width="61" height="17" font="7">See SEAS </text>
<text top="332" left="749" width="80" height="17" font="7">study in Table </text>
<text top="349" left="749" width="10" height="17" font="7">4 </text>
<text top="315" left="847" width="255" height="17" font="7">Aortic valve events (CV death, AVR,HF due to </text>
<text top="332" left="847" width="248" height="17" font="7">AS) at 46 mo were no different in pts with LG </text>
<text top="349" left="847" width="255" height="17" font="7">severe AS vs. those with moderate AS (48.5% </text>
<text top="366" left="847" width="106" height="17" font="7">vs. 44.6%; p=0.37) </text>
<text top="315" left="1124" width="218" height="17" font="7">In 223 pts with LFLG severe AS pLVEF </text>
<text top="332" left="1124" width="20" height="17" font="7">(SV</text>
<text top="338" left="1145" width="4" height="11" font="9">i </text>
<text top="332" left="1149" width="56" height="17" font="7">≤35 mL/m</text>
<text top="333" left="1205" width="4" height="11" font="9">2</text>
<text top="332" left="1209" width="143" height="17" font="7">) aortic valve events were </text>
<text top="349" left="1124" width="192" height="17" font="7">no different compared to pts with a </text>
<text top="366" left="1124" width="219" height="17" font="7">normal SVi (46.2% vs. 50.9%; p=0.53).  </text>
<text top="404" left="42" width="111" height="17" font="7">Tarantini, 2011 (61) </text>
<text top="421" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21619977">21619977</a></text>
<text top="421" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21619977"> </a></text>
<text top="438" left="42" width="3" height="17" font="7"> </text>
<text top="404" left="170" width="141" height="17" font="7">Investigate outcome after </text>
<text top="421" left="170" width="140" height="17" font="7">AVR for LFLG severe AS </text>
<text top="438" left="170" width="66" height="17" font="7">with pLVEF </text>
<text top="404" left="330" width="78" height="17" font="7">Retrospective </text>
<text top="421" left="330" width="85" height="17" font="7">surgical series  </text>
<text top="404" left="448" width="49" height="17" font="7">73 AVR  </text>
<text top="421" left="448" width="81" height="17" font="7">29 medical Rx </text>
<text top="404" left="553" width="73" height="17" font="7">AVA ≤1.0 cm</text>
<text top="405" left="626" width="4" height="11" font="9">2</text>
<text top="404" left="631" width="3" height="17" font="7"> </text>
<text top="421" left="553" width="69" height="17" font="7">LVEF &gt;50% </text>
<text top="439" left="553" width="9" height="18" font="10"></text>
<text top="440" left="563" width="8" height="17" font="7">P</text>
<text top="445" left="571" width="20" height="11" font="9">mean</text>
<text top="440" left="591" width="72" height="17" font="7"> ≤30 mm Hg </text>
<text top="404" left="749" width="59" height="17" font="7">Age &lt;18 y </text>
<text top="421" left="749" width="66" height="17" font="7">Other valve </text>
<text top="438" left="749" width="46" height="17" font="7">disease </text>
<text top="456" left="749" width="83" height="17" font="7">Previous valve </text>
<text top="473" left="749" width="44" height="17" font="7">surgery </text>
<text top="404" left="847" width="262" height="17" font="7">Overall mortality 37% at mean 42 mo follow-up. </text>
<text top="421" left="847" width="252" height="17" font="7">Cardiac death in 13 (18%) AVR and 15 (52%) </text>
<text top="438" left="847" width="141" height="17" font="7">medical Rx pts (p=0.001) </text>
<text top="456" left="847" width="258" height="17" font="7">AVR was a predictor of survival on multivariate </text>
<text top="473" left="847" width="222" height="17" font="7">analysis, even in the 78 pts with an AVA </text>
<text top="490" left="847" width="131" height="17" font="7">between 0.8 and 1.0 cm</text>
<text top="491" left="979" width="4" height="11" font="9">2</text>
<text top="490" left="983" width="10" height="17" font="7">.  </text>
<text top="404" left="1124" width="222" height="17" font="7">Low SVi present in 20 (27%) AVR and 6 </text>
<text top="421" left="1124" width="220" height="17" font="7">(21%) medical Rx pts with no difference </text>
<text top="438" left="1124" width="186" height="17" font="7">in outcome for normal vs. low SVi </text>
<text top="456" left="1124" width="3" height="17" font="7"> </text>
<text top="473" left="1124" width="226" height="17" font="7">Retrospective database of 2,055 pts with </text>
<text top="490" left="1124" width="90" height="17" font="7">an AVA ≤1.0 cm</text>
<text top="491" left="1214" width="4" height="11" font="9">2</text>
<text top="490" left="1219" width="117" height="17" font="7">; LVEF &lt;50% in 25% </text>
<text top="507" left="1124" width="24" height="17" font="7">and </text>
<text top="508" left="1148" width="2" height="11" font="9"> </text>
<text top="507" left="1150" width="203" height="17" font="7">LFLG severe AS pLVEF in 5% of pts </text>
<text top="525" left="42" width="97" height="17" font="7">Clavel, 2012 (62) </text>
<text top="543" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22657269">22657269</a></text>
<text top="543" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22657269"> </a></text>
<text top="525" left="170" width="137" height="17" font="7">Compare outcome in AS </text>
<text top="543" left="170" width="140" height="17" font="7">with normal LVEF with 1) </text>
<text top="560" left="170" width="139" height="17" font="7">LFLG severe AS, 2) high </text>
<text top="577" left="170" width="134" height="17" font="7">mean gradient (&gt;40 mm </text>
<text top="594" left="170" width="125" height="17" font="7">Hg) severe AS, and 3) </text>
<text top="611" left="170" width="135" height="17" font="7">moderate AS (AVA &gt;1.0 </text>
<text top="629" left="170" width="16" height="17" font="7">cm</text>
<text top="630" left="186" width="4" height="11" font="9">2</text>
<text top="629" left="191" width="8" height="17" font="7">) </text>
<text top="525" left="330" width="201" height="17" font="7">Case match study  187 with LFLG </text>
<text top="543" left="448" width="60" height="17" font="7">severe AS </text>
<text top="560" left="448" width="88" height="17" font="7">matched to 187 </text>
<text top="577" left="448" width="75" height="17" font="7">moderate AS </text>
<text top="594" left="448" width="75" height="17" font="7">and 187 high-</text>
<text top="611" left="448" width="85" height="17" font="7">flow severe AS </text>
<text top="525" left="553" width="9" height="18" font="10"></text>
<text top="526" left="563" width="8" height="17" font="7">P</text>
<text top="532" left="571" width="20" height="11" font="9">mean</text>
<text top="526" left="591" width="71" height="17" font="7"> &lt;40 mm Hg </text>
<text top="544" left="553" width="16" height="17" font="7">SV</text>
<text top="549" left="570" width="2" height="11" font="9">i</text>
<text top="544" left="571" width="58" height="17" font="7"> &lt;35 mL/m</text>
<text top="545" left="630" width="4" height="11" font="9">2</text>
<text top="544" left="634" width="31" height="17" font="7"> and  </text>
<text top="561" left="553" width="73" height="17" font="7">AVA ≤1.0 cm</text>
<text top="562" left="626" width="7" height="11" font="9">2 </text>
<text top="561" left="633" width="3" height="17" font="7"> </text>
<text top="525" left="749" width="73" height="17" font="7">LVEF &lt;50%  </text>
<text top="525" left="847" width="118" height="17" font="7">Survival at 1 and 5 y: </text>
<text top="543" left="847" width="236" height="17" font="7">LFLG severe AS pLVEF           89±2% and </text>
<text top="560" left="847" width="43" height="17" font="7">64±4% </text>
<text top="577" left="847" width="235" height="17" font="7">High-gradient severe AS          96±1% and </text>
<text top="594" left="847" width="43" height="17" font="7">82±3% </text>
<text top="611" left="847" width="234" height="17" font="7">Moderate AS                            96±1% and </text>
<text top="629" left="847" width="43" height="17" font="7">81±3% </text>
<text top="525" left="1124" width="215" height="17" font="7">AVR associated with improved survival </text>
<text top="543" left="1124" width="212" height="17" font="7">for high-gradient severe AS (HR: 0.18; </text>
<text top="560" left="1124" width="211" height="17" font="7">p=0.001) and LFLG severe AS pLVEF </text>
<text top="577" left="1124" width="223" height="17" font="7">(HR: 0.50; p=0.04), but not for moderate </text>
<text top="594" left="1124" width="23" height="17" font="7">AS  </text>
<text top="647" left="42" width="93" height="17" font="7">Lancellotti, 2012 </text>
<text top="664" left="42" width="25" height="17" font="7">(63) </text>
<text top="681" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22240128">22240128</a></text>
<text top="681" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22240128"> </a></text>
<text top="647" left="170" width="145" height="17" font="7">Evaluate clinical course in </text>
<text top="664" left="170" width="128" height="17" font="7">AS pts stratified by SVi </text>
<text top="682" left="170" width="24" height="17" font="7">and </text>
<text top="681" left="194" width="9" height="18" font="10"></text>
<text top="682" left="203" width="8" height="17" font="7">P</text>
<text top="688" left="211" width="20" height="11" font="9">mean</text>
<text top="682" left="231" width="3" height="17" font="7"> </text>
<text top="647" left="330" width="71" height="17" font="7">Prospective  </text>
<text top="647" left="448" width="24" height="17" font="7">150 </text>
<text top="664" left="448" width="88" height="17" font="7">consecutive pts </text>
<text top="681" left="448" width="25" height="17" font="7">with </text>
<text top="698" left="448" width="79" height="17" font="7">asymptomatic </text>
<text top="715" left="448" width="60" height="17" font="7">severe AS </text>
<text top="733" left="448" width="76" height="17" font="7">(AVA &lt;1.0 cm</text>
<text top="734" left="525" width="4" height="11" font="9">2</text>
<text top="733" left="529" width="8" height="17" font="7">) </text>
<text top="750" left="448" width="91" height="17" font="7">referred for ETT </text>
<text top="647" left="553" width="21" height="17" font="7">LF: </text>
<text top="664" left="553" width="88" height="17" font="7">SVi &lt;35 mL/m2 </text>
<text top="682" left="553" width="23" height="17" font="7">LG: </text>
<text top="681" left="577" width="9" height="18" font="10"></text>
<text top="682" left="586" width="8" height="17" font="7">P</text>
<text top="688" left="594" width="22" height="11" font="9">mean </text>
<text top="682" left="616" width="71" height="17" font="7"> &lt;40 mm Hg </text>
<text top="699" left="553" width="116" height="17" font="7">(all had AVA &lt;1.0 cm</text>
<text top="700" left="669" width="4" height="11" font="9">2</text>
<text top="699" left="674" width="8" height="17" font="7">) </text>
<text top="647" left="749" width="73" height="17" font="7">LVEF &lt;55%, </text>
<text top="664" left="749" width="63" height="17" font="7">other valve </text>
<text top="681" left="749" width="72" height="17" font="7">disease, AS, </text>
<text top="698" left="749" width="61" height="17" font="7">pulmonary </text>
<text top="715" left="749" width="49" height="17" font="7">disease, </text>
<text top="733" left="749" width="58" height="17" font="7">inability to </text>
<text top="750" left="749" width="49" height="17" font="7">exercise </text>
<text top="647" left="847" width="205" height="17" font="7">Event free survival at 2 y (p&lt;0.0001): </text>
<text top="665" left="856" width="3" height="17" font="7"> </text>
<text top="665" left="994" width="151" height="17" font="7">Normal flow (SVi ≥35 mL/m</text>
<text top="666" left="1145" width="4" height="11" font="9">2</text>
<text top="665" left="1149" width="8" height="17" font="7">) </text>
<text top="665" left="1183" width="134" height="17" font="7">Low-flow (SVi &lt;35 mL/m</text>
<text top="666" left="1316" width="4" height="11" font="9">2</text>
<text top="665" left="1321" width="8" height="17" font="7">) </text>
<text top="689" left="856" width="81" height="17" font="7">High-gradient  </text>
<text top="706" left="856" width="9" height="18" font="10"></text>
<text top="707" left="865" width="8" height="17" font="7">P</text>
<text top="713" left="873" width="22" height="11" font="9">mean </text>
<text top="707" left="896" width="75" height="17" font="7"> ≥40 mm Hg  </text>
<text top="689" left="994" width="82" height="17" font="7">44±6% (n=78) </text>
<text top="689" left="1183" width="89" height="17" font="7">30±12% (n=15) </text>
<text top="727" left="856" width="78" height="17" font="7">Low-gradient  </text>
<text top="744" left="856" width="9" height="18" font="10"></text>
<text top="745" left="865" width="8" height="17" font="7">P</text>
<text top="751" left="873" width="22" height="11" font="9">mean </text>
<text top="745" left="896" width="71" height="17" font="7"> &lt;40 mm Hg </text>
<text top="727" left="994" width="82" height="17" font="7">83±6% (n=46) </text>
<text top="727" left="1183" width="89" height="17" font="7">27±13% (n=11) </text>
<text top="765" left="847" width="3" height="17" font="7"> </text>
<text top="782" left="847" width="330" height="17" font="7">Predefined endpoints were CV death in 6 and AVR in 70 pts </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">15 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="81" width="38" height="17" font="6"><b>Study </b></text>
<text top="108" left="204" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="348" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="462" width="66" height="17" font="6"><b>Study Size </b></text>
<text top="108" left="558" width="174" height="17" font="6"><b>Definition of LFLG severe AS </b></text>
<text top="108" left="761" width="61" height="17" font="6"><b>Exclusion </b></text>
<text top="126" left="769" width="46" height="17" font="6"><b>Criteria </b></text>
<text top="108" left="924" width="111" height="17" font="6"><b>Clinical Outcomes </b></text>
<text top="108" left="1205" width="67" height="17" font="6"><b>Comments </b></text>
<text top="156" left="42" width="114" height="17" font="7">Herrmann 2013 (15) </text>
<text top="173" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23661722">23661722</a></text>
<text top="173" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23661722"> </a></text>
<text top="156" left="170" width="133" height="17" font="7">Evaluate outcomes with </text>
<text top="173" left="170" width="108" height="17" font="7">TAVR compared to </text>
<text top="190" left="170" width="135" height="17" font="7">medical therapy with LG </text>
<text top="207" left="170" width="60" height="17" font="7">severe AS </text>
<text top="156" left="330" width="104" height="17" font="7">Subgroup analysis </text>
<text top="173" left="330" width="46" height="17" font="7">of RCT  </text>
<text top="156" left="448" width="81" height="17" font="7">52 inoperable  </text>
<text top="173" left="448" width="72" height="17" font="7">symptomatic </text>
<text top="190" left="448" width="79" height="17" font="7">pts with LFLG </text>
<text top="207" left="448" width="85" height="17" font="7">severe AS with </text>
<text top="225" left="448" width="79" height="17" font="7">normal LVEF  </text>
<text top="156" left="553" width="9" height="18" font="10"></text>
<text top="157" left="563" width="8" height="17" font="7">P</text>
<text top="163" left="571" width="20" height="11" font="9">mean</text>
<text top="157" left="591" width="71" height="17" font="7"> &lt;40 mm Hg </text>
<text top="174" left="553" width="16" height="17" font="7">SV</text>
<text top="180" left="570" width="2" height="11" font="9">i</text>
<text top="174" left="571" width="58" height="17" font="7"> &lt;35 mL/m</text>
<text top="175" left="630" width="4" height="11" font="9">2</text>
<text top="174" left="634" width="31" height="17" font="7"> and  </text>
<text top="191" left="553" width="72" height="17" font="7">AVA &lt;0.8 cm</text>
<text top="192" left="625" width="7" height="11" font="9">2 </text>
<text top="191" left="632" width="73" height="17" font="7">or AVAi &lt;0.5 </text>
<text top="209" left="553" width="16" height="17" font="7">cm</text>
<text top="210" left="570" width="4" height="11" font="9">2</text>
<text top="209" left="574" width="14" height="17" font="7">/m</text>
<text top="210" left="588" width="7" height="16" font="9">2 </text>
<text top="156" left="749" width="69" height="17" font="7">LVEF &lt;50% </text>
<text top="173" left="749" width="3" height="17" font="7"> </text>
<text top="156" left="847" width="501" height="17" font="7">In 52 inoperable pts with LFLG severe AS with preserved LVEF, 1-y mortality was 66% with </text>
<text top="173" left="847" width="360" height="17" font="7">TAVR compared to 35% with medical therapy (HR: 0.38; p=0.02). </text>
<text top="190" left="847" width="499" height="17" font="7">In 87 pts at high risk for surgery, there was no difference between TAVR and SAVR (39.0% </text>
<text top="207" left="847" width="270" height="17" font="7">vs. 38.3%; HR: 0.91; 95% CI: 0.57–1.45; p=0.69. </text>
<text top="243" left="42" width="98" height="17" font="7">Le Ven 2013 (64) </text>
<text top="260" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23770162">23770162</a></text>
<text top="260" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23770162"> </a></text>
<text top="277" left="42" width="3" height="17" font="7"> </text>
<text top="243" left="170" width="136" height="17" font="7">Evaluate effect of LV EF </text>
<text top="260" left="170" width="146" height="17" font="7">and gradient on outcomes </text>
<text top="277" left="170" width="64" height="17" font="7">after TAVR </text>
<text top="243" left="330" width="78" height="17" font="7">Retrospective </text>
<text top="260" left="330" width="105" height="17" font="7">analysis of registry </text>
<text top="277" left="330" width="27" height="17" font="7">data </text>
<text top="243" left="448" width="84" height="17" font="7">639 severe AS </text>
<text top="260" left="448" width="65" height="17" font="7">undergoing </text>
<text top="277" left="448" width="36" height="17" font="7">TAVR </text>
<text top="243" left="553" width="133" height="17" font="7">Low flow (SVi &lt;35 mL/m</text>
<text top="244" left="686" width="4" height="11" font="9">2</text>
<text top="243" left="691" width="43" height="17" font="7">) with a </text>
<text top="260" left="553" width="173" height="17" font="7">normal EF (&gt;50%) was present </text>
<text top="277" left="553" width="103" height="17" font="7">in 86 (13%) of pts  </text>
<text top="243" left="749" width="16" height="17" font="7">--- </text>
<text top="243" left="847" width="476" height="17" font="7">Low flow (but not low EF) was an independent predictor of 30-day mortality (odds ratio: </text>
<text top="260" left="847" width="454" height="17" font="7">1.94, p=0.026), cumulative all-cause mortality (hazard ratio: 1.27 per 10 mL/m² SVi </text>
<text top="277" left="847" width="473" height="17" font="7">decrease, p=0.016), and cumulative cardiovascular mortality (hazard ratio: 1.29 per 10 </text>
<text top="294" left="847" width="148" height="17" font="7">mL/m² decrease, p=0.04).  </text>
<text top="312" left="42" width="109" height="17" font="7">Mehrotra 2013 (65) </text>
<text top="329" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23533186">23533186</a></text>
<text top="329" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23533186"> </a></text>
<text top="312" left="170" width="94" height="17" font="7">Compare clinical </text>
<text top="329" left="170" width="106" height="17" font="7">characteristics and </text>
<text top="347" left="170" width="89" height="17" font="7">outcomes in AS </text>
<text top="364" left="170" width="61" height="17" font="7">subgroups </text>
<text top="312" left="330" width="78" height="17" font="7">Retrospective </text>
<text top="329" left="330" width="104" height="17" font="7">echocardiographic </text>
<text top="347" left="330" width="54" height="17" font="7">database </text>
<text top="312" left="448" width="74" height="17" font="7">LFLG severe </text>
<text top="329" left="448" width="73" height="17" font="7">AS in 38 pts, </text>
<text top="347" left="448" width="89" height="17" font="7">compared to 75 </text>
<text top="364" left="448" width="88" height="17" font="7">normal flow low </text>
<text top="381" left="448" width="89" height="17" font="7">gradient and 70 </text>
<text top="398" left="448" width="75" height="17" font="7">moderate AS </text>
<text top="415" left="448" width="23" height="17" font="7">pts. </text>
<text top="314" left="553" width="28" height="17" font="7">AVA </text>
<text top="312" left="581" width="8" height="18" font="10"></text>
<text top="314" left="590" width="103" height="17" font="7">1.0 cm2 with LVEF</text>
<text top="312" left="693" width="8" height="18" font="10"></text>
<text top="314" left="701" width="35" height="17" font="7"> 55%, </text>
<text top="331" left="553" width="173" height="17" font="7">mead gradient &lt;40 mm Hg and </text>
<text top="348" left="553" width="77" height="17" font="7">SVi &lt;35 mL/m</text>
<text top="349" left="631" width="4" height="11" font="9">2</text>
<text top="348" left="635" width="10" height="17" font="7">.  </text>
<text top="312" left="749" width="65" height="17" font="7">Mitral valve </text>
<text top="329" left="749" width="83" height="17" font="7">disease, aortic </text>
<text top="347" left="749" width="75" height="17" font="7">regurgitation, </text>
<text top="364" left="749" width="67" height="17" font="7">poor quality </text>
<text top="381" left="749" width="40" height="17" font="7">study.  </text>
<text top="398" left="749" width="62" height="17" font="7">Severe AS </text>
<text top="415" left="749" width="59" height="17" font="7">with mean </text>
<text top="433" left="749" width="72" height="17" font="7">gradient &gt;40 </text>
<text top="450" left="749" width="50" height="17" font="7">mm Hg.  </text>
<text top="312" left="847" width="484" height="17" font="7">Survival at 3 years was significantly lower in LF LG compared with NF LG (p=0.006) and </text>
<text top="329" left="847" width="466" height="17" font="7">moderate AS (p=0.002), but not different between NF LG and moderate AS (p=0.49). </text>
<text top="468" left="42" width="95" height="17" font="7">Ozkan 2013 (66) </text>
<text top="485" left="42" width="58" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23812184">23812184 </a></text>
<text top="485" left="100" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23812184"> </a></text>
<text top="468" left="170" width="144" height="17" font="7">Compare outcomes of LG </text>
<text top="485" left="170" width="128" height="17" font="7">severe AS with AVR or </text>
<text top="502" left="170" width="90" height="17" font="7">medical therapy </text>
<text top="468" left="330" width="67" height="17" font="7">Prospective </text>
<text top="485" left="330" width="66" height="17" font="7">follow-up of </text>
<text top="502" left="330" width="72" height="17" font="7">symptomatic </text>
<text top="519" left="330" width="80" height="17" font="7">severe LG AS </text>
<text top="468" left="448" width="72" height="17" font="7">260 pts  with </text>
<text top="485" left="448" width="72" height="17" font="7">symptomatic </text>
<text top="502" left="448" width="60" height="17" font="7">severe AS </text>
<text top="521" left="448" width="35" height="17" font="7">(AVAi </text>
<text top="520" left="483" width="8" height="18" font="10"></text>
<text top="521" left="491" width="21" height="17" font="7">0.6 </text>
<text top="538" left="448" width="16" height="17" font="7">cm</text>
<text top="539" left="465" width="4" height="11" font="9">2</text>
<text top="538" left="469" width="14" height="17" font="7">/m</text>
<text top="539" left="483" width="7" height="11" font="9">2 </text>
<text top="538" left="490" width="31" height="17" font="7">) and </text>
<text top="555" left="448" width="82" height="17" font="7">mean gradient </text>
<text top="572" left="448" width="64" height="17" font="7">&lt;40 mm Hg</text>
<text top="578" left="512" width="2" height="11" font="9"> </text>
<text top="468" left="553" width="175" height="17" font="7">Normal flow present in 125; low </text>
<text top="485" left="553" width="108" height="17" font="7">flow (SVi ≤35 mL/m</text>
<text top="486" left="661" width="4" height="11" font="9">2</text>
<text top="485" left="666" width="48" height="17" font="7">) in 135. </text>
<text top="468" left="749" width="83" height="17" font="7">Mitral disease, </text>
<text top="485" left="749" width="33" height="17" font="7">aortic </text>
<text top="502" left="749" width="72" height="17" font="7">regurgitation </text>
<text top="468" left="847" width="490" height="17" font="7">At 28 ±24 mos follow-up, 105 pts died (40%): 32 (30%) in the AVR group and 73 (70%) in </text>
<text top="485" left="847" width="494" height="17" font="7">the medical treatment group. AVR (hazard ratio, 0.54; 95% confidence interval, 0.32–0.94; </text>
<text top="502" left="847" width="487" height="17" font="7">p&lt;0.001) was independently associated with outcome and remained a strong predictor of </text>
<text top="519" left="847" width="489" height="17" font="7">survival after adjustment for propensity score.  The protective effect of AVR was similar in </text>
<text top="537" left="847" width="307" height="17" font="7">125 pts with normal flow (stroke volume index &gt;35 mL/m</text>
<text top="538" left="1155" width="4" height="11" font="9">2</text>
<text top="537" left="1159" width="56" height="17" font="7">; p=0.22). </text>
<text top="590" left="42" width="87" height="17" font="7">Eleid 2013 (67) </text>
<text top="607" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24048203">24048203</a></text>
<text top="607" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24048203"> </a></text>
<text top="590" left="170" width="141" height="17" font="7">Evaluate impact of stroke </text>
<text top="607" left="170" width="145" height="17" font="7">volume with normal EF on </text>
<text top="625" left="170" width="146" height="17" font="7">outcomes with severe AS  </text>
<text top="590" left="330" width="105" height="17" font="7">Echocardiographic </text>
<text top="607" left="330" width="57" height="17" font="7">database. </text>
<text top="590" left="448" width="34" height="17" font="7">1,704 </text>
<text top="607" left="448" width="88" height="17" font="7">consecutive pts </text>
<text top="625" left="448" width="85" height="17" font="7">with severe AS </text>
<text top="642" left="448" width="76" height="17" font="7">(AVA &lt;1.0 cm</text>
<text top="643" left="525" width="4" height="11" font="9">2</text>
<text top="642" left="529" width="8" height="17" font="7">) </text>
<text top="660" left="448" width="54" height="17" font="7">and LVEF</text>
<text top="659" left="503" width="8" height="18" font="10"></text>
<text top="660" left="511" width="28" height="17" font="7">50% </text>
<text top="590" left="553" width="140" height="17" font="7">Low flow = SVi ≤35 mL/m</text>
<text top="591" left="694" width="7" height="11" font="9">2 </text>
<text top="607" left="553" width="145" height="17" font="7">Low gradient &lt;40 mm Hg. </text>
<text top="625" left="553" width="3" height="17" font="7"> </text>
<text top="642" left="553" width="158" height="17" font="7">LFLG present in 53 pts (3%) </text>
<text top="659" left="553" width="158" height="17" font="7">compared to normal flow LG </text>
<text top="676" left="553" width="142" height="17" font="7">(n=352, 21%) and to high </text>
<text top="694" left="553" width="115" height="17" font="7">gradient severe AS.  </text>
<text top="590" left="749" width="58" height="17" font="7">Prosthetic </text>
<text top="607" left="749" width="35" height="17" font="7">valve, </text>
<text top="625" left="749" width="74" height="17" font="7">congenital or </text>
<text top="642" left="749" width="68" height="17" font="7">other native </text>
<text top="659" left="749" width="78" height="17" font="7">valve disease </text>
<text top="590" left="847" width="475" height="17" font="7">AVR was associated with a 69% mortality reduction (HR 0.31 (0.25, 0.39) p&lt;0.0001) in </text>
<text top="607" left="847" width="471" height="17" font="7">LF/LG and NF/HG, with no survival benefit associated with AVR in NF/LG and LF/HG. </text>
<text top="712" left="34" width="1278" height="17" font="7">AS indicates aortic stenosis; AVAi, aortic valve area indexed to body surface area; AVR, aortic valve replacement; BSA, body surface area; CV, cardiovascular; ETT, exercise treadmill testing; HG, high gradient; HF, heart failure; LFLG, </text>
<text top="730" left="34" width="765" height="17" font="7">low-flow low-gradient; LF, low-flow; LG, low-gradient; LV, left ventricular; NF, normal flow; pLVEF, preserved left ventricular ejection fraction; </text>
<text top="729" left="799" width="9" height="18" font="10"></text>
<text top="730" left="808" width="8" height="17" font="7">P</text>
<text top="736" left="816" width="20" height="11" font="9">mean</text>
<text top="730" left="836" width="475" height="17" font="7">, mean transaortic systolic pressure gradient; RCT, randomized controlled clinical trial;  </text>
<text top="747" left="34" width="820" height="17" font="7">Rx, prescription; SEAS, Simvastatin Ezetimibe in Aortic Stenosis study; SVi, stroke volume index; TAVR, transcatheter aortic valve replacement; and V</text>
<text top="753" left="854" width="20" height="11" font="9">max, </text>
<text top="747" left="874" width="98" height="17" font="7">maximum velocity</text>
<text top="753" left="971" width="7" height="11" font="9">.  </text>
<text top="770" left="108" width="2" height="11" font="9"> </text>
<text top="787" left="108" width="2" height="11" font="9"> </text>
<text top="787" left="324" width="2" height="11" font="9"> </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">16 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="34" width="1245" height="21" font="4"><b>Data Supplement 9. Choice of Intervention in Symptomatic Adults With Severe Aortic Stenosis (stage D): Surgical Versus Transcatheter Aortic Valve Replacement (Section 3.2.4) </b></text>
<text top="129" left="64" width="41" height="17" font="6"><b>Study  </b></text>
<text top="129" left="141" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="129" left="246" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="249" width="32" height="17" font="6"><b>Type </b></text>
<text top="129" left="317" width="112" height="17" font="6"><b>Study Groups (N)   </b></text>
<text top="129" left="536" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="129" left="846" width="100" height="17" font="6"><b>Major Endpoints </b></text>
<text top="129" left="1154" width="84" height="17" font="6"><b>Other Results </b></text>
<text top="146" left="1195" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="42" width="62" height="17" font="7">PARTNER </text>
<text top="182" left="42" width="68" height="17" font="7">COHORT A </text>
<text top="199" left="42" width="77" height="17" font="7">(high-surgical </text>
<text top="216" left="42" width="30" height="17" font="7">risk)  </text>
<text top="233" left="42" width="25" height="17" font="7">(68) </text>
<text top="250" left="42" width="55" height="17" font="8"><a href="file:///C:/Users/Jenny/AppData/Local/Temp/4vkfgit0.tmp/%5dhttp:/www.ncbi.nlm.nih.gov/pubmed/21639811">21639811</a></text>
<text top="250" left="96" width="3" height="17" font="7"><a href="file:///C:/Users/Jenny/AppData/Local/Temp/4vkfgit0.tmp/%5dhttp:/www.ncbi.nlm.nih.gov/pubmed/21639811"> </a></text>
<text top="268" left="42" width="25" height="17" font="7">(69) </text>
<text top="285" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22443479">22443479</a></text>
<text top="285" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22443479"> </a></text>
<text top="302" left="42" width="3" height="17" font="7"> </text>
<text top="164" left="136" width="74" height="17" font="7">To show that </text>
<text top="182" left="136" width="69" height="17" font="7">TAVR is not </text>
<text top="199" left="136" width="55" height="17" font="7">inferior to </text>
<text top="216" left="136" width="40" height="17" font="7">SAVR  </text>
<text top="164" left="238" width="32" height="17" font="7">RCT  </text>
<text top="164" left="305" width="116" height="17" font="7">TAVR 348 vs. SAVR </text>
<text top="182" left="305" width="24" height="17" font="7">351 </text>
<text top="199" left="305" width="3" height="17" font="7"> </text>
<text top="216" left="305" width="61" height="17" font="7">TAVR was </text>
<text top="233" left="305" width="109" height="17" font="7">transfemoral in 244 </text>
<text top="250" left="305" width="127" height="17" font="7">and transapical in 104  </text>
<text top="164" left="447" width="277" height="17" font="6"><b>Severe symptomatic calcific AS</b> defined as AVA </text>
<text top="183" left="447" width="44" height="17" font="7">&lt;0.8 cm</text>
<text top="184" left="491" width="4" height="11" font="9">2</text>
<text top="183" left="495" width="74" height="17" font="7"> plus a mean </text>
<text top="182" left="569" width="9" height="18" font="10"></text>
<text top="183" left="578" width="102" height="17" font="7">P ≥40 mm Hg or V</text>
<text top="188" left="681" width="15" height="11" font="9">max</text>
<text top="183" left="696" width="32" height="17" font="7"> ≥4.0 </text>
<text top="200" left="447" width="210" height="17" font="7">m/s with NYHA class II-IV symptoms.  </text>
<text top="217" left="447" width="3" height="17" font="7"> </text>
<text top="234" left="447" width="290" height="17" font="6"><b>High surgical risk</b> defined as ≥15% risk of death by </text>
<text top="252" left="447" width="279" height="17" font="7">30 d after the procedure. An STS score ≥10% was </text>
<text top="269" left="447" width="288" height="17" font="7">used for guidance with an actual mean STS score of </text>
<text top="286" left="447" width="64" height="17" font="7">11.8±3.3% </text>
<text top="303" left="447" width="3" height="17" font="7"> </text>
<text top="320" left="447" width="245" height="17" font="6"><b>Exclusions</b> were bicuspid aortic valve, AMI, </text>
<text top="338" left="447" width="279" height="17" font="7">significant CAD, LVEF&lt;20%, aortic annulus &lt;18 or </text>
<text top="355" left="447" width="259" height="17" font="7">&gt;25 mm, severe AR or MR, TIA within 6 mo, or </text>
<text top="372" left="447" width="141" height="17" font="7">severe renal insufficiency </text>
<text top="164" left="751" width="262" height="17" font="6"><b>All cause death (intention to treat analysis):  </b></text>
<text top="182" left="759" width="3" height="17" font="6"><b> </b></text>
<text top="182" left="825" width="154" height="17" font="6"><b>TAVR  SAVR  p-value </b></text>
<text top="202" left="759" width="28" height="17" font="6"><b>30 d </b></text>
<text top="202" left="825" width="31" height="17" font="7">3.4% </text>
<text top="202" left="879" width="31" height="17" font="7">6.5% </text>
<text top="202" left="933" width="27" height="17" font="7">0.07 </text>
<text top="222" left="759" width="25" height="17" font="6"><b>1 y* </b></text>
<text top="222" left="825" width="146" height="17" font="7">24.2%  26.8%  0.44% </text>
<text top="243" left="759" width="21" height="17" font="6"><b>2 y </b></text>
<text top="243" left="825" width="135" height="17" font="7">33.9%  35.0%  0.78 </text>
<text top="264" left="751" width="153" height="17" font="7">*(p=0.001 for noninferiority) </text>
<text top="281" left="751" width="3" height="17" font="7"> </text>
<text top="298" left="751" width="161" height="17" font="6"><b>Composite endpoint at 2 y  </b></text>
<text top="315" left="751" width="159" height="17" font="6"><b>–all-cause death or stroke</b>: </text>
<text top="332" left="751" width="219" height="17" font="7">TAVR 37.1% vs. SAVR 36.4% (p=0.85) </text>
<text top="350" left="751" width="206" height="17" font="7">HR: 0.93; 95% CI: 0.73–1.18; p=0.55 </text>
<text top="164" left="1054" width="114" height="17" font="11"><i>Stroke or TIA at 2 y</i><b>: </b></text>
<text top="182" left="1054" width="222" height="17" font="7">TAVR 11.2 % vs. SAVR 6.5 % (p=0.05)  </text>
<text top="199" left="1054" width="3" height="17" font="11"><i> </i></text>
<text top="216" left="1054" width="206" height="17" font="11"><i>Major vascular complications at 30 d:</i> </text>
<text top="233" left="1054" width="219" height="17" font="7">TAVR 11.0% vs. SAVR 3.2% (p&lt;0.001) </text>
<text top="250" left="1054" width="3" height="17" font="11"><i> </i></text>
<text top="268" left="1054" width="129" height="17" font="11"><i>Major bleeding at 30 d: </i></text>
<text top="285" left="1054" width="222" height="17" font="7">TAVR 9.3% vs. SAVR 19.5% (p&lt;0.001)  </text>
<text top="302" left="1054" width="3" height="17" font="11"><i> </i></text>
<text top="319" left="1054" width="129" height="17" font="11"><i>New-onset AF at 30 d: </i> </text>
<text top="337" left="1054" width="222" height="17" font="7">TAVR 8.6% vs. SAVR 16.0% (p=0.006). </text>
<text top="390" left="42" width="62" height="17" font="7">PARTNER </text>
<text top="407" left="42" width="68" height="17" font="7">COHORT B </text>
<text top="424" left="42" width="73" height="17" font="7">(inoperable)  </text>
<text top="442" left="42" width="25" height="17" font="7">(70) </text>
<text top="459" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22443478">22443478</a></text>
<text top="459" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22443478"> </a></text>
<text top="476" left="42" width="25" height="17" font="7">(71) </text>
<text top="493" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20961243">20961243</a></text>
<text top="493" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20961243"> </a></text>
<text top="510" left="42" width="3" height="17" font="7"> </text>
<text top="390" left="136" width="54" height="17" font="7">Compare </text>
<text top="407" left="136" width="50" height="17" font="7">TAVR to </text>
<text top="424" left="136" width="77" height="17" font="7">medical Rx in </text>
<text top="442" left="136" width="81" height="17" font="7">inoperable pts </text>
<text top="459" left="136" width="65" height="17" font="7">with severe </text>
<text top="476" left="136" width="72" height="17" font="7">symptomatic </text>
<text top="493" left="136" width="23" height="17" font="7">AS  </text>
<text top="390" left="238" width="29" height="17" font="7">RCT </text>
<text top="390" left="305" width="92" height="17" font="7">TAVR in 179 vs. </text>
<text top="407" left="305" width="97" height="17" font="7">standard medical </text>
<text top="424" left="305" width="81" height="17" font="7">therapy in 179 </text>
<text top="442" left="305" width="121" height="17" font="7">(including BAV in 150 </text>
<text top="459" left="305" width="36" height="17" font="7">(84%) </text>
<text top="390" left="447" width="277" height="17" font="6"><b>Severe symptomatic calcific AS</b> defined as AVA </text>
<text top="409" left="447" width="44" height="17" font="7">&lt;0.8 cm</text>
<text top="410" left="491" width="4" height="11" font="9">2</text>
<text top="409" left="495" width="74" height="17" font="7"> plus a mean </text>
<text top="408" left="569" width="9" height="18" font="10"></text>
<text top="409" left="578" width="102" height="17" font="7">P ≥40 mm Hg or V</text>
<text top="414" left="681" width="15" height="11" font="9">max</text>
<text top="409" left="696" width="32" height="17" font="7"> ≥4.0 </text>
<text top="426" left="447" width="210" height="17" font="7">m/s with NYHA class II-IV symptoms.  </text>
<text top="443" left="447" width="3" height="17" font="7"> </text>
<text top="460" left="447" width="245" height="17" font="6"><b>Inoperable</b> due to coexisting conditions with </text>
<text top="477" left="447" width="237" height="17" font="7">predicted ≥50% risk of death within 30 d of </text>
<text top="494" left="447" width="258" height="17" font="7">intervention or a serious irreversible condition.  </text>
<text top="512" left="447" width="3" height="17" font="7"> </text>
<text top="529" left="447" width="245" height="17" font="6"><b>Exclusions </b>were bicuspid aortic valve, AMI, </text>
<text top="546" left="447" width="279" height="17" font="7">significant CAD, LVEF&lt;20%, aortic annulus &lt;18 or </text>
<text top="563" left="447" width="258" height="17" font="7">&gt;25 mm, severe AR or MR, TIA within 6 mo, or </text>
<text top="580" left="447" width="141" height="17" font="7">severe renal insufficiency </text>
<text top="390" left="751" width="220" height="17" font="6"><b>All-cause death at 2 y</b> (Kaplan–Meier): </text>
<text top="407" left="751" width="224" height="17" font="7">TAVR 43.3% vs. standard therapy 68%   </text>
<text top="424" left="751" width="279" height="17" font="7">HR: with TAVR, 0.58 (95% CI: 0.36–0.92; p=0.02). </text>
<text top="442" left="751" width="3" height="17" font="7"> </text>
<text top="459" left="751" width="138" height="17" font="6"><b>Repeat hospitalization: </b></text>
<text top="476" left="751" width="281" height="17" font="7">TAVR 55% vs. 72.5% standard therapy (p&lt;0.001).  </text>
<text top="493" left="751" width="3" height="17" font="7"> </text>
<text top="510" left="751" width="288" height="17" font="6"><b>Survival benefit of TAVR stratified by STS score: </b></text>
<text top="528" left="751" width="93" height="17" font="11"><i>STS score &lt;5%</i>  </text>
<text top="545" left="751" width="214" height="17" font="7">HR: 0.37 (95% CI: 0.13–1.01 ); p=0.04 </text>
<text top="562" left="751" width="124" height="17" font="11"><i>STS score 5%</i>–<i>14.9% </i></text>
<text top="579" left="751" width="217" height="17" font="7">HR: 0.58 (95% CI: 0.41–0.81); p=0.002 </text>
<text top="597" left="751" width="101" height="17" font="11"><i>STS score ≥15%  </i></text>
<text top="614" left="751" width="210" height="17" font="7">HR: 0.77 (95% CI: 0.46–1.28); p=0.31 </text>
<text top="390" left="1054" width="264" height="17" font="6"><b>Cardiac symptoms</b> (NYHA class III or IV) were </text>
<text top="407" left="1054" width="279" height="17" font="7">present in 25.2% of survivors at 1 y after TAVR vs. </text>
<text top="424" left="1054" width="209" height="17" font="7">58% with standard therapy (p&lt;0.001). </text>
<text top="442" left="1054" width="7" height="17" font="7">  </text>
<text top="459" left="1054" width="283" height="17" font="6"><b>Major stroke</b> rate at 30 d, was 5.0% with TAVR vs. </text>
<text top="476" left="1054" width="281" height="17" font="7">1.1% with standard therapy (p=0.06) and remained </text>
<text top="493" left="1054" width="264" height="17" font="7">high at 2 y 13.8% with TAVR vs. 5.5% (p=0.01)  </text>
<text top="510" left="1054" width="3" height="17" font="7"> </text>
<text top="528" left="1054" width="278" height="17" font="6"><b>Major vascular complications</b> occurred in 16.2% </text>
<text top="545" left="1054" width="233" height="17" font="7">with TAVR vs. 1.1% with standard therapy </text>
<text top="562" left="1054" width="60" height="17" font="7">(p&lt;0.001). </text>
<text top="632" left="34" width="1290" height="17" font="7">AF indicates atrial fibrillation; AMI, acute myocardial infarction; AS, aortic stenosis; AR, aortic regurgitation; AVA, aortic valve area; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MR, mitral </text>
<text top="650" left="34" width="276" height="17" font="7">regurgitation; NYHA, New York Heart Association; </text>
<text top="649" left="310" width="9" height="18" font="10"></text>
<text top="650" left="319" width="1002" height="17" font="7">P, mean transaortic pressure gradient; pt(s), patient(s); RCT, randomized controlled trial; Rx, prescription; SAVR, surgical aortic valve replacement; STS, Society of Thoracic Surgeons; </text>
<text top="667" left="34" width="454" height="17" font="7">TAVR, transcatheter aortic valve replacement; TIA, transient ischemic attack; and V</text>
<text top="673" left="488" width="15" height="11" font="9">max</text>
<text top="667" left="503" width="177" height="17" font="7">, aortic valve maximum velocity. </text>
<text top="685" left="108" width="3" height="17" font="7"> </text>
<text top="685" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">17 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="903" height="21" font="4"><b>Data Supplement 10. Clinical Outcomes of Asymptomatic Patients With Chronic Aortic Regurgitation (Sections 4.3.1.1 and 4.3.3) </b></text>
<text top="129" left="48" width="71" height="17" font="6"><b>Study, Year </b></text>
<text top="129" left="158" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="129" left="301" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="418" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="413" width="47" height="17" font="6"><b>Size (n) </b></text>
<text top="129" left="484" width="35" height="17" font="6"><b>Mean </b></text>
<text top="146" left="478" width="43" height="17" font="6"><b>Follow-</b></text>
<text top="164" left="482" width="38" height="17" font="6"><b>Up (y) </b></text>
<text top="129" left="615" width="151" height="17" font="6"><b>Inclusion Criteria, Details </b></text>
<text top="146" left="688" width="3" height="17" font="6"><b> </b></text>
<text top="129" left="945" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="129" left="1161" width="139" height="17" font="6"><b>Comments, Limitations </b></text>
<text top="182" left="42" width="75" height="17" font="7">Bonow, 1983 </text>
<text top="199" left="42" width="3" height="17" font="7"> </text>
<text top="216" left="42" width="25" height="17" font="7">(72) </text>
<text top="233" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6872164">6872164</a></text>
<text top="233" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6872164"> </a></text>
<text top="182" left="137" width="100" height="17" font="7">Determine clinical </text>
<text top="199" left="137" width="64" height="17" font="7">outcome of </text>
<text top="216" left="137" width="99" height="17" font="7">asymptomatic pts </text>
<text top="233" left="137" width="113" height="17" font="7">with chronic AR and </text>
<text top="250" left="137" width="103" height="17" font="7">normal LV systolic </text>
<text top="268" left="137" width="46" height="17" font="7">function </text>
<text top="182" left="271" width="71" height="17" font="7">Prospective, </text>
<text top="199" left="271" width="116" height="17" font="7">observational series; </text>
<text top="216" left="271" width="88" height="17" font="7">consecutive pts </text>
<text top="233" left="271" width="113" height="17" font="7">enrolled 1973-1982; </text>
<text top="250" left="271" width="91" height="17" font="7">single institution </text>
<text top="182" left="413" width="17" height="17" font="7">77 </text>
<text top="182" left="474" width="21" height="17" font="7">4.1 </text>
<text top="182" left="541" width="294" height="17" font="7">Initially asymptomatic pts with chronic AR and normal </text>
<text top="199" left="541" width="109" height="17" font="7">LV systolic function </text>
<text top="216" left="541" width="166" height="17" font="7">Mean age 37 y (range 17–67) </text>
<text top="233" left="541" width="278" height="17" font="7">Serial echo and radionuclide angiographic studies  </text>
<text top="250" left="541" width="3" height="17" font="7"> </text>
<text top="268" left="541" width="293" height="17" font="7">63 pts had 3+–4+ AR on aortic root angiography, and </text>
<text top="285" left="541" width="274" height="17" font="7">the other 14 pts had pulse pressures &gt;70 mm Hg  </text>
<text top="302" left="541" width="3" height="17" font="7"> </text>
<text top="319" left="541" width="290" height="17" font="7">Endpoints: death, symptoms, LV systolic dysfunction </text>
<text top="182" left="852" width="63" height="17" font="7">No pt died  </text>
<text top="199" left="852" width="3" height="17" font="7"> </text>
<text top="216" left="852" width="249" height="17" font="7">12 pts underwent AVR because of symptoms </text>
<text top="233" left="852" width="250" height="17" font="7">(n=11) or asymptomatic LV dysfunction (n=1) </text>
<text top="250" left="852" width="3" height="17" font="7"> </text>
<text top="268" left="852" width="244" height="17" font="7">Progression to symptoms or LV dysfunction: </text>
<text top="285" left="852" width="84" height="17" font="7">less than 4%/y </text>
<text top="302" left="852" width="3" height="17" font="7"> </text>
<text top="319" left="852" width="193" height="17" font="7">No perioperative deaths in pts who </text>
<text top="337" left="852" width="90" height="17" font="7">underwent AVR </text>
<text top="182" left="1115" width="221" height="17" font="7">Percent of pts who did not need surgery </text>
<text top="199" left="1115" width="220" height="17" font="7">was 90±3% (±SE) at 3 y, 81+6% at 5 y, </text>
<text top="216" left="1115" width="104" height="17" font="7">and 75±7% at 7 y. </text>
<text top="233" left="1115" width="3" height="17" font="7"> </text>
<text top="250" left="1115" width="188" height="17" font="7">Outcome associated with LVESD, </text>
<text top="268" left="1115" width="187" height="17" font="7">LVEDD, FS, change in LVEF with </text>
<text top="285" left="1115" width="49" height="17" font="7">exercise </text>
<text top="354" left="42" width="81" height="17" font="7">Scognomiglio, </text>
<text top="372" left="42" width="34" height="17" font="7">1986  </text>
<text top="389" left="42" width="25" height="17" font="7">(73) </text>
<text top="406" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3720042">3720042</a></text>
<text top="406" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3720042"> </a></text>
<text top="354" left="137" width="100" height="17" font="7">Determine factors </text>
<text top="372" left="137" width="70" height="17" font="7">predictive of </text>
<text top="389" left="137" width="100" height="17" font="7">progression to LV </text>
<text top="406" left="137" width="113" height="17" font="7">systolic dysfunction  </text>
<text top="354" left="271" width="119" height="17" font="7">Observational series; </text>
<text top="372" left="271" width="91" height="17" font="7">single institution </text>
<text top="354" left="413" width="17" height="17" font="7">30 </text>
<text top="354" left="474" width="21" height="17" font="7">4.7 </text>
<text top="354" left="541" width="279" height="17" font="7">38 initially asymptomatic pts with chronic AR, 30 of </text>
<text top="372" left="541" width="234" height="17" font="7">whom had normal LV fractional shortening </text>
<text top="389" left="541" width="107" height="17" font="7">Mean age 26±10 y </text>
<text top="406" left="541" width="107" height="17" font="7">Serial echo studies </text>
<text top="423" left="541" width="295" height="17" font="7">Endpoints: death, symptoms, subnormal LV fractional </text>
<text top="440" left="541" width="64" height="17" font="7">shortening  </text>
<text top="354" left="852" width="60" height="17" font="7">No pt died </text>
<text top="372" left="852" width="244" height="17" font="7">Progression to symptoms or LV dysfunction: </text>
<text top="389" left="852" width="41" height="17" font="7">2.1%/y </text>
<text top="406" left="852" width="249" height="17" font="7">Progression to asymptomatic LV dysfunction: </text>
<text top="423" left="852" width="41" height="17" font="7">2.1%/y </text>
<text top="354" left="1115" width="191" height="17" font="7">3 pts developing asymptomatic LV </text>
<text top="372" left="1115" width="210" height="17" font="7">dysfunction had lower initial PAP/ESV </text>
<text top="389" left="1115" width="210" height="17" font="7">ratios and trend toward higher LVESD </text>
<text top="406" left="1115" width="178" height="17" font="7">and LVEDD and lower fractional </text>
<text top="423" left="1115" width="64" height="17" font="7">shortening  </text>
<text top="458" left="42" width="76" height="17" font="7">Siemienczuk, </text>
<text top="476" left="42" width="34" height="17" font="7">1989  </text>
<text top="493" left="42" width="25" height="17" font="7">(74) </text>
<text top="510" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2930091">2930091</a></text>
<text top="510" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2930091"> </a></text>
<text top="458" left="137" width="100" height="17" font="7">Determine clinical </text>
<text top="476" left="137" width="64" height="17" font="7">outcome of </text>
<text top="493" left="137" width="99" height="17" font="7">asymptomatic pts </text>
<text top="510" left="137" width="113" height="17" font="7">with chronic AR and </text>
<text top="527" left="137" width="109" height="17" font="7">normal LV function. </text>
<text top="458" left="271" width="115" height="17" font="7">Observational series </text>
<text top="476" left="271" width="128" height="17" font="7">derived from screening </text>
<text top="493" left="271" width="126" height="17" font="7">for randomized clinical </text>
<text top="510" left="271" width="118" height="17" font="7">trial; single institution </text>
<text top="458" left="413" width="17" height="17" font="7">50 </text>
<text top="458" left="474" width="21" height="17" font="7">3.7 </text>
<text top="458" left="541" width="273" height="17" font="7">Pts included those receiving placebo and medical </text>
<text top="476" left="541" width="273" height="17" font="7">dropouts in a randomized drug trial of hydralazine </text>
<text top="493" left="541" width="286" height="17" font="7">therapy; included some pts with NYHA II symptoms. </text>
<text top="510" left="541" width="107" height="17" font="7">Mean age 48±16 y </text>
<text top="527" left="541" width="293" height="17" font="7">Serial echo and radionuclide LV angiographic studies </text>
<text top="458" left="852" width="60" height="17" font="7">No pt died </text>
<text top="476" left="852" width="244" height="17" font="7">Progression to symptoms or LV dysfunction: </text>
<text top="493" left="852" width="41" height="17" font="7">4.0%/y </text>
<text top="510" left="852" width="249" height="17" font="7">Progression to asymptomatic LV dysfunction: </text>
<text top="527" left="852" width="41" height="17" font="7">0.5%/y </text>
<text top="458" left="1115" width="219" height="17" font="7">Outcome associated with LVESV, EDV, </text>
<text top="476" left="1115" width="217" height="17" font="7">change in LVEF with exercise, and end-</text>
<text top="493" left="1115" width="105" height="17" font="7">systolic wall stress </text>
<text top="545" left="42" width="75" height="17" font="7">Bonow, 1991 </text>
<text top="562" left="42" width="25" height="17" font="7">(75) </text>
<text top="580" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1914102">1914102</a></text>
<text top="580" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1914102"> </a></text>
<text top="545" left="137" width="117" height="17" font="7">Determine outcomes </text>
<text top="562" left="137" width="113" height="17" font="7">of asymptomatic pts </text>
<text top="580" left="137" width="92" height="17" font="7">with chronic AR; </text>
<text top="597" left="137" width="114" height="17" font="7">extension of Bonow, </text>
<text top="614" left="137" width="34" height="17" font="7">1983  </text>
<text top="545" left="271" width="71" height="17" font="7">Prospective, </text>
<text top="562" left="271" width="116" height="17" font="7">observational series; </text>
<text top="580" left="271" width="88" height="17" font="7">consecutive pts </text>
<text top="597" left="271" width="113" height="17" font="7">enrolled 1973-1988; </text>
<text top="614" left="271" width="91" height="17" font="7">single institution </text>
<text top="545" left="413" width="24" height="17" font="7">104 </text>
<text top="545" left="474" width="21" height="17" font="7">8.0 </text>
<text top="545" left="541" width="294" height="17" font="7">Initially asymptomatic pts with chronic AR and normal </text>
<text top="562" left="541" width="116" height="17" font="7">LV systolic function   </text>
<text top="580" left="541" width="166" height="17" font="7">Mean age 37 y (range 17–67) </text>
<text top="597" left="541" width="288" height="17" font="7">Serial echo (average 7.5 per pt) and radionuclide LV </text>
<text top="614" left="541" width="228" height="17" font="7">angiographic (average 5.0 per pt) studies </text>
<text top="631" left="541" width="290" height="17" font="7">Endpoints: death, symptoms, LV systolic dysfunction </text>
<text top="545" left="852" width="109" height="17" font="7">2 pts died suddenly </text>
<text top="562" left="852" width="244" height="17" font="7">Progression to symptoms or LV dysfunction: </text>
<text top="580" left="852" width="41" height="17" font="7">2.1%/y </text>
<text top="597" left="852" width="249" height="17" font="7">Progression to asymptomatic LV dysfunction: </text>
<text top="614" left="852" width="41" height="17" font="7">2.1%/y </text>
<text top="545" left="1115" width="215" height="17" font="7">Outcome associated with age, LVESD, </text>
<text top="562" left="1115" width="217" height="17" font="7">LVEDD, change in LVEF with exercise, </text>
<text top="580" left="1115" width="221" height="17" font="7">and rate of change in LVESD and LVEF </text>
<text top="597" left="1115" width="90" height="17" font="7">at rest with time </text>
<text top="614" left="1115" width="3" height="17" font="7"> </text>
<text top="631" left="1115" width="212" height="17" font="7">Initial LVESD &gt;50 mm was associated </text>
<text top="649" left="1115" width="219" height="17" font="7">with risk of death, symptoms, and/or LV </text>
<text top="666" left="1115" width="138" height="17" font="7">dysfunction of 19% per y </text>
<text top="684" left="42" width="81" height="17" font="7">Scognomiglio, </text>
<text top="701" left="42" width="34" height="17" font="7">1994  </text>
<text top="718" left="42" width="25" height="17" font="7">(76) </text>
<text top="736" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8058074">8058074</a></text>
<text top="736" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8058074"> </a></text>
<text top="684" left="137" width="104" height="17" font="7">Effect of nifedipine </text>
<text top="701" left="137" width="107" height="17" font="7">on outcomes of pts </text>
<text top="718" left="137" width="110" height="17" font="7">with severe AR and </text>
<text top="736" left="137" width="106" height="17" font="7">normal LV function </text>
<text top="684" left="271" width="113" height="17" font="7">Randomized clinical </text>
<text top="701" left="271" width="108" height="17" font="7">drug trial (see Data </text>
<text top="718" left="271" width="94" height="17" font="7">Supplement 11); </text>
<text top="736" left="271" width="91" height="17" font="7">single institution </text>
<text top="684" left="413" width="17" height="17" font="7">74 </text>
<text top="684" left="474" width="21" height="17" font="7">6.0 </text>
<text top="684" left="541" width="294" height="17" font="7">Initially asymptomatic pts with chronic AR and normal </text>
<text top="701" left="541" width="112" height="17" font="7">LV systolic function  </text>
<text top="718" left="541" width="107" height="17" font="7">Mean age 36±12 y </text>
<text top="736" left="541" width="111" height="17" font="7">Serial echo studies  </text>
<text top="753" left="541" width="290" height="17" font="7">Endpoints: death, symptoms, LV systolic dysfunction </text>
<text top="684" left="852" width="60" height="17" font="7">No pt died </text>
<text top="701" left="852" width="213" height="17" font="7">Progression to death, symptoms or LV </text>
<text top="718" left="852" width="110" height="17" font="7">dysfunction: 5.7%/y </text>
<text top="736" left="852" width="249" height="17" font="7">Progression to asymptomatic LV dysfunction: </text>
<text top="753" left="852" width="41" height="17" font="7">3.4%/y </text>
<text top="684" left="1115" width="192" height="17" font="7">This table include only the pts who </text>
<text top="701" left="1115" width="225" height="17" font="7">received digoxin as part of a randomized </text>
<text top="718" left="1115" width="23" height="17" font="7">trial </text>
<text top="736" left="1115" width="228" height="17" font="7">See Data Supplement 11 for outcomes in </text>
<text top="753" left="1115" width="213" height="17" font="7">those receiving active drug (nifedipine, </text>
<text top="770" left="1115" width="35" height="17" font="7">n=69) </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">18 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="48" width="71" height="17" font="6"><b>Study, Year </b></text>
<text top="108" left="158" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="301" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="418" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="413" width="47" height="17" font="6"><b>Size (n) </b></text>
<text top="108" left="484" width="35" height="17" font="6"><b>Mean </b></text>
<text top="126" left="478" width="43" height="17" font="6"><b>Follow-</b></text>
<text top="143" left="482" width="38" height="17" font="6"><b>Up (y) </b></text>
<text top="108" left="615" width="151" height="17" font="6"><b>Inclusion Criteria, Details </b></text>
<text top="126" left="688" width="3" height="17" font="6"><b> </b></text>
<text top="108" left="945" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="108" left="1161" width="139" height="17" font="6"><b>Comments, Limitations </b></text>
<text top="161" left="42" width="76" height="17" font="7">Tornos, 1995 </text>
<text top="178" left="42" width="25" height="17" font="7">(77) </text>
<text top="195" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7631617">7631617</a></text>
<text top="195" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7631617"> </a></text>
<text top="161" left="137" width="100" height="17" font="7">Determine clinical </text>
<text top="178" left="137" width="64" height="17" font="7">outcome of </text>
<text top="195" left="137" width="99" height="17" font="7">asymptomatic pts </text>
<text top="212" left="137" width="113" height="17" font="7">with chronic AR and </text>
<text top="230" left="137" width="103" height="17" font="7">normal LV systolic </text>
<text top="247" left="137" width="46" height="17" font="7">function </text>
<text top="161" left="271" width="71" height="17" font="7">Prospective, </text>
<text top="178" left="271" width="116" height="17" font="7">observational series; </text>
<text top="195" left="271" width="88" height="17" font="7">consecutive pts </text>
<text top="212" left="271" width="104" height="17" font="7">beginning in 1982; </text>
<text top="230" left="271" width="91" height="17" font="7">single institution </text>
<text top="161" left="413" width="24" height="17" font="7">101 </text>
<text top="161" left="474" width="21" height="17" font="7">4.6 </text>
<text top="161" left="541" width="294" height="17" font="7">Initially asymptomatic pts with chronic AR and normal </text>
<text top="178" left="541" width="112" height="17" font="7">LV systolic function  </text>
<text top="195" left="541" width="107" height="17" font="7">Mean age 41±14 y </text>
<text top="212" left="541" width="293" height="17" font="7">Serial echo and radionuclide LV angiographic studies </text>
<text top="230" left="541" width="290" height="17" font="7">Endpoints: death, symptoms, LV systolic dysfunction </text>
<text top="161" left="852" width="60" height="17" font="7">No pt died </text>
<text top="178" left="852" width="244" height="17" font="7">Progression to symptoms or LV dysfunction: </text>
<text top="195" left="852" width="41" height="17" font="7">3.0%/y </text>
<text top="212" left="852" width="249" height="17" font="7">Progression to asymptomatic LV dysfunction: </text>
<text top="230" left="852" width="41" height="17" font="7">1.3%/y </text>
<text top="161" left="1115" width="228" height="17" font="7">Outcome associated with pulse pressure, </text>
<text top="178" left="1115" width="191" height="17" font="7">LVESD, LVEDD, and LVEF at rest </text>
<text top="195" left="1115" width="3" height="17" font="7"> </text>
<text top="212" left="1115" width="212" height="17" font="7">Initial LVESD &gt;50 mm was associated </text>
<text top="230" left="1115" width="219" height="17" font="7">with risk of death, symptoms, and/or LV </text>
<text top="247" left="1115" width="131" height="17" font="7">dysfunction of 7% per y </text>
<text top="265" left="42" width="63" height="17" font="7">Ishii, 1996  </text>
<text top="282" left="42" width="25" height="17" font="7">(78) </text>
<text top="299" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8759822">8759822</a></text>
<text top="299" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8759822"> </a></text>
<text top="265" left="137" width="121" height="17" font="7">Clinical outcome and  </text>
<text top="282" left="137" width="86" height="17" font="7">LV response to </text>
<text top="299" left="137" width="64" height="17" font="7">chronic AR </text>
<text top="265" left="271" width="71" height="17" font="7">Prospective, </text>
<text top="282" left="271" width="116" height="17" font="7">observational series; </text>
<text top="299" left="271" width="119" height="17" font="7">consecutive pts 1970-</text>
<text top="317" left="271" width="125" height="17" font="7">1990; single institution </text>
<text top="265" left="413" width="17" height="17" font="7">27 </text>
<text top="265" left="474" width="27" height="17" font="7">14.2 </text>
<text top="265" left="541" width="251" height="17" font="7">94 consecutive pts followed for ≥6 mo; the 27 </text>
<text top="282" left="541" width="252" height="17" font="7">asymptomatic pts with normal LV function are </text>
<text top="299" left="541" width="77" height="17" font="7">included here </text>
<text top="317" left="541" width="107" height="17" font="7">Mean age 42±12 y </text>
<text top="334" left="541" width="167" height="17" font="7">LV function assessed by echo </text>
<text top="265" left="852" width="60" height="17" font="7">No pt died </text>
<text top="282" left="852" width="244" height="17" font="7">Progression to symptoms or LV dysfunction: </text>
<text top="299" left="852" width="41" height="17" font="7">3.6%/y </text>
<text top="265" left="1115" width="211" height="17" font="7">Development of symptoms associated </text>
<text top="282" left="1115" width="220" height="17" font="7">with systolic BP, LVESD, LVEDD, mass </text>
<text top="299" left="1115" width="146" height="17" font="7">index, and wall thickness.  </text>
<text top="317" left="1115" width="3" height="17" font="7"> </text>
<text top="334" left="1115" width="183" height="17" font="7">LV function not reported in all pts </text>
<text top="352" left="42" width="68" height="17" font="7">Borer, 1998 </text>
<text top="369" left="42" width="25" height="17" font="7">(79) </text>
<text top="386" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9494022">9494022</a></text>
<text top="386" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9494022"> </a></text>
<text top="352" left="137" width="100" height="17" font="7">Determine clinical </text>
<text top="369" left="137" width="64" height="17" font="7">outcome of </text>
<text top="386" left="137" width="99" height="17" font="7">asymptomatic pts </text>
<text top="403" left="137" width="113" height="17" font="7">with chronic AR and </text>
<text top="421" left="137" width="103" height="17" font="7">normal LV systolic </text>
<text top="438" left="137" width="46" height="17" font="7">function </text>
<text top="352" left="271" width="71" height="17" font="7">Prospective, </text>
<text top="369" left="271" width="116" height="17" font="7">observational series; </text>
<text top="386" left="271" width="88" height="17" font="7">consecutive pts </text>
<text top="403" left="271" width="104" height="17" font="7">beginning in 1979; </text>
<text top="421" left="271" width="91" height="17" font="7">single institution </text>
<text top="352" left="413" width="24" height="17" font="7">104 </text>
<text top="352" left="474" width="21" height="17" font="7">7.3 </text>
<text top="352" left="541" width="294" height="17" font="7">Initially asymptomatic pts with chronic AR and normal </text>
<text top="369" left="541" width="112" height="17" font="7">LV systolic function  </text>
<text top="386" left="541" width="107" height="17" font="7">Mean age 46±15 y </text>
<text top="403" left="541" width="163" height="17" font="7">20% of pts in NYHA II initially </text>
<text top="421" left="541" width="293" height="17" font="7">Serial echo and radionuclide LV angiographic studies </text>
<text top="438" left="541" width="290" height="17" font="7">Endpoints: death, symptoms, LV systolic dysfunction </text>
<text top="352" left="852" width="109" height="17" font="7">4 pts died suddenly </text>
<text top="369" left="852" width="244" height="17" font="7">Progression to symptoms or LV dysfunction: </text>
<text top="386" left="852" width="41" height="17" font="7">6.2%/y </text>
<text top="403" left="852" width="249" height="17" font="7">Progression to asymptomatic LV dysfunction: </text>
<text top="421" left="852" width="41" height="17" font="7">0.9%/y </text>
<text top="352" left="1115" width="212" height="17" font="7">Change in LVEF from rest to exercise, </text>
<text top="369" left="1115" width="206" height="17" font="7">normalized for change in end-systolic </text>
<text top="386" left="1115" width="176" height="17" font="7">stress from rest to exercise was </text>
<text top="403" left="1115" width="221" height="17" font="7">strongest predictor of any endpoint or of </text>
<text top="421" left="1115" width="155" height="17" font="7">sudden cardiac death alone </text>
<text top="438" left="1115" width="3" height="17" font="7"> </text>
<text top="455" left="1115" width="198" height="17" font="7">Outcome also associated with initial </text>
<text top="472" left="1115" width="227" height="17" font="7">NYHA II symptoms, change in LVEF with </text>
<text top="489" left="1115" width="158" height="17" font="7">exercise, LVESD, and LVFS </text>
<text top="507" left="42" width="71" height="17" font="7">Tarasoutchi, </text>
<text top="525" left="42" width="34" height="17" font="7">2003  </text>
<text top="542" left="42" width="25" height="17" font="7">(80) </text>
<text top="559" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12706927">12706927</a></text>
<text top="559" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12706927"> </a></text>
<text top="507" left="137" width="107" height="17" font="7">Clinical outcome of </text>
<text top="525" left="137" width="99" height="17" font="7">asymptomatic pts </text>
<text top="542" left="137" width="113" height="17" font="7">with chronic AR and </text>
<text top="559" left="137" width="103" height="17" font="7">normal LV systolic </text>
<text top="576" left="137" width="46" height="17" font="7">function </text>
<text top="507" left="271" width="71" height="17" font="7">Prospective, </text>
<text top="525" left="271" width="116" height="17" font="7">observational series; </text>
<text top="542" left="271" width="88" height="17" font="7">consecutive pts </text>
<text top="559" left="271" width="104" height="17" font="7">beginning in 1979; </text>
<text top="576" left="271" width="91" height="17" font="7">single institution </text>
<text top="507" left="413" width="17" height="17" font="7">72 </text>
<text top="507" left="474" width="17" height="17" font="7">10 </text>
<text top="507" left="541" width="294" height="17" font="7">Initially asymptomatic pts with chronic AR and normal </text>
<text top="525" left="541" width="112" height="17" font="7">LV systolic function  </text>
<text top="542" left="541" width="100" height="17" font="7">Mean age 28±9 y </text>
<text top="559" left="541" width="293" height="17" font="7">Serial echo and radionuclide LV angiographic studies </text>
<text top="576" left="541" width="290" height="17" font="7">Endpoints: death, symptoms, LV systolic dysfunction </text>
<text top="507" left="852" width="60" height="17" font="7">No pt died </text>
<text top="525" left="852" width="244" height="17" font="7">Progression to symptoms or LV dysfunction: </text>
<text top="542" left="852" width="41" height="17" font="7">4.7%/y </text>
<text top="559" left="852" width="249" height="17" font="7">Progression to asymptomatic LV dysfunction: </text>
<text top="576" left="852" width="41" height="17" font="7">0.1%/y </text>
<text top="507" left="1115" width="209" height="17" font="7">AR of predominant rheumatic etiology </text>
<text top="525" left="1115" width="183" height="17" font="7">LV function not reported in all pts </text>
<text top="542" left="1115" width="211" height="17" font="7">Development of symptoms associated </text>
<text top="559" left="1115" width="137" height="17" font="7">with LVESD and LVEDD </text>
<text top="576" left="1115" width="212" height="17" font="7">Initial LVESD &gt;50 mm was associated </text>
<text top="593" left="1115" width="178" height="17" font="7">with risk of symptoms and/or LV </text>
<text top="611" left="1115" width="120" height="17" font="7">dysfunction of 7.6%/y </text>
<text top="629" left="42" width="70" height="17" font="7">Evangelista, </text>
<text top="646" left="42" width="34" height="17" font="7">2005  </text>
<text top="663" left="42" width="25" height="17" font="7">(81) </text>
<text top="680" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16192479">16192479</a></text>
<text top="680" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16192479"> </a></text>
<text top="629" left="137" width="104" height="17" font="7">Effect of nifedipine </text>
<text top="646" left="137" width="107" height="17" font="7">versus enalapril on </text>
<text top="663" left="137" width="115" height="17" font="7">outcomes of pts with </text>
<text top="680" left="137" width="85" height="17" font="7">severe AR and </text>
<text top="698" left="137" width="106" height="17" font="7">normal LV function </text>
<text top="629" left="271" width="113" height="17" font="7">Randomized clinical </text>
<text top="646" left="271" width="108" height="17" font="7">drug trial (see Data </text>
<text top="663" left="271" width="94" height="17" font="7">Supplement 11); </text>
<text top="680" left="271" width="91" height="17" font="7">single institution </text>
<text top="629" left="413" width="17" height="17" font="7">31 </text>
<text top="629" left="474" width="10" height="17" font="7">7 </text>
<text top="629" left="541" width="294" height="17" font="7">Initially asymptomatic pts with chronic AR and normal </text>
<text top="646" left="541" width="112" height="17" font="7">LV systolic function  </text>
<text top="663" left="541" width="107" height="17" font="7">Mean age 42±15 y </text>
<text top="680" left="541" width="111" height="17" font="7">Serial echo studies  </text>
<text top="698" left="541" width="290" height="17" font="7">Endpoints: death, symptoms, LV systolic dysfunction </text>
<text top="629" left="852" width="98" height="17" font="7">1 pt died from HF </text>
<text top="646" left="852" width="3" height="17" font="7"> </text>
<text top="663" left="852" width="213" height="17" font="7">Progression to death, symptoms or LV </text>
<text top="680" left="852" width="110" height="17" font="7">dysfunction: 3.6%/y </text>
<text top="629" left="1115" width="202" height="17" font="7">Pts reported here were in the control </text>
<text top="646" left="1115" width="189" height="17" font="7">(placebo) group of this clinical trial </text>
<text top="663" left="1115" width="3" height="17" font="7"> </text>
<text top="680" left="1115" width="178" height="17" font="7">See Data Supplement 11 for pts </text>
<text top="698" left="1115" width="218" height="17" font="7">receiving active drugs nifedipine (n=32) </text>
<text top="715" left="1115" width="117" height="17" font="7">and enalapril (n=31)  </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">19 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="48" width="71" height="17" font="6"><b>Study, Year </b></text>
<text top="108" left="158" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="301" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="418" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="413" width="47" height="17" font="6"><b>Size (n) </b></text>
<text top="108" left="484" width="35" height="17" font="6"><b>Mean </b></text>
<text top="126" left="478" width="43" height="17" font="6"><b>Follow-</b></text>
<text top="143" left="482" width="38" height="17" font="6"><b>Up (y) </b></text>
<text top="108" left="615" width="151" height="17" font="6"><b>Inclusion Criteria, Details </b></text>
<text top="126" left="688" width="3" height="17" font="6"><b> </b></text>
<text top="108" left="945" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="108" left="1161" width="139" height="17" font="6"><b>Comments, Limitations </b></text>
<text top="161" left="42" width="76" height="17" font="7">Detaint, 2008 </text>
<text top="178" left="42" width="25" height="17" font="7">(82) </text>
<text top="195" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19356398">19356398</a></text>
<text top="195" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19356398"> </a></text>
<text top="161" left="137" width="104" height="17" font="7">Predictive value of </text>
<text top="178" left="137" width="66" height="17" font="7">quantitative </text>
<text top="195" left="137" width="91" height="17" font="7">measures of AR </text>
<text top="212" left="137" width="88" height="17" font="7">severity and LV </text>
<text top="230" left="137" width="62" height="17" font="7">volumes in </text>
<text top="247" left="137" width="99" height="17" font="7">asymptomatic pts </text>
<text top="264" left="137" width="113" height="17" font="7">with chronic AR and </text>
<text top="281" left="137" width="103" height="17" font="7">normal LV systolic </text>
<text top="299" left="137" width="46" height="17" font="7">function </text>
<text top="161" left="271" width="71" height="17" font="7">Prospective, </text>
<text top="178" left="271" width="116" height="17" font="7">observational series; </text>
<text top="195" left="271" width="88" height="17" font="7">consecutive pts </text>
<text top="212" left="271" width="109" height="17" font="7">enrolled from 1991–</text>
<text top="230" left="271" width="129" height="17" font="7">2003; single institution. </text>
<text top="161" left="413" width="24" height="17" font="7">251 </text>
<text top="161" left="474" width="10" height="17" font="7">8 </text>
<text top="161" left="541" width="294" height="17" font="7">Initially asymptomatic pts with chronic AR and normal </text>
<text top="178" left="541" width="112" height="17" font="7">LV systolic function  </text>
<text top="195" left="541" width="107" height="17" font="7">Mean age 60±17 y </text>
<text top="212" left="541" width="277" height="17" font="7">Serial echo studies to assess severity of AR (ROA </text>
<text top="230" left="541" width="263" height="17" font="7">and RV) as well as LV dimensions and volumes </text>
<text top="247" left="541" width="189" height="17" font="7">Endpoints: death, HF, AF, surgery </text>
<text top="161" left="852" width="64" height="17" font="7">33 pts died </text>
<text top="178" left="852" width="3" height="17" font="7"> </text>
<text top="195" left="852" width="220" height="17" font="7">Progression to death or surgery: 5.0%/y </text>
<text top="212" left="852" width="3" height="17" font="7"> </text>
<text top="230" left="852" width="94" height="17" font="7">Survival at 10 y:  </text>
<text top="247" left="852" width="120" height="17" font="7">        Mild AR: 92±4% </text>
<text top="264" left="852" width="150" height="17" font="7">        Moderate AR: 75±6% </text>
<text top="281" left="852" width="140" height="17" font="7">        Severe AR: 69±9%  </text>
<text top="299" left="852" width="3" height="17" font="7"> </text>
<text top="316" left="852" width="176" height="17" font="7">Survival free from AVR at 10 y:  </text>
<text top="333" left="852" width="120" height="17" font="7">        Mild AR: 92±4% </text>
<text top="350" left="852" width="150" height="17" font="7">        Moderate AR: 57±6% </text>
<text top="368" left="852" width="137" height="17" font="7">        Severe AR: 20±5% </text>
<text top="161" left="1115" width="218" height="17" font="7">Surgical indications included symptoms </text>
<text top="178" left="1115" width="213" height="17" font="7">(n=38), LV dysfunction or enlargement </text>
<text top="195" left="1115" width="223" height="17" font="7">(n=17), aortic aneurysm (n=11), IE (n=3, </text>
<text top="212" left="1115" width="228" height="17" font="7">and clinician and/or pt preference [n=11]) </text>
<text top="230" left="1115" width="3" height="17" font="7"> </text>
<text top="247" left="1115" width="193" height="17" font="7">Cardiac events (defined as cardiac </text>
<text top="264" left="1115" width="173" height="17" font="7">death, HR, or new onset of AF) </text>
<text top="281" left="1115" width="219" height="17" font="7">associated with RV and ROA as well as </text>
<text top="299" left="1115" width="215" height="17" font="7">ESV index, which superseded M-mode </text>
<text top="316" left="1115" width="84" height="17" font="7">LV dimensions </text>
<text top="333" left="1115" width="3" height="17" font="7"> </text>
<text top="350" left="1115" width="215" height="17" font="7">Mortality rate in this series is highest of </text>
<text top="368" left="1115" width="52" height="17" font="7">all series </text>
<text top="385" left="1115" width="3" height="17" font="7"> </text>
<text top="402" left="1115" width="208" height="17" font="7">Pts in this series older than all others; </text>
<text top="419" left="1115" width="209" height="17" font="7">only 1 death in pts &lt;50 y in this series </text>
<text top="437" left="42" width="78" height="17" font="7">Pizzaro, 2011 </text>
<text top="454" left="42" width="25" height="17" font="7">(83) </text>
<text top="472" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21982316">21982316</a></text>
<text top="472" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21982316"> </a></text>
<text top="437" left="137" width="104" height="17" font="7">Predictive value of </text>
<text top="454" left="137" width="119" height="17" font="7">BNP and quantitative </text>
<text top="472" left="137" width="91" height="17" font="7">measures of AR </text>
<text top="489" left="137" width="88" height="17" font="7">severity and LV </text>
<text top="506" left="137" width="62" height="17" font="7">volumes in </text>
<text top="523" left="137" width="99" height="17" font="7">asymptomatic pts </text>
<text top="540" left="137" width="113" height="17" font="7">with chronic AR and </text>
<text top="558" left="137" width="103" height="17" font="7">normal LV systolic </text>
<text top="575" left="137" width="46" height="17" font="7">function </text>
<text top="437" left="271" width="71" height="17" font="7">Prospective, </text>
<text top="454" left="271" width="116" height="17" font="7">observational series; </text>
<text top="472" left="271" width="88" height="17" font="7">consecutive pts </text>
<text top="489" left="271" width="109" height="17" font="7">enrolled from 1991–</text>
<text top="506" left="271" width="125" height="17" font="7">2003; single institution </text>
<text top="437" left="413" width="24" height="17" font="7">294 </text>
<text top="437" left="474" width="21" height="17" font="7">3.5 </text>
<text top="437" left="541" width="294" height="17" font="7">Initially asymptomatic pts with chronic AR and normal </text>
<text top="454" left="541" width="112" height="17" font="7">LV systolic function  </text>
<text top="472" left="541" width="279" height="17" font="7">The first 160 consecutive pts were analyzed as the </text>
<text top="489" left="541" width="229" height="17" font="7">derivation set of data (mean age 51±9 y)  </text>
<text top="506" left="541" width="283" height="17" font="7">The next 134 consecutive pts were analyzed as the </text>
<text top="523" left="541" width="190" height="17" font="7">validation set (mean age 53±10 y) </text>
<text top="540" left="541" width="293" height="17" font="7">BNP and serial echo studies to assess severity of AR </text>
<text top="558" left="541" width="297" height="17" font="7">(ROA and RV) as well as LV dimensions and volumes </text>
<text top="437" left="852" width="57" height="17" font="7">5 pts died </text>
<text top="454" left="852" width="244" height="17" font="7">Progression to symptoms or LV dysfunction: </text>
<text top="472" left="852" width="38" height="17" font="7">10%/y </text>
<text top="489" left="852" width="249" height="17" font="7">Progression to asymptomatic LV dysfunction: </text>
<text top="506" left="852" width="41" height="17" font="7">2.8%/y </text>
<text top="437" left="1115" width="201" height="17" font="7">Outcome associated with BNP &gt;130 </text>
<text top="454" left="1115" width="38" height="17" font="7">pg/mL </text>
<text top="472" left="1115" width="3" height="17" font="7"> </text>
<text top="489" left="1115" width="224" height="17" font="7">Outcome also associated with RV, ROA, </text>
<text top="506" left="1115" width="225" height="17" font="7">LVESD index, LVEDD index, ESV index, </text>
<text top="523" left="1115" width="85" height="17" font="7">and EDV index </text>
<text top="593" left="42" width="70" height="17" font="7">Olsen, 2011 </text>
<text top="610" left="42" width="25" height="17" font="7">(84) </text>
<text top="627" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21414568">21414568</a></text>
<text top="627" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21414568"> </a></text>
<text top="593" left="137" width="104" height="17" font="7">Predictive value of </text>
<text top="610" left="137" width="92" height="17" font="7">speckle-tracking </text>
<text top="627" left="137" width="43" height="17" font="7">echo in </text>
<text top="644" left="137" width="99" height="17" font="7">asymptomatic pts </text>
<text top="662" left="137" width="113" height="17" font="7">with chronic AR and </text>
<text top="679" left="137" width="103" height="17" font="7">normal LV systolic </text>
<text top="696" left="137" width="46" height="17" font="7">function </text>
<text top="593" left="271" width="24" height="17" font="7">N/A </text>
<text top="593" left="413" width="17" height="17" font="7">35 </text>
<text top="593" left="474" width="21" height="17" font="7">1.6 </text>
<text top="593" left="541" width="269" height="17" font="7">35 initially asymptomatic pts with chronic AR and </text>
<text top="610" left="541" width="297" height="17" font="7">normal LV systolic function were followed sequentially </text>
<text top="627" left="541" width="107" height="17" font="7">Mean age 56±14 y </text>
<text top="644" left="541" width="107" height="17" font="7">Serial echo studies </text>
<text top="662" left="541" width="284" height="17" font="7">Endpoints: symptoms, increase in LVEDV &gt;15%, or </text>
<text top="679" left="541" width="136" height="17" font="7">decrease in LVEF &gt;10% </text>
<text top="696" left="541" width="279" height="17" font="7">29 additional pts who underwent AVR at the outset </text>
<text top="713" left="541" width="119" height="17" font="7">are not reported here </text>
<text top="593" left="852" width="66" height="17" font="7">No pts died </text>
<text top="610" left="852" width="3" height="17" font="7"> </text>
<text top="627" left="852" width="246" height="17" font="7">Progression to death, symptoms, increase in </text>
<text top="644" left="852" width="211" height="17" font="7">LVEDV or decrease in LVEF: 14.3%/y </text>
<text top="593" left="1115" width="175" height="17" font="7">Disease progression defined as </text>
<text top="610" left="1115" width="222" height="17" font="7">symptoms, increase in LVEDV &gt;15%, or </text>
<text top="627" left="1115" width="136" height="17" font="7">decrease in LVEF &gt;10% </text>
<text top="644" left="1115" width="3" height="17" font="7"> </text>
<text top="662" left="1115" width="203" height="17" font="7">Disease progression associated with </text>
<text top="679" left="1115" width="191" height="17" font="7">reduced myocardial systolic strain, </text>
<text top="696" left="1115" width="207" height="17" font="7">systolic strain rate, and early diastolic </text>
<text top="713" left="1115" width="58" height="17" font="7">strain rate </text>
<text top="731" left="34" width="1307" height="17" font="7">AF indicates atrial fibrillation; AR, aortic regurgitation; AVR, aortic valve replacement; BNP; brain natriuretic peptide; BP, blood pressure; EDV, end-diastolic volume; ESV, end-systolic volume; HF, heart failure; Hx, history; LV, left ventricular; </text>
<text top="748" left="34" width="1263" height="17" font="7">LVEDD, end-diastolic dimension; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic volume; IE, infective endocarditis; N/A, not applicable; NYHA, New York Heart </text>
<text top="766" left="34" width="772" height="17" font="7">Association; PAP, pulmonary artery pressure; pt(s), patient(s); ROA, regurgitant orifice area; RV, regurgitant volume; and SE, standard error.  </text>
<text top="766" left="1018" width="3" height="17" font="7"> </text>
</page>
<page number="20" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="16" size="12" family="Times" color="#000000"/>
<text top="832" left="721" width="21" height="17" font="0">20 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="831" height="21" font="4"><b>Data Supplement 11. Vasodilator Therapy in Asymptomatic Patients With Chronic Aortic Regurgitation (Section 4.3.2)  </b></text>
<text top="129" left="47" width="78" height="17" font="6"><b>Study Name, </b></text>
<text top="146" left="47" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="129" left="155" width="64" height="17" font="6"><b>Study Aim </b></text>
<text top="129" left="245" width="73" height="17" font="6"><b>Study Type/ </b></text>
<text top="146" left="257" width="49" height="17" font="6"><b>Size (N) </b></text>
<text top="129" left="363" width="94" height="17" font="6"><b>Intervention vs. </b></text>
<text top="146" left="364" width="92" height="17" font="6"><b>Comparator (n) </b></text>
<text top="129" left="557" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="129" left="743" width="111" height="17" font="6"><b>Study Intervention </b></text>
<text top="129" left="894" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="877" width="73" height="17" font="6"><b>Comparator </b></text>
<text top="129" left="979" width="64" height="17" font="6"><b>Endpoints </b></text>
<text top="129" left="1176" width="48" height="17" font="6"><b>Results </b></text>
<text top="199" left="84" width="3" height="17" font="6"><b> </b></text>
<text top="199" left="186" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="199" left="280" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="199" left="408" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="182" left="520" width="58" height="17" font="16"><i><b>Inclusion </b></i></text>
<text top="199" left="525" width="46" height="17" font="16"><i><b>Criteria </b></i></text>
<text top="199" left="612" width="108" height="17" font="16"><i><b>Exclusion Criteria </b></i></text>
<text top="199" left="797" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="199" left="911" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="164" left="986" width="49" height="17" font="16"><i><b>Primary </b></i></text>
<text top="182" left="976" width="69" height="17" font="16"><i><b>Endpoint &amp; </b></i></text>
<text top="199" left="987" width="48" height="17" font="16"><i><b>Results </b></i></text>
<text top="199" left="1198" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="217" left="42" width="70" height="17" font="7">Evangelista, </text>
<text top="234" left="42" width="34" height="17" font="7">2005  </text>
<text top="251" left="42" width="25" height="17" font="7">(81) </text>
<text top="268" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16192479">16192479</a></text>
<text top="268" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16192479"> </a></text>
<text top="217" left="143" width="55" height="17" font="7">Effects of </text>
<text top="234" left="143" width="63" height="17" font="7">vasodilator </text>
<text top="251" left="143" width="80" height="17" font="7">therapy on LV </text>
<text top="268" left="143" width="70" height="17" font="7">function and </text>
<text top="286" left="143" width="73" height="17" font="7">time to AVR  </text>
<text top="217" left="244" width="46" height="17" font="7">RCT/95 </text>
<text top="217" left="332" width="132" height="17" font="7">Intervention: open-label </text>
<text top="234" left="332" width="135" height="17" font="7">nifedipine-32 pts (20 mg </text>
<text top="251" left="332" width="83" height="17" font="7">every 12 h) or  </text>
<text top="268" left="332" width="148" height="17" font="7">open label enalapril-32 pts </text>
<text top="286" left="332" width="126" height="17" font="7">(20 mg every 12 h) vs. </text>
<text top="303" left="332" width="75" height="17" font="7">Comparator:  </text>
<text top="320" left="332" width="110" height="17" font="7">no treatment-31 pts </text>
<text top="217" left="501" width="84" height="17" font="7">Asymptomatic, </text>
<text top="234" left="501" width="87" height="17" font="7">chronic, severe </text>
<text top="251" left="501" width="85" height="17" font="7">AR and normal </text>
<text top="268" left="501" width="65" height="17" font="7">LV function </text>
<text top="217" left="609" width="108" height="17" font="7">LVEF &lt;50%., other </text>
<text top="234" left="609" width="85" height="17" font="7">valve disease.  </text>
<text top="251" left="609" width="102" height="17" font="7">Hypertension, AF, </text>
<text top="268" left="609" width="66" height="17" font="7">CAD, aortic </text>
<text top="286" left="609" width="61" height="17" font="7">aneurysm  </text>
<text top="217" left="737" width="120" height="17" font="7">Open-label nifedipine </text>
<text top="234" left="737" width="121" height="17" font="7">(20 mg every 12 h) or </text>
<text top="251" left="737" width="111" height="17" font="7">open-label enalapril </text>
<text top="268" left="737" width="56" height="17" font="7">(20 mg/d) </text>
<text top="217" left="872" width="75" height="17" font="7">No treatment </text>
<text top="217" left="967" width="34" height="17" font="7">LVEF </text>
<text top="234" left="967" width="3" height="17" font="7"> </text>
<text top="251" left="967" width="73" height="17" font="7">Time to AVR </text>
<text top="217" left="1068" width="246" height="17" font="7">Rate of AVR was similar among the groups:  </text>
<text top="234" left="1068" width="106" height="17" font="7">Control group 39% </text>
<text top="251" left="1068" width="114" height="17" font="7">Enalapril group 50% </text>
<text top="268" left="1068" width="231" height="17" font="7">Nifedipine group 41%; p=0.62)                   </text>
<text top="286" left="1068" width="3" height="17" font="7"> </text>
<text top="303" left="1068" width="258" height="17" font="7">No significant group differences in AR severity, </text>
<text top="320" left="1068" width="96" height="17" font="7">LV size or LVEF. </text>
<text top="337" left="1068" width="3" height="17" font="7"> </text>
<text top="354" left="1068" width="111" height="17" font="7">Follow-up mean 7 y </text>
<text top="372" left="42" width="81" height="17" font="7">Scognomiglio, </text>
<text top="390" left="42" width="34" height="17" font="7">1994  </text>
<text top="407" left="42" width="25" height="17" font="7">(76) </text>
<text top="424" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8058074">8058074</a></text>
<text top="424" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8058074"> </a></text>
<text top="372" left="143" width="43" height="17" font="7">Assess </text>
<text top="390" left="143" width="47" height="17" font="7">whether </text>
<text top="407" left="143" width="63" height="17" font="7">vasodilator </text>
<text top="424" left="143" width="44" height="17" font="7">therapy </text>
<text top="441" left="143" width="62" height="17" font="7">reduces or </text>
<text top="458" left="143" width="59" height="17" font="7">delays the </text>
<text top="476" left="143" width="77" height="17" font="7">need for AVR </text>
<text top="372" left="244" width="53" height="17" font="7">RCT/143 </text>
<text top="372" left="332" width="150" height="17" font="7">Intervention: Nifedipine (20 </text>
<text top="390" left="332" width="141" height="17" font="7">mg twice daily)-69 pts vs. </text>
<text top="407" left="332" width="75" height="17" font="7">Comparator:  </text>
<text top="424" left="332" width="128" height="17" font="7">Digoxin (0.25 mg twice </text>
<text top="441" left="332" width="70" height="17" font="7">daily)-74 pts </text>
<text top="372" left="501" width="80" height="17" font="7">Asymptomatic </text>
<text top="390" left="501" width="83" height="17" font="7">chronic severe </text>
<text top="407" left="501" width="87" height="17" font="7">AR with normal </text>
<text top="424" left="501" width="65" height="17" font="7">LV function </text>
<text top="372" left="609" width="110" height="17" font="7">LVEF &lt;50%, recent </text>
<text top="390" left="609" width="97" height="17" font="7">or worsening AR, </text>
<text top="407" left="609" width="110" height="17" font="7">hypertension, CAD, </text>
<text top="424" left="609" width="87" height="17" font="7">AS, other valve </text>
<text top="441" left="609" width="49" height="17" font="7">disease. </text>
<text top="372" left="737" width="58" height="17" font="7">Nifedipine </text>
<text top="372" left="872" width="44" height="17" font="7">Digoxin </text>
<text top="372" left="967" width="77" height="17" font="7">Time to AVR  </text>
<text top="372" left="1068" width="227" height="17" font="7">AVR in 34%+6% of pts on digoxin versus </text>
<text top="390" left="1068" width="260" height="17" font="7">15%+3% of pts on nifedipine pts (p&lt;0.001) at 6 </text>
<text top="407" left="1068" width="62" height="17" font="7">y follow-up </text>
<text top="494" left="34" width="1315" height="17" font="7">AF indicates atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; AVR, aortic valve replacement; CAD, coronary artery disease; LV, left ventricular; LVEF, left ventricular ejection fraction; pts, patients; and, RCT, randomized controlled </text>
<text top="511" left="34" width="30" height="17" font="7">trial.  </text>
<text top="528" left="108" width="3" height="17" font="7"> </text>
<text top="528" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="21" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">21 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="767" height="21" font="4"><b>Data Supplement 12. Determinants of Outcome After Surgery for Chronic Aortic Regurgitation (Section 4.3.3) </b></text>
<text top="129" left="42" width="71" height="17" font="6"><b>Study, Year </b></text>
<text top="129" left="154" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="129" left="318" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="449" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="453" width="28" height="17" font="6"><b>Size </b></text>
<text top="164" left="458" width="19" height="17" font="6"><b>(n) </b></text>
<text top="129" left="521" width="35" height="17" font="6"><b>Mean </b></text>
<text top="146" left="507" width="63" height="17" font="6"><b>Follow-Up </b></text>
<text top="164" left="529" width="19" height="17" font="6"><b>(y) </b></text>
<text top="129" left="601" width="225" height="17" font="6"><b>Inclusion Criteria, Outcome Assessed </b></text>
<text top="129" left="945" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="129" left="1161" width="139" height="17" font="6"><b>Comments, Limitations </b></text>
<text top="182" left="39" width="76" height="17" font="7">Forman 1980 </text>
<text top="199" left="39" width="29" height="17" font="7">(85)  </text>
<text top="216" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7377109">7377109</a></text>
<text top="216" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7377109"> </a></text>
<text top="182" left="130" width="90" height="17" font="7">Determinants of </text>
<text top="199" left="130" width="102" height="17" font="7">survival after AVR </text>
<text top="182" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="199" left="271" width="153" height="17" font="7">series; pts undergoing AVR </text>
<text top="216" left="271" width="159" height="17" font="7">1972–1978; single institution </text>
<text top="182" left="447" width="17" height="17" font="7">90 </text>
<text top="182" left="501" width="10" height="17" font="7">3 </text>
<text top="182" left="589" width="229" height="17" font="7">Indications for AVR not specified; age not </text>
<text top="199" left="589" width="52" height="17" font="7">specified </text>
<text top="216" left="589" width="144" height="17" font="7">Preoperative angiography </text>
<text top="233" left="589" width="237" height="17" font="7">Lillehei-Kastor, Starr Edwards model 2400, </text>
<text top="250" left="589" width="244" height="17" font="7">and Bjork-Shiley mechanical valves and first </text>
<text top="268" left="589" width="185" height="17" font="7">generation porcine bioprostheses </text>
<text top="285" left="589" width="100" height="17" font="7">Endpoint: survival </text>
<text top="182" left="852" width="69" height="17" font="7">3-y survival: </text>
<text top="199" left="852" width="3" height="17" font="7"> </text>
<text top="216" left="852" width="85" height="17" font="7">Overall 79±6% </text>
<text top="233" left="852" width="114" height="17" font="7">LVEF ≥50% 93±4% </text>
<text top="250" left="852" width="119" height="17" font="7">LVEF &lt;50% 64±10% </text>
<text top="268" left="884" width="41" height="17" font="7">p&lt;0.02 </text>
<text top="285" left="852" width="82" height="17" font="7">CI: ≥2.5 L/m/m</text>
<text top="286" left="934" width="4" height="11" font="9">2</text>
<text top="285" left="938" width="46" height="17" font="7"> 93±4% </text>
<text top="302" left="852" width="81" height="17" font="7">CI: &lt;2.5 L/m/m</text>
<text top="303" left="933" width="4" height="11" font="9">2</text>
<text top="302" left="937" width="53" height="17" font="7"> 63±10% </text>
<text top="319" left="884" width="41" height="17" font="7">p&lt;0.02 </text>
<text top="182" left="1115" width="228" height="17" font="7">High-risk group identified by preoperative </text>
<text top="199" left="1115" width="228" height="17" font="7">angiographic LVEF &lt;50% and/or CI: &lt;2.5 </text>
<text top="216" left="1115" width="34" height="17" font="7">L/m/m</text>
<text top="217" left="1149" width="4" height="11" font="9">2</text>
<text top="216" left="1154" width="3" height="17" font="7"> </text>
<text top="337" left="39" width="70" height="17" font="7">Henry 1980  </text>
<text top="354" left="39" width="25" height="17" font="7">(86) </text>
<text top="372" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7353236">7353236</a></text>
<text top="372" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7353236"> </a></text>
<text top="337" left="130" width="90" height="17" font="7">Determinants of </text>
<text top="354" left="130" width="102" height="17" font="7">survival after AVR </text>
<text top="337" left="271" width="148" height="17" font="7">Prospective, observational </text>
<text top="354" left="271" width="127" height="17" font="7">series; consecutive pts </text>
<text top="372" left="271" width="162" height="17" font="7">undergoing AVR 1972–1977; </text>
<text top="389" left="271" width="91" height="17" font="7">single institution </text>
<text top="337" left="447" width="17" height="17" font="7">50 </text>
<text top="337" left="501" width="21" height="17" font="7">3.7 </text>
<text top="337" left="589" width="172" height="17" font="7">Indications for AVR; symptoms </text>
<text top="354" left="589" width="179" height="17" font="7">Mean age 46 y (range 19–68 y)  </text>
<text top="372" left="589" width="217" height="17" font="7">Preoperative echo and hemodynamics  </text>
<text top="389" left="589" width="104" height="17" font="7">Endpoint: survival  </text>
<text top="337" left="852" width="73" height="17" font="7">4-y survival:  </text>
<text top="354" left="852" width="70" height="17" font="7">Overall 61% </text>
<text top="372" left="852" width="120" height="17" font="7">LVESD &lt;55 mm 75% </text>
<text top="389" left="852" width="118" height="17" font="7">LVESD ≥55mm 38% </text>
<text top="406" left="898" width="48" height="17" font="7">p=0.006 </text>
<text top="337" left="1115" width="228" height="17" font="7">High-risk group identified by preoperative </text>
<text top="354" left="1115" width="212" height="17" font="7">echocardiographic LVFS &lt;25% and/or </text>
<text top="372" left="1115" width="92" height="17" font="7">LVESD &gt;55 mm </text>
<text top="424" left="39" width="74" height="17" font="7">Cunha 1980  </text>
<text top="441" left="39" width="29" height="17" font="7">(87)  </text>
<text top="458" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7351849">7351849</a></text>
<text top="458" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7351849"> </a></text>
<text top="424" left="130" width="90" height="17" font="7">Determinants of </text>
<text top="441" left="130" width="102" height="17" font="7">survival after AVR </text>
<text top="424" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="441" left="271" width="128" height="17" font="7">series; consecutive pts </text>
<text top="458" left="271" width="162" height="17" font="7">undergoing AVR 1973–1977; </text>
<text top="476" left="271" width="91" height="17" font="7">single institution </text>
<text top="424" left="447" width="17" height="17" font="7">86 </text>
<text top="424" left="501" width="60" height="17" font="7">2.4 (range </text>
<text top="441" left="501" width="38" height="17" font="7">1–5.4) </text>
<text top="424" left="589" width="206" height="17" font="7">79 symptomatic pts, 7 asymptomatic  </text>
<text top="441" left="589" width="189" height="17" font="7">Mean age 49.6 y (range 17–82 y)  </text>
<text top="458" left="589" width="171" height="17" font="7">Preoperative echo (all pts) and </text>
<text top="476" left="589" width="131" height="17" font="7">hemodynamics (37 pts) </text>
<text top="493" left="589" width="104" height="17" font="7">Endpoint: survival  </text>
<text top="424" left="852" width="69" height="17" font="7">3-y survival: </text>
<text top="441" left="852" width="104" height="17" font="7">LVFS &gt;35% 100% </text>
<text top="458" left="852" width="108" height="17" font="7">LVFS 31-35% 91% </text>
<text top="476" left="852" width="98" height="17" font="7">LVFS ≤30% 78% </text>
<text top="493" left="884" width="41" height="17" font="7">p&lt;0.05 </text>
<text top="510" left="852" width="105" height="17" font="7">LVEF ≥60% 100% </text>
<text top="527" left="852" width="97" height="17" font="7">LVEF &lt;60% 77% </text>
<text top="544" left="884" width="41" height="17" font="7">p&lt;0.05 </text>
<text top="424" left="1115" width="228" height="17" font="7">High-risk group identified by preoperative </text>
<text top="441" left="1115" width="177" height="17" font="7">echocardiographic LVFS &lt;30%. </text>
<text top="458" left="1115" width="205" height="17" font="7">Mortality also significantly associated </text>
<text top="476" left="1115" width="144" height="17" font="7">with preoperative LVESD. </text>
<text top="493" left="1115" width="195" height="17" font="7">Among pts with FS &lt;30%, mortality </text>
<text top="510" left="1115" width="179" height="17" font="7">higher in NYHA III-IV than in I-II. </text>
<text top="562" left="39" width="75" height="17" font="7">Bonow 1980  </text>
<text top="580" left="39" width="25" height="17" font="7">(88) </text>
<text top="597" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6777072">6777072</a></text>
<text top="597" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6777072"> </a></text>
<text top="562" left="130" width="90" height="17" font="7">Determinants of </text>
<text top="580" left="130" width="87" height="17" font="7">survival and LV </text>
<text top="597" left="130" width="103" height="17" font="7">function after AVR </text>
<text top="562" left="271" width="148" height="17" font="7">Prospective, observational </text>
<text top="580" left="271" width="153" height="17" font="7">series; pts undergoing AVR </text>
<text top="597" left="271" width="157" height="17" font="7">1972-1978; single institution </text>
<text top="562" left="447" width="17" height="17" font="7">45 </text>
<text top="562" left="501" width="21" height="17" font="7">3.2 </text>
<text top="562" left="589" width="188" height="17" font="7">Symptomatic pts undergoing AVR </text>
<text top="580" left="589" width="172" height="17" font="7">Mean age 44 y (range 20-68 y) </text>
<text top="597" left="589" width="192" height="17" font="7">Studied with echo, radionuclide LV </text>
<text top="614" left="589" width="230" height="17" font="7">angiography, and graded treadmill testing </text>
<text top="631" left="589" width="242" height="17" font="7">Good exercise capacity defined as &gt;stage 1 </text>
<text top="649" left="589" width="85" height="17" font="7">of NIH protocol </text>
<text top="666" left="589" width="196" height="17" font="7">Endpoints: survival and LV function </text>
<text top="562" left="852" width="236" height="17" font="7">Among 32 pts with subnormal LVFS, those </text>
<text top="580" left="852" width="232" height="17" font="7">with good vs. poor exercise capacity had:  </text>
<text top="597" left="852" width="220" height="17" font="7">Better survival (100% vs. 47%, p&lt;0.01). </text>
<text top="614" left="852" width="214" height="17" font="7">Lower postoperative LVEDD (56±8 vs. </text>
<text top="631" left="852" width="119" height="17" font="7">68±11 mm, p&lt;0.005) </text>
<text top="649" left="852" width="225" height="17" font="7">Higher exercise LVEF (5±15 vs. 42±8%, </text>
<text top="666" left="852" width="46" height="17" font="7">p&lt;0.01) </text>
<text top="562" left="1115" width="226" height="17" font="7">Exercise capacity imprecise in assessing </text>
<text top="580" left="1115" width="222" height="17" font="7">preoperative LV function in symptomatic </text>
<text top="597" left="1115" width="223" height="17" font="7">pts with AR, but useful in predicting long-</text>
<text top="614" left="1115" width="218" height="17" font="7">term survival after AVR and reversibility </text>
<text top="631" left="1115" width="218" height="17" font="7">of LV dilatation and systolic dysfunction </text>
<text top="684" left="39" width="69" height="17" font="7">Borow 1980 </text>
<text top="701" left="39" width="25" height="17" font="7">(89) </text>
<text top="718" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7377221">7377221</a></text>
<text top="718" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7377221"> </a></text>
<text top="684" left="130" width="108" height="17" font="7">Determinants of LV </text>
<text top="701" left="130" width="103" height="17" font="7">function after AVR </text>
<text top="684" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="701" left="271" width="153" height="17" font="7">series; pts undergoing AVR </text>
<text top="718" left="271" width="113" height="17" font="7">starting 1971; single </text>
<text top="736" left="271" width="55" height="17" font="7">institution </text>
<text top="684" left="447" width="17" height="17" font="7">20 </text>
<text top="684" left="501" width="21" height="17" font="7">2.0 </text>
<text top="701" left="501" width="63" height="17" font="7">(range 0.5–</text>
<text top="718" left="501" width="25" height="17" font="7">5.8) </text>
<text top="684" left="589" width="196" height="17" font="7">NYHA: II (20%), III (70%), IV (10%) </text>
<text top="701" left="589" width="183" height="17" font="7">Preoperative hemodynamics and </text>
<text top="718" left="589" width="185" height="17" font="7">angiography; postoperative echo  </text>
<text top="736" left="589" width="163" height="17" font="7">Endpoint: LV function (LVFS) </text>
<text top="684" left="852" width="202" height="17" font="7">Preoperative LVESVi correlated with </text>
<text top="701" left="852" width="158" height="17" font="7">postoperative LVFS (r=0.77) </text>
<text top="718" left="852" width="237" height="17" font="7">The 3 postoperative deaths occurred in pts </text>
<text top="736" left="852" width="201" height="17" font="7">with preoperative LVESVi 0.60 mL/m</text>
<text top="737" left="1053" width="4" height="11" font="9">2</text>
<text top="736" left="1057" width="3" height="17" font="7"> </text>
<text top="684" left="1115" width="227" height="17" font="7">In symptomatic pts with AR, preoperative </text>
<text top="701" left="1115" width="209" height="17" font="7">LVESV is an important determinant of </text>
<text top="718" left="1115" width="186" height="17" font="7">postoperative LV systolic function </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">22 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="42" width="71" height="17" font="6"><b>Study, Year </b></text>
<text top="108" left="154" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="318" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="449" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="453" width="28" height="17" font="6"><b>Size </b></text>
<text top="143" left="458" width="19" height="17" font="6"><b>(n) </b></text>
<text top="108" left="521" width="35" height="17" font="6"><b>Mean </b></text>
<text top="126" left="507" width="63" height="17" font="6"><b>Follow-Up </b></text>
<text top="143" left="529" width="19" height="17" font="6"><b>(y) </b></text>
<text top="108" left="601" width="225" height="17" font="6"><b>Inclusion Criteria, Outcome Assessed </b></text>
<text top="108" left="945" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="108" left="1161" width="139" height="17" font="6"><b>Comments, Limitations </b></text>
<text top="161" left="39" width="74" height="17" font="7">Greves 1981 </text>
<text top="178" left="39" width="25" height="17" font="7">(90) </text>
<text top="195" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6451163">6451163</a></text>
<text top="195" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6451163"> </a></text>
<text top="161" left="130" width="90" height="17" font="7">Determinants of </text>
<text top="178" left="130" width="102" height="17" font="7">survival after AVR </text>
<text top="161" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="178" left="271" width="153" height="17" font="7">series; pts undergoing AVR </text>
<text top="195" left="271" width="159" height="17" font="7">1973–1979; single institution </text>
<text top="161" left="447" width="17" height="17" font="7">42 </text>
<text top="161" left="501" width="21" height="17" font="7">3.7 </text>
<text top="178" left="501" width="63" height="17" font="7">(range 0.2–</text>
<text top="195" left="501" width="25" height="17" font="7">6.6) </text>
<text top="161" left="589" width="206" height="17" font="7">38 symptomatic pts, 4 asymptomatic  </text>
<text top="178" left="589" width="156" height="17" font="7">Mean age 45 (range 14–74) </text>
<text top="195" left="589" width="183" height="17" font="7">Preoperative hemodynamics and </text>
<text top="212" left="589" width="71" height="17" font="7">angiography </text>
<text top="230" left="589" width="100" height="17" font="7">Endpoint: survival </text>
<text top="161" left="852" width="73" height="17" font="7">5-y survival:  </text>
<text top="178" left="852" width="134" height="17" font="7">Overall 65.3±7.8% (SE) </text>
<text top="195" left="852" width="134" height="17" font="7">LVEF ≥45% 86.6±6.2% </text>
<text top="212" left="852" width="140" height="17" font="7">LVEF &lt;45% 53.6±20.1% </text>
<text top="230" left="884" width="41" height="17" font="7">p=0.04 </text>
<text top="247" left="852" width="141" height="17" font="7">Cardiac index: ≥2.5L/m/m</text>
<text top="248" left="993" width="4" height="11" font="9">2</text>
<text top="247" left="998" width="47" height="17" font="7"> 92±6% </text>
<text top="264" left="852" width="140" height="17" font="7">Cardiac index: &lt;2.5L/m/m</text>
<text top="265" left="992" width="4" height="11" font="9">2</text>
<text top="264" left="997" width="64" height="17" font="7"> 66±16.1% </text>
<text top="281" left="884" width="41" height="17" font="7">p&lt;0.02 </text>
<text top="161" left="1115" width="227" height="17" font="7">High-risk group identified by preoperative </text>
<text top="178" left="1115" width="225" height="17" font="7">angiographic LVEF &lt;45% and/or cardiac </text>
<text top="195" left="1115" width="98" height="17" font="7">index: &lt;2.5 L/m/m</text>
<text top="196" left="1213" width="4" height="11" font="9">2</text>
<text top="195" left="1218" width="3" height="17" font="7"> </text>
<text top="212" left="1115" width="210" height="17" font="7">Among pts with LVEF &lt;45%, mortality </text>
<text top="230" left="1115" width="179" height="17" font="7">higher in NYHA III-IV than in I-II. </text>
<text top="299" left="39" width="55" height="17" font="7">Kumpuris </text>
<text top="317" left="39" width="34" height="17" font="7">1982  </text>
<text top="334" left="39" width="25" height="17" font="7">(91) </text>
<text top="351" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6461239">6461239</a></text>
<text top="351" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6461239"> </a></text>
<text top="299" left="130" width="90" height="17" font="7">Determinants of </text>
<text top="317" left="130" width="117" height="17" font="7">survival, LV function, </text>
<text top="334" left="130" width="116" height="17" font="7">symptoms after AVR </text>
<text top="299" left="271" width="148" height="17" font="7">Prospective, observational </text>
<text top="317" left="271" width="128" height="17" font="7">series; consecutive pts </text>
<text top="334" left="271" width="162" height="17" font="7">undergoing AVR 1973–1979; </text>
<text top="351" left="271" width="91" height="17" font="7">single institution </text>
<text top="299" left="447" width="17" height="17" font="7">43 </text>
<text top="299" left="501" width="27" height="17" font="7">0.67 </text>
<text top="299" left="589" width="245" height="17" font="7">43 pts with chronic AR and 14 pts with acute </text>
<text top="317" left="589" width="228" height="17" font="7">AR; only the pts with chronic AR reported </text>
<text top="334" left="589" width="28" height="17" font="7">here </text>
<text top="351" left="589" width="175" height="17" font="7">Mean age 46 y (range 18–72 y) </text>
<text top="368" left="589" width="168" height="17" font="7">Pre- and postoperative echos  </text>
<text top="385" left="589" width="192" height="17" font="7">Endpoint: survival, HF, LV function </text>
<text top="299" left="852" width="228" height="17" font="7">Prediction of persistent LV dilatation after </text>
<text top="317" left="852" width="133" height="17" font="7">AVR (LVEDD &gt;58 mm): </text>
<text top="334" left="852" width="163" height="17" font="7">Index                       Accuracy </text>
<text top="351" left="852" width="137" height="17" font="7">LVEDD 72 mm        77% </text>
<text top="368" left="852" width="140" height="17" font="7">LVESD 50 mm         86% </text>
<text top="385" left="852" width="140" height="17" font="7">FS 28%                    70% </text>
<text top="403" left="852" width="140" height="17" font="7">Mean R/Th 2.5         93% </text>
<text top="420" left="852" width="139" height="17" font="7">MWS 300 mm Hg    88% </text>
<text top="437" left="852" width="140" height="17" font="7">ESS 235 mm Hg      91% </text>
<text top="299" left="1115" width="186" height="17" font="7">Persistent LV dilatation after AVR </text>
<text top="317" left="1115" width="219" height="17" font="7">predicted by preoperative LVESD, R/Th </text>
<text top="334" left="1115" width="221" height="17" font="7">ratio, mean and end-systolic wall stress; </text>
<text top="351" left="1115" width="222" height="17" font="7">greater precision than LVFS or LVEDD.  </text>
<text top="368" left="1115" width="223" height="17" font="7">All deaths occurred in pts with persistent </text>
<text top="385" left="1115" width="75" height="17" font="7">LV dilatation. </text>
<text top="455" left="39" width="77" height="17" font="7">Gaasch 1983 </text>
<text top="472" left="39" width="25" height="17" font="7">(92) </text>
<text top="489" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6219153">6219153</a></text>
<text top="489" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6219153"> </a></text>
<text top="455" left="130" width="108" height="17" font="7">Determinants of LV </text>
<text top="472" left="130" width="109" height="17" font="7">function, symptoms </text>
<text top="489" left="130" width="57" height="17" font="7">after AVR </text>
<text top="455" left="271" width="148" height="17" font="7">Prospective, observational </text>
<text top="472" left="271" width="153" height="17" font="7">series; pts undergoing AVR </text>
<text top="489" left="271" width="159" height="17" font="7">1975–1980; single institution </text>
<text top="455" left="447" width="17" height="17" font="7">32 </text>
<text top="455" left="501" width="64" height="17" font="7">Range 1–6 </text>
<text top="455" left="589" width="228" height="17" font="7">Group A: 25 pts with normal LVEDD after </text>
<text top="472" left="589" width="211" height="17" font="7">AVR (mean age 45 y, range 18–63 y)  </text>
<text top="489" left="589" width="211" height="17" font="7">Group B: 7 pts with LVEDD &gt;33 mm/m</text>
<text top="491" left="800" width="4" height="11" font="9">2</text>
<text top="489" left="804" width="31" height="17" font="7"> after </text>
<text top="507" left="589" width="211" height="17" font="7">AVR (mean age 58 y, range 23–74 y)  </text>
<text top="524" left="589" width="230" height="17" font="7">24 symptomatic pts, 9 asymptomatic (8 in </text>
<text top="541" left="589" width="57" height="17" font="7">Group A)  </text>
<text top="558" left="589" width="200" height="17" font="7">Pre- and serial postoperative echos  </text>
<text top="575" left="589" width="183" height="17" font="7">Endpoint: symptoms, LV function </text>
<text top="455" left="852" width="222" height="17" font="7">Preoperative data, Group A vs. Group B </text>
<text top="472" left="852" width="60" height="17" font="7">(p&lt;0.001): </text>
<text top="489" left="852" width="192" height="17" font="7">—LVEDD 69±6 mm vs. 79±6 mm  </text>
<text top="507" left="852" width="187" height="17" font="7">—LVESD 46±7 mm vs. 58±7 mm </text>
<text top="524" left="852" width="155" height="17" font="7">—LVFS 34±6% vs. 27±6%  </text>
<text top="541" left="852" width="153" height="17" font="7">—R/Th 3.4±0.4 vs. 4.1±0.3 </text>
<text top="558" left="852" width="231" height="17" font="7">More postoperative symptoms in Group B </text>
<text top="455" left="1115" width="186" height="17" font="7">Persistent LV dilatation after AVR </text>
<text top="472" left="1115" width="218" height="17" font="7">predicted by echocardiographic LVESD </text>
<text top="489" left="1115" width="58" height="17" font="7">&gt;2.6 cm/m</text>
<text top="491" left="1173" width="7" height="11" font="9">2 </text>
<text top="489" left="1180" width="116" height="17" font="7">and R/Th ratio &gt;3.8.  </text>
<text top="507" left="1115" width="219" height="17" font="7">Trend toward worse survival in Group B </text>
<text top="524" left="1115" width="220" height="17" font="7">(but only 2 deaths in each group at 4 y). </text>
<text top="541" left="1115" width="218" height="17" font="7">Note: Group B was also 12 y older than </text>
<text top="558" left="1115" width="181" height="17" font="7">Group A and more symptomatic. </text>
<text top="605" left="39" width="72" height="17" font="7">Fioretti 1983 </text>
<text top="622" left="39" width="25" height="17" font="7">(93) </text>
<text top="639" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6847800">6847800</a></text>
<text top="639" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6847800"> </a></text>
<text top="605" left="130" width="108" height="17" font="7">Determinants of LV </text>
<text top="622" left="130" width="103" height="17" font="7">function after AVR </text>
<text top="605" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="622" left="271" width="128" height="17" font="7">series; consecutive pts </text>
<text top="639" left="271" width="162" height="17" font="7">undergoing AVR 1972–1980; </text>
<text top="656" left="271" width="91" height="17" font="7">single institution </text>
<text top="605" left="447" width="17" height="17" font="7">47 </text>
<text top="605" left="501" width="21" height="17" font="7">3.4 </text>
<text top="622" left="501" width="63" height="17" font="7">(range 0.5–</text>
<text top="639" left="501" width="25" height="17" font="7">6.3) </text>
<text top="605" left="589" width="109" height="17" font="7">All pts symptomatic </text>
<text top="622" left="589" width="238" height="17" font="7">Group A: 27 pts with LVESD &lt;55 mm (45 y </text>
<text top="639" left="589" width="128" height="17" font="7">of age, range 22-75 y)  </text>
<text top="656" left="589" width="239" height="17" font="7">Group B: 20 pts with LVESD ≥55 mm (49 y </text>
<text top="674" left="589" width="128" height="17" font="7">of age, range 22-65 y)  </text>
<text top="691" left="589" width="228" height="17" font="7">NYHA III-IV: Group A 26%, Group B 65% </text>
<text top="708" left="589" width="232" height="17" font="7">Preoperative echo and angiographic data; </text>
<text top="725" left="589" width="213" height="17" font="7">postoperative echo at 3 mo and 36 mo </text>
<text top="743" left="589" width="120" height="17" font="7">Endpoint: LV function </text>
<text top="605" left="852" width="222" height="17" font="7">Preoperative data, Group A vs. Group B </text>
<text top="622" left="852" width="60" height="17" font="7">(p&lt;0.001): </text>
<text top="639" left="852" width="164" height="17" font="7">—LVEDD 67±7 vs. 82±6 mm </text>
<text top="656" left="852" width="141" height="17" font="7">—LVFS 33±6 vs. 24±6% </text>
<text top="674" left="852" width="198" height="17" font="7">—LVEDV 147±43 vs. 247±42 mL/m</text>
<text top="675" left="1050" width="4" height="11" font="9">2</text>
<text top="674" left="1054" width="7" height="17" font="7">  </text>
<text top="691" left="852" width="141" height="17" font="7">—LVEF 54±7 vs. 42±9% </text>
<text top="708" left="852" width="231" height="17" font="7">Postoperative data, Group A vs. Group B: </text>
<text top="725" left="852" width="164" height="17" font="7">—LVEDD 53±8 vs. 63±7 mm </text>
<text top="743" left="852" width="67" height="17" font="7">   (p&lt;0.001) </text>
<text top="605" left="1115" width="212" height="17" font="7">Persistent LV dysfunction predicted by </text>
<text top="622" left="1115" width="204" height="17" font="7">preoperative LVEDD ≥75 mm and/or </text>
<text top="639" left="1115" width="96" height="17" font="7">LVESD ≥55 mm. </text>
<text top="656" left="1115" width="216" height="17" font="7">Note greater preoperative symptoms in </text>
<text top="674" left="1115" width="129" height="17" font="7">Group B than Group A  </text>
</page>
<page number="23" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">23 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="42" width="71" height="17" font="6"><b>Study, Year </b></text>
<text top="108" left="154" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="318" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="449" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="453" width="28" height="17" font="6"><b>Size </b></text>
<text top="143" left="458" width="19" height="17" font="6"><b>(n) </b></text>
<text top="108" left="521" width="35" height="17" font="6"><b>Mean </b></text>
<text top="126" left="507" width="63" height="17" font="6"><b>Follow-Up </b></text>
<text top="143" left="529" width="19" height="17" font="6"><b>(y) </b></text>
<text top="108" left="601" width="225" height="17" font="6"><b>Inclusion Criteria, Outcome Assessed </b></text>
<text top="108" left="945" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="108" left="1161" width="139" height="17" font="6"><b>Comments, Limitations </b></text>
<text top="161" left="39" width="70" height="17" font="7">Stone 1984  </text>
<text top="178" left="39" width="25" height="17" font="7">(94) </text>
<text top="195" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6707364">6707364</a></text>
<text top="195" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6707364"> </a></text>
<text top="161" left="130" width="108" height="17" font="7">Determinants of LV </text>
<text top="178" left="130" width="103" height="17" font="7">function after AVR </text>
<text top="161" left="271" width="148" height="17" font="7">Prospective, observational </text>
<text top="178" left="271" width="128" height="17" font="7">series; consecutive pts </text>
<text top="195" left="271" width="162" height="17" font="7">undergoing AVR 1962–1977; </text>
<text top="212" left="271" width="94" height="17" font="7">single institution. </text>
<text top="161" left="447" width="24" height="17" font="7">113 </text>
<text top="161" left="501" width="46" height="17" font="7">4.6±3.3 </text>
<text top="161" left="589" width="120" height="17" font="7">108 pts symptomatic  </text>
<text top="178" left="589" width="175" height="17" font="7">Mean age 51 y (range 25–77 y) </text>
<text top="195" left="589" width="235" height="17" font="7">Hemodynamics and angiography in all pts; </text>
<text top="212" left="589" width="80" height="17" font="7">echo in 44 pts </text>
<text top="230" left="589" width="225" height="17" font="7">20 pts with pre- and postoperative echos </text>
<text top="247" left="589" width="233" height="17" font="7">Endpoint: survival (all pts) and LV function </text>
<text top="264" left="589" width="45" height="17" font="7">(20 pts) </text>
<text top="161" left="852" width="207" height="17" font="7">43 pts died after AVR (8 from HF), no </text>
<text top="178" left="852" width="105" height="17" font="7">predictors of death </text>
<text top="195" left="852" width="247" height="17" font="7">Predictors of postoperative LVEDD ≤57 mm: </text>
<text top="212" left="852" width="142" height="17" font="7">LVESD, LVFS, R/Th ratio </text>
<text top="230" left="852" width="246" height="17" font="7">Predictors of postoperative LVESD ≤40 mm: </text>
<text top="247" left="852" width="146" height="17" font="7">LVESD, LVEDD, LV mass </text>
<text top="161" left="1115" width="191" height="17" font="7">No preoperative variable predicted </text>
<text top="178" left="1115" width="146" height="17" font="7">postoperative LV function. </text>
<text top="195" left="1115" width="217" height="17" font="7">Normal LV size after AVR most likely in </text>
<text top="212" left="1115" width="190" height="17" font="7">pts with preoperative LVFS &gt;26%, </text>
<text top="230" left="1115" width="212" height="17" font="7">LVESD &lt;55 mm, and LVEDD &lt;80 mm </text>
<text top="282" left="39" width="75" height="17" font="7">Bonow 1985  </text>
<text top="299" left="39" width="25" height="17" font="7">(95) </text>
<text top="317" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4064269">4064269</a></text>
<text top="317" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4064269"> </a></text>
<text top="282" left="130" width="90" height="17" font="7">Determinants of </text>
<text top="299" left="130" width="87" height="17" font="7">survival and LV </text>
<text top="317" left="130" width="103" height="17" font="7">function after AVR </text>
<text top="282" left="271" width="148" height="17" font="7">Prospective, observational </text>
<text top="299" left="271" width="127" height="17" font="7">series; consecutive pts </text>
<text top="317" left="271" width="162" height="17" font="7">undergoing AVR 1976–1983; </text>
<text top="334" left="271" width="94" height="17" font="7">single institution. </text>
<text top="282" left="447" width="17" height="17" font="7">80 </text>
<text top="282" left="501" width="27" height="17" font="7">3.75 </text>
<text top="299" left="501" width="63" height="17" font="7">(range 0.5–</text>
<text top="317" left="501" width="28" height="17" font="7">7.5)  </text>
<text top="282" left="589" width="237" height="17" font="7">96 consecutive pts; 16 with CAD excluded  </text>
<text top="299" left="589" width="194" height="17" font="7">Group A: 30 pts with normal LVEF  </text>
<text top="317" left="589" width="213" height="17" font="7">Group B: 50 pts with subnormal LVEF  </text>
<text top="334" left="589" width="175" height="17" font="7">Mean age 44 y (range 15–74 y) </text>
<text top="351" left="589" width="228" height="17" font="7">Preoperative and postoperative echo and </text>
<text top="368" left="589" width="216" height="17" font="7">radionuclide angiography; preoperative </text>
<text top="385" left="589" width="89" height="17" font="7">exercise testing </text>
<text top="403" left="589" width="171" height="17" font="7">Endpoint: Survival, LV function </text>
<text top="282" left="852" width="239" height="17" font="7">5 y survival was 83±5%, significantly better </text>
<text top="299" left="852" width="234" height="17" font="7">than pts undergoing AVR from 1972–1976 </text>
<text top="317" left="852" width="51" height="17" font="7">(62±9%) </text>
<text top="334" left="852" width="239" height="17" font="7">Preoperative determinants of postoperative </text>
<text top="351" left="852" width="233" height="17" font="7">survival: LVEF and FS (both p&lt;0.001) and </text>
<text top="368" left="852" width="93" height="17" font="7">LVESD (p&lt;0.01) </text>
<text top="385" left="852" width="240" height="17" font="7">5 y survival: 96±3% in Group A, 63±12% in </text>
<text top="403" left="852" width="106" height="17" font="7">Group B (p&lt;0.001) </text>
<text top="282" left="1115" width="217" height="17" font="7">High-risk group identified by subnormal </text>
<text top="299" left="1115" width="79" height="17" font="7">LVEF at rest.  </text>
<text top="317" left="1115" width="186" height="17" font="7">Pts in Group B with poor exercise </text>
<text top="334" left="1115" width="216" height="17" font="7">tolerance and prolonged duration of LV </text>
<text top="351" left="1115" width="217" height="17" font="7">dysfunction were the highest-risk group </text>
<text top="368" left="1115" width="202" height="17" font="7">(5 y survival 52±11) and had greater </text>
<text top="385" left="1115" width="219" height="17" font="7">LVEDD and lower LVEF (both p&lt;0.001) </text>
<text top="403" left="1115" width="89" height="17" font="7">than the others. </text>
<text top="421" left="39" width="73" height="17" font="7">Daniel 1985  </text>
<text top="438" left="39" width="25" height="17" font="7">(96) </text>
<text top="455" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3156010">3156010</a></text>
<text top="455" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3156010"> </a></text>
<text top="421" left="130" width="90" height="17" font="7">Determinants of </text>
<text top="438" left="130" width="108" height="17" font="7">survival, symptoms </text>
<text top="455" left="130" width="117" height="17" font="7">and LV function after </text>
<text top="472" left="130" width="29" height="17" font="7">AVR </text>
<text top="421" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="438" left="271" width="153" height="17" font="7">series; pts undergoing AVR </text>
<text top="455" left="271" width="104" height="17" font="7">1975–1983; single </text>
<text top="472" left="271" width="59" height="17" font="7">institution. </text>
<text top="421" left="447" width="17" height="17" font="7">84 </text>
<text top="421" left="501" width="21" height="17" font="7">2.5 </text>
<text top="421" left="589" width="232" height="17" font="7">Consecutive series of pts with high-quality </text>
<text top="438" left="589" width="36" height="17" font="7">echos </text>
<text top="455" left="589" width="205" height="17" font="7">Preoperative symptoms not specified </text>
<text top="472" left="589" width="155" height="17" font="7">Age 46±11 y (range 18–71) </text>
<text top="489" left="589" width="129" height="17" font="7">Pts with CAD excluded </text>
<text top="507" left="589" width="234" height="17" font="7">Endpoint: Survival, symptoms, LV function </text>
<text top="421" left="852" width="225" height="17" font="7">Survival at 2.5 y: 90.5% in pts with LVFS </text>
<text top="438" left="852" width="230" height="17" font="7">&gt;25% and LVESD ≤55 mm, but only 70% </text>
<text top="455" left="852" width="215" height="17" font="7">with LVESD &gt;55 mm and LVFS ≤25%. </text>
<text top="472" left="852" width="248" height="17" font="7">Survival at 2.5 y: 79% in pts with LVESD &gt;55 </text>
<text top="489" left="852" width="112" height="17" font="7">mm or LVFS ≤25%. </text>
<text top="421" left="1115" width="180" height="17" font="7">Outcome after AVR predicted by </text>
<text top="438" left="1115" width="181" height="17" font="7">preoperative LVFS and LVESD.  </text>
<text top="455" left="1115" width="212" height="17" font="7">Pts with preoperative LVFS ≤25% had </text>
<text top="472" left="1115" width="222" height="17" font="7">greater postoperative LVEDD compared </text>
<text top="489" left="1115" width="203" height="17" font="7">to those with LVFS &gt;25%: 62±10 vs. </text>
<text top="507" left="1115" width="106" height="17" font="7">54±7 mm (p&lt;0.05) </text>
<text top="525" left="39" width="47" height="17" font="7">Cormier </text>
<text top="542" left="39" width="31" height="17" font="7">1986 </text>
<text top="559" left="39" width="25" height="17" font="7">(97) </text>
<text top="576" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3727677">3727677</a></text>
<text top="576" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3727677"> </a></text>
<text top="525" left="130" width="90" height="17" font="7">Determinants of </text>
<text top="542" left="130" width="102" height="17" font="7">survival after AVR </text>
<text top="525" left="271" width="148" height="17" font="7">Prospective, observational </text>
<text top="542" left="271" width="128" height="17" font="7">series; consecutive pts </text>
<text top="559" left="271" width="162" height="17" font="7">undergoing AVR 1968–1983; </text>
<text top="576" left="271" width="94" height="17" font="7">single institution. </text>
<text top="525" left="447" width="17" height="17" font="7">73 </text>
<text top="525" left="501" width="46" height="17" font="7">4.9±0.8 </text>
<text top="542" left="501" width="63" height="17" font="7">(range 0.3–</text>
<text top="559" left="501" width="21" height="17" font="7">14) </text>
<text top="525" left="589" width="231" height="17" font="7">All pts in NYHA FC I-II (26 FC I, 47 FC II)  </text>
<text top="542" left="589" width="164" height="17" font="7">Age 46±11 y (range 14–76 y) </text>
<text top="559" left="589" width="196" height="17" font="7">Echo in 58 pts (LVEDD 70±12 mm; </text>
<text top="576" left="589" width="235" height="17" font="7">hemodynamics and angiography in 62 pts) </text>
<text top="593" left="589" width="124" height="17" font="7">(LVEDV 222±55 mL/m</text>
<text top="595" left="713" width="4" height="11" font="9">2</text>
<text top="593" left="718" width="8" height="17" font="7">) </text>
<text top="611" left="589" width="129" height="17" font="7">Pts with CAD excluded </text>
<text top="628" left="589" width="106" height="17" font="7">Endpoint: Survival  </text>
<text top="525" left="852" width="107" height="17" font="7">84% survival at 8 y </text>
<text top="542" left="852" width="235" height="17" font="7">There were only 2 determinants of survival </text>
<text top="559" left="852" width="211" height="17" font="7">after AVR: LVEF (p&lt;0.05) and LVESD </text>
<text top="576" left="852" width="49" height="17" font="7">(p&lt;0.05) </text>
<text top="525" left="1115" width="131" height="17" font="7">Overall survival good in </text>
<text top="542" left="1115" width="206" height="17" font="7">asymptomatic/mildly symptomatic pts </text>
<text top="559" left="1115" width="227" height="17" font="7">High-risk group identified by preoperative </text>
<text top="576" left="1115" width="190" height="17" font="7">LVEF &lt;40% and LVESD ≥55 mm. </text>
<text top="646" left="39" width="48" height="17" font="7">Sheiban </text>
<text top="663" left="39" width="31" height="17" font="7">1986 </text>
<text top="680" left="39" width="25" height="17" font="7">(98) </text>
<text top="698" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3727678">3727678</a></text>
<text top="698" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3727678"> </a></text>
<text top="646" left="130" width="90" height="17" font="7">Determinants of </text>
<text top="663" left="130" width="102" height="17" font="7">survival after AVR </text>
<text top="646" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="663" left="271" width="128" height="17" font="7">series; consecutive pts </text>
<text top="680" left="271" width="162" height="17" font="7">undergoing AVR 1973–1982; </text>
<text top="698" left="271" width="94" height="17" font="7">single institution. </text>
<text top="646" left="447" width="17" height="17" font="7">84 </text>
<text top="646" left="501" width="21" height="17" font="7">6.5 </text>
<text top="663" left="501" width="42" height="17" font="7">(range  </text>
<text top="680" left="501" width="35" height="17" font="7">3–10) </text>
<text top="646" left="589" width="242" height="17" font="7">NYHA: I (12%), II (33%), III (45%), IV (10%) </text>
<text top="663" left="589" width="166" height="17" font="7">Mean age 42 y (range 20–68) </text>
<text top="680" left="589" width="220" height="17" font="7">Echo, hemodynamics, and angiography </text>
<text top="698" left="589" width="103" height="17" font="7">Endpoint: Survival </text>
<text top="646" left="852" width="125" height="17" font="7">10-y survival (p&lt;0.01): </text>
<text top="663" left="852" width="206" height="17" font="7">NYHA I 100%, II 86%, III 70%, IV 0% </text>
<text top="680" left="852" width="122" height="17" font="7">5-y survival (p&lt;0.01):  </text>
<text top="698" left="852" width="150" height="17" font="7">—82% in LVESD ≤55 mm; </text>
<text top="715" left="852" width="145" height="17" font="7">—37% in LVESD &lt;55 mm </text>
<text top="732" left="852" width="241" height="17" font="7">—81% in LVEF ≥50% ; 62% in LVEF &lt;50% </text>
<text top="646" left="1115" width="228" height="17" font="7">High-risk group identified by preoperative </text>
<text top="663" left="1115" width="189" height="17" font="7">LVEF &lt;50% and LVESD &gt;55 mm. </text>
<text top="680" left="1115" width="193" height="17" font="7">Severity of preoperative symptoms </text>
<text top="698" left="1115" width="156" height="17" font="7">associated with late survival </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">24 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="42" width="71" height="17" font="6"><b>Study, Year </b></text>
<text top="108" left="154" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="318" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="449" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="453" width="28" height="17" font="6"><b>Size </b></text>
<text top="143" left="458" width="19" height="17" font="6"><b>(n) </b></text>
<text top="108" left="521" width="35" height="17" font="6"><b>Mean </b></text>
<text top="126" left="507" width="63" height="17" font="6"><b>Follow-Up </b></text>
<text top="143" left="529" width="19" height="17" font="6"><b>(y) </b></text>
<text top="108" left="601" width="225" height="17" font="6"><b>Inclusion Criteria, Outcome Assessed </b></text>
<text top="108" left="945" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="108" left="1161" width="139" height="17" font="6"><b>Comments, Limitations </b></text>
<text top="161" left="39" width="56" height="17" font="7">Carabello </text>
<text top="178" left="39" width="31" height="17" font="7">1986 </text>
<text top="195" left="39" width="25" height="17" font="7">(99) </text>
<text top="212" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3779916">3779916</a></text>
<text top="212" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3779916"> </a></text>
<text top="161" left="130" width="108" height="17" font="7">Determinants of LV </text>
<text top="178" left="130" width="116" height="17" font="7">function after AVR in </text>
<text top="195" left="130" width="117" height="17" font="7">pts with preoperative </text>
<text top="212" left="130" width="84" height="17" font="7">LV dysfunction </text>
<text top="161" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="178" left="271" width="153" height="17" font="7">series; pts undergoing AVR </text>
<text top="195" left="271" width="104" height="17" font="7">1980–1987; single </text>
<text top="212" left="271" width="59" height="17" font="7">institution. </text>
<text top="161" left="447" width="17" height="17" font="7">14 </text>
<text top="161" left="501" width="53" height="17" font="7">1.9±0.67 </text>
<text top="178" left="501" width="63" height="17" font="7">(range 0.5–</text>
<text top="195" left="501" width="14" height="17" font="7">6) </text>
<text top="161" left="589" width="247" height="17" font="7">Pts with isolated severe AR and LVEF &lt;55% </text>
<text top="178" left="589" width="100" height="17" font="7">Mean age 49±6 y </text>
<text top="195" left="589" width="129" height="17" font="7">Pts with CAD excluded </text>
<text top="212" left="589" width="238" height="17" font="7">Preoperative hemodynamic and echo data; </text>
<text top="230" left="589" width="218" height="17" font="7">postoperative radionuclide angiography </text>
<text top="247" left="589" width="120" height="17" font="7">Endpoint: LV function </text>
<text top="161" left="852" width="173" height="17" font="7">Preoperative LVESD 57±3 mm </text>
<text top="178" left="852" width="204" height="17" font="7">Correlation with postoperative LVEF: </text>
<text top="195" left="852" width="144" height="17" font="7">—LVEDD r=-0.47; p&lt;0.05 </text>
<text top="212" left="852" width="130" height="17" font="7">—LVEF r=0.55; p&lt;0.05 </text>
<text top="230" left="852" width="130" height="17" font="7">—R/Th r=-0.56; p&lt;0.05 </text>
<text top="247" left="852" width="143" height="17" font="7">—LVESV r=-0.62; p&lt;0.05 </text>
<text top="264" left="852" width="130" height="17" font="7">—LVFS r=0.71; p&lt;0.01 </text>
<text top="281" left="852" width="150" height="17" font="7">—LVESD r=-0.91; p&lt;0.001 </text>
<text top="161" left="1115" width="196" height="17" font="7">Postoperative LVEF correlated with </text>
<text top="178" left="1115" width="219" height="17" font="7">preoperative LVESD, FS, LVEDD, R/Th </text>
<text top="195" left="1115" width="27" height="17" font="7">ratio </text>
<text top="212" left="1115" width="189" height="17" font="7">Postoperative LVEF most strongly </text>
<text top="230" left="1115" width="203" height="17" font="7">associated with preoperative LVESD </text>
<text top="299" left="39" width="57" height="17" font="7">Taniguchi </text>
<text top="317" left="39" width="34" height="17" font="7">1987  </text>
<text top="334" left="39" width="32" height="17" font="7">(100) </text>
<text top="351" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3624657">3624657</a></text>
<text top="351" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3624657"> </a></text>
<text top="299" left="130" width="90" height="17" font="7">Determinants of </text>
<text top="317" left="130" width="102" height="17" font="7">survival after AVR </text>
<text top="299" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="317" left="271" width="128" height="17" font="7">series; consecutive pts </text>
<text top="334" left="271" width="162" height="17" font="7">undergoing AVR 1978–1985; </text>
<text top="351" left="271" width="94" height="17" font="7">single institution. </text>
<text top="299" left="447" width="17" height="17" font="7">62 </text>
<text top="299" left="501" width="46" height="17" font="7">3.8±2.2 </text>
<text top="299" left="589" width="155" height="17" font="7">Age 43±12 y (range 18–64) </text>
<text top="317" left="589" width="157" height="17" font="7">Group A: LVESV &lt;200 mL/m</text>
<text top="318" left="746" width="4" height="11" font="9">2</text>
<text top="317" left="751" width="84" height="17" font="7"> (n=48), Group </text>
<text top="334" left="589" width="120" height="17" font="7">B: LVESV &gt;200 mL/m</text>
<text top="335" left="709" width="4" height="11" font="9">2</text>
<text top="334" left="713" width="46" height="17" font="7"> (n=12)  </text>
<text top="351" left="589" width="129" height="17" font="7">Pts with CAD excluded </text>
<text top="368" left="589" width="177" height="17" font="7">Preoperative hemodynamic and </text>
<text top="385" left="589" width="101" height="17" font="7">angiographic data </text>
<text top="403" left="589" width="212" height="17" font="7">Postoperative catheterization in 29 pts </text>
<text top="420" left="589" width="192" height="17" font="7">Endpoint: Survival and LV function </text>
<text top="299" left="852" width="109" height="17" font="7">7-y survival 83±5% </text>
<text top="317" left="852" width="204" height="17" font="7">Preoperative LVESV index was most </text>
<text top="334" left="852" width="230" height="17" font="7">important indicator of postoperative death </text>
<text top="351" left="852" width="56" height="17" font="7">(p&lt;0.001) </text>
<text top="368" left="852" width="79" height="17" font="7">6.5 y survival: </text>
<text top="385" left="852" width="221" height="17" font="7">92±4% in Group A, 51±16% in Group B </text>
<text top="403" left="852" width="56" height="17" font="7">(p&lt;0.001) </text>
<text top="420" left="852" width="227" height="17" font="7">Postoperative data, Group A vs. Group B </text>
<text top="437" left="852" width="60" height="17" font="7">(p&lt;0.001)  </text>
<text top="454" left="852" width="144" height="17" font="7">—LVEF: 62±7 vs. 42±8% </text>
<text top="472" left="852" width="194" height="17" font="7">—LVEDV: 98±19 vs. 124±58 mL/m</text>
<text top="473" left="1046" width="4" height="11" font="9">2</text>
<text top="472" left="1051" width="3" height="17" font="7"> </text>
<text top="299" left="1115" width="228" height="17" font="7">High-risk group identified by preoperative </text>
<text top="317" left="1115" width="138" height="17" font="7">LVESV index &gt;200 mL/m</text>
<text top="318" left="1253" width="7" height="11" font="9">2 </text>
<text top="317" left="1260" width="72" height="17" font="7">and/or LVEF </text>
<text top="334" left="1115" width="39" height="17" font="7">&lt;40%. </text>
<text top="351" left="1115" width="165" height="17" font="7">No cardiac deaths in Group A </text>
<text top="489" left="39" width="72" height="17" font="7">Bonow 1988 </text>
<text top="507" left="39" width="25" height="17" font="7">(95) </text>
<text top="524" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4064269">4064269</a></text>
<text top="524" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/4064269"> </a></text>
<text top="489" left="130" width="106" height="17" font="7">Factors influencing </text>
<text top="507" left="130" width="114" height="17" font="7">short- and long-term </text>
<text top="524" left="130" width="128" height="17" font="7">changes in LV function </text>
<text top="541" left="130" width="60" height="17" font="7">after AVR  </text>
<text top="489" left="271" width="148" height="17" font="7">Prospective, observational </text>
<text top="507" left="271" width="153" height="17" font="7">series; pts undergoing AVR </text>
<text top="524" left="271" width="104" height="17" font="7">1976–1983; single </text>
<text top="541" left="271" width="59" height="17" font="7">institution. </text>
<text top="489" left="447" width="17" height="17" font="7">80 </text>
<text top="489" left="501" width="43" height="17" font="7">Range  </text>
<text top="507" left="501" width="21" height="17" font="7">3-7 </text>
<text top="489" left="589" width="179" height="17" font="7">Mean age 43 y (range 19–72 y)  </text>
<text top="507" left="589" width="129" height="17" font="7">Pts with CAD excluded </text>
<text top="524" left="589" width="238" height="17" font="7">Echo and radionuclide angiography before, </text>
<text top="541" left="589" width="219" height="17" font="7">6–8 mo after AVR and 3–7 y after AVR; </text>
<text top="558" left="589" width="161" height="17" font="7">preoperative exercise testing </text>
<text top="575" left="589" width="124" height="17" font="7">Endpoint: LV function  </text>
<text top="489" left="852" width="244" height="17" font="7">Preoperative to early postoperative changes </text>
<text top="507" left="852" width="60" height="17" font="7">(p&lt;0.001): </text>
<text top="524" left="852" width="159" height="17" font="7">—LVEDD 75±6 to 56±9 mm </text>
<text top="541" left="852" width="142" height="17" font="7">—LVEF 43±9 to 51±16% </text>
<text top="558" left="852" width="213" height="17" font="7">—LVPSS 247±50 to 163±42 dynes/cm</text>
<text top="559" left="1065" width="4" height="11" font="9">2</text>
<text top="558" left="1070" width="3" height="17" font="7"> </text>
<text top="575" left="852" width="223" height="17" font="7">Early to late postoperative: no change in </text>
<text top="593" left="852" width="247" height="17" font="7">LVEDD or PSS, but further increase in LVEF </text>
<text top="610" left="852" width="120" height="17" font="7">to 56±19% (p&lt;0.001) </text>
<text top="489" left="1115" width="209" height="17" font="7">Short- and long-term LV function after </text>
<text top="507" left="1115" width="208" height="17" font="7">AVR predicted by preoperative LVEF, </text>
<text top="524" left="1115" width="73" height="17" font="7">FS, LVESD.  </text>
<text top="541" left="1115" width="220" height="17" font="7">Among pts with subnormal preoperative </text>
<text top="558" left="1115" width="227" height="17" font="7">LVEF, those with poor exercise tolerance </text>
<text top="575" left="1115" width="218" height="17" font="7">or prolonged duration of LV dysfunction </text>
<text top="593" left="1115" width="193" height="17" font="7">are at highest risk for persistent LV </text>
<text top="610" left="1115" width="66" height="17" font="7">dysfunction </text>
<text top="628" left="39" width="70" height="17" font="7">Michel 1995 </text>
<text top="645" left="39" width="32" height="17" font="7">(101) </text>
<text top="662" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8563993">8563993</a></text>
<text top="662" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8563993"> </a></text>
<text top="628" left="130" width="118" height="17" font="7">Determinants of long-</text>
<text top="645" left="130" width="101" height="17" font="7">term survival after </text>
<text top="662" left="130" width="29" height="17" font="7">AVR </text>
<text top="628" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="645" left="271" width="128" height="17" font="7">series; consecutive pts </text>
<text top="662" left="271" width="162" height="17" font="7">undergoing AVR 1980–1994; </text>
<text top="679" left="271" width="94" height="17" font="7">single institution. </text>
<text top="628" left="447" width="24" height="17" font="7">286 </text>
<text top="628" left="501" width="10" height="17" font="7">6 </text>
<text top="628" left="589" width="235" height="17" font="7">NYHA: I (19%), II (34%), III (44%), IV (3%) </text>
<text top="645" left="589" width="164" height="17" font="7">Age 52±13 y (range 17–76 y) </text>
<text top="662" left="589" width="129" height="17" font="7">Pts with CAD excluded </text>
<text top="679" left="589" width="163" height="17" font="7">Hemodynamic and echo data </text>
<text top="697" left="589" width="218" height="17" font="7">Endpoint: Postoperative LV dysfunction </text>
<text top="714" left="589" width="208" height="17" font="7">defined as clinical HF or LVEF &lt;40%  </text>
<text top="731" left="589" width="231" height="17" font="7">Group A: no postoperative LV dysfunction </text>
<text top="748" left="589" width="198" height="17" font="7">(n=247); Group B: postoperative LV </text>
<text top="766" left="589" width="105" height="17" font="7">dysfunction (n=28) </text>
<text top="628" left="852" width="194" height="17" font="7">5- and 10-y survival 80% and 60%, </text>
<text top="645" left="852" width="68" height="17" font="7">respectively </text>
<text top="662" left="852" width="222" height="17" font="7">Preoperative data, Group A vs. Group B </text>
<text top="679" left="852" width="60" height="17" font="7">(p&lt;0.001): </text>
<text top="697" left="852" width="144" height="17" font="7">—LVEF: 48±9 vs. 37±5% </text>
<text top="714" left="852" width="144" height="17" font="7">—LVFS: 29±7 vs. 21±5% </text>
<text top="731" left="852" width="168" height="17" font="7">—LVEDD: 69±7 vs. 76±7 mm </text>
<text top="748" left="852" width="167" height="17" font="7">—LVESD: 49±7 vs. 61±5 mm </text>
<text top="766" left="852" width="132" height="17" font="7">—NYHA: 44% vs. 82%  </text>
<text top="628" left="1115" width="217" height="17" font="7">Postoperative LV dysfunction predicted </text>
<text top="645" left="1115" width="207" height="17" font="7">by severity of preoperative symptoms </text>
<text top="662" left="1115" width="203" height="17" font="7">and preoperative LVEF, FS, LVESD, </text>
<text top="679" left="1115" width="48" height="17" font="7">LVEDD. </text>
<text top="697" left="1115" width="209" height="17" font="7">On multivariate analysis, preoperative </text>
<text top="714" left="1115" width="230" height="17" font="7">symptoms (p&lt;0.01), LVESD (p&lt;0.03) and </text>
<text top="731" left="1115" width="216" height="17" font="7">LVEF (p&lt;0.04) were significant factors. </text>
<text top="748" left="1115" width="217" height="17" font="7">Determinants of survival not presented. </text>
</page>
<page number="25" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">25 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="42" width="71" height="17" font="6"><b>Study, Year </b></text>
<text top="108" left="154" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="318" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="449" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="453" width="28" height="17" font="6"><b>Size </b></text>
<text top="143" left="458" width="19" height="17" font="6"><b>(n) </b></text>
<text top="108" left="521" width="35" height="17" font="6"><b>Mean </b></text>
<text top="126" left="507" width="63" height="17" font="6"><b>Follow-Up </b></text>
<text top="143" left="529" width="19" height="17" font="6"><b>(y) </b></text>
<text top="108" left="601" width="225" height="17" font="6"><b>Inclusion Criteria, Outcome Assessed </b></text>
<text top="108" left="945" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="108" left="1161" width="139" height="17" font="6"><b>Comments, Limitations </b></text>
<text top="161" left="39" width="75" height="17" font="7">Klodas 1996  </text>
<text top="178" left="39" width="32" height="17" font="7">(102) </text>
<text top="195" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8606280">8606280</a></text>
<text top="195" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8606280"> </a></text>
<text top="161" left="130" width="119" height="17" font="7">Impact of LV function </text>
<text top="178" left="130" width="119" height="17" font="7">on survival after AVR </text>
<text top="161" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="178" left="271" width="128" height="17" font="7">series; consecutive pts </text>
<text top="195" left="271" width="162" height="17" font="7">undergoing AVR 1980–1989; </text>
<text top="212" left="271" width="91" height="17" font="7">single institution </text>
<text top="161" left="447" width="24" height="17" font="7">219 </text>
<text top="161" left="501" width="72" height="17" font="7">5-y and 10-y </text>
<text top="178" left="501" width="72" height="17" font="7">survival data </text>
<text top="195" left="501" width="49" height="17" font="7">reported </text>
<text top="161" left="589" width="217" height="17" font="7">Group A: preoperative LVEDD &lt;80 mm </text>
<text top="178" left="589" width="122" height="17" font="7">(n=188, age 55±16 y) </text>
<text top="195" left="589" width="248" height="17" font="7">Group B: preoperative LVDD ≥80 mm (n=31, </text>
<text top="212" left="589" width="77" height="17" font="7">age 50±15 y) </text>
<text top="230" left="589" width="248" height="17" font="7">NYHA III-IV symptoms: Group A 37%, Group </text>
<text top="247" left="589" width="40" height="17" font="7">B 29% </text>
<text top="264" left="589" width="245" height="17" font="7">Includes pts with CAD: Group A 37%, Group </text>
<text top="281" left="589" width="40" height="17" font="7">B 29% </text>
<text top="299" left="589" width="103" height="17" font="7">Endpoint: Survival </text>
<text top="161" left="852" width="222" height="17" font="7">Preoperative data, Group A vs. Group B </text>
<text top="178" left="852" width="63" height="17" font="7">(p&lt;0.001):  </text>
<text top="195" left="852" width="158" height="17" font="7">—LVEF: 53±11 vs. 43±12% </text>
<text top="212" left="852" width="168" height="17" font="7">—LVEDD: 67±8 vs. 84±4 mm </text>
<text top="230" left="852" width="167" height="17" font="7">—LVESD: 45±9 vs. 63±8 mm </text>
<text top="247" left="852" width="242" height="17" font="7">—LVESS: 96±39 vs. 147±39 dynes x 105/s </text>
<text top="264" left="852" width="245" height="17" font="7">Postoperative survival, Group A vs. Group B </text>
<text top="281" left="852" width="49" height="17" font="7">(p=NS):  </text>
<text top="299" left="852" width="141" height="17" font="7">—5 y: 89±3% vs. 87±6% </text>
<text top="316" left="852" width="151" height="17" font="7">—10 y: 73±5% vs. 71±9%  </text>
<text top="333" left="852" width="217" height="17" font="7">Postoperative survival, LVEF ≥50% vs. </text>
<text top="350" left="852" width="92" height="17" font="7">&lt;50% (p&lt;0.01):  </text>
<text top="368" left="852" width="148" height="17" font="7">—10 y: 80±5% vs. 63±7% </text>
<text top="161" left="1115" width="226" height="17" font="7">Extreme LV dilatation associated with LV </text>
<text top="178" left="1115" width="109" height="17" font="7">systolic dysfunction </text>
<text top="195" left="1115" width="205" height="17" font="7">Preoperative LVEF, not degree of LV </text>
<text top="212" left="1115" width="189" height="17" font="7">dilatation, associated with survival </text>
<text top="385" left="39" width="72" height="17" font="7">Klodas 1997 </text>
<text top="403" left="39" width="32" height="17" font="7">(103) </text>
<text top="420" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9283535">9283535</a></text>
<text top="420" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9283535"> </a></text>
<text top="385" left="130" width="107" height="17" font="7">Impact of symptom </text>
<text top="403" left="130" width="108" height="17" font="7">severity on survival </text>
<text top="420" left="130" width="57" height="17" font="7">after AVR </text>
<text top="385" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="403" left="271" width="128" height="17" font="7">series; consecutive pts </text>
<text top="420" left="271" width="162" height="17" font="7">undergoing AVR 1980–1989; </text>
<text top="437" left="271" width="91" height="17" font="7">single institution </text>
<text top="385" left="447" width="24" height="17" font="7">289 </text>
<text top="385" left="501" width="72" height="17" font="7">5-y and 10-y </text>
<text top="403" left="501" width="72" height="17" font="7">survival data </text>
<text top="420" left="501" width="49" height="17" font="7">reported </text>
<text top="385" left="589" width="230" height="17" font="7">Group A: NYHA I-II (n=161, age 50±16 y, </text>
<text top="403" left="589" width="59" height="17" font="7">86% men) </text>
<text top="420" left="589" width="241" height="17" font="7">Group B: NYHA III-IV (n=128, age 61±14 y, </text>
<text top="437" left="589" width="59" height="17" font="7">70% men) </text>
<text top="454" left="589" width="245" height="17" font="7">Includes pts with CAD: Group A 11%, Group </text>
<text top="472" left="589" width="153" height="17" font="7">B 35%; including AVR plus  </text>
<text top="489" left="589" width="224" height="17" font="7">CABG: Group A 8%, Group B 32% (both </text>
<text top="506" left="589" width="59" height="17" font="7">p&lt;0.0001) </text>
<text top="523" left="589" width="116" height="17" font="7">Echo data in 249 pts </text>
<text top="540" left="589" width="100" height="17" font="7">Endpoint: survival </text>
<text top="385" left="852" width="222" height="17" font="7">Preoperative data, Group A vs. Group B </text>
<text top="403" left="852" width="56" height="17" font="7">(p&lt;0.05):  </text>
<text top="420" left="852" width="165" height="17" font="7">—LVEF: 5 3±11 vs. 49±14%  </text>
<text top="437" left="852" width="250" height="17" font="7">10-y survival, Group A vs. Group B (p&lt;0.001) </text>
<text top="454" left="852" width="152" height="17" font="7">—Total: 78±7% vs.45±4%  </text>
<text top="472" left="852" width="161" height="17" font="7">—LVEF ≥50%: 82% vs. 40% </text>
<text top="489" left="852" width="160" height="17" font="7">—LVEF &lt;50%: 73% vs. 40% </text>
<text top="506" left="852" width="118" height="17" font="7">—Men: 80% vs. 55% </text>
<text top="523" left="852" width="137" height="17" font="7">—Women: 73% vs. 21% </text>
<text top="540" left="852" width="120" height="17" font="7">—CAD: 76% vs. 39% </text>
<text top="558" left="852" width="139" height="17" font="7">—No CAD: 79% vs. 48% </text>
<text top="385" left="1115" width="209" height="17" font="7">High-risk group identified by symptom </text>
<text top="403" left="1115" width="211" height="17" font="7">severity and preoperative LVEF &lt;50% </text>
<text top="420" left="1115" width="223" height="17" font="7">Survival in Group A equivalent to normal </text>
<text top="437" left="1115" width="161" height="17" font="7">age/sex matched population  </text>
<text top="454" left="1115" width="230" height="17" font="7">Note higher frequency of CAD and CABG </text>
<text top="472" left="1115" width="217" height="17" font="7">surgery (and other comorbidities) in the </text>
<text top="489" left="1115" width="153" height="17" font="7">more symptomatic Group B </text>
<text top="575" left="39" width="69" height="17" font="7">Turina 1998 </text>
<text top="593" left="39" width="32" height="17" font="7">(104) </text>
<text top="610" left="39" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9852889">9852889</a></text>
<text top="610" left="87" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9852889"> </a></text>
<text top="575" left="130" width="90" height="17" font="7">Determinants of </text>
<text top="593" left="130" width="102" height="17" font="7">survival after AVR </text>
<text top="575" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="593" left="271" width="128" height="17" font="7">series; consecutive pts </text>
<text top="610" left="271" width="162" height="17" font="7">undergoing AVR 1970–1983; </text>
<text top="627" left="271" width="91" height="17" font="7">single institution </text>
<text top="575" left="447" width="24" height="17" font="7">192 </text>
<text top="575" left="501" width="66" height="17" font="7">18.7 (range </text>
<text top="593" left="501" width="42" height="17" font="7">13–26) </text>
<text top="575" left="589" width="88" height="17" font="7">Mean age 44 y  </text>
<text top="593" left="589" width="103" height="17" font="7">Endpoint: Survival </text>
<text top="575" left="852" width="222" height="17" font="7">Survival rates 76% at 10 y, 55% at 20 y. </text>
<text top="593" left="852" width="222" height="17" font="7">83% of long-term survivors in NYHA I-II. </text>
<text top="610" left="852" width="236" height="17" font="7">Multivariate predictors of late survival: age, </text>
<text top="627" left="852" width="156" height="17" font="7">LVESV, NYHA, previous IE. </text>
<text top="644" left="852" width="213" height="17" font="7">LVEF significant in univariate analysis. </text>
<text top="575" left="1115" width="209" height="17" font="7">High-risk group identified by symptom </text>
<text top="593" left="1115" width="214" height="17" font="7">severity, low LVEF, and elevated ESV. </text>
<text top="679" left="39" width="71" height="17" font="7">Chaliki 2002 </text>
<text top="696" left="39" width="32" height="17" font="7">(105) </text>
<text top="713" left="39" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12438294">12438294</a></text>
<text top="713" left="94" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12438294"> </a></text>
<text top="679" left="130" width="117" height="17" font="7">Survival after AVR in </text>
<text top="696" left="130" width="126" height="17" font="7">pts with normal versus </text>
<text top="713" left="130" width="113" height="17" font="7">reduced LV function </text>
<text top="679" left="271" width="158" height="17" font="7">Retrospective, observational </text>
<text top="696" left="271" width="127" height="17" font="7">series; consecutive pts </text>
<text top="713" left="271" width="162" height="17" font="7">undergoing AVR 1980–1995; </text>
<text top="730" left="271" width="91" height="17" font="7">single institution </text>
<text top="679" left="447" width="24" height="17" font="7">450 </text>
<text top="679" left="501" width="21" height="17" font="7">8.1 </text>
<text top="696" left="501" width="52" height="17" font="7">(median) </text>
<text top="679" left="589" width="227" height="17" font="7">Group A (273 pts, age 56±16) with LVEF </text>
<text top="696" left="589" width="40" height="17" font="7">≥50%  </text>
<text top="713" left="589" width="227" height="17" font="7">Group B (134 pts, age 58±15) with LVEF </text>
<text top="730" left="589" width="60" height="17" font="7">35%–50% </text>
<text top="748" left="589" width="221" height="17" font="7">Group C (43 pts, age 58±14) with LVEF </text>
<text top="765" left="589" width="35" height="17" font="7">&lt;35% </text>
<text top="782" left="589" width="222" height="17" font="7">LVEF measured by left ventriculography </text>
<text top="679" left="852" width="225" height="17" font="7">Operative mortality, Group A vs. B vs. C: </text>
<text top="696" left="852" width="147" height="17" font="7">3.7%, 6.7%, 14% (p=0.02) </text>
<text top="713" left="852" width="196" height="17" font="7">10-y mortality, Group A vs. B vs. C: </text>
<text top="730" left="852" width="147" height="17" font="7">30%, 44%, 59% (p&lt;0.001) </text>
<text top="748" left="852" width="190" height="17" font="7">10-y HF rate, Group A vs. B vs. C: </text>
<text top="765" left="852" width="141" height="17" font="7">9%, 17%, 25% (p&lt;0.003) </text>
<text top="782" left="852" width="241" height="17" font="7">Postoperative change in LVEF, Group A vs. </text>
<text top="679" left="1115" width="216" height="17" font="7">Pts with markedly low LVEF incur have </text>
<text top="696" left="1115" width="185" height="17" font="7">high rates of short- and long-term </text>
<text top="713" left="1115" width="157" height="17" font="7">mortality and HF after AVR.  </text>
<text top="730" left="1115" width="220" height="17" font="7">However, postoperative LVEF improves </text>
<text top="748" left="1115" width="229" height="17" font="7">significantly, and most pts survive without </text>
<text top="765" left="1115" width="99" height="17" font="7">recurrence of HF. </text>
<text top="782" left="1115" width="221" height="17" font="7">Thus they should not be denied benefits </text>
</page>
<page number="26" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">26 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="42" width="71" height="17" font="6"><b>Study, Year </b></text>
<text top="108" left="154" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="318" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="449" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="453" width="28" height="17" font="6"><b>Size </b></text>
<text top="143" left="458" width="19" height="17" font="6"><b>(n) </b></text>
<text top="108" left="521" width="35" height="17" font="6"><b>Mean </b></text>
<text top="126" left="507" width="63" height="17" font="6"><b>Follow-Up </b></text>
<text top="143" left="529" width="19" height="17" font="6"><b>(y) </b></text>
<text top="108" left="601" width="225" height="17" font="6"><b>Inclusion Criteria, Outcome Assessed </b></text>
<text top="108" left="945" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="108" left="1161" width="139" height="17" font="6"><b>Comments, Limitations </b></text>
<text top="161" left="589" width="68" height="17" font="7">and/or echo </text>
<text top="178" left="589" width="103" height="17" font="7">Endpoint: Survival </text>
<text top="161" left="852" width="46" height="17" font="7">B vs. C: </text>
<text top="178" left="852" width="145" height="17" font="7">-2.3%, 4%, 4.9% (p&lt;0.01) </text>
<text top="161" left="1115" width="46" height="17" font="7">of AVR. </text>
<text top="196" left="39" width="73" height="17" font="7">Tornos 2006 </text>
<text top="213" left="39" width="32" height="17" font="7">(106) </text>
<text top="230" left="39" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16516086">16516086</a></text>
<text top="230" left="94" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16516086"> </a></text>
<text top="196" left="130" width="90" height="17" font="7">Determinants of </text>
<text top="213" left="130" width="102" height="17" font="7">survival after AVR </text>
<text top="196" left="271" width="148" height="17" font="7">Prospective, observational </text>
<text top="213" left="271" width="128" height="17" font="7">series; consecutive pts </text>
<text top="230" left="271" width="162" height="17" font="7">undergoing AVR 1982–2002; </text>
<text top="248" left="271" width="91" height="17" font="7">single institution </text>
<text top="196" left="447" width="24" height="17" font="7">170 </text>
<text top="196" left="501" width="32" height="17" font="7">10±6 </text>
<text top="213" left="501" width="42" height="17" font="7">(range  </text>
<text top="230" left="501" width="35" height="17" font="7">1–22) </text>
<text top="196" left="589" width="243" height="17" font="7">Group A (60 pts age 47±15) mild symptoms </text>
<text top="213" left="589" width="228" height="17" font="7">(NYHA II), mild LV dysfunction (LVEF 45–</text>
<text top="230" left="589" width="152" height="17" font="7">50%) or LVESD 50–55 mm </text>
<text top="248" left="589" width="241" height="17" font="7">Group B (110 pts age 53±14) with NYHA III-</text>
<text top="265" left="589" width="244" height="17" font="7">IV symptoms or more severe LV dysfunction </text>
<text top="282" left="589" width="184" height="17" font="7">(LVEF &lt;45% or LVESD &gt;55 mm) </text>
<text top="299" left="589" width="62" height="17" font="7">Echo data  </text>
<text top="317" left="589" width="103" height="17" font="7">Endpoint: Survival </text>
<text top="196" left="852" width="248" height="17" font="7">Cardiac deaths: 5 (9%) in Group A, 28 (28%) </text>
<text top="213" left="852" width="122" height="17" font="7">in Group B (p=0.002). </text>
<text top="230" left="852" width="228" height="17" font="7">Survival Group A vs. Group B (p=0.009):  </text>
<text top="248" left="864" width="126" height="17" font="7">90% vs. 75% at 5 y,     </text>
<text top="265" left="864" width="119" height="17" font="7">86% vs. 64% at 10 y, </text>
<text top="282" left="864" width="116" height="17" font="7">78% vs. 53% at 15 y </text>
<text top="196" left="1115" width="185" height="17" font="7">Early AVR as defined in the 2006 </text>
<text top="213" left="1115" width="205" height="17" font="7">ACCF/AHA guidelines improves long-</text>
<text top="230" left="1115" width="198" height="17" font="7">term survival in pts with chronic AR. </text>
<text top="248" left="1115" width="178" height="17" font="7">Delaying AVR until more severe </text>
<text top="265" left="1115" width="229" height="17" font="7">symptoms or more severe LV dysfunction </text>
<text top="282" left="1115" width="186" height="17" font="7">decreases postoperative survival. </text>
<text top="335" left="39" width="73" height="17" font="7">Bhudia 2007 </text>
<text top="352" left="39" width="32" height="17" font="7">(107) </text>
<text top="369" left="39" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17397676">17397676</a></text>
<text top="369" left="94" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17397676"> </a></text>
<text top="335" left="130" width="117" height="17" font="7">Survival after AVR in </text>
<text top="352" left="130" width="108" height="17" font="7">pts with marked LV </text>
<text top="369" left="130" width="124" height="17" font="7">dysfunction compared </text>
<text top="386" left="130" width="119" height="17" font="7">to normal LV function </text>
<text top="403" left="130" width="124" height="17" font="7">or mild LV dysfunction </text>
<text top="335" left="271" width="148" height="17" font="7">Prospective, observational </text>
<text top="352" left="271" width="127" height="17" font="7">series; consecutive pts </text>
<text top="369" left="271" width="162" height="17" font="7">undergoing AVR 1972–1999; </text>
<text top="386" left="271" width="91" height="17" font="7">single institution </text>
<text top="335" left="447" width="24" height="17" font="7">724 </text>
<text top="335" left="501" width="46" height="17" font="7">8.3±6.5 </text>
<text top="335" left="589" width="245" height="17" font="7">Group A (88 pts, age 56±12) with severe LV </text>
<text top="352" left="589" width="143" height="17" font="7">dysfunction (LVEF &lt;30%) </text>
<text top="369" left="589" width="227" height="17" font="7">Group B (636 pts, age 50±15) with either </text>
<text top="386" left="589" width="223" height="17" font="7">less severe LV dysfunction or normal LV </text>
<text top="403" left="589" width="50" height="17" font="7">function  </text>
<text top="421" left="589" width="103" height="17" font="7">Endpoint: Survival </text>
<text top="335" left="852" width="234" height="17" font="7">Survival diminished in Group A (severe LV </text>
<text top="352" left="852" width="244" height="17" font="7">dysfunction) compared to Group B (p=0.04): </text>
<text top="369" left="864" width="112" height="17" font="7">81% vs. 92% at 1 y, </text>
<text top="386" left="864" width="112" height="17" font="7">68% vs. 81% at 5 y, </text>
<text top="403" left="864" width="119" height="17" font="7">46% vs. 62% at 10 y, </text>
<text top="421" left="864" width="119" height="17" font="7">26% vs. 41% at 15 y, </text>
<text top="438" left="864" width="116" height="17" font="7">12% vs. 24% at 20 y </text>
<text top="335" left="1115" width="211" height="17" font="7">In propensity matched pts since 1985, </text>
<text top="352" left="1115" width="223" height="17" font="7">these survival trends persisted, but were </text>
<text top="369" left="1115" width="217" height="17" font="7">not significant between pts in Groups A </text>
<text top="386" left="1115" width="82" height="17" font="7">and B (p=0.9): </text>
<text top="403" left="1127" width="119" height="17" font="7">92% vs. 96% at 1 y,   </text>
<text top="421" left="1127" width="112" height="17" font="7">79% vs. 83% at 5 y, </text>
<text top="438" left="1127" width="119" height="17" font="7">51% vs. 55% at 10 y  </text>
<text top="456" left="33" width="1268" height="17" font="7">AR indicates aortic regurgitation; AVR, aortic valve replacement; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; echo, echocardiography; ESS, end-systolic stress; ESV, end-systolic volume; FS, fractional </text>
<text top="473" left="33" width="1318" height="17" font="7">shortening; HF, heart failure; IE, infective endocarditis; LV, left ventricular; LVEDD, left ejection end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; LVESV (i), left ejection end-systolic </text>
<text top="490" left="33" width="1297" height="17" font="7">volume (indexed to body surface area); LVFS, left ventricular fractional shortening; LVPSS, left ventricular peak systolic wall stress; MWS, mean wall stress; NIH, National Institute of Health; NYHA , New York Heart Association; PSS, peak </text>
<text top="507" left="33" width="403" height="17" font="7">systolic wall stress; pts, patients; and, R/Th, radius to wall thickness ratio. </text>
<text top="525" left="108" width="3" height="17" font="7"> </text>
<text top="525" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">27 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="1300" height="21" font="4"><b>Data Supplement 13. Hemodynamic Effects Percutaneous Mitral Balloon Commissurotomy (PMBC) Compared to Surgical Closed Commissurotomy (CC) or Open Commissurotomy (OC) </b></text>
<text top="128" left="32" width="104" height="21" font="4"><b>(Section 6.2.3) </b></text>
<text top="151" left="54" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="151" left="173" width="35" height="17" font="6"><b>Mean </b></text>
<text top="168" left="159" width="63" height="17" font="6"><b>Follow-Up </b></text>
<text top="151" left="243" width="64" height="17" font="6"><b>Procedure </b></text>
<text top="151" left="337" width="38" height="17" font="6"><b>No. of </b></text>
<text top="168" left="330" width="51" height="17" font="6"><b>Patients </b></text>
<text top="151" left="420" width="40" height="17" font="6"><b>Age, y </b></text>
<text top="151" left="516" width="52" height="17" font="6"><b>Average </b></text>
<text top="168" left="505" width="74" height="17" font="6"><b>Morphology </b></text>
<text top="185" left="521" width="42" height="17" font="6"><b>Score* </b></text>
<text top="151" left="612" width="147" height="17" font="6"><b>Mitral Gradient (mm Hg)  </b></text>
<text top="151" left="798" width="124" height="17" font="6"><b>Mitral Valve Area (cm</b></text>
<text top="152" left="922" width="4" height="11" font="15"><b>2</b></text>
<text top="151" left="926" width="11" height="17" font="6"><b>)  </b></text>
<text top="151" left="975" width="92" height="17" font="6"><b>Restenosis (%) </b></text>
<text top="151" left="1111" width="90" height="17" font="6"><b>Freedom From </b></text>
<text top="168" left="1100" width="112" height="17" font="6"><b>Reintervention (%) </b></text>
<text top="151" left="1240" width="68" height="17" font="6"><b>NYHA I (%) </b></text>
<text top="177" left="635" width="23" height="17" font="6"><b>Pre </b></text>
<text top="177" left="719" width="30" height="17" font="6"><b>Post </b></text>
<text top="177" left="797" width="23" height="17" font="6"><b>Pre </b></text>
<text top="177" left="888" width="30" height="17" font="6"><b>Post </b></text>
<text top="204" left="42" width="62" height="17" font="7">Patel 1991 </text>
<text top="221" left="42" width="32" height="17" font="7">(108) </text>
<text top="238" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1918709">1918709</a></text>
<text top="238" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1918709"> </a></text>
<text top="204" left="157" width="61" height="17" font="7">Immediate </text>
<text top="204" left="238" width="39" height="17" font="7">PMBC </text>
<text top="221" left="238" width="3" height="17" font="7"> </text>
<text top="204" left="325" width="17" height="17" font="7">23 </text>
<text top="204" left="400" width="39" height="17" font="7">30±11 </text>
<text top="204" left="494" width="21" height="17" font="7">6.0 </text>
<text top="204" left="602" width="32" height="17" font="7">12±4 </text>
<text top="204" left="703" width="25" height="17" font="7">4±3 </text>
<text top="204" left="778" width="46" height="17" font="7">0.8±0.3 </text>
<text top="204" left="852" width="53" height="17" font="7">2.1±0.7† </text>
<text top="204" left="967" width="24" height="17" font="7">N/A </text>
<text top="204" left="1088" width="24" height="17" font="7">N/A </text>
<text top="204" left="1237" width="17" height="17" font="7">91 </text>
<text top="255" left="42" width="3" height="17" font="7"> </text>
<text top="255" left="157" width="3" height="17" font="7"> </text>
<text top="255" left="238" width="21" height="17" font="7">CC </text>
<text top="255" left="325" width="17" height="17" font="7">22 </text>
<text top="255" left="400" width="39" height="17" font="7">26±26 </text>
<text top="255" left="494" width="21" height="17" font="7">6.0 </text>
<text top="255" left="602" width="32" height="17" font="7">12±5 </text>
<text top="255" left="703" width="25" height="17" font="7">6±3 </text>
<text top="255" left="778" width="46" height="17" font="7">0.7±0.2 </text>
<text top="255" left="852" width="46" height="17" font="7">1.3±0.3 </text>
<text top="255" left="967" width="24" height="17" font="7">N/A </text>
<text top="255" left="1088" width="24" height="17" font="7">N/A </text>
<text top="255" left="1237" width="24" height="17" font="7">N/A </text>
<text top="273" left="42" width="55" height="17" font="7">Turi 1991 </text>
<text top="290" left="42" width="32" height="17" font="7">(109) </text>
<text top="308" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2013139">2013139</a></text>
<text top="308" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2013139"> </a></text>
<text top="273" left="157" width="31" height="17" font="7">7 mo </text>
<text top="273" left="238" width="39" height="17" font="7">PMBC </text>
<text top="273" left="325" width="17" height="17" font="7">20 </text>
<text top="273" left="400" width="32" height="17" font="7">27±8 </text>
<text top="273" left="494" width="21" height="17" font="7">7.2 </text>
<text top="273" left="602" width="32" height="17" font="7">18±4 </text>
<text top="273" left="703" width="32" height="17" font="7">10±2 </text>
<text top="273" left="778" width="36" height="17" font="7">0.8±2 </text>
<text top="273" left="852" width="46" height="17" font="7">1.6±0.2 </text>
<text top="273" left="967" width="24" height="17" font="7">N/A </text>
<text top="273" left="1088" width="24" height="17" font="7">N/A </text>
<text top="273" left="1237" width="24" height="17" font="7">N/A </text>
<text top="325" left="42" width="3" height="17" font="7"> </text>
<text top="325" left="157" width="3" height="17" font="7"> </text>
<text top="325" left="238" width="21" height="17" font="7">CC </text>
<text top="325" left="325" width="17" height="17" font="7">20 </text>
<text top="325" left="400" width="32" height="17" font="7">28±1 </text>
<text top="325" left="494" width="21" height="17" font="7">8.4 </text>
<text top="325" left="602" width="32" height="17" font="7">20±6 </text>
<text top="325" left="703" width="32" height="17" font="7">12±2 </text>
<text top="325" left="778" width="46" height="17" font="7">0.9±0.4 </text>
<text top="325" left="852" width="46" height="17" font="7">1.7±0.2 </text>
<text top="325" left="967" width="24" height="17" font="7">N/A </text>
<text top="325" left="1088" width="24" height="17" font="7">N/A </text>
<text top="325" left="1237" width="24" height="17" font="7">N/A </text>
<text top="344" left="42" width="68" height="17" font="7">Arora 1993  </text>
<text top="361" left="42" width="32" height="17" font="7">(110) </text>
<text top="378" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8465732">8465732</a></text>
<text top="378" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8465732"> </a></text>
<text top="344" left="157" width="38" height="17" font="7">22 mo </text>
<text top="344" left="238" width="39" height="17" font="7">PMBC </text>
<text top="344" left="325" width="24" height="17" font="7">100 </text>
<text top="344" left="400" width="32" height="17" font="7">19±5 </text>
<text top="344" left="494" width="24" height="17" font="7">N/A </text>
<text top="344" left="602" width="24" height="17" font="7">N/A </text>
<text top="344" left="703" width="24" height="17" font="7">N/A </text>
<text top="344" left="778" width="46" height="17" font="7">0.8±0.3 </text>
<text top="344" left="852" width="46" height="17" font="7">2.3±0.1 </text>
<text top="344" left="967" width="10" height="17" font="7">5 </text>
<text top="344" left="1088" width="24" height="17" font="7">N/A </text>
<text top="344" left="1237" width="24" height="17" font="7">N/A </text>
<text top="395" left="42" width="3" height="17" font="7"> </text>
<text top="395" left="157" width="3" height="17" font="7"> </text>
<text top="395" left="238" width="21" height="17" font="7">CC </text>
<text top="395" left="325" width="24" height="17" font="7">100 </text>
<text top="395" left="400" width="32" height="17" font="7">20±6 </text>
<text top="395" left="494" width="24" height="17" font="7">N/A </text>
<text top="395" left="602" width="24" height="17" font="7">N/A </text>
<text top="395" left="703" width="24" height="17" font="7">N/A </text>
<text top="395" left="778" width="46" height="17" font="7">0.8±0.2 </text>
<text top="395" left="852" width="46" height="17" font="7">2.1±0.4 </text>
<text top="395" left="967" width="10" height="17" font="7">4 </text>
<text top="395" left="1088" width="24" height="17" font="7">N/A </text>
<text top="395" left="1237" width="24" height="17" font="7">N/A </text>
<text top="414" left="42" width="73" height="17" font="7">Reyes 1994  </text>
<text top="431" left="42" width="32" height="17" font="7">(111) </text>
<text top="449" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8084354">8084354</a></text>
<text top="449" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8084354"> </a></text>
<text top="414" left="157" width="20" height="17" font="7">3 y </text>
<text top="414" left="238" width="39" height="17" font="7">PMBC </text>
<text top="414" left="325" width="17" height="17" font="7">30 </text>
<text top="414" left="400" width="32" height="17" font="7">30±9 </text>
<text top="414" left="494" width="21" height="17" font="7">6.7 </text>
<text top="414" left="602" width="24" height="17" font="7">N/A </text>
<text top="414" left="703" width="24" height="17" font="7">N/A </text>
<text top="414" left="778" width="46" height="17" font="7">0.9±0.3 </text>
<text top="414" left="852" width="53" height="17" font="7">2.4±0.4† </text>
<text top="414" left="967" width="17" height="17" font="7">10 </text>
<text top="414" left="1088" width="24" height="17" font="7">N/A </text>
<text top="414" left="1237" width="17" height="17" font="7">72 </text>
<text top="466" left="42" width="3" height="17" font="7"> </text>
<text top="466" left="157" width="3" height="17" font="7"> </text>
<text top="466" left="238" width="21" height="17" font="7">CC </text>
<text top="466" left="325" width="17" height="17" font="7">30 </text>
<text top="466" left="400" width="32" height="17" font="7">31±9 </text>
<text top="466" left="494" width="21" height="17" font="7">7.0 </text>
<text top="466" left="602" width="24" height="17" font="7">N/A </text>
<text top="466" left="703" width="24" height="17" font="7">N/A </text>
<text top="466" left="778" width="46" height="17" font="7">0.9±0.3 </text>
<text top="466" left="852" width="46" height="17" font="7">1.8±0.4 </text>
<text top="466" left="967" width="17" height="17" font="7">13 </text>
<text top="466" left="1088" width="24" height="17" font="7">N/A </text>
<text top="466" left="1237" width="17" height="17" font="7">57 </text>
<text top="484" left="42" width="98" height="17" font="7">Ben Farhat 1998  </text>
<text top="502" left="42" width="32" height="17" font="7">(112) </text>
<text top="519" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9462525">9462525</a></text>
<text top="519" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9462525"> </a></text>
<text top="484" left="157" width="20" height="17" font="7">7 y </text>
<text top="484" left="238" width="39" height="17" font="7">PMBC </text>
<text top="484" left="325" width="17" height="17" font="7">30 </text>
<text top="484" left="400" width="39" height="17" font="7">29±12 </text>
<text top="484" left="494" width="21" height="17" font="7">6.0 </text>
<text top="484" left="602" width="24" height="17" font="7">N/A </text>
<text top="484" left="703" width="24" height="17" font="7">N/A </text>
<text top="484" left="778" width="46" height="17" font="7">0.9±0.2 </text>
<text top="484" left="852" width="46" height="17" font="7">1.8±0.4 </text>
<text top="484" left="967" width="24" height="17" font="7">N/A </text>
<text top="484" left="1088" width="17" height="17" font="7">90 </text>
<text top="484" left="1237" width="17" height="17" font="7">87 </text>
<text top="536" left="42" width="3" height="17" font="7"> </text>
<text top="536" left="157" width="3" height="17" font="7"> </text>
<text top="536" left="238" width="22" height="17" font="7">OC </text>
<text top="536" left="325" width="17" height="17" font="7">30 </text>
<text top="536" left="400" width="32" height="17" font="7">27±9 </text>
<text top="536" left="494" width="21" height="17" font="7">6.0 </text>
<text top="536" left="602" width="24" height="17" font="7">N/A </text>
<text top="536" left="703" width="24" height="17" font="7">N/A </text>
<text top="536" left="778" width="46" height="17" font="7">0.9±0.2 </text>
<text top="536" left="852" width="46" height="17" font="7">1.8±0.3 </text>
<text top="536" left="967" width="24" height="17" font="7">N/A </text>
<text top="536" left="1088" width="17" height="17" font="7">93 </text>
<text top="536" left="1237" width="17" height="17" font="7">90 </text>
<text top="553" left="42" width="3" height="17" font="7"> </text>
<text top="553" left="157" width="3" height="17" font="7"> </text>
<text top="553" left="238" width="21" height="17" font="7">CC </text>
<text top="553" left="325" width="17" height="17" font="7">30 </text>
<text top="553" left="400" width="39" height="17" font="7">28±10 </text>
<text top="553" left="494" width="21" height="17" font="7">6.0 </text>
<text top="553" left="602" width="24" height="17" font="7">N/A </text>
<text top="553" left="703" width="24" height="17" font="7">N/A </text>
<text top="553" left="778" width="46" height="17" font="7">0.9±0.2 </text>
<text top="553" left="852" width="46" height="17" font="7">1.3±0.3 </text>
<text top="553" left="967" width="24" height="17" font="7">N/A </text>
<text top="553" left="1088" width="17" height="17" font="7">50 </text>
<text top="553" left="1237" width="17" height="17" font="7">33 </text>
<text top="572" left="42" width="78" height="17" font="7">Cotrufo 1999  </text>
<text top="589" left="42" width="32" height="17" font="7">(113) </text>
<text top="606" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10386411">10386411</a></text>
<text top="606" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10386411"> </a></text>
<text top="572" left="157" width="38" height="17" font="7">38 mo </text>
<text top="572" left="238" width="39" height="17" font="7">PMBC </text>
<text top="572" left="325" width="24" height="17" font="7">111 </text>
<text top="572" left="400" width="39" height="17" font="7">47±14 </text>
<text top="572" left="494" width="21" height="17" font="7">7.6 </text>
<text top="572" left="602" width="24" height="17" font="7">N/A </text>
<text top="572" left="703" width="24" height="17" font="7">N/A </text>
<text top="572" left="778" width="46" height="17" font="7">1.0±0.2 </text>
<text top="572" left="852" width="46" height="17" font="7">1.8±0.3 </text>
<text top="572" left="967" width="17" height="17" font="7">28 </text>
<text top="572" left="1088" width="17" height="17" font="7">88 </text>
<text top="572" left="1237" width="17" height="17" font="7">67 </text>
<text top="624" left="42" width="3" height="17" font="7"> </text>
<text top="624" left="157" width="38" height="17" font="7">50 mo </text>
<text top="624" left="238" width="22" height="17" font="7">OC </text>
<text top="624" left="325" width="17" height="17" font="7">82 </text>
<text top="624" left="400" width="39" height="17" font="7">49±10 </text>
<text top="624" left="494" width="21" height="17" font="7">8.2 </text>
<text top="624" left="602" width="24" height="17" font="7">N/A </text>
<text top="624" left="703" width="24" height="17" font="7">N/A </text>
<text top="624" left="778" width="46" height="17" font="7">1.0±0.2 </text>
<text top="624" left="852" width="46" height="17" font="7">2.3±0.3 </text>
<text top="624" left="967" width="17" height="17" font="7">18 </text>
<text top="624" left="1088" width="17" height="17" font="7">96 </text>
<text top="624" left="1237" width="17" height="17" font="7">84 </text>
<text top="642" left="34" width="968" height="17" font="7">*Wilkins echocardiographic mitral valve morphology score, the sum of a 0 to 4 score for each of 4 characteristics: eaflet mobility, thickness, calcification and chordal involvement . </text>
<text top="660" left="34" width="622" height="17" font="7">†Significant difference (p&lt;0.05) in increased mitral valve area by PMBC compared with surgical commissurotomy. </text>
<text top="677" left="34" width="1223" height="17" font="7">CC indicates closed commissurotomy; N/A, not available; NYHA, New York Heart Association; OC, open commissurotomy; Post, postprocedure; PMBC, percutaneous mitral balloon commissurotomy; and, Pre, preprocedure.  </text>
<text top="694" left="34" width="184" height="17" font="7">Adapted from Bonow et al. (114). </text>
<text top="711" left="34" width="1082" height="17" font="7">Bhudia SK, McCarthy PM, Kumpati GS, et al. Improved outcomes after aortic valve surgery for chronic aortic regurgitation with severe left ventricular dysfunction. J Am Coll Cardiol. 2007;49;1465-71. </text>
<text top="729" left="108" width="3" height="17" font="7"> </text>
<text top="729" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="28" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">28 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="905" height="21" font="4"><b>Data Supplement 14. Echocardiographic Prediction of Outcome of Percutaneous Balloon Mitral Commissurotomy (Section 6.2.3) </b></text>
<text top="129" left="71" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="129" left="190" width="78" height="17" font="6"><b>Mean Follow-</b></text>
<text top="146" left="208" width="45" height="17" font="6"><b>Up, mo </b></text>
<text top="129" left="309" width="80" height="17" font="6"><b>Echo Criteria </b></text>
<text top="129" left="435" width="65" height="17" font="6"><b>Number of </b></text>
<text top="146" left="442" width="51" height="17" font="6"><b>Patients </b></text>
<text top="129" left="562" width="27" height="17" font="6"><b>Age </b></text>
<text top="146" left="554" width="44" height="17" font="6"><b>(y</b>±<b>SD) </b></text>
<text top="129" left="677" width="74" height="17" font="6"><b>Survival (%) </b></text>
<text top="129" left="812" width="162" height="17" font="6"><b>Survival Free of Events (%) </b></text>
<text top="129" left="1034" width="44" height="17" font="6"><b>Events </b></text>
<text top="164" left="42" width="107" height="17" font="7">Cohen et al., 1992  </text>
<text top="182" left="42" width="36" height="17" font="7">(115)  </text>
<text top="199" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1406834">1406834</a></text>
<text top="199" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1406834"> </a></text>
<text top="164" left="190" width="39" height="17" font="7">36±20 </text>
<text top="164" left="285" width="54" height="17" font="7">Score ≤8 </text>
<text top="182" left="285" width="53" height="17" font="7">Score &gt;8 </text>
<text top="164" left="427" width="17" height="17" font="7">84 </text>
<text top="182" left="427" width="17" height="17" font="7">52 </text>
<text top="164" left="521" width="23" height="19" font="0">N/A</text>
<text top="166" left="544" width="3" height="17" font="7"> </text>
<text top="164" left="643" width="23" height="19" font="0">N/A</text>
<text top="166" left="665" width="3" height="17" font="7"> </text>
<text top="164" left="798" width="62" height="17" font="7">68% at 5 y </text>
<text top="182" left="798" width="62" height="17" font="7">28% at 5 y </text>
<text top="164" left="1000" width="151" height="17" font="7">Death, MVR, repeat PMBC </text>
<text top="217" left="42" width="118" height="17" font="7">Palacios et al., 1995  </text>
<text top="234" left="42" width="36" height="17" font="7">(116)  </text>
<text top="251" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7828292">7828292</a></text>
<text top="251" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7828292"> </a></text>
<text top="217" left="190" width="39" height="17" font="7">20±12 </text>
<text top="217" left="285" width="54" height="17" font="7">Score ≤8 </text>
<text top="234" left="285" width="53" height="17" font="7">Score &gt;8 </text>
<text top="217" left="427" width="24" height="17" font="7">211 </text>
<text top="234" left="427" width="24" height="17" font="7">116 </text>
<text top="217" left="521" width="39" height="17" font="7">48±14 </text>
<text top="234" left="521" width="39" height="17" font="7">64±11 </text>
<text top="217" left="643" width="62" height="17" font="7">98% at 4 y </text>
<text top="234" left="643" width="3" height="17" font="7"> </text>
<text top="251" left="643" width="62" height="17" font="7">39% at 4 y </text>
<text top="217" left="798" width="62" height="17" font="7">98% at 4 y </text>
<text top="234" left="798" width="62" height="17" font="7">39% at 4 y </text>
<text top="217" left="1000" width="200" height="17" font="7">Death, MVR, NYHA III-IV symptoms </text>
<text top="269" left="42" width="101" height="17" font="7">Dean et al., 1996  </text>
<text top="286" left="42" width="36" height="17" font="7">(117)  </text>
<text top="304" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8917257">8917257</a></text>
<text top="304" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8917257"> </a></text>
<text top="269" left="190" width="39" height="17" font="7">38±16 </text>
<text top="269" left="285" width="54" height="17" font="7">Score ≤8 </text>
<text top="286" left="285" width="66" height="17" font="7">Score 8–12 </text>
<text top="304" left="285" width="60" height="17" font="7">Score &gt;12 </text>
<text top="269" left="427" width="24" height="17" font="7">272 </text>
<text top="286" left="427" width="24" height="17" font="7">306 </text>
<text top="304" left="427" width="17" height="17" font="7">24 </text>
<text top="269" left="521" width="39" height="17" font="7">49±13 </text>
<text top="286" left="521" width="39" height="17" font="7">58±15 </text>
<text top="304" left="521" width="39" height="17" font="7">58±15 </text>
<text top="269" left="643" width="62" height="17" font="7">95% at 4 y </text>
<text top="286" left="643" width="62" height="17" font="7">83% at 4 y </text>
<text top="304" left="643" width="62" height="17" font="7">24% at 4 y </text>
<text top="269" left="798" width="23" height="19" font="0">N/A</text>
<text top="271" left="820" width="3" height="17" font="7"> </text>
<text top="269" left="1000" width="36" height="17" font="7">Death </text>
<text top="321" left="42" width="95" height="17" font="7">Iung et al., 1996  </text>
<text top="339" left="42" width="36" height="17" font="7">(118)  </text>
<text top="356" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8557913">8557913</a></text>
<text top="356" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8557913"> </a></text>
<text top="321" left="190" width="39" height="17" font="7">32±18 </text>
<text top="321" left="285" width="48" height="17" font="7">Group 1 </text>
<text top="339" left="285" width="48" height="17" font="7">Group 2 </text>
<text top="356" left="285" width="48" height="17" font="7">Group 3 </text>
<text top="321" left="427" width="17" height="17" font="7">87 </text>
<text top="339" left="427" width="24" height="17" font="7">311 </text>
<text top="356" left="427" width="24" height="17" font="7">130 </text>
<text top="321" left="521" width="3" height="17" font="7"> </text>
<text top="339" left="521" width="39" height="17" font="7">46±13 </text>
<text top="356" left="521" width="3" height="17" font="7"> </text>
<text top="322" left="643" width="23" height="19" font="0">N/A</text>
<text top="323" left="665" width="3" height="17" font="7"> </text>
<text top="321" left="798" width="62" height="17" font="7">89% at 3 y </text>
<text top="339" left="798" width="62" height="17" font="7">78% at 3 y </text>
<text top="356" left="798" width="62" height="17" font="7">65% at 3 y </text>
<text top="321" left="1000" width="204" height="17" font="7">Death, MVR, repeat PMBC, FC III-IV </text>
<text top="339" left="1000" width="59" height="17" font="7">symptoms </text>
<text top="374" left="42" width="114" height="17" font="7">Cannan et al., 1997  </text>
<text top="391" left="42" width="36" height="17" font="7">(119)  </text>
<text top="408" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8996311">8996311</a></text>
<text top="408" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8996311"> </a></text>
<text top="374" left="190" width="39" height="17" font="7">22±10 </text>
<text top="374" left="285" width="53" height="17" font="7">Com Ca- </text>
<text top="391" left="285" width="56" height="17" font="7">Com Ca+ </text>
<text top="374" left="427" width="24" height="17" font="7">120 </text>
<text top="391" left="427" width="17" height="17" font="7">29 </text>
<text top="374" left="521" width="23" height="19" font="0">N/A</text>
<text top="375" left="544" width="3" height="17" font="7"> </text>
<text top="374" left="643" width="23" height="19" font="0">N/A</text>
<text top="375" left="665" width="3" height="17" font="7"> </text>
<text top="374" left="798" width="62" height="17" font="7">86% at 3 y </text>
<text top="391" left="798" width="62" height="17" font="7">40% at 3 y </text>
<text top="374" left="1000" width="151" height="17" font="7">Death, MVR, repeat PMBC </text>
<text top="426" left="42" width="118" height="17" font="7">Palacios et al., 2002  </text>
<text top="443" left="42" width="36" height="17" font="7">(120)  </text>
<text top="461" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11914256">11914256</a></text>
<text top="461" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11914256"> </a></text>
<text top="426" left="190" width="39" height="17" font="7">50±44 </text>
<text top="426" left="285" width="53" height="17" font="7">Score &gt;8 </text>
<text top="443" left="285" width="53" height="17" font="7">Score &lt;8 </text>
<text top="426" left="427" width="24" height="17" font="7">278 </text>
<text top="443" left="427" width="24" height="17" font="7">601 </text>
<text top="426" left="521" width="38" height="17" font="7">63+14 </text>
<text top="443" left="521" width="38" height="17" font="7">51+14 </text>
<text top="426" left="643" width="68" height="17" font="7">82% at 12 y </text>
<text top="443" left="643" width="68" height="17" font="7">57% at 12 y </text>
<text top="426" left="798" width="68" height="17" font="7">38% at 12 y </text>
<text top="443" left="798" width="68" height="17" font="7">22% at 12 y </text>
<text top="426" left="1000" width="151" height="17" font="7">Death, MVR, repeat PMBC </text>
<text top="479" left="34" width="1314" height="17" font="7">Echo score based on scoring system of Wilkins et al. (121) mitral valve morphology score, the sum of a 0 to 4 score for each of 4 characteristics: leaflet mobility, thickness, calcification and chordal involvement. Echo groups defined as 1, 2, or </text>
<text top="496" left="34" width="458" height="17" font="7">3 based on valve flexibility, chordal fusion and valve calcification (Iung, et al. (112)). </text>
<text top="513" left="34" width="1187" height="17" font="7">Com Ca indicates commissural calcification; echo, echocardiographic; MVR, mitral valve replacement; N/A, not available; NYHA, New York Heart Association; and, PMBC, percutaneous mitral balloon commissurotomy. </text>
<text top="530" left="34" width="3" height="17" font="7"> </text>
<text top="530" left="250" width="3" height="17" font="7"> </text>
</page>
<page number="29" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">29 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="986" height="21" font="4"><b>Data Supplement 15. Randomized Trials of Percutaneous Mitral Balloon Commissurotomy Versus Surgery for Mitral Stenosis (Section 6.2.3) </b></text>
<text top="129" left="44" width="78" height="17" font="6"><b>Study Name, </b></text>
<text top="146" left="45" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="129" left="155" width="64" height="17" font="6"><b>Study Aim </b></text>
<text top="129" left="263" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="264" width="36" height="17" font="6"><b>Type/ </b></text>
<text top="164" left="258" width="49" height="17" font="6"><b>Size (N) </b></text>
<text top="129" left="329" width="94" height="17" font="6"><b>Intervention vs. </b></text>
<text top="146" left="331" width="92" height="17" font="6"><b>Comparator (n) </b></text>
<text top="129" left="534" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="129" left="777" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="758" width="74" height="17" font="6"><b>Intervention </b></text>
<text top="129" left="884" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="867" width="73" height="17" font="6"><b>Comparator </b></text>
<text top="129" left="1072" width="51" height="17" font="6"><b>Results  </b></text>
<text top="182" left="82" width="3" height="17" font="6"><b> </b></text>
<text top="182" left="186" width="3" height="17" font="6"><b> </b></text>
<text top="182" left="280" width="3" height="17" font="6"><b> </b></text>
<text top="182" left="375" width="3" height="17" font="6"><b> </b></text>
<text top="182" left="456" width="104" height="17" font="16"><i><b>Inclusion Criteria </b></i></text>
<text top="182" left="610" width="108" height="17" font="16"><i><b>Exclusion Criteria </b></i></text>
<text top="182" left="794" width="3" height="17" font="6"><b> </b></text>
<text top="182" left="902" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="182" left="1126" width="3" height="17" font="6"><b> </b></text>
<text top="200" left="43" width="66" height="17" font="7">Patel 1991  </text>
<text top="217" left="43" width="36" height="17" font="7">(108)  </text>
<text top="234" left="43" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1918709">1918709</a></text>
<text top="234" left="91" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1918709"> </a></text>
<text top="200" left="136" width="93" height="17" font="7">Compare PMBC </text>
<text top="217" left="136" width="100" height="17" font="7">by single catheter </text>
<text top="234" left="136" width="96" height="17" font="7">technique versus </text>
<text top="251" left="136" width="25" height="17" font="7">CC  </text>
<text top="200" left="251" width="46" height="17" font="7">RCT/45 </text>
<text top="217" left="251" width="3" height="17" font="7"> </text>
<text top="200" left="325" width="88" height="17" font="7">Intervention: 23 </text>
<text top="217" left="325" width="42" height="17" font="7">PMBC  </text>
<text top="234" left="325" width="92" height="17" font="7">vs. comparator:  </text>
<text top="251" left="325" width="38" height="17" font="7">22 CC </text>
<text top="200" left="440" width="122" height="17" font="7">Symptomatic NYHA II </text>
<text top="217" left="440" width="80" height="17" font="7">or III, tight MS </text>
<text top="200" left="589" width="147" height="17" font="7">Mitral valve calcification or </text>
<text top="217" left="589" width="141" height="17" font="7">left atrial thrombus on 2D </text>
<text top="234" left="589" width="141" height="17" font="7">echo, more than mild MR </text>
<text top="251" left="589" width="143" height="17" font="7">or AR, history of systemic </text>
<text top="268" left="589" width="135" height="17" font="7">embolism within 3 mo of </text>
<text top="286" left="589" width="71" height="17" font="7">presentation </text>
<text top="200" left="751" width="42" height="17" font="7"> PBMC </text>
<text top="200" left="852" width="87" height="17" font="7">Closed surgical </text>
<text top="217" left="852" width="59" height="17" font="7">valvotomy </text>
<text top="200" left="967" width="218" height="17" font="7">PBMC: MVA increased from 0.8+0.3 cm</text>
<text top="201" left="1185" width="4" height="11" font="9">2</text>
<text top="200" left="1190" width="79" height="17" font="7"> to 2.1±0.7 cm</text>
<text top="201" left="1269" width="7" height="11" font="9">2 </text>
<text top="217" left="967" width="56" height="17" font="7">(p&lt;0.001) </text>
<text top="234" left="967" width="205" height="17" font="7">CC: MVA increased from  0.7±0.2 cm</text>
<text top="235" left="1172" width="4" height="11" font="9">2</text>
<text top="234" left="1177" width="79" height="17" font="7"> to 1.3±0.3 cm</text>
<text top="235" left="1256" width="4" height="11" font="9">2</text>
<text top="234" left="1261" width="3" height="17" font="7"> </text>
<text top="251" left="967" width="60" height="17" font="7">(p&lt;0.001)  </text>
<text top="305" left="43" width="56" height="17" font="7">Ben 1998 </text>
<text top="322" left="43" width="32" height="17" font="7">(112) </text>
<text top="339" left="43" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9462525">9462525</a></text>
<text top="339" left="91" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9462525"> </a></text>
<text top="305" left="136" width="74" height="17" font="7">Compare the </text>
<text top="322" left="136" width="102" height="17" font="7">early invasive and </text>
<text top="339" left="136" width="84" height="17" font="7">long-term (7 y) </text>
<text top="357" left="136" width="94" height="17" font="7">clinical and echo </text>
<text top="374" left="136" width="92" height="17" font="7">follow-up results </text>
<text top="391" left="136" width="78" height="17" font="7">of PBMC with </text>
<text top="408" left="136" width="93" height="17" font="7">those of OC and </text>
<text top="425" left="136" width="59" height="17" font="7">CC for the </text>
<text top="443" left="136" width="96" height="17" font="7">treatment of tight </text>
<text top="460" left="136" width="96" height="17" font="7">pliable rheumatic </text>
<text top="477" left="136" width="22" height="17" font="7">MS </text>
<text top="305" left="251" width="46" height="17" font="7">RCT/90 </text>
<text top="305" left="325" width="71" height="17" font="7">Intervention: </text>
<text top="322" left="325" width="58" height="17" font="7">PBMC vs. </text>
<text top="339" left="325" width="73" height="17" font="7">comparator:  </text>
<text top="357" left="325" width="46" height="17" font="7">CC; OC </text>
<text top="305" left="440" width="89" height="17" font="7">Rheumatic tight </text>
<text top="322" left="440" width="123" height="17" font="7">rheumatic mitral valve </text>
<text top="339" left="440" width="110" height="17" font="7">stenosis (MVA &lt;1.3 </text>
<text top="357" left="440" width="16" height="17" font="7">cm</text>
<text top="358" left="457" width="4" height="11" font="9">2</text>
<text top="357" left="461" width="14" height="17" font="7">),  </text>
<text top="305" left="589" width="115" height="17" font="7">Other valve disease, </text>
<text top="322" left="589" width="50" height="17" font="7">previous </text>
<text top="339" left="589" width="138" height="17" font="7">thromboembolism, mitral </text>
<text top="357" left="589" width="146" height="17" font="7">valve calcification, and left </text>
<text top="374" left="589" width="118" height="17" font="7">atrium thrombus, AF, </text>
<text top="391" left="589" width="101" height="17" font="7">severe pulmonary </text>
<text top="408" left="589" width="129" height="17" font="7">hypertension or mild-to-</text>
<text top="425" left="589" width="75" height="17" font="7">moderate TR </text>
<text top="305" left="751" width="42" height="17" font="7">PBMC  </text>
<text top="305" left="852" width="57" height="17" font="7">CC or OC </text>
<text top="305" left="967" width="137" height="17" font="7">Increase in Gorlin MVA : </text>
<text top="322" left="967" width="200" height="17" font="7">PBMC (from 0.9±0.16 to 2.2±0.4 cm</text>
<text top="323" left="1167" width="4" height="11" font="9">2</text>
<text top="322" left="1171" width="11" height="17" font="7">), </text>
<text top="339" left="967" width="175" height="17" font="7">OC (from 0.9+0.2 to 2.2±0.4 cm</text>
<text top="340" left="1142" width="4" height="11" font="9">2</text>
<text top="339" left="1146" width="14" height="17" font="7">),  </text>
<text top="357" left="967" width="175" height="17" font="7">CC (from 0.9±0.2 to 1.6±0.4 cm</text>
<text top="358" left="1142" width="4" height="11" font="9">2</text>
<text top="357" left="1147" width="14" height="17" font="7">).  </text>
<text top="374" left="967" width="151" height="17" font="7">Residual MS (MVA &lt;1.5 cm</text>
<text top="375" left="1118" width="4" height="11" font="9">2</text>
<text top="374" left="1123" width="159" height="17" font="7">): 0% after PBMC or OC and </text>
<text top="391" left="967" width="84" height="17" font="7">27% after CC.  </text>
<text top="408" left="967" width="313" height="17" font="7">No early or late mortality or thromboembolism among the </text>
<text top="425" left="967" width="58" height="17" font="7">3 groups.  </text>
<text top="443" left="967" width="310" height="17" font="7">At 7-y follow-up, echo MVA was similar and greater after </text>
<text top="460" left="967" width="151" height="17" font="7">PBMC and OC (1.8±0.4 cm</text>
<text top="461" left="1118" width="4" height="11" font="9">2</text>
<text top="460" left="1123" width="150" height="17" font="7">) than after CC (1.3±0.3 cm</text>
<text top="461" left="1273" width="4" height="11" font="9">2</text>
<text top="460" left="1278" width="7" height="17" font="7">; </text>
<text top="477" left="967" width="59" height="17" font="7">p&lt;0.001).  </text>
<text top="494" left="967" width="142" height="17" font="7">Restenosis (MVA &lt;1.5 cm</text>
<text top="495" left="1109" width="4" height="11" font="9">2</text>
<text top="494" left="1114" width="170" height="17" font="7">) rate was 6.6% after PBMC or </text>
<text top="511" left="967" width="125" height="17" font="7">OC vs. 37% after CC.  </text>
<text top="529" left="967" width="296" height="17" font="7">Residual ASD in 2 pts and 3+ MR in 1 pt in the PBMC </text>
<text top="546" left="967" width="42" height="17" font="7">group.  </text>
<text top="563" left="967" width="303" height="17" font="7">NYHA class I in 87% of pts after PBMC and 90% of pts </text>
<text top="580" left="967" width="185" height="17" font="7">after OC vs. CC 33% (p&lt;0.0001)  </text>
<text top="597" left="967" width="313" height="17" font="7">Freedom from reintervention 90% after PBMC, 93% after </text>
<text top="615" left="967" width="133" height="17" font="7">OC, and 50% after CC.  </text>
<text top="633" left="43" width="55" height="17" font="7">Turi 1991 </text>
<text top="650" left="43" width="32" height="17" font="7">(109) </text>
<text top="667" left="43" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2013139">2013139</a></text>
<text top="667" left="91" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2013139"> </a></text>
<text top="633" left="136" width="93" height="17" font="7">Compare PBMC </text>
<text top="650" left="136" width="96" height="17" font="7">with surgical CC  </text>
<text top="633" left="251" width="46" height="17" font="7">RCT/40 </text>
<text top="633" left="325" width="88" height="17" font="7">Intervention: 20 </text>
<text top="650" left="325" width="58" height="17" font="7">PBMC vs. </text>
<text top="667" left="325" width="89" height="17" font="7">Comparator: 20 </text>
<text top="684" left="325" width="21" height="17" font="7">CC </text>
<text top="633" left="440" width="132" height="17" font="7">Pts deemed acceptable </text>
<text top="650" left="440" width="124" height="17" font="7">as candidates for both </text>
<text top="667" left="440" width="68" height="17" font="7">procedures  </text>
<text top="633" left="589" width="24" height="17" font="7">N/A </text>
<text top="633" left="751" width="39" height="17" font="7">PBMC </text>
<text top="633" left="852" width="69" height="17" font="7">Surgical CC </text>
<text top="633" left="967" width="282" height="17" font="7">No differences between groups in pulmonary artery </text>
<text top="650" left="967" width="320" height="17" font="7">wedge pressures, mitral valve gradients, and MVA at 1 wk </text>
<text top="667" left="967" width="134" height="17" font="7">and at 8 mo. (all p&gt;0.4). </text>
<text top="702" left="43" width="64" height="17" font="7">Arora 1993 </text>
<text top="719" left="43" width="32" height="17" font="7">(110) </text>
<text top="737" left="43" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8465732">8465732</a></text>
<text top="737" left="91" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8465732"> </a></text>
<text top="702" left="136" width="74" height="17" font="7">Compare the </text>
<text top="719" left="136" width="84" height="17" font="7">immediate and </text>
<text top="737" left="136" width="95" height="17" font="7">long-term results </text>
<text top="754" left="136" width="72" height="17" font="7">of PBMC vs. </text>
<text top="771" left="136" width="32" height="17" font="7">CMC </text>
<text top="702" left="251" width="53" height="17" font="7">RCT/200 </text>
<text top="702" left="325" width="95" height="17" font="7">Intervention: 100 </text>
<text top="719" left="325" width="91" height="17" font="7">vs. Comparator: </text>
<text top="737" left="325" width="24" height="17" font="7">100 </text>
<text top="702" left="440" width="120" height="17" font="7">Symptomatic pts with </text>
<text top="719" left="440" width="136" height="17" font="7">moderate-to-severe MS  </text>
<text top="702" left="589" width="105" height="17" font="7">Pts with more than </text>
<text top="719" left="589" width="111" height="17" font="7">minimal mitral valve </text>
<text top="737" left="589" width="128" height="17" font="7">calcification AF, or &gt;2+ </text>
<text top="754" left="589" width="22" height="17" font="7">MR </text>
<text top="702" left="751" width="39" height="17" font="7">PBMC </text>
<text top="702" left="852" width="21" height="17" font="7">CC </text>
<text top="702" left="967" width="274" height="17" font="7">Both procedures resulted in significant and similar </text>
<text top="719" left="967" width="293" height="17" font="7">increases in MVA (PBMV: 0.85+0.28 to 2.39±0.94 cm</text>
<text top="721" left="1260" width="4" height="11" font="9">2</text>
<text top="719" left="1265" width="7" height="17" font="7">; </text>
<text top="737" left="967" width="167" height="17" font="7">CC: 0.79±0.21 to 2.2±0.85 cm</text>
<text top="738" left="1134" width="4" height="11" font="9">2</text>
<text top="737" left="1138" width="52" height="17" font="7">; p=NS).  </text>
<text top="754" left="967" width="301" height="17" font="7">MR developed in 14 pts after PBMC and in 12 pts after </text>
<text top="771" left="967" width="31" height="17" font="7">CC.   </text>
<text top="788" left="967" width="300" height="17" font="7">Restenosis (defined as a loss of &gt;50% of the achieved </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">30 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="44" width="78" height="17" font="6"><b>Study Name, </b></text>
<text top="126" left="45" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="108" left="155" width="64" height="17" font="6"><b>Study Aim </b></text>
<text top="108" left="263" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="264" width="36" height="17" font="6"><b>Type/ </b></text>
<text top="143" left="258" width="49" height="17" font="6"><b>Size (N) </b></text>
<text top="108" left="329" width="94" height="17" font="6"><b>Intervention vs. </b></text>
<text top="126" left="331" width="92" height="17" font="6"><b>Comparator (n) </b></text>
<text top="108" left="534" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="108" left="777" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="758" width="74" height="17" font="6"><b>Intervention </b></text>
<text top="108" left="884" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="867" width="73" height="17" font="6"><b>Comparator </b></text>
<text top="108" left="1072" width="51" height="17" font="6"><b>Results  </b></text>
<text top="161" left="82" width="3" height="17" font="6"><b> </b></text>
<text top="161" left="186" width="3" height="17" font="6"><b> </b></text>
<text top="161" left="280" width="3" height="17" font="6"><b> </b></text>
<text top="161" left="375" width="3" height="17" font="6"><b> </b></text>
<text top="161" left="456" width="104" height="17" font="16"><i><b>Inclusion Criteria </b></i></text>
<text top="161" left="610" width="108" height="17" font="16"><i><b>Exclusion Criteria </b></i></text>
<text top="161" left="794" width="3" height="17" font="6"><b> </b></text>
<text top="161" left="902" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="161" left="1126" width="3" height="17" font="6"><b> </b></text>
<text top="179" left="967" width="315" height="17" font="7">increase in MVA) was seen in 4 (5%) pts after PBMV and </text>
<text top="196" left="967" width="109" height="17" font="7">in 3 (4%) after CC.  </text>
<text top="214" left="43" width="69" height="17" font="7">Reyes 1994 </text>
<text top="231" left="43" width="32" height="17" font="7">(111) </text>
<text top="248" left="43" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8084354">8084354</a></text>
<text top="248" left="91" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8084354"> </a></text>
<text top="214" left="136" width="93" height="17" font="7">Compare PBMC </text>
<text top="231" left="136" width="53" height="17" font="7">to OC for </text>
<text top="248" left="136" width="69" height="17" font="7">treatment of </text>
<text top="266" left="136" width="79" height="17" font="7">rheumatic MS </text>
<text top="214" left="251" width="46" height="17" font="7">RCT/60 </text>
<text top="214" left="325" width="88" height="17" font="7">Intervention: 30 </text>
<text top="231" left="325" width="91" height="17" font="7">vs. Comparator: </text>
<text top="248" left="325" width="17" height="17" font="7">30 </text>
<text top="214" left="440" width="125" height="17" font="7">Severe rheumatic MS, </text>
<text top="231" left="440" width="106" height="17" font="7">in sinus rhythm, no </text>
<text top="248" left="440" width="106" height="17" font="7">severe subvalvular </text>
<text top="266" left="440" width="130" height="17" font="7">disease/ calcification or </text>
<text top="283" left="440" width="107" height="17" font="7">more than mild MR </text>
<text top="214" left="589" width="135" height="17" font="7">Coexisting other cardiac </text>
<text top="231" left="589" width="136" height="17" font="7">or valve disease, stroke, </text>
<text top="248" left="589" width="101" height="17" font="7">severe pulmonary </text>
<text top="266" left="589" width="129" height="17" font="7">hypertension, low body </text>
<text top="283" left="589" width="122" height="17" font="7">weight, Lutembacjer's </text>
<text top="300" left="589" width="147" height="17" font="7">syndrome, and pt decision </text>
<text top="317" left="589" width="119" height="17" font="7">not to be randomized </text>
<text top="214" left="751" width="39" height="17" font="7">PBMC </text>
<text top="214" left="852" width="79" height="17" font="7">Open surgical </text>
<text top="231" left="852" width="100" height="17" font="7">commissurotomy  </text>
<text top="214" left="967" width="281" height="17" font="7">MVA at 3 years was larger after PBMC (2.4±0.6 cm</text>
<text top="215" left="1248" width="4" height="11" font="9">2</text>
<text top="214" left="1253" width="30" height="17" font="7"> ) vs. </text>
<text top="231" left="967" width="88" height="17" font="7">OC (1.8±0.4 cm</text>
<text top="232" left="1055" width="4" height="11" font="9">2</text>
<text top="231" left="1060" width="8" height="17" font="7">).</text>
<text top="232" left="1067" width="2" height="11" font="9"> </text>
<text top="248" left="967" width="313" height="17" font="7">NYHA class I at 3 years in 72% or PBMC pts and 57% of </text>
<text top="266" left="967" width="42" height="17" font="7">OC pts </text>
<text top="335" left="43" width="75" height="17" font="7">Cotrufo 1999 </text>
<text top="353" left="43" width="32" height="17" font="7">(113) </text>
<text top="370" left="43" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10386411">10386411</a></text>
<text top="370" left="98" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10386411"> </a></text>
<text top="335" left="136" width="93" height="17" font="7">Compare PPMC </text>
<text top="353" left="136" width="41" height="17" font="7">vs. OC </text>
<text top="335" left="251" width="53" height="17" font="7">RCT/193 </text>
<text top="335" left="325" width="75" height="17" font="7">Intervention:  </text>
<text top="353" left="325" width="63" height="17" font="7">PBMC 111 </text>
<text top="370" left="325" width="91" height="17" font="7">vs. Comparator: </text>
<text top="387" left="325" width="39" height="17" font="7">OC 82 </text>
<text top="335" left="440" width="24" height="17" font="7">N/A </text>
<text top="335" left="589" width="24" height="17" font="7">N/A </text>
<text top="335" left="751" width="39" height="17" font="7">PBMC </text>
<text top="335" left="852" width="22" height="17" font="7">OC </text>
<text top="335" left="967" width="272" height="17" font="7">Survival, event free analysis, recurrent restenosis </text>
<text top="353" left="967" width="239" height="17" font="7">No hospital mortality in both groups (p=0.3) </text>
<text top="370" left="967" width="314" height="17" font="7">Hospital complications: 4/111 PBMC vs. 1/82 OC (p=0.3) </text>
<text top="405" left="33" width="1263" height="17" font="7">2D indicates 2-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; ASD, atrial septal defect; CC, closed commissurotomy; echo, echocardiography; MR, mitral regurgitation, MS, mitral stenosis; MVA, mitral valve area; N/A, not </text>
<text top="422" left="33" width="1257" height="17" font="7">applicable; NS, nonsignificant; NYHA, New York Heart Association; OC, open commissurotomy; PMBC; percutaneous mitral balloon commissurotomy; pts, patients; RCT, randomized controlled trial; and, TR, tricuspid regurgitation. <b> </b></text>
<text top="442" left="108" width="3" height="15" font="6"><b> </b></text>
<text top="440" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="31" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">31 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="34" width="734" height="21" font="4"><b>Data Supplement 16. Preoperative Predictors of Surgical Outcome in Mitral Regurgitation (Section 7.3.3) </b></text>
<text top="129" left="77" width="71" height="17" font="6"><b>Study, Year </b></text>
<text top="129" left="221" width="82" height="17" font="6"><b>Study Design </b></text>
<text top="129" left="341" width="97" height="17" font="6"><b>Type of Surgery </b></text>
<text top="129" left="455" width="65" height="17" font="6"><b>Number of </b></text>
<text top="146" left="462" width="51" height="17" font="6"><b>Patients </b></text>
<text top="129" left="554" width="118" height="17" font="6"><b>Outcome Assessed </b></text>
<text top="129" left="960" width="55" height="17" font="6"><b>Findings </b></text>
<text top="164" left="42" width="79" height="17" font="7">Schuler 1979  </text>
<text top="182" left="42" width="32" height="17" font="7">(122) </text>
<text top="199" left="42" width="41" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/436214">436214</a></text>
<text top="199" left="83" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/436214"> </a></text>
<text top="164" left="197" width="79" height="17" font="7">Retrospective </text>
<text top="164" left="339" width="31" height="17" font="7">MVR </text>
<text top="164" left="454" width="17" height="17" font="7">20 </text>
<text top="164" left="535" width="65" height="17" font="7">LV function </text>
<text top="164" left="703" width="540" height="17" font="7">12 pts with average LVEF 0.70 had normal postoperative LVEF; 4 pts with average LVEF 0.58 had </text>
<text top="182" left="703" width="142" height="17" font="7">postoperative LVEF 0.25. </text>
<text top="217" left="42" width="73" height="17" font="7">Phillips 1981 </text>
<text top="234" left="42" width="32" height="17" font="7">(123) </text>
<text top="251" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7282546">7282546</a></text>
<text top="251" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7282546"> </a></text>
<text top="217" left="197" width="79" height="17" font="7">Retrospective </text>
<text top="217" left="339" width="31" height="17" font="7">MVR </text>
<text top="217" left="454" width="24" height="17" font="7">105 </text>
<text top="217" left="535" width="47" height="17" font="7">Survival </text>
<text top="217" left="703" width="199" height="17" font="7">LVEF &lt;0.50 predicted poor survival. </text>
<text top="269" left="42" width="54" height="17" font="7">Zile 1984 </text>
<text top="286" left="42" width="32" height="17" font="7">(124) </text>
<text top="304" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6693615">6693615</a></text>
<text top="304" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6693615"> </a></text>
<text top="269" left="197" width="68" height="17" font="7">Prospective </text>
<text top="269" left="339" width="31" height="17" font="7">MVR </text>
<text top="269" left="454" width="17" height="17" font="7">16 </text>
<text top="269" left="535" width="27" height="17" font="7">HF,  </text>
<text top="286" left="535" width="65" height="17" font="7">LV function </text>
<text top="269" left="703" width="134" height="17" font="7">LVESD index &gt;2.6 cm/m</text>
<text top="270" left="838" width="4" height="11" font="9">2</text>
<text top="269" left="842" width="282" height="17" font="7"> (45 mm) and LVFS &lt;0.32 predicted poor outcome. </text>
<text top="321" left="42" width="87" height="17" font="7">Crawford 1990  </text>
<text top="339" left="42" width="32" height="17" font="7">(125) </text>
<text top="356" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2317900">2317900</a></text>
<text top="356" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2317900"> </a></text>
<text top="321" left="197" width="68" height="17" font="7">Prospective </text>
<text top="321" left="339" width="31" height="17" font="7">MVR </text>
<text top="321" left="454" width="17" height="17" font="7">48 </text>
<text top="321" left="535" width="54" height="17" font="7">Survival,  </text>
<text top="339" left="535" width="65" height="17" font="7">LV function </text>
<text top="321" left="703" width="302" height="17" font="7">LVEF &lt;0.50 predicted reduced survival; ESV &gt;50 mL/m</text>
<text top="323" left="1005" width="4" height="11" font="9">2</text>
<text top="321" left="1010" width="189" height="17" font="7"> predicted persistent LV dilatation. </text>
<text top="374" left="42" width="106" height="17" font="7">Wisenbaugh 1994  </text>
<text top="391" left="42" width="32" height="17" font="7">(126) </text>
<text top="408" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8012639">8012639</a></text>
<text top="408" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8012639"> </a></text>
<text top="374" left="197" width="49" height="17" font="7">Registry </text>
<text top="374" left="339" width="31" height="17" font="7">MVR </text>
<text top="374" left="454" width="17" height="17" font="7">26 </text>
<text top="374" left="535" width="51" height="17" font="7">Survival, </text>
<text top="391" left="535" width="68" height="17" font="7"> LV function </text>
<text top="374" left="703" width="565" height="17" font="7">LVESD, LVEDD, and FS predicted poor survival and LV function; only LVESD significant in multivariate </text>
<text top="391" left="703" width="51" height="17" font="7">analysis. </text>
<text top="425" left="42" width="3" height="17" font="7"> </text>
<text top="425" left="197" width="3" height="17" font="7"> </text>
<text top="425" left="339" width="52" height="17" font="7">MVR-CP </text>
<text top="425" left="454" width="17" height="17" font="7">35 </text>
<text top="425" left="535" width="3" height="17" font="7"> </text>
<text top="425" left="703" width="3" height="17" font="7"> </text>
<text top="443" left="42" width="130" height="17" font="7">Enriquez-Sarano 1994  </text>
<text top="461" left="42" width="32" height="17" font="7">(127) </text>
<text top="478" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8044955">8044955</a></text>
<text top="478" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8044955"> </a></text>
<text top="443" left="197" width="79" height="17" font="7">Retrospective </text>
<text top="443" left="339" width="31" height="17" font="7">MVR </text>
<text top="443" left="454" width="24" height="17" font="7">214 </text>
<text top="443" left="535" width="47" height="17" font="7">Survival </text>
<text top="443" left="703" width="553" height="17" font="7">LVEF &lt;0.60 predicted poor survival whether MVR or CP was preformed; LVEF estimated by echo FS </text>
<text top="461" left="703" width="100" height="17" font="7">or visual analysis. </text>
<text top="495" left="42" width="3" height="17" font="7"> </text>
<text top="495" left="197" width="3" height="17" font="7"> </text>
<text top="495" left="339" width="40" height="17" font="7">Repair </text>
<text top="495" left="454" width="24" height="17" font="7">195 </text>
<text top="495" left="535" width="3" height="17" font="7"> </text>
<text top="495" left="703" width="3" height="17" font="7"> </text>
<text top="513" left="42" width="130" height="17" font="7">Enriquez-Sarano 1994  </text>
<text top="530" left="42" width="32" height="17" font="7">(128) </text>
<text top="548" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7930287">7930287</a></text>
<text top="548" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7930287"> </a></text>
<text top="513" left="197" width="79" height="17" font="7">Retrospective </text>
<text top="513" left="339" width="31" height="17" font="7">MVR </text>
<text top="513" left="454" width="24" height="17" font="7">104 </text>
<text top="513" left="535" width="65" height="17" font="7">LV function </text>
<text top="513" left="703" width="532" height="17" font="7">LVEF, LVESD, LV diameter/thickness ratio and end-systolic wall stress predicted outcome; LVEF </text>
<text top="530" left="703" width="223" height="17" font="7">estimated by echo FS or visual analysis. </text>
<text top="565" left="42" width="3" height="17" font="7"> </text>
<text top="565" left="197" width="3" height="17" font="7"> </text>
<text top="565" left="339" width="40" height="17" font="7">Repair </text>
<text top="565" left="454" width="24" height="17" font="7">162 </text>
<text top="565" left="535" width="3" height="17" font="7"> </text>
<text top="565" left="703" width="3" height="17" font="7"> </text>
<text top="583" left="34" width="1318" height="17" font="7">CP indicates chordal preservation procedure; ESV, end-systolic volume; FS, fractional shortening; HF, heart failure; LA, left atrial; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; LVFS, </text>
<text top="600" left="34" width="706" height="17" font="7">left ventricular fractional shortening; MVR, mitral valve replacement; PAWP, pulmonary artery wedge pressure; and, pts, patients. </text>
<text top="617" left="108" width="3" height="17" font="7"> </text>
<text top="617" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="32" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">32 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="648" height="21" font="4"><b>Data Supplement 17. Primary Mitral Regurgitation—Evidence for Intervention (Section 7.3.3) </b></text>
<text top="129" left="49" width="125" height="17" font="6"><b>Study Name, Author, </b></text>
<text top="146" left="96" width="30" height="17" font="6"><b>Year </b></text>
<text top="129" left="244" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="129" left="406" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="516" width="86" height="17" font="6"><b>Study Size (N) </b></text>
<text top="129" left="628" width="152" height="17" font="6"><b>Study Intervention Group </b></text>
<text top="146" left="694" width="19" height="17" font="6"><b>(n) </b></text>
<text top="129" left="808" width="170" height="17" font="6"><b>Study Comparator Group (n) </b></text>
<text top="129" left="1068" width="57" height="17" font="6"><b>Outcome </b></text>
<text top="164" left="42" width="90" height="17" font="7">Tribouilloy 1999 </text>
<text top="182" left="42" width="32" height="17" font="7">(129) </text>
<text top="199" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9918527">9918527</a></text>
<text top="199" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9918527"> </a></text>
<text top="164" left="193" width="149" height="17" font="7">Assess impact of symptom </text>
<text top="182" left="193" width="104" height="17" font="7">status on outcome </text>
<text top="164" left="386" width="79" height="17" font="7">Retrospective </text>
<text top="164" left="547" width="24" height="17" font="7">478 </text>
<text top="164" left="622" width="78" height="17" font="7">Mitral surgery </text>
<text top="164" left="798" width="122" height="17" font="7">NYHA class I,II, III, IV </text>
<text top="164" left="1000" width="300" height="17" font="7">Advanced preoperative symptoms increased operative </text>
<text top="182" left="1000" width="292" height="17" font="7">mortality by 10 fold. Long-term survival also reduced. </text>
<text top="222" left="42" width="75" height="17" font="7">Gillinov 2010 </text>
<text top="240" left="42" width="32" height="17" font="7">(130) </text>
<text top="257" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20667334">20667334</a></text>
<text top="257" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20667334"> </a></text>
<text top="222" left="193" width="173" height="17" font="7">Assess impact of symptoms on </text>
<text top="240" left="193" width="57" height="17" font="7">outcomes </text>
<text top="222" left="386" width="78" height="17" font="7">Retrospective </text>
<text top="240" left="386" width="61" height="17" font="7">propensity-</text>
<text top="257" left="386" width="54" height="17" font="7">matched  </text>
<text top="222" left="542" width="34" height="17" font="7">4,253 </text>
<text top="222" left="622" width="31" height="17" font="7">MVR </text>
<text top="222" left="798" width="85" height="17" font="7">NYHA all class </text>
<text top="222" left="1000" width="316" height="17" font="7">Even NYHA class II preoperative symptoms impaired late </text>
<text top="240" left="1000" width="49" height="17" font="7">survival. </text>
<text top="275" left="42" width="90" height="17" font="7">Rosenhek 2006 </text>
<text top="292" left="42" width="32" height="17" font="7">(131) </text>
<text top="309" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16651470">16651470</a></text>
<text top="309" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16651470"> </a></text>
<text top="275" left="193" width="167" height="17" font="7">Assess outcome with watchful </text>
<text top="292" left="193" width="42" height="17" font="7">waiting </text>
<text top="275" left="386" width="68" height="17" font="7">Prospective </text>
<text top="275" left="547" width="24" height="17" font="7">132 </text>
<text top="275" left="622" width="151" height="17" font="7">Watchful waiting for severe </text>
<text top="292" left="622" width="22" height="17" font="7">MR </text>
<text top="275" left="798" width="24" height="17" font="7">N/A </text>
<text top="275" left="1000" width="282" height="17" font="7">Survival for watchful waiting identical to age normal </text>
<text top="292" left="1000" width="300" height="17" font="7">population, but triggers for surgery occurred early after </text>
<text top="309" left="1000" width="105" height="17" font="7">enrollment in 50%. </text>
<text top="327" left="42" width="63" height="17" font="7">Kang 2009 </text>
<text top="344" left="42" width="32" height="17" font="7">(132) </text>
<text top="362" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19188506">19188506</a></text>
<text top="362" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19188506"> </a></text>
<text top="327" left="193" width="167" height="17" font="7">Assess outcome with watchful </text>
<text top="344" left="193" width="42" height="17" font="7">waiting </text>
<text top="327" left="386" width="68" height="17" font="7">Prospective </text>
<text top="327" left="547" width="24" height="17" font="7">447 </text>
<text top="327" left="622" width="78" height="17" font="7">Mitral surgery </text>
<text top="327" left="798" width="185" height="17" font="7">Early surgery vs. watchful waiting </text>
<text top="327" left="1000" width="312" height="17" font="7">Early surgery appeared superior, but several unoperated </text>
<text top="344" left="1000" width="267" height="17" font="7">pts refused surgery despite presence of triggers. </text>
<text top="380" left="42" width="127" height="17" font="7">Enriquez-Sarano 1994 </text>
<text top="397" left="42" width="32" height="17" font="7">(127) </text>
<text top="414" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8044955">8044955</a></text>
<text top="414" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8044955"> </a></text>
<text top="380" left="193" width="165" height="17" font="7">Assess predictors of outcome </text>
<text top="380" left="386" width="79" height="17" font="7">Retrospective </text>
<text top="380" left="547" width="24" height="17" font="7">409 </text>
<text top="380" left="622" width="78" height="17" font="7">Mitral surgery </text>
<text top="380" left="798" width="125" height="17" font="7">LVEF &gt;60, 50-60, &lt;50 </text>
<text top="380" left="1000" width="303" height="17" font="7">Survival at 10 y, 72% for LVEF &gt;60, 53%, 50–60, 32%, </text>
<text top="397" left="1000" width="28" height="17" font="7">&lt;50. </text>
<text top="432" left="42" width="90" height="17" font="7">Tribouilloy 2009 </text>
<text top="449" left="42" width="32" height="17" font="7">(133) </text>
<text top="467" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19909877">19909877</a></text>
<text top="467" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19909877"> </a></text>
<text top="432" left="193" width="157" height="17" font="7">Assess impact of LVESD on </text>
<text top="449" left="193" width="51" height="17" font="7">outcome </text>
<text top="432" left="386" width="79" height="17" font="7">Retrospective </text>
<text top="432" left="547" width="24" height="17" font="7">739 </text>
<text top="432" left="622" width="78" height="17" font="7">Mitral surgery </text>
<text top="432" left="798" width="112" height="17" font="7">LVESD &lt;40 vs. ≥40 </text>
<text top="432" left="1000" width="275" height="17" font="7">LVESD &gt;40 mm nearly doubled late mortality risk. </text>
<text top="484" left="42" width="127" height="17" font="7">Enriquez-Sarano 2005 </text>
<text top="502" left="42" width="32" height="17" font="7">(134) </text>
<text top="519" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15745978">15745978</a></text>
<text top="519" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15745978"> </a></text>
<text top="484" left="193" width="168" height="17" font="7">Assess impact of MR severity  </text>
<text top="484" left="386" width="68" height="17" font="7">Prospective </text>
<text top="484" left="547" width="24" height="17" font="7">450 </text>
<text top="484" left="622" width="24" height="17" font="7">N/A </text>
<text top="484" left="798" width="123" height="17" font="7">ERO of different sizes </text>
<text top="484" left="1000" width="74" height="17" font="7">ERO &gt;0.4 cm</text>
<text top="485" left="1074" width="7" height="11" font="9">2 </text>
<text top="484" left="1081" width="223" height="17" font="7">nearly tripled mortality, but mortality was </text>
<text top="502" left="1000" width="112" height="17" font="7">reduced by surgery. </text>
<text top="537" left="42" width="84" height="17" font="7">Ghoreshi 2011 </text>
<text top="554" left="42" width="32" height="17" font="7">(135) </text>
<text top="571" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21962906">21962906</a></text>
<text top="571" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21962906"> </a></text>
<text top="537" left="193" width="157" height="17" font="7">Assess impact of pulmonary </text>
<text top="554" left="193" width="96" height="17" font="7">HTN on outcome </text>
<text top="537" left="386" width="79" height="17" font="7">Retrospective </text>
<text top="537" left="547" width="24" height="17" font="7">873 </text>
<text top="537" left="622" width="78" height="17" font="7">Mitral surgery </text>
<text top="537" left="798" width="177" height="17" font="7">Preoperative-pulmonary HTN of </text>
<text top="554" left="798" width="91" height="17" font="7">various degrees </text>
<text top="537" left="1000" width="266" height="17" font="7">5 y survival 88% for PAP &lt;40 vs. 52% PAP &gt;60. </text>
<text top="589" left="42" width="84" height="17" font="7">Goldman 1987 </text>
<text top="606" left="42" width="32" height="17" font="7">(136) </text>
<text top="624" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3624663">3624663</a></text>
<text top="624" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/3624663"> </a></text>
<text top="589" left="193" width="147" height="17" font="7">Compare LV function after </text>
<text top="606" left="193" width="98" height="17" font="7">replace vs. repair </text>
<text top="589" left="386" width="68" height="17" font="7">Prospective </text>
<text top="589" left="550" width="17" height="17" font="7">18 </text>
<text top="589" left="622" width="78" height="17" font="7">Mitral surgery </text>
<text top="589" left="798" width="130" height="17" font="7">Repair vs. replacement </text>
<text top="589" left="1000" width="259" height="17" font="7">LVEF fell following replacement, but not repair. </text>
<text top="642" left="42" width="66" height="17" font="7">David 1984 </text>
<text top="659" left="42" width="32" height="17" font="7">(137) </text>
<text top="676" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6492840">6492840</a></text>
<text top="676" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6492840"> </a></text>
<text top="642" left="193" width="154" height="17" font="7">Compare outcome with and </text>
<text top="659" left="193" width="157" height="17" font="7">without chordal presentation </text>
<text top="642" left="386" width="68" height="17" font="7">Prospective </text>
<text top="642" left="550" width="17" height="17" font="7">27 </text>
<text top="642" left="622" width="78" height="17" font="7">Mitral surgery </text>
<text top="642" left="798" width="158" height="17" font="7">MV surgery with and without </text>
<text top="659" left="798" width="115" height="17" font="7">chordal preservation </text>
<text top="642" left="1000" width="321" height="17" font="7">LVEF decreased without preservation, but was maintained </text>
<text top="659" left="1000" width="100" height="17" font="7">with preservation. </text>
<text top="700" left="42" width="72" height="17" font="7">Rozich 1992 </text>
<text top="717" left="42" width="32" height="17" font="7">(138) </text>
<text top="734" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1451243">1451243</a></text>
<text top="734" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1451243"> </a></text>
<text top="700" left="193" width="96" height="17" font="7">Examined LVEF  </text>
<text top="700" left="386" width="79" height="17" font="7">Retrospective </text>
<text top="700" left="550" width="17" height="17" font="7">15 </text>
<text top="700" left="622" width="78" height="17" font="7">Mitral surgery </text>
<text top="700" left="798" width="137" height="17" font="7">Chordal preservation vs. </text>
<text top="717" left="798" width="64" height="17" font="7">destruction </text>
<text top="700" left="1000" width="292" height="17" font="7">Afterload increased following chordal destruction, but </text>
<text top="717" left="1000" width="186" height="17" font="7">decreases following preservation. </text>
<text top="752" left="42" width="77" height="17" font="7">Grigioni 2008 </text>
<text top="769" left="42" width="32" height="17" font="7">(139) </text>
<text top="787" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19356418">19356418</a></text>
<text top="787" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19356418"> </a></text>
<text top="752" left="193" width="121" height="17" font="7">Outcome of repair vs. </text>
<text top="769" left="193" width="71" height="17" font="7">replacement </text>
<text top="752" left="386" width="68" height="17" font="7">Prospective </text>
<text top="752" left="547" width="24" height="17" font="7">394 </text>
<text top="752" left="622" width="78" height="17" font="7">Mitral surgery </text>
<text top="752" left="798" width="149" height="17" font="7">Repair vs. replacement vs. </text>
<text top="769" left="798" width="65" height="17" font="7">nonsurgery </text>
<text top="752" left="1000" width="273" height="17" font="7">92% 54 y survival for repair 80% for replacement. </text>
</page>
<page number="33" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">33 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="49" width="125" height="17" font="6"><b>Study Name, Author, </b></text>
<text top="126" left="96" width="30" height="17" font="6"><b>Year </b></text>
<text top="108" left="244" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="406" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="516" width="86" height="17" font="6"><b>Study Size (N) </b></text>
<text top="108" left="628" width="152" height="17" font="6"><b>Study Intervention Group </b></text>
<text top="126" left="694" width="19" height="17" font="6"><b>(n) </b></text>
<text top="108" left="808" width="170" height="17" font="6"><b>Study Comparator Group (n) </b></text>
<text top="108" left="1068" width="57" height="17" font="6"><b>Outcome </b></text>
<text top="144" left="42" width="75" height="17" font="7">Gillinov 2008 </text>
<text top="161" left="42" width="32" height="17" font="7">(140) </text>
<text top="178" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18721551">18721551</a></text>
<text top="178" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18721551"> </a></text>
<text top="144" left="193" width="121" height="17" font="7">Outcome of repair vs. </text>
<text top="161" left="193" width="71" height="17" font="7">replacement </text>
<text top="144" left="386" width="79" height="17" font="7">Retrospective </text>
<text top="144" left="547" width="24" height="17" font="7">328 </text>
<text top="144" left="622" width="24" height="17" font="7">N/A </text>
<text top="144" left="798" width="130" height="17" font="7">Repair vs. replacement </text>
<text top="161" left="798" width="64" height="17" font="7">propensity  </text>
<text top="144" left="1000" width="280" height="17" font="7">5, 10, 15 y survival 95, 87, 68 repair vs. -80, 60, 44 </text>
<text top="161" left="1000" width="75" height="17" font="7">replacement. </text>
<text top="196" left="41" width="1308" height="17" font="7">ERO indicates effective regurgitant orifice; HTN, hypertension; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; MR, mitral regurgitation; MV, mitral valve; MVR, mitral valve repair; N/A </text>
<text top="213" left="41" width="570" height="17" font="7">not applicable; NYHA, New York Heart Association; PAP, pulmonary artery pressure; and, pts, patients.  </text>
<text top="231" left="108" width="3" height="17" font="7"> </text>
<text top="231" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="34" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">34 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="611" height="21" font="4"><b>Data Supplement 18. Secondary Mitral Regurgitation—Evidence for Intervention (7.4.3) </b></text>
<text top="130" left="47" width="125" height="17" font="6"><b>Study Name, Author, </b></text>
<text top="147" left="95" width="30" height="17" font="6"><b>Year </b></text>
<text top="130" left="256" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="130" left="429" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="130" left="529" width="65" height="17" font="6"><b>Study Size </b></text>
<text top="147" left="552" width="21" height="17" font="6"><b>(N) </b></text>
<text top="130" left="611" width="152" height="17" font="6"><b>Study Intervention Group </b></text>
<text top="147" left="677" width="19" height="17" font="6"><b>(n) </b></text>
<text top="130" left="784" width="170" height="17" font="6"><b>Study Comparator Group (n) </b></text>
<text top="130" left="1111" width="57" height="17" font="6"><b>Outcome </b></text>
<text top="165" left="36" width="63" height="17" font="7">Kang 2006 </text>
<text top="182" left="36" width="32" height="17" font="7">(141) </text>
<text top="200" left="36" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16820626">16820626</a></text>
<text top="200" left="91" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16820626"> </a></text>
<text top="165" left="185" width="222" height="17" font="7">Outcome surgery in moderate-to-severe </text>
<text top="182" left="185" width="74" height="17" font="7">ischemic MR </text>
<text top="165" left="407" width="79" height="17" font="7">Retrospective </text>
<text top="165" left="550" width="24" height="17" font="7">107 </text>
<text top="165" left="603" width="87" height="17" font="7"> CABG + repair </text>
<text top="165" left="772" width="42" height="17" font="7">CABG  </text>
<text top="165" left="968" width="342" height="17" font="7">Higher operative mortality with CABG and MV repair vs CABG </text>
<text top="182" left="968" width="329" height="17" font="7">alone (12% vs 2%) but similar 5 year survival (88% vs 87%) </text>
<text top="218" left="36" width="65" height="17" font="7">Rossi 2011 </text>
<text top="235" left="36" width="32" height="17" font="7">(142) </text>
<text top="252" left="36" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21807656">21807656</a></text>
<text top="252" left="91" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21807656"> </a></text>
<text top="218" left="185" width="152" height="17" font="7">Impact of SMR on outcome </text>
<text top="218" left="407" width="82" height="17" font="7">Retrospective  </text>
<text top="218" left="545" width="34" height="17" font="7">1,256 </text>
<text top="218" left="603" width="33" height="17" font="7">None </text>
<text top="218" left="772" width="122" height="17" font="7">Impact of SMR on HF </text>
<text top="218" left="968" width="318" height="17" font="7">After adjusting for LVEF and other factors-SMR increased </text>
<text top="235" left="968" width="100" height="17" font="7">mortality by 2-fold </text>
<text top="271" left="36" width="53" height="17" font="7">Wu 2005 </text>
<text top="288" left="36" width="32" height="17" font="7">(143) </text>
<text top="305" left="36" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15680716">15680716</a></text>
<text top="305" left="91" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15680716"> </a></text>
<text top="271" left="185" width="212" height="17" font="7">Impact of surgery on moderate-severe </text>
<text top="288" left="185" width="22" height="17" font="7">MR </text>
<text top="271" left="407" width="79" height="17" font="7">Retrospective </text>
<text top="271" left="550" width="24" height="17" font="7">126 </text>
<text top="271" left="603" width="105" height="17" font="7">Surgery with mitral </text>
<text top="288" left="603" width="76" height="17" font="7">annuloplasty  </text>
<text top="271" left="772" width="46" height="17" font="7">Med Rx </text>
<text top="271" left="968" width="277" height="17" font="7">No survival advantage to mitral valve annuloplasty </text>
<text top="323" left="36" width="88" height="17" font="7">Mihaljevic 2007 </text>
<text top="341" left="36" width="32" height="17" font="7">(144) </text>
<text top="358" left="36" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17543639">17543639</a></text>
<text top="358" left="91" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17543639"> </a></text>
<text top="323" left="185" width="188" height="17" font="7">Impact of mitral surgery moderate-</text>
<text top="341" left="185" width="88" height="17" font="7">severe on SMR </text>
<text top="323" left="407" width="79" height="17" font="7">Retrospective </text>
<text top="323" left="550" width="24" height="17" font="7">290 </text>
<text top="323" left="603" width="119" height="17" font="7">CABG+ MV surgery   </text>
<text top="323" left="772" width="42" height="17" font="7">CABG  </text>
<text top="323" left="968" width="334" height="17" font="7">1-, 5-, 10-y survival -88, 75, 47 CABG vs. 92, 74, 39 CABG + </text>
<text top="341" left="968" width="310" height="17" font="7">MV Sx; (p=NS) functional class improved equally in both </text>
<text top="358" left="968" width="41" height="17" font="7">groups </text>
<text top="376" left="36" width="90" height="17" font="7">Benedetto 2009 </text>
<text top="393" left="36" width="32" height="17" font="7">(145) </text>
<text top="411" left="36" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19377377">19377377</a></text>
<text top="411" left="91" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19377377"> </a></text>
<text top="376" left="185" width="168" height="17" font="7">Impact of MV surgery on SMR </text>
<text top="376" left="407" width="79" height="17" font="7">Meta-analysis </text>
<text top="376" left="545" width="34" height="17" font="7">2,479 </text>
<text top="376" left="603" width="112" height="17" font="7">CAGB+MV surgery  </text>
<text top="376" left="772" width="42" height="17" font="7">CABG  </text>
<text top="376" left="968" width="258" height="17" font="7">No difference in survival or symptomatic status </text>
<text top="429" left="36" width="82" height="17" font="7">Fattouch 2009 </text>
<text top="446" left="36" width="32" height="17" font="7">(146) </text>
<text top="463" left="36" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19619766">19619766</a></text>
<text top="463" left="91" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19619766"> </a></text>
<text top="429" left="185" width="295" height="17" font="7">Impact of MV surgery in ischemic MR  Randomized </text>
<text top="446" left="407" width="66" height="17" font="7">prospective </text>
<text top="429" left="550" width="24" height="17" font="7">102 </text>
<text top="429" left="603" width="84" height="17" font="7">CABG + repair </text>
<text top="429" left="772" width="42" height="17" font="7">CABG  </text>
<text top="429" left="968" width="332" height="17" font="7">No difference in mortality. Repair group had reduced cardiac </text>
<text top="446" left="968" width="240" height="17" font="7">dimensions and symptoms vs. CABG alone </text>
<text top="482" left="36" width="60" height="17" font="7">Deja 2012 </text>
<text top="499" left="36" width="32" height="17" font="7">(147) </text>
<text top="516" left="36" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22553307">22553307</a></text>
<text top="516" left="91" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22553307"> </a></text>
<text top="482" left="185" width="184" height="17" font="7">Impact of repair in ischemic SMR </text>
<text top="482" left="407" width="86" height="17" font="7">Randomized to </text>
<text top="499" left="407" width="83" height="17" font="7">medical Rx vs. </text>
<text top="516" left="407" width="44" height="17" font="7">surgery </text>
<text top="482" left="550" width="24" height="17" font="7">104 </text>
<text top="482" left="603" width="84" height="17" font="7">CABG + repair </text>
<text top="482" left="772" width="42" height="17" font="7">CABG  </text>
<text top="482" left="968" width="342" height="17" font="7">53% mortality CABG, vs. 43% mortality CABG + MVR (p=NS); </text>
<text top="499" left="968" width="275" height="17" font="7">after adjustment CABG + MVR had better survival </text>
<text top="534" left="34" width="1289" height="17" font="7">CABG indicates coronary artery bypass graft; HF, heart failure; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; MV, mitral valve, MVR, mitral valve repair; NS, nonsignificant; pts, patients; Rx, prescription; SMR, secondary </text>
<text top="552" left="34" width="220" height="17" font="7">mitral regurgitation; and, Sx, symptoms. </text>
<text top="569" left="108" width="3" height="17" font="7"> </text>
<text top="569" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">35 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="34" width="906" height="21" font="4"><b>Data Supplement 19. Functional Tricuspid Regurgitation: Outcomes Following Tricuspid Valve Surgery (Sections 8.2.3 and 8.4.3) </b></text>
<text top="129" left="57" width="71" height="17" font="6"><b>Study, Year </b></text>
<text top="129" left="198" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="129" left="368" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="556" width="113" height="17" font="6"><b>Study Size, Details </b></text>
<text top="129" left="912" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="129" left="1171" width="139" height="17" font="6"><b>Comments, Limitations </b></text>
<text top="147" left="42" width="80" height="17" font="7">Dreyfus, 2005 </text>
<text top="165" left="42" width="32" height="17" font="7">(148) </text>
<text top="182" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15620928">15620928</a></text>
<text top="182" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15620928"> </a></text>
<text top="147" left="157" width="133" height="17" font="7">Determine benefit of TV </text>
<text top="165" left="157" width="126" height="17" font="7">annuloplasty based on </text>
<text top="182" left="157" width="157" height="17" font="7">intraoperative measurement </text>
<text top="199" left="157" width="58" height="17" font="7">of TA size </text>
<text top="147" left="332" width="71" height="17" font="7">Prospective, </text>
<text top="165" left="332" width="113" height="17" font="7">observational series </text>
<text top="182" left="332" width="104" height="17" font="7">1989–2001; single </text>
<text top="199" left="332" width="48" height="17" font="7">surgeon </text>
<text top="147" left="487" width="241" height="17" font="7">311 pts undergoing MVR for chronic severe </text>
<text top="165" left="487" width="26" height="17" font="7">MR. </text>
<text top="182" left="487" width="232" height="17" font="7">163 pts with TA &lt;70 mm received isolated </text>
<text top="199" left="487" width="228" height="17" font="7">MVR (Group 1); 148 pts with TA ≥70 mm </text>
<text top="216" left="487" width="179" height="17" font="7">received MVR + TVR (Group 2). </text>
<text top="233" left="487" width="221" height="17" font="7">88% of pts had 0-1+ TR preoperatively.  </text>
<text top="251" left="487" width="215" height="17" font="7">No pts in Group 1 had &gt;2+ TR; 2 pts in </text>
<text top="268" left="487" width="112" height="17" font="7">Group 2 had 3+ TR. </text>
<text top="147" left="751" width="343" height="17" font="7">Postoperative TR grade 2.1±1.0 Group 1 vs. 0.4±0.6 Group 2; </text>
<text top="165" left="751" width="60" height="17" font="7">(p&lt;0.001). </text>
<text top="182" left="751" width="357" height="17" font="7">TR severity increased &gt;2 grades in 48% of Group 1 pts vs. 2% of </text>
<text top="199" left="751" width="78" height="17" font="7">Group 2 pts.   </text>
<text top="216" left="751" width="378" height="17" font="7">Progressive TR occurred independent of residual MR, LVEF, and PA </text>
<text top="233" left="751" width="61" height="17" font="7">pressures. </text>
<text top="251" left="751" width="366" height="17" font="7">No differences between groups in 10-y actuarial survival or cardiac </text>
<text top="268" left="751" width="107" height="17" font="7">event-free survival. </text>
<text top="147" left="1149" width="100" height="17" font="7">No echo core lab. </text>
<text top="165" left="1149" width="156" height="17" font="7">Time at which postoperative </text>
<text top="182" left="1149" width="157" height="17" font="7">echo obtained not specified. </text>
<text top="199" left="1149" width="140" height="17" font="7">Median y of follow-up not </text>
<text top="216" left="1149" width="55" height="17" font="7">specified. </text>
<text top="233" left="1149" width="172" height="17" font="7">Predictors of worsening TR not </text>
<text top="251" left="1149" width="53" height="17" font="7">reported. </text>
<text top="286" left="42" width="99" height="17" font="7">Chan, 2009 (149) </text>
<text top="303" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19766809">19766809</a></text>
<text top="303" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19766809"> </a></text>
<text top="286" left="157" width="154" height="17" font="7">Determine the effects of TR </text>
<text top="303" left="157" width="159" height="17" font="7">and TV repair on clinical and </text>
<text top="320" left="157" width="116" height="17" font="7">TTE outcomes in pts </text>
<text top="337" left="157" width="161" height="17" font="7">undergoing MV replacement. </text>
<text top="286" left="332" width="82" height="17" font="7">Retrospective, </text>
<text top="303" left="332" width="115" height="17" font="7">observational, single </text>
<text top="320" left="332" width="106" height="17" font="7">center, 1990–2005 </text>
<text top="286" left="487" width="205" height="17" font="7">624 pts undergoing MV replacement. </text>
<text top="303" left="487" width="243" height="17" font="7">231 with ≥2+TR; 125 received TVR, 106 did </text>
<text top="320" left="487" width="24" height="17" font="7">not. </text>
<text top="337" left="487" width="146" height="17" font="7">Mean follow-up 6.8±4.8 y. </text>
<text top="286" left="751" width="379" height="17" font="7">TVR was associated with a reduction in TR grade and HF symptoms. </text>
<text top="303" left="751" width="229" height="17" font="7">No difference in survival between groups. </text>
<text top="320" left="751" width="316" height="17" font="7">Trend for worsening TR in pts with ≤1+TR but dilated TA. </text>
<text top="286" left="1149" width="98" height="17" font="7">Study spans 15 y </text>
<text top="303" left="1149" width="181" height="17" font="7">Multiple annuloplasty techniques </text>
<text top="320" left="1149" width="156" height="17" font="7">used. 22% of pts had suture </text>
<text top="337" left="1149" width="76" height="17" font="7">annuloplasty. </text>
<text top="355" left="42" width="90" height="17" font="7">Calafiore, 2009  </text>
<text top="373" left="42" width="32" height="17" font="7">(150) </text>
<text top="390" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19231373">19231373</a></text>
<text top="390" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19231373"> </a></text>
<text top="355" left="157" width="162" height="17" font="7">Evaluate clinical outcomes of </text>
<text top="373" left="157" width="104" height="17" font="7">pts undergoing TV </text>
<text top="390" left="157" width="154" height="17" font="7">annuloplasty for ≥moderate </text>
<text top="407" left="157" width="122" height="17" font="7">TR at time of MVR for </text>
<text top="424" left="157" width="82" height="17" font="7">functional MR. </text>
<text top="355" left="332" width="82" height="17" font="7">Retrospective, </text>
<text top="373" left="332" width="115" height="17" font="7">observational, single </text>
<text top="390" left="332" width="106" height="17" font="7">center, 1988–2003 </text>
<text top="355" left="487" width="248" height="17" font="7">110 pts with ≥moderate TR undergoing MVR </text>
<text top="373" left="487" width="100" height="17" font="7">for functional MR. </text>
<text top="390" left="487" width="243" height="17" font="7">51 pts underwent TV annuloplasty (treated). </text>
<text top="407" left="487" width="199" height="17" font="7">59 pts did not have TV annuloplasty </text>
<text top="424" left="487" width="67" height="17" font="7">(untreated). </text>
<text top="441" left="487" width="193" height="17" font="7">Midterm propensity score analysis. </text>
<text top="355" left="751" width="333" height="17" font="7">Adjusted 5-y survival was 45.0±6.1% in untreated group and </text>
<text top="373" left="751" width="213" height="17" font="7">74.5±5.1% in treated group (p=0.004). </text>
<text top="390" left="751" width="380" height="17" font="7">Untreated ≥moderate TR a risk factor for lower midterm survival (HR: </text>
<text top="407" left="751" width="383" height="17" font="7">2.7; 95% CI: 1.3–5.4) and survival in NYHA class I or II (HR: 1.9; 95% </text>
<text top="424" left="751" width="75" height="17" font="7">CI: 1.1–3.4).  </text>
<text top="441" left="751" width="369" height="17" font="7">Follow-up functional TR progression rate (3+/4+) was 5% in treated </text>
<text top="459" left="751" width="245" height="17" font="7">group vs. 40% in untreated group (p&lt;0.001). </text>
<text top="476" left="751" width="375" height="17" font="7">The progression of functional TR grade at follow-up was a risk factor </text>
<text top="493" left="751" width="377" height="17" font="7">for worse survival and the possibility to be alive in NYHA class I or II. </text>
<text top="355" left="1149" width="95" height="17" font="7">Study span 15 y. </text>
<text top="373" left="1149" width="172" height="17" font="7">DeVega annuloplasty in all pts. </text>
<text top="390" left="1149" width="143" height="17" font="7">All pts had functional MR. </text>
<text top="407" left="1149" width="146" height="17" font="7">Incomplete TTE follow-up. </text>
<text top="511" left="42" width="87" height="17" font="7">Di Mauro, 2009 </text>
<text top="528" left="42" width="19" height="17" font="7">(4) </text>
<text top="546" left="42" width="32" height="17" font="7">(151) </text>
<text top="563" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19233670">19233670</a></text>
<text top="563" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19233670"> </a></text>
<text top="511" left="157" width="104" height="17" font="7">Evaluate impact of </text>
<text top="528" left="157" width="148" height="17" font="7">≥moderate TR on midterm </text>
<text top="546" left="157" width="155" height="17" font="7">outcomes of pts undergoing </text>
<text top="563" left="157" width="141" height="17" font="7">surgery for functional MR </text>
<text top="511" left="332" width="82" height="17" font="7">Retrospective, </text>
<text top="528" left="332" width="115" height="17" font="7">observational, single </text>
<text top="546" left="332" width="103" height="17" font="7">center 1988–2003 </text>
<text top="511" left="487" width="247" height="17" font="7">165 pts with functional MR and untreated TR </text>
<text top="528" left="487" width="114" height="17" font="7">102 pts with 0-1+TR </text>
<text top="546" left="487" width="107" height="17" font="7">63 pts with 2-3+TR </text>
<text top="511" left="751" width="305" height="17" font="7">5-y survival and NYHA class better for pts with 0-1+TR. </text>
<text top="528" left="751" width="373" height="17" font="7">Negative impact on survival of untreated moderate or more TR (HR: </text>
<text top="546" left="751" width="175" height="17" font="7">3.1; 95% CI: 1.8–5.1; p&lt;0.001). </text>
<text top="563" left="751" width="368" height="17" font="7">TR grade initially declined after MV surgery, but then progressed in </text>
<text top="580" left="751" width="172" height="17" font="7">pts with 2-3+ preoperative TR.  </text>
<text top="511" left="1149" width="95" height="17" font="7">Study span 15 y. </text>
<text top="528" left="1149" width="146" height="17" font="7">Incomplete TTE follow-up. </text>
<text top="546" left="1149" width="162" height="17" font="7">No information on success of </text>
<text top="563" left="1149" width="70" height="17" font="7">MV surgery. </text>
<text top="580" left="1149" width="169" height="17" font="7">Same pt cohort as reported by </text>
<text top="597" left="1149" width="87" height="17" font="7">Calafiore 2009. </text>
<text top="615" left="42" width="78" height="17" font="7">Van de Veire, </text>
<text top="632" left="42" width="34" height="17" font="7">2011  </text>
<text top="650" left="42" width="32" height="17" font="7">(152) </text>
<text top="667" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20832082">20832082</a></text>
<text top="667" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20832082"> </a></text>
<text top="615" left="157" width="161" height="17" font="7">Determine if TV annuloplasty </text>
<text top="632" left="157" width="130" height="17" font="7">in pts with TA dilatation </text>
<text top="650" left="157" width="146" height="17" font="7">undergoing MVR prevents </text>
<text top="667" left="157" width="145" height="17" font="7">progression of TR and RV </text>
<text top="684" left="157" width="64" height="17" font="7">remodeling </text>
<text top="615" left="332" width="82" height="17" font="7">Retrospective, </text>
<text top="632" left="332" width="115" height="17" font="7">observational, single </text>
<text top="650" left="332" width="139" height="17" font="7">center series, 2 separate </text>
<text top="667" left="332" width="133" height="17" font="7">cohorts: 2002 and 2004 </text>
<text top="615" left="487" width="224" height="17" font="7">2002: 13 pts with 3-4+ TR underwent TV </text>
<text top="632" left="487" width="157" height="17" font="7">annuloplasty at time of MVR </text>
<text top="650" left="487" width="246" height="17" font="7">2004: 21 pts with 3-4+TR and 43 pts with TA </text>
<text top="667" left="487" width="242" height="17" font="7">≥40 mm underwent TV annuloplasty at time </text>
<text top="684" left="487" width="48" height="17" font="7">of MVR  </text>
<text top="615" left="751" width="342" height="17" font="7">2002 cohort: no evidence of RV reverse remodeling; TR grade </text>
<text top="632" left="751" width="358" height="17" font="7">unchanged. For 23 pts without 3-4+ TR but with TA dilatation, TR </text>
<text top="650" left="751" width="213" height="17" font="7">grade worse and RV size larger at 2 y. </text>
<text top="667" left="751" width="378" height="17" font="7">2004 cohort: RV reverse remodeling with reduction in TR grade in 43 </text>
<text top="684" left="751" width="299" height="17" font="7">pts with TA dilatation who underwent TV annuloplasty. </text>
<text top="615" left="1149" width="114" height="17" font="7">Limited clinical data. </text>
<text top="632" left="1149" width="160" height="17" font="7">Reason for choice of these 2 </text>
<text top="650" left="1149" width="154" height="17" font="7">observational pt cohorts not </text>
<text top="667" left="1149" width="54" height="17" font="7">provided. </text>
<text top="702" left="42" width="75" height="17" font="7">Yilmaz, 2011 </text>
<text top="719" left="42" width="32" height="17" font="7">(153) </text>
<text top="736" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21277597">21277597</a></text>
<text top="736" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21277597"> </a></text>
<text top="702" left="157" width="142" height="17" font="7">Examine clinical and TTE </text>
<text top="719" left="157" width="115" height="17" font="7">outcomes of pts with </text>
<text top="736" left="157" width="109" height="17" font="7">“clinically silent” TR </text>
<text top="754" left="157" width="159" height="17" font="7">undergoing isolated MVR for </text>
<text top="771" left="157" width="51" height="17" font="7">prolapse </text>
<text top="702" left="332" width="82" height="17" font="7">Retrospective, </text>
<text top="719" left="332" width="115" height="17" font="7">observational, single </text>
<text top="736" left="332" width="106" height="17" font="7">center, 1995–2006 </text>
<text top="702" left="487" width="113" height="17" font="7">n=699 pts with MVP </text>
<text top="719" left="487" width="244" height="17" font="7">Preoperative TR grade was 1-2+ in ≥80% of </text>
<text top="736" left="487" width="23" height="17" font="7">pts. </text>
<text top="754" left="487" width="228" height="17" font="7">Pts with right HF or primary TR excluded. </text>
<text top="702" left="751" width="262" height="17" font="7">Overall TR grade decreased significantly at 1 y. </text>
<text top="719" left="751" width="347" height="17" font="7">Independent risk factors for worsening TR included female sex, </text>
<text top="736" left="751" width="193" height="17" font="7">preoperative AF, diabetes mellitus. </text>
<text top="754" left="751" width="352" height="17" font="7">In pts with &lt;moderate preoperative TR (mean grade, 1.6 [0.49]), </text>
<text top="771" left="751" width="376" height="17" font="7">mean TR grade remained stable and increased only slightly after 5-y </text>
<text top="788" left="751" width="201" height="17" font="7">follow-up (mean, 2.0 [0.86]; p&lt;0.01). </text>
<text top="702" left="1149" width="179" height="17" font="7">TA measurements not provided. </text>
<text top="719" left="1149" width="94" height="17" font="7">All pts had MVP. </text>
<text top="736" left="1149" width="167" height="17" font="7">Other, but not all investigators </text>
<text top="754" left="1149" width="179" height="17" font="7">have reported that the incidence </text>
<text top="771" left="1149" width="136" height="17" font="7">of TR after MVR may be </text>
<text top="788" left="1149" width="159" height="17" font="7">dependent on the etiology of </text>
</page>
<page number="36" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">36 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="57" width="71" height="17" font="6"><b>Study, Year </b></text>
<text top="108" left="198" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="368" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="556" width="113" height="17" font="6"><b>Study Size, Details </b></text>
<text top="108" left="912" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="108" left="1171" width="139" height="17" font="6"><b>Comments, Limitations </b></text>
<text top="127" left="751" width="341" height="17" font="7">In pts with at least moderate preoperative TR, mean TR grade </text>
<text top="144" left="751" width="378" height="17" font="7">decreased significantly from preoperative values after MVR (p&lt;0.001 </text>
<text top="161" left="751" width="382" height="17" font="7">at hospital discharge, &lt;1 y, and 1–3 y). Mean TR grade trended down </text>
<text top="178" left="751" width="334" height="17" font="7">at 3 and 5 y after surgery (p=0.18 after 3 y; p=0.33 after 5 y). </text>
<text top="196" left="751" width="350" height="17" font="7">Degree of preoperative TR was not associated with early or late </text>
<text top="213" left="751" width="57" height="17" font="7">mortality.  </text>
<text top="127" left="1149" width="26" height="17" font="7">MR. </text>
<text top="144" left="1149" width="138" height="17" font="7">Effect of recurrent TR on </text>
<text top="161" left="1149" width="118" height="17" font="7">survival not reported. </text>
<text top="231" left="42" width="87" height="17" font="7">Calafiore, 2011 </text>
<text top="248" left="42" width="32" height="17" font="7">(154) </text>
<text top="265" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21163499">21163499</a></text>
<text top="265" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21163499"> </a></text>
<text top="231" left="157" width="133" height="17" font="7">Determine benefit of TV </text>
<text top="248" left="157" width="147" height="17" font="7">annuloplasty for TR based </text>
<text top="265" left="157" width="87" height="17" font="7">on TA diameter </text>
<text top="231" left="332" width="82" height="17" font="7">Retrospective, </text>
<text top="248" left="332" width="115" height="17" font="7">observational, single </text>
<text top="265" left="332" width="103" height="17" font="7">center 2006–2008 </text>
<text top="231" left="487" width="249" height="17" font="7">298 pts with ≥1+ TR undergoing MV surgery. </text>
<text top="248" left="487" width="249" height="17" font="7">167 underwent TVR, 108 with ≥moderate TR </text>
<text top="265" left="487" width="137" height="17" font="7">and 59 with TA &gt;24 mm. </text>
<text top="282" left="487" width="232" height="17" font="7">137 did not have TVR, 16 with ≥moderate </text>
<text top="300" left="487" width="157" height="17" font="7">TR and 81 with TA &gt;24 mm. </text>
<text top="231" left="751" width="357" height="17" font="7">In pts who did not undergo TVR, TA &gt;24 mm was a risk factor for </text>
<text top="248" left="751" width="352" height="17" font="7">increasing TR grade during follow-up (HR: 2.4; 95% CI: 1.4–5.1; </text>
<text top="265" left="751" width="56" height="17" font="7">p=0.020). </text>
<text top="231" left="1149" width="179" height="17" font="7">DeVega annuloplasty used in all </text>
<text top="248" left="1149" width="116" height="17" font="7">pts with TA &lt;28 mm. </text>
<text top="265" left="1149" width="107" height="17" font="7">Small cohort sizes. </text>
<text top="318" left="42" width="69" height="17" font="7">Navia, 2012 </text>
<text top="335" left="42" width="32" height="17" font="7">(155) </text>
<text top="352" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22093694">22093694</a></text>
<text top="352" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22093694"> </a></text>
<text top="318" left="157" width="145" height="17" font="7">Identify factors associated </text>
<text top="335" left="157" width="158" height="17" font="7">with TVR; assess safety and </text>
<text top="352" left="157" width="87" height="17" font="7">efficacy of TVR </text>
<text top="318" left="332" width="82" height="17" font="7">Retrospective, </text>
<text top="335" left="332" width="115" height="17" font="7">observational, single </text>
<text top="352" left="332" width="139" height="17" font="7">center series 1997–2008 </text>
<text top="318" left="487" width="238" height="17" font="7">91(5%) of 1,724 pts with 2+ TR undergoing </text>
<text top="335" left="487" width="165" height="17" font="7">left-sided heart valve surgery. </text>
<text top="352" left="487" width="204" height="17" font="7">Propensity analysis performed for 91 </text>
<text top="369" left="487" width="87" height="17" font="7">matched pairs.  </text>
<text top="386" left="487" width="246" height="17" font="7">Pts nonrandomly selected for TVR had more </text>
<text top="404" left="487" width="225" height="17" font="7">severe indices of RV remodeling with TV </text>
<text top="421" left="487" width="55" height="17" font="7">tethering. </text>
<text top="318" left="751" width="374" height="17" font="7">In propensity-matched groups, prevalence of early postoperative TR </text>
<text top="335" left="751" width="363" height="17" font="7">grades 0 and 1 was 83% after TVR vs. 46% in the no-repair group </text>
<text top="352" left="751" width="344" height="17" font="7">11% of the repair group had persistent grade 2+ TR after TVR, </text>
<text top="369" left="751" width="237" height="17" font="7">compared with 39% of the no-repair group. </text>
<text top="386" left="751" width="380" height="17" font="7">Worse TR on was present in 7% of the TVR group, vs. 15% of the no-</text>
<text top="404" left="751" width="136" height="17" font="7">repair group (p&lt;0.0001). </text>
<text top="421" left="751" width="372" height="17" font="7">Differences in TR grade for matched pts were sustained at over 3 y. </text>
<text top="438" left="751" width="334" height="17" font="7">TVR did not add significant in-hospital morbidity or mortality.  </text>
<text top="455" left="751" width="323" height="17" font="7">Long-term survival of propensity matched pts did not differ. </text>
<text top="318" left="1149" width="167" height="17" font="7">Multiple TVR techniques used </text>
<text top="335" left="1149" width="173" height="17" font="7">Limited long-term outcome and </text>
<text top="352" left="1149" width="57" height="17" font="7">TTE data. </text>
<text top="369" left="1149" width="125" height="17" font="7">Matched pairs differed </text>
<text top="386" left="1149" width="70" height="17" font="7">significantly. </text>
<text top="473" left="42" width="62" height="17" font="7">Kim, 2012  </text>
<text top="490" left="42" width="32" height="17" font="7">(156) </text>
<text top="508" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21930721">21930721</a></text>
<text top="508" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21930721"> </a></text>
<text top="473" left="157" width="134" height="17" font="7">Assess clinical and TTE </text>
<text top="490" left="157" width="156" height="17" font="7">outcomes of TVR in pts with </text>
<text top="508" left="157" width="156" height="17" font="7">mild-to-moderate TR at time </text>
<text top="525" left="157" width="110" height="17" font="7">of MV replacement  </text>
<text top="473" left="332" width="82" height="17" font="7">Retrospective, </text>
<text top="490" left="332" width="115" height="17" font="7">observational, single </text>
<text top="508" left="332" width="103" height="17" font="7">center, 1997-2008 </text>
<text top="473" left="487" width="236" height="17" font="7">236 pts with mild-moderate TR undergoing </text>
<text top="490" left="487" width="234" height="17" font="7">mechanical MV replacement for rheumatic </text>
<text top="508" left="487" width="49" height="17" font="7">disease. </text>
<text top="525" left="487" width="136" height="17" font="7">123 pts underwent TVR. </text>
<text top="542" left="487" width="164" height="17" font="7">113 pts did not undergo TVR. </text>
<text top="473" left="751" width="377" height="17" font="7">Freedom from moderate-severe TR at 5 y 92.9±2.9% in repair group </text>
<text top="490" left="751" width="255" height="17" font="7">vs. 60.8+/16.9% in nonrepair group (p&lt;0.001). </text>
<text top="508" left="751" width="345" height="17" font="7">Approximately 10% of pts with mild TR who did not have repair </text>
<text top="525" left="751" width="220" height="17" font="7">progressed to ≥moderate TR over 10 y. </text>
<text top="542" left="751" width="376" height="17" font="7">No differences between groups in mortality, need for TV reoperation, </text>
<text top="559" left="751" width="38" height="17" font="7">or HF. </text>
<text top="577" left="751" width="348" height="17" font="7">Postoperative moderate-severe TR an independent predictor of </text>
<text top="594" left="751" width="258" height="17" font="7">poorer event-free survival (HR: 2.90; p=0.038). </text>
<text top="473" left="1149" width="140" height="17" font="7">All pts had rheumatic MV </text>
<text top="490" left="1149" width="49" height="17" font="7">disease. </text>
<text top="508" left="1149" width="178" height="17" font="7">Groups significantly unbalanced </text>
<text top="525" left="1149" width="66" height="17" font="7">at baseline. </text>
<text top="542" left="1149" width="122" height="17" font="7">Limited TTE follow-up </text>
<text top="559" left="1149" width="180" height="17" font="7">information, especially regarding </text>
<text top="577" left="1149" width="151" height="17" font="7">MV prosthesis function, PA </text>
<text top="594" left="1149" width="87" height="17" font="7">pressures, etc.  </text>
<text top="612" left="42" width="94" height="17" font="7">Benedetto 2012  </text>
<text top="629" left="42" width="32" height="17" font="7">(157) </text>
<text top="646" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22244561">22244561</a></text>
<text top="646" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22244561"> </a></text>
<text top="612" left="157" width="161" height="17" font="7">Determine if TV annuloplasty </text>
<text top="629" left="157" width="154" height="17" font="7">in pts with TA dilatation and </text>
<text top="646" left="157" width="154" height="17" font="7">≤moderate TR prevents TR </text>
<text top="663" left="157" width="162" height="17" font="7">progression after MV surgery </text>
<text top="612" left="332" width="76" height="17" font="7">Randomized, </text>
<text top="629" left="332" width="105" height="17" font="7">prospective, single </text>
<text top="646" left="332" width="121" height="17" font="7">institution, 2008-2009<b> </b></text>
<text top="612" left="487" width="239" height="17" font="7">44 pts undergoing MV surgery with ≤2+ TR </text>
<text top="629" left="487" width="211" height="17" font="7">and TA ≥40 mm on preoperative TTE. </text>
<text top="646" left="487" width="234" height="17" font="7">Randomized 1:1 to TV annuloplasty with a </text>
<text top="663" left="487" width="192" height="17" font="7">flexible ring or no TV annuloplasty. </text>
<text top="681" left="487" width="182" height="17" font="7">Primary endpoint: ≥3+ TR at 1 y. </text>
<text top="612" left="751" width="317" height="17" font="7">≥3+ TR at 1 y 0% in TV annuloplasty group vs. 28% in no </text>
<text top="629" left="751" width="160" height="17" font="7">annuloplasty group (p=0.02). </text>
<text top="646" left="751" width="330" height="17" font="7">Compared with no annuloplasty, TV annuloplasty resulted in </text>
<text top="663" left="751" width="191" height="17" font="7">significant RV reverse remodeling. </text>
<text top="681" left="751" width="377" height="17" font="7">Distance during 6-min walk test greater in the TV annuloplasty group </text>
<text top="698" left="751" width="60" height="17" font="7">(p=0.008). </text>
<text top="612" left="1149" width="106" height="17" font="7">Small sample size. </text>
<text top="629" left="1149" width="116" height="17" font="7">Nonblinded endpoint </text>
<text top="646" left="1149" width="73" height="17" font="7">assessment. </text>
<text top="716" left="34" width="1255" height="17" font="7">AF indicates atrial fibrillation; echo, echocardiography; HF, heart failure; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; MV, mitral valve; MVP, mitral valve prolapse; MVR, mitral valve repair; NYHA, New York Heart </text>
<text top="733" left="34" width="1141" height="17" font="7">Association; PA, pulmonary artery; pt(s), patients; RV, right ventricle; TA, tricuspid annulus; TR, tricuspid regurgitation; TTE, transthoracic echocardiography TV, tricuspid valve; and, TVR, tricuspid valve repair.  </text>
<text top="750" left="108" width="3" height="17" font="7"> </text>
<text top="750" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="37" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">37 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="695" height="21" font="4"><b>Data Supplement 20. Clinical Outcomes With Bioprosthetic and Mechanical Valves (Section 11.1.2) </b></text>
<text top="129" left="63" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="129" left="196" width="69" height="17" font="6"><b>Study Size  </b></text>
<text top="129" left="318" width="57" height="17" font="6"><b>Methods  </b></text>
<text top="129" left="517" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="146" left="571" width="3" height="17" font="6"><b> </b></text>
<text top="129" left="767" width="63" height="17" font="6"><b>Follow-Up </b></text>
<text top="129" left="996" width="67" height="17" font="6"><b>Outcomes  </b></text>
<text top="129" left="1224" width="107" height="17" font="6"><b>Study Limitations </b></text>
<text top="164" left="42" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="174" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="296" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="446" width="104" height="17" font="6"><b>Inclusion Criteria </b></text>
<text top="164" left="616" width="108" height="17" font="6"><b>Exclusion Criteria </b></text>
<text top="164" left="797" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="164" left="1026" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="164" left="1210" width="3" height="17" font="6"><b> </b></text>
<text top="182" left="42" width="91" height="17" font="7">Hammermeister </text>
<text top="200" left="42" width="31" height="17" font="7">2000 </text>
<text top="217" left="42" width="32" height="17" font="7">(158) </text>
<text top="234" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11028464">11028464</a></text>
<text top="234" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11028464"> </a></text>
<text top="182" left="174" width="109" height="17" font="7">575 pts undergoing </text>
<text top="200" left="174" width="106" height="17" font="7">isolated AVR (394) </text>
<text top="217" left="174" width="108" height="17" font="7">or MVR (181) at 13 </text>
<text top="234" left="174" width="65" height="17" font="7">VA medical </text>
<text top="251" left="174" width="82" height="17" font="7">centers (1977–</text>
<text top="268" left="174" width="35" height="17" font="7">1982) </text>
<text top="182" left="296" width="32" height="17" font="7">RCT  </text>
<text top="182" left="407" width="124" height="17" font="7">Isolated AVR or MVR. </text>
<text top="200" left="407" width="175" height="17" font="7">Concurrent CABG performed in </text>
<text top="217" left="407" width="167" height="17" font="7">39% of AVR and 36% of MVR </text>
<text top="234" left="407" width="23" height="17" font="7">pts. </text>
<text top="182" left="602" width="49" height="17" font="7">Women, </text>
<text top="200" left="602" width="109" height="17" font="7">contraindications to </text>
<text top="217" left="602" width="117" height="17" font="7">VKA anticoagulation, </text>
<text top="234" left="602" width="87" height="17" font="7">requirement for </text>
<text top="251" left="602" width="111" height="17" font="7">antiplatelet therapy, </text>
<text top="270" left="602" width="57" height="17" font="7">valve size </text>
<text top="269" left="659" width="8" height="18" font="10"></text>
<text top="270" left="668" width="70" height="17" font="7">19 mm AVR </text>
<text top="288" left="602" width="14" height="17" font="7">or </text>
<text top="287" left="617" width="8" height="18" font="10"></text>
<text top="288" left="625" width="110" height="17" font="7">25 mm MVR, active </text>
<text top="305" left="602" width="73" height="17" font="7">endocarditis. </text>
<text top="182" left="751" width="30" height="17" font="7">15 y  </text>
<text top="182" left="859" width="333" height="17" font="7">AVR, all-cause mortality at 15 y was lower for MHV vs. BHV: </text>
<text top="200" left="859" width="318" height="17" font="7">(66±3% [mean±SE] vs. 79±3%; p=0.02) No difference for </text>
<text top="217" left="859" width="34" height="17" font="7">MVR. </text>
<text top="234" left="859" width="3" height="17" font="7"> </text>
<text top="251" left="859" width="333" height="17" font="7">Primary valve failure was significantly greater with a BHV vs. </text>
<text top="268" left="859" width="329" height="17" font="7">MHV valve, both for AVR (23±5% vs. 0±0%; p=0.0001) and </text>
<text top="286" left="859" width="314" height="17" font="7">MVR (44±8% vs. 5±4%; p=0.0002). Primary valve failure </text>
<text top="303" left="859" width="242" height="17" font="7">nearly always (93%) occurred in pts &lt;65 y.   </text>
<text top="320" left="859" width="3" height="17" font="7"> </text>
<text top="337" left="859" width="330" height="17" font="7">AVR reoperation was higher after BHV vs. MHV (29±5% vs. </text>
<text top="354" left="859" width="317" height="17" font="7">10±3%; p=0.004). No statistically significant difference for </text>
<text top="372" left="859" width="38" height="17" font="7">MVR.  </text>
<text top="182" left="1210" width="74" height="17" font="7">Pts receiving </text>
<text top="200" left="1210" width="126" height="17" font="7">mechanical MVR were </text>
<text top="217" left="1210" width="110" height="17" font="7">older and had more </text>
<text top="234" left="1210" width="135" height="17" font="7">hypertension than those </text>
<text top="251" left="1210" width="109" height="17" font="7">with a bioprosthetic </text>
<text top="268" left="1210" width="34" height="17" font="7">MVR. </text>
<text top="390" left="42" width="91" height="17" font="7">Oxenham, 2003 </text>
<text top="407" left="42" width="32" height="17" font="7">(159) </text>
<text top="424" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12807838">12807838</a></text>
<text top="424" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12807838"> </a></text>
<text top="390" left="174" width="109" height="17" font="7">541 pts undergoing </text>
<text top="407" left="174" width="95" height="17" font="7">MVR (261), AVR </text>
<text top="424" left="174" width="103" height="17" font="7">(211), or both (61) </text>
<text top="441" left="174" width="65" height="17" font="7">1975–1979 </text>
<text top="390" left="296" width="29" height="17" font="7">RCT </text>
<text top="390" left="407" width="134" height="17" font="7">Mean age 53.9 (10.6) y. </text>
<text top="407" left="407" width="72" height="17" font="7">56% female. </text>
<text top="390" left="602" width="89" height="17" font="7">Additional valve </text>
<text top="407" left="602" width="100" height="17" font="7">procedures or not </text>
<text top="424" left="602" width="87" height="17" font="7">eligible for VKA </text>
<text top="441" left="602" width="90" height="17" font="7">anticoagulation. </text>
<text top="390" left="751" width="27" height="17" font="7">20 y </text>
<text top="390" left="859" width="310" height="17" font="7">No difference in overall survival (Bjork-Shiley vs. porcine </text>
<text top="407" left="859" width="318" height="17" font="7">prosthesis [mean (SEM]): 25.0 (2.7)% vs<i>.</i> 22.6 (2.7)%, log </text>
<text top="424" left="859" width="95" height="17" font="7">rank test p=0.39. </text>
<text top="441" left="859" width="3" height="17" font="7"> </text>
<text top="458" left="859" width="312" height="17" font="7">Combined endpoint of death and reoperation occurred in </text>
<text top="476" left="859" width="338" height="17" font="7">23.5 (2.6)% with BHV <i> </i>vs. 6.7 (1.6)% with MHV (log rank test; </text>
<text top="493" left="859" width="66" height="17" font="7">p&lt;0.0001).  </text>
<text top="510" left="859" width="3" height="17" font="7"> </text>
<text top="527" left="859" width="312" height="17" font="7">Major bleeding was more common in pts with MHV (40.7 </text>
<text top="544" left="859" width="337" height="17" font="7">[5.4]% vs. 27.9 [8.4]% after 20 y; p=0.008), with no significant </text>
<text top="562" left="859" width="248" height="17" font="7">difference in major embolism or endocarditis. </text>
<text top="390" left="1210" width="127" height="17" font="7">Older generation valve </text>
<text top="407" left="1210" width="40" height="17" font="7">types.  </text>
<text top="580" left="42" width="85" height="17" font="7">Stassano 2009 </text>
<text top="597" left="42" width="32" height="17" font="7">(160) </text>
<text top="614" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19892237">19892237</a></text>
<text top="614" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19892237"> </a></text>
<text top="580" left="174" width="109" height="17" font="7">310 pts undergoing </text>
<text top="597" left="174" width="29" height="17" font="7">AVR </text>
<text top="614" left="174" width="65" height="17" font="7">1995–2003 </text>
<text top="580" left="296" width="29" height="17" font="7">RCT </text>
<text top="580" left="407" width="73" height="17" font="7">Age 55–70 y </text>
<text top="580" left="602" width="118" height="17" font="7">Other valve surgery.  </text>
<text top="597" left="602" width="134" height="17" font="7">Contraindication to VKA </text>
<text top="614" left="602" width="86" height="17" font="7">anticoagulation </text>
<text top="580" left="751" width="80" height="17" font="7">Mean 106±28 </text>
<text top="597" left="751" width="21" height="17" font="7">mo </text>
<text top="580" left="859" width="295" height="17" font="7">No survival difference at 13 y between BHV and MHV </text>
<text top="597" left="859" width="44" height="17" font="7">groups. </text>
<text top="614" left="859" width="3" height="17" font="7"> </text>
<text top="631" left="859" width="316" height="17" font="7">Valve failures and reoperations were more frequent in the </text>
<text top="649" left="859" width="316" height="17" font="7">BHV group compared with the MHV group (p=0.0001 and </text>
<text top="666" left="859" width="138" height="17" font="7">p=0.0003, respectively).  </text>
<text top="683" left="859" width="3" height="17" font="7"> </text>
<text top="700" left="859" width="315" height="17" font="7">No differences in the linearized rate of thromboembolism, </text>
<text top="718" left="859" width="314" height="17" font="7">bleeding, endocarditis, and MAPE between the MHV and </text>
<text top="735" left="859" width="105" height="17" font="7">BHV valve groups. </text>
<text top="580" left="1210" width="102" height="17" font="7">Power may not be </text>
<text top="597" left="1210" width="116" height="17" font="7">adequate to detect a </text>
<text top="614" left="1210" width="113" height="17" font="7">clinically meaningful </text>
<text top="631" left="1210" width="109" height="17" font="7">difference at longer </text>
<text top="649" left="1210" width="56" height="17" font="7">follow-up. </text>
<text top="753" left="42" width="63" height="17" font="7">Khan 2001 </text>
<text top="770" left="42" width="32" height="17" font="7">(161) </text>
<text top="787" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11479498">11479498</a></text>
<text top="787" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11479498"> </a></text>
<text top="753" left="174" width="104" height="17" font="7">Initial AVR in 1389 </text>
<text top="770" left="174" width="91" height="17" font="7">pts, MVR in 915 </text>
<text top="787" left="174" width="102" height="17" font="7">pts, 1976–2001 at </text>
<text top="753" left="296" width="82" height="17" font="7">Retrospective, </text>
<text top="770" left="296" width="77" height="17" font="7">observational </text>
<text top="753" left="407" width="143" height="17" font="7">Age 64.5±12.9 y for MHV </text>
<text top="770" left="407" width="141" height="17" font="7">Age 72.0±12.6 y for BHV </text>
<text top="753" left="602" width="127" height="17" font="7">Homografts, combined </text>
<text top="770" left="602" width="83" height="17" font="7">MHV and BHV </text>
<text top="787" left="602" width="135" height="17" font="7">procedure, any previous </text>
<text top="753" left="751" width="27" height="17" font="7">20 y </text>
<text top="753" left="859" width="329" height="17" font="7">Freedom from reoperation at 15 y for AVR was 67±4.8% for </text>
<text top="770" left="859" width="290" height="17" font="7">BHV and 99±0.5% for MVH. For MVR, freedom from </text>
<text top="787" left="859" width="327" height="17" font="7">reoperation was 52±5.7% for BHV and 93±3.2% for MHV.   </text>
<text top="753" left="1210" width="113" height="17" font="7">Not prospective, not </text>
<text top="770" left="1210" width="75" height="17" font="7">randomized.  </text>
<text top="787" left="1210" width="115" height="17" font="7">Concurrent CABG in </text>
</page>
<page number="38" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">38 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="63" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="108" left="196" width="69" height="17" font="6"><b>Study Size  </b></text>
<text top="108" left="318" width="57" height="17" font="6"><b>Methods  </b></text>
<text top="108" left="517" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="126" left="571" width="3" height="17" font="6"><b> </b></text>
<text top="108" left="767" width="63" height="17" font="6"><b>Follow-Up </b></text>
<text top="108" left="996" width="67" height="17" font="6"><b>Outcomes  </b></text>
<text top="108" left="1224" width="107" height="17" font="6"><b>Study Limitations </b></text>
<text top="144" left="42" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="174" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="296" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="446" width="104" height="17" font="6"><b>Inclusion Criteria </b></text>
<text top="144" left="616" width="108" height="17" font="6"><b>Exclusion Criteria </b></text>
<text top="144" left="797" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="144" left="1026" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="144" left="1210" width="3" height="17" font="6"><b> </b></text>
<text top="162" left="174" width="91" height="17" font="7">a single medical </text>
<text top="179" left="174" width="41" height="17" font="7">center. </text>
<text top="162" left="602" width="76" height="17" font="7">valve surgery </text>
<text top="162" left="859" width="3" height="17" font="7"> </text>
<text top="179" left="859" width="253" height="17" font="7">Survival at 15 y (BHV vs. MHV, p=NS for all):  </text>
<text top="196" left="859" width="317" height="17" font="7">AVR in pts &lt;65 y (55±5.9 vs. 61±5.3%), AVR in pts &gt;65 y </text>
<text top="213" left="859" width="130" height="17" font="7">(17±3.4 vs. 17±3.8%).  </text>
<text top="230" left="859" width="321" height="17" font="7">MVR in pts &lt;65 y (32±5.5 vs. 51±5.4%), MVR in pts &gt;65 y </text>
<text top="248" left="859" width="123" height="17" font="7">(12±3.5 vs. 18±3.8%) </text>
<text top="162" left="1210" width="35" height="17" font="7">50%.  </text>
<text top="266" left="42" width="64" height="17" font="7">Chan 2006 </text>
<text top="283" left="42" width="32" height="17" font="7">(162) </text>
<text top="300" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16733156">16733156</a></text>
<text top="300" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16733156"> </a></text>
<text top="266" left="174" width="54" height="17" font="7">3,063 pts </text>
<text top="283" left="174" width="93" height="17" font="7">undergoing AVR </text>
<text top="300" left="174" width="65" height="17" font="7">1982–1998 </text>
<text top="266" left="296" width="82" height="17" font="7">Retrospective, </text>
<text top="283" left="296" width="77" height="17" font="7">observational </text>
<text top="266" left="407" width="148" height="17" font="7">2,195 BHV and 980 MHV.  </text>
<text top="266" left="602" width="94" height="17" font="7">Previous cardiac </text>
<text top="283" left="602" width="44" height="17" font="7">surgery </text>
<text top="266" left="751" width="85" height="17" font="7">Average follow-</text>
<text top="283" left="751" width="84" height="17" font="7">ups in y for the </text>
<text top="300" left="751" width="83" height="17" font="7">BHV and MHV </text>
<text top="317" left="751" width="71" height="17" font="7">groups were </text>
<text top="335" left="751" width="81" height="17" font="7">7.5±4.7% and </text>
<text top="352" left="751" width="57" height="17" font="7">5.9±3.3% </text>
<text top="369" left="751" width="60" height="17" font="11"><i>(</i>p&lt;0.001), </text>
<text top="386" left="751" width="68" height="17" font="7">respectively </text>
<text top="266" left="859" width="324" height="17" font="7">Valve-related mortality (per pt-y): BHV 1.0% vs. MHV 0.7% </text>
<text top="283" left="859" width="3" height="17" font="7"> </text>
<text top="300" left="859" width="308" height="17" font="7">Valve-related reoperation (per pt-y): BHV 1.3% vs. MHV </text>
<text top="317" left="859" width="88" height="17" font="7">0.3% (p&lt;0.001) </text>
<text top="335" left="859" width="3" height="17" font="7"> </text>
<text top="352" left="859" width="331" height="17" font="7">Valve-related morbidity: BHV 0.4% vs. MHV 2.1% (p&lt;0.001) </text>
<text top="369" left="859" width="3" height="17" font="7"> </text>
<text top="386" left="859" width="329" height="17" font="7">Actual freedom from valve-related reoperation favored MHV </text>
<text top="403" left="859" width="316" height="17" font="7">for pts &lt;60 y. Actual freedom from valve-related morbidity </text>
<text top="421" left="859" width="336" height="17" font="7">favored BHV for pts &gt;40 y. Actual freedom from valve-related </text>
<text top="438" left="859" width="248" height="17" font="7">mortality was similar for BHV vs. MHV &gt;50 y. </text>
<text top="266" left="1210" width="94" height="17" font="7">Not randomized. </text>
<text top="283" left="1210" width="58" height="17" font="7">AVR only. </text>
<text top="300" left="1210" width="124" height="17" font="7">Concomitant CABG in </text>
<text top="317" left="1210" width="124" height="17" font="7">43.5% of BHV pts and </text>
<text top="335" left="1210" width="106" height="17" font="7">26.0% of MHV pts. </text>
<text top="456" left="42" width="61" height="17" font="7">Kulik 2006 </text>
<text top="473" left="42" width="32" height="17" font="7">(163) </text>
<text top="490" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16857373">16857373</a></text>
<text top="490" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16857373"> </a></text>
<text top="456" left="174" width="105" height="17" font="7">659 pts age 50–65 </text>
<text top="473" left="174" width="95" height="17" font="7">y with initial AVR </text>
<text top="490" left="174" width="52" height="17" font="7">or MVR   </text>
<text top="456" left="296" width="71" height="17" font="7">Prospective, </text>
<text top="473" left="296" width="77" height="17" font="7">observational </text>
<text top="456" left="407" width="181" height="17" font="7">AVR in 388 (MHV 306, BHV 48). </text>
<text top="473" left="407" width="158" height="17" font="7">MVR in 236 (MHV 188, BHV </text>
<text top="490" left="407" width="25" height="17" font="7">48). </text>
<text top="456" left="602" width="133" height="17" font="7">Enrolled only if survived </text>
<text top="473" left="602" width="119" height="17" font="7">perioperative period.  </text>
<text top="490" left="602" width="129" height="17" font="7">Valve repair excluded.  </text>
<text top="456" left="751" width="93" height="17" font="7">Mean 5.1±4.1 y; </text>
<text top="473" left="751" width="94" height="17" font="7">maximum 18.3 y </text>
<text top="456" left="859" width="327" height="17" font="7">Freedom from primary endpoint MAPE at 10 y (reoperation, </text>
<text top="473" left="859" width="284" height="17" font="7">endocarditis, major bleeding, or thromboembolism): </text>
<text top="490" left="859" width="284" height="17" font="7">AVR MHV 70±4.1% vs. BHV 41.0±30.3% (p=0.55)  </text>
<text top="507" left="859" width="286" height="17" font="7">MVR MHV 53.3±8.8% vs. BHV 61.2±9.2% (p=0.34) </text>
<text top="525" left="859" width="289" height="17" font="7">Multivariate analysis did not identify valve type as an </text>
<text top="542" left="859" width="184" height="17" font="7">independent risk factor for MAPE </text>
<text top="456" left="1210" width="94" height="17" font="7">Not randomized. </text>
<text top="473" left="1210" width="135" height="17" font="7">Surgeon choice of valve </text>
<text top="490" left="1210" width="33" height="17" font="7">type.  </text>
<text top="507" left="1210" width="115" height="17" font="7">Concurrent CABG in </text>
<text top="525" left="1210" width="31" height="17" font="7">29%. </text>
<text top="560" left="42" width="60" height="17" font="7">Ruel 2007 </text>
<text top="577" left="42" width="32" height="17" font="7">(164) </text>
<text top="594" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17846320">17846320</a></text>
<text top="594" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17846320"> </a></text>
<text top="560" left="174" width="109" height="17" font="7">567 pts undergoing </text>
<text top="577" left="174" width="74" height="17" font="7">AVR or MVR </text>
<text top="560" left="296" width="82" height="17" font="7">Retrospective, </text>
<text top="577" left="296" width="77" height="17" font="7">observational </text>
<text top="560" left="407" width="63" height="17" font="7">Age &lt;60 y. </text>
<text top="577" left="407" width="152" height="17" font="7">First heart valve operation.  </text>
<text top="560" left="602" width="24" height="17" font="7">N/A </text>
<text top="560" left="751" width="81" height="17" font="7">Mean survivor </text>
<text top="577" left="751" width="56" height="17" font="7">follow-up, </text>
<text top="594" left="751" width="62" height="17" font="7">24.0±3.1 y </text>
<text top="560" left="859" width="295" height="17" font="7">Survival in AVR: no difference between BHV vs. MHV </text>
<text top="577" left="859" width="159" height="17" font="7">(HR:0.95, 95% CI: 0.7–1.3);  </text>
<text top="594" left="859" width="321" height="17" font="7">Survival in MVR: no difference between BHV or MHV (HR: </text>
<text top="611" left="859" width="130" height="17" font="7">0.9, 95% CI: 0.5–1.4);   </text>
<text top="629" left="859" width="321" height="17" font="7">Long-term survival worse in MVR than AVR (HR: 1.4, 95% </text>
<text top="646" left="859" width="71" height="17" font="7">CI: 1.1–1.8); </text>
<text top="663" left="859" width="307" height="17" font="7">Reoperation in 89% of BHV AVR and 84% of BHV MVR </text>
<text top="680" left="859" width="321" height="17" font="7">(older generation devices) with reoperative mortality 4.3%. </text>
<text top="560" left="1210" width="104" height="17" font="7">Not randomized or </text>
<text top="577" left="1210" width="122" height="17" font="7">prospective, follow-up </text>
<text top="594" left="1210" width="133" height="17" font="7">available in only 23% of </text>
<text top="611" left="1210" width="84" height="17" font="7">original cohort. </text>
<text top="698" left="42" width="101" height="17" font="7">van Geldorp 2009 </text>
<text top="716" left="42" width="32" height="17" font="7">(165) </text>
<text top="733" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19327512">19327512</a></text>
<text top="733" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19327512"> </a></text>
<text top="698" left="174" width="74" height="17" font="7">Bioprosthetic </text>
<text top="716" left="174" width="103" height="17" font="7">AVR=2,860 (73%) </text>
<text top="733" left="174" width="85" height="17" font="7">vs. mechanical </text>
<text top="750" left="174" width="103" height="17" font="7">AVR=1,074 (27%) </text>
<text top="698" left="296" width="78" height="17" font="7">Retrospective </text>
<text top="716" left="296" width="76" height="17" font="7">cohort (1982–</text>
<text top="733" left="296" width="35" height="17" font="7">2003) </text>
<text top="750" left="296" width="89" height="17" font="7">Microsimulation </text>
<text top="767" left="296" width="96" height="17" font="7">used to calculate </text>
<text top="784" left="296" width="83" height="17" font="7">age-specific pt </text>
<text top="698" left="407" width="141" height="17" font="7">Bioprosthetic AVR: mean </text>
<text top="716" left="407" width="182" height="17" font="7">age=70 y, mean follow-up=6.1 y, </text>
<text top="733" left="407" width="93" height="17" font="7">CABG=47% vs.  </text>
<text top="750" left="407" width="177" height="17" font="7">Mechanical AVR: mean age=58 </text>
<text top="767" left="407" width="137" height="17" font="7">y, mean follow-up=8.5 y, </text>
<text top="784" left="407" width="73" height="17" font="7">CABG=28%  </text>
<text top="698" left="602" width="24" height="17" font="7">N/A </text>
<text top="698" left="751" width="74" height="17" font="7">Bioprosthetic </text>
<text top="716" left="751" width="66" height="17" font="7">AVR: mean </text>
<text top="733" left="751" width="90" height="17" font="7">follow-up=6.1 y. </text>
<text top="750" left="751" width="65" height="17" font="7">Mechanical </text>
<text top="767" left="751" width="66" height="17" font="7">AVR: mean </text>
<text top="784" left="751" width="90" height="17" font="7">follow-up=8.5 y. </text>
<text top="698" left="859" width="325" height="17" font="7">Simulated events for a 60-y man undergoing AVR, favors a </text>
<text top="716" left="859" width="64" height="17" font="7">BP vs. MP: </text>
<text top="733" left="886" width="7" height="18" font="10"></text>
<text top="737" left="892" width="4" height="14" font="7"> </text>
<text top="734" left="913" width="176" height="17" font="7">life-expectancy: 11.9 vs. 12.2 y, </text>
<text top="751" left="886" width="7" height="18" font="10"></text>
<text top="755" left="892" width="4" height="14" font="7"> </text>
<text top="752" left="913" width="181" height="17" font="7">event-free survival: 9.8 vs. 9.3 y, </text>
<text top="769" left="886" width="7" height="18" font="10"></text>
<text top="773" left="892" width="4" height="14" font="7"> </text>
<text top="770" left="913" width="181" height="17" font="7">reoperation-free: 10.5 vs. 11.9 y, </text>
<text top="788" left="886" width="7" height="18" font="10"></text>
<text top="792" left="892" width="4" height="14" font="7"> </text>
<text top="789" left="913" width="163" height="17" font="7">reoperation risk: 25% vs. 3%, </text>
<text top="698" left="1210" width="87" height="17" font="7">Methodology of </text>
<text top="716" left="1210" width="101" height="17" font="7">microsimulation is </text>
<text top="733" left="1210" width="131" height="17" font="7">dependent on quality of </text>
<text top="750" left="1210" width="76" height="17" font="7">dataset, wide </text>
<text top="767" left="1210" width="113" height="17" font="7">chronological age of </text>
<text top="784" left="1210" width="67" height="17" font="7">prostheses. </text>
</page>
<page number="39" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">39 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="63" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="108" left="196" width="69" height="17" font="6"><b>Study Size  </b></text>
<text top="108" left="318" width="57" height="17" font="6"><b>Methods  </b></text>
<text top="108" left="517" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="126" left="571" width="3" height="17" font="6"><b> </b></text>
<text top="108" left="767" width="63" height="17" font="6"><b>Follow-Up </b></text>
<text top="108" left="996" width="67" height="17" font="6"><b>Outcomes  </b></text>
<text top="108" left="1224" width="107" height="17" font="6"><b>Study Limitations </b></text>
<text top="144" left="42" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="174" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="296" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="446" width="104" height="17" font="6"><b>Inclusion Criteria </b></text>
<text top="144" left="616" width="108" height="17" font="6"><b>Exclusion Criteria </b></text>
<text top="144" left="797" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="144" left="1026" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="144" left="1210" width="3" height="17" font="6"><b> </b></text>
<text top="162" left="296" width="79" height="17" font="7">outcome after </text>
<text top="179" left="296" width="32" height="17" font="7">AVR  </text>
<text top="162" left="886" width="7" height="18" font="10"></text>
<text top="166" left="892" width="4" height="14" font="7"> </text>
<text top="163" left="913" width="165" height="17" font="7">risk of bleeding: 12% vs. 41% </text>
<text top="197" left="42" width="83" height="17" font="7">Badhwar 2012 </text>
<text top="214" left="42" width="32" height="17" font="7">(166) </text>
<text top="231" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22364968">22364968</a></text>
<text top="231" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22364968"> </a></text>
<text top="197" left="174" width="109" height="17" font="7">172 pts undergoing </text>
<text top="214" left="174" width="89" height="17" font="7">isolated AVR or </text>
<text top="231" left="174" width="104" height="17" font="7">MVR (2003–2007) </text>
<text top="197" left="296" width="71" height="17" font="7">Prospective, </text>
<text top="214" left="296" width="92" height="17" font="7">nonrandomized, </text>
<text top="231" left="296" width="98" height="17" font="7">matched pairs for </text>
<text top="248" left="296" width="61" height="17" font="7">BP vs. MP </text>
<text top="197" left="407" width="163" height="17" font="7">Mean age 56.2±9.6 y (range, </text>
<text top="214" left="407" width="55" height="17" font="7">24–72 y). </text>
<text top="197" left="602" width="108" height="17" font="7">Limited 5 y survival </text>
<text top="214" left="602" width="120" height="17" font="7">based on comorbidity </text>
<text top="231" left="602" width="3" height="17" font="7"> </text>
<text top="197" left="751" width="79" height="17" font="7">Median follow-</text>
<text top="214" left="751" width="47" height="17" font="7">up 4.0 y </text>
<text top="197" left="859" width="328" height="17" font="7">At a median 4-y follow-up, thromboembolism was 0.77% for </text>
<text top="214" left="859" width="165" height="17" font="7">MP and 0.78% for BP (p=NS) </text>
<text top="231" left="859" width="3" height="17" font="7"> </text>
<text top="248" left="859" width="333" height="17" font="7">There was a survival benefit of mechanical prostheses at 7.5 </text>
<text top="266" left="859" width="296" height="17" font="7">y. Noninferiority to bioprosthetic AVR for bleeding and </text>
<text top="283" left="859" width="176" height="17" font="7">thromboembolic complications.  </text>
<text top="197" left="1210" width="116" height="17" font="7">Prosthesis choice by </text>
<text top="214" left="1210" width="72" height="17" font="7">surgeon, not </text>
<text top="231" left="1210" width="71" height="17" font="7">randomized. </text>
<text top="248" left="1210" width="128" height="17" font="7">Low INR targets (AVR: </text>
<text top="266" left="1210" width="108" height="17" font="7">2.0, MVR: 2.5) with </text>
<text top="283" left="1210" width="126" height="17" font="7">home monitoring point-</text>
<text top="300" left="1210" width="84" height="17" font="7">of-care system </text>
<text top="318" left="42" width="70" height="17" font="7">Weber 2012 </text>
<text top="335" left="42" width="32" height="17" font="7">(167) </text>
<text top="353" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22341653">22341653</a></text>
<text top="353" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22341653"> </a></text>
<text top="318" left="174" width="109" height="17" font="7">206 pts undergoing </text>
<text top="335" left="174" width="102" height="17" font="7">AVR (2000–2009) </text>
<text top="318" left="296" width="82" height="17" font="7">Retrospective, </text>
<text top="335" left="296" width="85" height="17" font="7">with propensity </text>
<text top="353" left="296" width="91" height="17" font="7">matching of 103 </text>
<text top="370" left="296" width="79" height="17" font="7">BP to 103 MP </text>
<text top="387" left="296" width="29" height="17" font="7">AVR </text>
<text top="318" left="407" width="63" height="17" font="7">Age &lt;60 y. </text>
<text top="335" left="407" width="172" height="17" font="7">AVR with or without concurrent </text>
<text top="353" left="407" width="181" height="17" font="7">CABG, aortic root surgery, mitral </text>
<text top="370" left="407" width="134" height="17" font="7">or tricuspid valve repair. </text>
<text top="318" left="602" width="89" height="17" font="7">Additional valve </text>
<text top="335" left="602" width="75" height="17" font="7">replacement. </text>
<text top="318" left="751" width="79" height="17" font="7">Median follow-</text>
<text top="335" left="751" width="77" height="17" font="7">up 33±24 mo </text>
<text top="353" left="751" width="66" height="17" font="7">(2–120 mo) </text>
<text top="318" left="859" width="313" height="17" font="7">Overall survival was worse with BP (90.3% vs. MP=98%, </text>
<text top="335" left="859" width="186" height="17" font="7">p=0.038; HR:0.243, 0.054–0.923  </text>
<text top="353" left="859" width="3" height="17" font="7"> </text>
<text top="370" left="859" width="328" height="17" font="7">Freedom from valve related complication complications was </text>
<text top="387" left="859" width="225" height="17" font="7">similar: BP=54.5% vs. MP=51.6%, p=NS </text>
<text top="318" left="1210" width="115" height="17" font="7">Concurrent CABG in </text>
<text top="335" left="1210" width="100" height="17" font="7">49.9%, 14% were </text>
<text top="353" left="1210" width="72" height="17" font="7">reoperations </text>
<text top="405" left="34" width="1296" height="17" font="7">AVR indicates aortic valve replacement; BHV, bioprosthetic heart valve; CABG, coronary artery bypass graft; HTN, hypertension; INR, international normalized ratio; MAPE, major adverse prosthesis-related events; MHV, mechanical heart </text>
<text top="422" left="34" width="984" height="17" font="7">valve; MVR,  mitral valve replacement; N/A, not applicable; NS, nonsignificant; RCT, randomized controlled trial; pts, patients; VA, Veterans Affairs; and, VKA, vitamin K antagonist.  </text>
<text top="440" left="108" width="3" height="17" font="7"> </text>
<text top="440" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="40" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">40 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="704" height="21" font="4"><b>Data Supplement 21. Bridging Anticoagulation Therapy for Mechanical Heart Valves (Section 11.3.2) </b></text>
<text top="129" left="51" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="129" left="159" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="334" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="146" left="388" width="3" height="17" font="6"><b> </b></text>
<text top="129" left="551" width="184" height="17" font="6"><b>Study Size and Comparator (N) </b></text>
<text top="129" left="893" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="129" left="1162" width="107" height="17" font="6"><b>Study Limitations </b></text>
<text top="164" left="88" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="192" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="277" width="104" height="17" font="6"><b>Inclusion Criteria </b></text>
<text top="164" left="420" width="108" height="17" font="6"><b>Exclusion Criteria </b></text>
<text top="164" left="641" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="923" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="164" left="1214" width="3" height="17" font="6"><b> </b></text>
<text top="182" left="42" width="79" height="17" font="7">Hammerstingl </text>
<text top="200" left="42" width="31" height="17" font="7">2007 </text>
<text top="217" left="42" width="32" height="17" font="7">(168) </text>
<text top="234" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17578050">17578050</a></text>
<text top="234" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17578050"> </a></text>
<text top="182" left="150" width="71" height="17" font="7">Prospective, </text>
<text top="200" left="150" width="77" height="17" font="7">observational </text>
<text top="182" left="251" width="142" height="17" font="7">Pts with MHV undergoing </text>
<text top="200" left="251" width="132" height="17" font="7">major surgery (n=25) or </text>
<text top="217" left="251" width="156" height="17" font="7">minor surgery (n=36), pacer </text>
<text top="234" left="251" width="127" height="17" font="7">implantation (n=21), or </text>
<text top="251" left="251" width="112" height="17" font="7">cardiac cath (n=34)  </text>
<text top="182" left="420" width="24" height="17" font="7">N/A </text>
<text top="182" left="541" width="47" height="17" font="7">116 pts: </text>
<text top="200" left="541" width="62" height="17" font="7">MVR 31) ,  </text>
<text top="217" left="541" width="72" height="17" font="7">AVR (76) or  </text>
<text top="234" left="541" width="48" height="17" font="7">DVR (9) </text>
<text top="251" left="541" width="3" height="17" font="7"> </text>
<text top="268" left="541" width="201" height="17" font="7">Bridging with enoxaparin in all (renal </text>
<text top="286" left="541" width="131" height="17" font="7">function dose adjusted) </text>
<text top="182" left="757" width="292" height="17" font="7">No thromboembolic (95% CI: 0–3.1%) complications. </text>
<text top="200" left="757" width="3" height="17" font="7"> </text>
<text top="217" left="757" width="329" height="17" font="7">1 major bleeding complication (0.86%; 95% CI: 0.02–4.7%). </text>
<text top="234" left="757" width="3" height="17" font="7"> </text>
<text top="251" left="757" width="310" height="17" font="7">Minor bleeding in 10 pts (8.6%; 95% CI: 4.2–15.3%) at a </text>
<text top="268" left="757" width="193" height="17" font="7">mean of 5.4±1.4 d LMWH therapy. </text>
<text top="182" left="1106" width="216" height="17" font="7">Not randomized, no comparison group, </text>
<text top="200" left="1106" width="159" height="17" font="7">relatively small study group.  </text>
<text top="304" left="42" width="72" height="17" font="7">Spyropoulos </text>
<text top="321" left="42" width="31" height="17" font="7">2008 </text>
<text top="338" left="42" width="32" height="17" font="7">(169) </text>
<text top="355" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18805116">18805116</a></text>
<text top="355" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18805116"> </a></text>
<text top="304" left="150" width="83" height="17" font="7">Observational, </text>
<text top="321" left="150" width="70" height="17" font="7">prospective, </text>
<text top="338" left="150" width="63" height="17" font="7">multicenter </text>
<text top="355" left="150" width="57" height="17" font="7">registry in </text>
<text top="372" left="150" width="79" height="17" font="7">USA, Canada </text>
<text top="304" left="251" width="147" height="17" font="7">Adults undergoing elective </text>
<text top="321" left="251" width="106" height="17" font="7">surgery or invasive </text>
<text top="338" left="251" width="94" height="17" font="7">procedure with a </text>
<text top="355" left="251" width="142" height="17" font="7">mechanical valve on long-</text>
<text top="372" left="251" width="56" height="17" font="7">term VKA </text>
<text top="304" left="420" width="107" height="17" font="7">Enrolled in another </text>
<text top="321" left="420" width="80" height="17" font="7">bridging study </text>
<text top="338" left="420" width="66" height="17" font="7">within 30 d. </text>
<text top="304" left="541" width="90" height="17" font="7">73 with IV UFH  </text>
<text top="321" left="541" width="116" height="17" font="7">(1,535±532 U/h) vs.  </text>
<text top="338" left="541" width="3" height="17" font="7"> </text>
<text top="355" left="541" width="115" height="17" font="7">172 with SQ LMWH  </text>
<text top="372" left="541" width="194" height="17" font="7">(76% enoxaparin 1 mg/kg bid, 13% </text>
<text top="390" left="541" width="154" height="17" font="7">dalteparin 100 U/kg bid, 4% </text>
<text top="407" left="541" width="124" height="17" font="7">tinzaparin 175 U/kg/d) </text>
<text top="304" left="757" width="311" height="17" font="7">Major adverse event rates (5.5% vs. 10.3%; p=0.23) and </text>
<text top="321" left="757" width="311" height="17" font="7">major bleeds (4.2% vs. 8.8%; p=0.17) were similar in the </text>
<text top="338" left="757" width="261" height="17" font="7">LMWH and UFH groups, respectively; 1 arterial </text>
<text top="355" left="757" width="260" height="17" font="7">thromboembolic event occurred in each group.  </text>
<text top="372" left="757" width="3" height="17" font="7"> </text>
<text top="390" left="757" width="277" height="17" font="7">More LMWH-bridged pts were treated as outpts or </text>
<text top="407" left="757" width="326" height="17" font="7">discharged from the hospital in &lt;24 hours (68.6% vs. 6.8%; </text>
<text top="424" left="757" width="69" height="17" font="7">p &lt;0.0001).  </text>
<text top="441" left="757" width="3" height="17" font="7"> </text>
<text top="458" left="757" width="328" height="17" font="7">Multivariate logistic analysis found no significant differences </text>
<text top="476" left="757" width="324" height="17" font="7">in major bleeds and major composite adverse events when </text>
<text top="493" left="757" width="293" height="17" font="7">adjusting for cardiothoracic or major surgery between </text>
<text top="510" left="757" width="44" height="17" font="7">groups. </text>
<text top="304" left="1106" width="185" height="17" font="7">Not randomized, bridging therapy </text>
<text top="321" left="1106" width="110" height="17" font="7">chosen by clinician. </text>
<text top="338" left="1106" width="3" height="17" font="7"> </text>
<text top="355" left="1106" width="195" height="17" font="7">The LMWH group was less likely to </text>
<text top="372" left="1106" width="189" height="17" font="7">undergo major surgery (33.7% vs. </text>
<text top="390" left="1106" width="205" height="17" font="7">58.9%; p=0.0002) and cardiothoracic </text>
<text top="407" left="1106" width="197" height="17" font="7">surgery (7.6% vs. 19.2%; p=0.008), </text>
<text top="424" left="1106" width="166" height="17" font="7">and to receive intraprocedural </text>
<text top="441" left="1106" width="208" height="17" font="7">anticoagulants or thrombolytics (4.1% </text>
<text top="458" left="1106" width="113" height="17" font="7">vs. 13.7%; p=0.007) </text>
<text top="528" left="42" width="70" height="17" font="7">Pengo 2009 </text>
<text top="545" left="42" width="32" height="17" font="7">(170) </text>
<text top="562" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19470892">19470892</a></text>
<text top="562" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19470892"> </a></text>
<text top="528" left="150" width="67" height="17" font="7">Prospective </text>
<text top="545" left="150" width="53" height="17" font="7">inception </text>
<text top="562" left="150" width="68" height="17" font="7">cohort at 22 </text>
<text top="580" left="150" width="83" height="17" font="7">Italian centers, </text>
<text top="597" left="150" width="65" height="17" font="7">2005–2007 </text>
<text top="528" left="251" width="148" height="17" font="7">Adults undergoing surgical </text>
<text top="545" left="251" width="151" height="17" font="7">or invasive procedures that </text>
<text top="562" left="251" width="127" height="17" font="7">required interruption of </text>
<text top="580" left="251" width="131" height="17" font="7">long-term VKA therapy  </text>
<text top="528" left="420" width="95" height="17" font="7">Body weight &lt;40 </text>
<text top="545" left="420" width="20" height="17" font="7">kg. </text>
<text top="562" left="420" width="87" height="17" font="7">Creatinine &gt;2.0 </text>
<text top="580" left="420" width="41" height="17" font="7">mg/dL, </text>
<text top="597" left="420" width="103" height="17" font="7">contraindication to </text>
<text top="614" left="420" width="93" height="17" font="7">LMWH, need for </text>
<text top="631" left="420" width="108" height="17" font="7">dual antiplatelet Rx </text>
<text top="528" left="541" width="195" height="17" font="7">N=189 MHV valve pts (15% of total </text>
<text top="545" left="541" width="114" height="17" font="7">study size of 1,262). </text>
<text top="562" left="541" width="3" height="17" font="7"> </text>
<text top="580" left="541" width="200" height="17" font="7">Bridging with 70 anti-Xa U/kg/bid for </text>
<text top="597" left="541" width="73" height="17" font="7">high-risk pts. </text>
<text top="528" left="757" width="311" height="17" font="7">Intention-to-treat analysis for the entire study population: </text>
<text top="545" left="757" width="331" height="17" font="7">Thromboembolic events in 5 pts (0.4%; 95% CI: 0.1–0.9), all </text>
<text top="562" left="757" width="174" height="17" font="7">in high-thromboembolic-risk pts </text>
<text top="580" left="757" width="307" height="17" font="7">Major bleeding in 15 (1.2%; 95% CI: 0.7–2.0) and minor </text>
<text top="597" left="757" width="241" height="17" font="7">bleeding in 53 pts (4.2%; 95% CI: 3.2–5.5).  </text>
<text top="614" left="757" width="330" height="17" font="7">Major bleeding was associated with twice-daily LMWH (high-</text>
<text top="631" left="757" width="306" height="17" font="7">risk pts), but not with the bleeding risk of the procedure. </text>
<text top="528" left="1106" width="205" height="17" font="7">Only 15% had mechanical valves, no </text>
<text top="545" left="1106" width="105" height="17" font="7">comparison group. </text>
<text top="562" left="1106" width="209" height="17" font="7">Safety in pts with MHV valves has not </text>
<text top="580" left="1106" width="166" height="17" font="7">been conclusively established </text>
</page>
<page number="41" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">41 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="51" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="108" left="159" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="334" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="126" left="388" width="3" height="17" font="6"><b> </b></text>
<text top="108" left="551" width="184" height="17" font="6"><b>Study Size and Comparator (N) </b></text>
<text top="108" left="893" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="108" left="1162" width="107" height="17" font="6"><b>Study Limitations </b></text>
<text top="144" left="88" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="192" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="277" width="104" height="17" font="6"><b>Inclusion Criteria </b></text>
<text top="144" left="420" width="108" height="17" font="6"><b>Exclusion Criteria </b></text>
<text top="144" left="641" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="923" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="144" left="1214" width="3" height="17" font="6"><b> </b></text>
<text top="162" left="42" width="75" height="17" font="7">Daniels 2009 </text>
<text top="179" left="42" width="32" height="17" font="7">(171) </text>
<text top="196" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19232682">19232682</a></text>
<text top="196" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19232682"> </a></text>
<text top="162" left="150" width="78" height="17" font="7">Retrospective </text>
<text top="179" left="150" width="75" height="17" font="7">cohort, 1997–</text>
<text top="196" left="150" width="31" height="17" font="7">2003 </text>
<text top="162" left="251" width="119" height="17" font="7">MHV on chronic VKA </text>
<text top="179" left="251" width="109" height="17" font="7">therapy undergoing </text>
<text top="196" left="251" width="127" height="17" font="7">invasive procedures or </text>
<text top="213" left="251" width="48" height="17" font="7">surgery  </text>
<text top="162" left="420" width="24" height="17" font="7">N/A </text>
<text top="162" left="541" width="144" height="17" font="7">A total of 580 procedures: </text>
<text top="179" left="541" width="152" height="17" font="7">372 AVR, 136 MVR and 48 </text>
<text top="196" left="541" width="75" height="17" font="7">multivalvular. </text>
<text top="213" left="541" width="3" height="17" font="7"> </text>
<text top="230" left="541" width="174" height="17" font="7">UFH or LMWH bridging used in </text>
<text top="248" left="541" width="194" height="17" font="7">high-risk pts (older AVR, any MVR, </text>
<text top="265" left="541" width="163" height="17" font="7">additional risk factors for TE). </text>
<text top="282" left="541" width="3" height="17" font="7"> </text>
<text top="299" left="541" width="181" height="17" font="7">No bridging in isolated AVR pts.  </text>
<text top="173" left="768" width="90" height="17" font="6"><b>Events at 3 mo </b></text>
<text top="190" left="795" width="35" height="17" font="6"><b>N (%) </b></text>
<text top="163" left="900" width="20" height="17" font="6"><b>No </b></text>
<text top="180" left="885" width="49" height="17" font="6"><b>Heparin </b></text>
<text top="171" left="944" width="142" height="17" font="6"><b>LMWH Only  Any UFH </b></text>
<text top="199" left="890" width="40" height="17" font="6"><b>N=213 </b></text>
<text top="199" left="961" width="40" height="17" font="6"><b>N=243 </b></text>
<text top="199" left="1043" width="33" height="17" font="6"><b>N=99 </b></text>
<text top="219" left="760" width="105" height="17" font="7">Thromboembolism </text>
<text top="219" left="890" width="39" height="17" font="7">1 (0.5) </text>
<text top="219" left="961" width="39" height="17" font="7">2 (0.8) </text>
<text top="219" left="1040" width="39" height="17" font="7">2 (3.1) </text>
<text top="238" left="770" width="85" height="17" font="7">Major Bleeding </text>
<text top="238" left="890" width="39" height="17" font="7">5 (2.4) </text>
<text top="238" left="961" width="39" height="17" font="7">9 (3.7) </text>
<text top="238" left="1040" width="39" height="17" font="7">6 (6.1) </text>
<text top="258" left="770" width="85" height="17" font="7">Minor Bleeding </text>
<text top="258" left="887" width="46" height="17" font="7">13 (6.1) </text>
<text top="258" left="958" width="46" height="17" font="7">13 (5.4) </text>
<text top="258" left="1040" width="39" height="17" font="7">8 (8.1) </text>
<text top="276" left="923" width="3" height="17" font="7"> </text>
<text top="293" left="757" width="313" height="17" font="7">Overall cumulative incidence of TE at 3 mo was 0.9%; all </text>
<text top="311" left="757" width="329" height="17" font="7">events occurred within 1 wk of the procedure. No TE events </text>
<text top="328" left="757" width="246" height="17" font="7">in 93 pts with isolated AVR with no bridging.  </text>
<text top="162" left="1106" width="191" height="17" font="7">Not randomized, choice of therapy </text>
<text top="179" left="1106" width="207" height="17" font="7">individualized based on estimated TE </text>
<text top="196" left="1106" width="100" height="17" font="7">and bleeding risk. </text>
<text top="213" left="1106" width="3" height="17" font="7"> </text>
<text top="230" left="1106" width="190" height="17" font="7">Most frequent procedures were GI </text>
<text top="248" left="1106" width="159" height="17" font="7">endoscopy (19.1%), urologic </text>
<text top="265" left="1106" width="200" height="17" font="7">procedures (14.0%), angiography or </text>
<text top="282" left="1106" width="198" height="17" font="7">transcatheter interventions (10.5%), </text>
<text top="299" left="1106" width="179" height="17" font="7">and orthopedic surgery (10.3%). </text>
<text top="346" left="42" width="72" height="17" font="7">Bui HT 2009 </text>
<text top="363" left="42" width="32" height="17" font="7">(172) </text>
<text top="380" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19892063">19892063</a></text>
<text top="380" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19892063"> </a></text>
<text top="346" left="150" width="78" height="17" font="7">Retrospective </text>
<text top="363" left="150" width="70" height="17" font="7">cohort study </text>
<text top="346" left="251" width="89" height="17" font="7">173 pts on VKA </text>
<text top="363" left="251" width="134" height="17" font="7">anticoagulation for MHV </text>
<text top="380" left="251" width="138" height="17" font="7">(n=90) or for nonvalvular </text>
<text top="397" left="251" width="146" height="17" font="7">AF undergoing invasive or </text>
<text top="415" left="251" width="111" height="17" font="7">surgical procedures </text>
<text top="346" left="420" width="63" height="17" font="7">Age &lt;18 y, </text>
<text top="363" left="420" width="65" height="17" font="7">Pregnancy, </text>
<text top="380" left="420" width="96" height="17" font="7">Hypercoagulable </text>
<text top="397" left="420" width="56" height="17" font="7">condition, </text>
<text top="415" left="420" width="105" height="17" font="7">bioprosthetic valve </text>
<text top="346" left="541" width="190" height="17" font="7">130 bridging episodes with LMWH </text>
<text top="363" left="541" width="195" height="17" font="7">were used to compare outcomes in </text>
<text top="380" left="541" width="118" height="17" font="7">MHV vs. pts with AF. </text>
<text top="346" left="757" width="252" height="17" font="7">No deaths or thromboembolic events at 2 mo. </text>
<text top="363" left="757" width="3" height="17" font="7"> </text>
<text top="380" left="757" width="312" height="17" font="7">Major and minor bleeding rates were similar between the </text>
<text top="397" left="757" width="310" height="17" font="7">MHV and AF groups (3.2% and 2.9%, 14.5% and 13.2% </text>
<text top="415" left="757" width="114" height="17" font="7">respectively, p=NS). </text>
<text top="346" left="1106" width="155" height="17" font="7">Isolated AVR in 43 (48%) of </text>
<text top="363" left="1106" width="124" height="17" font="7">mechanical valve pts.  </text>
<text top="380" left="1106" width="3" height="17" font="7"> </text>
<text top="397" left="1106" width="210" height="17" font="7">Not randomized. Comparator group of </text>
<text top="415" left="1106" width="177" height="17" font="7">AF may not require bridging. No </text>
<text top="432" left="1106" width="198" height="17" font="7">sample size calculation for power of </text>
<text top="449" left="1106" width="36" height="17" font="7">study. </text>
<text top="467" left="42" width="76" height="17" font="7">Biteker 2012  </text>
<text top="484" left="42" width="32" height="17" font="7">(173) </text>
<text top="501" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22591673">22591673</a></text>
<text top="501" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22591673"> </a></text>
<text top="467" left="150" width="67" height="17" font="7">Prospective </text>
<text top="484" left="150" width="76" height="17" font="7">cohort, single </text>
<text top="501" left="150" width="38" height="17" font="7">center </text>
<text top="467" left="251" width="156" height="17" font="7">Consecutive pts undergoing </text>
<text top="484" left="251" width="108" height="17" font="7">noncardiac surgery </text>
<text top="467" left="420" width="74" height="17" font="7">Bioprosthetic </text>
<text top="484" left="420" width="108" height="17" font="7">valves, severe liver </text>
<text top="501" left="420" width="94" height="17" font="7">or renal disease, </text>
<text top="519" left="420" width="103" height="17" font="7">contraindication to </text>
<text top="536" left="420" width="44" height="17" font="7">heparin </text>
<text top="467" left="541" width="170" height="17" font="7">140 pts with MHV (77 AVR, 46 </text>
<text top="484" left="541" width="161" height="17" font="7">MVR, and 17 DVR) receiving </text>
<text top="501" left="541" width="203" height="17" font="7">enoxaparin 1 mg/kg bid compared to </text>
<text top="519" left="541" width="198" height="17" font="7">1,200 pts with native valves (control </text>
<text top="536" left="541" width="198" height="17" font="7">group) receiving no anticoagulation. </text>
<text top="478" left="753" width="84" height="17" font="6"><b>Events (3 mo) </b></text>
<text top="495" left="753" width="35" height="17" font="6"><b>N (%) </b></text>
<text top="468" left="886" width="59" height="17" font="6"><b>MHV with </b></text>
<text top="485" left="886" width="42" height="17" font="6"><b>LMWH </b></text>
<text top="468" left="960" width="40" height="17" font="6"><b>Native </b></text>
<text top="485" left="960" width="41" height="17" font="6"><b>valves </b></text>
<text top="468" left="1034" width="3" height="17" font="6"><b> </b></text>
<text top="505" left="886" width="40" height="17" font="6"><b>N=140 </b></text>
<text top="505" left="960" width="47" height="17" font="6"><b>N=1200 </b></text>
<text top="505" left="1034" width="46" height="17" font="6"><b>p-value </b></text>
<text top="524" left="753" width="51" height="17" font="7">Bleeding </text>
<text top="524" left="886" width="38" height="17" font="7">18.6% </text>
<text top="524" left="960" width="38" height="17" font="7">14.2% </text>
<text top="524" left="1034" width="21" height="17" font="7">NS </text>
<text top="544" left="753" width="105" height="17" font="7">Thromboembolism </text>
<text top="544" left="886" width="31" height="17" font="7">3.6% </text>
<text top="544" left="960" width="21" height="17" font="7">2% </text>
<text top="544" left="1034" width="21" height="17" font="7">NS </text>
<text top="563" left="753" width="50" height="17" font="7">Mortality </text>
<text top="563" left="886" width="31" height="17" font="7">1.4% </text>
<text top="563" left="960" width="31" height="17" font="7">1.3% </text>
<text top="563" left="1034" width="21" height="17" font="7">NS </text>
<text top="583" left="753" width="170" height="17" font="7">Cardiovascular events  10.8% </text>
<text top="583" left="960" width="38" height="17" font="7">10.7% </text>
<text top="583" left="1034" width="21" height="17" font="7">NS </text>
<text top="601" left="757" width="0" height="1" font="12"> </text>
<text top="467" left="1106" width="218" height="17" font="7">Not randomized. Comparison group did </text>
<text top="484" left="1106" width="188" height="17" font="7">not have valve disease. No power </text>
<text top="501" left="1106" width="208" height="17" font="7">calculation with small number of MHV </text>
<text top="519" left="1106" width="27" height="17" font="7">pts.  </text>
<text top="602" left="42" width="68" height="17" font="7">Weiss 2013 </text>
<text top="619" left="42" width="32" height="17" font="7">(174) </text>
<text top="636" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23648452">23648452</a></text>
<text top="636" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23648452"> </a></text>
<text top="602" left="150" width="82" height="17" font="7">Retrospective, </text>
<text top="619" left="150" width="74" height="17" font="7">single-center </text>
<text top="636" left="150" width="70" height="17" font="7">cohort study </text>
<text top="602" left="251" width="142" height="17" font="7">Consecutive pts requiring </text>
<text top="619" left="251" width="124" height="17" font="7">postoperative bridging </text>
<text top="636" left="251" width="115" height="17" font="7">therapy after cardiac </text>
<text top="653" left="251" width="130" height="17" font="7">surgery during a 19 mo </text>
<text top="671" left="251" width="38" height="17" font="7">period </text>
<text top="602" left="420" width="24" height="17" font="7">N/A </text>
<text top="602" left="541" width="93" height="17" font="7">N=402 receiving </text>
<text top="619" left="541" width="197" height="17" font="7">LMWH (enoxaparin): comparison of </text>
<text top="636" left="541" width="190" height="17" font="7">full-dose (FD=1 mg/kg bodyweight </text>
<text top="653" left="541" width="202" height="17" font="7">bid) to half-dose (HD=0.5 mg/kg bid) </text>
<text top="671" left="541" width="200" height="17" font="7">with renal function dose adjustment. </text>
<text top="604" left="753" width="116" height="17" font="6"><b>Events (by hospital </b></text>
<text top="621" left="753" width="66" height="17" font="6"><b>discharge) </b></text>
<text top="638" left="753" width="35" height="17" font="6"><b>N (%) </b></text>
<text top="603" left="886" width="58" height="17" font="6"><b>Full dose </b></text>
<text top="620" left="886" width="42" height="17" font="6"><b>LMWH </b></text>
<text top="603" left="960" width="60" height="17" font="6"><b>Low dose </b></text>
<text top="620" left="960" width="40" height="17" font="6"><b>LVWH </b></text>
<text top="603" left="1034" width="3" height="17" font="6"><b> </b></text>
<text top="640" left="886" width="40" height="17" font="6"><b>N=210 </b></text>
<text top="640" left="960" width="40" height="17" font="6"><b>N=210 </b></text>
<text top="640" left="1034" width="46" height="17" font="6"><b>p-value </b></text>
<text top="659" left="753" width="50" height="17" font="7">Mortality </text>
<text top="659" left="886" width="31" height="17" font="7">0.5% </text>
<text top="659" left="960" width="31" height="17" font="7">5.5% </text>
<text top="659" left="1034" width="34" height="17" font="7">0.003 </text>
<text top="679" left="753" width="105" height="17" font="7">Thromboembolism </text>
<text top="679" left="886" width="21" height="17" font="7">5% </text>
<text top="679" left="960" width="21" height="17" font="7">9% </text>
<text top="679" left="1034" width="34" height="17" font="7">0.277 </text>
<text top="698" left="753" width="51" height="17" font="7">Bleeding </text>
<text top="698" left="886" width="28" height="17" font="7">11% </text>
<text top="698" left="960" width="21" height="17" font="7">5% </text>
<text top="698" left="1034" width="34" height="17" font="7">0.126 </text>
<text top="718" left="753" width="92" height="17" font="7">Hospital stay (d) </text>
<text top="718" left="886" width="53" height="17" font="7">15.1±9.3 </text>
<text top="718" left="960" width="53" height="17" font="7">12.5±8.1 </text>
<text top="718" left="1034" width="34" height="17" font="7">0.003 </text>
<text top="735" left="757" width="0" height="1" font="12"> </text>
<text top="602" left="1106" width="217" height="17" font="7">Not randomized, but well matched (first </text>
<text top="619" left="1106" width="214" height="17" font="7">half of cohort received FD, second half </text>
<text top="636" left="1106" width="212" height="17" font="7">HD) Included only 100 (25.9% of total) </text>
<text top="653" left="1106" width="187" height="17" font="7">pts with MHV, also included AF in </text>
<text top="671" left="1106" width="45" height="17" font="7">83.6%.  </text>
<text top="737" left="34" width="1259" height="17" font="7">AF indicates atrial fibrillation; AVR, aortic valve replacement; DVR, double-valve replacement; FD, dull dose; GI, gastrointestinal; HD, half dose; LMWH, low molecular weight heparin; MHV, mechanical heart valve; MVR, mitral valve </text>
<text top="754" left="34" width="1014" height="17" font="7">replacement; N/A, not available; NS, nonsignificant; pt(s), patient(s); TE, thromboembolism; UFH, unfractionated heparin; USA, United States of America; and, VKA, vitamin K antagonist. </text>
<text top="771" left="108" width="3" height="17" font="7"> </text>
<text top="771" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="42" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">42 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="638" height="21" font="4"><b>Data Supplement 22. Fibrinolytic Therapy for Prosthetic Valve Thrombosis (Section 11.6.2) </b></text>
<text top="129" left="47" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="129" left="159" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="334" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="129" left="565" width="94" height="17" font="6"><b>Intervention vs. </b></text>
<text top="146" left="567" width="92" height="17" font="6"><b>Comparator (n) </b></text>
<text top="129" left="874" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="129" left="1163" width="107" height="17" font="6"><b>Study Limitations </b></text>
<text top="164" left="84" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="192" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="277" width="104" height="17" font="6"><b>Inclusion Criteria </b></text>
<text top="164" left="413" width="108" height="17" font="6"><b>Exclusion Criteria </b></text>
<text top="164" left="611" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="904" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="1215" width="3" height="17" font="6"><b> </b></text>
<text top="196" left="42" width="66" height="17" font="7">Deviri 1991 </text>
<text top="213" left="42" width="32" height="17" font="7">(175) </text>
<text top="230" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1993782">1993782</a></text>
<text top="230" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/1993782"> </a></text>
<text top="196" left="143" width="83" height="17" font="7">Observational, </text>
<text top="213" left="143" width="76" height="17" font="7">single center, </text>
<text top="230" left="143" width="101" height="17" font="7">surgical treatment </text>
<text top="248" left="143" width="83" height="17" font="7">for PVT, 1980–</text>
<text top="265" left="143" width="31" height="17" font="7">1989 </text>
<text top="196" left="258" width="134" height="17" font="7">n=100 (32 male) aged 5 </text>
<text top="213" left="258" width="129" height="17" font="7">mo–82 y (median 32 y) </text>
<text top="230" left="258" width="106" height="17" font="7">with PVT (n=61) or </text>
<text top="248" left="258" width="121" height="17" font="7">pannus (n=7), or both </text>
<text top="265" left="258" width="43" height="17" font="7">(n=44)  </text>
<text top="196" left="413" width="24" height="17" font="7">N/A </text>
<text top="196" left="535" width="98" height="17" font="7">Only included pts </text>
<text top="213" left="535" width="154" height="17" font="7">undergoing surgery for PVT </text>
<text top="230" left="535" width="62" height="17" font="7">or pannus. </text>
<text top="248" left="535" width="142" height="17" font="7">AVR in 51 (48%), MVR in </text>
<text top="265" left="535" width="131" height="17" font="7">49 (46%), and both in 6 </text>
<text top="282" left="535" width="29" height="17" font="7">(6%) </text>
<text top="196" left="703" width="162" height="17" font="7">Early mortality 12.3% (n=13)  </text>
<text top="213" left="703" width="3" height="17" font="7"> </text>
<text top="230" left="703" width="399" height="17" font="7">Perioperative mortality higher in pts with NYHA IV (17.5%) vs. NYHA I-III </text>
<text top="248" left="703" width="144" height="17" font="7">(4.7%) symptoms, p&lt;0.05 </text>
<text top="265" left="703" width="3" height="17" font="7"> </text>
<text top="282" left="703" width="314" height="17" font="7">Same outcome between valve replacement vs. declotting </text>
<text top="196" left="1122" width="160" height="17" font="7">Older generation mechanical </text>
<text top="213" left="1122" width="152" height="17" font="7">PHV, chart-recovered data, </text>
<text top="230" left="1122" width="173" height="17" font="7">various diagnostic approaches. </text>
<text top="300" left="42" width="62" height="17" font="7">Tong 2004 </text>
<text top="317" left="42" width="32" height="17" font="7">(176) </text>
<text top="335" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14715187">14715187</a></text>
<text top="335" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14715187"> </a></text>
<text top="300" left="143" width="71" height="17" font="7">International </text>
<text top="317" left="143" width="77" height="17" font="7">registry of pts </text>
<text top="335" left="143" width="85" height="17" font="7">with suspected </text>
<text top="352" left="143" width="96" height="17" font="7">PVT, 1985–2001 </text>
<text top="300" left="258" width="139" height="17" font="7">107 pts (71 females; age </text>
<text top="317" left="258" width="107" height="17" font="7">24 to 86 y) from 14 </text>
<text top="335" left="258" width="123" height="17" font="7">centers (6 in the U.S.) </text>
<text top="352" left="258" width="108" height="17" font="7">MVR=79, AVR=13, </text>
<text top="369" left="258" width="49" height="17" font="7">TVR=15 </text>
<text top="300" left="413" width="24" height="17" font="7">N/A </text>
<text top="300" left="535" width="123" height="17" font="7">Only included pts with </text>
<text top="317" left="535" width="113" height="17" font="7">suspected PVT who </text>
<text top="335" left="535" width="142" height="17" font="7">underwent TEE and were </text>
<text top="352" left="535" width="85" height="17" font="7">treated with FT </text>
<text top="300" left="703" width="183" height="17" font="7">Hemodynamic success rate 85% </text>
<text top="317" left="703" width="183" height="17" font="7">Overall complications rate 17.8% </text>
<text top="335" left="703" width="81" height="17" font="7">Death in 5.6% </text>
<text top="352" left="703" width="3" height="17" font="7"> </text>
<text top="369" left="703" width="228" height="17" font="7">Independent predictors of complications:  </text>
<text top="386" left="703" width="138" height="17" font="7">1) thrombus area &gt;0.8cm</text>
<text top="387" left="841" width="4" height="11" font="9">2</text>
<text top="386" left="846" width="97" height="17" font="7"> (OR: 2.41 per cm</text>
<text top="387" left="943" width="4" height="11" font="9">2</text>
<text top="386" left="948" width="159" height="17" font="7">, CI: 1.12–5.19) and 2) Hx of </text>
<text top="403" left="703" width="199" height="17" font="7">stroke (OR: 4.55, CI: 1.35–15.380)   </text>
<text top="421" left="703" width="3" height="17" font="7"> </text>
<text top="438" left="703" width="405" height="17" font="7">Presentation with shock was associated with clinical failure 10.7% vs. 0%; </text>
<text top="455" left="703" width="55" height="17" font="7">p=0.0032 </text>
<text top="300" left="1122" width="178" height="17" font="7">Not all pts had PHV obstruction, </text>
<text top="317" left="1122" width="133" height="17" font="7">thrombolysis criteria not </text>
<text top="335" left="1122" width="178" height="17" font="7">standardized. Goal of study was </text>
<text top="352" left="1122" width="120" height="17" font="7">to assess role of TEE </text>
<text top="369" left="1122" width="147" height="17" font="7">measurement of thrombus </text>
<text top="386" left="1122" width="49" height="17" font="7">burden.  </text>
<text top="473" left="42" width="81" height="17" font="7">Roudaut 2009 </text>
<text top="490" left="42" width="32" height="17" font="7">(177) </text>
<text top="507" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19427604">19427604</a></text>
<text top="507" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19427604"> </a></text>
<text top="473" left="143" width="83" height="17" font="7">Observational, </text>
<text top="490" left="143" width="88" height="17" font="7">nonrandomized </text>
<text top="507" left="143" width="100" height="17" font="7">single center over </text>
<text top="525" left="143" width="95" height="17" font="7">20 y, 1978–2001 </text>
<text top="473" left="258" width="127" height="17" font="7">n=263 episodes in 210 </text>
<text top="490" left="258" width="104" height="17" font="7">pts (98% left sided </text>
<text top="507" left="258" width="42" height="17" font="7">valves) </text>
<text top="473" left="413" width="68" height="17" font="7">Decision for </text>
<text top="490" left="413" width="83" height="17" font="7">surgical vs. FT </text>
<text top="507" left="413" width="81" height="17" font="7">made by each </text>
<text top="525" left="413" width="54" height="17" font="7">clinician.  </text>
<text top="473" left="535" width="74" height="17" font="7">Surgery=136 </text>
<text top="490" left="535" width="93" height="17" font="7">Fibrinolysis=127 </text>
<text top="475" left="705" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="492" left="705" width="3" height="17" font="6"><b> </b></text>
<text top="474" left="838" width="79" height="17" font="6"><b>Surgery   FT </b></text>
<text top="474" left="973" width="50" height="17" font="6"><b>p-value  </b></text>
<text top="494" left="838" width="40" height="17" font="6"><b>N=136 </b></text>
<text top="494" left="898" width="40" height="17" font="6"><b>N=127 </b></text>
<text top="494" left="973" width="19" height="17" font="6"><b>…. </b></text>
<text top="513" left="705" width="98" height="17" font="7">Restored valve fx </text>
<text top="513" left="838" width="28" height="17" font="7">89% </text>
<text top="513" left="898" width="38" height="17" font="7">70.9% </text>
<text top="513" left="973" width="41" height="17" font="7">&lt;0.001 </text>
<text top="532" left="705" width="78" height="17" font="7">Mortality (6 y) </text>
<text top="532" left="838" width="28" height="17" font="7">26% </text>
<text top="532" left="898" width="28" height="17" font="7">48% </text>
<text top="532" left="973" width="34" height="17" font="7">0.002 </text>
<text top="552" left="705" width="105" height="17" font="7">Thromboembolism </text>
<text top="552" left="838" width="31" height="17" font="7">0.7% </text>
<text top="552" left="898" width="28" height="17" font="7">15% </text>
<text top="552" left="973" width="41" height="17" font="7">&lt;0.001 </text>
<text top="571" left="705" width="74" height="17" font="7">Major Comp. </text>
<text top="571" left="838" width="38" height="17" font="7">11.1% </text>
<text top="571" left="898" width="38" height="17" font="7">25.2% </text>
<text top="571" left="973" width="27" height="17" font="7">0.05 </text>
<text top="591" left="705" width="85" height="17" font="7">Recurrent PVT </text>
<text top="591" left="838" width="31" height="17" font="7">11%  </text>
<text top="591" left="898" width="28" height="17" font="7">25% </text>
<text top="591" left="973" width="34" height="17" font="7">0.021 </text>
<text top="609" left="703" width="0" height="1" font="12"> </text>
<text top="473" left="1122" width="186" height="17" font="7">Not randomized (standard clinical </text>
<text top="490" left="1122" width="172" height="17" font="7">practice). Use of FT decreased </text>
<text top="507" left="1122" width="140" height="17" font="7">over study interval. Older </text>
<text top="525" left="1122" width="107" height="17" font="7">generation valves.  </text>
<text top="610" left="42" width="68" height="17" font="7">Karthikeyan </text>
<text top="627" left="42" width="31" height="17" font="7">2009 </text>
<text top="644" left="42" width="32" height="17" font="7">(178) </text>
<text top="662" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19738134">19738134</a></text>
<text top="662" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19738134"> </a></text>
<text top="610" left="143" width="76" height="17" font="7">Randomized, </text>
<text top="627" left="143" width="95" height="17" font="7">controlled, single </text>
<text top="644" left="143" width="75" height="17" font="7">Indian center </text>
<text top="610" left="258" width="139" height="17" font="7">120 pts with first episode </text>
<text top="627" left="258" width="94" height="17" font="7">of left sided PVT </text>
<text top="610" left="413" width="98" height="17" font="7">Contraindications </text>
<text top="627" left="413" width="89" height="17" font="7">to FT, symptom </text>
<text top="644" left="413" width="87" height="17" font="7">duration &gt;2 wk, </text>
<text top="662" left="413" width="83" height="17" font="7">recurrent PVT  </text>
<text top="610" left="535" width="128" height="17" font="7">Accelerated infusion of </text>
<text top="627" left="535" width="96" height="17" font="7">streptokinase vs. </text>
<text top="644" left="535" width="118" height="17" font="7">conventional infusion </text>
<text top="610" left="703" width="326" height="17" font="7">Complete clinical response: Accelerated=38/59 (64.4%) vs. </text>
<text top="627" left="703" width="356" height="17" font="7">Conventional=32/60 (53.3%), HR: 1.6, 95% CI: 0.9-2.5, p=0.055. </text>
<text top="644" left="703" width="3" height="17" font="7"> </text>
<text top="662" left="703" width="371" height="17" font="7">Overall success rate 59%, with lower success rate (24%) in pts with </text>
<text top="679" left="703" width="133" height="17" font="7">NYHA III/IV symptoms.  </text>
<text top="696" left="703" width="3" height="17" font="7"> </text>
<text top="713" left="703" width="388" height="17" font="7">Composite secondary outcome (death, major bleeding, embolic stroke, </text>
<text top="730" left="703" width="270" height="17" font="7">systemic TE): HR: 1.4%,95% CI: 0.5–3.5; p=0.50 </text>
<text top="748" left="703" width="3" height="17" font="7"> </text>
<text top="765" left="703" width="273" height="17" font="7">Major bleeding: HR: 2.2, 95% CI: 0.6–7.7, p=0.24 </text>
<text top="610" left="1122" width="170" height="17" font="7">No surgical comparison group. </text>
<text top="627" left="1122" width="184" height="17" font="7">Low success rate with both types </text>
<text top="644" left="1122" width="62" height="17" font="7">of therapy. </text>
<text top="783" left="42" width="83" height="17" font="7">Keuleers 2011 </text>
<text top="783" left="143" width="82" height="17" font="7">Retrospective, </text>
<text top="783" left="258" width="62" height="17" font="7">n=31 PVT: </text>
<text top="783" left="413" width="98" height="17" font="7">Contraindications </text>
<text top="783" left="535" width="144" height="17" font="7">Surgery (n=18) compared </text>
<text top="783" left="703" width="218" height="17" font="7">Surgery: 2 (11%) perioperative deaths,  </text>
<text top="783" left="1122" width="150" height="17" font="7">Small numbers, no data on </text>
</page>
<page number="43" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">43 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="47" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="108" left="159" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="334" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="108" left="565" width="94" height="17" font="6"><b>Intervention vs. </b></text>
<text top="126" left="567" width="92" height="17" font="6"><b>Comparator (n) </b></text>
<text top="108" left="874" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="108" left="1163" width="107" height="17" font="6"><b>Study Limitations </b></text>
<text top="144" left="84" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="192" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="277" width="104" height="17" font="6"><b>Inclusion Criteria </b></text>
<text top="144" left="413" width="108" height="17" font="6"><b>Exclusion Criteria </b></text>
<text top="144" left="611" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="904" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="1215" width="3" height="17" font="6"><b> </b></text>
<text top="175" left="42" width="32" height="17" font="7">(179) </text>
<text top="193" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21211605">21211605</a></text>
<text top="193" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21211605"> </a></text>
<text top="175" left="143" width="92" height="17" font="7">nonrandomized, </text>
<text top="193" left="143" width="76" height="17" font="7">single center, </text>
<text top="210" left="143" width="65" height="17" font="7">1988–2008 </text>
<text top="175" left="258" width="91" height="17" font="7">MVR=17 (55%), </text>
<text top="193" left="258" width="82" height="17" font="7">AVR=8 (26%), </text>
<text top="210" left="258" width="82" height="17" font="7">TVR=6 (19%). </text>
<text top="175" left="413" width="32" height="17" font="7">to FT </text>
<text top="175" left="535" width="71" height="17" font="7">to FT (n=13) </text>
<text top="175" left="703" width="276" height="17" font="7">               2 (11%) recurrent PVT (follow-up 76 mo) </text>
<text top="193" left="703" width="319" height="17" font="7">FT:         8 (61%) with restoration of normal valve function. </text>
<text top="210" left="703" width="280" height="17" font="7">               4 (31%) recurrent PVT (follow-up 18 mo)  </text>
<text top="227" left="749" width="345" height="17" font="7">  4 (31%) major complications (death, stroke, TIA, or bleeding   </text>
<text top="244" left="749" width="103" height="17" font="7">requiring  surgery) </text>
<text top="175" left="1122" width="83" height="17" font="7">thrombus size  </text>
<text top="262" left="42" width="70" height="17" font="7">Özkan 2013 </text>
<text top="279" left="42" width="25" height="17" font="7">(66) </text>
<text top="297" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23489534">23489534</a></text>
<text top="297" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23489534"> </a></text>
<text top="262" left="143" width="86" height="17" font="7">Observational , </text>
<text top="279" left="143" width="73" height="17" font="7">single center </text>
<text top="297" left="143" width="40" height="17" font="7">clinical </text>
<text top="314" left="143" width="67" height="17" font="7">experience, </text>
<text top="331" left="143" width="65" height="17" font="7">1993–2009 </text>
<text top="262" left="258" width="124" height="17" font="7">TEE-guided FT in 182 </text>
<text top="279" left="258" width="137" height="17" font="7">consecutive pts with 220 </text>
<text top="297" left="258" width="130" height="17" font="7">episodes of PVT in 220 </text>
<text top="314" left="258" width="128" height="17" font="7">different episodes (156 </text>
<text top="331" left="258" width="108" height="17" font="7">women; mean age, </text>
<text top="348" left="258" width="87" height="17" font="7">43.2±13.06 y).  </text>
<text top="262" left="413" width="98" height="17" font="7">Contraindications </text>
<text top="279" left="413" width="36" height="17" font="7">to FT, </text>
<text top="297" left="413" width="106" height="17" font="7">asymptomatic PVT </text>
<text top="314" left="413" width="98" height="17" font="7">with normal valve </text>
<text top="331" left="413" width="86" height="17" font="7">hemodynamics </text>
<text top="348" left="413" width="103" height="17" font="7">and no TE or with, </text>
<text top="366" left="413" width="104" height="17" font="7">thrombus size &lt;10 </text>
<text top="383" left="413" width="27" height="17" font="7">mm. </text>
<text top="262" left="535" width="144" height="17" font="7">FT regimen adjusted over </text>
<text top="279" left="535" width="153" height="17" font="7">study duration with Groups: </text>
<text top="297" left="535" width="117" height="17" font="6"><b>I</b>–Slow streptokinase </text>
<text top="314" left="535" width="126" height="17" font="6"><b>II</b>–Rapid streptokinase </text>
<text top="331" left="535" width="126" height="17" font="6"><b>III</b>–tPA 100 mg (bolus) </text>
<text top="348" left="535" width="146" height="17" font="6"><b>IV</b>–tPA 50 mg 6 h infusion </text>
<text top="366" left="535" width="142" height="17" font="6"><b>V</b>–tPA 25 mg 6 h infusion </text>
<text top="265" left="705" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="282" left="705" width="12" height="17" font="6"><b>N </b></text>
<text top="263" left="872" width="10" height="17" font="6"><b>I  </b></text>
<text top="263" left="933" width="10" height="17" font="6"><b>II </b></text>
<text top="263" left="1021" width="14" height="17" font="6"><b>III </b></text>
<text top="263" left="1068" width="19" height="17" font="6"><b>IV  </b></text>
<text top="263" left="1156" width="12" height="17" font="6"><b>V </b></text>
<text top="263" left="1210" width="46" height="17" font="6"><b>p-value </b></text>
<text top="283" left="872" width="17" height="17" font="7">16 </text>
<text top="283" left="933" width="17" height="17" font="7">41 </text>
<text top="283" left="1021" width="17" height="17" font="7">12 </text>
<text top="283" left="1068" width="17" height="17" font="7">27 </text>
<text top="283" left="1156" width="24" height="17" font="7">124 </text>
<text top="283" left="1210" width="3" height="17" font="7"> </text>
<text top="302" left="705" width="94" height="17" font="7">Overall success  </text>
<text top="302" left="872" width="38" height="17" font="7">68.8% </text>
<text top="302" left="933" width="38" height="17" font="7">85.4% </text>
<text top="302" left="1021" width="28" height="17" font="7">75% </text>
<text top="302" left="1068" width="38" height="17" font="7">81.5% </text>
<text top="302" left="1156" width="81" height="17" font="7">85.5%  0.46 </text>
<text top="322" left="705" width="118" height="17" font="7">Major nonfatal comp. </text>
<text top="322" left="872" width="38" height="17" font="7">12.5% </text>
<text top="322" left="933" width="38" height="17" font="7">12.2% </text>
<text top="322" left="1021" width="86" height="17" font="7">8.3%  11.1% </text>
<text top="322" left="1156" width="31" height="17" font="7">4.8% </text>
<text top="322" left="1210" width="21" height="17" font="7">NS </text>
<text top="341" left="705" width="36" height="17" font="7">Death </text>
<text top="341" left="872" width="42" height="17" font="7">12.5%  </text>
<text top="341" left="933" width="31" height="17" font="7">2.4% </text>
<text top="341" left="1021" width="79" height="17" font="7">16.7%  3.7% </text>
<text top="341" left="1156" width="21" height="17" font="7">0% </text>
<text top="341" left="1210" width="27" height="17" font="7">0.01 </text>
<text top="360" left="703" width="376" height="17" font="7">Multivariate predictors of mortality plus major nonfatal complications: </text>
<text top="377" left="703" width="449" height="17" font="7">Any thrombolytic therapy regimen other than Group V and a history of stroke/TIA.  </text>
<text top="401" left="42" width="68" height="17" font="7">Karthikeyan </text>
<text top="418" left="42" width="31" height="17" font="7">2013 </text>
<text top="435" left="42" width="32" height="17" font="7">(180) </text>
<text top="452" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23329151">23329151</a></text>
<text top="452" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23329151"> </a></text>
<text top="401" left="143" width="83" height="17" font="7">Meta-analysis  </text>
<text top="401" left="258" width="137" height="17" font="7">Published articles on left-</text>
<text top="418" left="258" width="138" height="17" font="7">sided PVT with at least 5 </text>
<text top="435" left="258" width="117" height="17" font="7">pts each treated with </text>
<text top="452" left="258" width="87" height="17" font="7">surgery and FT </text>
<text top="401" left="413" width="87" height="17" font="7">Lack of data on </text>
<text top="418" left="413" width="95" height="17" font="7">primary outcome </text>
<text top="435" left="413" width="79" height="17" font="7">(restoration of </text>
<text top="452" left="413" width="73" height="17" font="7">normal valve </text>
<text top="470" left="413" width="51" height="17" font="7">function) </text>
<text top="401" left="535" width="154" height="17" font="7">7 studies with 690 episodes </text>
<text top="418" left="535" width="121" height="17" font="7">of left sided PVT, 446 </text>
<text top="435" left="535" width="139" height="17" font="7">treated with surgery, and </text>
<text top="452" left="535" width="71" height="17" font="7">244 with FT. </text>
<text top="403" left="737" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="420" left="767" width="3" height="17" font="7"> </text>
<text top="402" left="840" width="50" height="17" font="6"><b>Surgery </b></text>
<text top="402" left="927" width="19" height="17" font="6"><b>FT </b></text>
<text top="402" left="1054" width="22" height="17" font="6"><b>OR </b></text>
<text top="402" left="1160" width="46" height="17" font="6"><b>p-value </b></text>
<text top="421" left="831" width="40" height="17" font="7">N=446 </text>
<text top="421" left="898" width="40" height="17" font="7">N=244 </text>
<text top="430" left="973" width="3" height="17" font="7"> </text>
<text top="421" left="1156" width="3" height="17" font="7"> </text>
<text top="441" left="705" width="103" height="17" font="7">Restored valve Fx </text>
<text top="441" left="831" width="38" height="17" font="7">86.5% </text>
<text top="441" left="898" width="38" height="17" font="7">69.7% </text>
<text top="441" left="973" width="136" height="17" font="7">2.53, 95% CI: 0.94–6.78 </text>
<text top="441" left="1156" width="34" height="17" font="7">0.066 </text>
<text top="460" left="705" width="36" height="17" font="7">Death </text>
<text top="460" left="831" width="38" height="17" font="7">13.5% </text>
<text top="460" left="898" width="21" height="17" font="7">9% </text>
<text top="460" left="973" width="136" height="17" font="7">1.95, 95% CI: 0.63–5.98 </text>
<text top="460" left="1156" width="34" height="17" font="7">0.244 </text>
<text top="480" left="705" width="105" height="17" font="7">Thromboembolism </text>
<text top="480" left="831" width="31" height="17" font="7">1.6% </text>
<text top="480" left="898" width="28" height="17" font="7">16% </text>
<text top="480" left="973" width="136" height="17" font="7">0.10, 95% CI: 0.04–0.24 </text>
<text top="480" left="1156" width="41" height="17" font="7">&lt;0.001 </text>
<text top="499" left="705" width="86" height="17" font="7">Major Bleeding </text>
<text top="499" left="831" width="31" height="17" font="7">1.4% </text>
<text top="499" left="898" width="21" height="17" font="7">5% </text>
<text top="499" left="973" width="136" height="17" font="7">0.27, 95% CI: 0.08–0.98 </text>
<text top="499" left="1156" width="34" height="17" font="7">0.046 </text>
<text top="519" left="705" width="85" height="17" font="7">Recurrent PVT </text>
<text top="519" left="831" width="31" height="17" font="7">7.1% </text>
<text top="519" left="898" width="38" height="17" font="7">25.4% </text>
<text top="519" left="973" width="136" height="17" font="7">0.25, 95% CI: 0.08–0.74 </text>
<text top="519" left="1156" width="34" height="17" font="7">0.013 </text>
<text top="537" left="703" width="0" height="1" font="12"> </text>
<text top="538" left="34" width="1300" height="17" font="7">AVR indicates aortic valve replacement; FT, fibrinolytic therapy; fx, function; Hx, history; MVR, mitral valve replacement, N/A, not available; NS, nonsignificant; NYHA, New York Heart Association; PHV, prosthetic heart valves; pts, patients; </text>
<text top="555" left="34" width="1086" height="17" font="7">PVT, prosthetic valve thrombosis; TE, thromboembolism, TEE, transesophageal echocardiography; TIA, transient ischemic attack (stroke); TVR, tricuspid valve replacement; and, U.S., United States.  </text>
<text top="572" left="108" width="3" height="17" font="7"> </text>
<text top="572" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="44" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">44 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="454" height="21" font="4"><b>Data Supplement 23. Paravalvular Regurgitation (Section 11.8.3) </b></text>
<text top="129" left="44" width="78" height="17" font="6"><b>Study Name, </b></text>
<text top="149" left="44" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="129" left="196" width="64" height="17" font="6"><b>Study Aim </b></text>
<text top="129" left="334" width="98" height="17" font="6"><b>Study Type/Size </b></text>
<text top="149" left="373" width="21" height="17" font="6"><b>(N) </b></text>
<text top="129" left="471" width="94" height="17" font="6"><b>Intervention vs. </b></text>
<text top="149" left="472" width="92" height="17" font="6"><b>Comparator (n) </b></text>
<text top="129" left="624" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="129" left="955" width="64" height="17" font="6"><b>Endpoints </b></text>
<text top="129" left="1233" width="96" height="17" font="6"><b>Adverse Events </b></text>
<text top="184" left="81" width="3" height="17" font="6"><b> </b></text>
<text top="184" left="226" width="3" height="17" font="6"><b> </b></text>
<text top="184" left="381" width="3" height="17" font="6"><b> </b></text>
<text top="184" left="516" width="3" height="17" font="6"><b> </b></text>
<text top="184" left="621" width="119" height="17" font="6"><b>Inclusion/Exclusion </b></text>
<text top="202" left="657" width="46" height="17" font="6"><b>Criteria </b></text>
<text top="184" left="793" width="166" height="17" font="6"><b>Primary Endpoint &amp; Results </b></text>
<text top="184" left="1007" width="183" height="17" font="6"><b>Secondary Endpoint &amp; Results </b></text>
<text top="184" left="1279" width="3" height="17" font="6"><b> </b></text>
<text top="220" left="42" width="52" height="17" font="7">Orszulak </text>
<text top="237" left="42" width="31" height="17" font="7">1983 </text>
<text top="254" left="42" width="32" height="17" font="7">(181) </text>
<text top="271" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6860002">6860002</a></text>
<text top="271" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6860002"> </a></text>
<text top="220" left="136" width="175" height="17" font="7">To report outcome with surgical </text>
<text top="237" left="136" width="112" height="17" font="7">reoperation for PVR </text>
<text top="220" left="332" width="79" height="17" font="7">Retrospective </text>
<text top="237" left="332" width="43" height="17" font="7">N=105  </text>
<text top="220" left="447" width="113" height="17" font="7">Surgical reoperative </text>
<text top="237" left="447" width="138" height="17" font="7">repair of prosthetic PVR  </text>
<text top="220" left="602" width="127" height="17" font="7">Aortic PVR (n=75) and </text>
<text top="237" left="602" width="102" height="17" font="7">mitral PVR (n=29) </text>
<text top="220" left="771" width="209" height="17" font="7">Early mortality for entire cohort: 5.7%. </text>
<text top="237" left="771" width="199" height="17" font="7">5-y survival was 94% for aortic PVR </text>
<text top="254" left="771" width="175" height="17" font="7">pts and 75% for mitral PVR pts. </text>
<text top="220" left="994" width="210" height="17" font="7">21 pts required multiple operations for </text>
<text top="237" left="994" width="89" height="17" font="7">persistent PVR. </text>
<text top="254" left="994" width="209" height="17" font="7">85% of survivors at follow-up up to 14 </text>
<text top="271" left="994" width="112" height="17" font="7">y were NYHA I or II. </text>
<text top="288" left="994" width="202" height="17" font="7">Murmur of residual or recurrent PVR </text>
<text top="306" left="994" width="121" height="17" font="7">evident in 21% of pts. </text>
<text top="220" left="1216" width="24" height="17" font="7">N/A </text>
<text top="324" left="42" width="64" height="17" font="7">Miller 1995 </text>
<text top="341" left="42" width="32" height="17" font="7">(182) </text>
<text top="358" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8556176">8556176</a></text>
<text top="358" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8556176"> </a></text>
<text top="324" left="136" width="172" height="17" font="7">To identify clinical features that </text>
<text top="341" left="136" width="150" height="17" font="7">predict occurrence of PVR. </text>
<text top="358" left="136" width="162" height="17" font="7">Outcome after surgical repair </text>
<text top="375" left="136" width="75" height="17" font="7">also reported </text>
<text top="324" left="332" width="79" height="17" font="7">Retrospective </text>
<text top="341" left="332" width="37" height="17" font="7">N=30  </text>
<text top="324" left="447" width="113" height="17" font="7">Surgical reoperative </text>
<text top="341" left="447" width="139" height="17" font="7">repair of aortic prosthetic </text>
<text top="358" left="447" width="32" height="17" font="7">PVR  </text>
<text top="324" left="602" width="120" height="17" font="7">Aortic prosthetic PVR </text>
<text top="324" left="771" width="112" height="17" font="7">30-d survival=90%;  </text>
<text top="341" left="771" width="102" height="17" font="7">5-d survival=73%  </text>
<text top="324" left="994" width="203" height="17" font="7">Prosthesis replacement in 26, suture </text>
<text top="341" left="994" width="62" height="17" font="7">repair in 4. </text>
<text top="358" left="994" width="199" height="17" font="7">Trivial or no residual regurgitation in </text>
<text top="375" left="994" width="187" height="17" font="7">16 of 20 with echocardiography in </text>
<text top="393" left="994" width="56" height="17" font="7">follow-up. </text>
<text top="324" left="1216" width="24" height="17" font="7">N/A </text>
<text top="411" left="42" width="64" height="17" font="7">Akins 2005 </text>
<text top="428" left="42" width="32" height="17" font="7">(183) </text>
<text top="445" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16359061">16359061</a></text>
<text top="445" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16359061"> </a></text>
<text top="411" left="136" width="181" height="17" font="7">To examine acute and long-term </text>
<text top="428" left="136" width="155" height="17" font="7">outcome of surgery for PVR </text>
<text top="411" left="332" width="79" height="17" font="7">Retrospective </text>
<text top="428" left="332" width="40" height="17" font="7">N=136 </text>
<text top="411" left="447" width="113" height="17" font="7">Surgical reoperative </text>
<text top="428" left="447" width="130" height="17" font="7">repair of aortic or mitral </text>
<text top="445" left="447" width="85" height="17" font="7">prosthetic PVR </text>
<text top="411" left="602" width="103" height="17" font="7">Mitral PVR in 68% </text>
<text top="428" left="602" width="105" height="17" font="7">Aortic PVR in 32% </text>
<text top="411" left="771" width="141" height="17" font="7">Operative mortality, 6.6% </text>
<text top="428" left="771" width="148" height="17" font="7">Perioperative stroke, 5.1% </text>
<text top="445" left="771" width="104" height="17" font="7">10-y survival, 30% </text>
<text top="411" left="994" width="184" height="17" font="7">Primary repair in 48%, prosthesis </text>
<text top="428" left="994" width="112" height="17" font="7">replacement in 52% </text>
<text top="411" left="1216" width="24" height="17" font="7">N/A </text>
<text top="463" left="42" width="60" height="17" font="7">Pate 2006 </text>
<text top="480" left="42" width="32" height="17" font="7">(184) </text>
<text top="497" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16969856">16969856</a></text>
<text top="497" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16969856"> </a></text>
<text top="463" left="136" width="181" height="17" font="7">To describe outcome in series of </text>
<text top="480" left="136" width="163" height="17" font="7">pts undergoing percutaneous </text>
<text top="497" left="136" width="77" height="17" font="7">repair of PVR </text>
<text top="463" left="332" width="79" height="17" font="7">Retrospective </text>
<text top="480" left="332" width="102" height="17" font="7">N=10 (10 defects) </text>
<text top="463" left="447" width="128" height="17" font="7">Percutaneous repair of </text>
<text top="480" left="447" width="29" height="17" font="7">PVR </text>
<text top="463" left="602" width="152" height="17" font="7">Mitral PVR (n=9) and aortic </text>
<text top="480" left="602" width="125" height="17" font="7">PVR (n=1); 9 were not </text>
<text top="497" left="602" width="109" height="17" font="7">surgical candidates </text>
<text top="463" left="771" width="155" height="17" font="7">7 with successful procedure </text>
<text top="480" left="771" width="90" height="17" font="7">3 pts died at 1 y </text>
<text top="463" left="994" width="192" height="17" font="7">4 of 10 required second procedure </text>
<text top="480" left="994" width="179" height="17" font="7">6 with sustained improvement in </text>
<text top="497" left="994" width="59" height="17" font="7">symptoms </text>
<text top="463" left="1216" width="127" height="17" font="7">1 retroperitoneal bleed </text>
<text top="480" left="1216" width="126" height="17" font="7">1 device dislodgement </text>
<text top="515" left="42" width="77" height="17" font="7">Shapira 2007 </text>
<text top="533" left="42" width="32" height="17" font="7">(185) </text>
<text top="550" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11479246">11479246</a></text>
<text top="550" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11479246"> </a></text>
<text top="515" left="136" width="166" height="17" font="7">To examine the feasibility and </text>
<text top="533" left="136" width="172" height="17" font="7">early outcome of percutaneous </text>
<text top="550" left="136" width="77" height="17" font="7">repair of PVR </text>
<text top="515" left="332" width="79" height="17" font="7">Retrospective </text>
<text top="533" left="332" width="102" height="17" font="7">N=11 (13 defects) </text>
<text top="515" left="447" width="128" height="17" font="7">Percutaneous repair of </text>
<text top="533" left="447" width="29" height="17" font="7">PVR </text>
<text top="515" left="602" width="131" height="17" font="7">Mitral PVR (n=8), aortic </text>
<text top="533" left="602" width="149" height="17" font="7">PVR (n=1), and both aortic </text>
<text top="550" left="602" width="119" height="17" font="7">and mitral PVR (n=2) </text>
<text top="567" left="602" width="104" height="17" font="7">Estimated surgical </text>
<text top="584" left="602" width="92" height="17" font="7">mortality, 17.8% </text>
<text top="515" left="771" width="148" height="17" font="7">10 with device deployment </text>
<text top="533" left="771" width="174" height="17" font="7">6 with reduction in regurgitation </text>
<text top="550" left="771" width="209" height="17" font="7">5 with NYHA improvement by 1 class  </text>
<text top="515" left="994" width="197" height="17" font="7">Hemolysis improved in 4, worsened </text>
<text top="533" left="994" width="206" height="17" font="7">in 4, and was unchanged in 2 in early </text>
<text top="550" left="994" width="53" height="17" font="7">follow-up </text>
<text top="567" left="994" width="116" height="17" font="7">3 deaths in follow-up </text>
<text top="515" left="1216" width="24" height="17" font="7">N/A </text>
<text top="602" left="42" width="70" height="17" font="7">Cortes 2008 </text>
<text top="619" left="42" width="32" height="17" font="7">(186) </text>
<text top="637" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18237605">18237605</a></text>
<text top="637" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18237605"> </a></text>
<text top="602" left="136" width="153" height="17" font="7">To examine utility of TEE in </text>
<text top="619" left="136" width="155" height="17" font="7">percutaneous repair of PVR </text>
<text top="602" left="332" width="79" height="17" font="7">Retrospective </text>
<text top="619" left="332" width="102" height="17" font="7">N=27 (27 defects) </text>
<text top="602" left="447" width="89" height="17" font="7">TEE before and </text>
<text top="619" left="447" width="136" height="17" font="7">procedure (n=27) and at </text>
<text top="637" left="447" width="134" height="17" font="7">follow-up ≥1 mo (n=17)  </text>
<text top="602" left="602" width="140" height="17" font="7">Mechanical mitral PVR in </text>
<text top="619" left="602" width="148" height="17" font="7">pts at high risk for surgery  </text>
<text top="602" left="771" width="160" height="17" font="7">62% with procedure success </text>
<text top="619" left="771" width="184" height="17" font="7">TEE helped guide procedure and </text>
<text top="637" left="771" width="184" height="17" font="7">identified variety of complications </text>
<text top="602" left="994" width="24" height="17" font="7">N/A </text>
<text top="602" left="1216" width="47" height="17" font="7">2 stroke </text>
<text top="619" left="1216" width="119" height="17" font="7">1 cardiac perforation  </text>
<text top="637" left="1216" width="91" height="17" font="7">6 needing blood </text>
<text top="654" left="1216" width="81" height="17" font="7">transfusion for </text>
<text top="671" left="1216" width="129" height="17" font="7">postprocedural anemia </text>
<text top="689" left="42" width="59" height="17" font="7">Ruiz 2011 </text>
<text top="706" left="42" width="32" height="17" font="7">(187) </text>
<text top="723" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22078427">22078427</a></text>
<text top="723" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22078427"> </a></text>
<text top="689" left="136" width="145" height="17" font="7">To examine feasibility and </text>
<text top="706" left="136" width="157" height="17" font="7">efficacy of the percutaneous </text>
<text top="723" left="136" width="77" height="17" font="7">repair of PVR </text>
<text top="689" left="332" width="82" height="17" font="7">Retrospective/ </text>
<text top="706" left="332" width="102" height="17" font="7">N=43 (57 defects) </text>
<text top="689" left="447" width="128" height="17" font="7">Percutaneous repair of </text>
<text top="706" left="447" width="32" height="17" font="7">PVR  </text>
<text top="689" left="602" width="138" height="17" font="7">Mitral PVR (n=36), aortic </text>
<text top="706" left="602" width="149" height="17" font="7">PVR (n=9), and both aortic </text>
<text top="723" left="602" width="119" height="17" font="7">and mitral PVR (n=2) </text>
<text top="689" left="771" width="196" height="17" font="7">Device deployment success in 86% </text>
<text top="706" left="771" width="131" height="17" font="7">of pts and 86% of leaks </text>
<text top="723" left="771" width="196" height="17" font="7">Survival: 92% at 6 m, 86% at 18 m  </text>
<text top="689" left="994" width="196" height="17" font="7">12 pts required multiple procedures </text>
<text top="706" left="994" width="204" height="17" font="7">Reduction in need for transfusions or </text>
<text top="723" left="994" width="99" height="17" font="7">EPO from 56–5% </text>
<text top="741" left="994" width="205" height="17" font="7">NYHA class improved by ≥1 in 28/35 </text>
<text top="758" left="994" width="20" height="17" font="7">pts </text>
<text top="689" left="1216" width="128" height="17" font="7">2 device embolizations </text>
<text top="706" left="1216" width="119" height="17" font="7">1 emergency surgery </text>
<text top="723" left="1216" width="59" height="17" font="7">1 vascular </text>
<text top="741" left="1216" width="72" height="17" font="7">complication </text>
<text top="758" left="1216" width="106" height="17" font="7">1 procedural death </text>
<text top="776" left="42" width="73" height="17" font="7">Sorajja 2011 </text>
<text top="776" left="136" width="166" height="17" font="7">To examine the feasibility and </text>
<text top="776" left="332" width="79" height="17" font="7">Retrospective </text>
<text top="776" left="447" width="128" height="17" font="7">Percutaneous repair of </text>
<text top="776" left="602" width="318" height="17" font="7">78% mitral PVR, 22% aortic  Device deployment in 89% </text>
<text top="776" left="994" width="159" height="17" font="7">Leaflet impingement in 4.3% </text>
<text top="776" left="1216" width="68" height="17" font="7">30-d events </text>
</page>
<page number="45" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">45 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="44" width="78" height="17" font="6"><b>Study Name, </b></text>
<text top="128" left="44" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="109" left="196" width="64" height="17" font="6"><b>Study Aim </b></text>
<text top="108" left="334" width="98" height="17" font="6"><b>Study Type/Size </b></text>
<text top="128" left="373" width="21" height="17" font="6"><b>(N) </b></text>
<text top="108" left="471" width="94" height="17" font="6"><b>Intervention vs. </b></text>
<text top="128" left="472" width="92" height="17" font="6"><b>Comparator (n) </b></text>
<text top="109" left="624" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="109" left="955" width="64" height="17" font="6"><b>Endpoints </b></text>
<text top="109" left="1233" width="96" height="17" font="6"><b>Adverse Events </b></text>
<text top="164" left="81" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="226" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="381" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="516" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="621" width="119" height="17" font="6"><b>Inclusion/Exclusion </b></text>
<text top="181" left="657" width="46" height="17" font="6"><b>Criteria </b></text>
<text top="164" left="793" width="166" height="17" font="6"><b>Primary Endpoint &amp; Results </b></text>
<text top="164" left="1007" width="183" height="17" font="6"><b>Secondary Endpoint &amp; Results </b></text>
<text top="164" left="1279" width="3" height="17" font="6"><b> </b></text>
<text top="199" left="42" width="32" height="17" font="7">(188) </text>
<text top="216" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21791673">21791673</a></text>
<text top="216" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21791673"> </a></text>
<text top="199" left="136" width="172" height="17" font="7">early outcome of percutaneous </text>
<text top="216" left="136" width="77" height="17" font="7">repair of PVR </text>
<text top="199" left="332" width="88" height="17" font="7">N=115 pts (141 </text>
<text top="216" left="332" width="47" height="17" font="7">defects) </text>
<text top="199" left="447" width="29" height="17" font="7">PVR </text>
<text top="199" left="602" width="29" height="17" font="7">PVR </text>
<text top="216" left="602" width="99" height="17" font="7">Average STS risk </text>
<text top="233" left="602" width="69" height="17" font="7">score=6.9% </text>
<text top="199" left="771" width="188" height="17" font="7">Mild or no residual regurgitation in </text>
<text top="216" left="771" width="28" height="17" font="7">77% </text>
<text top="233" left="771" width="115" height="17" font="7">No procedural death </text>
<text top="199" left="994" width="206" height="17" font="7">Procedure time average 147 min and </text>
<text top="216" left="994" width="179" height="17" font="7">decreased with case experience </text>
<text top="199" left="1216" width="71" height="17" font="7">Death, 1.7% </text>
<text top="216" left="1216" width="74" height="17" font="7">Stroke, 2.6% </text>
<text top="233" left="1216" width="113" height="17" font="7">Emergency surgery, </text>
<text top="251" left="1216" width="35" height="17" font="7">0.9%, </text>
<text top="268" left="1216" width="87" height="17" font="7">Bleeding=5.2% </text>
<text top="286" left="42" width="76" height="17" font="7">Sorajja 2011  </text>
<text top="303" left="42" width="32" height="17" font="7">(189) </text>
<text top="320" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22078428">22078428</a></text>
<text top="320" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22078428"> </a></text>
<text top="286" left="136" width="152" height="17" font="7">To determine the long-term </text>
<text top="303" left="136" width="177" height="17" font="7">clinical efficacy of percutaneous </text>
<text top="320" left="136" width="77" height="17" font="7">repair of PVR </text>
<text top="286" left="332" width="79" height="17" font="7">Retrospective </text>
<text top="303" left="332" width="68" height="17" font="7">N=126 (154 </text>
<text top="320" left="332" width="47" height="17" font="7">defects) </text>
<text top="286" left="447" width="128" height="17" font="7">Percutaneous repair of </text>
<text top="303" left="447" width="29" height="17" font="7">PVR </text>
<text top="286" left="602" width="155" height="17" font="7">79% mitral PVR, 21% aortic </text>
<text top="303" left="602" width="29" height="17" font="7">PVR </text>
<text top="320" left="602" width="99" height="17" font="7">Average STS risk </text>
<text top="337" left="602" width="69" height="17" font="7">score=6.7% </text>
<text top="286" left="771" width="100" height="17" font="7">3-y survival, 64%  </text>
<text top="303" left="771" width="179" height="17" font="7">HF accounted to 37% of deaths; </text>
<text top="320" left="771" width="141" height="17" font="7">noncardiac cause in 30% </text>
<text top="286" left="994" width="207" height="17" font="7">Symptom improvement occurred only </text>
<text top="303" left="994" width="162" height="17" font="7">in pts with mild or no residual </text>
<text top="320" left="994" width="72" height="17" font="7">regurgitation </text>
<text top="337" left="994" width="198" height="17" font="7">Hemolytic anemia persisted in 14 of </text>
<text top="355" left="994" width="37" height="17" font="7">29 pts </text>
<text top="286" left="1216" width="119" height="17" font="7">Survival free of death </text>
<text top="303" left="1216" width="106" height="17" font="7">or need for cardiac </text>
<text top="320" left="1216" width="121" height="17" font="7">surgery was 54% at 3 </text>
<text top="337" left="1216" width="10" height="17" font="7">y </text>
<text top="355" left="1216" width="93" height="17" font="7">Need for cardiac </text>
<text top="372" left="1216" width="99" height="17" font="7">surgery related to </text>
<text top="389" left="1216" width="102" height="17" font="7">degree of residual </text>
<text top="406" left="1216" width="72" height="17" font="7">regurgitation </text>
<text top="424" left="34" width="1276" height="17" font="7">EPO indicates erythropoietin; HF, heart failure; N/A, not applicable; NYHA, New York Heart Association; pts, patients; PVR, paravalvular regurgitation; STS, Society of Thoracic Surgeons; and, TEE, transesophageal echocardiography. </text>
<text top="442" left="108" width="3" height="17" font="7"> </text>
<text top="442" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="46" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">46 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="34" width="542" height="21" font="4"><b>Data Supplement 24. Surgical Outcome in Infective Endocarditis (Section 12) </b></text>
<text top="129" left="53" width="47" height="17" font="6"><b>Author/ </b></text>
<text top="146" left="62" width="30" height="17" font="6"><b>Year </b></text>
<text top="129" left="144" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="129" left="264" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="354" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="359" width="28" height="17" font="6"><b>Size </b></text>
<text top="164" left="363" width="21" height="17" font="6"><b>(N) </b></text>
<text top="129" left="425" width="44" height="17" font="6"><b>Patient </b></text>
<text top="146" left="414" width="67" height="17" font="6"><b>Population </b></text>
<text top="129" left="553" width="111" height="17" font="6"><b>Study Intervention </b></text>
<text top="129" left="830" width="106" height="17" font="6"><b>Primary Endpoint </b></text>
<text top="129" left="1135" width="136" height="17" font="6"><b>Predictors of Outcome </b></text>
<text top="182" left="44" width="64" height="17" font="7">Jault, 1997 </text>
<text top="199" left="44" width="32" height="17" font="7">(190) </text>
<text top="216" left="44" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9205176">9205176</a></text>
<text top="216" left="92" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9205176"> </a></text>
<text top="182" left="123" width="101" height="17" font="7">Identify significant </text>
<text top="199" left="123" width="71" height="17" font="7">predictors of </text>
<text top="216" left="123" width="107" height="17" font="7">operative mortality, </text>
<text top="233" left="123" width="93" height="17" font="7">reoperation, and </text>
<text top="250" left="123" width="74" height="17" font="7">recurrent IEs </text>
<text top="182" left="258" width="78" height="17" font="7">Retrospective </text>
<text top="199" left="258" width="74" height="17" font="7">single-center </text>
<text top="216" left="258" width="46" height="17" font="7">surgical </text>
<text top="233" left="258" width="70" height="17" font="7">cohort study </text>
<text top="182" left="352" width="24" height="17" font="7">247 </text>
<text top="182" left="406" width="65" height="17" font="7">NVE alone; </text>
<text top="199" left="406" width="79" height="17" font="7">surgery 100% </text>
<text top="182" left="501" width="195" height="17" font="7">Registration of epidemiological and </text>
<text top="199" left="501" width="136" height="17" font="7">microbiological features, </text>
<text top="216" left="501" width="187" height="17" font="7">echocardiography data, treatment </text>
<text top="233" left="501" width="51" height="17" font="7">strategy  </text>
<text top="182" left="730" width="290" height="17" font="7">Operative mortality was 7.6% (n=19). Overall survival</text>
<text top="183" left="1021" width="2" height="11" font="9"> </text>
<text top="199" left="730" width="290" height="17" font="7">rate (operative mortality excluded) was 71.3% at 9 y. </text>
<text top="216" left="730" width="236" height="17" font="7">The probability of freedom from reoperation</text>
<text top="217" left="967" width="2" height="11" font="9"> </text>
<text top="216" left="969" width="58" height="17" font="7">(operative </text>
<text top="233" left="730" width="213" height="17" font="7">mortality included) was 73.3±4.2% at 8</text>
<text top="234" left="943" width="2" height="11" font="9"> </text>
<text top="233" left="945" width="13" height="17" font="7">y. </text>
<text top="250" left="730" width="283" height="17" font="7">The rate of IE of the implanted prosthetic valve was </text>
<text top="268" left="730" width="28" height="17" font="7">7%.  </text>
<text top="182" left="1048" width="81" height="17" font="7">Increased age,</text>
<text top="183" left="1129" width="2" height="11" font="9"> </text>
<text top="182" left="1131" width="176" height="17" font="7">cardiogenic shock at the time of </text>
<text top="199" left="1048" width="147" height="17" font="7">operation, insidious illness,</text>
<text top="200" left="1195" width="2" height="11" font="9"> </text>
<text top="199" left="1197" width="140" height="17" font="7">and greater thoracic ratio </text>
<text top="216" left="1048" width="177" height="17" font="7">(&gt;0.5) were the predominant risk</text>
<text top="217" left="1225" width="2" height="11" font="9"> </text>
<text top="216" left="1227" width="112" height="17" font="7">factors for operative </text>
<text top="233" left="1048" width="290" height="17" font="7">mortality; the length of antibiotic therapy appeared to </text>
<text top="250" left="1048" width="103" height="17" font="7">have no influence. </text>
<text top="268" left="1048" width="294" height="17" font="7">Increased age, preoperative neurologic complications,</text>
<text top="269" left="1342" width="2" height="11" font="9"> </text>
<text top="285" left="1048" width="276" height="17" font="7">cardiogenic shock at the time of operation, shorter </text>
<text top="302" left="1048" width="44" height="17" font="7">duration</text>
<text top="303" left="1092" width="2" height="11" font="9"> </text>
<text top="302" left="1094" width="223" height="17" font="7">of the illness, insidious illness before the </text>
<text top="319" left="1048" width="79" height="17" font="7">operation, and</text>
<text top="320" left="1126" width="2" height="11" font="9"> </text>
<text top="319" left="1129" width="186" height="17" font="7">mitral valve endocarditis were the </text>
<text top="337" left="1048" width="131" height="17" font="7">predominant risk factors</text>
<text top="338" left="1179" width="2" height="11" font="9"> </text>
<text top="337" left="1181" width="94" height="17" font="7">for late mortality. </text>
<text top="354" left="1048" width="310" height="17" font="7">Risk factors for reoperation were younger age and aortic </text>
<text top="371" left="1048" width="105" height="17" font="7">valve endocarditis. </text>
<text top="389" left="44" width="47" height="17" font="7">Castillo, </text>
<text top="406" left="44" width="31" height="17" font="7">2000 </text>
<text top="423" left="44" width="32" height="17" font="7">(191) </text>
<text top="440" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10768901">10768901</a></text>
<text top="440" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10768901"> </a></text>
<text top="389" left="123" width="96" height="17" font="7">To determine the </text>
<text top="406" left="123" width="112" height="17" font="7">clinical features and </text>
<text top="423" left="123" width="112" height="17" font="7">long-term prognosis </text>
<text top="440" left="123" width="117" height="17" font="7">of IE in pts who were </text>
<text top="458" left="123" width="86" height="17" font="7">not drug users. </text>
<text top="389" left="258" width="67" height="17" font="7">Prospective </text>
<text top="406" left="258" width="74" height="17" font="7">single-center </text>
<text top="423" left="258" width="66" height="17" font="7">case series </text>
<text top="389" left="352" width="24" height="17" font="7">138 </text>
<text top="389" left="406" width="60" height="17" font="7">NVE 69%, </text>
<text top="406" left="406" width="59" height="17" font="7">PVE 31%; </text>
<text top="423" left="406" width="73" height="17" font="7">surgery 51% </text>
<text top="389" left="501" width="195" height="17" font="7">Registration of epidemiological and </text>
<text top="406" left="501" width="136" height="17" font="7">microbiological features, </text>
<text top="423" left="501" width="187" height="17" font="7">echocardiography data, treatment </text>
<text top="440" left="501" width="47" height="17" font="7">strategy </text>
<text top="389" left="730" width="272" height="17" font="7">Severe complications (HF, embolic phenomenon, </text>
<text top="406" left="730" width="301" height="17" font="7">severe valve dysfunction, abscesses, renal failure, and </text>
<text top="423" left="730" width="281" height="17" font="7">immunologic phenomenon) occurred in 83% of pts. </text>
<text top="440" left="730" width="297" height="17" font="7">51% of pts underwent surgery during the active phase </text>
<text top="458" left="730" width="170" height="17" font="7">(22% was emergency surgery) </text>
<text top="475" left="730" width="134" height="17" font="7">Inpt mortality was 21%.  </text>
<text top="492" left="730" width="168" height="17" font="7">Overall 10 y survival was 71% </text>
<text top="389" left="1048" width="262" height="17" font="7">There were no significant differences in survival </text>
<text top="406" left="1048" width="302" height="17" font="7">depending on the type of treatment received during the </text>
<text top="423" left="1048" width="307" height="17" font="7">hospital stay (medical vs. combined medical-surgical) in </text>
<text top="440" left="1048" width="135" height="17" font="7">this observational study. </text>
<text top="510" left="44" width="47" height="17" font="7">Alexiou, </text>
<text top="527" left="44" width="31" height="17" font="7">2000 </text>
<text top="544" left="44" width="32" height="17" font="7">(192) </text>
<text top="562" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10881821">10881821</a></text>
<text top="562" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10881821"> </a></text>
<text top="510" left="123" width="34" height="17" font="7">Single</text>
<text top="511" left="157" width="2" height="11" font="9"> </text>
<text top="510" left="159" width="38" height="17" font="7">center </text>
<text top="527" left="123" width="97" height="17" font="7">experience in the </text>
<text top="544" left="123" width="115" height="17" font="7">surgical treatment of </text>
<text top="562" left="123" width="118" height="17" font="7">active culture-positive</text>
<text top="563" left="241" width="2" height="11" font="9"> </text>
<text top="579" left="123" width="81" height="17" font="7">IE and identify </text>
<text top="596" left="123" width="118" height="17" font="7">determinants of early </text>
<text top="613" left="123" width="98" height="17" font="7">and late outcome </text>
<text top="510" left="258" width="78" height="17" font="7">Retrospective </text>
<text top="527" left="258" width="74" height="17" font="7">single-center </text>
<text top="544" left="258" width="46" height="17" font="7">surgical </text>
<text top="562" left="258" width="70" height="17" font="7">cohort study </text>
<text top="510" left="352" width="24" height="17" font="7">118 </text>
<text top="510" left="406" width="60" height="17" font="7">NVE 70%, </text>
<text top="527" left="406" width="59" height="17" font="7">PVE 30%; </text>
<text top="544" left="406" width="68" height="17" font="7">100% of pts </text>
<text top="562" left="406" width="61" height="17" font="7">underwent </text>
<text top="579" left="406" width="44" height="17" font="7">surgery </text>
<text top="510" left="501" width="195" height="17" font="7">Registration of epidemiological and </text>
<text top="527" left="501" width="136" height="17" font="7">microbiological features, </text>
<text top="544" left="501" width="187" height="17" font="7">echocardiography data, treatment </text>
<text top="562" left="501" width="47" height="17" font="7">strategy </text>
<text top="510" left="730" width="205" height="17" font="7">Operative mortality was 7.6% (9 pts). </text>
<text top="527" left="730" width="289" height="17" font="7">Endocarditis recurred in 8 (6.7%). A reoperation was </text>
<text top="544" left="730" width="132" height="17" font="7">required in 12 (10.2%).  </text>
<text top="562" left="730" width="258" height="17" font="7">There were 24 late deaths, 17 of them cardiac. </text>
<text top="579" left="730" width="254" height="17" font="7">Actuarial freedom from recurrent endocarditis, </text>
<text top="596" left="730" width="297" height="17" font="7">reoperation, late cardiac death, and long-term survival </text>
<text top="613" left="730" width="261" height="17" font="7">at 10 y were 85.9%, 87.2%, 85.2%, and 73.1%, </text>
<text top="631" left="730" width="72" height="17" font="7">respectively. </text>
<text top="510" left="1048" width="272" height="17" font="7">Predictors of operative mortality: HF, impaired LV </text>
<text top="527" left="1048" width="50" height="17" font="7">function. </text>
<text top="544" left="1048" width="173" height="17" font="7">Predictors of recurrence: PVE.  </text>
<text top="562" left="1048" width="264" height="17" font="7">Predictors of late mortality: myocardial invasion, </text>
<text top="579" left="1048" width="73" height="17" font="7">reoperation.  </text>
<text top="596" left="1048" width="264" height="17" font="7">Predictors of poor long-term survival: coagulase-</text>
<text top="613" left="1048" width="288" height="17" font="7">negative staphylococcus, annular abscess, long ICU </text>
<text top="631" left="1048" width="29" height="17" font="7">stay. </text>
<text top="649" left="44" width="50" height="17" font="7">Wallace, </text>
<text top="666" left="44" width="31" height="17" font="7">2002 </text>
<text top="683" left="44" width="32" height="17" font="7">(193) </text>
<text top="700" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12067945">12067945</a></text>
<text top="700" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12067945"> </a></text>
<text top="649" left="123" width="100" height="17" font="7">To identify clinical </text>
<text top="666" left="123" width="100" height="17" font="7">markers available </text>
<text top="683" left="123" width="120" height="17" font="7">within the first 48 h of </text>
<text top="700" left="123" width="104" height="17" font="7">admission that are </text>
<text top="718" left="123" width="115" height="17" font="7">associated with poor </text>
<text top="735" left="123" width="79" height="17" font="7">outcome in IE </text>
<text top="649" left="258" width="78" height="17" font="7">Retrospective </text>
<text top="666" left="258" width="74" height="17" font="7">single-center </text>
<text top="683" left="258" width="70" height="17" font="7">cohort study </text>
<text top="649" left="352" width="24" height="17" font="7">208 </text>
<text top="649" left="406" width="60" height="17" font="7">NVE 68%, </text>
<text top="666" left="406" width="59" height="17" font="7">PVE 32%; </text>
<text top="683" left="406" width="73" height="17" font="7">surgery 52% </text>
<text top="649" left="501" width="174" height="17" font="7">Registration of epidemiological, </text>
<text top="666" left="501" width="184" height="17" font="7">clinical, microbiological and other </text>
<text top="683" left="501" width="210" height="17" font="7">laboratory features, echocardiography </text>
<text top="700" left="501" width="157" height="17" font="7">data, and treatment strategy </text>
<text top="649" left="730" width="274" height="17" font="7">Mortality at discharge was 18% and at 6 mo 27%. </text>
<text top="666" left="730" width="231" height="17" font="7">Surgery was performed in 107 (51%) pts.  </text>
<text top="683" left="730" width="276" height="17" font="7">In-hospital mortality was not inﬂuenced by surgery </text>
<text top="700" left="730" width="256" height="17" font="7">(23% vs. 15% in the nonsurgical group); p=0.3 </text>
<text top="718" left="730" width="297" height="17" font="7">At 6 mo there was a trend towards increased mortality </text>
<text top="735" left="730" width="198" height="17" font="7">in the surgical group (33% vs. 20%) </text>
<text top="649" left="1048" width="266" height="17" font="7">Duration of illness, age, gender, site of infection, </text>
<text top="666" left="1048" width="284" height="17" font="7">organism, and LV function did not predict outcome.  </text>
<text top="683" left="1048" width="297" height="17" font="7">Abnormal white cell count, raised creatinine, ≥2 major </text>
<text top="700" left="1048" width="271" height="17" font="7">Duke criteria, or visible vegetation conferred poor </text>
<text top="718" left="1048" width="60" height="17" font="7">prognosis. </text>
<text top="753" left="44" width="49" height="17" font="7">Hasbun, </text>
<text top="770" left="44" width="31" height="17" font="7">2003 </text>
<text top="787" left="44" width="32" height="17" font="7">(194) </text>
<text top="753" left="123" width="79" height="17" font="7">To derive and </text>
<text top="770" left="123" width="112" height="17" font="7">externally validate a </text>
<text top="787" left="123" width="60" height="17" font="7">prognostic </text>
<text top="753" left="258" width="78" height="17" font="7">Retrospective </text>
<text top="770" left="258" width="63" height="17" font="7">multicenter </text>
<text top="787" left="258" width="70" height="17" font="7">cohort study </text>
<text top="753" left="352" width="24" height="17" font="7">513 </text>
<text top="753" left="406" width="67" height="17" font="7">Pts with left-</text>
<text top="770" left="406" width="61" height="17" font="7">sided NVE </text>
<text top="787" left="406" width="67" height="17" font="7">with current </text>
<text top="753" left="501" width="191" height="17" font="7">Registration of clinical information, </text>
<text top="770" left="501" width="188" height="17" font="7">sociodemographic data, comorbid </text>
<text top="787" left="501" width="193" height="17" font="7">conditions, previous heart disease, </text>
<text top="753" left="730" width="269" height="17" font="7">In the derivation and validation cohorts, the 6-mo </text>
<text top="770" left="730" width="266" height="17" font="7">mortality rates were 25% and 26%, respectively. </text>
<text top="787" left="730" width="269" height="17" font="7">In the derivation cohort, pts were classified into 4 </text>
<text top="753" left="1048" width="305" height="17" font="7">5 baseline features were independently associated with </text>
<text top="770" left="1048" width="298" height="17" font="7">6 mo mortality (comorbidity [p=0.03], abnormal mental </text>
<text top="787" left="1048" width="281" height="17" font="7">status [p=0.02], moderate-to-severe congestive HF </text>
</page>
<page number="47" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">47 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="53" width="47" height="17" font="6"><b>Author/ </b></text>
<text top="126" left="62" width="30" height="17" font="6"><b>Year </b></text>
<text top="108" left="144" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="264" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="354" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="359" width="28" height="17" font="6"><b>Size </b></text>
<text top="143" left="363" width="21" height="17" font="6"><b>(N) </b></text>
<text top="108" left="425" width="44" height="17" font="6"><b>Patient </b></text>
<text top="126" left="414" width="67" height="17" font="6"><b>Population </b></text>
<text top="108" left="553" width="111" height="17" font="6"><b>Study Intervention </b></text>
<text top="108" left="830" width="106" height="17" font="6"><b>Primary Endpoint </b></text>
<text top="108" left="1135" width="136" height="17" font="6"><b>Predictors of Outcome </b></text>
<text top="161" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12697795">12697795</a></text>
<text top="161" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12697795"> </a></text>
<text top="161" left="123" width="115" height="17" font="7">classification system </text>
<text top="178" left="123" width="63" height="17" font="7">for pts with </text>
<text top="195" left="123" width="89" height="17" font="7">complicated left-</text>
<text top="212" left="123" width="116" height="17" font="7">sided native valve IE </text>
<text top="161" left="406" width="69" height="17" font="7">indication of </text>
<text top="178" left="406" width="57" height="17" font="7">surgery in </text>
<text top="195" left="406" width="32" height="17" font="7">45%` </text>
<text top="161" left="501" width="193" height="17" font="7">symptoms, physical findings, blood </text>
<text top="178" left="501" width="155" height="17" font="7">cultures, electrocardiogram, </text>
<text top="195" left="501" width="189" height="17" font="7">echocardiography, type of surgery </text>
<text top="212" left="501" width="187" height="17" font="7">performed, and operative findings </text>
<text top="161" left="730" width="275" height="17" font="7">groups with increasing risk for 6-mo mortality: 5%, </text>
<text top="178" left="730" width="178" height="17" font="7">15%, 31%, and 59% (p&lt;0.001).  </text>
<text top="195" left="730" width="274" height="17" font="7">In the validation cohort, a similar risk among the 4 </text>
<text top="212" left="730" width="263" height="17" font="7">groups was observed: 7%, 19%, 32%, and 69% </text>
<text top="230" left="730" width="60" height="17" font="7">(p&lt;0.001). </text>
<text top="161" left="1048" width="252" height="17" font="7">[p=0.01], bacterial etiology other than viridans </text>
<text top="178" left="1048" width="299" height="17" font="7">streptococci [p&lt;0.001 except <i>S. aureus</i>, p=0.004], and </text>
<text top="195" left="1048" width="268" height="17" font="7">medical therapy without valve surgery [p=0.002]) </text>
<text top="248" left="44" width="45" height="17" font="7">Vikram, </text>
<text top="265" left="44" width="31" height="17" font="7">2003 </text>
<text top="282" left="44" width="32" height="17" font="7">(195) </text>
<text top="299" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14693873">14693873</a></text>
<text top="299" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14693873"> </a></text>
<text top="248" left="123" width="76" height="17" font="7">To determine </text>
<text top="265" left="123" width="79" height="17" font="7">whether valve </text>
<text top="282" left="123" width="119" height="17" font="7">surgery is associated </text>
<text top="299" left="123" width="73" height="17" font="7">with reduced </text>
<text top="317" left="123" width="108" height="17" font="7">mortality in pts with </text>
<text top="334" left="123" width="93" height="17" font="7">complicated, left-</text>
<text top="351" left="123" width="116" height="17" font="7">sided native valve IE </text>
<text top="248" left="258" width="78" height="17" font="7">Retrospective </text>
<text top="265" left="258" width="63" height="17" font="7">multicenter </text>
<text top="282" left="258" width="74" height="17" font="7">cohort study; </text>
<text top="299" left="258" width="61" height="17" font="7">Propensity </text>
<text top="317" left="258" width="51" height="17" font="7">analysis  </text>
<text top="248" left="352" width="24" height="17" font="7">513 </text>
<text top="248" left="406" width="66" height="17" font="7">Pts with left </text>
<text top="265" left="406" width="61" height="17" font="7">sided NVE </text>
<text top="282" left="406" width="67" height="17" font="7">with current </text>
<text top="299" left="406" width="46" height="17" font="7">surgical </text>
<text top="317" left="406" width="80" height="17" font="7">intervention in </text>
<text top="334" left="406" width="28" height="17" font="7">45% </text>
<text top="248" left="501" width="191" height="17" font="7">Registration of clinical information, </text>
<text top="265" left="501" width="188" height="17" font="7">sociodemographic data, comorbid </text>
<text top="282" left="501" width="193" height="17" font="7">conditions, previous heart disease, </text>
<text top="299" left="501" width="193" height="17" font="7">symptoms, physical findings, blood </text>
<text top="317" left="501" width="215" height="17" font="7">cultures, ECG, echocardiography, type </text>
<text top="334" left="501" width="199" height="17" font="7">of surgery performed, and operative </text>
<text top="351" left="501" width="46" height="17" font="7">findings </text>
<text top="248" left="730" width="300" height="17" font="7">After adjustment for baseline variables associated with </text>
<text top="265" left="730" width="271" height="17" font="7">mortality (including hospital site, comorbidity, HF, </text>
<text top="282" left="730" width="256" height="17" font="7">microbial etiology, immunocompromised state, </text>
<text top="299" left="730" width="303" height="17" font="7">abnormal mental status, and refractory infection), valve </text>
<text top="317" left="730" width="284" height="17" font="7">surgery remained associated with reduced mortality </text>
<text top="334" left="730" width="271" height="17" font="7">(adjusted HR: 0.35; 95% CI: 0.23–0.54; p&lt;0.02).  </text>
<text top="351" left="730" width="289" height="17" font="7">In further analyses of 218 pts matched by propensity </text>
<text top="368" left="730" width="262" height="17" font="7">scores, valve surgery remained associated with </text>
<text top="385" left="730" width="283" height="17" font="7">reduced mortality (15% vs. 28%; HR: 0.45; 95% CI: </text>
<text top="403" left="730" width="117" height="17" font="7">0.23–0.86; p=0.01).   </text>
<text top="420" left="730" width="301" height="17" font="7">After additional adjustment for variables that contribute </text>
<text top="437" left="730" width="241" height="17" font="7">to heterogeneity and confounding within the </text>
<text top="454" left="730" width="294" height="17" font="7">propensity-matched group, surgical therapy remained </text>
<text top="472" left="730" width="276" height="17" font="7">significantly associated with a lower mortality (HR: </text>
<text top="489" left="730" width="186" height="17" font="7">0.40; 95% CI: 0.18-0.91; p=0.03). </text>
<text top="506" left="730" width="287" height="17" font="7">In this propensity-matched group, pts with moderate-</text>
<text top="523" left="730" width="251" height="17" font="7">to-severe congestive HF showed the greatest </text>
<text top="540" left="730" width="301" height="17" font="7">reduction in mortality with valve surgery (14% vs. 51%; </text>
<text top="558" left="730" width="220" height="17" font="7">HR: 0.22; 95% CI: 0.09–0.53; p=0.001). </text>
<text top="248" left="1048" width="291" height="17" font="7">Pts with moderate-to-severe HF showed the greatest </text>
<text top="265" left="1048" width="226" height="17" font="7">reduction in mortality with valve surgery.  </text>
<text top="282" left="1048" width="306" height="17" font="7">Stratifying the data by congestive HF among propensity-</text>
<text top="299" left="1048" width="295" height="17" font="7">matched pts undergoing surgery revealed that among </text>
<text top="317" left="1048" width="261" height="17" font="7">pts with none to mild HF, valve surgery was not </text>
<text top="334" left="1048" width="268" height="17" font="7">associated with reduced mortality compared with </text>
<text top="351" left="1048" width="311" height="17" font="7">medical therapy (HR: 1.04; 95% CI: 0.43–2.48; p=0.93).  </text>
<text top="368" left="1048" width="310" height="17" font="7">Among propensity-matched pts with moderate-to-severe </text>
<text top="385" left="1048" width="281" height="17" font="7">HF, valve surgery was associated with a significant </text>
<text top="403" left="1048" width="291" height="17" font="7">reduction in mortality compared with medical therapy </text>
<text top="420" left="1048" width="217" height="17" font="7">(HR: 0.22; 95% CI: 0.08–0.53; p=0.01). </text>
<text top="575" left="44" width="39" height="17" font="7">Habib, </text>
<text top="593" left="44" width="31" height="17" font="7">2005 </text>
<text top="610" left="44" width="32" height="17" font="7">(196) </text>
<text top="627" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15958370">15958370</a></text>
<text top="627" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15958370"> </a></text>
<text top="575" left="123" width="120" height="17" font="7">To identify prognostic </text>
<text top="593" left="123" width="105" height="17" font="7">markers in 104 pts </text>
<text top="610" left="123" width="98" height="17" font="7">with PVE and the </text>
<text top="627" left="123" width="109" height="17" font="7">effects of a medical </text>
<text top="644" left="123" width="85" height="17" font="7">versus surgical </text>
<text top="662" left="123" width="111" height="17" font="7">strategy outcome in </text>
<text top="679" left="123" width="32" height="17" font="7">PVE  </text>
<text top="575" left="258" width="78" height="17" font="7">Retrospective </text>
<text top="593" left="258" width="63" height="17" font="7">multicenter </text>
<text top="610" left="258" width="70" height="17" font="7">cohort study </text>
<text top="575" left="352" width="24" height="17" font="7">104 </text>
<text top="575" left="406" width="63" height="17" font="7">100% PVE </text>
<text top="593" left="406" width="68" height="17" font="7">pts; surgery </text>
<text top="610" left="406" width="28" height="17" font="7">49% </text>
<text top="575" left="501" width="174" height="17" font="7">Registration of epidemiological, </text>
<text top="593" left="501" width="184" height="17" font="7">clinical, microbiological and other </text>
<text top="610" left="501" width="210" height="17" font="7">laboratory features, echocardiography </text>
<text top="627" left="501" width="157" height="17" font="7">data, and treatment strategy </text>
<text top="575" left="730" width="188" height="17" font="7">Overall, 22 (21%) died in hospital. </text>
<text top="593" left="730" width="288" height="17" font="7">By multivariate analysis, severe HF (OR: 5.5) and <i>S. </i></text>
<text top="610" left="730" width="292" height="17" font="11"><i>aureus</i> infection (OR: 6.1) were the only independent </text>
<text top="627" left="730" width="168" height="17" font="7">predictors of in-hospital death. </text>
<text top="644" left="730" width="303" height="17" font="7">Among 82 in-hospital survivors, 21 (26%) died during a </text>
<text top="662" left="730" width="94" height="17" font="7">32 mo follow-up. </text>
<text top="679" left="730" width="260" height="17" font="7">Mortality was not significantly different between </text>
<text top="696" left="730" width="238" height="17" font="7">surgical and nonsurgical pts (17% vs. 25%, </text>
<text top="713" left="730" width="161" height="17" font="7">respectively, not significant).  </text>
<text top="730" left="730" width="295" height="17" font="7">Both in-hospital and long-term mortality were reduced </text>
<text top="748" left="730" width="284" height="17" font="7">by a surgical approach in high-risk subgroups of pts </text>
<text top="765" left="730" width="262" height="17" font="7">with staphylococcal PVE and complicated PVE. </text>
<text top="575" left="1048" width="296" height="17" font="7">Factors associated with in-hospital death were severe </text>
<text top="593" left="1048" width="308" height="17" font="7">comorbidity (6% of survivors vs. 41% of those who died; </text>
<text top="610" left="1048" width="301" height="17" font="7">p=0.05), renal failure (28% vs.45%, p=0.05), moderate-</text>
<text top="627" left="1048" width="265" height="17" font="7">to-severe regurgitation (22% vs. 54%; p=0.006), </text>
<text top="644" left="1048" width="133" height="17" font="7">staphylococcal infection </text>
<text top="662" left="1048" width="281" height="17" font="7">(16% vs. 54%; p=0.001), severe HF (22% vs. 64%; </text>
<text top="679" left="1048" width="304" height="17" font="7">p=0.001), and occurrence of any complication (60% vs. </text>
<text top="696" left="1048" width="80" height="17" font="7">90%; p=0.05). </text>
<text top="783" left="44" width="44" height="17" font="7">Revilla, </text>
<text top="783" left="123" width="109" height="17" font="7">Describe the proﬁle </text>
<text top="783" left="258" width="67" height="17" font="7">Prospective </text>
<text top="783" left="352" width="24" height="17" font="7">508 </text>
<text top="783" left="406" width="60" height="17" font="7">NVE 66%, </text>
<text top="783" left="501" width="185" height="17" font="7">Brucella, Q fever, Legionella, and </text>
<text top="783" left="730" width="274" height="17" font="7">Of these 508 episodes, 132 (34%) were electively </text>
<text top="783" left="1048" width="305" height="17" font="7">Univariate analysis identiﬁed renal failure, septic shock, </text>
</page>
<page number="48" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="17" size="12" family="Times" color="#292425"/>
	<fontspec id="18" size="12" family="Times" color="#181818"/>
<text top="832" left="721" width="21" height="17" font="0">48 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="53" width="47" height="17" font="6"><b>Author/ </b></text>
<text top="126" left="62" width="30" height="17" font="6"><b>Year </b></text>
<text top="108" left="144" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="264" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="354" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="359" width="28" height="17" font="6"><b>Size </b></text>
<text top="143" left="363" width="21" height="17" font="6"><b>(N) </b></text>
<text top="108" left="425" width="44" height="17" font="6"><b>Patient </b></text>
<text top="126" left="414" width="67" height="17" font="6"><b>Population </b></text>
<text top="108" left="553" width="111" height="17" font="6"><b>Study Intervention </b></text>
<text top="108" left="830" width="106" height="17" font="6"><b>Primary Endpoint </b></text>
<text top="108" left="1135" width="136" height="17" font="6"><b>Predictors of Outcome </b></text>
<text top="161" left="44" width="31" height="17" font="7">2007 </text>
<text top="178" left="44" width="32" height="17" font="7">(197) </text>
<text top="195" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17032690">17032690</a></text>
<text top="195" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17032690"> </a></text>
<text top="161" left="123" width="112" height="17" font="7">of pts with left-sided </text>
<text top="178" left="123" width="102" height="17" font="7">IE who underwent </text>
<text top="195" left="123" width="120" height="17" font="7">urgent surgery and to </text>
<text top="212" left="123" width="113" height="17" font="7">identify predictors of </text>
<text top="230" left="123" width="50" height="17" font="7">mortality </text>
<text top="161" left="258" width="63" height="17" font="7">multicenter </text>
<text top="178" left="258" width="70" height="17" font="7">cohort study </text>
<text top="161" left="406" width="59" height="17" font="7">PVE 34%; </text>
<text top="178" left="406" width="44" height="17" font="7">surgery </text>
<text top="195" left="406" width="81" height="17" font="7">studied for the </text>
<text top="212" left="406" width="80" height="17" font="7">present report </text>
<text top="161" left="501" width="79" height="17" font="7">Mycoplasma.  </text>
<text top="178" left="501" width="216" height="17" font="7">Persistent infection despite appropriate </text>
<text top="195" left="501" width="150" height="17" font="7">antibiotic treatment (31%).  </text>
<text top="161" left="730" width="265" height="17" font="7">operated on, and 89 pts required urgent surgery </text>
<text top="178" left="730" width="282" height="17" font="7">(defined as prior to completion of antibiotic course). </text>
<text top="195" left="730" width="277" height="17" font="7">Primary reasons for urgent surgery in these 89 pts </text>
<text top="212" left="730" width="299" height="17" font="7">were HF that did not respond to medication (72%) and </text>
<text top="230" left="730" width="266" height="17" font="7">persistent infection despite appropriate antibiotic </text>
<text top="247" left="730" width="98" height="17" font="7">treatment (31%).  </text>
<text top="264" left="730" width="282" height="17" font="7">32 pts (36%) died during their hospital stay. 32% of </text>
<text top="281" left="730" width="273" height="17" font="7">NVE died vs. 45% of pts with PVE. Late PVE was </text>
<text top="299" left="730" width="302" height="17" font="7">associated with a higher mortality than early PVE (53% </text>
<text top="316" left="730" width="51" height="17" font="7">vs. 36%) </text>
<text top="161" left="1048" width="268" height="17" font="7">Gram-negative bacteria, persistent infection, and </text>
<text top="178" left="1048" width="287" height="17" font="7">surgery for persistent infection as factors associated </text>
<text top="195" left="1048" width="79" height="17" font="7">with mortality. </text>
<text top="212" left="1048" width="303" height="17" font="7">Multivariate analysis conﬁrmed only persistent infection </text>
<text top="230" left="1048" width="262" height="17" font="7">and renal insufﬁciency as factors independently </text>
<text top="247" left="1048" width="186" height="17" font="7">associated with a poor prognosis. </text>
<text top="334" left="44" width="55" height="17" font="7">Hill, 2007 </text>
<text top="351" left="44" width="32" height="17" font="7">(198) </text>
<text top="368" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17158121">17158121</a></text>
<text top="368" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17158121"> </a></text>
<text top="334" left="123" width="47" height="17" font="17">Analyze </text>
<text top="351" left="123" width="79" height="17" font="17">epidemiology, </text>
<text top="368" left="123" width="102" height="17" font="17">optimal treatment, </text>
<text top="385" left="123" width="106" height="17" font="17">and predictors of 6-</text>
<text top="403" left="123" width="98" height="17" font="17">mo mortality in IE </text>
<text top="403" left="221" width="3" height="17" font="7"> </text>
<text top="334" left="258" width="67" height="17" font="7">Prospective </text>
<text top="351" left="258" width="74" height="17" font="7">single-center </text>
<text top="368" left="258" width="70" height="17" font="7">cohort study </text>
<text top="334" left="352" width="24" height="17" font="7">193 </text>
<text top="334" left="406" width="60" height="17" font="7">NVE 66%, </text>
<text top="351" left="406" width="59" height="17" font="7">PVE 34%; </text>
<text top="368" left="406" width="73" height="17" font="7">surgery 63% </text>
<text top="334" left="501" width="174" height="17" font="7">Registration of epidemiological, </text>
<text top="351" left="501" width="184" height="17" font="7">clinical, microbiological and other </text>
<text top="368" left="501" width="210" height="17" font="7">laboratory features, echocardiography </text>
<text top="385" left="501" width="157" height="17" font="7">data, and treatment strategy </text>
<text top="334" left="730" width="282" height="17" font="7">43% included staphylococci, 26% streptococci, and </text>
<text top="351" left="730" width="101" height="17" font="7">17% enterococci.  </text>
<text top="368" left="730" width="253" height="17" font="7">At least 1 complication occurred in 79% of the </text>
<text top="385" left="730" width="248" height="17" font="7">episodes and 63% had surgical intervention.  </text>
<text top="403" left="730" width="292" height="17" font="7">6-mo mortality was 22%: 33% for staphylococci, 24% </text>
<text top="420" left="730" width="223" height="17" font="7">for enterococci, and 8% for streptococci. </text>
<text top="437" left="730" width="304" height="17" font="7">74% of pts with a contraindication to surgery died when </text>
<text top="454" left="730" width="283" height="17" font="7">compared with 7% with medical treatment without a </text>
<text top="472" left="730" width="271" height="17" font="7">contraindication and 16% with surgical treatment. </text>
<text top="334" left="1048" width="269" height="17" font="11"><i>S. aureus</i>, contraindication to surgery (present in </text>
<text top="351" left="1048" width="90" height="17" font="7">50% of deaths). </text>
<text top="489" left="44" width="49" height="17" font="7">Remadi, </text>
<text top="507" left="44" width="31" height="17" font="7">2007 </text>
<text top="524" left="44" width="32" height="17" font="7">(199) </text>
<text top="541" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17383330">17383330</a></text>
<text top="541" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17383330"> </a></text>
<text top="489" left="123" width="88" height="17" font="7">To evaluate the </text>
<text top="507" left="123" width="122" height="17" font="7">predictors of outcome </text>
<text top="524" left="123" width="89" height="17" font="7">and to establish </text>
<text top="541" left="123" width="122" height="17" font="7">whether early surgery </text>
<text top="558" left="123" width="100" height="17" font="7">is associated with </text>
<text top="575" left="123" width="98" height="17" font="7">reduced mortality </text>
<text top="489" left="258" width="67" height="17" font="7">Prospective </text>
<text top="507" left="258" width="63" height="17" font="7">multicenter </text>
<text top="524" left="258" width="70" height="17" font="7">cohort study </text>
<text top="489" left="352" width="24" height="17" font="7">116 </text>
<text top="489" left="406" width="71" height="17" font="11"><i>S. aureus</i> IE </text>
<text top="507" left="406" width="66" height="17" font="7">alone; NVE </text>
<text top="524" left="406" width="59" height="17" font="7">83%, PVE </text>
<text top="541" left="406" width="76" height="17" font="7">17%; surgery </text>
<text top="558" left="406" width="28" height="17" font="7">47% </text>
<text top="489" left="501" width="174" height="17" font="7">Registration of epidemiological, </text>
<text top="507" left="501" width="184" height="17" font="7">clinical, microbiological and other </text>
<text top="524" left="501" width="211" height="17" font="7">laboratory features, echocardiography </text>
<text top="541" left="501" width="214" height="17" font="7">data, and treatment strategy. Antibiotic </text>
<text top="558" left="501" width="59" height="17" font="7">treatment. </text>
<text top="489" left="730" width="298" height="17" font="7">The in-hospital mortality rate was 26%, and the 36-mo </text>
<text top="507" left="730" width="127" height="17" font="7">survival rate was 57%  </text>
<text top="524" left="730" width="266" height="17" font="7">Surgical group mortality was 16% vs. 34% in the </text>
<text top="541" left="730" width="181" height="17" font="7">medically treated group (p&lt;0.05) </text>
<text top="558" left="730" width="280" height="17" font="7">In unadjusted analyses, early surgery performed in </text>
<text top="575" left="730" width="267" height="17" font="7">47% of pts was associated with lower in-hospital </text>
<text top="593" left="730" width="287" height="17" font="7">mortality (16% vs. 34%; p=0.034) and with better 36-</text>
<text top="610" left="730" width="208" height="17" font="7">mo survival (77% vs. 39%; p&lt;0.001).  </text>
<text top="489" left="1048" width="297" height="17" font="7">Multivariate analyses identiﬁed comorbidity index, HF, </text>
<text top="507" left="1048" width="307" height="17" font="7">severe sepsis, prosthetic valve IE, and major neurologic </text>
<text top="524" left="1048" width="237" height="17" font="7">events as predictors of in-hospital mortality </text>
<text top="541" left="1048" width="305" height="17" font="7">Severe sepsis and comorbidity index were predictors of </text>
<text top="558" left="1048" width="90" height="17" font="7">overall mortality </text>
<text top="575" left="1048" width="263" height="17" font="7">After adjustment of baseline variables related to </text>
<text top="593" left="1048" width="270" height="17" font="7">mortality, early surgery remained associated with </text>
<text top="610" left="1048" width="141" height="17" font="7">reduced overall mortality. </text>
<text top="628" left="44" width="40" height="17" font="7">Aksoy, </text>
<text top="645" left="44" width="31" height="17" font="7">2007 </text>
<text top="662" left="44" width="32" height="17" font="7">(200) </text>
<text top="679" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17205442">17205442</a></text>
<text top="679" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17205442"> </a></text>
<text top="628" left="123" width="118" height="17" font="7">To better understand </text>
<text top="645" left="123" width="118" height="17" font="7">the impact of surgery </text>
<text top="662" left="123" width="93" height="17" font="7">on the long-term </text>
<text top="679" left="123" width="119" height="17" font="7">survival of pts with IE </text>
<text top="628" left="258" width="67" height="17" font="7">Prospective </text>
<text top="645" left="258" width="74" height="17" font="7">single-center </text>
<text top="662" left="258" width="70" height="17" font="7">cohort study </text>
<text top="679" left="258" width="25" height="17" font="7">with </text>
<text top="697" left="258" width="60" height="17" font="7">propensity </text>
<text top="714" left="258" width="33" height="17" font="7">score </text>
<text top="731" left="258" width="57" height="17" font="7">matching  </text>
<text top="628" left="352" width="24" height="17" font="7">426 </text>
<text top="628" left="406" width="60" height="17" font="7">NVE 69%, </text>
<text top="645" left="406" width="59" height="17" font="7">PVE 19%, </text>
<text top="662" left="406" width="71" height="17" font="7">“other” 12%; </text>
<text top="679" left="406" width="57" height="17" font="7">surgery in </text>
<text top="697" left="406" width="28" height="17" font="7">29% </text>
<text top="628" left="501" width="174" height="17" font="7">Registration of epidemiological, </text>
<text top="645" left="501" width="184" height="17" font="7">clinical, microbiological and other </text>
<text top="662" left="501" width="210" height="17" font="7">laboratory features, echocardiography </text>
<text top="679" left="501" width="185" height="17" font="7">data, and treatment strategy. Pts’ </text>
<text top="697" left="501" width="132" height="17" font="7">propensities for surgery </text>
<text top="628" left="730" width="256" height="17" font="7">The ﬁt of the propensity model to the data was </text>
<text top="645" left="730" width="286" height="17" font="7">assessed using the concordance index with pts who </text>
<text top="662" left="730" width="269" height="17" font="7">underwent surgery matched to those who did not </text>
<text top="679" left="730" width="291" height="17" font="7">undergo surgery, using individual propensity scores.  </text>
<text top="697" left="730" width="296" height="17" font="7">The following factors were statistically associated with </text>
<text top="714" left="730" width="303" height="17" font="7">surgical therapy: age, transfer from an outside hospital, </text>
<text top="731" left="730" width="294" height="17" font="7">evidence of IE on physical examination, the presence </text>
<text top="748" left="730" width="259" height="17" font="7">of infection with staphylococci, HF, intracardiac </text>
<text top="766" left="730" width="297" height="17" font="7">abscess, and hemodialysis without a chronic catheter. </text>
<text top="628" left="1048" width="297" height="17" font="7">Revealed that surgery was associated with decreased </text>
<text top="645" left="1048" width="222" height="17" font="7">mortality (HR: 0.27; 95% CI: 0.13–0.55). </text>
<text top="662" left="1048" width="297" height="17" font="7">A history of diabetes mellitus (HR: 4.81; 95% CI: 2.41–</text>
<text top="679" left="1048" width="301" height="17" font="7">9.62), the presence of chronic intravenous catheters at </text>
<text top="697" left="1048" width="295" height="17" font="7">the beginning of the episode (HR: 2.65; 95% CI: 1.31–</text>
<text top="714" left="1048" width="194" height="17" font="7">5.33), and with increased mortality. </text>
<text top="784" left="44" width="46" height="17" font="7">Tleyjeh, </text>
<text top="784" left="123" width="18" height="17" font="7">To </text>
<text top="784" left="141" width="77" height="17" font="18">examined the </text>
<text top="784" left="258" width="51" height="17" font="7">Matched </text>
<text top="784" left="352" width="24" height="17" font="7">546 </text>
<text top="784" left="406" width="65" height="17" font="7">NVE alone; </text>
<text top="784" left="501" width="189" height="17" font="18">Propensity score to undergo valve </text>
<text top="784" left="730" width="275" height="17" font="18">Death occurred in 99 of the 417 pts (23.7%) in the </text>
<text top="784" left="1048" width="301" height="17" font="18">After adjustment for early (operative) mortality, surgery </text>
</page>
<page number="49" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="19" size="12" family="Times" color="#221f1f"/>
<text top="832" left="721" width="21" height="17" font="0">49 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="53" width="47" height="17" font="6"><b>Author/ </b></text>
<text top="126" left="62" width="30" height="17" font="6"><b>Year </b></text>
<text top="108" left="144" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="264" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="354" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="359" width="28" height="17" font="6"><b>Size </b></text>
<text top="143" left="363" width="21" height="17" font="6"><b>(N) </b></text>
<text top="108" left="425" width="44" height="17" font="6"><b>Patient </b></text>
<text top="126" left="414" width="67" height="17" font="6"><b>Population </b></text>
<text top="108" left="553" width="111" height="17" font="6"><b>Study Intervention </b></text>
<text top="108" left="830" width="106" height="17" font="6"><b>Primary Endpoint </b></text>
<text top="108" left="1135" width="136" height="17" font="6"><b>Predictors of Outcome </b></text>
<text top="161" left="44" width="31" height="17" font="7">2007 </text>
<text top="178" left="44" width="32" height="17" font="7">(201) </text>
<text top="195" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17372170">17372170</a></text>
<text top="195" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17372170"> </a></text>
<text top="161" left="123" width="115" height="17" font="18">association between </text>
<text top="178" left="123" width="117" height="17" font="18">valve surgery and all-</text>
<text top="195" left="123" width="117" height="17" font="18">cause 6 mo mortality </text>
<text top="212" left="123" width="107" height="17" font="18">among pts with left-</text>
<text top="230" left="123" width="44" height="17" font="18">sided IE</text>
<text top="230" left="167" width="3" height="17" font="7"> </text>
<text top="161" left="258" width="60" height="17" font="7">propensity </text>
<text top="178" left="258" width="48" height="17" font="7">analysis </text>
<text top="161" left="406" width="73" height="17" font="7">surgery 24% </text>
<text top="161" left="501" width="204" height="17" font="18">surgery was used to match pts in the </text>
<text top="178" left="501" width="198" height="17" font="18">surgical and nonsurgical groups. To </text>
<text top="195" left="501" width="203" height="17" font="18">adjust for survivor bias, the follow-up </text>
<text top="212" left="501" width="199" height="17" font="18">time was matched so that each pt in </text>
<text top="230" left="501" width="214" height="17" font="18">the nonsurgical group survived at least </text>
<text top="247" left="501" width="198" height="17" font="18">as long as the time to surgery in the </text>
<text top="264" left="501" width="208" height="17" font="18">respective surgically-treated pt. Valve </text>
<text top="281" left="501" width="215" height="17" font="18">surgery was used as a time-dependent </text>
<text top="299" left="501" width="182" height="17" font="18">covariate in different Cox models.</text>
<text top="299" left="683" width="3" height="17" font="7"> </text>
<text top="161" left="730" width="283" height="17" font="18">nonsurgical group vs. 35 deaths among the 129 pts </text>
<text top="178" left="730" width="301" height="17" font="18">(27.1%) in the surgical group. 18 of 35 (51%) pts in the </text>
<text top="195" left="730" width="253" height="17" font="18">surgical group died within 7 d of valve surgery.</text>
<text top="195" left="983" width="3" height="17" font="7"> </text>
<text top="161" left="1048" width="307" height="17" font="18">was not associated with a survival benefit (adjusted HR: </text>
<text top="178" left="1048" width="102" height="17" font="18">0.92; 95% CI: 0.48</text>
<text top="178" left="1149" width="7" height="17" font="7">–</text>
<text top="178" left="1156" width="31" height="17" font="18">1.76).</text>
<text top="178" left="1188" width="3" height="17" font="7"> </text>
<text top="317" left="44" width="46" height="17" font="7">Tleyjeh, </text>
<text top="334" left="44" width="31" height="17" font="7">2008 </text>
<text top="351" left="44" width="32" height="17" font="7">(202) </text>
<text top="368" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18308866">18308866</a></text>
<text top="368" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18308866"> </a></text>
<text top="317" left="123" width="88" height="17" font="7">To examine the </text>
<text top="334" left="123" width="115" height="17" font="7">association between </text>
<text top="351" left="123" width="102" height="17" font="7">the timing of valve </text>
<text top="368" left="123" width="87" height="17" font="7">surgery after IE </text>
<text top="385" left="123" width="111" height="17" font="7">diagnosis and 6-mo </text>
<text top="403" left="123" width="111" height="17" font="7">mortality among pts </text>
<text top="420" left="123" width="94" height="17" font="7">with left-sided IE </text>
<text top="317" left="258" width="78" height="17" font="7">Retrospective </text>
<text top="334" left="258" width="74" height="17" font="7">single-center </text>
<text top="351" left="258" width="38" height="17" font="7">cohort </text>
<text top="368" left="258" width="60" height="17" font="7">propensity </text>
<text top="385" left="258" width="51" height="17" font="7">analysis  </text>
<text top="317" left="352" width="24" height="17" font="7">546 </text>
<text top="317" left="406" width="65" height="17" font="7">NVE alone; </text>
<text top="334" left="406" width="73" height="17" font="7">surgery 24% </text>
<text top="317" left="501" width="209" height="17" font="7">The association between time from IE </text>
<text top="334" left="501" width="200" height="17" font="7">diagnosis to surgery and all-cause 6 </text>
<text top="351" left="501" width="209" height="17" font="7">mo mortality was assessed using Cox </text>
<text top="368" left="501" width="197" height="17" font="7">proportional hazards modeling after </text>
<text top="385" left="501" width="202" height="17" font="7">adjusting for the propensity score (to </text>
<text top="403" left="501" width="184" height="17" font="7">undergo surgery 0–11 d vs. 11 d, </text>
<text top="420" left="501" width="180" height="17" font="7">median time, after IE diagnosis). </text>
<text top="317" left="730" width="283" height="17" font="7">The median time between IE diagnosis and surgery </text>
<text top="334" left="730" width="258" height="17" font="7">was 11 d (range 1–30). Using Cox proportional </text>
<text top="351" left="730" width="299" height="17" font="7">hazards modeling, propensity score and longer time to </text>
<text top="368" left="730" width="298" height="17" font="7">surgery (in d) were associated with unadjusted HRs of </text>
<text top="385" left="730" width="263" height="17" font="7">(1.15, 95% CI: 1.04–1.28, per 0.10 unit change; </text>
<text top="403" left="730" width="304" height="17" font="7">p=0.009) and (0.93; 95% CI: 0.88–0.99, per d; p=0.03), </text>
<text top="420" left="730" width="75" height="17" font="7">respectively.  </text>
<text top="437" left="730" width="289" height="17" font="7">In multivariate analysis, a longer time to surgery was </text>
<text top="454" left="730" width="288" height="17" font="7">associated with an adjusted HR (0.97; 95% CI: 0.90–</text>
<text top="472" left="730" width="301" height="17" font="7">1.03). The propensity score and time from diagnosis to </text>
<text top="489" left="730" width="304" height="17" font="7">surgery had a correlation coefficient of r=20.63, making </text>
<text top="506" left="730" width="283" height="17" font="7">multicollinearity an issue in the multivariable model. </text>
<text top="317" left="1048" width="306" height="17" font="7">On univariate analysis, a longer time to surgery showed </text>
<text top="334" left="1048" width="261" height="17" font="7">a significant protective effect for the outcome of </text>
<text top="351" left="1048" width="57" height="17" font="7">mortality.  </text>
<text top="368" left="1048" width="287" height="17" font="7">After adjusting for the propensity to undergo surgery </text>
<text top="385" left="1048" width="309" height="17" font="7">early versus late, a longer time to surgery was no longer </text>
<text top="403" left="1048" width="284" height="17" font="7">significant, but remained in the protective direction.  </text>
<text top="524" left="44" width="41" height="17" font="7">Thuny, </text>
<text top="541" left="44" width="31" height="17" font="7">2009 </text>
<text top="558" left="44" width="32" height="17" font="7">(203) </text>
<text top="575" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19329497">19329497</a></text>
<text top="575" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19329497"> </a></text>
<text top="524" left="123" width="76" height="17" font="19">To determine </text>
<text top="541" left="123" width="117" height="17" font="19">whether the timing of </text>
<text top="558" left="123" width="77" height="17" font="19">surgery could </text>
<text top="575" left="123" width="102" height="17" font="19">influence mortality </text>
<text top="593" left="123" width="110" height="17" font="19">and morbidity in pts </text>
<text top="610" left="123" width="106" height="17" font="19">with complicated IE</text>
<text top="610" left="229" width="3" height="17" font="7"> </text>
<text top="524" left="258" width="78" height="17" font="7">Retrospective </text>
<text top="541" left="258" width="74" height="17" font="7">single-center </text>
<text top="558" left="258" width="38" height="17" font="7">cohort </text>
<text top="575" left="258" width="60" height="17" font="7">propensity </text>
<text top="593" left="258" width="48" height="17" font="7">analysis </text>
<text top="524" left="352" width="24" height="17" font="7">291 </text>
<text top="524" left="406" width="60" height="17" font="7">NVE 82%, </text>
<text top="541" left="406" width="59" height="17" font="7">PVE 18%; </text>
<text top="558" left="406" width="79" height="17" font="7">surgery 100% </text>
<text top="524" left="501" width="213" height="17" font="7">The time between the beginning of the </text>
<text top="541" left="501" width="206" height="17" font="7">appropriate antimicrobial therapy and </text>
<text top="558" left="501" width="189" height="17" font="7">surgery was used as a continuous </text>
<text top="575" left="501" width="206" height="17" font="7">variable and as a categorical variable </text>
<text top="593" left="501" width="183" height="17" font="7">with a cut-off of 7 d to assess the </text>
<text top="610" left="501" width="151" height="17" font="7">impact of timing of surgery. </text>
<text top="627" left="501" width="213" height="17" font="7">2 groups of pts were formed according </text>
<text top="644" left="501" width="170" height="17" font="7">to the timing of surgery: the “&lt;1</text>
<text top="645" left="671" width="6" height="11" font="9">st</text>
<text top="644" left="678" width="22" height="17" font="7"> wk </text>
<text top="662" left="501" width="146" height="17" font="7">surgery group” and the “&gt;1</text>
<text top="663" left="647" width="6" height="11" font="9">st</text>
<text top="662" left="653" width="22" height="17" font="7"> wk </text>
<text top="679" left="501" width="87" height="17" font="7">surgery group”. </text>
<text top="696" left="501" width="210" height="17" font="7">The impact of the timing of surgery on </text>
<text top="713" left="501" width="215" height="17" font="7">6 mo mortality, relapses, and PVD was </text>
<text top="730" left="501" width="161" height="17" font="7">analyzed using PS analyses. </text>
<text top="524" left="730" width="7" height="17" font="7">1</text>
<text top="525" left="737" width="6" height="11" font="9">st</text>
<text top="524" left="743" width="289" height="17" font="7"> wk surgery was associated with a trend of decrease </text>
<text top="541" left="730" width="279" height="17" font="7">in 6-mo mortality in the quintile of pts with the most </text>
<text top="558" left="730" width="232" height="17" font="7">likelihood of undergoing this early surgical </text>
<text top="575" left="730" width="298" height="17" font="7">management (quintile 5: 11% vs. 33%, OR: 0.18, 95% </text>
<text top="593" left="730" width="136" height="17" font="7">CI: 0.04 –0.83; p=0.03).  </text>
<text top="610" left="730" width="299" height="17" font="7">Pts of this subgroup were younger, were more likely to </text>
<text top="627" left="730" width="289" height="17" font="7">have <i>S. aureus</i> infections, congestive HF, and larger </text>
<text top="644" left="730" width="73" height="17" font="7">vegetations.  </text>
<text top="662" left="730" width="14" height="17" font="7">&lt;1</text>
<text top="663" left="744" width="6" height="11" font="9">st</text>
<text top="662" left="751" width="253" height="17" font="7"> wk surgery was associated with an increased </text>
<text top="679" left="730" width="303" height="17" font="7">number of relapses or PVD (16% vs. 4%, adjusted OR: </text>
<text top="696" left="730" width="182" height="17" font="7">2.9, 95% CI: 0.99–8.40; p=0.05). </text>
<text top="524" left="1048" width="281" height="17" font="7">Very early surgery (&lt;7 d) associated with improved </text>
<text top="541" left="1048" width="276" height="17" font="7">survival (especially in highest risk pts), but greater </text>
<text top="558" left="1048" width="309" height="17" font="7">likelihood of relapse or post-operative valve dysfunction. </text>
<text top="748" left="44" width="44" height="17" font="7">Manne, </text>
<text top="766" left="44" width="31" height="17" font="7">2012 </text>
<text top="783" left="44" width="32" height="17" font="7">(204) </text>
<text top="748" left="123" width="72" height="17" font="7">Describe the </text>
<text top="766" left="123" width="77" height="17" font="7">morbidity and </text>
<text top="783" left="123" width="112" height="17" font="7">mortality associated </text>
<text top="748" left="258" width="78" height="17" font="7">Retrospective </text>
<text top="766" left="258" width="74" height="17" font="7">single-center </text>
<text top="783" left="258" width="46" height="17" font="7">surgical </text>
<text top="748" left="352" width="24" height="17" font="7">428 </text>
<text top="748" left="406" width="60" height="17" font="7">NVE 58%, </text>
<text top="766" left="406" width="59" height="17" font="7">PVE 42%; </text>
<text top="783" left="406" width="79" height="17" font="7">surgery 100% </text>
<text top="748" left="501" width="174" height="17" font="7">Registration of epidemiological, </text>
<text top="766" left="501" width="184" height="17" font="7">clinical, microbiological and other </text>
<text top="783" left="501" width="210" height="17" font="7">laboratory features, echocardiography </text>
<text top="748" left="730" width="276" height="17" font="7">Overall 90% of pts survived to hospital discharge.  </text>
<text top="766" left="730" width="293" height="17" font="7">When compared with pts with NVE, pts with PVE had </text>
<text top="783" left="730" width="269" height="17" font="7">significantly higher 30-d mortality (13% vs. 5.6%; </text>
<text top="748" left="1048" width="306" height="17" font="7">Pts with IE caused by <i>S. aureus</i> had significantly higher </text>
<text top="766" left="1048" width="262" height="17" font="7">hospital mortality (15% vs. 8.4%; p&lt;0.05), 6 mo </text>
<text top="783" left="1048" width="307" height="17" font="7">mortality (23% vs. 15%; p=0.05), and 1 y mortality (28% </text>
</page>
<page number="50" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">50 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="53" width="47" height="17" font="6"><b>Author/ </b></text>
<text top="126" left="62" width="30" height="17" font="6"><b>Year </b></text>
<text top="108" left="144" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="264" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="354" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="359" width="28" height="17" font="6"><b>Size </b></text>
<text top="143" left="363" width="21" height="17" font="6"><b>(N) </b></text>
<text top="108" left="425" width="44" height="17" font="6"><b>Patient </b></text>
<text top="126" left="414" width="67" height="17" font="6"><b>Population </b></text>
<text top="108" left="553" width="111" height="17" font="6"><b>Study Intervention </b></text>
<text top="108" left="830" width="106" height="17" font="6"><b>Primary Endpoint </b></text>
<text top="108" left="1135" width="136" height="17" font="6"><b>Predictors of Outcome </b></text>
<text top="161" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22206953">22206953</a></text>
<text top="161" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22206953"> </a></text>
<text top="161" left="123" width="102" height="17" font="7">with surgery for IE </text>
<text top="178" left="123" width="75" height="17" font="7">and compare </text>
<text top="195" left="123" width="76" height="17" font="7">differences in </text>
<text top="212" left="123" width="85" height="17" font="7">characteristics, </text>
<text top="230" left="123" width="88" height="17" font="7">pathogens, and </text>
<text top="247" left="123" width="119" height="17" font="7">outcomes for pts with </text>
<text top="264" left="123" width="119" height="17" font="7">NVE and PVE from a </text>
<text top="281" left="123" width="120" height="17" font="7">large surgery-minded </text>
<text top="299" left="123" width="121" height="17" font="7">tertiary referral center </text>
<text top="161" left="258" width="70" height="17" font="7">cohort study </text>
<text top="161" left="501" width="157" height="17" font="7">data, and treatment strategy </text>
<text top="161" left="730" width="283" height="17" font="7">p&lt;0.01), but long-term survival was not significantly </text>
<text top="178" left="730" width="179" height="17" font="7">different (35% vs. 29%; p=0.19). </text>
<text top="161" left="1048" width="281" height="17" font="7">vs. 18%; p=0.02) compared with non–<i>S. aureus</i> IE. </text>
<text top="317" left="44" width="35" height="17" font="7">Kang, </text>
<text top="334" left="44" width="31" height="17" font="7">2012 </text>
<text top="351" left="44" width="32" height="17" font="7">(205) </text>
<text top="368" left="44" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22738096">22738096</a></text>
<text top="368" left="99" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22738096"> </a></text>
<text top="317" left="123" width="109" height="17" font="7">To compare clinical </text>
<text top="334" left="123" width="100" height="17" font="7">outcomes of early </text>
<text top="351" left="123" width="68" height="17" font="7">surgery and </text>
<text top="368" left="123" width="72" height="17" font="7">conventional </text>
<text top="385" left="123" width="113" height="17" font="7">treatment in pts with </text>
<text top="403" left="123" width="15" height="17" font="7">IE </text>
<text top="317" left="258" width="67" height="17" font="7">Prospective </text>
<text top="334" left="258" width="68" height="17" font="7">randomized </text>
<text top="351" left="258" width="47" height="17" font="7">trial at 2 </text>
<text top="368" left="258" width="69" height="17" font="7">centers with </text>
<text top="385" left="258" width="63" height="17" font="7">intention to </text>
<text top="403" left="258" width="79" height="17" font="7">treat analysis  </text>
<text top="317" left="352" width="17" height="17" font="7">76 </text>
<text top="317" left="406" width="79" height="17" font="7">Left-side NVE </text>
<text top="334" left="406" width="73" height="17" font="7">and high risk </text>
<text top="351" left="406" width="70" height="17" font="7">of embolism </text>
<text top="368" left="406" width="44" height="17" font="7">to early </text>
<text top="385" left="406" width="80" height="17" font="7">surgery (49%) </text>
<text top="403" left="406" width="19" height="17" font="7">vs. </text>
<text top="420" left="406" width="72" height="17" font="7">conventional </text>
<text top="437" left="406" width="55" height="17" font="7">treatment </text>
<text top="454" left="406" width="36" height="17" font="7">(51%) </text>
<text top="317" left="501" width="202" height="17" font="7">Pts were randomly assigned in a 1:1 </text>
<text top="334" left="501" width="206" height="17" font="7">ratio to the early-surgery group or the </text>
<text top="351" left="501" width="209" height="17" font="7">conventional-treatment group with the </text>
<text top="368" left="501" width="173" height="17" font="7">use of a Web-based interactive </text>
<text top="385" left="501" width="100" height="17" font="7">response system. </text>
<text top="403" left="501" width="193" height="17" font="7">The protocol specified that pts who </text>
<text top="420" left="501" width="192" height="17" font="7">were assigned to the early-surgery </text>
<text top="437" left="501" width="202" height="17" font="7">group should undergo surgery within </text>
<text top="454" left="501" width="213" height="17" font="7">48 h after randomization. Pts assigned </text>
<text top="472" left="501" width="198" height="17" font="7">to the conventional-treatment group </text>
<text top="489" left="501" width="191" height="17" font="7">were treated according to the AHA </text>
<text top="506" left="501" width="215" height="17" font="7">guidelines, and surgery was performed </text>
<text top="523" left="501" width="203" height="17" font="7">only if complications requiring urgent </text>
<text top="540" left="501" width="188" height="17" font="7">surgery developed during medical </text>
<text top="558" left="501" width="192" height="17" font="7">treatment or if symptoms persisted </text>
<text top="575" left="501" width="177" height="17" font="7">after the completion of antibiotic </text>
<text top="592" left="501" width="48" height="17" font="7">therapy. </text>
<text top="317" left="730" width="290" height="17" font="7">The primary endpoint (composite of in-hospital death </text>
<text top="334" left="730" width="276" height="17" font="7">and embolic events that occurred within 6 wk after </text>
<text top="351" left="730" width="266" height="17" font="7">randomization) occurred in 1 pt (3%) in the early </text>
<text top="368" left="730" width="259" height="17" font="7">surgery group as compared with 9 (23%) in the </text>
<text top="385" left="730" width="297" height="17" font="7">conventional-treatment group (HR: 0.10; 95% CI: 0.01 </text>
<text top="403" left="730" width="93" height="17" font="7">–0.82; p=0.03).   </text>
<text top="420" left="730" width="259" height="17" font="7">There was no significant difference in all-cause </text>
<text top="437" left="730" width="300" height="17" font="7">mortality at 6 mo in the early-surgery and conventional-</text>
<text top="454" left="730" width="297" height="17" font="7">treatment groups (3% and 5%, respectively; HR: 0.51; </text>
<text top="472" left="730" width="165" height="17" font="7">95% CI: 0.05–5.66; p=0.59).   </text>
<text top="489" left="730" width="289" height="17" font="7">The rate of the composite en point of death from any </text>
<text top="506" left="730" width="303" height="17" font="7">cause, embolic events, or recurrence of IE at 6 mo was </text>
<text top="523" left="730" width="250" height="17" font="7">3% in the early-surgery group and 28% in the </text>
<text top="540" left="730" width="301" height="17" font="7">conventional-treatment group (HR: 0.08; 95% CI: 0.01–</text>
<text top="558" left="730" width="80" height="17" font="7">0.65; p=0.02). </text>
<text top="317" left="1048" width="307" height="17" font="7">As compared with conventional treatment, early surgery </text>
<text top="334" left="1048" width="309" height="17" font="7">in pts with IE and large vegetations significantly reduced </text>
<text top="351" left="1048" width="290" height="17" font="7">the composite endpoint of death from any cause and </text>
<text top="368" left="1048" width="280" height="17" font="7">embolic events by effectively decreasing the risk of </text>
<text top="385" left="1048" width="111" height="17" font="7">systemic embolism. </text>
<text top="610" left="34" width="1197" height="17" font="7">AHA indicates American Heart Association; HF, heart failure; ICU, intensive care unit, IE, infective endocarditis; NVE, native valve endocarditis; pts, patients; PVE, prosthetic valve; and <i>S. aureus, </i>Staphylococcus aureus. </text>
<text top="627" left="34" width="745" height="17" font="7">Table modified from Prendergast BD and Tornos P. Surgery for infective endocarditis: who and when? Circulation 2010, 121:1141-1152. </text>
</page>
<page number="51" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">51 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="1113" height="21" font="4"><b>Data Supplement 25.Outcomes in Pregnant Women With a Mechanical Prosthetic Valve Treated with Warfarin or Unfractionated Heparin (UFH) (Section 13.3.2) </b></text>
<text top="129" left="51" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="129" left="169" width="64" height="17" font="6"><b>Study Aim </b></text>
<text top="129" left="269" width="65" height="17" font="6"><b>Study Size </b></text>
<text top="146" left="292" width="21" height="17" font="6"><b>(N) </b></text>
<text top="129" left="371" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="129" left="520" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="643" width="47" height="17" font="6"><b>Type of </b></text>
<text top="146" left="618" width="96" height="17" font="6"><b>Anticoagulation </b></text>
<text top="129" left="844" width="64" height="17" font="6"><b>Endpoints </b></text>
<text top="129" left="1093" width="59" height="17" font="6"><b>Summary </b></text>
<text top="129" left="1263" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="1247" width="69" height="17" font="6"><b>Limitations </b></text>
<text top="164" left="88" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="199" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="300" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="425" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="164" left="553" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="665" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="164" left="792" width="57" height="17" font="16"><i><b>Maternal  </b></i></text>
<text top="164" left="947" width="32" height="17" font="16"><i><b>Fetal </b></i></text>
<text top="164" left="1120" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="1280" width="3" height="17" font="6"><b> </b></text>
<text top="182" left="42" width="67" height="17" font="7">Chan, 2000 </text>
<text top="200" left="42" width="32" height="17" font="7">(206) </text>
<text top="217" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10647757">10647757</a></text>
<text top="217" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10647757"> </a></text>
<text top="182" left="150" width="63" height="17" font="7">Systematic </text>
<text top="200" left="150" width="39" height="17" font="7">review </text>
<text top="217" left="150" width="86" height="17" font="7">anticoagulation </text>
<text top="234" left="150" width="65" height="17" font="7">mechanical </text>
<text top="251" left="150" width="38" height="17" font="7">valves </text>
<text top="182" left="265" width="34" height="17" font="7">1,234 </text>
<text top="200" left="265" width="70" height="17" font="7">pregnancies </text>
<text top="217" left="265" width="37" height="17" font="7">in 976 </text>
<text top="234" left="265" width="43" height="17" font="7">women </text>
<text top="182" left="352" width="128" height="17" font="7">All pts with mechanical </text>
<text top="200" left="352" width="126" height="17" font="7">prosthesis–40 articles–</text>
<text top="217" left="352" width="114" height="17" font="7">treated with differing </text>
<text top="234" left="352" width="140" height="17" font="7">anticoagulation regimens </text>
<text top="251" left="352" width="65" height="17" font="7">1966–1997 </text>
<text top="268" left="352" width="3" height="17" font="7"> </text>
<text top="182" left="514" width="63" height="17" font="7">Systematic </text>
<text top="200" left="514" width="52" height="17" font="7">review of </text>
<text top="217" left="514" width="51" height="17" font="7">literature </text>
<text top="182" left="609" width="64" height="17" font="7">1. Warfarin </text>
<text top="200" left="609" width="62" height="17" font="7">throughout </text>
<text top="217" left="609" width="49" height="17" font="7">2. UFH 1</text>
<text top="218" left="658" width="6" height="11" font="9">st</text>
<text top="217" left="664" width="58" height="17" font="7"> trimester, </text>
<text top="234" left="609" width="75" height="17" font="7">then warfarin </text>
<text top="251" left="609" width="104" height="17" font="7">3. UFH throughout </text>
<text top="268" left="609" width="61" height="17" font="7">pregnancy </text>
<text top="286" left="609" width="53" height="17" font="7">4. No AC </text>
<text top="182" left="737" width="87" height="17" font="7">Maternal Death </text>
<text top="200" left="737" width="59" height="17" font="7">1.  1.8% </text>
<text top="217" left="737" width="59" height="17" font="7">2.  4.2% </text>
<text top="234" left="737" width="55" height="17" font="7">3.  15% </text>
<text top="251" left="737" width="59" height="17" font="7">4.  4.7% </text>
<text top="268" left="737" width="95" height="17" font="7">Thromboembolic </text>
<text top="286" left="737" width="59" height="17" font="7">1.  3.9% </text>
<text top="303" left="737" width="59" height="17" font="7">2.  9.2% </text>
<text top="320" left="737" width="55" height="17" font="7">3.  33% </text>
<text top="337" left="737" width="55" height="17" font="7">4.  24% </text>
<text top="182" left="913" width="90" height="17" font="7">Fetal anomalies </text>
<text top="200" left="913" width="58" height="17" font="7">1.  6.4% </text>
<text top="217" left="913" width="58" height="17" font="7">2.  3.4% </text>
<text top="234" left="913" width="48" height="17" font="7">3.  0% </text>
<text top="251" left="913" width="58" height="17" font="7">4.  3.3% </text>
<text top="268" left="913" width="80" height="17" font="7">Fetal wastage </text>
<text top="286" left="913" width="55" height="17" font="7">1.  33% </text>
<text top="303" left="913" width="55" height="17" font="7">2.  26% </text>
<text top="320" left="913" width="55" height="17" font="7">3.  43% </text>
<text top="337" left="913" width="55" height="17" font="7">4.  20% </text>
<text top="182" left="1027" width="163" height="17" font="7">Reduction of thromboembolic </text>
<text top="200" left="1027" width="172" height="17" font="7">events for mother greatest with </text>
<text top="217" left="1027" width="174" height="17" font="7">warfarin throughout pregnancy, </text>
<text top="234" left="1027" width="163" height="17" font="7">worse maternal outcome with </text>
<text top="251" left="1027" width="171" height="17" font="7">heparin throughout pregnancy. </text>
<text top="268" left="1027" width="66" height="17" font="7">Heparin in 1</text>
<text top="269" left="1094" width="6" height="11" font="9">st</text>
<text top="268" left="1100" width="102" height="17" font="7"> trimester reduces </text>
<text top="286" left="1027" width="182" height="17" font="7">risk of fetopathic effects, but with </text>
<text top="303" left="1027" width="184" height="17" font="7">increased risk of thromboembolic </text>
<text top="320" left="1027" width="89" height="17" font="7">embolic events. </text>
<text top="182" left="1230" width="78" height="17" font="7">Retrospective </text>
<text top="200" left="1230" width="61" height="17" font="7">systematic </text>
<text top="217" left="1230" width="84" height="17" font="7">review–prior to </text>
<text top="234" left="1230" width="64" height="17" font="7">LMWH use </text>
<text top="355" left="42" width="90" height="17" font="7">Meschengieser, </text>
<text top="372" left="42" width="31" height="17" font="7">1999 </text>
<text top="390" left="42" width="32" height="17" font="7">(207) </text>
<text top="407" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10377303">10377303</a></text>
<text top="407" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10377303"> </a></text>
<text top="355" left="150" width="75" height="17" font="7">Single center </text>
<text top="372" left="150" width="63" height="17" font="7">experience </text>
<text top="390" left="150" width="86" height="17" font="7">anticoagulation </text>
<text top="407" left="150" width="65" height="17" font="7">mechanical </text>
<text top="424" left="150" width="38" height="17" font="7">valves </text>
<text top="355" left="265" width="17" height="17" font="7">92 </text>
<text top="372" left="265" width="70" height="17" font="7">pregnancies </text>
<text top="390" left="265" width="73" height="17" font="7">in 59 women </text>
<text top="355" left="352" width="134" height="17" font="7">Consecutive unselected </text>
<text top="372" left="352" width="120" height="17" font="7">pregnancies between </text>
<text top="390" left="352" width="65" height="17" font="7">1986–1997 </text>
<text top="407" left="352" width="3" height="17" font="7"> </text>
<text top="355" left="514" width="158" height="17" font="7">Observational   1. Warfarin </text>
<text top="372" left="609" width="62" height="17" font="7">throughout </text>
<text top="390" left="609" width="61" height="17" font="7">pregnancy </text>
<text top="407" left="609" width="49" height="17" font="7">2. UFH 1</text>
<text top="408" left="658" width="6" height="11" font="9">st</text>
<text top="407" left="664" width="58" height="17" font="7"> trimester, </text>
<text top="424" left="609" width="75" height="17" font="7">then warfarin </text>
<text top="441" left="609" width="104" height="17" font="7">3. UFH throughout </text>
<text top="458" left="609" width="61" height="17" font="7">pregnancy </text>
<text top="476" left="609" width="57" height="17" font="7">4. No A/C </text>
<text top="355" left="737" width="95" height="17" font="7">Thromboembolic </text>
<text top="372" left="736" width="158" height="17" font="7">1.  0.3 episodes/100 pt mo </text>
<text top="390" left="736" width="158" height="17" font="7">2.  4.9 episodes/100 pt mo </text>
<text top="355" left="913" width="80" height="17" font="7">Fetal wastage </text>
<text top="372" left="918" width="55" height="17" font="7">1.  25% </text>
<text top="390" left="918" width="55" height="17" font="7">2.  19% </text>
<text top="355" left="1027" width="163" height="17" font="7">Reduction of thromboembolic </text>
<text top="372" left="1027" width="172" height="17" font="7">events for mother greatest with </text>
<text top="390" left="1027" width="174" height="17" font="7">warfarin throughout pregnancy. </text>
<text top="407" left="1027" width="157" height="17" font="7">No maternal deaths or valve </text>
<text top="424" left="1027" width="187" height="17" font="7">thrombosis occurred in this study. </text>
<text top="355" left="1230" width="78" height="17" font="7">Retrospective </text>
<text top="372" left="1230" width="85" height="17" font="7">review of small </text>
<text top="390" left="1230" width="96" height="17" font="7">number pts–prior </text>
<text top="407" left="1230" width="78" height="17" font="7">to LMWH use </text>
<text top="494" left="42" width="68" height="17" font="7">Vitale, 1999 </text>
<text top="511" left="42" width="32" height="17" font="7">(208) </text>
<text top="528" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10334435">10334435</a></text>
<text top="528" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10334435"> </a></text>
<text top="494" left="150" width="75" height="17" font="7">Single center </text>
<text top="511" left="150" width="63" height="17" font="7">experience </text>
<text top="528" left="150" width="86" height="17" font="7">anticoagulation </text>
<text top="545" left="150" width="65" height="17" font="7">mechanical </text>
<text top="562" left="150" width="38" height="17" font="7">valves </text>
<text top="494" left="265" width="17" height="17" font="7">58 </text>
<text top="511" left="265" width="70" height="17" font="7">pregnancies </text>
<text top="528" left="265" width="50" height="17" font="7">in 43 pts </text>
<text top="494" left="352" width="134" height="17" font="7">Consecutive unselected </text>
<text top="511" left="352" width="120" height="17" font="7">pregnancies between </text>
<text top="528" left="352" width="65" height="17" font="7">1987–1997 </text>
<text top="545" left="352" width="3" height="17" font="7"> </text>
<text top="494" left="514" width="207" height="17" font="7">Observational  Warfarin throughout </text>
<text top="511" left="609" width="64" height="17" font="7">pregnancy: </text>
<text top="528" left="609" width="111" height="17" font="7"> A. Dose &lt;5 mg vs.  </text>
<text top="545" left="609" width="85" height="17" font="7">B. Dose &gt;5 mg </text>
<text top="494" left="737" width="87" height="17" font="7">Maternal Death </text>
<text top="511" left="737" width="33" height="17" font="7">None </text>
<text top="528" left="737" width="98" height="17" font="7">Valve thrombosis </text>
<text top="545" left="737" width="30" height="17" font="7">2 pts </text>
<text top="494" left="913" width="31" height="17" font="7">Fetal </text>
<text top="511" left="913" width="78" height="17" font="7">complications </text>
<text top="528" left="913" width="101" height="17" font="7">A. 4 SA and 1 GR </text>
<text top="545" left="913" width="81" height="17" font="7">(28/32 healthy </text>
<text top="562" left="913" width="66" height="17" font="7">babies) vs.  </text>
<text top="580" left="913" width="92" height="17" font="7">B: 2 WE, 18 SA, </text>
<text top="597" left="913" width="72" height="17" font="7">1 SB, 1 VSD </text>
<text top="614" left="913" width="74" height="17" font="7">(3/25 healthy </text>
<text top="631" left="913" width="44" height="17" font="7">babies) </text>
<text top="494" left="1027" width="124" height="17" font="7">First to show that fetal </text>
<text top="511" left="1027" width="130" height="17" font="7">complications are dose-</text>
<text top="528" left="1027" width="183" height="17" font="7">dependent, relatively safe if dose </text>
<text top="545" left="1027" width="39" height="17" font="7">≤5 mg </text>
<text top="494" left="1230" width="78" height="17" font="7">Retrospective </text>
<text top="511" left="1230" width="68" height="17" font="7">review–only </text>
<text top="528" left="1230" width="47" height="17" font="7">warfarin </text>
<text top="545" left="1230" width="87" height="17" font="7">throughout was </text>
<text top="562" left="1230" width="33" height="17" font="7">used  </text>
<text top="649" left="42" width="79" height="17" font="7">Salazar, 1996 </text>
<text top="667" left="42" width="32" height="17" font="7">(209) </text>
<text top="684" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8636556">8636556</a></text>
<text top="684" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8636556"> </a></text>
<text top="649" left="150" width="75" height="17" font="7">Single center </text>
<text top="667" left="150" width="63" height="17" font="7">experience </text>
<text top="684" left="150" width="86" height="17" font="7">anticoagulation </text>
<text top="701" left="150" width="65" height="17" font="7">mechanical </text>
<text top="718" left="150" width="38" height="17" font="7">valves </text>
<text top="649" left="265" width="17" height="17" font="7">40 </text>
<text top="667" left="265" width="70" height="17" font="7">pregnancies </text>
<text top="684" left="265" width="50" height="17" font="7">in 37 pts </text>
<text top="649" left="352" width="138" height="17" font="7">Single center experience </text>
<text top="667" left="352" width="137" height="17" font="7">of a prospective protocol </text>
<text top="684" left="352" width="141" height="17" font="7">using UFH SQ during the </text>
<text top="701" left="352" width="7" height="17" font="7">1</text>
<text top="702" left="359" width="6" height="11" font="9">st</text>
<text top="701" left="365" width="55" height="17" font="7"> trimester </text>
<text top="718" left="352" width="3" height="17" font="7"> </text>
<text top="649" left="514" width="67" height="17" font="7">Prospective </text>
<text top="667" left="514" width="61" height="17" font="7">cohort trial </text>
<text top="649" left="609" width="110" height="17" font="7">All pts had SQ UFH </text>
<text top="667" left="609" width="101" height="17" font="7">from 6–12 wk and </text>
<text top="684" left="609" width="108" height="17" font="7">then during the last </text>
<text top="701" left="609" width="105" height="17" font="7">2 wks of  gestation </text>
<text top="649" left="737" width="108" height="17" font="7">2 cases of massive </text>
<text top="667" left="737" width="150" height="17" font="7">thrombosis of a MVR tilting </text>
<text top="684" left="737" width="29" height="17" font="7">disk. </text>
<text top="701" left="737" width="139" height="17" font="7">1 death from GI bleeding </text>
<text top="718" left="737" width="88" height="17" font="7">during warfarin. </text>
<text top="649" left="913" width="102" height="17" font="7">37% spontaneous </text>
<text top="667" left="913" width="48" height="17" font="7">abortion </text>
<text top="684" left="913" width="82" height="17" font="7">2.5% neonatal </text>
<text top="701" left="913" width="38" height="17" font="7">death  </text>
<text top="718" left="913" width="94" height="17" font="7">No embryopathy </text>
<text top="649" left="1027" width="180" height="17" font="7">UFH is a poor anticoagulant and </text>
<text top="667" left="1027" width="143" height="17" font="7">does not prevent massive </text>
<text top="684" left="1027" width="64" height="17" font="7">thrombosis </text>
<text top="649" left="1230" width="102" height="17" font="7">Trial stopped after </text>
<text top="667" left="1230" width="101" height="17" font="7">2 events occurred </text>
<text top="736" left="42" width="87" height="17" font="7">Sbarouni, 1994 </text>
<text top="753" left="42" width="32" height="17" font="7">(210) </text>
<text top="771" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8130033/">8130033</a></text>
<text top="771" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8130033/"> </a></text>
<text top="736" left="150" width="94" height="17" font="7">Questionnaire to </text>
<text top="753" left="150" width="59" height="17" font="7">all cardiac </text>
<text top="771" left="150" width="100" height="17" font="7">centers in Europe </text>
<text top="736" left="265" width="24" height="17" font="7">214 </text>
<text top="753" left="265" width="70" height="17" font="7">pregnancies </text>
<text top="771" left="265" width="57" height="17" font="7">in 182 pts </text>
<text top="788" left="265" width="53" height="17" font="7">(133 with </text>
<text top="736" left="352" width="137" height="17" font="7">Questionnaire sent 1994 </text>
<text top="753" left="352" width="129" height="17" font="7">to all cardiac centers in </text>
<text top="771" left="352" width="43" height="17" font="7">Europe </text>
<text top="788" left="352" width="3" height="17" font="7"> </text>
<text top="736" left="514" width="80" height="17" font="7">Questionnaire </text>
<text top="753" left="514" width="27" height="17" font="7">data </text>
<text top="736" left="609" width="24" height="17" font="7">N/A </text>
<text top="736" left="737" width="148" height="17" font="7">6 maternal deaths (4 valve </text>
<text top="753" left="737" width="125" height="17" font="7">thrombosis, 1 cerebral </text>
<text top="771" left="737" width="130" height="17" font="7">embolism, 1 pulmonary </text>
<text top="788" left="737" width="45" height="17" font="7">edema) </text>
<text top="736" left="913" width="19" height="17" font="7">No </text>
<text top="753" left="913" width="97" height="17" font="7">embryopathies in </text>
<text top="771" left="913" width="77" height="17" font="7">36 women on </text>
<text top="788" left="913" width="47" height="17" font="7">warfarin </text>
<text top="736" left="1027" width="163" height="17" font="7">Heparin is neither effective or </text>
<text top="753" left="1027" width="168" height="17" font="7">safe for both fetus and mother </text>
<text top="771" left="1027" width="104" height="17" font="7">with increased risk </text>
<text top="788" left="1027" width="175" height="17" font="7">thromboembolism and bleeding </text>
<text top="736" left="1230" width="65" height="17" font="7">No detailed </text>
<text top="753" left="1230" width="81" height="17" font="7">information on </text>
<text top="771" left="1230" width="42" height="17" font="7">level of </text>
<text top="788" left="1230" width="86" height="17" font="7">anticoagulation </text>
</page>
<page number="52" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">52 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="51" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="108" left="169" width="64" height="17" font="6"><b>Study Aim </b></text>
<text top="108" left="269" width="65" height="17" font="6"><b>Study Size </b></text>
<text top="126" left="292" width="21" height="17" font="6"><b>(N) </b></text>
<text top="108" left="371" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="108" left="520" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="643" width="47" height="17" font="6"><b>Type of </b></text>
<text top="126" left="618" width="96" height="17" font="6"><b>Anticoagulation </b></text>
<text top="108" left="844" width="64" height="17" font="6"><b>Endpoints </b></text>
<text top="108" left="1093" width="59" height="17" font="6"><b>Summary </b></text>
<text top="108" left="1263" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="1247" width="69" height="17" font="6"><b>Limitations </b></text>
<text top="144" left="88" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="199" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="300" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="425" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="144" left="553" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="665" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="144" left="792" width="57" height="17" font="16"><i><b>Maternal  </b></i></text>
<text top="144" left="947" width="32" height="17" font="16"><i><b>Fetal </b></i></text>
<text top="144" left="1120" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="1280" width="3" height="17" font="6"><b> </b></text>
<text top="162" left="265" width="65" height="17" font="7">mechanical </text>
<text top="179" left="265" width="64" height="17" font="7">prosthesis) </text>
<text top="162" left="737" width="150" height="17" font="7">13 valve thrombosis–10/13 </text>
<text top="179" left="737" width="130" height="17" font="7">on heparin, 12/13 MVR </text>
<text top="196" left="737" width="120" height="17" font="7">8 embolic events–5/8 </text>
<text top="213" left="737" width="44" height="17" font="7">heparin </text>
<text top="162" left="913" width="81" height="17" font="7">Fetal outcome </text>
<text top="179" left="913" width="57" height="17" font="7">similar for </text>
<text top="196" left="913" width="66" height="17" font="7">warfarin vs. </text>
<text top="213" left="913" width="76" height="17" font="7">heparin–22% </text>
<text top="230" left="913" width="100" height="17" font="7">abortion and 10% </text>
<text top="248" left="913" width="51" height="17" font="7">stillbirths </text>
<text top="162" left="1230" width="87" height="17" font="7">dose. Selection </text>
<text top="179" left="1230" width="99" height="17" font="7">bias of those who </text>
<text top="196" left="1230" width="96" height="17" font="7">responded to the </text>
<text top="213" left="1230" width="77" height="17" font="7">questionnaire </text>
<text top="266" left="42" width="85" height="17" font="7">Al-Lawati 2002 </text>
<text top="283" left="42" width="32" height="17" font="7">(211) </text>
<text top="300" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12142189">12142189</a></text>
<text top="300" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12142189"> </a></text>
<text top="266" left="150" width="75" height="17" font="7">Single center </text>
<text top="283" left="150" width="63" height="17" font="7">experience </text>
<text top="300" left="150" width="86" height="17" font="7">anticoagulation </text>
<text top="317" left="150" width="65" height="17" font="7">mechanical </text>
<text top="335" left="150" width="66" height="17" font="7">valves from </text>
<text top="352" left="150" width="94" height="17" font="7">country of Oman </text>
<text top="266" left="265" width="17" height="17" font="7">63 </text>
<text top="283" left="265" width="70" height="17" font="7">pregnancies </text>
<text top="300" left="265" width="50" height="17" font="7">in 21 pts </text>
<text top="266" left="352" width="134" height="17" font="7">Consecutive unselected </text>
<text top="283" left="352" width="120" height="17" font="7">pregnancies between </text>
<text top="300" left="352" width="65" height="17" font="7">1983–1997 </text>
<text top="317" left="352" width="3" height="17" font="7"> </text>
<text top="266" left="514" width="158" height="17" font="7">Observational  1. Warfarin </text>
<text top="283" left="609" width="62" height="17" font="7">throughout </text>
<text top="300" left="609" width="49" height="17" font="7">2. UFH 1</text>
<text top="301" left="658" width="6" height="11" font="9">st</text>
<text top="300" left="664" width="58" height="17" font="7"> trimester, </text>
<text top="317" left="609" width="77" height="17" font="7">then Warfarin </text>
<text top="266" left="737" width="123" height="17" font="7">Thrombosis of valves  </text>
<text top="283" left="737" width="60" height="17" font="7">1.  None </text>
<text top="300" left="737" width="57" height="17" font="7">2.  2 pts </text>
<text top="266" left="913" width="31" height="17" font="7">Fetal </text>
<text top="283" left="913" width="78" height="17" font="7">complications </text>
<text top="300" left="913" width="77" height="17" font="7">1.  74% live </text>
<text top="317" left="940" width="40" height="17" font="7">babies </text>
<text top="335" left="913" width="77" height="17" font="7">2.  71% live </text>
<text top="352" left="940" width="40" height="17" font="7">babies </text>
<text top="369" left="913" width="76" height="17" font="7">Spontaneous </text>
<text top="386" left="913" width="48" height="17" font="7">abortion </text>
<text top="403" left="913" width="55" height="17" font="7">1.  26% </text>
<text top="421" left="913" width="55" height="17" font="7">2.  14% </text>
<text top="438" left="913" width="94" height="17" font="7">No embryopathy </text>
<text top="455" left="913" width="93" height="17" font="7">(2 pts with 6 mg, </text>
<text top="474" left="913" width="49" height="17" font="7">rest with </text>
<text top="473" left="962" width="8" height="18" font="10"></text>
<text top="474" left="970" width="38" height="17" font="7">5 mg)  </text>
<text top="266" left="1027" width="164" height="17" font="7">Role of warfarin embryopathy </text>
<text top="283" left="1027" width="68" height="17" font="7">overstated.  </text>
<text top="300" left="1027" width="135" height="17" font="7">Warfarin recommended, </text>
<text top="317" left="1027" width="148" height="17" font="7">especially with low dose of </text>
<text top="335" left="1027" width="51" height="17" font="7">warfarin. </text>
<text top="352" left="1027" width="188" height="17" font="7">Valve thrombosis occurred only in </text>
<text top="369" left="1027" width="118" height="17" font="7">pts with UFH during 1</text>
<text top="370" left="1145" width="6" height="11" font="9">st</text>
<text top="369" left="1152" width="58" height="17" font="7"> trimester–</text>
<text top="386" left="1027" width="107" height="17" font="7">none with warfarin. </text>
<text top="266" left="1230" width="78" height="17" font="7">Retrospective </text>
<text top="283" left="1230" width="74" height="17" font="7">review—only </text>
<text top="300" left="1230" width="47" height="17" font="7">warfarin </text>
<text top="317" left="1230" width="87" height="17" font="7">throughout was </text>
<text top="335" left="1230" width="30" height="17" font="7">used </text>
<text top="491" left="42" width="70" height="17" font="7">Sadler 2000 </text>
<text top="509" left="42" width="32" height="17" font="7">(212) </text>
<text top="526" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10688509">10688509</a></text>
<text top="526" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10688509"> </a></text>
<text top="491" left="150" width="91" height="17" font="7">Historical cohort </text>
<text top="509" left="150" width="82" height="17" font="7">of women with </text>
<text top="526" left="150" width="69" height="17" font="7">mechanical, </text>
<text top="543" left="150" width="97" height="17" font="7">bioprosthetic and </text>
<text top="560" left="150" width="97" height="17" font="7">homograft valves </text>
<text top="577" left="150" width="56" height="17" font="7">from New </text>
<text top="595" left="150" width="48" height="17" font="7">Zealand </text>
<text top="491" left="265" width="24" height="17" font="7">147 </text>
<text top="509" left="265" width="70" height="17" font="7">pregnancies </text>
<text top="526" left="265" width="50" height="17" font="7">in 79 pts </text>
<text top="491" left="352" width="149" height="17" font="7">All women in New Zealand </text>
<text top="509" left="352" width="82" height="17" font="7">who had valve </text>
<text top="526" left="352" width="136" height="17" font="7">replacement 1972–1992 </text>
<text top="543" left="352" width="115" height="17" font="7">and had subsequent </text>
<text top="560" left="352" width="61" height="17" font="7">pregnancy </text>
<text top="577" left="352" width="3" height="17" font="7"> </text>
<text top="491" left="514" width="158" height="17" font="7">Observational  1. Warfarin </text>
<text top="509" left="609" width="62" height="17" font="7">throughout </text>
<text top="526" left="609" width="61" height="17" font="7">pregnancy </text>
<text top="543" left="609" width="110" height="17" font="7">2. Warfarin for 6 wk </text>
<text top="560" left="609" width="86" height="17" font="7">then subq UFH </text>
<text top="577" left="609" width="98" height="17" font="7">3. Warfarin for 28 </text>
<text top="595" left="609" width="105" height="17" font="7">wk then subq UFH </text>
<text top="491" left="737" width="98" height="17" font="7">Valve thrombosis </text>
<text top="509" left="737" width="48" height="17" font="7">1.  0% </text>
<text top="526" left="737" width="55" height="17" font="7">2.  20% </text>
<text top="543" left="737" width="48" height="17" font="7">3.  0% </text>
<text top="560" left="737" width="87" height="17" font="7">Embolic events </text>
<text top="577" left="737" width="48" height="17" font="7">1.  0% </text>
<text top="595" left="737" width="55" height="17" font="7">2.  20% </text>
<text top="612" left="737" width="55" height="17" font="7">3.  25% </text>
<text top="629" left="737" width="72" height="17" font="7">Hemorrhage </text>
<text top="646" left="737" width="48" height="17" font="7">1.  3% </text>
<text top="663" left="737" width="55" height="17" font="7">2.  30% </text>
<text top="681" left="737" width="55" height="17" font="7">3.  25% </text>
<text top="491" left="913" width="87" height="17" font="7">Pregnancy loss </text>
<text top="509" left="913" width="55" height="17" font="7">1.  70% </text>
<text top="526" left="913" width="55" height="17" font="7">2.  22% </text>
<text top="543" left="913" width="55" height="17" font="7">3.  33% </text>
<text top="491" left="1027" width="165" height="17" font="7">Warfarin had high rate of fetal </text>
<text top="509" left="1027" width="25" height="17" font="7">loss </text>
<text top="526" left="1027" width="169" height="17" font="7">High rate of thromboemboli on </text>
<text top="543" left="1027" width="81" height="17" font="7">heparin (29%) </text>
<text top="560" left="1027" width="187" height="17" font="7">Bioprosthesis or homografts were </text>
<text top="577" left="1027" width="148" height="17" font="7">associated with successful </text>
<text top="595" left="1027" width="70" height="17" font="7">pregnancies </text>
<text top="491" left="1230" width="78" height="17" font="7">Retrospective </text>
<text top="509" left="1230" width="85" height="17" font="7">review of small </text>
<text top="526" left="1230" width="102" height="17" font="7">number pts—prior </text>
<text top="543" left="1230" width="78" height="17" font="7">to LMWH use </text>
<text top="699" left="42" width="85" height="17" font="7">De Santo 2005 </text>
<text top="716" left="42" width="32" height="17" font="7">(213) </text>
<text top="733" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15999035">15999035</a></text>
<text top="733" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15999035"> </a></text>
<text top="699" left="150" width="75" height="17" font="7">Single center </text>
<text top="716" left="150" width="93" height="17" font="7">experience of all </text>
<text top="733" left="150" width="70" height="17" font="7">pts who had </text>
<text top="750" left="150" width="65" height="17" font="7">mechanical </text>
<text top="768" left="150" width="83" height="17" font="7">prosthesis and </text>
<text top="785" left="150" width="99" height="17" font="7">became pregnant </text>
<text top="699" left="265" width="17" height="17" font="7">48 </text>
<text top="716" left="265" width="70" height="17" font="7">pregnancies </text>
<text top="733" left="265" width="50" height="17" font="7">in 37 pts </text>
<text top="699" left="352" width="134" height="17" font="7">All women from a single </text>
<text top="716" left="352" width="149" height="17" font="7">center who had MVR 1975 </text>
<text top="733" left="352" width="92" height="17" font="7">to 2002 and had </text>
<text top="750" left="352" width="128" height="17" font="7">subsequent pregnancy </text>
<text top="768" left="352" width="3" height="17" font="7"> </text>
<text top="699" left="514" width="158" height="17" font="7">Observational  1. Warfarin </text>
<text top="716" left="609" width="62" height="17" font="7">throughout </text>
<text top="733" left="609" width="85" height="17" font="7">A. Dose &lt;5 mg </text>
<text top="750" left="609" width="89" height="17" font="7">B. Dose &gt;5 mg  </text>
<text top="768" left="609" width="98" height="17" font="7">2. 2 pts with UFH </text>
<text top="699" left="737" width="150" height="17" font="7">2/2 pts with UFH had valve </text>
<text top="716" left="737" width="64" height="17" font="7">thrombosis </text>
<text top="733" left="737" width="129" height="17" font="7">No pt with warfarin had </text>
<text top="750" left="737" width="136" height="17" font="7">adverse cardiac or valve </text>
<text top="768" left="737" width="75" height="17" font="7">related event </text>
<text top="699" left="913" width="89" height="17" font="7">1A. 2/23 (8.6%) </text>
<text top="716" left="913" width="74" height="17" font="7">adverse fetal </text>
<text top="733" left="913" width="33" height="17" font="7">event </text>
<text top="750" left="913" width="92" height="17" font="7">1B. 17/21 (81%) </text>
<text top="768" left="913" width="74" height="17" font="7">adverse fetal </text>
<text top="785" left="913" width="33" height="17" font="7">event </text>
<text top="699" left="1027" width="170" height="17" font="7">If continue warfarin throughout </text>
<text top="716" left="1027" width="185" height="17" font="7">pregnancy, there are no maternal </text>
<text top="733" left="1027" width="40" height="17" font="7">events </text>
<text top="750" left="1027" width="163" height="17" font="7">Adverse fetal events mainly if </text>
<text top="768" left="1027" width="68" height="17" font="7">dose &gt;5 mg </text>
<text top="699" left="1230" width="78" height="17" font="7">Retrospective </text>
<text top="716" left="1230" width="85" height="17" font="7">review of small </text>
<text top="733" left="1230" width="102" height="17" font="7">number pts—prior </text>
<text top="750" left="1230" width="78" height="17" font="7">to LMWH use </text>
</page>
<page number="53" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">53 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="34" width="1294" height="17" font="7">AC indicates anticoagulation; GI, gastrointestinal; GR, growth retardation; LMWH, low molecular weight heparin<b>; </b>MVR, mitral valve replacement<b>; </b>N/A, not available; pts, patients; SA, spontaneous abortion; SB, still birth; SQ subcutaneous<b>; </b></text>
<text top="125" left="34" width="513" height="17" font="7">UFH, unfractionated heparin; VSD, ventricular septal defect; and, WE, warfarin embryopathy.  </text>
<text top="146" left="108" width="4" height="17" font="0"> </text>
<text top="146" left="324" width="4" height="17" font="0"> </text>
</page>
<page number="54" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">54 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="1104" height="21" font="4"><b>Data Supplement 26. Outcomes in Pregnant Women With a Mechanical Prosthetic Valve Treated With Low Molecular Weight Heparin (LMWH) (Section 13.3.2) </b></text>
<text top="129" left="51" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="129" left="189" width="64" height="17" font="6"><b>Study Aim </b></text>
<text top="129" left="310" width="86" height="17" font="6"><b>Study Size (N) </b></text>
<text top="129" left="447" width="47" height="17" font="6"><b>Type of </b></text>
<text top="146" left="428" width="86" height="17" font="6"><b>Anticoagulant </b></text>
<text top="129" left="553" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="129" left="696" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="882" width="64" height="17" font="6"><b>Endpoints </b></text>
<text top="129" left="1095" width="59" height="17" font="6"><b>Summary </b></text>
<text top="129" left="1210" width="107" height="17" font="6"><b>Study Limitations </b></text>
<text top="164" left="88" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="219" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="351" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="469" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="607" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="164" left="729" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="826" width="54" height="17" font="16"><i><b>Maternal </b></i></text>
<text top="164" left="974" width="32" height="17" font="16"><i><b>Fetal </b></i></text>
<text top="164" left="1123" width="3" height="17" font="6"><b> </b></text>
<text top="164" left="1261" width="3" height="17" font="6"><b> </b></text>
<text top="182" left="42" width="73" height="17" font="7">Rowan 2001 </text>
<text top="200" left="42" width="32" height="17" font="7">(214) </text>
<text top="217" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11568791">11568791</a></text>
<text top="217" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11568791"> </a></text>
<text top="182" left="150" width="112" height="17" font="7">Examine pregnancy </text>
<text top="200" left="150" width="138" height="17" font="7">outcomes in women with </text>
<text top="217" left="150" width="125" height="17" font="7">mechanical prosthesis </text>
<text top="234" left="150" width="108" height="17" font="7">treated with LMWH </text>
<text top="251" left="150" width="123" height="17" font="7">throughout pregnancy </text>
<text top="182" left="305" width="87" height="17" font="7">14 pregnancies </text>
<text top="200" left="305" width="73" height="17" font="7">in 11 women </text>
<text top="182" left="413" width="103" height="17" font="7">LMWH throughout </text>
<text top="200" left="413" width="61" height="17" font="7">pregnancy </text>
<text top="182" left="541" width="128" height="17" font="7">All pts with mechanical </text>
<text top="200" left="541" width="126" height="17" font="7">prosthesis treated with </text>
<text top="217" left="541" width="123" height="17" font="7">LMWH single center—</text>
<text top="234" left="541" width="133" height="17" font="7">1997–1999—fixed dose </text>
<text top="251" left="541" width="41" height="17" font="7">LMWH </text>
<text top="268" left="541" width="3" height="17" font="7"> </text>
<text top="182" left="690" width="217" height="17" font="7">Observational  One valve thrombosis </text>
<text top="200" left="784" width="108" height="17" font="7">14.3% hemorrhage </text>
<text top="182" left="935" width="66" height="17" font="7">9 live births </text>
<text top="200" left="935" width="87" height="17" font="7">3 miscarriages  </text>
<text top="217" left="935" width="81" height="17" font="7">2 terminations </text>
<text top="182" left="1057" width="132" height="17" font="7">Can achieve successful </text>
<text top="200" left="1057" width="134" height="17" font="7">pregnancy using LMWH </text>
<text top="217" left="1057" width="126" height="17" font="7">throughout pregnancy, </text>
<text top="234" left="1057" width="89" height="17" font="7">but risk of valve </text>
<text top="251" left="1057" width="64" height="17" font="7">thrombosis </text>
<text top="182" left="1205" width="85" height="17" font="7">Use fixed dose </text>
<text top="200" left="1205" width="100" height="17" font="7">LMWH with mean </text>
<text top="217" left="1205" width="98" height="17" font="7">anti-Xa level 0.46 </text>
<text top="234" left="1205" width="103" height="17" font="7">pre- and 0.89 post </text>
<text top="251" left="1205" width="33" height="17" font="7">dose. </text>
<text top="268" left="1205" width="78" height="17" font="7">Retrospective </text>
<text top="286" left="1205" width="85" height="17" font="7">review of small </text>
<text top="303" left="1205" width="68" height="17" font="7">number pts. </text>
<text top="321" left="42" width="74" height="17" font="7">James, 2006 </text>
<text top="338" left="42" width="32" height="17" font="7">(215) </text>
<text top="355" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16966122">16966122</a></text>
<text top="355" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16966122"> </a></text>
<text top="321" left="150" width="112" height="17" font="7">Examine pregnancy </text>
<text top="338" left="150" width="138" height="17" font="7">outcomes in women with </text>
<text top="355" left="150" width="125" height="17" font="7">mechanical prosthesis </text>
<text top="372" left="150" width="108" height="17" font="7">treated with LMWH </text>
<text top="390" left="150" width="123" height="17" font="7">throughout pregnancy </text>
<text top="321" left="305" width="87" height="17" font="7">76 pregnancies </text>
<text top="321" left="413" width="103" height="17" font="7">LMWH throughout </text>
<text top="338" left="413" width="61" height="17" font="7">pregnancy </text>
<text top="321" left="541" width="117" height="17" font="7">Medline search of 73 </text>
<text top="338" left="541" width="135" height="17" font="7">cases 1966–2006 and 3 </text>
<text top="355" left="541" width="119" height="17" font="7">of single center using </text>
<text top="372" left="541" width="103" height="17" font="7">LMWH throughout </text>
<text top="390" left="541" width="64" height="17" font="7">pregnancy  </text>
<text top="321" left="690" width="223" height="17" font="7">Meta-analysis  22% thrombotic events </text>
<text top="338" left="784" width="122" height="17" font="7">4% maternal mortality </text>
<text top="321" left="935" width="78" height="17" font="7">No congenital </text>
<text top="338" left="935" width="60" height="17" font="7">anomalies </text>
<text top="355" left="935" width="84" height="17" font="7">8 spontaneous </text>
<text top="372" left="935" width="54" height="17" font="7">abortions </text>
<text top="321" left="1057" width="117" height="17" font="7">Use of LMWH during </text>
<text top="338" left="1057" width="123" height="17" font="7">pregnancy associated </text>
<text top="355" left="1057" width="107" height="17" font="7">with high risk of life </text>
<text top="372" left="1057" width="129" height="17" font="7">threatening thrombosis </text>
<text top="321" left="1205" width="100" height="17" font="7">No anti X-a levels </text>
<text top="338" left="1205" width="63" height="17" font="7">performed. </text>
<text top="355" left="1205" width="105" height="17" font="7">Meta-analysis only </text>
<text top="408" left="42" width="65" height="17" font="7">Abildgaard, </text>
<text top="425" left="42" width="31" height="17" font="7">2009 </text>
<text top="442" left="42" width="32" height="17" font="7">(216) </text>
<text top="459" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19162303">19162303</a></text>
<text top="459" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19162303"> </a></text>
<text top="408" left="150" width="112" height="17" font="7">Examine pregnancy </text>
<text top="425" left="150" width="138" height="17" font="7">outcomes in women with </text>
<text top="442" left="150" width="125" height="17" font="7">mechanical prosthesis </text>
<text top="459" left="150" width="108" height="17" font="7">treated with LMWH </text>
<text top="476" left="150" width="123" height="17" font="7">throughout pregnancy </text>
<text top="408" left="305" width="87" height="17" font="7">12 pregnancies </text>
<text top="425" left="305" width="73" height="17" font="7">in 12 women </text>
<text top="408" left="413" width="103" height="17" font="7">LMWH throughout </text>
<text top="425" left="413" width="61" height="17" font="7">pregnancy </text>
<text top="408" left="541" width="128" height="17" font="7">All pts with mechanical </text>
<text top="425" left="541" width="126" height="17" font="7">prosthesis treated with </text>
<text top="442" left="541" width="103" height="17" font="7">LMWH throughout </text>
<text top="459" left="541" width="117" height="17" font="7">pregnancy in country </text>
<text top="476" left="541" width="128" height="17" font="7">Norway—1997–2008—</text>
<text top="494" left="541" width="100" height="17" font="7">use anti-Xa levels </text>
<text top="511" left="541" width="3" height="17" font="7"> </text>
<text top="408" left="690" width="212" height="17" font="7">Observational  1 systemic embolism </text>
<text top="425" left="784" width="130" height="17" font="7">and 1 valve thrombosis </text>
<text top="442" left="784" width="115" height="17" font="7">(both subtherapeutic </text>
<text top="459" left="784" width="40" height="17" font="7">doses) </text>
<text top="476" left="784" width="78" height="17" font="7">Pooled risk of </text>
<text top="494" left="784" width="132" height="17" font="7">thromboembolism 7.1% </text>
<text top="511" left="784" width="128" height="17" font="7">vs. prior data 25% with </text>
<text top="528" left="784" width="29" height="17" font="7">UFH </text>
<text top="408" left="935" width="100" height="17" font="7">13 healthy babies </text>
<text top="408" left="1057" width="114" height="17" font="7">If use anti-Xa levels, </text>
<text top="425" left="1057" width="108" height="17" font="7">successful in 10/12 </text>
<text top="442" left="1057" width="129" height="17" font="7">pregnancies, risk lower </text>
<text top="459" left="1057" width="72" height="17" font="7">than UFH by </text>
<text top="476" left="1057" width="74" height="17" font="7">retrospective </text>
<text top="494" left="1057" width="67" height="17" font="7">comparison </text>
<text top="408" left="1205" width="78" height="17" font="7">Retrospective </text>
<text top="425" left="1205" width="85" height="17" font="7">review of small </text>
<text top="442" left="1205" width="65" height="17" font="7">number pts </text>
<text top="546" left="42" width="65" height="17" font="7">Oran, 2004 </text>
<text top="563" left="42" width="32" height="17" font="7">(217) </text>
<text top="580" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15467905">15467905</a></text>
<text top="580" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15467905"> </a></text>
<text top="546" left="150" width="93" height="17" font="7">Meta-analysis of </text>
<text top="563" left="150" width="130" height="17" font="7">pregnancy outcomes in </text>
<text top="580" left="150" width="134" height="17" font="7">women with mechanical </text>
<text top="598" left="150" width="126" height="17" font="7">prosthesis treated with </text>
<text top="615" left="150" width="133" height="17" font="7">differing anticoagulation </text>
<text top="632" left="150" width="109" height="17" font="7">regimens, including </text>
<text top="649" left="150" width="41" height="17" font="7">LMWH </text>
<text top="546" left="305" width="73" height="17" font="7">10 reports (2 </text>
<text top="563" left="305" width="70" height="17" font="7">prospective) </text>
<text top="580" left="305" width="87" height="17" font="7">81 pregnancies </text>
<text top="598" left="305" width="73" height="17" font="7">in 75 women </text>
<text top="546" left="413" width="48" height="17" font="7">LMWH 1</text>
<text top="547" left="461" width="6" height="11" font="9">st</text>
<text top="546" left="467" width="58" height="17" font="7"> trimester, </text>
<text top="563" left="413" width="94" height="17" font="7">then warfarin vs. </text>
<text top="580" left="413" width="103" height="17" font="7">LMWH throughout </text>
<text top="598" left="413" width="61" height="17" font="7">pregnancy </text>
<text top="546" left="541" width="100" height="17" font="7">Medline search of </text>
<text top="563" left="541" width="100" height="17" font="7">studies in pts with </text>
<text top="580" left="541" width="116" height="17" font="7">prostheses receiving </text>
<text top="598" left="541" width="138" height="17" font="7">LMWH from 1989–2004  </text>
<text top="615" left="541" width="3" height="17" font="7"> </text>
<text top="546" left="690" width="146" height="17" font="7">Meta-analysis  12% had </text>
<text top="563" left="784" width="104" height="17" font="7">thromboemboli–all </text>
<text top="580" left="784" width="116" height="17" font="7">MVR–all with LMWH </text>
<text top="598" left="784" width="133" height="17" font="7">throughout–9/10 did not </text>
<text top="615" left="784" width="137" height="17" font="7">have anti-Xa monitoring. </text>
<text top="632" left="784" width="133" height="17" font="7">Valve thrombosis 8.6%  </text>
<text top="546" left="935" width="76" height="17" font="7">Spontaneous </text>
<text top="563" left="935" width="92" height="17" font="7">abortion in 7.4% </text>
<text top="580" left="935" width="92" height="17" font="7">Stillbirth in 1.2% </text>
<text top="598" left="935" width="83" height="17" font="7">87% live births </text>
<text top="546" left="1057" width="102" height="17" font="7">All thromboemboli </text>
<text top="563" left="1057" width="109" height="17" font="7">occurred in pts with </text>
<text top="580" left="1057" width="119" height="17" font="7">mitral prosthesis who </text>
<text top="598" left="1057" width="127" height="17" font="7">had LMWH throughout </text>
<text top="615" left="1057" width="64" height="17" font="7">pregnancy. </text>
<text top="632" left="1057" width="128" height="17" font="7">Anti Xa levels were not </text>
<text top="649" left="1057" width="113" height="17" font="7">monitored in 90% of </text>
<text top="667" left="1057" width="134" height="17" font="7">thromboembolic events. </text>
<text top="546" left="1205" width="105" height="17" font="7">Meta-analysis only </text>
<text top="685" left="42" width="93" height="17" font="7">McLintock, 2009 </text>
<text top="702" left="42" width="32" height="17" font="7">(218) </text>
<text top="719" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19681850">19681850</a></text>
<text top="719" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19681850"> </a></text>
<text top="685" left="150" width="112" height="17" font="7">Examine pregnancy </text>
<text top="702" left="150" width="138" height="17" font="7">outcomes in women with </text>
<text top="719" left="150" width="125" height="17" font="7">mechanical prosthesis </text>
<text top="736" left="150" width="114" height="17" font="7">treated with differing </text>
<text top="753" left="150" width="140" height="17" font="7">anticoagulation regimens </text>
<text top="771" left="150" width="93" height="17" font="7">including LMWH </text>
<text top="685" left="305" width="87" height="17" font="7">47 pregnancies </text>
<text top="702" left="305" width="73" height="17" font="7">in 31 women </text>
<text top="685" left="413" width="112" height="17" font="7">Warfarin throughout </text>
<text top="702" left="413" width="80" height="17" font="7">pregnancy vs. </text>
<text top="719" left="413" width="48" height="17" font="7">LMWH 1</text>
<text top="720" left="461" width="6" height="11" font="9">st</text>
<text top="719" left="467" width="58" height="17" font="7"> trimester, </text>
<text top="736" left="413" width="94" height="17" font="7">then warfarin vs. </text>
<text top="753" left="413" width="103" height="17" font="7">LMWH throughout </text>
<text top="771" left="413" width="61" height="17" font="7">pregnancy </text>
<text top="685" left="541" width="128" height="17" font="7">All pts with mechanical </text>
<text top="702" left="541" width="126" height="17" font="7">prosthesis treated with </text>
<text top="719" left="541" width="133" height="17" font="7">differing anticoagulation </text>
<text top="736" left="541" width="106" height="17" font="7">regimens including </text>
<text top="753" left="541" width="113" height="17" font="7">LMWH—2 centers—</text>
<text top="771" left="541" width="121" height="17" font="7">1997–2008—use anti-</text>
<text top="788" left="541" width="53" height="17" font="7">Xa levels </text>
<text top="685" left="690" width="210" height="17" font="7">Observational  Thromboembolism 7 </text>
<text top="702" left="784" width="128" height="17" font="7">total–5 (10.6%) LMWH </text>
<text top="719" left="784" width="117" height="17" font="7">Antepartum bleeding </text>
<text top="736" left="784" width="83" height="17" font="7">10.6% LMWH  </text>
<text top="753" left="784" width="116" height="17" font="7">Postpartum bleeding </text>
<text top="771" left="784" width="86" height="17" font="7">12.7% LMWH   </text>
<text top="685" left="935" width="108" height="17" font="7">96% live births with </text>
<text top="702" left="935" width="88" height="17" font="7">LMWH vs. 75% </text>
<text top="719" left="935" width="80" height="17" font="7">live births with </text>
<text top="736" left="935" width="47" height="17" font="7">warfarin </text>
<text top="685" left="1057" width="109" height="17" font="7">Poor compliance or </text>
<text top="702" left="1057" width="126" height="17" font="7">subtherapeutic anti-Xa </text>
<text top="719" left="1057" width="122" height="17" font="7">levels were present in </text>
<text top="736" left="1057" width="128" height="17" font="7">all valve thrombosis on </text>
<text top="753" left="1057" width="41" height="17" font="7">LMWH </text>
<text top="685" left="1205" width="78" height="17" font="7">Retrospective </text>
<text top="702" left="1205" width="85" height="17" font="7">review of small </text>
<text top="719" left="1205" width="65" height="17" font="7">number pts </text>
</page>
<page number="55" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">55 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="51" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="108" left="189" width="64" height="17" font="6"><b>Study Aim </b></text>
<text top="108" left="310" width="86" height="17" font="6"><b>Study Size (N) </b></text>
<text top="108" left="447" width="47" height="17" font="6"><b>Type of </b></text>
<text top="126" left="428" width="86" height="17" font="6"><b>Anticoagulant </b></text>
<text top="108" left="553" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="108" left="696" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="882" width="64" height="17" font="6"><b>Endpoints </b></text>
<text top="108" left="1095" width="59" height="17" font="6"><b>Summary </b></text>
<text top="108" left="1210" width="107" height="17" font="6"><b>Study Limitations </b></text>
<text top="144" left="88" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="219" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="351" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="469" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="607" width="3" height="17" font="16"><i><b> </b></i></text>
<text top="144" left="729" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="826" width="54" height="17" font="16"><i><b>Maternal </b></i></text>
<text top="144" left="974" width="32" height="17" font="16"><i><b>Fetal </b></i></text>
<text top="144" left="1123" width="3" height="17" font="6"><b> </b></text>
<text top="144" left="1261" width="3" height="17" font="6"><b> </b></text>
<text top="162" left="42" width="69" height="17" font="7">Yinon, 2009 </text>
<text top="179" left="42" width="32" height="17" font="7">(219) </text>
<text top="196" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19840573">19840573</a></text>
<text top="196" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19840573"> </a></text>
<text top="162" left="150" width="112" height="17" font="7">Examine pregnancy </text>
<text top="179" left="150" width="138" height="17" font="7">outcomes in women with </text>
<text top="196" left="150" width="125" height="17" font="7">mechanical prosthesis </text>
<text top="213" left="150" width="108" height="17" font="7">treated with LMWH </text>
<text top="230" left="150" width="123" height="17" font="7">throughout pregnancy </text>
<text top="162" left="305" width="87" height="17" font="7">23 pregnancies </text>
<text top="179" left="305" width="73" height="17" font="7">in 17 women </text>
<text top="162" left="413" width="103" height="17" font="7">LMWH throughout </text>
<text top="179" left="413" width="61" height="17" font="7">pregnancy </text>
<text top="162" left="541" width="128" height="17" font="7">All pts with mechanical </text>
<text top="179" left="541" width="126" height="17" font="7">prosthesis treated with </text>
<text top="196" left="541" width="123" height="17" font="7">LMWH—single center </text>
<text top="213" left="541" width="121" height="17" font="7">1998–2008—use anti-</text>
<text top="230" left="541" width="53" height="17" font="7">Xa levels </text>
<text top="248" left="541" width="3" height="17" font="7"> </text>
<text top="162" left="690" width="185" height="17" font="7">Observational  1 (4%) maternal </text>
<text top="179" left="784" width="90" height="17" font="7">thrombosis died </text>
<text top="196" left="784" width="107" height="17" font="7">5 (22%) pulmonary </text>
<text top="213" left="784" width="115" height="17" font="7">edema, arrhythmias, </text>
<text top="230" left="784" width="94" height="17" font="7">and endocarditis </text>
<text top="248" left="784" width="93" height="17" font="7">13% postpartum </text>
<text top="265" left="784" width="70" height="17" font="7">hemorrhage </text>
<text top="162" left="935" width="73" height="17" font="7">19 live births </text>
<text top="179" left="935" width="85" height="17" font="7">2 first trimester </text>
<text top="196" left="935" width="76" height="17" font="7">miscarriages  </text>
<text top="213" left="935" width="75" height="17" font="7">2 intrauterine </text>
<text top="230" left="935" width="40" height="17" font="7">deaths </text>
<text top="162" left="1057" width="97" height="17" font="7">Even with careful </text>
<text top="179" left="1057" width="120" height="17" font="7">monitoring of anti X-a </text>
<text top="196" left="1057" width="125" height="17" font="7">levels thrombosis may </text>
<text top="213" left="1057" width="114" height="17" font="7">occur, even with low </text>
<text top="230" left="1057" width="51" height="17" font="7">risk AVR </text>
<text top="162" left="1205" width="78" height="17" font="7">Retrospective </text>
<text top="179" left="1205" width="85" height="17" font="7">review of small </text>
<text top="196" left="1205" width="65" height="17" font="7">number pts </text>
<text top="283" left="42" width="70" height="17" font="7">Quinn, 2009 </text>
<text top="300" left="42" width="32" height="17" font="7">(220) </text>
<text top="317" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19880782">19880782</a></text>
<text top="317" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19880782"> </a></text>
<text top="283" left="150" width="112" height="17" font="7">Examine pregnancy </text>
<text top="300" left="150" width="138" height="17" font="7">outcomes in women with </text>
<text top="317" left="150" width="125" height="17" font="7">mechanical prosthesis </text>
<text top="335" left="150" width="108" height="17" font="7">treated with LMWH </text>
<text top="352" left="150" width="123" height="17" font="7">throughout pregnancy </text>
<text top="283" left="305" width="87" height="17" font="7">12 pregnancies </text>
<text top="300" left="305" width="73" height="17" font="7">in 11 women </text>
<text top="283" left="413" width="103" height="17" font="7">LMWH throughout </text>
<text top="300" left="413" width="61" height="17" font="7">pregnancy </text>
<text top="283" left="541" width="128" height="17" font="7">All pts with mechanical </text>
<text top="300" left="541" width="126" height="17" font="7">prosthesis treated with </text>
<text top="317" left="541" width="132" height="17" font="7">LMWH—single center—</text>
<text top="335" left="541" width="121" height="17" font="7">2001–2007—use anti-</text>
<text top="352" left="541" width="53" height="17" font="7">Xa levels </text>
<text top="369" left="541" width="3" height="17" font="7"> </text>
<text top="283" left="690" width="179" height="17" font="7">Observational  3 major bleeds </text>
<text top="300" left="784" width="84" height="17" font="7">3 minor bleeds </text>
<text top="317" left="784" width="138" height="17" font="7">BS MVR thrombosis 1 pt </text>
<text top="335" left="784" width="126" height="17" font="7">(Xa level not done and </text>
<text top="352" left="784" width="116" height="17" font="7">later subtherapeutic) </text>
<text top="283" left="935" width="90" height="17" font="7">11/12 live births </text>
<text top="283" left="1057" width="131" height="17" font="7">Increasing dose LMWH </text>
<text top="300" left="1057" width="98" height="17" font="7">during pregnancy </text>
<text top="317" left="1057" width="60" height="17" font="7">necessary </text>
<text top="335" left="1057" width="124" height="17" font="7">Only valve thrombosis </text>
<text top="352" left="1057" width="103" height="17" font="7">occurred in pt with </text>
<text top="369" left="1057" width="131" height="17" font="7">subtherapeutic level Xa </text>
<text top="283" left="1205" width="78" height="17" font="7">Retrospective </text>
<text top="300" left="1205" width="85" height="17" font="7">review of small </text>
<text top="317" left="1205" width="65" height="17" font="7">number pts </text>
<text top="387" left="33" width="1292" height="17" font="7">AVR indicates aortic valve replacement; BS, Bjork-Shiley; GI, gastrointestinal; LMWH, low molecular weight heparin; MVR, mitral valve replacement; N/A, not available; pts, patients; UFH, unfractionated heparin; and, SES, socioeconomic </text>
<text top="404" left="33" width="43" height="17" font="7">status. <b> </b></text>
<text top="424" left="108" width="3" height="15" font="6"><b> </b></text>
<text top="422" left="324" width="3" height="17" font="7"> </text>
</page>
<page number="56" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">56 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="941" height="21" font="4"><b>Data Supplement 27. Outcomes With the Maze Procedure for Atrial Fibrillation in Patients With Valvular Heart Disease (Section 14.2.2) </b></text>
<text top="129" left="54" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="129" left="202" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="129" left="355" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="489" width="86" height="17" font="6"><b>Study Size (N) </b></text>
<text top="129" left="638" width="124" height="17" font="6"><b>Study “Intervention” </b></text>
<text top="146" left="671" width="59" height="17" font="6"><b>Group (n) </b></text>
<text top="129" left="800" width="151" height="17" font="6"><b>Study Comparator Group </b></text>
<text top="146" left="866" width="19" height="17" font="6"><b>(n) </b></text>
<text top="129" left="1121" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="164" left="42" width="284" height="17" font="6"><b>Prognostic Significant of AF at Time of Surgery  </b></text>
<text top="182" left="42" width="98" height="17" font="7">Eguchi et al 2005 </text>
<text top="200" left="42" width="32" height="17" font="7">(221) </text>
<text top="217" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15845559">15845559</a></text>
<text top="217" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15845559"> </a></text>
<text top="182" left="157" width="104" height="17" font="7">Examine impact of </text>
<text top="200" left="157" width="158" height="17" font="7">preoperative AF on outcome </text>
<text top="217" left="157" width="127" height="17" font="7">of MV repair for 1° MR </text>
<text top="182" left="339" width="78" height="17" font="7">Retrospective </text>
<text top="200" left="339" width="77" height="17" font="7">observational </text>
<text top="182" left="454" width="139" height="17" font="7">283 pts with moderate-to-</text>
<text top="200" left="454" width="149" height="17" font="7">severe MR who underwent </text>
<text top="217" left="454" width="137" height="17" font="7">MV repair between 1991 </text>
<text top="234" left="454" width="55" height="17" font="7">and 2002 </text>
<text top="182" left="622" width="56" height="17" font="7">129 in AF </text>
<text top="200" left="622" width="74" height="17" font="7">Age 59±13 y </text>
<text top="217" left="622" width="58" height="17" font="7">60% male </text>
<text top="182" left="791" width="66" height="17" font="7">154 in NSR </text>
<text top="200" left="791" width="74" height="17" font="7">Age 52±14 y </text>
<text top="217" left="791" width="58" height="17" font="7">67% male </text>
<text top="182" left="973" width="280" height="17" font="7">5 y outcomes were better in pts in NSR vs. AF for:  </text>
<text top="200" left="973" width="321" height="17" font="7">survival (96±2.1 vs. 87±3.2%; p=0.002) and freedom from </text>
<text top="217" left="973" width="257" height="17" font="7">cardiac events (96±2.0 vs. 75±4.4%; p&lt;0.001) </text>
<text top="252" left="42" width="75" height="17" font="7">Alexiou 2007 </text>
<text top="269" left="42" width="32" height="17" font="7">(222) </text>
<text top="286" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17280837">17280837</a></text>
<text top="286" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17280837"> </a></text>
<text top="252" left="157" width="162" height="17" font="7">Impact of preoperative AF on </text>
<text top="269" left="157" width="156" height="17" font="7">early and late outcome after </text>
<text top="286" left="157" width="60" height="17" font="7">MV repair  </text>
<text top="252" left="339" width="78" height="17" font="7">Retrospective </text>
<text top="269" left="339" width="77" height="17" font="7">observational </text>
<text top="252" left="454" width="130" height="17" font="7">349 pts undergoing MV </text>
<text top="269" left="454" width="120" height="17" font="7">repair for primary MR </text>
<text top="252" left="622" width="96" height="17" font="7">152 (44%) in AF  </text>
<text top="252" left="791" width="106" height="17" font="7">197 (56%) in NSR  </text>
<text top="252" left="973" width="343" height="17" font="7">Kaplan-Meier survival at 7 y was 75±6% for AF pts vs. 90±3% </text>
<text top="269" left="973" width="118" height="17" font="7">(p=0.005) for SR pts. </text>
<text top="304" left="42" width="77" height="17" font="7">Ngaage 2006 </text>
<text top="321" left="42" width="32" height="17" font="7">(223) </text>
<text top="339" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17643612">17643612</a></text>
<text top="339" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17643612"> </a></text>
<text top="304" left="157" width="143" height="17" font="7">Prognostic significance of </text>
<text top="321" left="157" width="165" height="17" font="7">preoperative AF at the time of </text>
<text top="339" left="157" width="29" height="17" font="7">AVR </text>
<text top="304" left="339" width="78" height="17" font="7">Retrospective </text>
<text top="321" left="339" width="80" height="17" font="7">observational, </text>
<text top="339" left="339" width="38" height="17" font="7">cohort </text>
<text top="356" left="339" width="70" height="17" font="7">comparison  </text>
<text top="304" left="454" width="138" height="17" font="7">381 AVR 1993 and 2002 </text>
<text top="321" left="454" width="141" height="17" font="7">matched for age, gender, </text>
<text top="339" left="454" width="58" height="17" font="7">and LVEF </text>
<text top="304" left="622" width="138" height="17" font="7">Preoperative AF (n=129) </text>
<text top="304" left="791" width="149" height="17" font="7">Preoperative NSR (n=252) </text>
<text top="304" left="973" width="333" height="17" font="7">Pts with preoperative AF had had worse late survival (RR for </text>
<text top="321" left="973" width="334" height="17" font="7">death=1.5; p=0.03) with 1-, 5-, and 7-y survival rates of 94%, </text>
<text top="339" left="973" width="348" height="17" font="7">87%, and 50%, respectively, for those in AF vs. 98%, 90%, and </text>
<text top="356" left="973" width="187" height="17" font="7">61% for pts in SR preoperatively.  </text>
<text top="373" left="973" width="317" height="17" font="7">Pts with AF more frequently developed HF (25% vs. 10%; </text>
<text top="390" left="973" width="335" height="17" font="7">p=0.005) and stroke (16% vs. 5%; p=0.005). By multivariable </text>
<text top="408" left="973" width="344" height="17" font="7">analysis, preoperative AF was an independent predictor of late </text>
<text top="425" left="973" width="350" height="17" font="7">adverse cardiac and cerebrovascular events, but not late death. </text>
<text top="443" left="42" width="345" height="17" font="6"><b>Predictors of Return of Sinus Rhythm After Valve Surgery  </b></text>
<text top="461" left="42" width="64" height="17" font="7">Chua 1994 </text>
<text top="478" left="42" width="32" height="17" font="7">(224) </text>
<text top="495" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8302059">8302059</a></text>
<text top="495" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8302059"> </a></text>
<text top="461" left="157" width="131" height="17" font="7">Determine frequency of </text>
<text top="478" left="157" width="147" height="17" font="7">reversion to NSR after MV </text>
<text top="495" left="157" width="121" height="17" font="7">repair among pts with </text>
<text top="512" left="157" width="91" height="17" font="7">preoperative AF </text>
<text top="461" left="339" width="82" height="17" font="7">Retrospective, </text>
<text top="478" left="339" width="80" height="17" font="7">observational  </text>
<text top="461" left="454" width="138" height="17" font="7">323 consecutive pts who </text>
<text top="478" left="454" width="128" height="17" font="7">underwent surgical MV </text>
<text top="495" left="454" width="142" height="17" font="7">valvuloplasty for MR from </text>
<text top="512" left="454" width="65" height="17" font="7">1980–1991 </text>
<text top="461" left="622" width="135" height="17" font="7">97 in AF before surgery  </text>
<text top="461" left="791" width="152" height="17" font="7">216 in NSR before surgery  </text>
<text top="461" left="973" width="355" height="17" font="7">At late follow-up (mean 2.6 y, range 3 mo–10 y), AF was present </text>
<text top="478" left="973" width="328" height="17" font="7">in 5% pts with preoperative NSR, 80% pts with preoperative </text>
<text top="495" left="973" width="318" height="17" font="7">chronic AF, and 0% pts with preoperative recent onset AF </text>
<text top="512" left="973" width="53" height="17" font="7">(p&lt;0.01)  </text>
<text top="530" left="42" width="74" height="17" font="7">Obadia 1997 </text>
<text top="548" left="42" width="32" height="17" font="7">(225) </text>
<text top="565" left="42" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9270633">9270633</a></text>
<text top="565" left="90" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9270633"> </a></text>
<text top="530" left="157" width="135" height="17" font="7">Determine predictors for </text>
<text top="548" left="157" width="137" height="17" font="7">return to NSR after MVR </text>
<text top="530" left="339" width="82" height="17" font="7">Retrospective, </text>
<text top="548" left="339" width="80" height="17" font="7">observational  </text>
<text top="530" left="454" width="153" height="17" font="7">191 pts undergoing surgery </text>
<text top="548" left="454" width="55" height="17" font="7">for MVR   </text>
<text top="530" left="622" width="122" height="17" font="7">Preoperative AF in 96 </text>
<text top="548" left="622" width="40" height="17" font="7">(50%)  </text>
<text top="530" left="791" width="520" height="17" font="7">Preoperative NSR in 95 (40%)   The probability of return to stable NSR was 93.7% when NSR </text>
<text top="548" left="973" width="356" height="17" font="7">was already present before the operation and 80% when AF was </text>
<text top="565" left="973" width="329" height="17" font="7">intermittent or of less than 1 y duration; probability of postop </text>
<text top="582" left="973" width="323" height="17" font="7">NSR declined abruptly for preoperative duration of AF &gt;1 y </text>
<text top="600" left="42" width="84" height="17" font="7">Jessurun 2000 </text>
<text top="617" left="42" width="32" height="17" font="7">(226) </text>
<text top="634" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10814915">10814915</a></text>
<text top="634" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10814915"> </a></text>
<text top="600" left="157" width="115" height="17" font="7">Outcome analysis of </text>
<text top="617" left="157" width="165" height="17" font="7">arrhythmias after MV surgery  </text>
<text top="600" left="339" width="82" height="17" font="7">Retrospective, </text>
<text top="617" left="339" width="80" height="17" font="7">observational  </text>
<text top="600" left="454" width="112" height="17" font="7">162 consecutive pts </text>
<text top="617" left="454" width="131" height="17" font="7">undergoing MV surgery </text>
<text top="634" left="454" width="135" height="17" font="7">between 1990 and 1993 </text>
<text top="600" left="622" width="148" height="17" font="7">Preoperative chronic AF in </text>
<text top="617" left="622" width="143" height="17" font="7">74 (46%) and paroxysmal </text>
<text top="634" left="622" width="85" height="17" font="7">AF in 29 (18%) </text>
<text top="600" left="791" width="506" height="17" font="7">Preoperative NSR in 59 (36%)  NSR present postop in 40 of 57 (70%) pts with preop NSR. </text>
<text top="617" left="973" width="357" height="17" font="7">AF present postop in 58 of 68 (85%) of pts with preop chronic AF </text>
<text top="634" left="973" width="39" height="17" font="7">(&gt;1 y). </text>
<text top="652" left="973" width="328" height="17" font="7">NSR present postop in 10 of 29 (34%) pts with preoperative </text>
<text top="669" left="973" width="89" height="17" font="7">paroxysmal AF. </text>
<text top="687" left="42" width="219" height="17" font="6"><b>Outcomes With Surgical Maze for AF </b></text>
<text top="706" left="42" width="77" height="17" font="7">Deneke 2002 </text>
<text top="723" left="42" width="32" height="17" font="7">(227) </text>
<text top="740" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11922646">11922646</a></text>
<text top="740" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11922646"> </a></text>
<text top="706" left="157" width="154" height="17" font="7">Efficacy of a modified maze </text>
<text top="723" left="157" width="160" height="17" font="7">procedure in pts with chronic </text>
<text top="740" left="157" width="115" height="17" font="7">AF undergoing MVR </text>
<text top="706" left="339" width="67" height="17" font="7">Prospective </text>
<text top="723" left="339" width="68" height="17" font="7">randomized </text>
<text top="706" left="454" width="105" height="17" font="7">30 consecutive pts </text>
<text top="723" left="454" width="99" height="17" font="7">undergoing MVR  </text>
<text top="706" left="622" width="137" height="17" font="7">Modified maze at time of </text>
<text top="723" left="622" width="31" height="17" font="7">MVR </text>
<text top="706" left="791" width="64" height="17" font="7">MVR alone </text>
<text top="706" left="973" width="331" height="17" font="7">After 12 mo, NSR was present significantly more often in pts </text>
<text top="723" left="973" width="311" height="17" font="7">undergoing modified maze (cumulative rate NSR=0.800) </text>
<text top="740" left="973" width="335" height="17" font="7">compared to pts with MV replacement alone (0.267) (p&lt;0.01) </text>
</page>
<page number="57" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">57 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="54" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="108" left="202" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="355" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="489" width="86" height="17" font="6"><b>Study Size (N) </b></text>
<text top="108" left="638" width="124" height="17" font="6"><b>Study “Intervention” </b></text>
<text top="126" left="671" width="59" height="17" font="6"><b>Group (n) </b></text>
<text top="108" left="800" width="151" height="17" font="6"><b>Study Comparator Group </b></text>
<text top="126" left="866" width="19" height="17" font="6"><b>(n) </b></text>
<text top="108" left="1121" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="144" left="42" width="76" height="17" font="7">Akpinar 2003 </text>
<text top="161" left="42" width="32" height="17" font="7">(228) </text>
<text top="178" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12895612">12895612</a></text>
<text top="178" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12895612"> </a></text>
<text top="144" left="157" width="141" height="17" font="7">Assess the feasibility and </text>
<text top="161" left="157" width="156" height="17" font="7">effectiveness of irrigated RF </text>
<text top="178" left="157" width="142" height="17" font="7">modified maze procedure </text>
<text top="195" left="157" width="122" height="17" font="7">through a port access </text>
<text top="212" left="157" width="159" height="17" font="7">approach during MV surgery </text>
<text top="144" left="339" width="67" height="17" font="7">Prospective </text>
<text top="161" left="339" width="68" height="17" font="7">randomized </text>
<text top="144" left="454" width="124" height="17" font="7">67 pts with chronic AF </text>
<text top="161" left="454" width="148" height="17" font="7">eligible for port access MV </text>
<text top="178" left="454" width="44" height="17" font="7">surgery </text>
<text top="144" left="622" width="134" height="17" font="7">33 irrigated RF modified </text>
<text top="161" left="622" width="92" height="17" font="7">Maze procedure </text>
<text top="144" left="791" width="142" height="17" font="7">34 valve procedure alone </text>
<text top="144" left="973" width="346" height="17" font="7">100% of pts who underwent RF modified maze were free of AF </text>
<text top="161" left="973" width="308" height="17" font="7">at the end of the operation (76% NSR, 24% pacemaker) </text>
<text top="178" left="973" width="339" height="17" font="7">compared with 41% of those who underwent MV repair alone. </text>
<text top="195" left="973" width="348" height="17" font="7">At 6 and 12 mo freedom from AF was 87.2 and 93.6% for those </text>
<text top="212" left="973" width="353" height="17" font="7">undergoing RF maze and 9.4% (p=0.0001) for those undergoing </text>
<text top="230" left="973" width="64" height="17" font="7">MVR alone </text>
<text top="248" left="42" width="84" height="17" font="7">Jessarun 2003 </text>
<text top="265" left="42" width="32" height="17" font="7">(229) </text>
<text top="282" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12627066">12627066</a></text>
<text top="282" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12627066"> </a></text>
<text top="248" left="157" width="167" height="17" font="7">Assess outcome of combining </text>
<text top="265" left="157" width="152" height="17" font="7">the Maze III procedure with </text>
<text top="282" left="157" width="66" height="17" font="7">MV surgery </text>
<text top="248" left="339" width="71" height="17" font="7">Prospective. </text>
<text top="265" left="339" width="68" height="17" font="7">randomized </text>
<text top="282" left="339" width="66" height="17" font="7">(2.5:1 ratio) </text>
<text top="248" left="454" width="146" height="17" font="7">35 pts with AF undergoing </text>
<text top="265" left="454" width="119" height="17" font="7">MVR. Mean age 64 y </text>
<text top="248" left="622" width="81" height="17" font="7">Maze III in 25  </text>
<text top="248" left="791" width="94" height="17" font="7">MVR along in 10 </text>
<text top="248" left="973" width="310" height="17" font="7">Freedom from AF in the maze + MVR group was 56% at </text>
<text top="265" left="973" width="163" height="17" font="7">discharge and 92% at 12 mo. </text>
<text top="282" left="973" width="356" height="17" font="7">MVR alone group, freedom from AF was 0% at discharge and 20 </text>
<text top="299" left="973" width="37" height="17" font="7">at 1 y. </text>
<text top="317" left="973" width="336" height="17" font="7">Group differences at discharge p=0.002 and at 1 y p=0.0007. </text>
<text top="335" left="42" width="97" height="17" font="7">Abreu Filho 2005 </text>
<text top="352" left="42" width="32" height="17" font="7">(230) </text>
<text top="369" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16159816">16159816</a></text>
<text top="369" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16159816"> </a></text>
<text top="335" left="157" width="140" height="17" font="7">Evaluate effectiveness of </text>
<text top="352" left="157" width="110" height="17" font="7">maze procedure for </text>
<text top="369" left="157" width="139" height="17" font="7">permanent AF in pts with </text>
<text top="386" left="157" width="125" height="17" font="7">rheumatic MV disease </text>
<text top="335" left="339" width="67" height="17" font="7">Prospective </text>
<text top="352" left="339" width="71" height="17" font="7">randomized  </text>
<text top="335" left="454" width="105" height="17" font="7">70 consecutive pts </text>
<text top="352" left="454" width="142" height="17" font="7">(2002−03) with rheumatic </text>
<text top="369" left="454" width="154" height="17" font="7">MV disease and permanent </text>
<text top="386" left="454" width="19" height="17" font="7">AF </text>
<text top="335" left="622" width="139" height="17" font="7">MV surgery plus Maze III </text>
<text top="352" left="622" width="144" height="17" font="7">procedure saline-Irrigated </text>
<text top="369" left="622" width="123" height="17" font="7">cooled-tip RF ablation </text>
<text top="335" left="791" width="103" height="17" font="7">MV surgery alone  </text>
<text top="335" left="973" width="357" height="17" font="7">Cumulative rates of NSR were 79.4% for those undergoing maze </text>
<text top="352" left="973" width="350" height="17" font="7">and 26.9% for those undergoing mitral surgery alone (p=0.001). </text>
<text top="369" left="973" width="348" height="17" font="7">Group differences were significant at discharge (p=0.002), after </text>
<text top="386" left="973" width="104" height="17" font="7">12 mo (p=0.0007). </text>
<text top="404" left="42" width="76" height="17" font="7">Doukas 2005 </text>
<text top="421" left="42" width="32" height="17" font="7">(231) </text>
<text top="439" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16278360">16278360</a></text>
<text top="439" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16278360"> </a></text>
<text top="404" left="157" width="123" height="17" font="7">To determine whether </text>
<text top="421" left="157" width="144" height="17" font="7">intraoperative RF ablation </text>
<text top="439" left="157" width="132" height="17" font="7">increases the long-term </text>
<text top="456" left="157" width="128" height="17" font="7">restoration of NSR and </text>
<text top="473" left="157" width="151" height="17" font="7">improves exercise capacity </text>
<text top="404" left="339" width="76" height="17" font="7">Randomized, </text>
<text top="421" left="339" width="94" height="17" font="7">double-blind trial </text>
<text top="404" left="454" width="123" height="17" font="7">97 pts referred for MV </text>
<text top="421" left="454" width="149" height="17" font="7">surgery with AF for at least </text>
<text top="439" left="454" width="31" height="17" font="7">6 mo </text>
<text top="404" left="622" width="132" height="17" font="7">MV surgery plus RF left </text>
<text top="421" left="622" width="77" height="17" font="7">atrial ablation </text>
<text top="404" left="791" width="100" height="17" font="7">MV surgery alone </text>
<text top="404" left="973" width="354" height="17" font="7">At 12 mo NSR was present in 20 (44.4%) of 45 RFA pts and in 2 </text>
<text top="421" left="973" width="322" height="17" font="7">(4.5%) of 44 controls, RR: 9.8; 95% CI: 2.4–86.3; p&lt;0.001  </text>
<text top="491" left="42" width="95" height="17" font="7">Von Oppell 2009 </text>
<text top="508" left="42" width="32" height="17" font="7">(232) </text>
<text top="525" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19233678">19233678</a></text>
<text top="525" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19233678"> </a></text>
<text top="491" left="157" width="152" height="17" font="7">Evaluate the effect of maze </text>
<text top="508" left="157" width="168" height="17" font="7">procedure on postop AF in pts </text>
<text top="525" left="157" width="135" height="17" font="7">undergoing MV surgery  </text>
<text top="491" left="339" width="67" height="17" font="7">Prospective </text>
<text top="508" left="339" width="71" height="17" font="7">randomized  </text>
<text top="491" left="454" width="124" height="17" font="7">49 pts undergoing MV </text>
<text top="508" left="454" width="134" height="17" font="7">surgery with AF of more </text>
<text top="525" left="454" width="119" height="17" font="7">than 6 mo duration in </text>
<text top="543" left="454" width="52" height="17" font="7">2004−06 </text>
<text top="491" left="622" width="145" height="17" font="7">MV surgery plus RF maze </text>
<text top="508" left="622" width="98" height="17" font="7">procedure (n=24) </text>
<text top="491" left="791" width="144" height="17" font="7">MV surgery plus intensive </text>
<text top="508" left="791" width="128" height="17" font="7">rhythm control strategy </text>
<text top="525" left="791" width="43" height="17" font="7">(n=25). </text>
<text top="491" left="973" width="356" height="17" font="7">At discharge, 3 and 12 mo follow-up, more pts in the maze group </text>
<text top="508" left="973" width="339" height="17" font="7">returned to NSR compared to control (29%, 57% and 75% vs. </text>
<text top="525" left="973" width="171" height="17" font="7">20%, 43% and 39%; p=0.030). </text>
<text top="561" left="42" width="70" height="17" font="7">Cheng 2010 </text>
<text top="578" left="42" width="32" height="17" font="7">(233) </text>
<text top="595" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22437354">22437354</a></text>
<text top="595" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22437354"> </a></text>
<text top="561" left="157" width="165" height="17" font="7">To determine if surgical maze </text>
<text top="578" left="157" width="136" height="17" font="7">ablation for AF improves </text>
<text top="595" left="157" width="121" height="17" font="7">clinical outcomes and </text>
<text top="612" left="157" width="109" height="17" font="7">resource utilization  </text>
<text top="561" left="339" width="79" height="17" font="7">Meta-analysis </text>
<text top="561" left="454" width="31" height="17" font="7">4647 </text>
<text top="561" left="622" width="143" height="17" font="7">Adults with persistent and </text>
<text top="578" left="622" width="146" height="17" font="7">permanent AF undergoing </text>
<text top="595" left="622" width="139" height="17" font="7">maze surgical ablation at </text>
<text top="612" left="622" width="148" height="17" font="7">the time of cardiac surgery </text>
<text top="561" left="791" width="154" height="17" font="7">Persistent or permanent AF </text>
<text top="578" left="791" width="152" height="17" font="7">undergoing cardiac surgery </text>
<text top="595" left="791" width="135" height="17" font="7">without maze procedure </text>
<text top="561" left="973" width="305" height="17" font="7">The number of pts in NSR was significantly improved at </text>
<text top="578" left="973" width="343" height="17" font="7">discharge in the surgical AF ablation group (68.6%) versus the </text>
<text top="595" left="973" width="336" height="17" font="7">surgery alone group (23.0%) in RCTs (OR: 10.1, 95% CI: 4.5-</text>
<text top="612" left="973" width="292" height="17" font="7">22.5) and non-RCTs (OR: 7.15, 95% CI: 3.42-14.95). </text>
<text top="629" left="973" width="349" height="17" font="7">Meta-analysis includes both coronary bypass and valve surgery </text>
<text top="647" left="973" width="120" height="17" font="7">(numbers not stated). </text>
<text top="665" left="42" width="316" height="17" font="6"><b>Long-Term Outcomes After Surgical Maze Procedure  </b></text>
<text top="683" left="42" width="70" height="17" font="7">Bando 2003 </text>
<text top="700" left="42" width="32" height="17" font="7">(234) </text>
<text top="717" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12928631">12928631</a></text>
<text top="717" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12928631"> </a></text>
<text top="683" left="157" width="124" height="17" font="7">Identify risk factors for </text>
<text top="700" left="157" width="139" height="17" font="7">mortality and stroke after </text>
<text top="717" left="157" width="100" height="17" font="7">mechanical MVR  </text>
<text top="683" left="339" width="79" height="17" font="7">Retrospective </text>
<text top="683" left="454" width="139" height="17" font="7">812 pts undergoing MVR </text>
<text top="700" left="454" width="119" height="17" font="7">between 1977−2001. </text>
<text top="717" left="454" width="146" height="17" font="7">Chronic AF present in 630 </text>
<text top="734" left="454" width="36" height="17" font="7">(78%) </text>
<text top="683" left="622" width="108" height="17" font="7">In addition to MVR: </text>
<text top="700" left="622" width="102" height="17" font="7">493 (61%) had LV </text>
<text top="717" left="622" width="108" height="17" font="7">appendage closure </text>
<text top="734" left="622" width="151" height="17" font="7">148 (18%) had LA plication </text>
<text top="752" left="622" width="117" height="17" font="7">185 (23%) had maze </text>
<text top="769" left="622" width="59" height="17" font="7">procedure </text>
<text top="786" left="622" width="133" height="17" font="7">348 (43%) had tricuspid </text>
<text top="683" left="791" width="165" height="17" font="7">Endpoints were early and late </text>
<text top="700" left="791" width="150" height="17" font="7">mortality and freedom from </text>
<text top="717" left="791" width="37" height="17" font="7">stroke </text>
<text top="683" left="973" width="344" height="17" font="7">At 8 y, freedom from stroke was significantly greater in pts with </text>
<text top="700" left="973" width="350" height="17" font="7">MVR plus maze (99%) compared to MVR alone (89%, p&lt;0.001) </text>
<text top="717" left="973" width="335" height="17" font="7">Of 72 pts with late stroke, 65 (90%) were in AF and 47 (65%) </text>
<text top="734" left="973" width="154" height="17" font="7">had LA appendage closure. </text>
<text top="752" left="973" width="351" height="17" font="7">Multivariate analysis show that late AF (OR: 3.39; 95% CI: 1.72–</text>
<text top="769" left="973" width="346" height="17" font="7">6.67; p=.0001) and omission of the maze procedure (OR: 3.40; </text>
<text top="786" left="973" width="337" height="17" font="7">95% CI: 1.14–10.14; p=0.003) were significant risk factors for </text>
</page>
<page number="58" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">58 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="54" width="77" height="17" font="6"><b>Author, Year </b></text>
<text top="108" left="202" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="355" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="489" width="86" height="17" font="6"><b>Study Size (N) </b></text>
<text top="108" left="638" width="124" height="17" font="6"><b>Study “Intervention” </b></text>
<text top="126" left="671" width="59" height="17" font="6"><b>Group (n) </b></text>
<text top="108" left="800" width="151" height="17" font="6"><b>Study Comparator Group </b></text>
<text top="126" left="866" width="19" height="17" font="6"><b>(n) </b></text>
<text top="108" left="1121" width="64" height="17" font="6"><b>Outcomes </b></text>
<text top="144" left="622" width="79" height="17" font="7">annuloplasty.  </text>
<text top="144" left="973" width="64" height="17" font="7">late stroke. </text>
<text top="162" left="42" width="84" height="17" font="7">Bum Kim 2012 </text>
<text top="179" left="42" width="32" height="17" font="7">(235) </text>
<text top="196" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22456472">22456472</a></text>
<text top="196" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22456472"> </a></text>
<text top="162" left="157" width="167" height="17" font="7">Evaluate long-term benefits of </text>
<text top="179" left="157" width="145" height="17" font="7">the maze procedure in pts </text>
<text top="196" left="157" width="152" height="17" font="7">with chronic AF undergoing </text>
<text top="213" left="157" width="96" height="17" font="7">mechanical MVR </text>
<text top="162" left="339" width="82" height="17" font="7">Retrospective, </text>
<text top="179" left="339" width="77" height="17" font="7">observational </text>
<text top="162" left="454" width="109" height="17" font="7">569 pts undergoing </text>
<text top="179" left="454" width="146" height="17" font="7">mechanical MVR between </text>
<text top="196" left="454" width="69" height="17" font="7">1997−2010  </text>
<text top="162" left="622" width="116" height="17" font="7">317 with MVR plus a </text>
<text top="179" left="622" width="103" height="17" font="7">concomitant maze </text>
<text top="196" left="622" width="59" height="17" font="7">procedure </text>
<text top="162" left="791" width="114" height="17" font="7">252 with MVR alone </text>
<text top="162" left="973" width="357" height="17" font="7">Pts who had undergone the maze procedure were at similar risks </text>
<text top="179" left="973" width="306" height="17" font="7">of death (HR: 1.15; 95% CI: 0.65–2.03; p=0.63) and the </text>
<text top="196" left="973" width="354" height="17" font="7">composite outcomes (HR: 0.82; 95% CI: 0.50–1.34; p=0.42), but </text>
<text top="213" left="973" width="336" height="17" font="7">a significantly lower risk of thromboembolic events (HR: 0.29; </text>
<text top="230" left="973" width="304" height="17" font="7">95% CI: 0.12–0.73; p=0.008) compared with those who </text>
<text top="248" left="973" width="198" height="17" font="7">underwent valve replacement alone </text>
<text top="266" left="42" width="83" height="17" font="7">Malaisrie 2012 </text>
<text top="283" left="42" width="32" height="17" font="7">(236) </text>
<text top="300" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22808837">22808837</a></text>
<text top="300" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22808837"> </a></text>
<text top="266" left="157" width="134" height="17" font="7">Determine the impact of </text>
<text top="283" left="157" width="168" height="17" font="7">concomitant AF ablation in pts </text>
<text top="300" left="157" width="100" height="17" font="7">undergoing AVR   </text>
<text top="266" left="339" width="82" height="17" font="7">Retrospective, </text>
<text top="283" left="339" width="77" height="17" font="7">observational </text>
<text top="266" left="454" width="145" height="17" font="7">124 pts (mean age 74±12 </text>
<text top="283" left="454" width="125" height="17" font="7">y) with pre-existing AF </text>
<text top="300" left="454" width="94" height="17" font="7">undergoing AVR </text>
<text top="266" left="622" width="147" height="17" font="7">80 (65%) had concomitant </text>
<text top="283" left="622" width="111" height="17" font="7">surgical AF ablation </text>
<text top="266" left="791" width="103" height="17" font="7">44 had AVR alone </text>
<text top="266" left="973" width="328" height="17" font="7">Postop freedom from AF when not receiving anti-arrhythmic </text>
<text top="283" left="973" width="348" height="17" font="7">drugs occurred in 58 pts (82%) in the ablation group, compared </text>
<text top="300" left="973" width="252" height="17" font="7">to 8 (36%) in the nonablation group (p&lt;0.001) </text>
<text top="318" left="42" width="51" height="17" font="7">Liu 2010 </text>
<text top="335" left="42" width="32" height="17" font="7">(237) </text>
<text top="353" left="42" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20573636">20573636</a></text>
<text top="353" left="96" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20573636"> </a></text>
<text top="318" left="157" width="141" height="17" font="7">Compare pulmonary vein </text>
<text top="335" left="157" width="121" height="17" font="7">isolation versus maze </text>
<text top="353" left="157" width="146" height="17" font="7">procedure for treatment of </text>
<text top="370" left="157" width="81" height="17" font="7">permanent AF </text>
<text top="318" left="339" width="67" height="17" font="7">Prospective </text>
<text top="335" left="339" width="68" height="17" font="7">randomized </text>
<text top="318" left="454" width="131" height="17" font="7">99 with rheumatic heart </text>
<text top="335" left="454" width="151" height="17" font="7">disease and permanent AF </text>
<text top="318" left="622" width="145" height="17" font="7">49 with valve surgery plus </text>
<text top="335" left="622" width="144" height="17" font="7">circumferential pulmonary </text>
<text top="353" left="622" width="75" height="17" font="7">vein isolation </text>
<text top="318" left="791" width="145" height="17" font="7">50 with valve surgery plus </text>
<text top="335" left="791" width="129" height="17" font="7">maze procedure for AF </text>
<text top="318" left="973" width="347" height="17" font="7">After one procedure, pts undergoing the maze procedure had a </text>
<text top="335" left="973" width="330" height="17" font="7">significantly higher freedom from atrial arrhythmias (82% vs. </text>
<text top="353" left="973" width="333" height="17" font="7">55.2%, p&lt;0.001). At 15–20 mo follow-up, cumulative rates of </text>
<text top="370" left="973" width="242" height="17" font="7">sinus rhythm were 71% vs. 88% (p&lt;0.001).  </text>
<text top="388" left="34" width="1295" height="17" font="7">1° indicates primary; AF, atrial fibrillation; AVR, aortic valve replacement; CABG, coronary artery bypass grafting; LA, left atrial; LV, left ventricle; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; MV, mitral valve; MVR, mitral </text>
<text top="405" left="34" width="1144" height="17" font="7">valve replacement; NSR, normal sinus rhythm; preop, preoperative; postop, postoperative; pts, patients; RCT, randomized clinical trial; RF, radiofrequency; RFA, radiofrequency ablation; and, SR, sinus rhythm.  </text>
<text top="405" left="1391" width="3" height="17" font="7"> </text>
</page>
<page number="59" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">59 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="672" height="21" font="4"><b>Data Supplement 28. Noncardiac Surgery in Patients With Valvular Heart Disease (Section 15.3) </b></text>
<text top="129" left="59" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="58" width="40" height="17" font="6"><b>Name, </b></text>
<text top="164" left="55" width="47" height="17" font="6"><b>Author, </b></text>
<text top="181" left="63" width="30" height="17" font="6"><b>Year </b></text>
<text top="129" left="132" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="129" left="240" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="129" left="363" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="344" width="74" height="17" font="6"><b>Intervention </b></text>
<text top="164" left="352" width="59" height="17" font="6"><b>Group (n) </b></text>
<text top="129" left="470" width="38" height="17" font="6"><b>Study </b></text>
<text top="146" left="452" width="73" height="17" font="6"><b>Comparator </b></text>
<text top="164" left="459" width="59" height="17" font="6"><b>Group (n) </b></text>
<text top="129" left="597" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="129" left="897" width="64" height="17" font="6"><b>Endpoints </b></text>
<text top="129" left="1122" width="79" height="17" font="6"><b>Predictors of </b></text>
<text top="146" left="1104" width="119" height="17" font="6"><b>Adverse Outcomes  </b></text>
<text top="129" left="1241" width="110" height="17" font="6"><b>Study Limitations  </b></text>
<text top="202" left="43" width="4" height="17" font="0"> </text>
<text top="202" left="126" width="4" height="17" font="0"> </text>
<text top="202" left="230" width="4" height="17" font="0"> </text>
<text top="202" left="332" width="4" height="17" font="0"> </text>
<text top="202" left="443" width="4" height="17" font="0"> </text>
<text top="199" left="547" width="104" height="17" font="16"><i><b>Inclusion Criteria </b></i></text>
<text top="199" left="680" width="61" height="17" font="16"><i><b>Exclusion </b></i></text>
<text top="216" left="688" width="46" height="17" font="16"><i><b>Criteria </b></i></text>
<text top="199" left="795" width="106" height="17" font="16"><i><b>Primary Endpoint </b></i></text>
<text top="216" left="782" width="132" height="17" font="16"><i><b>(Efficacy) and Results </b></i></text>
<text top="199" left="938" width="148" height="17" font="16"><i><b>Secondary Endpoint and </b></i></text>
<text top="216" left="988" width="48" height="17" font="16"><i><b>Results </b></i></text>
<text top="202" left="1099" width="4" height="17" font="0"> </text>
<text top="202" left="1236" width="4" height="17" font="0"> </text>
<text top="234" left="43" width="100" height="17" font="16"><i><b>Aortic Stenosis   </b></i></text>
<text top="252" left="43" width="48" height="17" font="7">Agarwal </text>
<text top="269" left="43" width="31" height="17" font="7">2013 </text>
<text top="286" left="43" width="32" height="17" font="7">(238) </text>
<text top="304" left="43" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23481524">23481524</a></text>
<text top="304" left="98" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23481524"> </a></text>
<text top="252" left="126" width="61" height="17" font="7">Compared </text>
<text top="269" left="126" width="82" height="17" font="7">outcomes with </text>
<text top="286" left="126" width="63" height="17" font="7">noncardiac </text>
<text top="304" left="126" width="77" height="17" font="7">surgery in pts </text>
<text top="321" left="126" width="81" height="17" font="7">with moderate </text>
<text top="338" left="126" width="86" height="17" font="7">vs. severe AS.  </text>
<text top="252" left="230" width="78" height="17" font="7">Retrospective </text>
<text top="269" left="230" width="70" height="17" font="7">surgical and </text>
<text top="286" left="230" width="85" height="17" font="7">echocardiograp</text>
<text top="304" left="230" width="73" height="17" font="7">hic database </text>
<text top="252" left="332" width="92" height="17" font="7">634 pts with AS; </text>
<text top="269" left="332" width="89" height="17" font="7">244 with severe </text>
<text top="286" left="332" width="93" height="17" font="7">AS and 390 with </text>
<text top="304" left="332" width="75" height="17" font="7">moderate AS </text>
<text top="252" left="443" width="81" height="17" font="7">2,536 controls </text>
<text top="269" left="443" width="62" height="17" font="7">without AS </text>
<text top="286" left="443" width="60" height="17" font="7">propensity </text>
<text top="304" left="443" width="79" height="17" font="7">matched for 6 </text>
<text top="321" left="443" width="86" height="17" font="7">revised cardiac </text>
<text top="338" left="443" width="55" height="17" font="7">risk index </text>
<text top="355" left="443" width="90" height="17" font="7">criteria plus age </text>
<text top="372" left="443" width="50" height="17" font="7">and sex. </text>
<text top="252" left="547" width="62" height="17" font="7">Severe AS </text>
<text top="269" left="547" width="92" height="17" font="7">defined as valve </text>
<text top="286" left="547" width="62" height="17" font="7">area &lt;1 cm</text>
<text top="287" left="609" width="4" height="11" font="9">2</text>
<text top="286" left="614" width="7" height="17" font="7">. </text>
<text top="304" left="547" width="91" height="17" font="7">Moderate AS as </text>
<text top="321" left="547" width="84" height="17" font="7">valve area 1.0–</text>
<text top="338" left="547" width="37" height="17" font="7">1.5 cm</text>
<text top="339" left="584" width="4" height="11" font="9">2</text>
<text top="338" left="588" width="3" height="17" font="7"> </text>
<text top="252" left="664" width="65" height="17" font="7">Emergency </text>
<text top="269" left="664" width="51" height="17" font="7">surgery.  </text>
<text top="252" left="771" width="104" height="17" font="7">Combined primary </text>
<text top="269" left="771" width="142" height="17" font="7">endpoint of 30-d mortality </text>
<text top="286" left="771" width="152" height="17" font="7">plus MI occurred in 4.9% of </text>
<text top="304" left="771" width="128" height="17" font="7">pts with AS vs. 2.1% in </text>
<text top="321" left="771" width="103" height="17" font="7">controls (p&lt;0.001) </text>
<text top="252" left="937" width="134" height="17" font="7">30-d mortality was 2.1% </text>
<text top="269" left="937" width="146" height="17" font="7">for pts with AS vs. 1.0% in </text>
<text top="286" left="937" width="91" height="17" font="7">non-AS controls </text>
<text top="304" left="937" width="60" height="17" font="7">(p=0.036). </text>
<text top="321" left="937" width="127" height="17" font="7">Post-op MI occurred in </text>
<text top="338" left="937" width="126" height="17" font="7">3.0% of AS vs 1.1% of </text>
<text top="355" left="937" width="106" height="17" font="7">controls (p=0.001). </text>
<text top="252" left="1099" width="119" height="17" font="7">Predictors of adverse </text>
<text top="269" left="1099" width="119" height="17" font="7">outcomes in AS were </text>
<text top="286" left="1099" width="113" height="17" font="7">symptomatic severe </text>
<text top="304" left="1099" width="100" height="17" font="7">AS, MR, coronary </text>
<text top="321" left="1099" width="49" height="17" font="7">disease. </text>
<text top="252" left="1236" width="100" height="17" font="7">Some pts with AS </text>
<text top="269" left="1236" width="106" height="17" font="7">were symptomatic. </text>
<text top="286" left="1236" width="75" height="17" font="7">Not an RCT.  </text>
<text top="396" left="43" width="41" height="17" font="7">Calleja </text>
<text top="414" left="43" width="31" height="17" font="7">2010 </text>
<text top="431" left="43" width="32" height="17" font="7">(239) </text>
<text top="448" left="43" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20381670">20381670</a></text>
<text top="448" left="98" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20381670"> </a></text>
<text top="396" left="126" width="78" height="17" font="7">Evaluate post-</text>
<text top="414" left="126" width="87" height="17" font="7">op outcomes of </text>
<text top="431" left="126" width="45" height="17" font="7">pts with </text>
<text top="448" left="126" width="83" height="17" font="7">asymptomatic, </text>
<text top="465" left="126" width="60" height="17" font="7">severe AS </text>
<text top="396" left="230" width="79" height="17" font="7">Retrospective </text>
<text top="396" left="332" width="62" height="17" font="7">30 pts with </text>
<text top="414" left="332" width="79" height="17" font="7">asymptomatic </text>
<text top="431" left="332" width="60" height="17" font="7">severe AS </text>
<text top="448" left="332" width="65" height="17" font="7">undergoing </text>
<text top="465" left="332" width="63" height="17" font="7">noncardiac </text>
<text top="482" left="332" width="48" height="17" font="7">surgery. </text>
<text top="396" left="443" width="62" height="17" font="7">60 pts with </text>
<text top="414" left="443" width="82" height="17" font="7">mild-moderate </text>
<text top="431" left="443" width="90" height="17" font="7">AS age and sex </text>
<text top="448" left="443" width="57" height="17" font="7">matched.  </text>
<text top="396" left="547" width="65" height="17" font="7">Noncardiac </text>
<text top="414" left="547" width="48" height="17" font="7">surgery, </text>
<text top="431" left="547" width="94" height="17" font="7">intermediate risk </text>
<text top="448" left="547" width="79" height="17" font="7">severe AS vs. </text>
<text top="465" left="547" width="96" height="17" font="7">mild or moderate </text>
<text top="482" left="547" width="102" height="17" font="7">AS=77% vs. 83%, </text>
<text top="500" left="547" width="89" height="17" font="7">ASA 3=63% vs. </text>
<text top="517" left="547" width="76" height="17" font="7">62%, general </text>
<text top="534" left="547" width="94" height="17" font="7">anesthesia=73% </text>
<text top="551" left="547" width="51" height="17" font="7">vs. 82%. </text>
<text top="396" left="664" width="86" height="17" font="7">AR &gt;moderate, </text>
<text top="414" left="664" width="72" height="17" font="7">symptomatic </text>
<text top="431" left="664" width="23" height="17" font="7">AS. </text>
<text top="396" left="771" width="113" height="17" font="7">Composite endpoint </text>
<text top="414" left="771" width="147" height="17" font="7">(hospital mortality, MI, HF, </text>
<text top="431" left="771" width="89" height="17" font="7">arrhythmia, and </text>
<text top="448" left="771" width="120" height="17" font="7">hypotensive requiring </text>
<text top="465" left="771" width="134" height="17" font="7">vasopressors) in severe </text>
<text top="482" left="771" width="147" height="17" font="7">AS: 10/30 (33%) vs. 14/60 </text>
<text top="500" left="771" width="147" height="17" font="7">(23%) in those with mild to </text>
<text top="517" left="771" width="144" height="17" font="7">moderate AS; p=0.06; MI: </text>
<text top="534" left="771" width="147" height="17" font="7">3% in both groups; p=0.74 </text>
<text top="396" left="937" width="135" height="17" font="7">Hypotension AS severe: </text>
<text top="414" left="937" width="102" height="17" font="7">9/30 (30%) vs. AS </text>
<text top="431" left="937" width="119" height="17" font="7">mild/moderate: 10/60 </text>
<text top="448" left="937" width="88" height="17" font="7">(17%); p=0.11.  </text>
<text top="396" left="1099" width="85" height="17" font="7">For severe AS: </text>
<text top="414" left="1099" width="121" height="17" font="7">Hypotension OR: 2.5, </text>
<text top="431" left="1099" width="112" height="17" font="7">CI: 0.8–7.6; p=0.11, </text>
<text top="448" left="1099" width="92" height="17" font="7">MI OR: 0.63, CI: </text>
<text top="465" left="1099" width="96" height="17" font="7">0.04–10; p=0.74. </text>
<text top="396" left="1236" width="98" height="17" font="7">Use of composite </text>
<text top="414" left="1236" width="114" height="17" font="7">endpoint. Majority of </text>
<text top="431" left="1236" width="81" height="17" font="7">pts underwent </text>
<text top="448" left="1236" width="96" height="17" font="7">intermediate (not </text>
<text top="465" left="1236" width="53" height="17" font="7">high) risk </text>
<text top="482" left="1236" width="115" height="17" font="7">noncardiac surgery.  </text>
<text top="592" left="43" width="55" height="17" font="7">Leibowitz </text>
<text top="609" left="43" width="31" height="17" font="7">2009 </text>
<text top="627" left="43" width="32" height="17" font="7">(240) </text>
<text top="644" left="43" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19287130">19287130</a></text>
<text top="644" left="98" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19287130"> </a></text>
<text top="592" left="126" width="87" height="17" font="7">Outcome of pts </text>
<text top="609" left="126" width="45" height="17" font="7">with AS </text>
<text top="627" left="126" width="85" height="17" font="7">undergoing hip </text>
<text top="644" left="126" width="80" height="17" font="7">fracture repair </text>
<text top="592" left="230" width="79" height="17" font="7">Retrospective </text>
<text top="592" left="332" width="66" height="17" font="7">Pts with AS </text>
<text top="609" left="332" width="39" height="17" font="7">(n=32) </text>
<text top="592" left="443" width="76" height="17" font="7">Age-matched </text>
<text top="609" left="443" width="83" height="17" font="7">control (n=88)  </text>
<text top="592" left="547" width="98" height="17" font="7">Elderly pts &gt;70 y, </text>
<text top="609" left="547" width="87" height="17" font="7">with AVA &lt;1 cm</text>
<text top="610" left="634" width="4" height="11" font="9">2</text>
<text top="609" left="639" width="3" height="17" font="7"> </text>
<text top="592" left="664" width="24" height="17" font="7">N/A </text>
<text top="592" left="771" width="136" height="17" font="7">30-d mortality AS=6.2%, </text>
<text top="609" left="771" width="76" height="17" font="7">control=6.8% </text>
<text top="592" left="937" width="145" height="17" font="7">Cardiac event rate (death, </text>
<text top="609" left="937" width="141" height="17" font="7">ACS, pulmonary edema): </text>
<text top="627" left="937" width="148" height="17" font="7">AS=18.7%, control=11.8% </text>
<text top="592" left="1099" width="24" height="17" font="7">N/A </text>
<text top="592" left="1236" width="110" height="17" font="7">Retrospective, 50% </text>
<text top="609" left="1236" width="109" height="17" font="7">of anesthetics were </text>
<text top="627" left="1236" width="110" height="17" font="7">regional techniques </text>
<text top="662" left="43" width="65" height="17" font="7">Zahid 2005 </text>
<text top="679" left="43" width="32" height="17" font="7">(241) </text>
<text top="696" left="43" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16054477">16054477</a></text>
<text top="696" left="98" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16054477"> </a></text>
<text top="662" left="126" width="72" height="17" font="7">Evaluate the </text>
<text top="679" left="126" width="74" height="17" font="7">perioperative </text>
<text top="696" left="126" width="36" height="17" font="7">risk of </text>
<text top="713" left="126" width="63" height="17" font="7">noncardiac </text>
<text top="731" left="126" width="77" height="17" font="7">surgery in pts </text>
<text top="748" left="126" width="49" height="17" font="7">with AS  </text>
<text top="662" left="230" width="79" height="17" font="7">Retrospective </text>
<text top="679" left="230" width="55" height="17" font="7">Based on </text>
<text top="696" left="230" width="48" height="17" font="7">National </text>
<text top="713" left="230" width="48" height="17" font="7">Hospital </text>
<text top="731" left="230" width="59" height="17" font="7">Discharge </text>
<text top="748" left="230" width="42" height="17" font="7">Survey </text>
<text top="662" left="332" width="58" height="17" font="7">AS=5,149 </text>
<text top="662" left="443" width="82" height="17" font="7">AS-no=10,284 </text>
<text top="679" left="443" width="70" height="17" font="7">age/surgical </text>
<text top="696" left="443" width="73" height="17" font="7">risk matched </text>
<text top="662" left="547" width="65" height="17" font="7">Noncardiac </text>
<text top="679" left="547" width="83" height="17" font="7">surgery (1996–</text>
<text top="696" left="547" width="35" height="17" font="7">2002) </text>
<text top="662" left="664" width="252" height="17" font="7">Cardiac surgery  The presence of AS is not </text>
<text top="679" left="771" width="137" height="17" font="7">a significant predictor for </text>
<text top="696" left="771" width="148" height="17" font="7">mortality after adjusting for </text>
<text top="713" left="771" width="130" height="17" font="7">all significant univariate </text>
<text top="731" left="771" width="124" height="17" font="7">predictor of in-hospital </text>
<text top="748" left="771" width="38" height="17" font="7">death. </text>
<text top="662" left="937" width="112" height="17" font="7">The presence of AS </text>
<text top="679" left="937" width="145" height="17" font="7">increased the likelihood of </text>
<text top="696" left="937" width="119" height="17" font="7">AMI (3.86% in AS vs. </text>
<text top="713" left="937" width="101" height="17" font="7">2.03% in controls, </text>
<text top="731" left="937" width="143" height="17" font="7">p&lt;0.001): OR: 1.55, 95%  </text>
<text top="748" left="937" width="122" height="17" font="7">CI: 1.27–1.9; p&lt;0.001 </text>
<text top="662" left="1099" width="24" height="17" font="7">N/A<b> </b></text>
<text top="662" left="1236" width="97" height="17" font="7">Pts with AS more </text>
<text top="679" left="1236" width="74" height="17" font="7">likely to have </text>
<text top="696" left="1236" width="99" height="17" font="7">concomitant CAD </text>
<text top="713" left="1236" width="102" height="17" font="7">and CHF, controls </text>
<text top="731" left="1236" width="106" height="17" font="7">more likely to have </text>
<text top="748" left="1236" width="79" height="17" font="7">DM and HTN. </text>
<text top="766" left="43" width="46" height="17" font="7">Torsher </text>
<text top="783" left="43" width="31" height="17" font="7">1998 </text>
<text top="766" left="126" width="73" height="17" font="7">Outcomes of </text>
<text top="783" left="126" width="65" height="17" font="7">pts with AS </text>
<text top="766" left="230" width="79" height="17" font="7">Retrospective </text>
<text top="766" left="332" width="83" height="17" font="7">Severe AS=19 </text>
<text top="766" left="443" width="24" height="17" font="7">N/A </text>
<text top="766" left="547" width="66" height="17" font="7">Noncardiac </text>
<text top="766" left="664" width="27" height="17" font="7">N/A  </text>
<text top="766" left="771" width="148" height="17" font="7">In selected pts with severe </text>
<text top="783" left="771" width="143" height="17" font="7">AS, the risk of noncardiac </text>
<text top="766" left="937" width="24" height="17" font="7">N/A </text>
<text top="783" left="937" width="3" height="17" font="7"> </text>
<text top="766" left="1099" width="24" height="17" font="7">N/A </text>
<text top="766" left="1236" width="87" height="17" font="7">Coexisting mild </text>
<text top="783" left="1236" width="93" height="17" font="7">AR=9, moderate </text>
</page>
<page number="60" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">60 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="59" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="58" width="40" height="17" font="6"><b>Name, </b></text>
<text top="143" left="55" width="47" height="17" font="6"><b>Author, </b></text>
<text top="160" left="63" width="30" height="17" font="6"><b>Year </b></text>
<text top="108" left="132" width="79" height="17" font="6"><b>Aim of Study </b></text>
<text top="108" left="240" width="70" height="17" font="6"><b>Study Type </b></text>
<text top="108" left="363" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="344" width="74" height="17" font="6"><b>Intervention </b></text>
<text top="143" left="352" width="59" height="17" font="6"><b>Group (n) </b></text>
<text top="108" left="470" width="38" height="17" font="6"><b>Study </b></text>
<text top="126" left="452" width="73" height="17" font="6"><b>Comparator </b></text>
<text top="143" left="459" width="59" height="17" font="6"><b>Group (n) </b></text>
<text top="108" left="597" width="111" height="17" font="6"><b>Patient Population </b></text>
<text top="108" left="897" width="64" height="17" font="6"><b>Endpoints </b></text>
<text top="108" left="1122" width="79" height="17" font="6"><b>Predictors of </b></text>
<text top="126" left="1104" width="119" height="17" font="6"><b>Adverse Outcomes  </b></text>
<text top="108" left="1241" width="110" height="17" font="6"><b>Study Limitations  </b></text>
<text top="181" left="43" width="4" height="17" font="0"> </text>
<text top="181" left="126" width="4" height="17" font="0"> </text>
<text top="181" left="230" width="4" height="17" font="0"> </text>
<text top="181" left="332" width="4" height="17" font="0"> </text>
<text top="181" left="443" width="4" height="17" font="0"> </text>
<text top="178" left="547" width="104" height="17" font="16"><i><b>Inclusion Criteria </b></i></text>
<text top="178" left="680" width="61" height="17" font="16"><i><b>Exclusion </b></i></text>
<text top="195" left="688" width="46" height="17" font="16"><i><b>Criteria </b></i></text>
<text top="178" left="795" width="106" height="17" font="16"><i><b>Primary Endpoint </b></i></text>
<text top="195" left="782" width="132" height="17" font="16"><i><b>(Efficacy) and Results </b></i></text>
<text top="178" left="938" width="148" height="17" font="16"><i><b>Secondary Endpoint and </b></i></text>
<text top="195" left="988" width="48" height="17" font="16"><i><b>Results </b></i></text>
<text top="181" left="1099" width="4" height="17" font="0"> </text>
<text top="181" left="1236" width="4" height="17" font="0"> </text>
<text top="213" left="43" width="32" height="17" font="7">(242) </text>
<text top="230" left="43" width="48" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9485135">9485135</a></text>
<text top="230" left="91" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/9485135"> </a></text>
<text top="213" left="126" width="65" height="17" font="7">undergoing </text>
<text top="230" left="126" width="63" height="17" font="7">noncardiac </text>
<text top="248" left="126" width="44" height="17" font="7">surgery </text>
<text top="213" left="771" width="123" height="17" font="7">surgery is acceptable: </text>
<text top="230" left="771" width="148" height="17" font="7">Death=2, hypotension was </text>
<text top="248" left="771" width="94" height="17" font="7">frequent (14 pts) </text>
<text top="213" left="1236" width="110" height="17" font="7">AR=4, mild MR=12, </text>
<text top="230" left="1236" width="76" height="17" font="7">balloon aortic </text>
<text top="248" left="1236" width="88" height="17" font="7">valvuloplasty=2 </text>
<text top="266" left="43" width="123" height="17" font="16"><i><b>Mitral Regurgitation </b></i> </text>
<text top="284" left="43" width="51" height="17" font="7">Lai 2007 </text>
<text top="301" left="43" width="32" height="17" font="7">(243) </text>
<text top="318" left="43" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17383316">17383316</a></text>
<text top="318" left="98" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17383316"> </a></text>
<text top="284" left="126" width="76" height="17" font="7">Perioperative </text>
<text top="301" left="126" width="84" height="17" font="7">outcome of pts </text>
<text top="318" left="126" width="48" height="17" font="7">with MR </text>
<text top="335" left="126" width="65" height="17" font="7">undergoing </text>
<text top="353" left="126" width="63" height="17" font="7">noncardiac </text>
<text top="370" left="126" width="44" height="17" font="7">surgery </text>
<text top="284" left="230" width="79" height="17" font="7">Retrospective </text>
<text top="284" left="332" width="62" height="17" font="7">84 pts with </text>
<text top="301" left="332" width="96" height="17" font="7">moderate-severe </text>
<text top="318" left="332" width="22" height="17" font="7">MR </text>
<text top="284" left="443" width="21" height="17" font="7">NA </text>
<text top="284" left="547" width="67" height="17" font="7">Undergoing </text>
<text top="301" left="547" width="63" height="17" font="7">noncardiac </text>
<text top="318" left="547" width="44" height="17" font="7">surgery </text>
<text top="284" left="664" width="51" height="17" font="7">Tracheal </text>
<text top="301" left="664" width="85" height="17" font="7">intubation prior </text>
<text top="318" left="664" width="77" height="17" font="7">to noncardiac </text>
<text top="335" left="664" width="44" height="17" font="7">surgery </text>
<text top="284" left="771" width="143" height="17" font="7">Intraoperative course had </text>
<text top="301" left="771" width="119" height="17" font="7">frequent (31%) minor </text>
<text top="318" left="771" width="147" height="17" font="7">complications: controllably </text>
<text top="335" left="771" width="94" height="17" font="7">hypotension and </text>
<text top="353" left="771" width="71" height="17" font="7">bradycardia  </text>
<text top="284" left="936" width="124" height="17" font="7">Post-op complications </text>
<text top="301" left="936" width="76" height="17" font="7">were serious: </text>
<text top="318" left="936" width="116" height="17" font="7">Death=11.9%, MI=0, </text>
<text top="335" left="936" width="90" height="17" font="7">Vtach/fib=4.8%, </text>
<text top="353" left="936" width="144" height="17" font="7">pulmonary edema=23.8% </text>
<text top="284" left="1099" width="66" height="17" font="7">For post-op </text>
<text top="301" left="1099" width="100" height="17" font="7">complications: AF </text>
<text top="318" left="1099" width="113" height="17" font="7">OR: 3.058, CI: 1.02–</text>
<text top="335" left="1099" width="102" height="17" font="7">9.14, intermediate </text>
<text top="353" left="1099" width="122" height="17" font="7">surgical risk=5.12, CI: </text>
<text top="370" left="1099" width="121" height="17" font="7">1.28–20.4, low LVEF: </text>
<text top="387" left="1099" width="108" height="17" font="7">0.96, CI: 0.92–0.99 </text>
<text top="284" left="1236" width="24" height="17" font="7">N/A </text>
<text top="405" left="43" width="129" height="17" font="16"><i><b>Aortic Regurgitation  </b></i> </text>
<text top="423" left="43" width="51" height="17" font="7">Lai 2010 </text>
<text top="440" left="43" width="32" height="17" font="7">(244) </text>
<text top="457" left="43" width="55" height="17" font="8"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19930243">19930243</a></text>
<text top="457" left="98" width="3" height="17" font="7"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19930243"> </a></text>
<text top="423" left="126" width="76" height="17" font="7">Perioperative </text>
<text top="440" left="126" width="64" height="17" font="7">outcome of </text>
<text top="457" left="126" width="46" height="17" font="7">chronic, </text>
<text top="474" left="126" width="56" height="17" font="7">moderate-</text>
<text top="492" left="126" width="87" height="17" font="7">severe AR who </text>
<text top="509" left="126" width="49" height="17" font="7">undergo </text>
<text top="526" left="126" width="63" height="17" font="7">noncardiac </text>
<text top="543" left="126" width="44" height="17" font="7">surgery </text>
<text top="423" left="230" width="78" height="17" font="7">Retrospective </text>
<text top="440" left="230" width="73" height="17" font="7">(1999–2006) </text>
<text top="423" left="332" width="49" height="17" font="7">Chronic, </text>
<text top="440" left="332" width="96" height="17" font="7">moderate-severe </text>
<text top="457" left="332" width="48" height="17" font="7">AR=167 </text>
<text top="423" left="443" width="33" height="17" font="7">Case-</text>
<text top="440" left="443" width="78" height="17" font="7">matched=167 </text>
<text top="423" left="547" width="46" height="17" font="7">Chronic </text>
<text top="440" left="547" width="96" height="17" font="7">moderate-severe </text>
<text top="457" left="547" width="21" height="17" font="7">AR </text>
<text top="423" left="664" width="24" height="17" font="7">N/A </text>
<text top="423" left="771" width="140" height="17" font="7">Prolonged intubation and </text>
<text top="440" left="771" width="139" height="17" font="7">acute pulmonary edema: </text>
<text top="457" left="771" width="144" height="17" font="7">16.2% vs. 5.4%; p=0.003, </text>
<text top="474" left="771" width="139" height="17" font="7">Death: AR=9% vs. 1.8%; </text>
<text top="492" left="771" width="48" height="17" font="7">p=0.008 </text>
<text top="423" left="936" width="137" height="17" font="7">LVEF, renal dysfunction, </text>
<text top="440" left="936" width="136" height="17" font="7">high surgical risk and no </text>
<text top="457" left="936" width="147" height="17" font="7">cardiac meds predictors of </text>
<text top="474" left="936" width="126" height="17" font="7">in-hospital death in pts </text>
<text top="492" left="936" width="124" height="17" font="7">with AR intraoperative </text>
<text top="509" left="936" width="94" height="17" font="7">hypotension and </text>
<text top="526" left="936" width="137" height="17" font="7">bradycardia were similar </text>
<text top="543" left="936" width="91" height="17" font="7">between groups </text>
<text top="423" left="1099" width="24" height="17" font="7">N/A </text>
<text top="423" left="1236" width="24" height="17" font="7">N/A </text>
<text top="561" left="34" width="1296" height="17" font="7">ACS indicates acute coronary syndrome; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, aspirin; AVA, aortic valve area; CAD, coronary artery disease; CHF, congestive heart failure; DM, diabetes mellitus; HF, heart </text>
<text top="581" left="34" width="1080" height="17" font="7">failure; HTN, hypertension; LV, left ventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MR, mitral regurgitation; N/A, not applicable; pts, patients; and, post-op, postoperative. </text>
<text top="581" left="1326" width="3" height="17" font="7"> </text>
</page>
<page number="61" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">61 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="108" left="32" width="84" height="21" font="4"><b>References </b></text>
<text top="132" left="729" width="4" height="17" font="0"> </text>
<text top="170" left="108" width="4" height="13" font="7"> </text>
<text top="170" left="137" width="1211" height="13" font="7">1.   deFilippi CR, Willett DL, Brickner ME, et al. Usefulness of dobutamine echocardiography in distinguishing severe from nonsevere valvular aortic stenosis in patients with depressed left ventricular </text>
<text top="187" left="162" width="434" height="13" font="7">function and low transvalvular gradients. Am J Cardiol. 1995;75:191-4. </text>
<text top="205" left="108" width="4" height="13" font="7"> </text>
<text top="205" left="137" width="1118" height="13" font="7">2.   Connolly HM, Oh JK, Orszulak TA, et al. Aortic valve replacement for aortic stenosis with severe left ventricular dysfunction. Prognostic indicators. Circulation. 1997;95:2395-400. </text>
<text top="222" left="108" width="4" height="13" font="7"> </text>
<text top="222" left="137" width="1198" height="13" font="7">3.   Pereira JJ, Lauer MS, Bashir M, et al. Survival after aortic valve replacement for severe aortic stenosis with low transvalvular gradients and severe left ventricular dysfunction. J Am Coll Cardiol. </text>
<text top="239" left="162" width="111" height="13" font="7">2002;39:1356-63. </text>
<text top="256" left="108" width="4" height="13" font="7"> </text>
<text top="256" left="137" width="1162" height="13" font="7">4.   Nishimura RA, Grantham JA, Connolly HM, et al. Low-output, low-gradient aortic stenosis in patients with depressed left ventricular systolic function: the clinical utility of the dobutamine </text>
<text top="274" left="162" width="446" height="13" font="7">challenge in the catheterization laboratory. Circulation. 2002;106:809-13. </text>
<text top="291" left="108" width="4" height="13" font="7"> </text>
<text top="291" left="137" width="1199" height="13" font="7">5.   Monin JL, Quere JP, Monchi M, et al. Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. </text>
<text top="308" left="162" width="186" height="13" font="7">Circulation. 2003;108:319-24. </text>
<text top="325" left="108" width="4" height="13" font="7"> </text>
<text top="325" left="137" width="1186" height="13" font="7">6.   Quere JP, Monin JL, Levy F, et al. Influence of preoperative left ventricular contractile reserve on postoperative ejection fraction in low-gradient aortic stenosis. Circulation. 2006;113:1738-44. </text>
<text top="343" left="108" width="4" height="13" font="7"> </text>
<text top="343" left="137" width="1145" height="13" font="7">7.   Blais C, Burwash IG, Mundigler G, et al. Projected valve area at normal flow rate improves the assessment of stenosis severity in patients with low-flow, low-gradient aortic stenosis: the </text>
<text top="360" left="162" width="601" height="13" font="7">multicenter TOPAS (Truly or Pseudo-Severe Aortic Stenosis) study. Circulation. 2006;113:711-21. </text>
<text top="377" left="108" width="4" height="13" font="7"> </text>
<text top="377" left="137" width="1084" height="13" font="7">8.   Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation. 2004;109:2302-8. </text>
<text top="394" left="108" width="4" height="13" font="7"> </text>
<text top="394" left="137" width="1213" height="13" font="7">9.   Pai RG, Varadarajan P, Razzouk A. Survival benefit of aortic valve replacement in patients with severe aortic stenosis with low ejection fraction and low gradient with normal ejection fraction. Ann </text>
<text top="412" left="162" width="185" height="13" font="7">Thorac Surg. 2008;86:1781-9. </text>
<text top="429" left="108" width="4" height="13" font="7"> </text>
<text top="429" left="130" width="1221" height="13" font="7">10.   Levy F, Laurent M, Monin JL, et al. Aortic valve replacement for low-flow/low-gradient aortic stenosis operative risk stratification and long-term outcome: a European multicenter study. J Am Coll </text>
<text top="446" left="162" width="163" height="13" font="7">Cardiol. 2008;51:1466-72. </text>
<text top="463" left="108" width="4" height="13" font="7"> </text>
<text top="463" left="130" width="1216" height="13" font="7">11.   Clavel MA, Webb JG, Rodes-Cabau J, et al. Comparison between transcatheter and surgical prosthetic valve implantation in patients with severe aortic stenosis and reduced left ventricular ejection </text>
<text top="481" left="162" width="247" height="13" font="7">fraction. Circulation. 2010;122:1928-36. </text>
<text top="498" left="108" width="4" height="13" font="7"> </text>
<text top="498" left="130" width="1217" height="13" font="7">12.   Tribouilloy C, Levy F, Rusinaru D, et al. Outcome after aortic valve replacement for low-flow/low-gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography. J Am </text>
<text top="515" left="162" width="193" height="13" font="7">Coll Cardiol. 2009;53:1865-73. </text>
<text top="532" left="108" width="4" height="13" font="7"> </text>
<text top="532" left="130" width="1162" height="13" font="7">13.   Gotzmann M, Lindstaedt M, Bojara W, et al. Clinical outcome of transcatheter aortic valve implantation in patients with low-flow, low gradient aortic stenosis. Catheter Cardiovasc Interv. </text>
<text top="550" left="162" width="111" height="13" font="7">2012;79:693-701. </text>
<text top="567" left="108" width="4" height="13" font="7"> </text>
<text top="567" left="130" width="929" height="13" font="7">14.   Fougeres E, Tribouilloy C, Monchi M, et al. Outcomes of pseudo-severe aortic stenosis under conservative treatment. Eur Heart J. 2012;33:2426-33. </text>
<text top="584" left="108" width="4" height="13" font="7"> </text>
<text top="584" left="130" width="1191" height="13" font="7">15.   Herrmann HC, Pibarot P, Hueter I, et al. Predictors of Mortality and Outcomes of Therapy in Low-Flow Severe Aortic Stenosis: A Placement of Aortic Transcatheter Valves (PARTNER) Trial </text>
<text top="601" left="162" width="253" height="13" font="7">Analysis. Circulation. 2013;127:2316-26. </text>
<text top="619" left="108" width="4" height="13" font="7"> </text>
<text top="619" left="130" width="1049" height="13" font="7">16.   Otto CM, Pearlman AS, Gardner CL. Hemodynamic progression of aortic stenosis in adults assessed by Doppler echocardiography. J Am Coll Cardiol. 1989;13:545-50. </text>
<text top="636" left="108" width="4" height="13" font="7"> </text>
<text top="636" left="130" width="974" height="13" font="7">17.   Roger VL, Tajik AJ, Bailey KR, et al. Progression of aortic stenosis in adults: new appraisal using Doppler echocardiography. Am Heart J. 1990;119:331-8. </text>
<text top="653" left="108" width="4" height="13" font="7"> </text>
<text top="653" left="130" width="817" height="13" font="7">18.   Faggiano P, Ghizzoni G, Sorgato A, et al. Rate of progression of valvular aortic stenosis in adults. Am J Cardiol. 1992;70:229-33. </text>
<text top="670" left="108" width="4" height="13" font="7"> </text>
<text top="670" left="130" width="924" height="13" font="7">19.   Peter M, Hoffmann A, Parker C, et al. Progression of aortic stenosis. Role of age and concomitant coronary artery disease. Chest. 1993;103:1715-9. </text>
<text top="688" left="108" width="4" height="13" font="7"> </text>
<text top="688" left="130" width="1151" height="13" font="7">20.   Brener SJ, Duffy CI, Thomas JD, et al. Progression of aortic stenosis in 394 patients: relation to changes in myocardial and mitral valve dysfunction. J Am Coll Cardiol. 1995;25:305-10. </text>
<text top="705" left="108" width="4" height="13" font="7"> </text>
<text top="705" left="130" width="1219" height="13" font="7">21.   Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation. 1997;95:2262-70. </text>
<text top="722" left="108" width="4" height="13" font="7"> </text>
<text top="722" left="130" width="836" height="13" font="7">22.   Bahler RC, Desser DR, Finkelhor RS, et al. Factors leading to progression of valvular aortic stenosis. Am J Cardiol. 1999;84:1044-8. </text>
<text top="739" left="108" width="4" height="13" font="7"> </text>
<text top="739" left="130" width="975" height="13" font="7">23.   Palta S, Pai AM, Gill KS, et al. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation. 2000;101:2497-502. </text>
<text top="757" left="108" width="4" height="13" font="7"> </text>
<text top="757" left="130" width="848" height="13" font="7">24.   Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343:611-7. </text>
<text top="774" left="108" width="4" height="13" font="7"> </text>
<text top="774" left="130" width="1042" height="13" font="7">25.   Rosenhek R, Klaar U, Schemper M, et al. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur Heart J. 2004;25:199-205. </text>
<text top="791" left="108" width="4" height="13" font="7"> </text>
<text top="791" left="130" width="954" height="13" font="7">26.   Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-56. </text>
</page>
<page number="62" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">62 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="111" left="108" width="4" height="13" font="7"> </text>
<text top="111" left="130" width="694" height="13" font="7">27.   Nylander E, Ekman I, Marklund T, et al. Severe aortic stenosis in elderly patients. Br Heart J. 1986;55:480-7. </text>
<text top="129" left="108" width="4" height="13" font="7"> </text>
<text top="129" left="130" width="1146" height="13" font="7">28.   Clyne CA, Arrighi JA, Maron BJ, et al. Systemic and left ventricular responses to exercise stress in asymptomatic patients with valvular aortic stenosis. Am J Cardiol. 1991;68:1469-76. </text>
<text top="146" left="108" width="4" height="13" font="7"> </text>
<text top="146" left="130" width="1148" height="13" font="7">29.   Otto CM, Pearlman AS, Kraft CD, et al. Physiologic changes with maximal exercise in asymptomatic valvular aortic stenosis assessed by Doppler echocardiography. J Am Coll Cardiol. </text>
<text top="163" left="162" width="103" height="13" font="7">1992;20:1160-7. </text>
<text top="180" left="108" width="4" height="13" font="7"> </text>
<text top="180" left="130" width="912" height="13" font="7">30.   Amato MC, Moffa PJ, Werner KE, et al. Treatment decision in asymptomatic aortic valve stenosis: role of exercise testing. Heart. 2001;86:381-6. </text>
<text top="198" left="108" width="4" height="13" font="7"> </text>
<text top="198" left="130" width="1224" height="13" font="7">31.   Alborino D, Hoffmann JL, Fournet PC, et al. Value of exercise testing to evaluate the indication for surgery in asymptomatic patients with valvular aortic stenosis. J Heart Valve Dis. 2002;11:204-9. </text>
<text top="215" left="108" width="4" height="13" font="7"> </text>
<text top="215" left="130" width="722" height="13" font="7">32.   Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur Heart J. 2005;26:1309-13. </text>
<text top="232" left="108" width="4" height="13" font="7"> </text>
<text top="232" left="130" width="1174" height="13" font="7">33.   Lancellotti P, Lebois F, Simon M, et al. Prognostic importance of quantitative exercise Doppler echocardiography in asymptomatic valvular aortic stenosis. Circulation. 2005;112:I377-I382. </text>
<text top="249" left="108" width="4" height="13" font="7"> </text>
<text top="249" left="130" width="1135" height="13" font="7">34.   Marechaux S, Hachicha Z, Bellouin A, et al. Usefulness of exercise-stress echocardiography for risk stratification of true asymptomatic patients with aortic valve stenosis. Eur Heart J. </text>
<text top="266" left="162" width="103" height="13" font="7">2010;31:1390-7. </text>
<text top="284" left="108" width="4" height="13" font="7"> </text>
<text top="284" left="130" width="1207" height="13" font="7">35.   Rajani R, Rimington H, Chambers JB. Treadmill exercise in apparently asymptomatic patients with moderate or severe aortic stenosis: relationship between cardiac index and revealed symptoms. </text>
<text top="301" left="162" width="144" height="13" font="7">Heart. 2010;96:689-95. </text>
<text top="318" left="108" width="4" height="13" font="7"> </text>
<text top="318" left="130" width="979" height="13" font="7">36.   Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389-97. </text>
<text top="336" left="108" width="4" height="13" font="7"> </text>
<text top="336" left="130" width="1062" height="13" font="7">37.   Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49:554-61. </text>
<text top="353" left="108" width="4" height="13" font="7"> </text>
<text top="353" left="130" width="1166" height="13" font="7">38.   Chan KL, Teo K, Dumesnil JG, et al. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of </text>
<text top="370" left="162" width="411" height="13" font="7">rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306-14. </text>
<text top="387" left="108" width="4" height="13" font="7"> </text>
<text top="387" left="130" width="1223" height="13" font="7">39.   Kelly TA, Rothbart RM, Cooper CM, et al. Comparison of outcome of asymptomatic to symptomatic patients older than 20 years of age with valvular aortic stenosis. Am J Cardiol. 1988;61:123-30. </text>
<text top="405" left="108" width="4" height="13" font="7"> </text>
<text top="405" left="130" width="1100" height="13" font="7">40.   Pellikka PA, Nishimura RA, Bailey KR, et al. The natural history of adults with asymptomatic, hemodynamically significant aortic stenosis. J Am Coll Cardiol. 1990;15:1012-7. </text>
<text top="422" left="108" width="4" height="13" font="7"> </text>
<text top="422" left="130" width="825" height="13" font="7">41.   Kennedy KD, Nishimura RA, Holmes DR, Jr., et al. Natural history of moderate aortic stenosis. J Am Coll Cardiol. 1991;17:313-9. </text>
<text top="439" left="108" width="4" height="13" font="7"> </text>
<text top="439" left="130" width="1206" height="13" font="7">42.   Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation. 2005;111:3290-5. </text>
<text top="456" left="108" width="4" height="13" font="7"> </text>
<text top="456" left="130" width="1209" height="13" font="7">43.   Lancellotti P, Donal E, Magne J, et al. Risk stratification in asymptomatic moderate to severe aortic stenosis: the importance of the valvular, arterial and ventricular interplay. Heart. 2010;96:1364-</text>
<text top="474" left="162" width="22" height="13" font="7">71. </text>
<text top="491" left="108" width="4" height="13" font="7"> </text>
<text top="491" left="130" width="961" height="13" font="7">44.   Kang DH, Park SJ, Rim JH, et al. Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. Circulation. 2010;121:1502-9. </text>
<text top="508" left="108" width="4" height="13" font="7"> </text>
<text top="508" left="130" width="1133" height="13" font="7">45.   Stewart RA, Kerr AJ, Whalley GA, et al. Left ventricular systolic and diastolic function assessed by tissue Doppler imaging and outcome in asymptomatic aortic stenosis. Eur Heart J. </text>
<text top="525" left="162" width="111" height="13" font="7">2010;31:2216-22. </text>
<text top="543" left="108" width="4" height="13" font="7"> </text>
<text top="543" left="130" width="768" height="13" font="7">46.   Rosenhek R, Zilberszac R, Schemper M, et al. Natural history of very severe aortic stenosis. Circulation. 2010;121:151-6. </text>
<text top="560" left="108" width="4" height="13" font="7"> </text>
<text top="560" left="130" width="1009" height="13" font="7">47.   Jander N, Minners J, Holme I, et al. Outcome of patients with low-gradient &#34;severe&#34; aortic stenosis and preserved ejection fraction. Circulation. 2011;123:887-95. </text>
<text top="577" left="108" width="4" height="13" font="7"> </text>
<text top="577" left="130" width="1000" height="13" font="7">48.   Saito T, Muro T, Takeda H, et al. Prognostic value of aortic valve area index in asymptomatic patients with severe aortic stenosis. Am J Cardiol. 2012;110:93-7. </text>
<text top="594" left="108" width="4" height="13" font="7"> </text>
<text top="594" left="130" width="951" height="13" font="7">49.   Monin JL, Lancellotti P, Monchi M, et al. Risk score for predicting outcome in patients with asymptomatic aortic stenosis. Circulation. 2009;120:69-75. </text>
<text top="612" left="108" width="4" height="13" font="7"> </text>
<text top="612" left="130" width="755" height="13" font="7">50.   Rosenhek R, Baumgartner H. Aortic Stenosis. In: The Practice of Clinical Echocardiography. Elsevier/Saunders ; 2012. </text>
<text top="629" left="108" width="4" height="13" font="7"> </text>
<text top="629" left="130" width="637" height="13" font="7">51.   Frank S, Johnson A, Ross J, Jr. Natural history of valvular aortic stenosis. Br Heart J. 1973;35:41-6. </text>
<text top="646" left="108" width="4" height="13" font="7"> </text>
<text top="646" left="130" width="741" height="13" font="7">52.   Chizner MA, Pearle DL, deLeon AC, Jr. The natural history of aortic stenosis in adults. Am Heart J. 1980;99:419-24. </text>
<text top="663" left="108" width="4" height="13" font="7"> </text>
<text top="663" left="130" width="821" height="13" font="7">53.   Lombard JT, Selzer A. Valvular aortic stenosis. A clinical and hemodynamic profile of patients. Ann Intern Med. 1987;106:292-8. </text>
<text top="681" left="108" width="4" height="13" font="7"> </text>
<text top="681" left="130" width="679" height="13" font="7">54.   Turina J, Hess O, Sepulcri F, et al. Spontaneous course of aortic valve disease. Eur Heart J. 1987;8:471-83. </text>
<text top="698" left="108" width="4" height="13" font="7"> </text>
<text top="698" left="130" width="662" height="13" font="7">55.   Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur Heart J. 1988;9 Suppl E:57-64. </text>
<text top="715" left="108" width="4" height="13" font="7"> </text>
<text top="715" left="130" width="1080" height="13" font="7">56.   Otto CM, Pearlman AS. Doppler echocardiography in adults with symptomatic aortic stenosis. Diagnostic utility and cost-effectiveness. Arch Intern Med. 1988;148:2553-60. </text>
<text top="732" left="108" width="4" height="13" font="7"> </text>
<text top="732" left="130" width="1215" height="13" font="7">57.   Oh JK, Taliercio CP, Holmes DR, Jr., et al. Prediction of the severity of aortic stenosis by Doppler aortic valve area determination: prospective Doppler-catheterization correlation in 100 patients. J </text>
<text top="750" left="162" width="219" height="13" font="7">Am Coll Cardiol. 1988;11:1227-34. </text>
<text top="767" left="108" width="4" height="13" font="7"> </text>
<text top="767" left="130" width="1147" height="13" font="7">58.   Galan A, Zoghbi WA, Quinones MA. Determination of severity of valvular aortic stenosis by Doppler echocardiography and relation of findings to clinical outcome and agreement with </text>
<text top="784" left="162" width="606" height="13" font="7">hemodynamic measurements determined at cardiac catheterization. Am J Cardiol. 1991;67:1007-12. </text>
</page>
<page number="63" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">63 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="111" left="108" width="4" height="13" font="7"> </text>
<text top="111" left="130" width="1101" height="13" font="7">59.   Otto CM, Mickel MC, Kennedy JW, et al. Three-year outcome after balloon aortic valvuloplasty. Insights into prognosis of valvular aortic stenosis. Circulation. 1994;89:642-50. </text>
<text top="129" left="108" width="4" height="13" font="7"> </text>
<text top="129" left="130" width="1190" height="13" font="7">60.   Hachicha Z, Dumesnil JG, Bogaty P, et al. Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival. </text>
<text top="146" left="162" width="193" height="13" font="7">Circulation. 2007;115:2856-64. </text>
<text top="163" left="108" width="4" height="13" font="7"> </text>
<text top="163" left="130" width="1175" height="13" font="7">61.   Tarantini G, Covolo E, Razzolini R, et al. Valve replacement for severe aortic stenosis with low transvalvular gradient and left ventricular ejection fraction exceeding 0.50. Ann Thorac Surg. </text>
<text top="180" left="162" width="111" height="13" font="7">2011;91:1808-15. </text>
<text top="198" left="108" width="4" height="13" font="7"> </text>
<text top="198" left="130" width="1205" height="13" font="7">62.   Clavel MA, Dumesnil JG, Capoulade R, et al. Outcome of patients with aortic stenosis, small valve area, and low-flow, low-gradient despite preserved left ventricular ejection fraction. J Am Coll </text>
<text top="215" left="162" width="163" height="13" font="7">Cardiol. 2012;60:1259-67. </text>
<text top="232" left="108" width="4" height="13" font="7"> </text>
<text top="232" left="130" width="1147" height="13" font="7">63.   Lancellotti P, Magne J, Donal E, et al. Clinical outcome in asymptomatic severe aortic stenosis: insights from the new proposed aortic stenosis grading classification. J Am Coll Cardiol. </text>
<text top="249" left="162" width="103" height="13" font="7">2012;59:235-43. </text>
<text top="266" left="108" width="4" height="13" font="7"> </text>
<text top="266" left="130" width="1103" height="13" font="7">64.   Le VF, Freeman M, Webb J, et al. Impact of low flow on the outcome of high-risk patients undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2013;62:782-8. </text>
<text top="284" left="108" width="4" height="13" font="7"> </text>
<text top="284" left="130" width="1209" height="13" font="7">65.   Mehrotra P, Jansen K, Flynn AW, et al. Differential left ventricular remodelling and longitudinal function distinguishes low flow from normal-flow preserved ejection fraction low-gradient severe </text>
<text top="301" left="162" width="280" height="13" font="7">aortic stenosis. Eur Heart J. 2013;34:1906-14. </text>
<text top="318" left="108" width="4" height="13" font="7"> </text>
<text top="318" left="130" width="1194" height="13" font="7">66.   Ozkan M, Gunduz S, Biteker M, et al. Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial. JACC Cardiovasc Imaging. 2013;6:206-16. </text>
<text top="336" left="108" width="4" height="13" font="7"> </text>
<text top="336" left="130" width="1140" height="13" font="7">67.   Eleid MF, Sorajja P, Michelena HI, et al. Flow-gradient patterns in severe aortic stenosis with preserved ejection fraction: clinical characteristics and predictors of survival. Circulation. </text>
<text top="353" left="162" width="111" height="13" font="7">2013;128:1781-9. </text>
<text top="370" left="108" width="4" height="13" font="7"> </text>
<text top="370" left="130" width="931" height="13" font="7">68.   Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187-98. </text>
<text top="387" left="108" width="4" height="13" font="7"> </text>
<text top="387" left="130" width="962" height="13" font="7">69.   Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366:1686-95. </text>
<text top="405" left="108" width="4" height="13" font="7"> </text>
<text top="405" left="130" width="977" height="13" font="7">70.   Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366:1696-704. </text>
<text top="422" left="108" width="4" height="13" font="7"> </text>
<text top="422" left="130" width="1069" height="13" font="7">71.   Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597-607. </text>
<text top="439" left="108" width="4" height="13" font="7"> </text>
<text top="439" left="130" width="1126" height="13" font="7">72.   Bonow RO, Rosing DR, McIntosh CL, et al. The natural history of asymptomatic patients with aortic regurgitation and normal left ventricular function. Circulation. 1983;68:509-17. </text>
<text top="456" left="108" width="4" height="13" font="7"> </text>
<text top="456" left="130" width="1016" height="13" font="7">73.   Scognamiglio R, Fasoli G, Dalla VS. Progression of myocardial dysfunction in asymptomatic patients with severe aortic insufficiency. Clin Cardiol. 1986;9:151-6. </text>
<text top="474" left="108" width="4" height="13" font="7"> </text>
<text top="474" left="130" width="1087" height="13" font="7">74.   Siemienczuk D, Greenberg B, Morris C, et al. Chronic aortic insufficiency: factors associated with progression to aortic valve replacement. Ann Intern Med. 1989;110:587-92. </text>
<text top="491" left="108" width="4" height="13" font="7"> </text>
<text top="491" left="130" width="1201" height="13" font="7">75.   Bonow RO, Lakatos E, Maron BJ, et al. Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function. </text>
<text top="508" left="162" width="186" height="13" font="7">Circulation. 1991;84:1625-35. </text>
<text top="525" left="108" width="4" height="13" font="7"> </text>
<text top="525" left="130" width="1166" height="13" font="7">76.   Scognamiglio R, Rahimtoola SH, Fasoli G, et al. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med. 1994;331:689-94. </text>
<text top="543" left="108" width="4" height="13" font="7"> </text>
<text top="543" left="130" width="1196" height="13" font="7">77.   Tornos MP, Olona M, Permanyer-Miralda G, et al. Clinical outcome of severe asymptomatic chronic aortic regurgitation: a long-term prospective follow-up study. Am Heart J. 1995;130:333-9. </text>
<text top="560" left="108" width="4" height="13" font="7"> </text>
<text top="560" left="130" width="879" height="13" font="7">78.   Ishii K, Hirota Y, Suwa M, et al. Natural history and left ventricular response in chronic aortic regurgitation. Am J Cardiol. 1996;78:357-61. </text>
<text top="577" left="108" width="4" height="13" font="7"> </text>
<text top="577" left="130" width="1216" height="13" font="7">79.   Borer JS, Hochreiter C, Herrold EM, et al. Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left </text>
<text top="594" left="162" width="330" height="13" font="7">ventricular performance. Circulation. 1998;97:525-34. </text>
<text top="612" left="108" width="4" height="13" font="7"> </text>
<text top="612" left="130" width="1204" height="13" font="7">80.   Tarasoutchi F, Grinberg M, Spina GS, et al. Ten-year clinical laboratory follow-up after application of a symptom-based therapeutic strategy to patients with severe chronic aortic regurgitation of </text>
<text top="629" left="162" width="429" height="13" font="7">predominant rheumatic etiology. J Am Coll Cardiol. 2003;41:1316-24. </text>
<text top="646" left="108" width="4" height="13" font="7"> </text>
<text top="646" left="130" width="945" height="13" font="7">81.   Evangelista A, Tornos P, Sambola A, et al. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med. 2005;353:1342-9. </text>
<text top="663" left="108" width="4" height="13" font="7"> </text>
<text top="663" left="130" width="1187" height="13" font="7">82.   Detaint D, Messika-Zeitoun D, Maalouf J, et al. Quantitative echocardiographic determinants of clinical outcome in asymptomatic patients with aortic regurgitation: a prospective study. JACC </text>
<text top="681" left="162" width="209" height="13" font="7">Cardiovasc Imaging. 2008;1:1-11. </text>
<text top="698" left="108" width="4" height="13" font="7"> </text>
<text top="698" left="130" width="1195" height="13" font="7">83.   Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic patients with chronic severe aortic regurgitation. J Am </text>
<text top="715" left="162" width="193" height="13" font="7">Coll Cardiol. 2011;58:1705-14. </text>
<text top="732" left="108" width="4" height="13" font="7"> </text>
<text top="732" left="130" width="1173" height="13" font="7">84.   Olsen NT, Sogaard P, Larsson HB, et al. Speckle-tracking echocardiography for predicting outcome in chronic aortic regurgitation during conservative management and after surgery. JACC </text>
<text top="750" left="162" width="224" height="13" font="7">Cardiovasc Imaging. 2011;4:223-30. </text>
<text top="767" left="108" width="4" height="13" font="7"> </text>
<text top="767" left="130" width="1220" height="13" font="7">85.   Forman R, Firth BG, Barnard MS. Prognostic significance of preoperative left ventricular ejection fraction and valve lesion in patients with aortic valve replacement. Am J Cardiol. 1980;45:1120-5. </text>
</page>
<page number="64" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">64 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="111" left="108" width="4" height="13" font="7"> </text>
<text top="111" left="130" width="1212" height="13" font="7">86.   Henry WL, Bonow RO, Borer JS, et al. Observations on the optimum time for operative intervention for aortic regurgitation. I. Evaluation of the results of aortic valve replacement in symptomatic </text>
<text top="129" left="162" width="233" height="13" font="7">patients. Circulation. 1980;61:471-83. </text>
<text top="146" left="108" width="4" height="13" font="7"> </text>
<text top="146" left="130" width="1169" height="13" font="7">87.   Cunha CL, Giuliani ER, Fuster V, et al. Preoperative M-mode echocardiography as a predictor of surgical results in chronic aortic insufficiency. J Thorac Cardiovasc Surg. 1980;79:256-65. </text>
<text top="163" left="108" width="4" height="13" font="7"> </text>
<text top="163" left="130" width="1177" height="13" font="7">88.   Bonow RO, Borer JS, Rosing DR, et al. Preoperative exercise capacity in symptomatic patients with aortic regurgitation as a predictor of postoperative left ventricular function and long-term </text>
<text top="180" left="162" width="252" height="13" font="7">prognosis. Circulation. 1980;62:1280-90. </text>
<text top="198" left="108" width="4" height="13" font="7"> </text>
<text top="198" left="130" width="1215" height="13" font="7">89.   Borow KM, Green LH, Mann T, et al. End-systolic volume as a predictor of postoperative left ventricular performance in volume overload from valvular regurgitation. Am J Med. 1980;68:655-63. </text>
<text top="215" left="108" width="4" height="13" font="7"> </text>
<text top="215" left="130" width="1140" height="13" font="7">90.   Greves J, Rahimtoola SH, McAnulty JH, et al. Preoperative criteria predictive of late survival following valve replacement for severe aortic regurgitation. Am Heart J. 1981;101:300-8. </text>
<text top="232" left="108" width="4" height="13" font="7"> </text>
<text top="232" left="130" width="1166" height="13" font="7">91.   Kumpuris AG, Quinones MA, Waggoner AD, et al. Importance of preoperative hypertrophy, wall stress and end-systolic dimension as echocardiographic predictors of normalization of left </text>
<text top="249" left="162" width="668" height="13" font="7">ventricular dilatation after valve replacement in chronic aortic insufficiency. Am J Cardiol. 1982;49:1091-100. </text>
<text top="266" left="108" width="4" height="13" font="7"> </text>
<text top="266" left="130" width="1176" height="13" font="7">92.   Gaasch WH, Carroll JD, Levine HJ, et al. Chronic aortic regurgitation: prognostic value of left ventricular end-systolic dimension and end-diastolic radius/thickness ratio. J Am Coll Cardiol. </text>
<text top="284" left="162" width="96" height="13" font="7">1983;1:775-82. </text>
<text top="301" left="108" width="4" height="13" font="7"> </text>
<text top="301" left="130" width="1176" height="13" font="7">93.   Fioretti P, Roelandt J, Bos RJ, et al. Echocardiography in chronic aortic insufficiency. Is valve replacement too late when left ventricular end-systolic dimension reaches 55 mm? Circulation. </text>
<text top="318" left="162" width="103" height="13" font="7">1983;67:216-21. </text>
<text top="336" left="108" width="4" height="13" font="7"> </text>
<text top="336" left="130" width="1135" height="13" font="7">94.   Stone PH, Clark RD, Goldschlager N, et al. Determinants of prognosis of patients with aortic regurgitation who undergo aortic valve replacement. J Am Coll Cardiol. 1984;3:1118-26. </text>
<text top="353" left="108" width="4" height="13" font="7"> </text>
<text top="353" left="130" width="1182" height="13" font="7">95.   Bonow RO, Picone AL, McIntosh CL, et al. Survival and functional results after valve replacement for aortic regurgitation from 1976 to 1983: impact of preoperative left ventricular function. </text>
<text top="370" left="162" width="186" height="13" font="7">Circulation. 1985;72:1244-56. </text>
<text top="387" left="108" width="4" height="13" font="7"> </text>
<text top="387" left="130" width="1167" height="13" font="7">96.   Daniel WG, Hood WP, Jr., Siart A, et al. Chronic aortic regurgitation: reassessment of the prognostic value of preoperative left ventricular end-systolic dimension and fractional shortening. </text>
<text top="405" left="162" width="178" height="13" font="7">Circulation. 1985;71:669-80. </text>
<text top="422" left="108" width="4" height="13" font="7"> </text>
<text top="422" left="130" width="997" height="13" font="7">97.   Cormier B, Vahanian A, Luxereau P, et al. Should asymptomatic or mildly symptomatic aortic regurgitation be operated on? Z Kardiol. 1986;75 Suppl 2:141-5. </text>
<text top="439" left="108" width="4" height="13" font="7"> </text>
<text top="439" left="130" width="1203" height="13" font="7">98.   Sheiban I, Trevi GP, Casarotto D, et al. Aortic valve replacement in patients with aortic incompetence. Preoperative parameters influencing long-term results. Z Kardiol. 1986;75 Suppl 2:146-54. </text>
<text top="456" left="108" width="4" height="13" font="7"> </text>
<text top="456" left="130" width="965" height="13" font="7">99.   Carabello BA, Williams H, Gash AK, et al. Hemodynamic predictors of outcome in patients undergoing valve replacement. Circulation. 1986;74:1309-16. </text>
<text top="474" left="108" width="1204" height="13" font="7">  100.   Taniguchi K, Nakano S, Hirose H, et al. Preoperative left ventricular function: minimal requirement for successful late results of valve replacement for aortic regurgitation. J Am Coll Cardiol. </text>
<text top="491" left="162" width="96" height="13" font="7">1987;10:510-8. </text>
<text top="508" left="108" width="1163" height="13" font="7">  101.   Michel PL, Iung B, Abou JS, et al. The effect of left ventricular systolic function on long term survival in mitral and aortic regurgitation. J Heart Valve Dis. 1995;4 Suppl 2:S160-S168. </text>
<text top="525" left="108" width="1235" height="13" font="7">  102.   Klodas E, Enriquez-Sarano M, Tajik AJ, et al. Aortic regurgitation complicated by extreme left ventricular dilation: long-term outcome after surgical correction. J Am Coll Cardiol. 1996;27:670-7. </text>
<text top="543" left="108" width="1177" height="13" font="7">  103.   Klodas E, Enriquez-Sarano M, Tajik AJ, et al. Optimizing timing of surgical correction in patients with severe aortic regurgitation: role of symptoms. J Am Coll Cardiol. 1997;30:746-52. </text>
<text top="560" left="108" width="1103" height="13" font="7">  104.   Turina J, Milincic J, Seifert B, et al. Valve replacement in chronic aortic regurgitation. True predictors of survival after extended follow-up. Circulation. 1998;98:II100-II106. </text>
<text top="577" left="108" width="1174" height="13" font="7">  105.   Chaliki HP, Mohty D, Avierinos JF, et al. Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation. </text>
<text top="594" left="162" width="118" height="13" font="7">2002;106:2687-93. </text>
<text top="612" left="108" width="1183" height="13" font="7">  106.   Tornos P, Sambola A, Permanyer-Miralda G, et al. Long-term outcome of surgically treated aortic regurgitation: influence of guideline adherence toward early surgery. J Am Coll Cardiol. </text>
<text top="629" left="162" width="103" height="13" font="7">2006;47:1012-7. </text>
<text top="646" left="108" width="1165" height="13" font="7">  107.   Bhudia SK, McCarthy PM, Kumpati GS, et al. Improved outcomes after aortic valve surgery for chronic aortic regurgitation with severe left ventricular dysfunction. J Am Coll Cardiol. </text>
<text top="663" left="162" width="111" height="13" font="7">2007;49:1465-71. </text>
<text top="681" left="108" width="1199" height="13" font="7">  108.   Patel JJ, Shama D, Mitha AS, et al. Balloon valvuloplasty versus closed commissurotomy for pliable mitral stenosis: a prospective hemodynamic study. J Am Coll Cardiol. 1991;18:1318-22. </text>
<text top="698" left="108" width="1144" height="13" font="7">  109.   Turi ZG, Reyes VP, Raju BS, et al. Percutaneous balloon versus surgical closed commissurotomy for mitral stenosis. A prospective, randomized trial. Circulation. 1991;83:1179-85. </text>
<text top="715" left="108" width="1143" height="13" font="7">  110.   Arora R, Nair M, Kalra GS, et al. Immediate and long-term results of balloon and surgical closed mitral valvotomy: a randomized comparative study. Am Heart J. 1993;125:1091-4. </text>
<text top="732" left="108" width="1085" height="13" font="7">  111.   Reyes VP, Raju BS, Wynne J, et al. Percutaneous balloon valvuloplasty compared with open surgical commissurotomy for mitral stenosis. N Engl J Med. 1994;331:961-7. </text>
<text top="750" left="108" width="1240" height="13" font="7">  112.   Ben FM, Ayari M, Maatouk F, et al. Percutaneous balloon versus surgical closed and open mitral commissurotomy: seven-year follow-up results of a randomized trial. Circulation. 1998;97:245-50. </text>
<text top="767" left="108" width="1140" height="13" font="7">  113.   Cotrufo M, Renzulli A, Ismeno G, et al. Percutaneous mitral commissurotomy versus open mitral commissurotomy: a comparative study. Eur J Cardiothorac Surg. 1999;15:646-51. </text>
</page>
<page number="65" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">65 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="111" left="108" width="1210" height="13" font="7">  114.   Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the </text>
<text top="129" left="162" width="1162" height="13" font="7">American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular </text>
<text top="146" left="162" width="1151" height="13" font="7">heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. </text>
<text top="163" left="162" width="103" height="13" font="7">2008;52:e1-142. </text>
<text top="180" left="108" width="995" height="13" font="7">  115.   Cohen DJ, Kuntz RE, Gordon SP, et al. Predictors of long-term outcome after percutaneous balloon mitral valvuloplasty. N Engl J Med. 1992;327:1329-35. </text>
<text top="198" left="108" width="985" height="13" font="7">  116.   Palacios IF, Tuzcu ME, Weyman AE, et al. Clinical follow-up of patients undergoing percutaneous mitral balloon valvotomy. Circulation. 1995;91:671-6. </text>
<text top="215" left="108" width="1236" height="13" font="7">  117.   Dean LS, Mickel M, Bonan R, et al. Four-year follow-up of patients undergoing percutaneous balloon mitral commissurotomy. A report from the National Heart, Lung, and Blood Institute Balloon </text>
<text top="232" left="162" width="368" height="13" font="7">Valvuloplasty Registry. J Am Coll Cardiol. 1996;28:1452-7. </text>
<text top="249" left="108" width="1212" height="13" font="7">  118.   Iung B, Cormier B, Ducimetiere P, et al. Functional results 5 years after successful percutaneous mitral commissurotomy in a series of 528 patients and analysis of predictive factors. J Am Coll </text>
<text top="266" left="162" width="156" height="13" font="7">Cardiol. 1996;27:407-14. </text>
<text top="284" left="108" width="1194" height="13" font="7">  119.   Cannan CR, Nishimura RA, Reeder GS, et al. Echocardiographic assessment of commissural calcium: a simple predictor of outcome after percutaneous mitral balloon valvotomy. J Am Coll </text>
<text top="301" left="162" width="156" height="13" font="7">Cardiol. 1997;29:175-80. </text>
<text top="318" left="108" width="1239" height="13" font="7">  120.   Palacios IF, Sanchez PL, Harrell LC, et al. Which patients benefit from percutaneous mitral balloon valvuloplasty? Prevalvuloplasty and postvalvuloplasty variables that predict long-term outcome. </text>
<text top="336" left="162" width="193" height="13" font="7">Circulation. 2002;105:1465-71. </text>
<text top="353" left="108" width="1239" height="13" font="7">  121.   Wilkins GT, Weyman AE, Abascal VM, et al. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br </text>
<text top="370" left="162" width="161" height="13" font="7">Heart J. 1988;60:299-308. </text>
<text top="387" left="108" width="945" height="13" font="7">  122.   Schuler G, Peterson KL, Johnson A, et al. Temporal response of left ventricular performance to mitral valve surgery. Circulation. 1979;59:1218-31. </text>
<text top="405" left="108" width="1232" height="13" font="7">  123.   Phillips HR, Levine FH, Carter JE, et al. Mitral valve replacement for isolated mitral regurgitation: analysis of clinical course and late postoperative left ventricular ejection fraction. Am J Cardiol. </text>
<text top="422" left="162" width="103" height="13" font="7">1981;48:647-54. </text>
<text top="439" left="108" width="1208" height="13" font="7">  124.   Zile MR, Gaasch WH, Carroll JD, et al. Chronic mitral regurgitation: predictive value of preoperative echocardiographic indexes of left ventricular function and wall stress. J Am Coll Cardiol. </text>
<text top="456" left="162" width="96" height="13" font="7">1984;3:235-42. </text>
<text top="474" left="108" width="1245" height="13" font="7">  125.   Crawford MH, Souchek J, Oprian CA, et al. Determinants of survival and left ventricular performance after mitral valve replacement. Department of Veterans Affairs Cooperative Study on Valvular </text>
<text top="491" left="162" width="277" height="13" font="7">Heart Disease. Circulation. 1990;81:1173-81. </text>
<text top="508" left="108" width="1233" height="13" font="7">  126.   Wisenbaugh T, Sinovich V, Dullabh A, et al. Six month pilot study of captopril for mildly symptomatic, severe isolated mitral and isolated aortic regurgitation. J Heart Valve Dis. 1994;3:197-204. </text>
<text top="525" left="108" width="1101" height="13" font="7">  127.   Enriquez-Sarano M, Tajik AJ, Schaff HV, et al. Echocardiographic prediction of survival after surgical correction of organic mitral regurgitation. Circulation. 1994;90:830-7. </text>
<text top="543" left="108" width="1240" height="13" font="7">  128.   Enriquez-Sarano M, Tajik AJ, Schaff HV, et al. Echocardiographic prediction of left ventricular function after correction of mitral regurgitation: results and clinical implications. J Am Coll Cardiol. </text>
<text top="560" left="162" width="111" height="13" font="7">1994;24:1536-43. </text>
<text top="577" left="108" width="1198" height="13" font="7">  129.   Tribouilloy CM, Enriquez-Sarano M, Schaff HV, et al. Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical </text>
<text top="594" left="162" width="244" height="13" font="7">indications. Circulation. 1999;99:400-5. </text>
<text top="612" left="108" width="1173" height="13" font="7">  130.   Gillinov AM, Mihaljevic T, Blackstone EH, et al. Should patients with severe degenerative mitral regurgitation delay surgery until symptoms develop? Ann Thorac Surg. 2010;90:481-8. </text>
<text top="629" left="108" width="922" height="13" font="7">  131.   Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation. 2006;113:2238-44. </text>
<text top="646" left="108" width="1084" height="13" font="7">  132.   Kang DH, Kim JH, Rim JH, et al. Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation. Circulation. 2009;119:797-804. </text>
<text top="663" left="108" width="1235" height="13" font="7">  133.   Tribouilloy C, Grigioni F, Avierinos JF, et al. Survival implication of left ventricular end-systolic diameter in mitral regurgitation due to flail leaflets a long-term follow-up multicenter study. J Am </text>
<text top="681" left="162" width="185" height="13" font="7">Coll Cardiol. 2009;54:1961-8. </text>
<text top="698" left="108" width="1104" height="13" font="7">  134.   Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. 2005;352:875-83. </text>
<text top="715" left="108" width="1229" height="13" font="7">  135.   Ghoreishi M, Evans CF, deFilippi CR, et al. Pulmonary hypertension adversely affects short- and long-term survival after mitral valve operation for mitral regurgitation: implications for timing of </text>
<text top="732" left="162" width="334" height="13" font="7">surgery. J Thorac Cardiovasc Surg. 2011;142:1439-52. </text>
<text top="750" left="108" width="1209" height="13" font="7">  136.   Goldman ME, Mora F, Guarino T, et al. Mitral valvuloplasty is superior to valve replacement for preservation of left ventricular function: an intraoperative two-dimensional echocardiographic </text>
<text top="767" left="162" width="261" height="13" font="7">study. J Am Coll Cardiol. 1987;10:568-75. </text>
<text top="784" left="108" width="1180" height="13" font="7">  137.   David TE, Burns RJ, Bacchus CM, et al. Mitral valve replacement for mitral regurgitation with and without preservation of chordae tendineae. J Thorac Cardiovasc Surg. 1984;88:718-25. </text>
</page>
<page number="66" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">66 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="111" left="108" width="1161" height="13" font="7">  138.   Rozich JD, Carabello BA, Usher BW, et al. Mitral valve replacement with and without chordal preservation in patients with chronic mitral regurgitation. Mechanisms for differences in </text>
<text top="129" left="162" width="405" height="13" font="7">postoperative ejection performance. Circulation. 1992;86:1718-26. </text>
<text top="146" left="108" width="1097" height="13" font="7">  139.   Grigioni F, Tribouilloy C, Avierinos JF, et al. Outcomes in mitral regurgitation due to flail leaflets a multicenter European study. JACC Cardiovasc Imaging. 2008;1:133-41. </text>
<text top="163" left="108" width="1016" height="13" font="7">  140.   Gillinov AM, Blackstone EH, Alaulaqi A, et al. Outcomes after repair of the anterior mitral leaflet for degenerative disease. Ann Thorac Surg. 2008;86:708-17. </text>
<text top="180" left="108" width="1067" height="13" font="7">  141.   Kang DH, Kim MJ, Kang SJ, et al. Mitral valve repair versus revascularization alone in the treatment of ischemic mitral regurgitation. Circulation. 2006;114:I499-I503. </text>
<text top="198" left="108" width="1221" height="13" font="7">  142.   Rossi A, Dini FL, Faggiano P, et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-</text>
<text top="215" left="162" width="365" height="13" font="7">ischaemic dilated cardiomyopathy. Heart. 2011;97:1675-80. </text>
<text top="232" left="108" width="1208" height="13" font="7">  143.   Wu AH, Aaronson KD, Bolling SF, et al. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol. </text>
<text top="249" left="162" width="96" height="13" font="7">2005;45:381-7. </text>
<text top="266" left="108" width="1197" height="13" font="7">  144.   Mihaljevic T, Lam BK, Rajeswaran J, et al. Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol. </text>
<text top="284" left="162" width="118" height="13" font="7">2007;49:2191-201. </text>
<text top="301" left="108" width="1231" height="13" font="7">  145.   Benedetto U, Melina G, Roscitano A, et al. Does combined mitral valve surgery improve survival when compared to revascularization alone in patients with ischemic mitral regurgitation? A meta-</text>
<text top="318" left="162" width="464" height="13" font="7">analysis on 2479 patients. J Cardiovasc Med (Hagerstown). 2009;10:109-14. </text>
<text top="336" left="108" width="1218" height="13" font="7">  146.   Fattouch K, Guccione F, Sampognaro R, et al. POINT: Efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve </text>
<text top="353" left="162" width="476" height="13" font="7">regurgitation: a randomized trial. J Thorac Cardiovasc Surg. 2009;138:278-85. </text>
<text top="370" left="108" width="1119" height="13" font="7">  147.   Deja MA, Grayburn PA, Sun B, et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation. 2012;125:2639-48. </text>
<text top="387" left="108" width="1084" height="13" font="7">  148.   Dreyfus GD, Corbi PJ, Chan KM, et al. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? Ann Thorac Surg. 2005;79:127-32. </text>
<text top="405" left="108" width="1236" height="13" font="7">  149.   Chan V, Burwash IG, Lam BK, et al. Clinical and echocardiographic impact of functional tricuspid regurgitation repair at the time of mitral valve replacement. Ann Thorac Surg. 2009;88:1209-15. </text>
<text top="422" left="108" width="1243" height="13" font="7">  150.   Calafiore AM, Gallina S, Iaco AL, et al. Mitral valve surgery for functional mitral regurgitation: should moderate-or-more tricuspid regurgitation be treated? a propensity score analysis. Ann Thorac </text>
<text top="439" left="162" width="147" height="13" font="7">Surg. 2009;87:698-703. </text>
<text top="456" left="108" width="1100" height="13" font="7">  151.   Di MM, Bivona A, Iaco AL, et al. Mitral valve surgery for functional mitral regurgitation: prognostic role of tricuspid regurgitation. Eur J Cardiothorac Surg. 2009;35:635-9. </text>
<text top="474" left="108" width="1197" height="13" font="7">  152.   Van de Veire NR, Braun J, Delgado V, et al. Tricuspid annuloplasty prevents right ventricular dilatation and progression of tricuspid regurgitation in patients with tricuspid annular dilatation </text>
<text top="491" left="162" width="464" height="13" font="7">undergoing mitral valve repair. J Thorac Cardiovasc Surg. 2011;141:1431-9. </text>
<text top="508" left="108" width="1222" height="13" font="7">  153.   Yilmaz O, Suri RM, Dearani JA, et al. Functional tricuspid regurgitation at the time of mitral valve repair for degenerative leaflet prolapse: the case for a selective approach. J Thorac Cardiovasc </text>
<text top="525" left="162" width="147" height="13" font="7">Surg. 2011;142:608-13. </text>
<text top="543" left="108" width="1013" height="13" font="7">  154.   Calafiore AM, Iaco AL, Romeo A, et al. Echocardiographic-based treatment of functional tricuspid regurgitation. J Thorac Cardiovasc Surg. 2011;142:308-13. </text>
<text top="560" left="108" width="1139" height="13" font="7">  155.   Navia JL, Brozzi NA, Klein AL, et al. Moderate tricuspid regurgitation with left-sided degenerative heart valve disease: to repair or not to repair? Ann Thorac Surg. 2012;93:59-67. </text>
<text top="577" left="108" width="1244" height="13" font="7">  156.   Kim JB, Yoo DG, Kim GS, et al. Mild-to-moderate functional tricuspid regurgitation in patients undergoing valve replacement for rheumatic mitral disease: the influence of tricuspid valve repair on </text>
<text top="594" left="162" width="390" height="13" font="7">clinical and echocardiographic outcomes. Heart. 2012;98:24-30. </text>
<text top="612" left="108" width="1241" height="13" font="7">  157.   Benedetto U, Melina G, Angeloni E, et al. Prophylactic tricuspid annuloplasty in patients with dilated tricuspid annulus undergoing mitral valve surgery. J Thorac Cardiovasc Surg. 2012;143:632-8. </text>
<text top="629" left="108" width="1240" height="13" font="7">  158.   Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. </text>
<text top="646" left="162" width="221" height="13" font="7">J Am Coll Cardiol. 2000;36:1152-8. </text>
<text top="663" left="108" width="1056" height="13" font="7">  159.   Oxenham H, Bloomfield P, Wheatley DJ, et al. Twenty year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses. Heart. 2003;89:715-21. </text>
<text top="681" left="108" width="1203" height="13" font="7">  160.   Stassano P, Di TL, Monaco M, et al. Aortic valve replacement: a prospective randomized evaluation of mechanical versus biological valves in patients ages 55 to 70 years. J Am Coll Cardiol. </text>
<text top="698" left="162" width="103" height="13" font="7">2009;54:1862-8. </text>
<text top="715" left="108" width="999" height="13" font="7">  161.   Khan SS, Trento A, DeRobertis M, et al. Twenty-year comparison of tissue and mechanical valve replacement. J Thorac Cardiovasc Surg. 2001;122:257-69. </text>
<text top="732" left="108" width="1240" height="13" font="7">  162.   Chan V, Jamieson WR, Germann E, et al. Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after aortic valve replacement. </text>
<text top="750" left="162" width="281" height="13" font="7">J Thorac Cardiovasc Surg. 2006;131:1267-73. </text>
<text top="767" left="108" width="981" height="13" font="7">  163.   Kulik A, Bedard P, Lam BK, et al. Mechanical versus bioprosthetic valve replacement in middle-aged patients. Eur J Cardiothorac Surg. 2006;30:485-91. </text>
</page>
<page number="67" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">67 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="111" left="108" width="1226" height="13" font="7">  164.   Ruel M, Chan V, Bedard P, et al. Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults &lt;60 years of age. Circulation. 2007;116:I294-</text>
<text top="129" left="162" width="35" height="13" font="7">I300. </text>
<text top="146" left="108" width="1233" height="13" font="7">  165.   van Geldorp MW, Eric Jamieson WR, Kappetein AP, et al. Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: weighing lifetime anticoagulant-related event </text>
<text top="163" left="162" width="441" height="13" font="7">risk against reoperation risk. J Thorac Cardiovasc Surg. 2009;137:881-5. </text>
<text top="180" left="108" width="1225" height="13" font="7">  166.   Badhwar V, Ofenloch JC, Rovin JD, et al. Noninferiority of closely monitored mechanical valves to bioprostheses overshadowed by early mortality benefit in younger patients. Ann Thorac Surg. </text>
<text top="198" left="162" width="103" height="13" font="7">2012;93:748-53. </text>
<text top="215" left="108" width="1234" height="13" font="7">  167.   Weber A, Noureddine H, Englberger L, et al. Ten-year comparison of pericardial tissue valves versus mechanical prostheses for aortic valve replacement in patients younger than 60 years of age. J </text>
<text top="232" left="162" width="272" height="13" font="7">Thorac Cardiovasc Surg. 2012;144:1075-83. </text>
<text top="249" left="108" width="1205" height="13" font="7">  168.   Hammerstingl C, Tripp C, Schmidt H, et al. Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: </text>
<text top="266" left="162" width="614" height="13" font="7">experience in 116 patients from the prospective BRAVE registry. J Heart Valve Dis. 2007;16:285-92. </text>
<text top="284" left="108" width="1216" height="13" font="7">  169.   Spyropoulos AC, Turpie AG, Dunn AS, et al. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on </text>
<text top="301" left="162" width="567" height="13" font="7">long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardiol. 2008;102:883-9. </text>
<text top="318" left="108" width="1215" height="13" font="7">  170.   Pengo V, Cucchini U, Denas G, et al. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception </text>
<text top="336" left="162" width="348" height="13" font="7">cohort management study. Circulation. 2009;119:2920-7. </text>
<text top="353" left="108" width="1039" height="13" font="7">  171.   Daniels PR, McBane RD, Litin SC, et al. Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. Thromb Res. 2009;124:300-5. </text>
<text top="370" left="108" width="1244" height="13" font="7">  172.   Bui HT, Krisnaswami A, Le CU, et al. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with </text>
<text top="387" left="162" width="388" height="13" font="7">nonvalvular atrial fibrillation. Am J Cardiol. 2009;104:1429-33. </text>
<text top="405" left="108" width="1034" height="13" font="7">  173.   Biteker M, Tekkesin AI, Can MM, et al. Outcome of noncardiac and nonvascular surgery in patients with mechanical heart valves. Am J Cardiol. 2012;110:562-7. </text>
<text top="422" left="108" width="1239" height="13" font="7">  174.   Weiss A, Brose S, Ploetze K, et al. Half-dose enoxaparin vs. full-dose enoxaparin for postoperative bridging therapy in patients after cardiac surgery: Which dose regimen should be preferred? Clin </text>
<text top="439" left="162" width="175" height="13" font="7">Hemorheol Microcirc. 2013. </text>
<text top="456" left="108" width="1076" height="13" font="7">  175.   Deviri E, Sareli P, Wisenbaugh T, et al. Obstruction of mechanical heart valve prostheses: clinical aspects and surgical management. J Am Coll Cardiol. 1991;17:646-50. </text>
<text top="474" left="108" width="1235" height="13" font="7">  176.   Tong AT, Roudaut R, Ozkan M, et al. Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. J </text>
<text top="491" left="162" width="204" height="13" font="7">Am Coll Cardiol. 2004;43:77-84. </text>
<text top="508" left="108" width="1231" height="13" font="7">  177.   Roudaut R, Lafitte S, Roudaut MF, et al. Management of prosthetic heart valve obstruction: fibrinolysis versus surgery. Early results and long-term follow-up in a single-centre study of 263 cases. </text>
<text top="525" left="162" width="244" height="13" font="7">Arch Cardiovasc Dis. 2009;102:269-77. </text>
<text top="543" left="108" width="1153" height="13" font="7">  178.   Karthikeyan G, Math RS, Mathew N, et al. Accelerated infusion of streptokinase for the treatment of left-sided prosthetic valve thrombosis: a randomized controlled trial. Circulation. </text>
<text top="560" left="162" width="118" height="13" font="7">2009;120:1108-14. </text>
<text top="577" left="108" width="1148" height="13" font="7">  179.   Keuleers S, Herijgers P, Herregods MC, et al. Comparison of thrombolysis versus surgery as a first line therapy for prosthetic heart valve thrombosis. Am J Cardiol. 2011;107:275-9. </text>
<text top="594" left="108" width="1225" height="13" font="7">  180.   Karthikeyan G, Senguttuvan NB, Joseph J, et al. Urgent surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic heart valve thrombosis: a systematic review and meta-</text>
<text top="612" left="162" width="315" height="13" font="7">analysis of observational studies. Eur Heart J. 2013. </text>
<text top="629" left="108" width="843" height="13" font="7">  181.   Orszulak TA, Schaff HV, Danielson GK, et al. Results of reoperation for periprosthetic leakage. Ann Thorac Surg. 1983;35:584-9. </text>
<text top="646" left="108" width="1147" height="13" font="7">  182.   Miller DL, Morris JJ, Schaff HV, et al. Reoperation for aortic valve periprosthetic leakage: identification of patients at risk and results of operation. J Heart Valve Dis. 1995;4:160-5. </text>
<text top="663" left="108" width="1075" height="13" font="7">  183.   Akins CW, Bitondo JM, Hilgenberg AD, et al. Early and late results of the surgical correction of cardiac prosthetic paravalvular leaks. J Heart Valve Dis. 2005;14:792-9. </text>
<text top="681" left="108" width="1037" height="13" font="7">  184.   Pate GE, Al ZA, Chandavimol M, et al. Percutaneous closure of prosthetic paravalvular leaks: case series and review. Catheter Cardiovasc Interv. 2006;68:528-33. </text>
<text top="698" left="108" width="1187" height="13" font="7">  185.   Shapira Y, Hirsch R, Kornowski R, et al. Percutaneous closure of perivalvular leaks with Amplatzer occluders: feasibility, safety, and shortterm results. J Heart Valve Dis. 2007;16:305-13. </text>
<text top="715" left="108" width="1182" height="13" font="7">  186.   Cortes M, Garcia E, Garcia-Fernandez MA, et al. Usefulness of transesophageal echocardiography in percutaneous transcatheter repairs of paravalvular mitral regurgitation. Am J Cardiol. </text>
<text top="732" left="162" width="103" height="13" font="7">2008;101:382-6. </text>
<text top="750" left="108" width="1094" height="13" font="7">  187.   Ruiz CE, Jelnin V, Kronzon I, et al. Clinical outcomes in patients undergoing percutaneous closure of periprosthetic paravalvular leaks. J Am Coll Cardiol. 2011;58:2210-7. </text>
<text top="767" left="108" width="1169" height="13" font="7">  188.   Sorajja P, Cabalka AK, Hagler DJ, et al. Percutaneous repair of paravalvular prosthetic regurgitation: acute and 30-day outcomes in 115 patients. Circ Cardiovasc Interv. 2011;4:314-21. </text>
<text top="784" left="108" width="1040" height="13" font="7">  189.   Sorajja P, Cabalka AK, Hagler DJ, et al. Long-term follow-up of percutaneous repair of paravalvular prosthetic regurgitation. J Am Coll Cardiol. 2011;58:2218-24. </text>
</page>
<page number="68" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">68 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="111" left="108" width="1019" height="13" font="7">  190.   Jault F, Gandjbakhch I, Rama A, et al. Active native valve endocarditis: determinants of operative death and late mortality. Ann Thorac Surg. 1997;63:1737-41. </text>
<text top="129" left="108" width="1062" height="13" font="7">  191.   Castillo JC, Anguita MP, Ramirez A, et al. Long term outcome of infective endocarditis in patients who were not drug addicts: a 10 year study. Heart. 2000;83:525-30. </text>
<text top="146" left="108" width="1065" height="13" font="7">  192.   Alexiou C, Langley SM, Stafford H, et al. Surgery for active culture-positive endocarditis: determinants of early and late outcome. Ann Thorac Surg. 2000;69:1448-54. </text>
<text top="163" left="108" width="892" height="13" font="7">  193.   Wallace SM, Walton BI, Kharbanda RK, et al. Mortality from infective endocarditis: clinical predictors of outcome. Heart. 2002;88:53-60. </text>
<text top="180" left="108" width="1023" height="13" font="7">  194.   Hasbun R, Vikram HR, Barakat LA, et al. Complicated left-sided native valve endocarditis in adults: risk classification for mortality. JAMA. 2003;289:1933-40. </text>
<text top="198" left="108" width="1171" height="13" font="7">  195.   Vikram HR, Buenconsejo J, Hasbun R, et al. Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis. JAMA. </text>
<text top="215" left="162" width="118" height="13" font="7">2003;290:3207-14. </text>
<text top="232" left="108" width="940" height="13" font="7">  196.   Habib G, Tribouilloy C, Thuny F, et al. Prosthetic valve endocarditis: who needs surgery? A multicentre study of 104 cases. Heart. 2005;91:954-9. </text>
<text top="249" left="108" width="1026" height="13" font="7">  197.   Revilla A, Lopez J, Vilacosta I, et al. Clinical and prognostic profile of patients with infective endocarditis who need urgent surgery. Eur Heart J. 2007;28:65-71. </text>
<text top="266" left="108" width="1127" height="13" font="7">  198.   Hill EE, Herijgers P, Claus P, et al. Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J. 2007;28:196-203. </text>
<text top="284" left="108" width="1048" height="13" font="7">  199.   Remadi JP, Habib G, Nadji G, et al. Predictors of death and impact of surgery in Staphylococcus aureus infective endocarditis. Ann Thorac Surg. 2007;83:1295-302. </text>
<text top="301" left="108" width="963" height="13" font="7">  200.   Aksoy O, Sexton DJ, Wang A, et al. Early surgery in patients with infective endocarditis: a propensity score analysis. Clin Infect Dis. 2007;44:364-72. </text>
<text top="318" left="108" width="1067" height="13" font="7">  201.   Tleyjeh IM, Ghomrawi HM, Steckelberg JM, et al. The impact of valve surgery on 6-month mortality in left-sided infective endocarditis. Circulation. 2007;115:1721-8. </text>
<text top="336" left="108" width="1156" height="13" font="7">  202.   Tleyjeh IM, Steckelberg JM, Georgescu G, et al. The association between the timing of valve surgery and 6-month mortality in left-sided infective endocarditis. Heart. 2008;94:892-6. </text>
<text top="353" left="108" width="1194" height="13" font="7">  203.   Thuny F, Beurtheret S, Mancini J, et al. The timing of surgery influences mortality and morbidity in adults with severe complicated infective endocarditis: a propensity analysis. Eur Heart J. </text>
<text top="370" left="162" width="111" height="13" font="7">2011;32:2027-33. </text>
<text top="387" left="108" width="1056" height="13" font="7">  204.   Manne MB, Shrestha NK, Lytle BW, et al. Outcomes after surgical treatment of native and prosthetic valve infective endocarditis. Ann Thorac Surg. 2012;93:489-93. </text>
<text top="405" left="108" width="901" height="13" font="7">  205.   Kang DH, Kim YJ, Kim SH, et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med. 2012;366:2466-73. </text>
<text top="422" left="108" width="1096" height="13" font="7">  206.   Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000;160:191-6. </text>
<text top="439" left="108" width="980" height="13" font="7">  207.   Meschengieser SS, Fondevila CG, Santarelli MT, et al. Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart. 1999;82:23-6. </text>
<text top="456" left="108" width="1101" height="13" font="7">  208.   Vitale N, De FM, De Santo LS, et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999;33:1637-41. </text>
<text top="474" left="108" width="1222" height="13" font="7">  209.   Salazar E, Izaguirre R, Verdejo J, et al. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J </text>
<text top="491" left="162" width="227" height="13" font="7">Am Coll Cardiol. 1996;27:1698-703. </text>
<text top="508" left="108" width="728" height="13" font="7">  210.   Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve prostheses. Br Heart J. 1994;71:196-201. </text>
<text top="525" left="108" width="1119" height="13" font="7">  211.   Al-Lawati AA, Venkitraman M, Al-Delaime T, et al. Pregnancy and mechanical heart valves replacement; dilemma of anticoagulation. Eur J Cardiothorac Surg. 2002;22:223-7. </text>
<text top="543" left="108" width="1121" height="13" font="7">  212.   Sadler L, McCowan L, White H, et al. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. BJOG. 2000;107:245-53. </text>
<text top="560" left="108" width="1225" height="13" font="7">  213.   De Santo LS, Romano G, Della CA, et al. Mitral mechanical replacement in young rheumatic women: analysis of long-term survival, valve-related complications, and pregnancy outcomes over a </text>
<text top="577" left="162" width="436" height="13" font="7">3707-patient-year follow-up. J Thorac Cardiovasc Surg. 2005;130:13-9. </text>
<text top="594" left="108" width="1062" height="13" font="7">  214.   Rowan JA, McCowan LM, Raudkivi PJ, et al. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol. 2001;185:633-7. </text>
<text top="612" left="108" width="1238" height="13" font="7">  215.   James AH, Brancazio LR, Gehrig TR, et al. Low-molecular-weight heparin for thromboprophylaxis in pregnant women with mechanical heart valves. J Matern Fetal Neonatal Med. 2006;19:543-9. </text>
<text top="629" left="108" width="1227" height="13" font="7">  216.   Abildgaard U, Sandset PM, Hammerstrom J, et al. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin. Thromb Res. </text>
<text top="646" left="162" width="103" height="13" font="7">2009;124:262-7. </text>
<text top="663" left="108" width="1218" height="13" font="7">  217.   Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost. </text>
<text top="681" left="162" width="103" height="13" font="7">2004;92:747-51. </text>
<text top="698" left="108" width="1215" height="13" font="7">  218.   McLintock C, McCowan LM, North RA. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. BJOG. 2009;116:1585-92. </text>
<text top="715" left="108" width="1024" height="13" font="7">  219.   Yinon Y, Siu SC, Warshafsky C, et al. Use of low molecular weight heparin in pregnant women with mechanical heart valves. Am J Cardiol. 2009;104:1259-63. </text>
<text top="732" left="108" width="1182" height="13" font="7">  220.   Quinn J, Von KK, Brooks R, et al. Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experience. </text>
<text top="750" left="162" width="209" height="13" font="7">Haematologica. 2009;94:1608-12. </text>
<text top="767" left="108" width="1243" height="13" font="7">  221.   Eguchi K, Ohtaki E, Matsumura T, et al. Pre-operative atrial fibrillation as the key determinant of outcome of mitral valve repair for degenerative mitral regurgitation. Eur Heart J. 2005;26:1866-72. </text>
</page>
<page number="69" position="absolute" top="0" left="0" height="918" width="1512">
<text top="832" left="721" width="21" height="17" font="0">69 </text>
<text top="852" left="108" width="405" height="12" font="1">© American College of Cardiology Foundation and American Heart Association, Inc.</text>
<text top="848" left="514" width="4" height="17" font="0"> </text>
<text top="111" left="108" width="1237" height="13" font="7">  222.   Alexiou C, Doukas G, Oc M, et al. The effect of preoperative atrial fibrillation on survival following mitral valve repair for degenerative mitral regurgitation. Eur J Cardiothorac Surg. 2007;31:586-</text>
<text top="129" left="162" width="22" height="13" font="7">91. </text>
<text top="146" left="108" width="1176" height="13" font="7">  223.   Ngaage DL, Schaff HV, Mullany CJ, et al. Influence of preoperative atrial fibrillation on late results of mitral repair: is concomitant ablation justified? Ann Thorac Surg. 2007;84:434-42. </text>
<text top="163" left="108" width="1243" height="13" font="7">  224.   Chua YL, Schaff HV, Orszulak TA, et al. Outcome of mitral valve repair in patients with preoperative atrial fibrillation. Should the maze procedure be combined with mitral valvuloplasty? J Thorac </text>
<text top="180" left="162" width="218" height="13" font="7">Cardiovasc Surg. 1994;107:408-15. </text>
<text top="198" left="108" width="878" height="13" font="7">  225.   Obadia JF, el FM, Bastien OH, et al. Outcome of atrial fibrillation after mitral valve repair. J Thorac Cardiovasc Surg. 1997;114:179-85. </text>
<text top="215" left="108" width="1091" height="13" font="7">  226.   Jessurun ER, van Hemel NM, Kelder JC, et al. Mitral valve surgery and atrial fibrillation: is atrial fibrillation surgery also needed? Eur J Cardiothorac Surg. 2000;17:530-7. </text>
<text top="232" left="108" width="1211" height="13" font="7">  227.   Deneke T, Khargi K, Grewe PH, et al. Efficacy of an additional MAZE procedure using cooled-tip radiofrequency ablation in patients with chronic atrial fibrillation and mitral valve disease. A </text>
<text top="249" left="162" width="362" height="13" font="7">randomized, prospective trial. Eur Heart J. 2002;23:558-66. </text>
<text top="266" left="108" width="1216" height="13" font="7">  228.   Akpinar B, Guden M, Sagbas E, et al. Combined radiofrequency modified maze and mitral valve procedure through a port access approach: early and mid-term results. Eur J Cardiothorac Surg. </text>
<text top="284" left="162" width="103" height="13" font="7">2003;24:223-30. </text>
<text top="301" left="108" width="1180" height="13" font="7">  229.   Jessurun ER, van Hemel NM, Defauw JJ, et al. A randomized study of combining maze surgery for atrial fibrillation with mitral valve surgery. J Cardiovasc Surg (Torino ). 2003;44:9-18. </text>
<text top="318" left="108" width="1235" height="13" font="7">  230.   Abreu Filho CA, Lisboa LA, Dallan LA, et al. Effectiveness of the maze procedure using cooled-tip radiofrequency ablation in patients with permanent atrial fibrillation and rheumatic mitral valve </text>
<text top="336" left="162" width="239" height="13" font="7">disease. Circulation. 2005;112:I20-I25. </text>
<text top="353" left="108" width="1213" height="13" font="7">  231.   Doukas G, Samani NJ, Alexiou C, et al. Left atrial radiofrequency ablation during mitral valve surgery for continuous atrial fibrillation: a randomized controlled trial. JAMA. 2005;294:2323-9. </text>
<text top="370" left="108" width="1235" height="13" font="7">  232.   Von Oppell UO, Masani N, O'Callaghan P, et al. Mitral valve surgery plus concomitant atrial fibrillation ablation is superior to mitral valve surgery alone with an intensive rhythm control strategy. </text>
<text top="387" left="162" width="256" height="13" font="7">Eur J Cardiothorac Surg. 2009;35:641-50. </text>
<text top="405" left="108" width="1089" height="13" font="7">  233.   Cheng DC, Ad N, Martin J, et al. Surgical Ablation for Atrial Fibrillation in Cardiac Surgery: A Meta-Analysis and Systematic Review. Innovations (Phila ). 2010;5:84-96. </text>
<text top="422" left="108" width="1212" height="13" font="7">  234.   Bando K, Kobayashi J, Hirata M, et al. Early and late stroke after mitral valve replacement with a mechanical prosthesis: risk factor analysis of a 24-year experience. J Thorac Cardiovasc Surg. </text>
<text top="439" left="162" width="111" height="13" font="7">2003;126:358-64. </text>
<text top="456" left="108" width="1166" height="13" font="7">  235.   Bum KJ, Suk MJ, Yun SC, et al. Long-term outcomes of mechanical valve replacement in patients with atrial fibrillation: impact of the maze procedure. Circulation. 2012;125:2071-80. </text>
<text top="474" left="108" width="932" height="13" font="7">  236.   Malaisrie SC, Lee R, Kruse J, et al. Atrial fibrillation ablation in patients undergoing aortic valve replacement. J Heart Valve Dis. 2012;21:350-7. </text>
<text top="491" left="108" width="1234" height="13" font="7">  237.   Liu X, Tan HW, Wang XH, et al. Efficacy of catheter ablation and surgical CryoMaze procedure in patients with long-lasting persistent atrial fibrillation and rheumatic heart disease: a randomized </text>
<text top="508" left="162" width="218" height="13" font="7">trial. Eur Heart J. 2010;31:2633-41. </text>
<text top="525" left="108" width="1116" height="13" font="7">  238.   Agarwal S, Rajamanickam A, Bajaj NS, et al. Impact of aortic stenosis on postoperative outcomes after noncardiac surgeries. Circ Cardiovasc Qual Outcomes. 2013;6:193-200. </text>
<text top="543" left="108" width="1220" height="13" font="7">  239.   Calleja AM, Dommaraju S, Gaddam R, et al. Cardiac risk in patients aged &gt;75 years with asymptomatic, severe aortic stenosis undergoing noncardiac surgery. Am J Cardiol. 2010;105:1159-63. </text>
<text top="560" left="108" width="1091" height="13" font="7">  240.   Leibowitz D, Rivkin G, Schiffman J, et al. Effect of severe aortic stenosis on the outcome in elderly patients undergoing repair of hip fracture. Gerontology. 2009;55:303-6. </text>
<text top="577" left="108" width="877" height="13" font="7">  241.   Zahid M, Sonel AF, Saba S, et al. Perioperative risk of noncardiac surgery associated with aortic stenosis. Am J Cardiol. 2005;96:436-8. </text>
<text top="594" left="108" width="930" height="13" font="7">  242.   Torsher LC, Shub C, Rettke SR, et al. Risk of patients with severe aortic stenosis undergoing noncardiac surgery. Am J Cardiol. 1998;81:448-52. </text>
<text top="612" left="108" width="904" height="13" font="7">  243.   Lai HC, Lai HC, Lee WL, et al. Mitral regurgitation complicates postoperative outcome of noncardiac surgery. Am Heart J. 2007;153:712-7. </text>
<text top="629" left="108" width="1109" height="13" font="7">  244.   Lai HC, Lai HC, Lee WL, et al. Impact of chronic advanced aortic regurgitation on the perioperative outcome of noncardiac surgery. Acta Anaesthesiol Scand. 2010;54:580-8. </text>
<text top="646" left="108" width="4" height="13" font="7"> </text>
<text top="663" left="108" width="4" height="13" font="7"> </text>
</page>
</pdf2xml>
